<SEC-DOCUMENT>0001787306-20-000010.txt : 20200512
<SEC-HEADER>0001787306-20-000010.hdr.sgml : 20200512
<ACCEPTANCE-DATETIME>20200512163230
ACCESSION NUMBER:		0001787306-20-000010
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200512
DATE AS OF CHANGE:		20200512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcutis Biotherapeutics, Inc.
		CENTRAL INDEX KEY:			0001787306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				812974255
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39186
		FILM NUMBER:		20869538

	BUSINESS ADDRESS:	
		STREET 1:		2945 TOWNSGATE ROAD
		STREET 2:		SUITE 110
		CITY:			WESTLAKE VILLAGE
		STATE:			CA
		ZIP:			91361
		BUSINESS PHONE:		805-418-5006

	MAIL ADDRESS:	
		STREET 1:		2945 TOWNSGATE ROAD
		STREET 2:		SUITE 110
		CITY:			WESTLAKE VILLAGE
		STATE:			CA
		ZIP:			91361

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arcutis, Inc.
		DATE OF NAME CHANGE:	20190905
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>arqt-20200331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:600b0262-d663-4687-ae47-6802ec869b02,g:c1b67e0b-9b7c-4732-b64c-b3f7b7d96647,d:eeb33ed1376b4f84a553eb9bccd9731d--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:arqt="http://arcutis.com/20200331" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arqt-20200331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF80L2ZyYWc6YzEwOTY3YjRhZDEyNDViZjk3NTkzMmRmZGViZjhlN2QvdGFibGU6M2ZhNDY0Y2M1ZjVmNGM4Mzg4M2IwNWI2Yjc0MWM4OGMvdGFibGVyYW5nZTozZmE0NjRjYzVmNWY0YzgzODgzYjA1YjZiNzQxYzg4Y18zLTEtMS0xLTE3MDI_335b0e21-9cc5-46fe-af79-aed734273f79">0001787306</ix:nonNumeric><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF80L2ZyYWc6YzEwOTY3YjRhZDEyNDViZjk3NTkzMmRmZGViZjhlN2QvdGFibGU6M2ZhNDY0Y2M1ZjVmNGM4Mzg4M2IwNWI2Yjc0MWM4OGMvdGFibGVyYW5nZTozZmE0NjRjYzVmNWY0YzgzODgzYjA1YjZiNzQxYzg4Y181LTEtMS0xLTE3MDI_98e20559-62b7-4bda-aa2e-0e72059b6e2c">12-31</ix:nonNumeric><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF80L2ZyYWc6YzEwOTY3YjRhZDEyNDViZjk3NTkzMmRmZGViZjhlN2QvdGFibGU6M2ZhNDY0Y2M1ZjVmNGM4Mzg4M2IwNWI2Yjc0MWM4OGMvdGFibGVyYW5nZTozZmE0NjRjYzVmNWY0YzgzODgzYjA1YjZiNzQxYzg4Y18xNy0xLTEtMS0xNzEw_6829bf38-512a-4adf-b829-ad08f5b3a49b">2020</ix:nonNumeric><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF80L2ZyYWc6YzEwOTY3YjRhZDEyNDViZjk3NTkzMmRmZGViZjhlN2QvdGFibGU6M2ZhNDY0Y2M1ZjVmNGM4Mzg4M2IwNWI2Yjc0MWM4OGMvdGFibGVyYW5nZTozZmE0NjRjYzVmNWY0YzgzODgzYjA1YjZiNzQxYzg4Y18xOC0xLTEtMS0xNzEw_6fcd06b9-e957-43f7-bacf-317459ca044d">Q1</ix:nonNumeric><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF80L2ZyYWc6YzEwOTY3YjRhZDEyNDViZjk3NTkzMmRmZGViZjhlN2QvdGFibGU6M2ZhNDY0Y2M1ZjVmNGM4Mzg4M2IwNWI2Yjc0MWM4OGMvdGFibGVyYW5nZTozZmE0NjRjYzVmNWY0YzgzODgzYjA1YjZiNzQxYzg4Y18xOS0xLTEtMS0xNzEw_a9619d55-6806-4f16-bb50-229d753654b2">False</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="idf2cb7e7d89e49ce95ca0662113be912_D20200117-20200117" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTc3L2ZyYWc6NzIzMzU1Zjk1OTIxNGYzOWIyOWJhNjc1NWJkMmFhZTgvdGV4dHJlZ2lvbjo3MjMzNTVmOTU5MjE0ZjM5YjI5YmE2NzU1YmQyYWFlOF80OTQ3ODAyMzI1NTM0_1f7c2a7c-db6a-4175-abea-a3d39c7ef806">0.4998</ix:nonFraction><ix:nonNumeric contextRef="i8e6455e64ac24ad4b0b835c47c9e7d60_D20200101-20200331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzY4NA_1160bc3e-4896-43bb-92b1-9fd3b49a3ce7">P4Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="icefe4f59d74b498eb9f973315e31aaec_D20160801-20160831" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTg4L2ZyYWc6NWU1NzY4MzRlODMzNDFiY2FiYWI1Y2RhMzU3MTMzY2UvdGV4dHJlZ2lvbjo1ZTU3NjgzNGU4MzM0MWJjYWJhYjVjZGEzNTcxMzNjZV80OTQ3ODAyMzI1MDAw_dd0526b9-fa89-46b3-a39c-06cb3a1433cf">0.25</ix:nonFraction><ix:nonNumeric contextRef="i8b84137f69724a55827a9c4614fa776b_I20200430" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3NzUy_a7f3f3c6-d01a-43c9-8f08-52810289a778">P5Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="arqt-20200331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i45ee5cbaa43a4c1b946d00944fd45974_I20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="idde51cc55856491d9916e0b6960bac95_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68dfa5b4689849b9a3cd771af6075ca9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ccb7f8264e14d269a33e7f94a0411d7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i004b33aa7ef84638a508f80804c3e4d6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58223e1e92e7484da16c8646830a5178_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3bef4868bf94e0b8bcd68b0c08ee9c3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3d98141ace44b3d91fa1e2bd76e3378_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbbb627a865342c3a3c8ca55197e411c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id40bc8ee44ed48b9b00785b5733d49e4_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cd5d9c6ed8543fbae65bfb9bf35030d_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5c62122ea184197a8cbcd8fac509f93_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d4d2679b1f24ea4bbc79894014b1394_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91f2e456e7ee436697728b99c6737875_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf934a45ca7144f39a0071e59f9cc564_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6be9162e0bdc434cae7c672714f4e731_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35625a47aaa94266be03155114268268_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if55289982bed4868bd75d4d6010753e2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb50c31a77604c0d8346a9ea0f57045a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74375cd2c8a64bbcb8ce7fdbc8b5f486_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80caeb9df5f44f8e9df282ee72186142_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d9f4b34db394927811febbebe7ee4a3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f6595d3666d4c0da7ef44540cc8c105_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21443e8563474055949c856249beb800_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fa655ae1882424ea70d7f3ba47275d5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic552471d830f40178487f9d46cbfe905_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb89b6585f024b53831de5e9407a4e25_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b1b978c4e7e4c51afcf56c572945237_D20200131-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-31</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61f2dde936ae43d5bc9eae7e34c66670_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb9e70228f484fc4a8a0c0a8c7d593b1_D20200131-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-31</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafc8add9248145199d7b4082ecba51b7_D20200131-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-31</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib256fcf2733e48fca730f3e92edbe1f6_I20200201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="idf2cb7e7d89e49ce95ca0662113be912_D20200117-20200117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-17</xbrli:startDate><xbrli:endDate>2020-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>arqt:segment</xbrli:measure></xbrli:unit><xbrli:context id="i1a9f8349a2ae4825872a95b128a3bfb7_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f576810c09241ed87b2a09e63227467_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i414921aba8984cb389a45a1e86d315ae_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibec66f62c1084ad691104a439aff6c7e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i270ae80ae8b042ce9201e7cc23f7ee58_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c8b8d5bfcec459fa278a039725bb9d9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c16b74ba53841fda7d28ab193530c1c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i543cf22b19c54a4a8b70297fbbf4dcce_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifff112eac82649f6b53d94ba1b504889_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife0a9b0f7f7b4864aebd29e91d92b75e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b5c3e06ddd5402c951cce1ad44ad6a3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic43770461fb141d1a3a708ae92c38e75_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03cc7f0a6da847ba8562f6f1fa69ad0f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic253eb34e85e4ebebda2388a08544c3e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id45d766b5bb440b8923015575e77b394_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i373b85f92fe343ac855524ea8acaff14_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae9ee5c735cf46908b0fabb85992ffc9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a1e096ff7d341be8c45b814509791ef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c56f67dfa884523897775d41e68872d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e5b4edc8170451689fbada6c48b86ed_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic86821562d79485eacbc135601a1eb43_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5950ca979d8342e2995ee8e69c309187_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib206c2db943b4ae485f8d863d2ee1318_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e5368a4e5b94d8cbc7278e0fef5cad3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafb6adcdf1a44ac9987418eaf92a8522_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0181ffefb7fd484bacde0b9b979a5d5b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib465f2fbb252499b9bc7fb53a1bf2efe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97d79ac716284e1a9866aca1e609b683_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45c31d7adba348da80a2ab2d537cf9e2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04008b35dd9c4edaa1167973c3f9f16a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9d55de80fa540a5b40168170c29f746_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb249010b3884d319f1f8408c75f9f32_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5360332e67b7489285d42523d9c524f4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b7f744e5e864a09ae29d5de55ad4859_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5df7418441b428c98e1af09b1d8f5f6_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64e39f6e0ee9449382ec819a3c86939a_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadbd597452bd467786da57f5e4d20c05_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27af3865d5bb4f39839b5fb35d6b8164_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9fd3340448d4bc7b2df04030b621bf3_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HengruiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cb916c47d6d4499899eba1d8e7cc49f_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HengruiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i624daddb81734c7dbdc63c375018d9a7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HengruiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d73b12f38b44b0fb374429942edff05_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HawkeyeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ba628de89d3418daf6fc6a0e95c1598_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arqt:HawkeyeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i764c4c795726470f9f77ab82e0e24792_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HawkeyeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8fd13a77a64486f820343c9c46cc851_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HawkeyeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a342eb6a9914eefbcddc6ecd7e9a425_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HawkeyeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="facility"><xbrli:measure>arqt:facility</xbrli:measure></xbrli:unit><xbrli:context id="i9ded77bb950b4e049558439a9f0bf11d_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d311753e065465a809d1745e3b2d439_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b476add02454015a5731c133e6fc7d7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e66cc37420547df82c325e4bd66ee97_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad26b06911dd45ed94719ead6186feb7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1062618a24794d61acad0065c0f8c0b6_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ffb101d690c48ea9f6c1d9b6bb0766a_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53f18004827140e6b2a5880ba03e14cd_D20180901-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20520734ab804d1c969a5f694d1a77fb_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i942ea4487a4f4c628dbc72aa9142bb0b_D20170401-20170430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2017-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27b66ebff3c74dffbed70e3df8d94527_I20170430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>arqt:tranche</xbrli:measure></xbrli:unit><xbrli:context id="ia747c28018db42518e5a81eb98a4730a_D20170401-20170430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2017-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic429b8e3655e404cb0d751419b0af0f5_D20170401-20170430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:StockPurchaseAgreementTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2017-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa626818057b4ec09c7780eda24ee280_I20170430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida7d99ff74274d4bb97416ec9c8ce692_D20170401-20170430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:StockPurchaseAgreementTranchesTwoAndThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2017-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad794190a8a2452ea081cd173d9a46c3_I20170430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:StockPurchaseAgreementTranchesTwoAndThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18c87385f652426f9c3d56028cd4c845_D20170401-20170430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:StockPurchaseAgreementTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2017-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d9f11fde515494ebe9f46b322624540_D20170401-20170430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:StockPurchaseAgreementTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2017-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i867ead9d7de94ae2b7a3e1230d8c1445_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:StockPurchaseAgreementTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61291be8ab45405ba6ff41986ea2bbf9_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:StockPurchaseAgreementTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dd4a2ea8e4e424cad9bf90013a09f85_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i152ee54c83c44c9c86787fc4619f617a_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:StockPurchaseAgreementTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>arqt:vote</xbrli:measure></xbrli:unit><xbrli:context id="i7b0f602239da479bbb94f0b7c7888beb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0cb10ec032b42cca2753ec0e703a0a9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i207e672bf24642c4940bf0d793c0d8ad_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a758e1969d84f21965d253803feda4d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c825f7e0bd049b3873b9f06a243c9cc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:StockAwardsFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10726fed81d54f6ab986a0927852ce81_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:StockAwardsFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia583a93b899d4da9a404725241db7368_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9c67f350dc54f669cff5762e4c650f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41086ad648ca4627b4da6abb4a3801d2_I20200204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b0b464dfc864b54803e7d3f742e0da3_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i547d9f383e9b4debbdbb809301a8f689_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b305cb4d63342bea9f25125973619f8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e6455e64ac24ad4b0b835c47c9e7d60_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idadd6a2a73da44689130341aaab4e04a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99319e5db9304bce8368150c3126f923_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i729f8784fd4e49eba8ee589ee7ffb428_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic428fc4a3f5544cdb4cd99f3463113b0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0baf33cc0dc243f780ad057920f62292_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ec1cf8ff84648708b4c86b19e7f6130_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36f41495899d443b9ef4ab7d9ca80854_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4ad05013c344f86873c31d6f40cb48b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60fc0bcc4f7e43c9b071698d2cab142b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79205ea8bd33408992b1551901172816_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i330111f8ba794d7fae3926a5518de13b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i032684c2259b4403a7e8ab7dc81e250c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4b3c7b09a81456aa8c7c67220c1937a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf1aac6536334060af468f8eeb2e8eb9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36e62b08be8541cfb10cebab50e8f747_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c280cdb092b45edb7e2214f3ed3cebe_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:ServiceConditionRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bbb52f6091c4868b5b32ba40fc51240_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:PerformanceConditionRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f0bea76e3b04ffcb5683a3e920f6fb6_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:ServiceConditionRestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5403a39d9824c61b323a823a99f5bd8_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:ServiceConditionRestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id48658e6817e4f45934cd7313bbee944_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:PerformanceConditionRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30fec8c2358b4835911058e60fbd15e1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:ServiceConditionRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i923788d1801d4b67b74f8a5857599515_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:ServiceConditionRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie85017a9a46f4ab9a78c0cc301027ce2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:ServiceConditionRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia32c63d0cf494637ad7c5a2bccd2b22f_D20200131-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-31</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae37041cedde4d51858dc7cf3548eb6d_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7383296af1344aea9cce30492f252802_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icefe4f59d74b498eb9f973315e31aaec_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e60ec54b5354f6d99fb37ca976d041f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99939ac91f9f4fa590b1fa4017ae602b_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc6873c2e10d441d9cc0b8acba203bb7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ddaa5b1d44a4fab8efeb9d63d3c55d8_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03053d48c20241778d8e2cfc418e60ae_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">arqt:EarlyExercisedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf2d176bc07e46b8a8d5d35b4960c50d_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">arqt:EarlyExercisedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i213a41c41500492487811d690788ac4f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6465c3a5b5c4daf823adc5f743d64b4_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ef81aa3fd074f2f9ad3100002a964f9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i875d6445002045038d95abd268509dc1_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i5d533bf2a9414af8876f332d4c35941e_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="arqt:LeaseDescriptionAxis">arqt:WestlakeVillageCaliforniaLeaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b84137f69724a55827a9c4614fa776b_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787306</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="arqt:LeaseDescriptionAxis">arqt:WestlakeVillageCaliforniaLeaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_1"></div><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:15.5pt;font-weight:700;line-height:115%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:15.5pt;font-weight:700;line-height:115%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Washington, D.C. 20549</span></div><div style="text-align:center;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.666%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.666%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.335%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:16pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:16pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6ZjM4NTA2MGViY2MxNGFmNmIwNDdhYzE5MDg5ODExNDIvdGFibGVyYW5nZTpmMzg1MDYwZWJjYzE0YWY2YjA0N2FjMTkwODk4MTE0Ml8wLTEtMS0xLTE1OTU_9b0a989d-5cbe-41c5-bbb4-1ad6e15f627e">10-Q</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:-45pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;">(Mark One)</span></div><div style="text-indent:-18pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjAw_237dadb8-f045-470a-8106-7dbb155a8519">&#9746;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;">   </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:-18pt;text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;">For the quarterly period ended <ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF82NTk3MDY5NzcwOTAx_76b26999-01a6-44ec-af9a-890adaf574d4">March 31, 2020</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;">OR</span></div><div style="text-indent:-18pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjA2_82a84d4d-025c-41ee-8d42-cbfeee2e56e2">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;">For transition period from </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration: underline;">       </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;"> to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration: underline;">       </span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;"> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:122%;">Commission File Number: <ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjA3_994207ca-af55-498f-8c88-97151b87087e">001-39186</ix:nonNumeric></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.334%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:115%;"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MTdiYTQwZTM0MjE0NGMzNWJiZTRhNWJlMWZjY2VkM2YvdGFibGVyYW5nZToxN2JhNDBlMzQyMTQ0YzM1YmJlNGE1YmUxZmNjZWQzZl8xLTAtMS0xLTE4NzMvdGV4dHJlZ2lvbjo4ODk2OTMwM2E0NGQ0YzVhYTg3ODA0MDAxZDEwNzNjNl80OTQ3ODAyMzI1MTA5_aac12579-1603-4fed-ba54-f198bf823176">ARCUTIS BIOTHERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-indent:127.95pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;">(Exact name of registrant as specified in its charter)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MzhkNTI2ODc3MDYxNDkzMjkyZmEyZjkzYmE1ZWU1NTcvdGFibGVyYW5nZTozOGQ1MjY4NzcwNjE0OTMyOTJmYTJmOTNiYTVlZTU1N18wLTAtMS0xLTE4NzYvdGV4dHJlZ2lvbjo1OTQ4ZTdjMmFiY2E0NTAzYTdjNDRjODY2ZGYzNGYwMl80OTQ3ODAyMzI1MDc1_f879f26c-1e21-4b50-aa79-61fd1f1c05a1">Delaware</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">(State or Other Jurisdiction of Incorporation or Organization)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MzhkNTI2ODc3MDYxNDkzMjkyZmEyZjkzYmE1ZWU1NTcvdGFibGVyYW5nZTozOGQ1MjY4NzcwNjE0OTMyOTJmYTJmOTNiYTVlZTU1N18wLTEtMS0xLTE4NzkvdGV4dHJlZ2lvbjo4YWY1N2E0NDBhNjQ0NDFmYjAxNDYxZGM3NWQ2MmY3Nl80OTQ3ODAyMzI1MTE2_856f7e49-a6f3-40f2-82a6-39b77d1ce57f">81-2974255</ix:nonNumeric></span></div><div style="text-indent:9.05pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;">(I.R.S. Employer Identification Number)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:0.15pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MzhkNTI2ODc3MDYxNDkzMjkyZmEyZjkzYmE1ZWU1NTcvdGFibGVyYW5nZTozOGQ1MjY4NzcwNjE0OTMyOTJmYTJmOTNiYTVlZTU1N18xLTAtMS0xLTE4ODIvdGV4dHJlZ2lvbjozZWNiMmRmMjU2MGU0ODNhYmY4ZTdjNTYwZTNhNzFhZl80OTQ3ODAyMzI1MTI3_eb57d2b8-b786-47fa-a26d-09628324f82a">2945 Townsgate Road</ix:nonNumeric> <ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MzhkNTI2ODc3MDYxNDkzMjkyZmEyZjkzYmE1ZWU1NTcvdGFibGVyYW5nZTozOGQ1MjY4NzcwNjE0OTMyOTJmYTJmOTNiYTVlZTU1N18xLTAtMS0xLTE4ODIvdGV4dHJlZ2lvbjozZWNiMmRmMjU2MGU0ODNhYmY4ZTdjNTYwZTNhNzFhZl82NTk3MDY5NzY2ODQy_1ae8212d-51fb-4185-9ae4-569fa4683093">Suite 110</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MzhkNTI2ODc3MDYxNDkzMjkyZmEyZjkzYmE1ZWU1NTcvdGFibGVyYW5nZTozOGQ1MjY4NzcwNjE0OTMyOTJmYTJmOTNiYTVlZTU1N18xLTAtMS0xLTE4ODIvdGV4dHJlZ2lvbjozZWNiMmRmMjU2MGU0ODNhYmY4ZTdjNTYwZTNhNzFhZl80OTQ3ODAyMzI1MTQ1_58dc927f-64ae-4ff7-af98-e22fe98708f8">Westlake Village</ix:nonNumeric>, <ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MzhkNTI2ODc3MDYxNDkzMjkyZmEyZjkzYmE1ZWU1NTcvdGFibGVyYW5nZTozOGQ1MjY4NzcwNjE0OTMyOTJmYTJmOTNiYTVlZTU1N18xLTAtMS0xLTE4ODIvdGV4dHJlZ2lvbjozZWNiMmRmMjU2MGU0ODNhYmY4ZTdjNTYwZTNhNzFhZl80OTQ3ODAyMzI1MTU3_2c7e5f17-a467-4834-bb43-2a538763f02c">California</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MzhkNTI2ODc3MDYxNDkzMjkyZmEyZjkzYmE1ZWU1NTcvdGFibGVyYW5nZTozOGQ1MjY4NzcwNjE0OTMyOTJmYTJmOTNiYTVlZTU1N18xLTEtMS0xLTE4OTEvdGV4dHJlZ2lvbjoyZjRkZWY4ZDZjYTU0M2Q1YmY0NzQ0ZDhhNzRiNzg1MF80OTQ3ODAyMzI1MDE3_cf4dee58-816d-4288-aab8-1a3ae044105b">91361</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">(Zip Code)</span></div></td></tr></table></div><div style="text-indent:0.15pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;">(<ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjA5_1f82b212-ab83-401a-8b92-9a8cbab35b2d">805</ix:nonNumeric>) <ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjEz_b0d02d2d-60ab-48b1-8026-5f62f86b7876">418-5006</ix:nonNumeric></span></div><div style="text-indent:0.2pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;">(Registrant's telephone number, including area code)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:38.058%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.883%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.059%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Title of each class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Trading Symbol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MGQyN2Y4YWRjN2MwNDBiZmFmYWFhNjc1MTRkZjZkY2QvdGFibGVyYW5nZTowZDI3ZjhhZGM3YzA0MGJmYWZhYWE2NzUxNGRmNmRjZF8xLTAtMS0xLTE4NjY_a8a9af85-6efd-4ae0-b9c4-6314b2238558">Common Stock, par value $0.0001</ix:nonNumeric> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MGQyN2Y4YWRjN2MwNDBiZmFmYWFhNjc1MTRkZjZkY2QvdGFibGVyYW5nZTowZDI3ZjhhZGM3YzA0MGJmYWZhYWE2NzUxNGRmNmRjZF8xLTEtMS0xLTE4Njg_d07508ec-4477-4055-8de4-1a0226e2fbc1">ARQT</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MGQyN2Y4YWRjN2MwNDBiZmFmYWFhNjc1MTRkZjZkY2QvdGFibGVyYW5nZTowZDI3ZjhhZGM3YzA0MGJmYWZhYWE2NzUxNGRmNmRjZF8xLTItMS0xLTE4NzA_799f309d-2364-4c7c-9e8b-631176d10c9c">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;">&#9744;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;"> <ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjE5_fa8688a5-10c6-401f-91be-9251aecdbe86">No</ix:nonNumeric> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;">&#9746;</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). <ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjIw_ba9e73c1-78da-4b3b-8298-42aa4c88554e">Yes</ix:nonNumeric> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;"> No </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;">&#9744;</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Act.</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.656%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.656%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.697%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.658%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Large accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6ZDNhMmRmOGRiMzljNDA4ZmEzOGRhZjc4MjQ4MjExM2IvdGFibGVyYW5nZTpkM2EyZGY4ZGIzOWM0MDhmYTM4ZGFmNzgyNDgyMTEzYl8xLTAtMS0xLTE5MDM_b407595b-e30f-4107-9b8a-4e21decdca1a">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller reporting company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6ZDNhMmRmOGRiMzljNDA4ZmEzOGRhZjc4MjQ4MjExM2IvdGFibGVyYW5nZTpkM2EyZGY4ZGIzOWM0MDhmYTM4ZGFmNzgyNDgyMTEzYl8xLTQtMS0xLTE5MTA_52fe1ea8-f84c-4fd0-96cc-5955e2e1aa33">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6ZDNhMmRmOGRiMzljNDA4ZmEzOGRhZjc4MjQ4MjExM2IvdGFibGVyYW5nZTpkM2EyZGY4ZGIzOWM0MDhmYTM4ZGFmNzgyNDgyMTEzYl8yLTEtMS0xLTE5MTI_d1eda50b-7965-4929-8295-2f16c40c6624">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:108%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:108%;"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjE1_f8c1d40a-2314-4763-b18c-7b41bcb3b48b">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjE4_da7857c1-e469-402b-aaee-cf918ffa7b36">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;"> No </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#9746;</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;">The number of shares of the registrant&#8217;s Common Stock outstanding as of May&#160;1, 2020 was <ix:nonFraction unitRef="shares" contextRef="i45ee5cbaa43a4c1b946d00944fd45974_I20200501" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF8xNjQ5MjY3NDQ1Nzk5_66659eae-7942-4eda-b019-3e5d166425d1">38,154,550</ix:nonFraction>.</span></div><div style="text-indent:127.9pt;text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:15.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_7"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INDEX</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:77.882%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.371%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_106">PART I</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_106">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_112">Item 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_112">Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_112">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_118">Condensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_118">Balance Sheets</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_118">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_124">Statements of </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_124">C</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_124">ondensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_124">Operations and Comprehensive Loss </a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_124">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_127">Statements of </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_127">Condensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_127">Convertible Preferred Stock and Stockholders&#8217; </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_127">Equity (</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_127">Deficit</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_127">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_130">Statements of </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_130">Condensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_130">Cash Flows</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_130">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_136">Notes to </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_136">Unaudited Condensed</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_136"> Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_136">4</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_46">Item 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_46">21</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_70">Item 3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_70">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_70">30</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_79">Item 4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_79">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_79">30</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_13">PART II</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_13">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_28">Item 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_28">31</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_19">Item 1A.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_19">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_19">31</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_37">Item </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_37">2</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_37">.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_37">Unregistered </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_37">Sales of Eq</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_37">uity Securities and U</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_37">se of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_37">76</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_1640">Item 3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_1640">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_1640">76</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_1630">Item </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_1630">4</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_1630">.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_1630">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_1630">76</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_82">Item </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_82">5</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_82">.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_82">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_82">76</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_109">Item </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_109">6</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_109">.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_109">Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_109">76</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_178">Signatures</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_106"></div><hr style="page-break-after:always"/><div style="height:63pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I. FINANCIAL INFORMATION</span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_112"></div><div style="padding-right:49.54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1. Financial Statements</span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_118"></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Balance Sheets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share and par value</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:73.877%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.698%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzQtMS0xLTEtMA_92bd9f88-55bd-4571-9787-8ac3fd683145">190,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzQtMy0xLTEtMA_eeaff5c4-795e-4530-9bd0-af7bb2398de9">63,336</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzUtMS0xLTEtMA_0050a9d0-1869-4eb4-b9af-27f649e83b7a">58,426</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzUtMy0xLTEtMA_39478ae2-3218-45f4-82a6-3c7232824a9f">37,929</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzYtMS0xLTEtMA_479b0e5b-d9b4-4532-a394-8a4ddc592f56">4,559</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzYtMy0xLTEtMA_1c545d10-ac7c-4525-b6b3-fcc1a476b735">5,209</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzctMS0xLTEtMA_9c7496dd-59a3-4a9f-b629-1023394fd55d">253,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzctMy0xLTEtMA_b94633ea-3947-4a14-a3d3-a047640b1451">106,474</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, plant, and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzgtMS0xLTEtMA_67b7648a-9b79-4876-bac2-6cfa755221c8">241</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzgtMy0xLTEtMA_b147d080-f5e2-420c-8275-0855ae7d5e74">227</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzktMS0xLTEtMA_5cce13e3-b97d-4111-9538-7054b6f16da0">226</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzktMy0xLTEtMA_af8a5f70-0438-40ce-8245-19d25203c2d9">264</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzEwLTEtMS0xLTA_cebe5291-7a27-4f5e-ae68-7260e977a6e1">47</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzEwLTMtMS0xLTA_93efda85-6ae7-4937-8cbe-142289ef2ba5">47</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzExLTEtMS0xLTA_a831ae94-a1b6-4495-89eb-f29c613a7ff8">254,392</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzExLTMtMS0xLTA_d8bf5f75-518d-4d5f-8ae2-56be0f332506">107,012</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE0LTEtMS0xLTA_e1a43353-6cd3-47d5-af2a-fff5b45b06bb">4,759</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE0LTMtMS0xLTA_b42fd4f0-c10c-4295-9058-f255d933782a">1,405</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE1LTEtMS0xLTA_3ad50584-ee41-4d69-8d80-d9082844e4b8">7,281</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE1LTMtMS0xLTA_ada81692-4e3a-463c-92a7-9d393027aa1b">3,654</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE2LTEtMS0xLTA_99d2f304-2582-42f6-8038-e78c8d54c7bc">182</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE2LTMtMS0xLTA_29fa21b5-abf9-41da-a13b-285cdad6079a">178</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE3LTEtMS0xLTA_90dcedc8-1e16-4c16-9245-1a4077b9527b">12,222</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE3LTMtMS0xLTA_53178593-9058-4cba-a7ac-a84bdce90050">5,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability, noncurrent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE4LTEtMS0xLTA_0ee20a38-b2f1-4133-b378-2599a35c3175">82</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE4LTMtMS0xLTA_38b86718-63d3-4453-b54f-c61da570c2c2">129</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE5LTEtMS0xLTA_d70f2cdb-3a17-497b-b715-d16de39e7eaf">206</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE5LTMtMS0xLTA_83a35b22-bc3d-4d0b-9dd9-e2a1e7038699">184</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIwLTEtMS0xLTA_8035842e-06e9-43b7-bc70-0d49986b6bb2">12,510</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIwLTMtMS0xLTA_e907603b-7d10-4c59-81f5-af1f5f456e43">5,550</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies (Note 6)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTEtMS0xLTE2MjA_98da0210-30f4-4ec0-a65a-1652e286ac85"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTMtMS0xLTE2MjA_fa3151b5-68f1-4474-965b-7439383df62d"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NmI1MGE3NTMzZjY0NzJmOWI1ZmIyMmU0NTY5NzVhYV8xNjQ5MjY3NDQxODk5_21b7c539-4a2b-47c4-985f-e43725c0b68e"><ix:nonFraction unitRef="usdPerShare" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NmI1MGE3NTMzZjY0NzJmOWI1ZmIyMmU0NTY5NzVhYV8xNjQ5MjY3NDQxODk5_fb57a25b-aac2-4f2f-9a12-9cdf7f93daf4">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NmI1MGE3NTMzZjY0NzJmOWI1ZmIyMmU0NTY5NzVhYV8xNjQ5MjY3NDQyOTQx_1625fb10-c75f-46c5-9e94-755d6d9ae70c">no</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NmI1MGE3NTMzZjY0NzJmOWI1ZmIyMmU0NTY5NzVhYV8xNjQ5MjY3NDQxOTE3_83bfa265-8ef6-41a8-b9ba-ae4d8b7236a9">48,787,898</ix:nonFraction> shares authorized at March 31, 2020 and December&#160;31, 2019, respectively;  <ix:nonFraction unitRef="shares" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NmI1MGE3NTMzZjY0NzJmOWI1ZmIyMmU0NTY5NzVhYV8yMTk5MDIzMjU2NTYx_22c66e81-6bc2-4f1c-9dcd-dbff38bd5720"><ix:nonFraction unitRef="shares" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NmI1MGE3NTMzZjY0NzJmOWI1ZmIyMmU0NTY5NzVhYV8yMTk5MDIzMjU2NTYx_2dade523-0799-4658-9c90-c1a5f9d16831">no</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NmI1MGE3NTMzZjY0NzJmOWI1ZmIyMmU0NTY5NzVhYV80OTQ3ODAyMzI1MjYz_6c30f385-aeed-44fe-8aa6-d66c4f5c54b2"><ix:nonFraction unitRef="shares" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NmI1MGE3NTMzZjY0NzJmOWI1ZmIyMmU0NTY5NzVhYV80OTQ3ODAyMzI1MjYz_e120cc6a-7751-4c0d-8f8b-eb420d97c522">24,385,388</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTEtMS0xLTA_4af4aad3-d95b-4db9-b8fc-2e9b2e14fcec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTMtMS0xLTA_f2bea1be-c202-426f-9d6d-ebb51fa57655">166,491</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders&#8217; equity (deficit):</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTAtMS0xLTc4MzUvdGV4dHJlZ2lvbjoyYjhiNzI1YjM0OGY0MjI5OGE3ZGJmMTA4NzI4YmQ4ZF8xNjQ5MjY3NDQxODc1_9232a070-72ee-4963-bf71-a03ce214b52f"><ix:nonFraction unitRef="usdPerShare" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTAtMS0xLTc4MzUvdGV4dHJlZ2lvbjoyYjhiNzI1YjM0OGY0MjI5OGE3ZGJmMTA4NzI4YmQ4ZF8xNjQ5MjY3NDQxODc1_a589da5a-4202-4a5d-9312-84dee826cb5e">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTAtMS0xLTc4MzUvdGV4dHJlZ2lvbjoyYjhiNzI1YjM0OGY0MjI5OGE3ZGJmMTA4NzI4YmQ4ZF8xNjQ5MjY3NDQxODk1_bc17a2da-ded1-48b0-9312-cb51a8669def">10,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTAtMS0xLTc4MzUvdGV4dHJlZ2lvbjoyYjhiNzI1YjM0OGY0MjI5OGE3ZGJmMTA4NzI4YmQ4ZF8xNjQ5MjY3NDQxOTIx_3d19dbf2-fe43-4947-9ecd-fd4ad0475446">no</ix:nonFraction> shares authorized at March 31, 2020 and December 31, 2019, respectively; <ix:nonFraction unitRef="shares" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTAtMS0xLTc4MzUvdGV4dHJlZ2lvbjoyYjhiNzI1YjM0OGY0MjI5OGE3ZGJmMTA4NzI4YmQ4ZF8xNjQ5MjY3NDQxOTMy_02be0d22-7c3a-4be0-b811-3bbf4308685b"><ix:nonFraction unitRef="shares" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTAtMS0xLTc4MzUvdGV4dHJlZ2lvbjoyYjhiNzI1YjM0OGY0MjI5OGE3ZGJmMTA4NzI4YmQ4ZF8xNjQ5MjY3NDQxOTMy_36992631-1951-4905-9093-f2dc296ffa0d"><ix:nonFraction unitRef="shares" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTAtMS0xLTc4MzUvdGV4dHJlZ2lvbjoyYjhiNzI1YjM0OGY0MjI5OGE3ZGJmMTA4NzI4YmQ4ZF8xNjQ5MjY3NDQxOTMy_669da65b-caf0-4bda-ace3-dc42810fdf62"><ix:nonFraction unitRef="shares" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTAtMS0xLTc4MzUvdGV4dHJlZ2lvbjoyYjhiNzI1YjM0OGY0MjI5OGE3ZGJmMTA4NzI4YmQ4ZF8xNjQ5MjY3NDQxOTMy_a182821e-b8cf-46e2-b574-ac7aa1911410">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2020 and December 31, 2019;</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTEtMS0xLTc4Njc_d65ddec2-7825-4da1-b953-92a4446e3b77">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTMtMS0xLTc4Njk_257a58f9-46a6-4113-a44e-f220a2df1fe1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMTc4MmJhNTMyMDM0YmVkYjJiNmNjN2E0ZTJkY2NmMl80OTQ3ODAyMzI1MzA4_1fba9eef-4f69-4c8f-ab27-7f83461fb2a4"><ix:nonFraction unitRef="usdPerShare" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMTc4MmJhNTMyMDM0YmVkYjJiNmNjN2E0ZTJkY2NmMl80OTQ3ODAyMzI1MzA4_9fded890-3db8-419d-ab92-ab5f95c548c0">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMTc4MmJhNTMyMDM0YmVkYjJiNmNjN2E0ZTJkY2NmMl8xNjQ5MjY3NDQyMDUz_0e7d22fb-d8eb-4f48-bbb9-81d7499c2a87">300,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMTc4MmJhNTMyMDM0YmVkYjJiNmNjN2E0ZTJkY2NmMl80OTQ3ODAyMzI1MzIw_e786f420-0fb7-4cbe-9064-51617409c2c3">65,820,000</ix:nonFraction> shares authorized at March 31, 2020 and December&#160;31, 2019, respectively; <ix:nonFraction unitRef="shares" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMTc4MmJhNTMyMDM0YmVkYjJiNmNjN2E0ZTJkY2NmMl80OTQ3ODAyMzI1MzQy_2a50310b-742f-4dc5-b83d-c7de4e3bb35f">38,154,550</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMTc4MmJhNTMyMDM0YmVkYjJiNmNjN2E0ZTJkY2NmMl80OTQ3ODAyMzI1MzM3_a628ea7d-7f68-4c07-bb65-6cec55cbb896">2,879,763</ix:nonFraction> shares issued at March 31, 2020 and December&#160;31, 2019, respectively; <ix:nonFraction unitRef="shares" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMTc4MmJhNTMyMDM0YmVkYjJiNmNjN2E0ZTJkY2NmMl80OTQ3ODAyMzI1MzU5_d979f421-5663-4ae4-9da2-97e7ef920223">37,471,997</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMTc4MmJhNTMyMDM0YmVkYjJiNmNjN2E0ZTJkY2NmMl80OTQ3ODAyMzI1MzUz_56381985-9b7b-412c-8490-c4d788d5e6d1">2,120,853</ix:nonFraction> shares outstanding at March 31, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTEtMS0xLTA_61aba347-cd1d-4f74-8367-590536236e02">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTMtMS0xLTA_a921a43c-d0ed-4dab-8f0a-89bb02821cc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTEtMS0xLTA_d95c870e-562a-413b-92a4-1247faa41325">336,145</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTMtMS0xLTA_000b4a1c-774c-4927-93b0-9f6fa8bc9672">1,244</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI2LTEtMS0xLTA_a0b98bbe-bd3b-49ba-8d04-5bed185d2b6b">19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI2LTMtMS0xLTA_2611384b-b863-47db-81bf-81c188a44a44">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI3LTEtMS0xLTA_134c15f3-eee4-4dc7-820a-a85e1e60ce4e">94,285</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI3LTMtMS0xLTA_863d0569-cc3e-4543-a046-682f13b7f4c9">66,272</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders&#8217; equity (deficit)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI4LTEtMS0xLTA_d33cfab6-c9b6-4ee3-9046-71ed05c74e7d">241,882</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI4LTMtMS0xLTA_00bd8468-5cf6-41ed-a891-68a246a37fd4">65,029</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI5LTEtMS0xLTA_ef9aaa33-d811-4d1c-ad1a-2a2c770bcc4a">254,392</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI5LTMtMS0xLTA_aef5e7ed-704d-4553-95b4-975841578ee6">107,012</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed financial statements.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_124"></div><hr style="page-break-after:always"/><div style="height:63pt;width:100%;"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:9pt;"><span><br/></span></div><div style="margin-top:18pt;"><span><br/></span></div></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share and per share data</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:71.753%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.756%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.758%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzMtMS0xLTEtMA_a801d95d-f56c-428d-b076-3bf5fea3d516">25,182</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzMtMy0xLTEtMA_42b39d56-4379-4887-8d3c-ebaff4adec49">6,203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzQtMS0xLTEtMA_167038a9-eeae-4163-a702-3cbc8a3965d0">3,469</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzQtMy0xLTEtMA_400006ed-8cd5-45fe-aa5d-9ec9d5bc12cc">749</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:29.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total operating expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzUtMS0xLTEtMA_d71e1f8f-1029-4953-9850-f39845f4c6d6">28,651</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzUtMy0xLTEtMA_57f17d61-8342-48b6-9ab9-e9316d67b656">6,952</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Loss from operations</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzYtMS0xLTEtMA_e51c63fc-3829-437f-9985-e2d1e34f6469">28,651</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzYtMy0xLTEtMA_1e8f70e3-7c9a-4b33-aca7-8a6bf9b0276e">6,952</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzctMS0xLTEtMA_8b18be2c-2d5a-4545-9468-b6e532d34244">638</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzctMy0xLTEtMA_c8aea642-12cc-4bc9-9106-d6c95d644444">294</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzgtMS0xLTEtMA_c7a52ace-4c15-4338-bc41-e7ddbf338f1b">28,013</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzgtMy0xLTEtMA_05c31c2c-889f-43b8-b04a-b988c590f30b">6,658</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain on marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzEwLTEtMS0xLTA_f4044ba9-cab8-4f13-93c3-b116e170c0d3">20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzEwLTMtMS0xLTA_9ed55771-21f8-4cd4-9091-cefd651fa776">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzExLTEtMS0xLTA_a8f81aa9-f2af-45b4-b99a-6e69f6734fe9">27,993</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzExLTMtMS0xLTA_03ed7da0-b062-4811-8ff0-e7abe43f36ca">6,657</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Per share information:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss per share, basic and diluted</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzEzLTEtMS0xLTA_0c0a429d-eb7d-4de7-83f2-332f64dfe2bc">1.15</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzEzLTMtMS0xLTA_871382db-06f5-4a90-bf8d-7ccd61a6a4a4">4.08</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares used in computing net loss per share, basic and diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzE0LTEtMS0xLTA_2e24ed0a-a51e-46d9-bb74-b602ba385c95">24,256,402</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzE0LTMtMS0xLTA_26b4ff3b-fe7a-439f-8493-270c03e69d5b">1,632,694</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed financial statements.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 2</span></div></div></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_127"></div><hr style="page-break-after:always"/><div style="height:54pt;width:100%;"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:9pt;"><span><br/></span></div><div style="margin-top:18pt;"><span><br/></span></div></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share data)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:21.778%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.460%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.328%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.328%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.460%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.460%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.328%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.328%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.460%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.520%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible<br/>Preferred Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Stockholders&#8217; Equity (Deficit)</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance&#8212;December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i68dfa5b4689849b9a3cd771af6075ca9_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzItMS0xLTEtMA_acea6dab-a590-452f-9713-71ad6444f6f5">16,262,425</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i68dfa5b4689849b9a3cd771af6075ca9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzItMy0xLTEtMA_cd125f29-31d2-4f99-a331-6610f0e6a938">72,252</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1ccb7f8264e14d269a33e7f94a0411d7_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzItNS0xLTEtMA_89a5d598-cd25-4741-a2df-91c2a9e8e467">1,557,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1ccb7f8264e14d269a33e7f94a0411d7_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzItNy0xLTEtMA_8b15fcbc-b69b-44ac-aaaf-ea9de396bd3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i004b33aa7ef84638a508f80804c3e4d6_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzItOS0xLTEtMA_88fd821a-f2f1-47fa-8a45-f06b626ddf70">289</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58223e1e92e7484da16c8646830a5178_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzItMTEtMS0xLTA_28fb37fd-a01d-4810-ac7f-08410cbe5c76">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib3bef4868bf94e0b8bcd68b0c08ee9c3_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzItMTMtMS0xLTA_a377d751-da6f-4b75-af5a-230f40ffe99c">24,276</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i68dfa5b4689849b9a3cd771af6075ca9_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzItMTUtMS0xLTA_753da9d8-beef-4c06-b57e-9c2c6eb664e3">23,987</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vesting of founder shares subject to repurchase</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic3d98141ace44b3d91fa1e2bd76e3378_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="arqt:StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzMtNS0xLTEtMA_6456accc-a5fa-4eb6-8bea-9045658ad437">68,931</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="arqt:StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzMtMTUtMS0xLTA_105aee4c-ee11-4ebc-a197-cb31be848ce5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lapse of repurchase rights related to common stock issued pursuant to early exercises</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic3d98141ace44b3d91fa1e2bd76e3378_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzQtNS0xLTEtMA_a3df24fc-44cc-4ed4-b522-3baabfcc5a9f">65,868</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibbbb627a865342c3a3c8ca55197e411c_D20190101-20190331" decimals="-3" name="arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzQtOS0xLTEtMA_75347866-aa47-40c3-87cd-d40ed9cd48d7">29</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" name="arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzQtMTUtMS0xLTA_0e620331-1f3e-4b20-a2a2-18634fad5dee">29</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibbbb627a865342c3a3c8ca55197e411c_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzUtOS0xLTEtMA_a8c1829c-f14e-4da4-a162-0da5ffbbb3cf">76</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzUtMTUtMS0xLTA_aceb1700-4cd5-4729-b46a-5807d2d8d4ea">76</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain on short term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id40bc8ee44ed48b9b00785b5733d49e4_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzYtMTEtMS0xLTA_50317093-a97e-4916-8be2-f22a125d0c8c">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzYtMTUtMS0xLTA_bb0b3d5f-5a7b-40c3-bff4-a1366b5ede82">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0cd5d9c6ed8543fbae65bfb9bf35030d_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzctMTMtMS0xLTA_8e4c47c5-24d8-44c0-ba99-d2d408542e2e">6,658</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzctMTUtMS0xLTA_8ab8f859-18ae-4e0e-ad30-92438217ec1d">6,658</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance&#8212;March 31, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic5c62122ea184197a8cbcd8fac509f93_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzgtMS0xLTEtMA_c1d155f6-a747-4ba3-bfb8-d102c001ffe4">16,262,425</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic5c62122ea184197a8cbcd8fac509f93_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzgtMy0xLTEtMA_2aa4ed45-8750-48b3-97fd-7841e1b7bc05">72,252</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2d4d2679b1f24ea4bbc79894014b1394_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzgtNS0xLTEtMA_34387937-8ead-4f81-95b2-b2a72fbb16d3">1,692,699</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2d4d2679b1f24ea4bbc79894014b1394_I20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzgtNy0xLTEtMA_6d1f997f-d4ba-400d-b1df-f6b8b0775cad">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i91f2e456e7ee436697728b99c6737875_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzgtOS0xLTEtMA_a8ccb2cb-e967-471b-9f26-5e31966ce333">394</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf934a45ca7144f39a0071e59f9cc564_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzgtMTEtMS0xLTA_cee096e6-b484-45ce-b5e2-5fc14b8f3c96">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6be9162e0bdc434cae7c672714f4e731_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzgtMTMtMS0xLTA_d7c3b66f-28c8-450a-8968-44d14c313bbe">30,934</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic5c62122ea184197a8cbcd8fac509f93_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzgtMTUtMS0xLTA_f19fece9-934a-41ce-b621-59c8f4328293">30,539</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:26pt;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:21pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="height:26pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:26pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:26pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:26pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:26pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:26pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:26pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:26pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:26pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:26pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:26pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:26pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:26pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:26pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:26pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:26pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:26pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:26pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:26pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:26pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:26pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:26pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:26pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:26pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible<br/>Preferred Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Stockholders&#8217; Equity (Deficit)</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance&#8212;December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE3LTEtMS0xLTA_0a0f4b99-cf7c-4b09-9421-0679287d898e">24,385,388</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE3LTMtMS0xLTA_b67ddfe5-6dbe-4315-9c98-cab395d9f4ec">166,491</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i35625a47aaa94266be03155114268268_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE3LTUtMS0xLTA_c49d1469-5c12-42c5-b7a4-7e06372f7960">2,120,853</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i35625a47aaa94266be03155114268268_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE3LTctMS0xLTA_e6a8f8f9-07ef-4a62-9bf2-d71db4238163">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if55289982bed4868bd75d4d6010753e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE3LTktMS0xLTA_609ce1ab-e649-430d-b241-293fede93abd">1,244</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifb50c31a77604c0d8346a9ea0f57045a_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE3LTExLTEtMS0w_c32d2a27-ecc7-4c5d-bbe6-eb21e4233585">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74375cd2c8a64bbcb8ce7fdbc8b5f486_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE3LTEzLTEtMS0w_03b0eead-48ea-42e3-b1d8-34d493bad66b">66,272</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE3LTE1LTEtMS0w_e79d19d8-b93a-49b5-9572-587091f69ed3">65,029</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Conversion of preferred stock into common stock upon initial public offering</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="arqt:TemporaryEquitySharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzExLTEtMS0xLTMxMDc_759370d6-4e7f-4538-aadc-cc82d55b1c1b">24,385,388</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="arqt:TemporaryEquityValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzExLTMtMS0xLTMxMDc_60f798a5-93ad-4e10-8e54-8a80e38d8059">166,491</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzExLTUtMS0xLTMxMDc_4d21a535-3826-4ee9-a55f-76837af18a9a">24,385,388</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzExLTctMS0xLTMxMDc_f08ea993-d7c9-499e-8120-89c9a412d931">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i80caeb9df5f44f8e9df282ee72186142_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzExLTktMS0xLTMxMDc_8be51be9-5c50-4840-9a99-b762c53170f2">166,489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzExLTE1LTEtMS0zMTA3_631a1cfa-fdad-4847-a2ed-907a3041adb6">166,491</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of shares of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzExLTAtMS0xLTMwODgvdGV4dHJlZ2lvbjplYjczOWRiNDMyNGM0NjUzOTg2NDY4YzQ0OTZhYjdjNF8yNzQ4Nzc5MDY5NTQ5_4fe5d7c2-0642-4c63-9035-419b0848bd1b">16.0</ix:nonFraction> million</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzEyLTUtMS0xLTMxMTg_6725b639-eaf7-48e8-96f3-9a57ef6defea">10,781,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzEyLTctMS0xLTMxMTg_d1879b0c-6c9b-44a8-9fc0-f71ffc758b01">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i80caeb9df5f44f8e9df282ee72186142_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzEyLTktMS0xLTMxMTg_a07ebe6c-fdd0-40fe-8fa0-cba79d26505e">167,240</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzEyLTE1LTEtMS0zMTE4_7ad1cb87-e674-485e-93a7-c52c91ac56b1">167,241</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock upon the exercise of stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE4LTUtMS0xLTA_71a3992d-c8fd-478d-b056-b7009adb408e">51,147</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i80caeb9df5f44f8e9df282ee72186142_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE4LTktMS0xLTA_c3ffb37d-95ac-4912-ac3c-08df8dd08394">152</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE4LTE1LTEtMS0w_5e9d1e0f-f839-4758-a4fb-b2bcd8b7759a">152</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vesting of founder shares subject to repurchase</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="arqt:StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIwLTUtMS0xLTA_fe0ea664-e17c-4d9d-b1b4-f6f369868259">68,931</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="arqt:StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIwLTE1LTEtMS0w_2680fd65-45a7-4c2c-8bed-3ce2ce94b118">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lapse of repurchase rights related to common stock issued pursuant to early exercises</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIxLTUtMS0xLTA_87761dbf-c4c0-4c09-9a38-126db256ec09">64,428</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i80caeb9df5f44f8e9df282ee72186142_D20200101-20200331" decimals="-3" name="arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIxLTktMS0xLTA_a65f43d1-ba68-455c-ad82-9de8ec92ba84">30</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" name="arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIxLTE1LTEtMS0w_0f842ddc-4eed-4008-aae0-273acc3505ad">30</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i80caeb9df5f44f8e9df282ee72186142_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIyLTktMS0xLTA_11a66138-29c0-457e-89ae-e9ef7c7c1360">990</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIyLTE1LTEtMS0w_4f596471-bb52-4d70-90d5-aa82b8f5745a">990</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain on short term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d9f4b34db394927811febbebe7ee4a3_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIzLTExLTEtMS0w_0c7cf475-9bdb-4323-bcb9-0c8e67f3fe9a">20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIzLTE1LTEtMS0w_19bc5267-2044-43b4-b0ee-a1f2c821aaf5">20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8f6595d3666d4c0da7ef44540cc8c105_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI0LTEzLTEtMS0w_b9cc9439-fb0a-47aa-8219-f2ec3a4314af">28,013</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI0LTE1LTEtMS0w_6a73e162-6613-4c9b-9710-c070988a672f">28,013</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance&#8212;March 31, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" format="ixt:zerodash" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI2LTEtMS0xLTA_6736381c-f767-432f-b40f-c565ba185c64">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI2LTMtMS0xLTA_bbd9f1ba-6244-4bfe-8202-c163e0b07c3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i21443e8563474055949c856249beb800_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI2LTUtMS0xLTA_99c59e0a-10c9-447a-910e-1054076caf76">37,471,997</ix:nonFraction></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i21443e8563474055949c856249beb800_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI2LTctMS0xLTA_0537dea3-22c3-4bc9-bf8e-23ed01543f6a">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fa655ae1882424ea70d7f3ba47275d5_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI2LTktMS0xLTA_eb8a0379-7799-4d43-ae6a-4e11036f173c">336,145</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic552471d830f40178487f9d46cbfe905_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI2LTExLTEtMS0w_7866b74f-d735-482d-8178-427e55a4e627">19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ieb89b6585f024b53831de5e9407a4e25_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI2LTEzLTEtMS0w_96356c93-1aa7-49d0-a7bd-90328606efc4">94,285</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI2LTE1LTEtMS0w_d17fc8f3-a7dd-4302-aec8-bfa58223c39c">241,882</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed financial statements.</span></div><div style="position:relative;width:100%;height:27pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 3</span></div></div></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_130"></div><hr style="page-break-after:always"/><div style="height:63pt;width:100%;"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:9pt;"><span><br/></span></div><div style="margin-top:18pt;"><span><br/></span></div></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">In thousands</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.953%;"><tr><td style="width:1.0%;"></td><td style="width:71.880%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.686%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.546%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.688%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzMtMS0xLTEtMA_015c4eb1-e1e7-48dc-bb9e-8369bacc79ce">28,013</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzMtMy0xLTEtMA_4f911447-439b-4a68-ad8d-13e909e304af">6,658</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzUtMS0xLTEtMA_dcdab196-723e-4d7a-bb38-b5f3867508c9">27</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzUtMy0xLTEtMA_5bf6ba19-6e20-4581-9209-70aaf9cf8451">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use asset amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" name="arqt:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzYtMS0xLTEtMA_3b2c41c3-d7e0-4e15-b8d8-8021cd9c92af">38</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" name="arqt:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzYtMy0xLTEtMA_bad7b8b0-cff2-4932-8234-16356ce91eb6">19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net amortization/accretion on marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzctMS0xLTEtMA_49e49a89-7e2f-4147-a1fb-888cf382d74f">192</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzctMy0xLTEtMA_783f3696-2944-411f-9a86-9e2e1f657bb0">120</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzgtMS0xLTEtMA_eefaebfb-c6bb-48df-95ee-90af3353c889">990</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzgtMy0xLTEtMA_6e1b36c4-4daf-4bbb-a17b-4b86765b0565">76</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzEzLTEtMS0xLTA_6ac60674-d367-4b38-9ab6-cf8d0498e416">1,097</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzEzLTMtMS0xLTA_b6a405b9-988b-4fee-b103-e5b844fa6ee5">315</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE0LTEtMS0xLTA_a3d980ee-974a-4177-85e6-b2814de2f506">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE0LTMtMS0xLTA_69d0f957-4977-4519-b9b9-c85740bd599b">47</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE1LTEtMS0xLTA_544b48a5-9d35-4cfb-a59b-a3e02ab65511">3,412</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE1LTMtMS0xLTA_93cb14da-a795-48f3-b44d-aa8b1a49d02f">393</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE2LTEtMS0xLTA_a156cf2e-2690-4555-a1ed-94cffe5cd10e">3,868</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE2LTMtMS0xLTA_9e76941c-e166-446c-82e6-2701a02e76fc">370</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" sign="-" name="arqt:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE3LTEtMS0xLTA_351c9f4a-5b87-4992-8c54-bf96711b1f0a">43</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" sign="-" name="arqt:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE3LTMtMS0xLTA_aa02b867-0f70-4f01-9cf2-549c0f75002a">11</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:78.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE4LTEtMS0xLTA_17c59587-efb1-4bcf-9b41-a76085623cec">21,010</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE4LTMtMS0xLTA_1b62150b-df23-4d4a-96de-b8ac48ab0cda">7,074</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzIwLTEtMS0xLTA_362f7ec0-dd8e-4db7-bf5c-27787fb908c9">35,285</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzIwLTMtMS0xLTA_e5d3ba03-b248-47bc-ab27-8c66f7f28bd2">11,687</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzIxLTEtMS0xLTA_5b1eb4fb-880d-4835-b0ec-ae160ccd53fd">15,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzIxLTMtMS0xLTA_6e362f34-8f62-488d-9a3f-536c4cf8935b">2,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzIyLTEtMS0xLTA_27741c26-c4da-4e18-b3d5-a6aed2226d08">41</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzIyLTMtMS0xLTA_5a7b27e2-d147-4ba0-9bda-5a669faa2fe9">183</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:78.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzIzLTEtMS0xLTA_19e7dc3f-aeaa-42f7-b6e5-8484751b83a3">20,326</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzIzLTMtMS0xLTA_f62e8032-f377-4261-aab9-58d950e6c3c9">9,270</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzI1LTEtMS0xLTA_6f9ed742-b573-486f-9ab3-9401a4eb6607">247</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzI1LTMtMS0xLTA_ac295bbb-c48b-4c82-ba3b-52b56a60e24f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from initial public offering, net of issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzI2LTEtMS0xLTA_69e4347c-92d9-46d7-8789-ec9ebce3dba3">168,646</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzI2LTMtMS0xLTA_ff1ad5b3-bb99-47d8-a841-7a36d2e891f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:78.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzMxLTEtMS0xLTA_7b5661bd-cd17-4eac-ab74-e890022e6e20">168,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzMxLTMtMS0xLTA_13679dac-e916-4bfb-ade5-8c5519ff56c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzMyLTEtMS0xLTA_0128de46-d463-4be4-a58f-858221c53f1c">127,557</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzMyLTMtMS0xLTA_8ae5c045-ffc1-4ea5-84ed-6d8de57c2516">16,344</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzMzLTEtMS0xLTA_9bd1889b-a1fa-42b1-8c14-999d30b8f6a6">63,336</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i68dfa5b4689849b9a3cd771af6075ca9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzMzLTMtMS0xLTA_71aabd04-5556-4f69-8d70-54c5c3eca14c">39,394</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzM0LTEtMS0xLTA_5b6206a4-6760-4e4e-b0e3-b013284b8cf7">190,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic5c62122ea184197a8cbcd8fac509f93_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzM0LTMtMS0xLTA_77ab0f00-3df1-4832-9183-db0ab140f030">23,050</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use asset obtained in exchange for lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzM5LTEtMS0xLTA_41a3581b-0f25-410e-ad97-f7619fb2c71d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzM5LTMtMS0xLTA_c509e83d-91f8-4a42-a1c9-3e5b9d7798f7">391</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred financing costs included in accounts payable and accrued liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="arqt:DeferredFinancingCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzQwLTEtMS0xLTA_554b67d4-d471-4e43-a25f-3a538ac79601">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic5c62122ea184197a8cbcd8fac509f93_I20190331" decimals="-3" format="ixt:zerodash" name="arqt:DeferredFinancingCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzQwLTMtMS0xLTA_81babdec-1211-411d-88a2-3e892de9bf02">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed financial statements.</span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_133"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_136"></div><div style="margin-top:18pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 4</span></div></div></div><hr style="page-break-after:always"/><div style="height:63pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div style="margin-top:18pt;"><span><br/></span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">1. <ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzQ5NDc4MDIzMzUyNzA_922cf613-5cf5-4094-b0e8-4c3cae3a4fb3" continuedAt="ic30656e335664e93a16978cbd4e4c1b4" escape="true">Organization and Description of Business</ix:nonNumeric></span></div><ix:continuation id="ic30656e335664e93a16978cbd4e4c1b4"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Arcutis Biotherapeutics, Inc., or the Company, is a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. The Company&#8217;s current portfolio is comprised of topical treatments with significant promise in addressing immune-mediated dermatological diseases and conditions, or immuno-dermatology. The Company&#8217;s strategy is to advance treatments that leverage validated biological targets in dermatology in order to deliver clinical profiles that address major shortcomings of existing therapies in its targeted indications. The Company believes this strategy uniquely positions it to rapidly advance its goal of bridging the treatment innovation gap in dermatology while maximizing its probability of technical success.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 17, 2020, the Company's Board of Directors approved a 1-for-2.0007 reverse stock split of the Company&#8217;s capital stock and the Company filed a certificate of amendment to its restated certificate of incorporation to effect the split. The par value and authorized shares of common stock and convertible preferred stock were not adjusted as a result of the reverse split. All share and per share information included in the accompanying financial statements has been adjusted to reflect this reverse stock split.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Initial Public Offering</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 31, 2020, the Company completed an initial public offering (&#8220;IPO&#8221;) issuing and selling </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonFraction unitRef="shares" contextRef="i2b1b978c4e7e4c51afcf56c572945237_D20200131-20200131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzQ5NDc4MDIzMzAyMzA_fd03f308-9afd-4892-b5bf-cbe3d6fad2f6">10,781,250</ix:nonFraction></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> shares of common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i61f2dde936ae43d5bc9eae7e34c66670_I20200131" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzE2NjY_9ffb586f-5eef-40e0-820a-6a93d921b2d9">17.00</ix:nonFraction> per share, including </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonFraction unitRef="shares" contextRef="ifb9e70228f484fc4a8a0c0a8c7d593b1_D20200131-20200131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzE2OTA_8aa9db4e-a70e-4294-89bb-1558535a62df">1,406,250</ix:nonFraction></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> shares sold pursuant to the underwriters&#8217; full exercise of their option to purchase additional shares. The aggregate net proceeds received by the Company from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="iafc8add9248145199d7b4082ecba51b7_D20200131-20200131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzE4OTA_6345be38-cb29-4919-b5db-32fd9e5cd2c5">167.2</ix:nonFraction>&#160;million,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> after deducting underwriting discounts, commissions and offering related transaction costs</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Upon the closing of the IPO, all of the outstanding shares of convertible preferred stock automatically converted into shares of common stock. Subsequent to the closing of the IPO, there were <ix:nonFraction unitRef="shares" contextRef="ib256fcf2733e48fca730f3e92edbe1f6_I20200201" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzQ5NDc4MDIzMzAyNTM_512c5237-94a0-49f2-b35a-8e97c06fbb97">no</ix:nonFraction> shares of convertible preferred stock outstanding.  The financial statements as of March&#160;31, 2020, including share and per share amounts, incorporate the effects of the IPO. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liquidity</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has incurred significant losses and negative cash flows from operations since its inception and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzIxOTkwMjMyNjA4MzQ_992b71b3-0ee4-487b-86e8-f6e390e33824">94.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzIxOTkwMjMyNjA4NTg_8e60d194-b76e-4c85-bff1-a461d3b8f1b8">66.3</ix:nonFraction> million as of March&#160;31, 2020 and December&#160;31, 2019, respectively. The Company had cash, cash equivalents and marketable securities of $<ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzIxOTkwMjMyNjA4ODQ_5ca13861-79df-4336-92b4-220dfd8b2c54">249.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzIxOTkwMjMyNjA4ODc_d46906d9-cddf-46d5-960e-1a364781ee59">101.3</ix:nonFraction> million as of March&#160;31, 2020 and December&#160;31, 2019, respectively. Prior to selling common stock in its IPO, the Company had historically financed its operations primarily through the sale of its convertible preferred stock. Management expects operating losses to continue for the foreseeable future.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes that its existing capital resources will be sufficient to meet the projected operating requirements for at least 12 months from the date of issuance of its financial statements. The Company will be required to raise additional capital to fund future operations. However, no assurance can be given as to whether additional needed financing will be available on terms acceptable to the Company, if at all. If sufficient funds on acceptable terms are not available when needed, the Company may be required to curtail planned activities to significantly reduce its operating expenses. Failure to manage discretionary spending or raise additional financing, as needed, may adversely impact the Company&#8217;s ability to achieve its intended business objectives and have an adverse effect on its results of operations and future prospects.</span></div><div style="margin-top:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Coronavirus Outbreak</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In March 2020, the World Health Organization declared a pandemic related to the global novel coronavirus disease 2019 (COVID-19) outbreak. As of May 12, 2020, the Company&#8217;s operations have not been significantly impacted by the COVID-19 pandemic.  The Company is monitoring the potential impact COVID-19 may have on the clinical development of its product candidates, including potential delays or modifications to its ongoing and planned trials. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak will have on its financial condition and operations, including ongoing and planned clinical trials.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 5</span></div></div></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_139"></div><hr style="page-break-after:always"/><div style="height:76.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2. <ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzODk3MjY_06bc9e4f-0dc7-465d-8ceb-1687af616a48" continuedAt="iaa3d9dba3617401e90b658e05c5e9fce" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="iaa3d9dba3617401e90b658e05c5e9fce" continuedAt="ic2aee746826c4b079dc361be72c519f7"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzODk3MjU_0f9a7ebf-30b7-44c9-8e2f-bb8829638c72" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s condensed financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NDk_6a88b518-6830-4ec4-a0d9-f028e4cfd48d" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements and accompanying notes. On an ongoing basis, management evaluates such estimates and assumptions for continued reasonableness. In particular, management makes estimates with respect to accruals for research and development activities, fair value of common stock and convertible preferred stock (prior to the IPO completed in January 2020), stock-based compensation expense and income taxes. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzU0OTc1NTgxNzkzNjA_219bd832-0039-46a8-9a52-463b323602ea" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segments</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, the Company has viewed its financial information on an aggregate basis for the purposes of evaluating financial performance and allocating the Company&#8217;s resources. Accordingly, the Company has determined that it operates in <ix:nonFraction unitRef="segment" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzE2NDkyNjc0NzYzMjI_2256f6d2-96ce-46f7-bcb4-7cbef7a03a1a">one</ix:nonFraction> segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="arqt:UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NTE_f07e284f-2da3-4a81-8c44-931dbe6564f6" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unaudited Interim Condensed Financial Statements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The interim condensed balance sheet as of March&#160;31, 2020, the interim condensed statements of operations and comprehensive loss, the condensed changes in convertible preferred stock and stockholders&#8217; equity (deficit) and cash flows for the three months ended March&#160;31, 2020 and 2019 are unaudited. These unaudited interim condensed financial statements have been prepared on the same basis as the Company&#8217;s audited annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair statement of the Company&#8217;s financial information. The financial data and the other financial information disclosed in these notes to the condensed financial statements related to the three-month periods are also unaudited. The condensed results of operations for the three months ended March&#160;31, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other future annual or interim period. The condensed balance sheet as of December 31, 2019 included herein was derived from the audited financial statements as of that date. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Therefore, these unaudited interim condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2019.</span></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NTI_ecd8f69c-ba5a-4128-a16f-b1afeb11afa7" continuedAt="ia5ae5f661f7547889a766388dac68b1f" escape="true">Cash and Cash Equivalents </ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ia5ae5f661f7547889a766388dac68b1f">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of money market funds, commercial paper, and government securities.</ix:continuation> </span></div><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NTQ_59ebf8af-efd6-466c-a603-cd30ddcb9ce5" continuedAt="iadcc1dbe406e4d6b941b63d770e02673" escape="true"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Marketable Securities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities consist of investment grade short to intermediate-term fixed income investments that have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase are classified as current based on their availability for use in current operations. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses as well as credit losses, if any, on marketable securities are included in other income (expense), net. The Company evaluated the underlying credit quality and credit ratings of </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 6</span></div></div></div><hr style="page-break-after:always"/><div style="height:76.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="ic2aee746826c4b079dc361be72c519f7" continuedAt="i21e5d8d8f948474ea3f0d295bb1e8442"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"><ix:continuation id="iadcc1dbe406e4d6b941b63d770e02673">the issuers during the period. To date, <ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzOTA4OTE_b85a3a4f-202a-401e-95cb-eb8ad6035cdd">no</ix:nonFraction> such credit losses have occurred or have been recorded. The cost of investments sold is based on the specific-identification method.</ix:continuation> As of March&#160;31, 2020, there were unrealized gains on marketable securities of $<ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzMyOTg1MzQ5MjU0MTY_b406ca4e-1273-4936-80a8-1a4af37fec36">19,000</ix:nonFraction> and as of December&#160;31, 2019, there were unrealized losses on marketable securities of  $<ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjcwMDY_fe4bb018-8f69-4b9a-b720-a6b0464ffeab">1,000</ix:nonFraction>. Unrealized gains and losses on marketable securities are reported as a component of Accumulated Other Comprehensive Income (Loss) on the balance sheet. There were <ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzM0OTQ_40edad0a-c368-4f7a-8ccc-0e56fa63a6cc"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzM0OTQ_bcc1f679-56c7-4b28-a793-573e09552d42">no</ix:nonFraction></ix:nonFraction> realized gains or losses on investments for the three months ended March 31, 2020 and 2019. Interest on marketable securities is included in Other income (expense), net.</span></div><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzODk3MjI_61563708-07a7-4197-9499-5e56b405ea32" escape="true"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash to the extent recorded on the balance sheets.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NTY_3484a2da-6492-42fd-b605-be53bbaae396" escape="true"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s financial instruments, in addition to those presented in Note 3 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, include cash equivalents, accounts payable and accrued liabilities. The carrying amount of cash equivalents, accounts payable and accrued liabilities approximate their fair values due to their short maturities.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active;</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NTc_141a4c64-d261-4678-b545-0bddf5444e52" continuedAt="i62b760e53cbb4410804ac4eb549767f0" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company leases a facility with a non-cancelable lease term of <ix:nonNumeric contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjY5MjE_235a1df2-85ea-4a9d-adf5-7668f7bed6ae">30</ix:nonNumeric> months. The term of the lease includes a renewal option at the election of the Company to extend the lease for an additional term. The renewal option has not been considered in the determination of the right-of-use, or ROU, asset or lease liability as the Company did not consider it reasonably certain it would exercise this option.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement is or contains a lease at inception. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The classification of the Company&#8217;s leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. The Company uses its incremental borrowing rate, based on the information available at commencement date, to determine the present value of lease payments when its leases do not provide an implicit rate. The Company uses the implicit rate when readily determinable. The ROU asset is based on the measurement of the lease liability, includes any lease payments made prior to or on lease </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 7</span></div></div></div><hr style="page-break-after:always"/><div style="height:76.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="i21e5d8d8f948474ea3f0d295bb1e8442" continuedAt="i5a72227a44a1431aa2e5f52d9e563e81"><ix:continuation id="i62b760e53cbb4410804ac4eb549767f0"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">commencement and excludes lease incentives and initial direct costs incurred, as applicable. Lease expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s lease agreement includes lease and non-lease components and the Company has elected to not separate such components. Further, the Company elected the short-term lease exception policy, permitting it to not apply the recognition requirements of this standard to leases with terms of 12 months or less (short-term leases) for all classes of assets.</span></div></ix:continuation><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="arqt:PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjY5MDY_fc8a0bde-24de-40e4-b7a9-5500c70a25f6" continuedAt="i0bd9cd50a290402eaab25e9447fe8b51" escape="true">Preclinical and Clinical Accruals and Costs</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i0bd9cd50a290402eaab25e9447fe8b51">The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical studies, clinical trials and contract manufacturing activities. These costs are a significant component of the Company&#8217;s research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities.</ix:continuation> For the three months ended March 31, 2020 and 2019, the Company has not experienced any material differences between accrued costs and actual costs incurred. </span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NTk_9730c5b3-334f-4383-a9e5-97dcf32336c2" continuedAt="ic0c0c2058beb405895b81f824aa01179" escape="true">Convertible Preferred Stock</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ic0c0c2058beb405895b81f824aa01179">Prior to its IPO, the Company classified its outstanding convertible preferred stock outside of stockholders&#8217; equity (deficit) on its balance sheets as the requirements of triggering a deemed liquidation event, as defined within its amended and restated certificate of incorporation, were not entirely within the Company&#8217;s control. In the event of such a deemed liquidation event, the proceeds from the event were to be distributed in accordance with the liquidation preferences, provided that the holders of convertible preferred stock had not converted their shares into common stock. The Company recorded the issuance of convertible preferred stock at the issuance price less related issuance costs. The Company did not adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because of the uncertainty as to whether or when a deemed liquidation event may have occurred.</ix:continuation>  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the IPO in January 2020, the Company&#8217;s outstanding shares of convertible preferred stock were automatically converted into <ix:nonFraction unitRef="shares" contextRef="i1a9f8349a2ae4825872a95b128a3bfb7_D20200101-20200131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzE2NDkyNjc0ODM2ODk_7f17467e-91a6-4300-aa63-eefb4dd012e8">24,385,388</ix:nonFraction> shares of common stock.  </span></div><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NjA_91eacd73-34eb-4a3d-93a1-7c80dba40b81" escape="true"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, license fees, stock-based compensation expense, materials, supplies, and the cost of services provided by outside contractors. All costs associated with research and development are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are rendered. Such payments are evaluated for current or long-term classification based on when they will be realized.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has entered into and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date none of the Company&#8217;s license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense when paid or become payable, provided there is no alternative future use of the rights in other research and development projects.</span></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NjE_cd33255b-e58a-4c8f-a995-a21a36f02cf5" continuedAt="i4cbff8389c4f43599cbc816e8bba7642" escape="true">Stock-Based Compensation </ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 8</span></div></div></div><hr style="page-break-after:always"/><div style="height:76.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="i5a72227a44a1431aa2e5f52d9e563e81" continuedAt="i6d1d0204f35240308a2bdc125eff3106"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i4cbff8389c4f43599cbc816e8bba7642">The Company accounts for share-based payments at fair value. The fair value of stock options is measured using the Black-Scholes option-pricing model. For share-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date for such awards is the date of grant and the expense is recognized on a straight-line basis, over the expected vesting period. For share-based awards that vest subject to a performance condition, the Company will recognize compensation cost for awards if and when the Company concludes that it is probable that the awards with a performance condition will be achieved on an accelerated attribution method. The Company accounts for forfeitures as they occur.</ix:continuation></span></div><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzU0OTc1NTgyMTQ4MjM_ed25ae2b-acca-4510-b010-1f127fa7e212" escape="true"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company records a valuation allowance to reduce deferred tax assets to an amount for which realization is more likely than not. Due to the Company&#8217;s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties incurred in relation to the unrecognized tax benefits.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was enacted by the United States Congress on March 27, 2020. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the U.S. economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act includes modifications to the limitations on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. The Company does not expect the CARES Act to have a material impact on the Company&#8217;s financial statements.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NjQ_f7458e52-5273-457f-8452-a91e9c0e2e82" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Variable Interest Entities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company reviews agreements it enters into with third-party entities, pursuant to which the Company may have a variable interest in the entity, in order to determine if the entity is a variable interest entity, or VIE. If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that entity. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. If the Company determines it is the primary beneficiary of a VIE, it consolidates that VIE into the Company&#8217;s financial statements. The Company&#8217;s determination about whether it should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation or deconsolidation event. The Company currently does not consolidate any VIEs.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NjU_eafdba0f-e285-49e8-861e-cb8b6c2ceef1" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share since the effects of potentially dilutive securities are antidilutive. Shares of common stock subject to repurchase are excluded from the weighted-average shares.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 9</span></div></div></div><hr style="page-break-after:always"/><div style="height:76.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="i6d1d0204f35240308a2bdc125eff3106" continuedAt="i9a90cefdd27241b888c90ca02a92be7f"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="arqt:EmergingGrowthCompanyStatusPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzODk3MjM_d7af14ac-1c5c-4ecd-83bd-06256c77626d" escape="true"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Emerging Growth Company Status</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzODk3MjQ_afde1f12-a88f-400d-aa50-af7490ec35a4" continuedAt="ie044d0bc7c7e44fcbd65219e77b615ba" escape="true"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> or ASU No. 2018-13, which removes, modifies, and adds various disclosure requirements on fair value measurements in Topic 820.&#160;ASU No. 2018-13&#160;is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company adopted this standard as of January 1, 2020, and it did not have a material impact on its condensed financial statements. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In June&#160;2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Financial Instruments&#8212;Credit Losses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">(Topic&#160;326): Measurement of Credit Losses on Financial Instruments,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> or ASU No. 2016-13</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> This update requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations now include forward-looking information in the determination of their credit loss estimates. Many of the previous loss estimation techniques are still permitted, although the inputs to those techniques have changed to reflect the full amount of expected credit losses. In addition, this update amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration.  The Company adopted this standard as of January 1, 2020, and it did not have a material impact on its condensed financial statements.  There was no impact on the Company's condensed financial statements from credit losses for the three months ended March 31, 2020.  </span></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt;margin-top:12pt;"><ix:continuation id="i9a90cefdd27241b888c90ca02a92be7f" continuedAt="i3bc142d9a16846029a2a90338b5a8b52"><ix:continuation id="ie044d0bc7c7e44fcbd65219e77b615ba" continuedAt="i1003e19b8ae74acfbceeb9e8fd89739e"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In December 2019, the FASB issued ASU No. 2019-12</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">, Income Taxes (Topic 740)</span></ix:continuation></ix:continuation><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"><ix:continuation id="i3bc142d9a16846029a2a90338b5a8b52"><ix:continuation id="i1003e19b8ae74acfbceeb9e8fd89739e"> which amends the existing guidance relating to the accounting for income taxes. This standard is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. The standard is effective for public business entities for fiscal years beginning after December 15, 2020, and interim periods therein. Early adoption is permitted. An entity that elects early adoption in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, an entity that elects early adoption should adopt all the amendments in the same period. The Company early adopted this guidance as of January 1, 2020, and it did not have a material impact on its condensed financial statements.</ix:continuation></ix:continuation> </span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_145"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">3. <ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90ZXh0cmVnaW9uOjJlYjk3YzZhNTBlNjQ5OWM4NTU1ZGNmYTY2YjRlYTY3XzQ5NDc4MDIzMzE0NzY_14629b79-90ff-4b9b-aa97-ce4201e19f3b" continuedAt="ic8e4ecb7e0474ab5ba9350e9d002464e" escape="true">Fair Value Measurements </ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:continuation id="ic8e4ecb7e0474ab5ba9350e9d002464e" continuedAt="i0cabb62e3f8b424f985208f2c0f83013"> </ix:continuation></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i0cabb62e3f8b424f985208f2c0f83013" continuedAt="if849cb1adfe34605a70eaaa1d01f2ed9"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90ZXh0cmVnaW9uOjJlYjk3YzZhNTBlNjQ5OWM4NTU1ZGNmYTY2YjRlYTY3XzQ5NDc4MDIzMzE0Nzc_aa0b158f-35cc-4273-9ad8-f88305720b7c" continuedAt="ic6b151f03e6b495696ad9593ba892ff5" escape="true">The following table sets forth the Company&#8217;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</ix:nonNumeric></ix:continuation></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 10</span></div></div></div><hr style="page-break-after:always"/><div style="height:76.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="if849cb1adfe34605a70eaaa1d01f2ed9" continuedAt="i0b562097a8424b4aaee0ca9cd6d78bb7"><ix:continuation id="ic6b151f03e6b495696ad9593ba892ff5"><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:48.951%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.713%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.713%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.713%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.714%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Assets:</span></div></td><td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds(1)</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f576810c09241ed87b2a09e63227467_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzMtMS0xLTEtMA_0f2efead-619a-436e-9404-5bc7c45d76b2">190,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i414921aba8984cb389a45a1e86d315ae_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzMtMy0xLTEtMA_fdfb3e57-0088-4c0a-b9d1-3b3c42c5ef25">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibec66f62c1084ad691104a439aff6c7e_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzMtNS0xLTEtMA_419ddc65-1cc8-4831-be3e-7854274f9747">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i270ae80ae8b042ce9201e7cc23f7ee58_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzMtNy0xLTEtMA_0b490f87-b4a2-4fc8-b77a-53fc413a632f">190,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial paper</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c8b8d5bfcec459fa278a039725bb9d9_I20200331" decimals="-3" format="ixt:zerodash" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzQtMS0xLTEtMA_57de9e28-b027-488a-a893-2d2c5cb7e6cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9c16b74ba53841fda7d28ab193530c1c_I20200331" decimals="-3" format="ixt:numdotdecimal" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzQtMy0xLTEtMA_7751fc94-c6df-49df-9a8d-25f508500d99">53,396</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i543cf22b19c54a4a8b70297fbbf4dcce_I20200331" decimals="-3" format="ixt:zerodash" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzQtNS0xLTEtMA_5d2ed59a-ce34-46a2-949e-4bbffb98f9d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifff112eac82649f6b53d94ba1b504889_I20200331" decimals="-3" format="ixt:numdotdecimal" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzQtNy0xLTEtMA_ccdbee81-d68b-4a41-b659-dd46d3a90ff5">53,396</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Government securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ife0a9b0f7f7b4864aebd29e91d92b75e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzUtMS0xLTEtMA_212d82ee-35b7-4d5f-83a4-d41497521094">5,030</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b5c3e06ddd5402c951cce1ad44ad6a3_I20200331" decimals="-3" format="ixt:zerodash" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzUtMy0xLTEtMA_fd5a3d60-1f58-4b1c-8c3d-4f32e6fce020">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic43770461fb141d1a3a708ae92c38e75_I20200331" decimals="-3" format="ixt:zerodash" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzUtNS0xLTEtMA_2a05a750-ffc9-4470-8099-96bf09bad9cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i03cc7f0a6da847ba8562f6f1fa69ad0f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzUtNy0xLTEtMA_a7ba78d5-63fa-4fb9-8539-a719b0b03a84">5,030</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic253eb34e85e4ebebda2388a08544c3e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzYtMS0xLTEtMA_4a34b08a-f481-48dd-afda-97cd18a807dc">195,923</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id45d766b5bb440b8923015575e77b394_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzYtMy0xLTEtMA_fc626ba8-e72b-4f0b-ae11-b21993f9760f">53,396</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i373b85f92fe343ac855524ea8acaff14_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzYtNS0xLTEtMA_0887dcdf-cf45-4130-a015-bfa6e681eb29">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzYtNy0xLTEtMA_afc0c914-5f64-42ed-88e7-d854c0c88bf2">249,319</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:48.951%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.713%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.713%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.713%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.714%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Level 1</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Level 2</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Level 3</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Assets:</span></div></td><td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds(1)</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae9ee5c735cf46908b0fabb85992ffc9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzMtMS0xLTEtMjY4_60a04c03-970c-4a42-b22b-f28d8f2d5928">43,558</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a1e096ff7d341be8c45b814509791ef_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzMtMy0xLTEtMjY4_5d08cc90-e294-4999-957b-8fcb0410a8a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c56f67dfa884523897775d41e68872d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzMtNS0xLTEtMjY4_e3d951c8-d6ed-428f-bf24-09bf3f2b303f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e5b4edc8170451689fbada6c48b86ed_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzMtNy0xLTEtMjY4_77af00d9-47d6-434f-82be-6ba1c3c5a405">43,558</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic86821562d79485eacbc135601a1eb43_I20191231" decimals="-3" format="ixt:zerodash" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzQtMS0xLTEtMjY4_5b555d74-65ee-4ebc-9753-0ac848a01da3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5950ca979d8342e2995ee8e69c309187_I20191231" decimals="-3" format="ixt:numdotdecimal" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzQtMy0xLTEtMjY4_28c61355-1a26-45a7-9007-f15e42a6e81d">44,689</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib206c2db943b4ae485f8d863d2ee1318_I20191231" decimals="-3" format="ixt:zerodash" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzQtNS0xLTEtMjY4_01c4a3c9-1873-4707-951a-2969b722b3cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e5368a4e5b94d8cbc7278e0fef5cad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzQtNy0xLTEtMjY4_ef84b19e-c111-45dd-ae73-d7f8edfd8149">44,689</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Government securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafb6adcdf1a44ac9987418eaf92a8522_I20191231" decimals="-3" format="ixt:numdotdecimal" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzUtMS0xLTEtMjY4_4091db1f-80a5-4d3c-ad6e-c12f1aa2aa07">13,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0181ffefb7fd484bacde0b9b979a5d5b_I20191231" decimals="-3" format="ixt:zerodash" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzUtMy0xLTEtMjY4_cc033639-07bf-4702-aa23-f5e3b3b534dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib465f2fbb252499b9bc7fb53a1bf2efe_I20191231" decimals="-3" format="ixt:zerodash" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzUtNS0xLTEtMjY4_7ad57aaf-6dc4-4c33-97a2-438ca4139338">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i97d79ac716284e1a9866aca1e609b683_I20191231" decimals="-3" format="ixt:numdotdecimal" name="arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzUtNy0xLTEtMjY4_33394c6e-3e99-4f9c-9744-6313679d8387">13,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i45c31d7adba348da80a2ab2d537cf9e2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzYtMS0xLTEtMjIwNQ_a0fa957d-63b8-445b-95a8-40557e3b8fcb">56,576</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i04008b35dd9c4edaa1167973c3f9f16a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzYtMy0xLTEtMjIwNQ_3eccd811-3c69-4996-b3a2-1a841fad4a8e">44,689</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9d55de80fa540a5b40168170c29f746_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzYtNS0xLTEtMjIwNQ_2176cf47-87ec-4fc6-ba9a-d325817f5c37">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzYtNy0xLTEtMjIwNQ_e9ac3541-7d72-45cf-9034-50d3b3c7831d">101,265</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt;">This balance includes cash requirements settled on a nightly basis.</span></div></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Commercial paper, money market funds and government securities are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs. There were no transfers between Levels&#160;1, 2 or 3 for any of the periods presented. </span></div><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90ZXh0cmVnaW9uOjJlYjk3YzZhNTBlNjQ5OWM4NTU1ZGNmYTY2YjRlYTY3XzU0OTc1NTgxNDY1MDA_367957dd-33e0-45c2-91ac-5507a16a1dd0" continuedAt="ia2602dd236fd4491872e519343e88c5a" escape="true"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90ZXh0cmVnaW9uOjJlYjk3YzZhNTBlNjQ5OWM4NTU1ZGNmYTY2YjRlYTY3XzU0OTc1NTgxNDY1MDA_fcd64f18-f699-463d-8c22-36c6df06da58" continuedAt="ib99e8c3454aa418f9ee1c8dda7eac6da" escape="true"><div style="text-indent:36pt;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the estimated value of the Company&#8217;s cash, cash equivalents and marketable securities and the gross unrealized holding gains and losses (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:48.951%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.713%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.713%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.713%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.714%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents:</span></div></td><td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i270ae80ae8b042ce9201e7cc23f7ee58_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzQtMS0xLTEtMA_753b9dec-b94b-4da9-88dd-fd26afcd3075">190,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i270ae80ae8b042ce9201e7cc23f7ee58_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzQtNy0xLTEtMA_7a21f1fe-bd87-4309-9ef7-86d61f82a01e">190,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzYtMS0xLTEtMA_95dc99b2-cf3d-4ce1-b013-3777850325a2">190,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzYtNy0xLTEtMA_275e64f5-e73a-45d1-ae81-74d23d4d7266">190,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifff112eac82649f6b53d94ba1b504889_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzgtMS0xLTEtMA_4d17ea91-bc77-4f27-86de-85a6b68ceb1b">53,396</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifff112eac82649f6b53d94ba1b504889_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzgtMy0xLTEtMA_b20a035f-a7bf-44ab-9342-16d46e32d42d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifff112eac82649f6b53d94ba1b504889_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzgtNS0xLTEtMA_2831aa4e-7809-413f-9d73-9f0ad147f5d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifff112eac82649f6b53d94ba1b504889_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzgtNy0xLTEtMA_99413052-7a3b-4a8a-8296-1ea03e79d60a">53,396</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i03cc7f0a6da847ba8562f6f1fa69ad0f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzktMS0xLTEtMA_b55b6b06-4dd8-4c47-94af-646fd5ee04ca">5,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i03cc7f0a6da847ba8562f6f1fa69ad0f_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzktMy0xLTEtMA_5d3c8f9b-05c2-4e47-a58b-f769d260e4fc">19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i03cc7f0a6da847ba8562f6f1fa69ad0f_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzktNS0xLTEtMA_8b693387-47be-48af-ba01-98be1f10ba98">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i03cc7f0a6da847ba8562f6f1fa69ad0f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzktNy0xLTEtMA_893b4dd1-94b1-4f54-bc48-16cc13310e11">5,030</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzEwLTEtMS0xLTA_154aef5d-bf1b-4212-94d1-14dd89e9f125">58,407</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzEwLTMtMS0xLTA_6c131409-50a0-4522-a682-33661670bf66">19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzEwLTUtMS0xLTA_afe54542-bad9-4c72-b2a8-d9e7aac3b854">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzEwLTctMS0xLTA_8dad1662-9f11-46dd-9519-1bab08eb9a59">58,426</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt;">This balance includes cash requirements settled on a nightly basis.</span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="text-indent:-18pt;"><span><br/></span></div><div style="text-indent:-18pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 11</span></div></div></div><hr style="page-break-after:always"/><div style="height:76.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div><ix:continuation id="i0b562097a8424b4aaee0ca9cd6d78bb7" continuedAt="i56d7519433d84c27ad1f711f4c9428ed"><ix:continuation id="ia2602dd236fd4491872e519343e88c5a"><ix:continuation id="ib99e8c3454aa418f9ee1c8dda7eac6da"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:49.461%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.702%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents:</span></td><td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb249010b3884d319f1f8408c75f9f32_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzMtMS0xLTEtMA_baf445ce-62c2-4971-a3c0-5a3f11f975ff">11,780</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb249010b3884d319f1f8408c75f9f32_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzMtNy0xLTEtMA_ea337664-e337-4a14-830a-0042e0440692">11,780</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds(1)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e5b4edc8170451689fbada6c48b86ed_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzQtMS0xLTEtMA_d015f3c3-4bae-4eb6-a214-95db72cec572">43,558</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e5b4edc8170451689fbada6c48b86ed_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzQtNy0xLTEtMA_5f0bb22f-7af6-43ab-94f4-6d5a20885509">43,558</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5360332e67b7489285d42523d9c524f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzUtMS0xLTEtMA_e019a980-df2e-4b30-8b34-73197c9eae08">7,998</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5360332e67b7489285d42523d9c524f4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzUtNy0xLTEtMA_ba69eac4-90a8-42bd-88ef-01c6cf1f12e7">7,998</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzYtMS0xLTEtMA_ceec2b09-8920-48fd-a0e4-c518eb6000a5">63,336</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzYtNy0xLTEtMA_be355ae5-e32b-4ddc-9bbd-7ba77d9a3fca">63,336</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e5368a4e5b94d8cbc7278e0fef5cad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzgtMS0xLTEtMA_8dc61d3a-e40d-4bb2-ae63-2fe6e56f59fd">32,909</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e5368a4e5b94d8cbc7278e0fef5cad3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzgtMy0xLTEtMA_bf797245-3a1a-4990-b2dc-75b5afbbda7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e5368a4e5b94d8cbc7278e0fef5cad3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzgtNS0xLTEtMA_3872fa3b-bf34-44bd-9e14-471252acdba5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e5368a4e5b94d8cbc7278e0fef5cad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzgtNy0xLTEtMA_76a6c863-3265-4ab2-a5d6-b6a5b4a3d814">32,909</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i97d79ac716284e1a9866aca1e609b683_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzktMS0xLTEtMjc4_63213de2-830f-4c92-96b6-d1db7befdfed">5,021</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i97d79ac716284e1a9866aca1e609b683_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzktMy0xLTEtMjc4_1c19a3cd-9d3d-4b04-8bbe-f905b3e7c863">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i97d79ac716284e1a9866aca1e609b683_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzktNS0xLTEtMjc4_ef79e98b-dc89-412f-9d0a-9a917e450ef8">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i97d79ac716284e1a9866aca1e609b683_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzktNy0xLTEtMjc4_12e7d4bb-6662-441f-926d-5e4992b8862b">5,020</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzktMS0xLTEtMA_caaf9f7f-0c9d-4c52-9da8-c7387175c6f0">37,930</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzktMy0xLTEtMA_5478cd4b-ef4b-415e-ad02-2a293f967adf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzktNS0xLTEtMA_e175ea45-002b-4bca-a280-81417e5c2700">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzktNy0xLTEtMA_da8c2859-52c1-481f-938f-b6a690a217ba">37,929</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></ix:continuation></ix:continuation></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i56d7519433d84c27ad1f711f4c9428ed">There were <ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90ZXh0cmVnaW9uOjJlYjk3YzZhNTBlNjQ5OWM4NTU1ZGNmYTY2YjRlYTY3XzI3NDg3NzkwNzYzMTk_40edad0a-c368-4f7a-8ccc-0e56fa63a6cc"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90ZXh0cmVnaW9uOjJlYjk3YzZhNTBlNjQ5OWM4NTU1ZGNmYTY2YjRlYTY3XzI3NDg3NzkwNzYzMTk_bcc1f679-56c7-4b28-a793-573e09552d42">no</ix:nonFraction></ix:nonFraction> realized gains or losses on investments for the three months ended March 31, 2020 and 2019.  As of March&#160;31, 2020 and December&#160;31, 2019, unrealized losses on marketable securities were not material, and accordingly, no allowance for credit losses was recorded as of March 31, 2020.  As of March&#160;31, 2020 and December&#160;31, 2019, all securities have a maturity of one year or less and all securities with gross unrealized losses have been in continuous loss position for less than twelve months.</ix:continuation>   </span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_151"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">4. <ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90ZXh0cmVnaW9uOjdkNTkzMjM1NzQxZjQyMTc4ZGY4NmUwMDE4MGUwYTAxXzQ5NDc4MDIzMjUyMzQ_5345e280-28b2-4971-8f00-985a57b3f5d3" continuedAt="i8135d33e22ca4115940dcb9774215d35" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="i8135d33e22ca4115940dcb9774215d35"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90ZXh0cmVnaW9uOjdkNTkzMjM1NzQxZjQyMTc4ZGY4NmUwMDE4MGUwYTAxXzQ5NDc4MDIzMjUyMzU_548b90fe-6a18-4a27-b726-b9bf44fc011c" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:73.877%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.698%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzItMS0xLTEtNzIyMg_75f9d375-bcd2-4b65-aed4-35b003efc7de">2,326</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzItMy0xLTEtNzIyMg_a61a909b-0720-4aa7-9349-70f7d0902eb3">62</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid clinical trial costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="arqt:PrepaidClinicalTrialTestCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzItMS0xLTEtMA_702ec3a0-ea7c-4499-8d7c-fbdb75e7844e">1,583</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="arqt:PrepaidClinicalTrialTestCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzItMy0xLTEtMA_17b887fe-fda7-4961-b7e3-38787eff330b">2,998</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred financing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzMtMS0xLTEtMA_a002d181-a52e-4c6d-bec9-7d51ebd419ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzMtMy0xLTEtMA_e86af3da-bdad-4bf2-9b39-78b298fa13bf">1,747</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other prepaid expenses and current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzQtMS0xLTEtMA_81fa4015-35cd-41d5-b66d-cba0b9df516f">650</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzQtMy0xLTEtMA_1048c16a-12f4-4c7f-a2ba-a38b6909ffd4">402</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzUtMS0xLTEtMA_9ae41441-754a-4e46-997b-726e7aeebb59">4,559</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzUtMy0xLTEtMA_4844bcc8-b482-40a0-a3f8-0688fd5ab642">5,209</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Liabilities</span></div><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90ZXh0cmVnaW9uOjdkNTkzMjM1NzQxZjQyMTc4ZGY4NmUwMDE4MGUwYTAxXzQ5NDc4MDIzMjUyMzY_bb90b086-b7c0-410f-8839-307dc2cf9d67" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:73.877%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.698%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical trial accruals</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="arqt:ClinicalTrialAccrualCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzItMS0xLTEtMA_866aa505-9793-41a4-a851-b5b44b290f1f">6,114</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="arqt:ClinicalTrialAccrualCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzItMy0xLTEtMA_36ac50f5-bc0f-44f2-84f4-c8937a715a9e">1,497</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzMtMS0xLTEtMA_b6274621-c12b-463c-b49d-42d09d4f3827">806</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzMtMy0xLTEtMA_26d71977-60bd-4048-a0b5-2b79365880d0">1,379</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Early exercise liability, current</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzQtMS0xLTEtMA_cbd570af-2827-4ecb-8040-a55d90ab03d9">269</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzQtMy0xLTEtMA_9703c64c-ec4a-44f9-9132-382e062caa15">225</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzUtMS0xLTEtMA_95d587a9-fd59-4e54-b8d0-df8ad5402eb2">92</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzUtMy0xLTEtMA_3190544f-c4fe-4042-b792-08de90beff8e">553</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total accrued liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzYtMS0xLTEtMA_498cc8d0-751e-4a2b-ad69-d0bba50f71bf">7,281</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzYtMy0xLTEtMA_3b463d8c-487b-43c9-a07e-e65a0e3f4a90">3,654</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_154"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">5. <ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzcxNDY4MjU1ODg3MzA_eded83a9-fe3e-437f-bbe7-0ddbcd6c7307" continuedAt="i5fb9b7f6b6ab428683471d2eb95c2373" escape="true">License Agreements</ix:nonNumeric></span></div><ix:continuation id="i5fb9b7f6b6ab428683471d2eb95c2373" continuedAt="i159d8e3910064256bd10ce08c1318b48"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">AstraZeneca License Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2018, the Company entered into an exclusive license agreement, or the AstraZeneca License Agreement, with AstraZeneca AB, or AstraZeneca, granting the Company a worldwide exclusive license, with the right to sublicense through multiple tiers, under certain AstraZeneca-controlled patent rights, know-how and </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 12</span></div></div></div><hr style="page-break-after:always"/><div style="height:76.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="i159d8e3910064256bd10ce08c1318b48" continuedAt="id87b075bec484113b86dd7a91f5de121"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">regulatory documentation, to research, develop, manufacture, commercialize and otherwise exploit products containing roflumilast in topical forms, as well as delivery systems sold with or for the administration of roflumilast, or collectively, the AZ-Licensed Products, for all diagnostic, prophylactic and therapeutic uses for human dermatological indications, or the Dermatology Field. Under this agreement, the Company has sole responsibility for development, regulatory, and commercialization activities for the AZ-Licensed Products in the Dermatology Field, at its expense, and it shall use commercially reasonable efforts to develop, obtain and maintain regulatory approvals for, and commercialize the AZ-Licensed Products in the Dermatology Field in each of the United States, Italy, Spain, Germany, the United Kingdom, France, China, and Japan.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company paid AstraZeneca an upfront non-refundable cash payment of $<ix:nonFraction unitRef="usd" contextRef="i2b7f744e5e864a09ae29d5de55ad4859_D20180701-20180731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzEyOTc_2693b5b3-a556-4a9e-bc23-a232361c5906">1.0</ix:nonFraction> million and issued <ix:nonFraction unitRef="shares" contextRef="id5df7418441b428c98e1af09b1d8f5f6_D20180701-20180731" decimals="INF" format="ixt:numdotdecimal" name="arqt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzEzMTE_9c35564a-2da5-4a4c-a7ea-2568af0d47ab">484,388</ix:nonFraction> shares of Series&#160;B preferred stock, valued at $<ix:nonFraction unitRef="usd" contextRef="id5df7418441b428c98e1af09b1d8f5f6_D20180701-20180731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzEzNjA_91b395c6-e8d8-4725-ae6a-cd9fbcfb3ddd">3.0</ix:nonFraction> million on the date of the AstraZeneca License Agreement. The company subsequently paid AstraZeneca the first milestone cash payment of $<ix:nonFraction unitRef="usd" contextRef="i64e39f6e0ee9449382ec819a3c86939a_D20190801-20190831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ5NDc4MDIzMzMxODA_c8f464d7-6a32-40c2-9100-a5d62568635b">2.0</ix:nonFraction>&#160;million upon the completion of a Phase 2b study of topical roflumilast cream (ARQ-151) in plaque psoriasis in August 2019 for the achievement of positive Phase 2 data for an AZ-licensed Product, which was recorded in research and development expense.  The Company has agreed to make additional cash payments to AstraZeneca of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="iadbd597452bd467786da57f5e4d20c05_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzE4MTY_ceb95fd1-5870-41d2-b339-6e87abac9291">12.5</ix:nonFraction> million upon the achievement of specified regulatory approval milestones with respect to the AZ-Licensed Products and payments up to an additional aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="iadbd597452bd467786da57f5e4d20c05_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzE5Nzg_0cf453c7-f923-48ae-a5de-34eca82b4c82">15.0</ix:nonFraction> million upon the achievement of certain aggregate worldwide net sales milestones. With respect to any AZ-Licensed Products the Company commercializes under the AstraZeneca License Agreement, it will pay AstraZeneca a low to high single-digit percentage royalty rate on the Company&#8217;s, its affiliates&#8217; and its sublicensees&#8217; net sales of such AZ-Licensed Products, subject to specified reductions, until, as determined on an AZ-Licensed Product-by-AZ-Licensed Product and country-by-country basis, the later of the date of the expiration of the last-to-expire AstraZeneca-licensed patent right containing a valid claim in such country and ten years from the first commercial sale of such AZ-Licensed Product in such country. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were <ix:nonFraction unitRef="usd" contextRef="i27af3865d5bb4f39839b5fb35d6b8164_D20190101-20190331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzY1OTcwNjk3NzQ5MTE_62b69ea1-9869-4a28-8c72-8e24933523ef"><ix:nonFraction unitRef="usd" contextRef="iadbd597452bd467786da57f5e4d20c05_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzY1OTcwNjk3NzQ5MTE_cefc53ee-dac9-43a1-a63f-1f8a8f3cf42c">no</ix:nonFraction></ix:nonFraction> payments made or due in connection with AZ-licensed Products for the three months ended March 31, 2020 and 2019.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Hengrui Exclusive Option and License Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2018, the Company entered into an exclusive option and license agreement, or the Hengrui License Agreement, with Jiangsu Hengrui Medicine Co., Ltd., or Hengrui, whereby Hengrui granted the Company an exclusive option to obtain certain exclusive rights to research, develop and commercialize products containing the compound designated by Hengrui as SHR0302, a JAK 1 inhibitor, in topical formulations for the treatment of skin diseases, disorders, and conditions in the United States, Japan, Canada and the European Union (including for clarity the United Kingdom). The Company made a $<ix:nonFraction unitRef="usd" contextRef="ia9fd3340448d4bc7b2df04030b621bf3_D20180101-20180131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzM5MDA_b1f27e3f-c033-4be6-9630-5c74013ccdf1">0.4</ix:nonFraction> million upfront non-refundable cash payment to Hengrui upon execution of the Hengrui Option and License Agreement which was recorded as research and development expense. In December 2019, the Company exercised its exclusive option under the agreement, for which it made a $<ix:nonFraction unitRef="usd" contextRef="i6cb916c47d6d4499899eba1d8e7cc49f_D20191201-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQxNTY_585dafe7-52c4-463f-b219-f5e96381b8bc">1.5</ix:nonFraction>&#160;million cash payment, which was recorded in research and development expense, and also contemporaneously amended the agreement to expand the territory to additionally include Canada. In addition, the Company has agreed to make cash payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i624daddb81734c7dbdc63c375018d9a7_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ0MTc_dfa504f3-6ba2-4157-9848-3ce59675292d">20.5</ix:nonFraction> million upon achievement of specified clinical development and regulatory approval milestones with respect to the licensed products and cash payments of up to an additional aggregate of $<ix:nonFraction unitRef="usd" contextRef="i624daddb81734c7dbdc63c375018d9a7_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ1OTg_1d4e14c5-ffed-40e7-aefc-4410d92a8bdd">200</ix:nonFraction> million in sales-based milestones based on certain aggregate annual net sales volumes with respect to a licensed product. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to any products the Company commercializes under the Hengrui License Agreement, it will pay tiered royalties to Hengrui on net sales of each licensed product by the Company, or its affiliates, or its sublicensees, ranging from mid single-digit to sub-teen percentage rates based on tiered annual net sales bands subject to specified reductions. The Company is obligated to pay royalties until the later of (1)&#160;expiration of the last valid claim of the licensed patent rights covering such licensed product in such country and (2)&#160;expiration of regulatory exclusivity for the relevant licensed product in the relevant country, on a licensed product-by-licensed product and country-by-country basis. Additionally, the Company is obligated to pay Hengrui a specified percentage, ranging from the low-thirties to the sub-teens, of certain non-royalty sublicensing income it receives from sublicensees of its rights to the licensed products, such percentage decreasing as the development stage of the licensed products advance.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 13</span></div></div></div><hr style="page-break-after:always"/><div style="height:76.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="id87b075bec484113b86dd7a91f5de121"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were <ix:nonFraction unitRef="usd" contextRef="i27af3865d5bb4f39839b5fb35d6b8164_D20190101-20190331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzIxOTkwMjMyNjQxODg_62b69ea1-9869-4a28-8c72-8e24933523ef"><ix:nonFraction unitRef="usd" contextRef="iadbd597452bd467786da57f5e4d20c05_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzIxOTkwMjMyNjQxODg_cefc53ee-dac9-43a1-a63f-1f8a8f3cf42c">no</ix:nonFraction></ix:nonFraction> payments made or due in connection with Hengrui for the three months ended March 31, 2020 and 2019.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Hawkeye Collaboration Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2019, the Company entered into a collaboration agreement, or Hawkeye Agreement, with Hawkeye Therapeutics, Inc., or Hawkeye, a related party with common ownership, for the development of one or more new applications of roflumilast. The Hawkeye Agreement grants Hawkeye an exclusive license to certain intellectual property developed under the agreement as it relates to the applications. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contemporaneously with the execution of the Hawkeye Agreement, the Company entered into a stock purchase agreement, purchasing <ix:nonFraction unitRef="shares" contextRef="i3d73b12f38b44b0fb374429942edff05_I20190630" decimals="INF" format="ixt:numdotdecimal" name="arqt:VariableInterestEntitiesNumberOfSharesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ5NDc4MDIzMzMyMTA_e839ccf8-ef86-412a-b704-c8709a34f3f8">995,000</ix:nonFraction> shares of Hawkeye&#8217;s common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="i7ba628de89d3418daf6fc6a0e95c1598_I20190630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ5NDc4MDIzMzMxOTQ_8f62de8b-4e8b-4ae5-917f-4e36cb973ed9">0.0001</ix:nonFraction> per share, representing <ix:nonFraction unitRef="number" contextRef="i764c4c795726470f9f77ab82e0e24792_D20190601-20190630" decimals="3" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ5NDc4MDIzMzMyMDM_61018faa-c661-4ba7-a5e5-a0aa394689ec">19.9</ix:nonFraction>% of the outstanding common stock of Hawkeye.  In the event that Hawkeye issues shares of Series A preferred stock with proceeds over $<ix:nonFraction unitRef="usd" contextRef="ic8fd13a77a64486f820343c9c46cc851_I20190630" decimals="-5" format="ixt:numdotdecimal" name="arqt:CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ5NDc4MDIzMzMyMTk_04eb2559-0959-4caf-99b7-d038d2b5a976">5.0</ix:nonFraction>&#160;million, Hawkeye is required to issue to the Company a number of fully-paid fully-vested shares of common stock determined by dividing (i)&#160;$<ix:nonFraction unitRef="usd" contextRef="ic8fd13a77a64486f820343c9c46cc851_I20190630" decimals="INF" format="ixt:numdotdecimal" name="arqt:CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ5NDc4MDIzMzMyMzM_8687c7ba-860d-4133-9291-cb69c93c5523">2,000,000</ix:nonFraction> by (ii)&#160;an amount equal to the cash price per share for Series A preferred stock.  Other than the potential issuance of this common stock, there are <ix:nonFraction unitRef="usd" contextRef="i0a342eb6a9914eefbcddc6ecd7e9a425_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="arqt:ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ5NDc4MDIzMzMyNDU_6bd45e8b-f177-4db0-840b-59d683ec5b2c">no</ix:nonFraction> upfront payments, milestones or royalties pursuant to the Hawkeye Agreement. The Company determined that Hawkeye is a variable interest entity for which consolidation is not required as it is not the primary beneficiary.</span></div></ix:continuation><div id="ieeb33ed1376b4f84a553eb9bccd9731d_157"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">6. <ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzQ5NDc4MDIzMjc0Mzg_66f6b49f-6ec1-49ab-8eae-354aecb593e1" continuedAt="i334d88d3efb34b2090a220379dff7f4c" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i334d88d3efb34b2090a220379dff7f4c" continuedAt="i8583f81128074c9ab603ec7a001c9b62"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Lease</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company leases <ix:nonFraction unitRef="facility" contextRef="i9ded77bb950b4e049558439a9f0bf11d_D20190201-20190228" decimals="INF" format="ixt-sec:numwordsen" name="arqt:LesseeOperatingLeasesNumberFacilitiesLeased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzQ5NDc4MDIzMjc0NTg_c03a150a-d2c0-4f18-a259-1eb22cfa0f6a">one</ix:nonFraction> facility in Westlake Village, California under an operating lease that commenced in February 2019 and has a non-cancelable lease term of <ix:nonNumeric contextRef="i5d311753e065465a809d1745e3b2d439_I20190228" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzQ5NDc4MDIzMjc0NDY_f46fdf36-8c7b-4e70-bed3-c1d815e35f29">30</ix:nonNumeric> months, subject to fixed escalation increases. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzQ5NDc4MDIzMjc0NTE_44044eca-c623-43c7-984b-ba2abbaeebb6" escape="true"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The minimum annual rental payments of the Company&#8217;s operating lease liability as of March&#160;31, 2020 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:85.280%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.720%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (April through December)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTozYzQ4ZjA5YTdkNmM0M2I2YWI2ZWVmY2IxMDVmZDYxMy90YWJsZXJhbmdlOjNjNDhmMDlhN2Q2YzQzYjZhYjZlZWZjYjEwNWZkNjEzXzEtMS0xLTEtMA_be8891df-02a8-4305-80f0-678e64ec2a81">145</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTozYzQ4ZjA5YTdkNmM0M2I2YWI2ZWVmY2IxMDVmZDYxMy90YWJsZXJhbmdlOjNjNDhmMDlhN2Q2YzQzYjZhYjZlZWZjYjEwNWZkNjEzXzItMS0xLTEtMA_d35b5dda-e0fe-4915-963b-6607384298db">132</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total minimum lease payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTozYzQ4ZjA5YTdkNmM0M2I2YWI2ZWVmY2IxMDVmZDYxMy90YWJsZXJhbmdlOjNjNDhmMDlhN2Q2YzQzYjZhYjZlZWZjYjEwNWZkNjEzXzMtMS0xLTEtMA_2f19d174-cdf6-4a03-bb00-724023adc33a">277</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Amounts representing interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTozYzQ4ZjA5YTdkNmM0M2I2YWI2ZWVmY2IxMDVmZDYxMy90YWJsZXJhbmdlOjNjNDhmMDlhN2Q2YzQzYjZhYjZlZWZjYjEwNWZkNjEzXzQtMS0xLTEtMA_9402598d-d439-4193-966c-b8cb52bd7c36">13</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of future minimum lease payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTozYzQ4ZjA5YTdkNmM0M2I2YWI2ZWVmY2IxMDVmZDYxMy90YWJsZXJhbmdlOjNjNDhmMDlhN2Q2YzQzYjZhYjZlZWZjYjEwNWZkNjEzXzUtMS0xLTEtMA_a6a6b29e-2e99-4c27-9345-ef6a81366988">264</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTozYzQ4ZjA5YTdkNmM0M2I2YWI2ZWVmY2IxMDVmZDYxMy90YWJsZXJhbmdlOjNjNDhmMDlhN2Q2YzQzYjZhYjZlZWZjYjEwNWZkNjEzXzYtMS0xLTEtMA_93a7eaf2-a364-4f0a-879b-00d2c1bd65c0">182</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability, noncurrent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTozYzQ4ZjA5YTdkNmM0M2I2YWI2ZWVmY2IxMDVmZDYxMy90YWJsZXJhbmdlOjNjNDhmMDlhN2Q2YzQzYjZhYjZlZWZjYjEwNWZkNjEzXzctMS0xLTEtMA_bd509ecc-dcce-463b-893f-8832f5588f38">82</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTozYzQ4ZjA5YTdkNmM0M2I2YWI2ZWVmY2IxMDVmZDYxMy90YWJsZXJhbmdlOjNjNDhmMDlhN2Q2YzQzYjZhYjZlZWZjYjEwNWZkNjEzXzgtMS0xLTEtMA_5acf0f89-4540-45c2-ad48-70d48a578e79">264</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Straight-line rent expense recognized for operating leases was $<ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzU5Nw_33b5febe-4f6e-4030-a204-74ed9e804007">43,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzMyOTg1MzQ4ODU3MjM_2458bbad-408d-433c-b59f-af0c62f295d5">24,000</ix:nonFraction> for the three months ended March 31, 2020 and 2019, respectively . There were <ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:VariableLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzE2NDkyNjc0NDQxMDg_01fd8a54-f639-40ea-938f-e4d6c5160249"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:VariableLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzE2NDkyNjc0NDQxMDg_a1c61e6f-fd83-47a8-89f9-16c0d3be6d54">no</ix:nonFraction></ix:nonFraction> variable lease payments, including non-lease components such as common area maintenance fees, recognized as rent expense for operating leases for the three months ended March 31, 2020 and 2019.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzQ5NDc4MDIzMzI4OTk_d4eb61fb-3c51-4af6-b9fa-b58db2ebee1f" continuedAt="i3f16e50ba45440d4aff740c6e83e8d3c" escape="true"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following information represents supplemental disclosure for the statement of cash flows related to the Company&#8217;s operating lease (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"><tr><td style="width:1.0%;"></td><td style="width:66.796%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.304%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.394%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.306%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTo3ZmJmZWY1NzdjZGY0MmE3ODEwYzhjZDEyNTc0NTZhYi90YWJsZXJhbmdlOjdmYmZlZjU3N2NkZjQyYTc4MTBjOGNkMTI1NzQ1NmFiXzItMS0xLTEtMA_6b8c67f5-8bfe-49ba-ae7f-4ba90d18a8b6">47</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTo3ZmJmZWY1NzdjZGY0MmE3ODEwYzhjZDEyNTc0NTZhYi90YWJsZXJhbmdlOjdmYmZlZjU3N2NkZjQyYTc4MTBjOGNkMTI1NzQ1NmFiXzItMi0xLTEtNTk4Mg_66e1afa3-3e06-4787-867a-6e6cd13ddaf1">16</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following summarizes additional information related to the operating lease:</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 14</span></div></div></div><hr style="page-break-after:always"/><div style="height:76.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="i8583f81128074c9ab603ec7a001c9b62"><div><ix:continuation id="i3f16e50ba45440d4aff740c6e83e8d3c"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:78.116%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.884%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTowNWQyYjBhYzQ1ZmM0YTM1OGVmM2ViZjMyZDZjNzRiYi90YWJsZXJhbmdlOjA1ZDJiMGFjNDVmYzRhMzU4ZWYzZWJmMzJkNmM3NGJiXzEtMS0xLTEtMA_bbc10808-e6b5-4312-9515-7a4daed6ec77">1.42</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average discount rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTowNWQyYjBhYzQ1ZmM0YTM1OGVmM2ViZjMyZDZjNzRiYi90YWJsZXJhbmdlOjA1ZDJiMGFjNDVmYzRhMzU4ZWYzZWJmMzJkNmM3NGJiXzItMS0xLTEtMA_8fdbdbd0-b212-4dfa-9bdf-efc0f801ae39">7.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></ix:continuation></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2020, the Company amended its lease agreement.  See Note 10. </span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Indemnification</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by California corporate law. The Company currently has directors&#8217; and officers&#8217; insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal.</span></div></ix:continuation><div id="ieeb33ed1376b4f84a553eb9bccd9731d_163"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">7. <ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzQ5NDc4MDIzODMxNDY_8d71f942-01fd-41b5-a1a5-f7552dd281b5" continuedAt="ifff91039a2634c518133fea4ef39ce32" escape="true">Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</ix:nonNumeric></span></div><ix:continuation id="ifff91039a2634c518133fea4ef39ce32" continuedAt="i2b774213164f4969b3edfaf223bc9fe3"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:TemporaryEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzQ5NDc4MDIzNzc1MDU_89d71b47-0318-4c66-bfe7-e35197cbc0a4" escape="true"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Convertible preferred stock as of December&#160;31, 2019 consisted of the following (in thousands, except share amounts):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:48.219%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.713%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.713%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.713%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.714%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible Preferred Stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Shares</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Authorized</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Shares</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Issued and</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Outstanding</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Net</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Carrying</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Value</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Liquidation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Preference</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Series A</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5b476add02454015a5731c133e6fc7d7_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzEtMi0xLTEtMA_f2c1c4b3-95cc-42d5-a4a4-a8eeac8be120">13,800,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5b476add02454015a5731c133e6fc7d7_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzEtNC0xLTEtMA_4b3b027c-a233-41bb-bd57-f147777853cb"><ix:nonFraction unitRef="shares" contextRef="i5b476add02454015a5731c133e6fc7d7_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzEtNC0xLTEtMA_e5d43803-501a-4b07-8cdc-5f08bb3fe9c9">6,897,575</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5b476add02454015a5731c133e6fc7d7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzEtNi0xLTEtMA_31a45924-c5e6-4c19-af97-15abc6d6cecf">14,340</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5b476add02454015a5731c133e6fc7d7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzEtOC0xLTEtMA_64a1497b-d523-45d5-a4fb-17c2a9cf7a99">13,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Series B</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5e66cc37420547df82c325e4bd66ee97_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzItMi0xLTEtMA_8737ed22-fbfe-4c70-a28c-9e259e9f69d0">18,736,270</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5e66cc37420547df82c325e4bd66ee97_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzItNC0xLTEtMA_49dc79fb-827c-4edb-8aca-b1f6ad20f45e"><ix:nonFraction unitRef="shares" contextRef="i5e66cc37420547df82c325e4bd66ee97_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzItNC0xLTEtMA_6809c3db-530a-436a-abd1-341238bd6e94">9,364,850</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e66cc37420547df82c325e4bd66ee97_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzItNi0xLTEtMA_6b143ff2-8c09-4f79-bdc9-a560e22ad6e4">57,912</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e66cc37420547df82c325e4bd66ee97_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzItOC0xLTEtMA_8d5bff2d-ee66-4e85-8906-745e32c5fb3e">58,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series C</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iad26b06911dd45ed94719ead6186feb7_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzMtMi0xLTEtMA_6ecec376-9f71-4772-9d79-cdfc6c36764f">16,251,628</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iad26b06911dd45ed94719ead6186feb7_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzMtNC0xLTEtMA_cabfd20a-fd5f-4a65-96d3-91531dab074b"><ix:nonFraction unitRef="shares" contextRef="iad26b06911dd45ed94719ead6186feb7_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzMtNC0xLTEtMA_de520705-752c-47d9-9664-a78885b2b1f6">8,122,963</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad26b06911dd45ed94719ead6186feb7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzMtNi0xLTEtMA_6e31200a-020a-4bea-8842-11ba5026a9aa">94,239</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad26b06911dd45ed94719ead6186feb7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzMtOC0xLTEtMA_430cdd66-157e-4ea3-a795-390b34f17b1a">94,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzQtMi0xLTEtMA_43a8cda3-c79b-496b-b119-b835be6d1c6c">48,787,898</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzQtNC0xLTEtMA_b430f93c-8e5a-4908-98b8-3f233f4027a4"><ix:nonFraction unitRef="shares" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzQtNC0xLTEtMA_d73ed3d6-2529-49b1-b657-06d93cc00393">24,385,388</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzQtNi0xLTEtMA_eb474867-a4a7-4f9c-a496-657b0afb9006">166,491</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzQtOC0xLTEtMA_3b31f118-82ad-4834-a15d-7cee978ce0ff">166,300</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In connection with the Company's IPO in January 2020, all of the Company&#8217;s outstanding shares of convertible preferred stock were automatically converted into <ix:nonFraction unitRef="shares" contextRef="i1a9f8349a2ae4825872a95b128a3bfb7_D20200101-20200131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzE2NDkyNjc0OTQxODI_2917ce16-5835-4d3e-9157-e5bb2a3747d5">24,385,388</ix:nonFraction> shares of common stock. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In October 2019, the Company issued <ix:nonFraction unitRef="shares" contextRef="i1062618a24794d61acad0065c0f8c0b6_D20191001-20191031" decimals="INF" format="ixt:numdotdecimal" name="arqt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEwOTk1MTE2ODU5MzI_9f09bd48-22c0-4700-87a1-1d121e4a0770">8,122,963</ix:nonFraction> shares of Series C convertible preferred stock at a purchase price of  $<ix:nonFraction unitRef="usdPerShare" contextRef="i1ffb101d690c48ea9f6c1d9b6bb0766a_I20191031" decimals="INF" name="arqt:TemporaryEquityStockIssuedDuringPeriodPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEwOTk1MTE2ODU5MzY_d969bde8-f076-426e-844d-8fb490054555">11.63</ix:nonFraction> per share for total gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i1062618a24794d61acad0065c0f8c0b6_D20191001-20191031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEwOTk1MTE2ODU5Mzk_d40a355a-5ae7-4649-9a7a-69da396db59a">94.5</ix:nonFraction>&#160;million, some of which were to related parties. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2018, the Company issued  <ix:nonFraction unitRef="shares" contextRef="i53f18004827140e6b2a5880ba03e14cd_D20180901-20180930" decimals="INF" format="ixt:numdotdecimal" name="arqt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEwOTk1MTE2ODU5NTc_7a0af26d-6a61-4f45-be12-e62a62d3ef50">9,364,850</ix:nonFraction> shares of Series B convertible preferred stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i20520734ab804d1c969a5f694d1a77fb_I20180930" decimals="INF" name="arqt:TemporaryEquityStockIssuedDuringPeriodPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEwOTk1MTE2ODU5NDc_267ea9e1-4242-42df-a625-a78bb234b948">6.19</ix:nonFraction> per share for total proceeds of $<ix:nonFraction unitRef="usd" contextRef="i53f18004827140e6b2a5880ba03e14cd_D20180901-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEwOTk1MTE2ODU5NTE_5dc72bf6-e914-4dca-b6a2-71a8483d0748">57.9</ix:nonFraction>&#160;million, some of which were to related parties.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In April 2017, the Company entered into a Stock Purchase Agreement with investors, some of which were related parties, to issue <ix:nonFraction unitRef="shares" contextRef="i942ea4487a4f4c628dbc72aa9142bb0b_D20170401-20170430" decimals="INF" format="ixt:numdotdecimal" name="arqt:StockPurchaseAgreementNumberOfSharesIssuable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzU4OA_4de1d247-7774-4bcc-853f-0538186a0bff">5,398,111</ix:nonFraction> shares of Series A convertible preferred stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="i27b66ebff3c74dffbed70e3df8d94527_I20170430" decimals="2" name="arqt:StockPurchaseAgreementPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzY0MQ_d97e26fe-693a-4842-a5a7-42d4db83b23c">2.00</ix:nonFraction> per share in <ix:nonFraction unitRef="tranche" contextRef="ia747c28018db42518e5a81eb98a4730a_D20170401-20170430" decimals="INF" format="ixt-sec:numwordsen" name="arqt:StockPurchaseAgreementNumberOfTranches" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzY1Nw_6ff6d23a-aa34-42f0-914c-5ce43c24ecfa">three</ix:nonFraction> tranches. The first tranche, consisting of <ix:nonFraction unitRef="shares" contextRef="ic429b8e3655e404cb0d751419b0af0f5_D20170401-20170430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzcwMw_59cef2bc-713e-4b8a-843f-474ff2ec0b7c">3,590,845</ix:nonFraction> shares for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic429b8e3655e404cb0d751419b0af0f5_D20170401-20170430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzczMw_92638d6d-9171-45f4-be70-b97c1900b89e">7.1</ix:nonFraction> million, was completed upon execution of the agreement. Additionally, the Company issued <ix:nonFraction unitRef="shares" contextRef="i942ea4487a4f4c628dbc72aa9142bb0b_D20170401-20170430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzgxNw_b939a027-f47f-4eb3-9193-02a8f167997f">149,946</ix:nonFraction> shares of Series A convertible preferred stock as a result of the conversion of convertible promissory notes with an outstanding principal amount of $<ix:nonFraction unitRef="usd" contextRef="iaa626818057b4ec09c7780eda24ee280_I20170430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3Xzk2OQ_352fcfff-761e-47ef-bfa5-823afec24918">154,000</ix:nonFraction> and the settlement of the derivative liability of $<ix:nonFraction unitRef="usd" contextRef="i27b66ebff3c74dffbed70e3df8d94527_I20170430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEwMjI_bbd8e025-79fb-41f5-abb3-2efe61a1d83f">150,000</ix:nonFraction>.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Series A investors were also granted freestanding rights to participate in additional tranches to raise a minimum of $<ix:nonFraction unitRef="usd" contextRef="ida7d99ff74274d4bb97416ec9c8ce692_D20170401-20170430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzExNjA_f8f91825-79e1-4fc9-960d-64fa6c3a0307">3.3</ix:nonFraction> million, upon election by the board of directors including at least one of the Series A directors, by purchasing <ix:nonFraction unitRef="shares" contextRef="ida7d99ff74274d4bb97416ec9c8ce692_D20170401-20170430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEyNjg_05e940f9-806e-47d1-ae03-19f7a3b3bcd3">1,657,314</ix:nonFraction> shares of Series A convertible preferred stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="iad794190a8a2452ea081cd173d9a46c3_I20170430" decimals="INF" name="arqt:StockPurchaseAgreementPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEzMjE_dc13fa23-38ed-479c-b358-1d7582395108">2.00</ix:nonFraction> per share in two tranches, provided such election occurred prior to April 2019. The two tranches consisted of <ix:nonFraction unitRef="shares" contextRef="i18c87385f652426f9c3d56028cd4c845_D20170401-20170430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzE0MzI_39462635-ae3e-4bfa-b7b2-3c1ddfac624b">828,654</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i3d9f11fde515494ebe9f46b322624540_D20170401-20170430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzE0NDY_dbe30d03-daed-46f0-b663-4035b5b68a8c">828,660</ix:nonFraction> shares, </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 15</span></div></div></div><hr style="page-break-after:always"/><div style="height:76.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="i2b774213164f4969b3edfaf223bc9fe3"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">respectively. The Company concluded that the investors&#8217; rights to purchase Series&#160;A convertible preferred shares met the definition of a freestanding financial instrument, as they were legally detachable and separately exercisable from the Series&#160;A convertible preferred stock, or the Series&#160;A Convertible Preferred Stock Liability. As the Series&#160;A Convertible Preferred Stock Liability was redeemable at the election of holders of the then-outstanding shares, it represented a liability to be accounted for at fair value and remeasured at each reporting period.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Changes in fair value were recognized as a gain or loss in other income (expense), net in the statement of operations. On the closing of the first tranche in April 2017, the Company recorded the initial fair value of the Series&#160;A Convertible Preferred Stock Liability of $<ix:nonFraction unitRef="usd" contextRef="iad794190a8a2452ea081cd173d9a46c3_I20170430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzIyOTA_12113265-a345-4d7d-9109-d614d2d46f71">219,000</ix:nonFraction> for the second and the third tranche participating rights by reducing the carrying value of Series&#160;A convertible preferred stock.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2018, the Company completed the second tranche closing and issued <ix:nonFraction unitRef="shares" contextRef="i867ead9d7de94ae2b7a3e1230d8c1445_D20180301-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzI0OTg_0eff7e56-ee7a-4fa7-ad01-4d2fd5ae9706">3,156,784</ix:nonFraction> shares of Series A convertible preferred stock to the investors at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i61291be8ab45405ba6ff41986ea2bbf9_I20180331" decimals="INF" name="arqt:StockPurchaseAgreementPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzI1ODg_fbf847d8-8d3b-48af-b249-54ec81ea9825">2.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i867ead9d7de94ae2b7a3e1230d8c1445_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzI2MjE_7b952237-62ec-43de-919d-41ffa62659b8">6.3</ix:nonFraction> million. The Series&#160;A Convertible Preferred Stock Liability was remeasured to fair value just prior to settlement and the carrying value of the liability of $<ix:nonFraction unitRef="usd" contextRef="i0dd4a2ea8e4e424cad9bf90013a09f85_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzI3NzM_2c09ff49-550f-4142-86b4-29ff2f28cfd6">891,000</ix:nonFraction> was reclassified to Series A convertible preferred stock. Concurrently with the closing of the second tranche, the Company amended the Series A convertible preferred stock purchase agreement to merge the second and third tranches and increased the maximum number of shares to be issued in the second tranche to <ix:nonFraction unitRef="shares" contextRef="i152ee54c83c44c9c86787fc4619f617a_D20180301-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzMwNzY_bc9fc96a-d325-4a06-85ab-5bb8778f7b87">3,156,784</ix:nonFraction> shares. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The holders of the Company&#8217;s common stock have <ix:nonFraction unitRef="vote" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="arqt:CommonStockVotingRightsNumberOfVotesPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3Xzg2OTY_5f3d90ce-7b59-4a57-88bb-4838a4ef2ee6">one</ix:nonFraction> vote for each share of common stock. Common stockholders are entitled to dividends when, as, and if declared by the Board of Directors. The holders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. As of March&#160;31, 2020, no dividends had been declared by the Board of Directors.</span></div><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzQ5NDc4MDIzNzc1MDY_6d5e8fab-1d95-4a5f-94b8-3fbbd65456a0" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company reserved the following shares of common stock for issuance as follows: </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:73.877%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.698%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible preferred stock outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7b0f602239da479bbb94f0b7c7888beb_I20200331" decimals="INF" format="ixt:zerodash" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzItMS0xLTEtMA_12c8196c-9e27-497c-8c87-3c01cb4b3796">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id0cb10ec032b42cca2753ec0e703a0a9_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzItMy0xLTEtMA_61722cc3-8f66-47f3-a928-83c53ad48d6a">24,385,388</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options issued and outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i207e672bf24642c4940bf0d793c0d8ad_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzMtMS0xLTEtMA_63d9906e-87f1-46d3-960d-4354b9ccacca">3,061,521</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0a758e1969d84f21965d253803feda4d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzMtMy0xLTEtMA_ab1529b9-f44c-41a8-ba8f-ee543a023bea">2,516,470</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock awards available for grant under employee benefit plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9c825f7e0bd049b3873b9f06a243c9cc_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzQtMS0xLTEtMA_680797c8-5f18-4b35-860a-1765e810e6f8">3,251,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i10726fed81d54f6ab986a0927852ce81_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzQtMy0xLTEtMA_cb22bdde-6eb8-400c-984f-e84e0baf16d8">1,550,150</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia583a93b899d4da9a404725241db7368_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzUtMS0xLTEtMTMzNw_10cf7720-fe3c-4afa-b18f-71dffe355f56">130,060</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if9c67f350dc54f669cff5762e4c650f0_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzUtMy0xLTEtMTMzNw_c5c07561-6f3b-4cdd-9da1-9c225bf97a59">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total common stock reserved</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzUtMS0xLTEtMA_5a937a74-c08c-48f3-9ed9-20231e7fc3ec">6,443,471</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzUtMy0xLTEtMA_bd77dbae-1054-4029-8887-e1a4b6563332">28,452,008</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Authorized Share Capital</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On February 4, 2020, the Company&#8217;s certificate of incorporation was amended and restated to provide for <ix:nonFraction unitRef="shares" contextRef="i41086ad648ca4627b4da6abb4a3801d2_I20200204" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzQ5NDc4MDIzNzc0NjQ_a2496e42-d262-4f24-ab89-8bce8b04bbc5">300,000,000</ix:nonFraction> authorized shares of common stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i41086ad648ca4627b4da6abb4a3801d2_I20200204" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzQ5NDc4MDIzNzc0NzY_8904a0d0-3f89-477c-9bde-a2e5b6f601c4">0.0001</ix:nonFraction> per share and <ix:nonFraction unitRef="shares" contextRef="i41086ad648ca4627b4da6abb4a3801d2_I20200204" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzQ5NDc4MDIzNzc0ODU_54a43335-1ecc-4526-b4eb-c787b0c0c62a">10,000,000</ix:nonFraction> authorized shares of preferred stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i41086ad648ca4627b4da6abb4a3801d2_I20200204" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzQ5NDc4MDIzNzc0OTc_e5bc15d5-dab4-4ae5-8913-6b80545f7ca7">0.0001</ix:nonFraction> per share.  There were <ix:nonFraction unitRef="shares" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzIxOTkwMjMzMTM2NTI_19191384-3824-45d0-8951-fa2467dba51c"><ix:nonFraction unitRef="shares" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzIxOTkwMjMzMTM2NTI_93c57fbe-0524-4f13-919a-7c02854daa59">no</ix:nonFraction></ix:nonFraction> shares of preferred stock outstanding as of March&#160;31, 2020 and December&#160;31, 2019.</span></div></ix:continuation><div id="ieeb33ed1376b4f84a553eb9bccd9731d_169"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">8. <ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2NTI_212809bc-8539-4a92-a091-fab3e6f37eb1" continuedAt="i02d8e5fe3bb74759b766c5239eb93aff" escape="true">Stock-Based Compensation  </ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i02d8e5fe3bb74759b766c5239eb93aff" continuedAt="i790731bd638d4449ac1343e9ef882c5a">In January 2020, the Company&#8217;s board of directors approved the 2020 Equity Incentive Plan, or the 2020 Plan, which became effective upon the completion of the IPO on January 31, 2020. The 2020 Plan serves as the successor incentive award plan to the Company&#8217;s 2017 Equity Incentive Plan, or the 2017 Plan, and has <ix:nonFraction unitRef="shares" contextRef="i1b0b464dfc864b54803e7d3f742e0da3_I20200131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2MDQ_de0d544c-56a1-4fb5-a4e6-3642a3dc395f">2,134,000</ix:nonFraction> shares of common stock available for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock-based awards, plus <ix:nonFraction unitRef="shares" contextRef="i547d9f383e9b4debbdbb809301a8f689_I20200131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzE2NDkyNjc0NTQ1OTE_138bfbc6-bd74-4b02-ba9a-bae5ab6b9e91">1,550,150</ix:nonFraction> shares of common stock that were reserved for issuance pursuant to future awards under the 2017 Plan at the time the 2020 Plan became effective, plus shares represented by awards outstanding under the 2017 Plan that are forfeited or lapse unexercised and which following the effective date of the 2020 Plan are not issued under the 2017 Plan. In addition, the 2020 Plan reserve will increase on January 1, 2021 </ix:continuation></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 16</span></div></div></div><hr style="page-break-after:always"/><div style="height:76.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="i790731bd638d4449ac1343e9ef882c5a" continuedAt="i8cbb65ae689b4d25b6535b3c6d3f4f2c"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and each subsequent anniversary through 2030, by an amount equal to the lesser of (a) <ix:nonFraction unitRef="number" contextRef="i1b0b464dfc864b54803e7d3f742e0da3_I20200131" decimals="INF" format="ixt-sec:numwordsen" name="arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzE2NDkyNjc0NTY2NjI_0dc8575c-2b29-4db5-8011-6192e9829cb7">four</ix:nonFraction> percent of the shares of stock outstanding (on an as converted basis) on the day immediately prior to the date of increase and (b) such smaller number of shares of stock as determined by our board of directors; provided, however, that no more than <ix:nonFraction unitRef="shares" contextRef="i1b0b464dfc864b54803e7d3f742e0da3_I20200131" decimals="INF" format="ixt:numdotdecimal" name="arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzE2NDkyNjc0NTY2NjQ_c2ed2f66-50b4-41c2-8008-9e4fe56440a4">11,000,000</ix:nonFraction> shares of stock may be issued upon the exercise of incentive stock options.  As of March&#160;31, 2020, the Company had <ix:nonFraction unitRef="shares" contextRef="i5b305cb4d63342bea9f25125973619f8_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzE2NDkyNjc0NjUzOTU_2db755a3-7950-43ab-a125-1b110b7a6323">2,900,890</ix:nonFraction> shares available for future grant under the 2020 Plan.</span><span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2020 Plan provides for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the board of directors and consultants of the Company under terms and provisions established by the board of directors. Under the terms of the 2020 Plan, options may be granted at an exercise price not less than fair market value. The Company generally grants stock-based awards with service conditions. Options granted typically vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzY4NA_1160bc3e-4896-43bb-92b1-9fd3b49a3ce7">four</span>-year period but may be granted with different vesting terms.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following the Company&#8217;s IPO and in connection with the effectiveness of the Company&#8217;s 2020 Plan, the 2017 Plan terminated and no further awards will be granted under that plan. However, all outstanding awards under the 2017 Plan will continue to be governed by their existing terms.</span></div><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2MTU_13e524d5-b94b-47dc-af1e-5edb50c3925e" escape="true"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Option Activity</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following summarizes option activity (in thousands, except share amounts):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:45.807%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.947%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.701%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Number of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Weighted-</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Term</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Aggregate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Intrinsic</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance&#8212;December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzEyLTEtMS0xLTA_65124c9d-addf-4c03-a2e9-ef06098795c7">2,516,470</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzEyLTMtMS0xLTA_8f4bfb73-0efd-4978-bd4d-b6b45739b268">3.47</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idadd6a2a73da44689130341aaab4e04a_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzEyLTUtMS0xLTA_f165a186-d4c8-4a38-9cc9-902f0653448a">9.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzEyLTctMS0xLTA_63af5f7b-616f-4e15-9d7c-7d8b19a8da53">7,673</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzItMS0xLTEtNDcw_90687a65-9d51-4640-a754-a5513278dd56">653,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzItMy0xLTEtNDcw_c5690a6c-5b6c-4772-881c-909990a25712">26.92</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzMtMS0xLTEtNDcw_60f30dcb-e6e5-49b9-8b8a-a1f4fd44b499">108,149</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzMtMy0xLTEtNDcw_19f0177e-96b9-4562-a65f-2ab844b39f65">2.30</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance&#8212;March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzYtMS0xLTEtNDcw_424ac7ac-3037-431b-99ab-39e883d7492f">3,061,521</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzYtMy0xLTEtNDc2_e1d052fa-0d9c-4485-bc8a-704a7f830139">8.52</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzYtNS0xLTEtNDcw_6773dc05-9831-4824-a23c-aefaaf4896e7">9.35</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzYtNy0xLTEtNDcw_cf372b6a-2f8e-4334-ab06-3344e55988dd">65,155</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable&#8212;March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzEzLTEtMS0xLTA_6a710ea1-9df4-4b58-a1d7-b4b92aa1ec0d">1,686,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzEzLTMtMS0xLTA_3c96d6d1-c906-4dd8-857a-879be550bf03">5.85</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzEzLTUtMS0xLTA_016f348b-275a-4f0c-b1d8-97686effba6a">9.24</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzEzLTctMS0xLTA_8823be8b-5a1c-40d6-8baf-c614a97e88fd">40,408</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt;">Options exercisable includes early exercisable options.</span></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock as of March&#160;31, 2020. As of December&#160;31, 2019, prior to the Company's IPO, the estimated fair value of the Company's common stock was determined by the board of directors.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The intrinsic value of options exercised for the three months ended March 31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDU3NDA_6a50ddad-f753-4e37-a82e-b8b87e247204">1.5</ix:nonFraction> million. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total grant-date fair value of the options vested during the three months ended March 31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDU3ODg_2c3d371a-3427-411c-85d5-d52ec749aa47">367,000</ix:nonFraction>. The weighted-average grant-date fair value of employee options granted during the three months ended March 31, 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDU4NzI_c724ac2a-5c16-4409-8623-71e75dd94f87">16.94</ix:nonFraction>.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Unit Activity</span></div><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzU0OTc1NTgxNzU3OTg_703c24c5-564b-43be-98f4-d4180258c43e" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes information regarding our restricted stock units (RSUs):</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:60.719%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.543%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.992%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.546%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance&#8212;December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if9c67f350dc54f669cff5762e4c650f0_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzEtMS0xLTEtMTQzMg_b8a7f81a-6dd7-4892-9488-aa71a8f8ab04">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="if9c67f350dc54f669cff5762e4c650f0_I20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzEtMy0xLTEtMTQzMg_53e62f64-784b-41cd-b8e2-f91277104772">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzItMS0xLTEtMTQzMg_b4c8a14e-0ead-4438-b5a2-f001ee58981c">130,060</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzItMy0xLTEtMTQzMg_41d8bea5-f5a3-4f83-9d23-8cee12f0696c">27.61</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzMtMS0xLTEtMTQzMg_62e14ecc-3751-4889-b536-836b99219b9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331" decimals="2" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzMtMy0xLTEtMTQzMg_2e7c30f9-ed79-440c-9327-615d2e02bd09">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzQtMS0xLTEtMTQzMg_f143e081-eab7-4aea-ac7f-3f53de9edfeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzQtMy0xLTEtMTQzMg_a0e94e2a-b988-491b-8afd-ba819c2f59fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested Balance&#8212;March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia583a93b899d4da9a404725241db7368_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzUtMS0xLTEtMTQzNg_faa4ace1-5cce-4061-91c9-4209b278f29a">130,060</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia583a93b899d4da9a404725241db7368_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzUtMy0xLTEtMTQzNg_91ee6784-5a8f-4b0c-b689-09cb2e1370c2">27.61</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 17</span></div></div></div><hr style="page-break-after:always"/><div style="height:76.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="i8cbb65ae689b4d25b6535b3c6d3f4f2c" continuedAt="i23d64a9c702c47cabbfd4ffdb17b9d49"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The grant date fair value of an RSU equals the closing price of our common stock on the grant date.  RSUs generally vest equally over <ix:nonNumeric contextRef="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzEyNjQ0MzgzNzU2MDU5_dc9c9b7c-d2ca-4516-96fe-2181c3e85e2c">4</ix:nonNumeric> years.  There were no RSU grants prior to January 1, 2020.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2MTc_cfca0240-f077-488f-a8c6-d5da918a58b9" escape="true"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation Expense</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation expense recognized in our Condensed Statements of Operations and Comprehensive Loss was as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:56.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.906%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.031%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i99319e5db9304bce8368150c3126f923_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTo0MGZkZWNhMjQ2YjE0N2M0YThjMzc5YjZiMzFkZjE2OS90YWJsZXJhbmdlOjQwZmRlY2EyNDZiMTQ3YzRhOGMzNzliNmIzMWRmMTY5XzItMS0xLTEtMA_fd3b8f9c-040e-493d-8138-9001e9a4ffe9">416</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i729f8784fd4e49eba8ee589ee7ffb428_D20190101-20190331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTo0MGZkZWNhMjQ2YjE0N2M0YThjMzc5YjZiMzFkZjE2OS90YWJsZXJhbmdlOjQwZmRlY2EyNDZiMTQ3YzRhOGMzNzliNmIzMWRmMTY5XzItMy0xLTEtMA_d86d94d3-e860-4f60-a5c4-20b0b2da2a5e">31</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic428fc4a3f5544cdb4cd99f3463113b0_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTo0MGZkZWNhMjQ2YjE0N2M0YThjMzc5YjZiMzFkZjE2OS90YWJsZXJhbmdlOjQwZmRlY2EyNDZiMTQ3YzRhOGMzNzliNmIzMWRmMTY5XzMtMS0xLTEtMA_900c69d1-cb3e-4575-b28a-ec39ce83a416">574</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0baf33cc0dc243f780ad057920f62292_D20190101-20190331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTo0MGZkZWNhMjQ2YjE0N2M0YThjMzc5YjZiMzFkZjE2OS90YWJsZXJhbmdlOjQwZmRlY2EyNDZiMTQ3YzRhOGMzNzliNmIzMWRmMTY5XzMtMy0xLTEtMA_4eed1f78-374f-4b2f-8961-ba903690c560">45</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stock-based compensation expense</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTo0MGZkZWNhMjQ2YjE0N2M0YThjMzc5YjZiMzFkZjE2OS90YWJsZXJhbmdlOjQwZmRlY2EyNDZiMTQ3YzRhOGMzNzliNmIzMWRmMTY5XzQtMS0xLTEtMA_657e2a29-62f4-4680-8851-59e77001fb29">990</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTo0MGZkZWNhMjQ2YjE0N2M0YThjMzc5YjZiMzFkZjE2OS90YWJsZXJhbmdlOjQwZmRlY2EyNDZiMTQ3YzRhOGMzNzliNmIzMWRmMTY5XzQtMy0xLTEtMA_b8cd45cd-fe57-4ef6-bdde-f58dac39dc44">76</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="idde51cc55856491d9916e0b6960bac95_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzI1NjI_4ad4b2cf-885e-462a-93dc-03d79c30078d">15.8</ix:nonFraction> million of total unrecognized compensation cost related to unvested options that are expected to vest, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i6ec1cf8ff84648708b4c86b19e7f6130_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzI3MzI_eb015534-16a4-4909-bf2e-d8a3abff3e9e">3.4</ix:nonNumeric> years.  As of March&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="ia583a93b899d4da9a404725241db7368_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzIxOTkwMjMyODk1ODg_940aad47-8b8a-4f9a-98fc-54b0daf23207">3.6</ix:nonFraction> million of total unrecognized compensation cost related to RSUs that is expected to vest, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzIxOTkwMjMyODk1ODU_90136fdd-2276-42c9-bcd3-3f93741f7909">3.9</ix:nonNumeric> years.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining the fair value of the stock options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment.</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair value of common stock&#8212;  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For options granted prior to IPO in the year ended December 31, 2019, given the absence of a public trading market, the Company&#8217;s board of directors with input from management considered numerous objective and subjective factors to determine the fair value of common stock. The factors included, but were not limited to: (i)&#160;third-party valuations of the Company&#8217;s common stock; (ii)&#160;the Company&#8217;s stage of development; (iii)&#160;the status of research and development efforts; (iv)&#160;the rights, preferences and privileges of the Company&#8217;s convertible preferred stock relative to those of the Company&#8217;s common stock; (v)&#160;the Company&#8217;s operating results and financial condition, including the Company&#8217;s levels of available capital resources; and (vi)&#160;equity market conditions affecting comparable public companies; (vii)&#160;general U.S. market conditions; and (viii)&#160;the lack of marketability of the Company&#8217;s common stock. For options granted after IPO, the Company uses its closing stock price as reported on Nasdaq on the grant date for the fair value of its stock.</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Term</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The Company&#8217;s expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding. The Company used the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term.</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Volatility</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;Since the Company does not have sufficient trading history for its common stock, the expected volatility was estimated based on the average historical volatilities for comparable publicly traded pharmaceutical companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle and area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-Free Interest Rate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Dividend Yield</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of <ix:nonFraction unitRef="number" contextRef="i36f41495899d443b9ef4ab7d9ca80854_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzUwOTg_58840bc0-f5a8-4c4e-bb65-f1e42e1b3410">zero</ix:nonFraction>.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 18</span></div></div></div><hr style="page-break-after:always"/><div style="height:76.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="i23d64a9c702c47cabbfd4ffdb17b9d49" continuedAt="i5ee6ac144772416aac8f64e402dd06bf"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2MTk_037d96a8-018a-4dbb-87e8-e9e8fd471470" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of stock option awards granted was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.736%;"><tr><td style="width:1.0%;"></td><td style="width:61.425%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.901%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.571%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.903%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expected term (in years)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="ic4ad05013c344f86873c31d6f40cb48b_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzItMS0xLTEtMC90ZXh0cmVnaW9uOmE5ZjNiMzU3NTZiMDRkNjliYjc4YzhjOTc3NjUxYmE3XzQ5NDc4MDIzMjUwMDg_e6c74bf5-3327-4179-8466-05a61d7c240e">5.5</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i60fc0bcc4f7e43c9b071698d2cab142b_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzItMS0xLTEtMC90ZXh0cmVnaW9uOmE5ZjNiMzU3NTZiMDRkNjliYjc4YzhjOTc3NjUxYmE3XzQ5NDc4MDIzMjUwMTM_756971e6-0935-4386-8e31-72d3691d1320">6.1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i79205ea8bd33408992b1551901172816_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzItMy0xLTEtMC90ZXh0cmVnaW9uOjRkZjU0NjRkYzc1YjQyZjBiNjk4YzYyMTcwNDU5OTg2XzQ5NDc4MDIzMjUwMjQ_d6aab670-461b-432e-a537-9944700f417a">5.1</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i330111f8ba794d7fae3926a5518de13b_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzItMy0xLTEtMC90ZXh0cmVnaW9uOjRkZjU0NjRkYzc1YjQyZjBiNjk4YzYyMTcwNDU5OTg2XzQ5NDc4MDIzMjUwMTM_b0220792-a3cf-4c3d-a9dd-0fdc9ded030a">6.6</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expected volatility</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i6ec1cf8ff84648708b4c86b19e7f6130_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjFhMTE0MTNiMTBmYjQ1NmQ4YjYwNzk4NDlhNmJlZjNhXzQ5NDc4MDIzMjUwMTI_efdc3ddc-0743-4f9c-ada2-75a8fc60b280">71.2</ix:nonFraction>&#160;&#8211;&#160;<ix:nonFraction unitRef="number" contextRef="i6ec1cf8ff84648708b4c86b19e7f6130_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjFhMTE0MTNiMTBmYjQ1NmQ4YjYwNzk4NDlhNmJlZjNhXzQ5NDc4MDIzMjUwMTk_4ceaed2b-701e-49e5-8524-64c6b41fb6f8">73.3</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i032684c2259b4403a7e8ab7dc81e250c_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzMtMy0xLTEtMC90ZXh0cmVnaW9uOjRjMTJhNjM2Y2EzMjQxNTNiMTFhYjQxZWQzZTNlYzkwXzQ5NDc4MDIzMjUwMTI_d2101a74-662d-42bd-96cc-0b6b28ac5501">68.6</ix:nonFraction>&#160;&#8211;&#160;<ix:nonFraction unitRef="number" contextRef="i032684c2259b4403a7e8ab7dc81e250c_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzMtMy0xLTEtMC90ZXh0cmVnaW9uOjRjMTJhNjM2Y2EzMjQxNTNiMTFhYjQxZWQzZTNlYzkwXzQ5NDc4MDIzMjUwMTk_527afd45-8635-4cd6-8baa-34674a83e685">72.5</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Risk-free interest rate</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i6ec1cf8ff84648708b4c86b19e7f6130_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmE0Y2ZkNzRjNmY0NTQ4MTVhMDY2ZjBkODYyYmQ0ZDliXzQ5NDc4MDIzMjUwMDk_688b824b-09be-4b2a-a776-3f1491a26864">0.5</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i6ec1cf8ff84648708b4c86b19e7f6130_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmE0Y2ZkNzRjNmY0NTQ4MTVhMDY2ZjBkODYyYmQ0ZDliXzQ5NDc4MDIzMjUwMTU_7a54600c-ee34-4dc9-a6c6-77afbde49985">1.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i032684c2259b4403a7e8ab7dc81e250c_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzQtMy0xLTEtMC90ZXh0cmVnaW9uOmY3ODQzNDJlMjlkYTQwZmQ5M2E2ZDc4NjA3MzMzZTk2XzQ5NDc4MDIzMjUwMDk_98fb9947-4216-4058-b6a9-d1280e49ee45">1.6</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i032684c2259b4403a7e8ab7dc81e250c_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzQtMy0xLTEtMC90ZXh0cmVnaW9uOmY3ODQzNDJlMjlkYTQwZmQ5M2E2ZDc4NjA3MzMzZTk2XzQ5NDc4MDIzMjUwMTU_1a243354-ae34-4a81-8d57-252da0240849">2.6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dividend yield</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6ec1cf8ff84648708b4c86b19e7f6130_D20200101-20200331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzUtMS0xLTEtMA_dc03b472-7f30-4e6c-9e82-a05b3477d067">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i032684c2259b4403a7e8ab7dc81e250c_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzUtMy0xLTEtMA_9f1e6437-ad7e-4e21-af29-e70207e52f22">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Early Exercise of Employee Options</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The terms of the 2017 and 2020 Plans permit certain option holders to exercise options before their options are vested, subject to certain limitations. Upon early exercise, the awards become subject to a restricted stock agreement. The shares of restricted stock granted upon early exercise of the options are subject to the same vesting provisions in the original stock option awards. Shares issued as a result of early exercise that have not vested are subject to repurchase by the Company upon termination of the purchaser&#8217;s employment, at the price paid by the purchaser. Such shares are not deemed to be issued for accounting purposes until they vest and are therefore excluded from shares outstanding and from basic and diluted net loss per share until the repurchase right lapses and the shares are no longer subject to the repurchase feature. The liability is reclassified into common stock and additional paid-in capital as the shares vest and the repurchase right lapses. Accordingly, the Company has recorded the unvested portion of the exercise proceeds of $<ix:nonFraction unitRef="usd" contextRef="if4b3c7b09a81456aa8c7c67220c1937a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDU5NTU_badc87b3-5fdc-4ead-83cf-405527a3360b">475,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="icf1aac6536334060af468f8eeb2e8eb9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDU5Nzc_d3a5e832-e22c-41a5-a2c2-0ac50e5b1de2">409,000</ix:nonFraction> as a liability from the early exercise in the accompanying balance sheet as of March&#160;31, 2020 and December&#160;31, 2019, respectively. As of March&#160;31, 2020 and December&#160;31, 2019,  there were $<ix:nonFraction unitRef="usd" contextRef="if4b3c7b09a81456aa8c7c67220c1937a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDYwMDU_b383d1ca-21c3-4202-99ee-aa92e46c0713">269,000</ix:nonFraction> and  $<ix:nonFraction unitRef="usd" contextRef="icf1aac6536334060af468f8eeb2e8eb9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDYwMjc_9493ec11-a50c-4732-b37d-23beba4504a1">225,000</ix:nonFraction> recorded in accrued liabilities, respectively, and $<ix:nonFraction unitRef="usd" contextRef="if4b3c7b09a81456aa8c7c67220c1937a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDYwMzA_3e0d0abb-3d95-4fba-993f-c54717cf53fe">206,000</ix:nonFraction> and  $<ix:nonFraction unitRef="usd" contextRef="icf1aac6536334060af468f8eeb2e8eb9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDYwMzM_596f6165-3c77-4261-84b8-561a88bbe8ea">184,000</ix:nonFraction> recorded in other long-term liabilities, respectively related to shares that were subject to repurchase.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Founder Awards</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2016, the Company issued <ix:nonFraction unitRef="shares" contextRef="i36e62b08be8541cfb10cebab50e8f747_D20160801-20160831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzY3MTE_641cdf98-8124-4b71-b2af-f723397a9274">1,187,738</ix:nonFraction> shares of restricted common stock to founders of which <ix:nonFraction unitRef="shares" contextRef="i7c280cdb092b45edb7e2214f3ed3cebe_D20160801-20160831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzY3Njk_5070470f-9085-408b-b7bf-996318260bc6">1,102,903</ix:nonFraction> shares vest under a service condition and <ix:nonFraction unitRef="shares" contextRef="i6bbb52f6091c4868b5b32ba40fc51240_D20160801-20160831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzY4MTQ_c0670544-4ae5-4622-858e-d2e9d2023f85">84,835</ix:nonFraction> shares vest under a performance condition. The shares were issued under the terms of the respective restricted stock purchase agreements, or the Stock Purchase Agreement, and unvested shares are subject to repurchase by the Company at the original purchase price per share upon the holder&#8217;s termination of his relationship with the Company. The restricted shares are not deemed to be issued for accounting purposes until they vest and are therefore excluded from shares outstanding and from basic and diluted net loss per share until the repurchase right lapses and the shares are no longer subject to the repurchase feature. One-fourth of the <ix:nonFraction unitRef="shares" contextRef="i7f0bea76e3b04ffcb5683a3e920f6fb6_D20160801-20160831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzc0NjE_ee0426a6-965f-4228-b0d0-47ebee67ccf1">1,102,903</ix:nonFraction> shares of restricted common stock were vested on the first-anniversary date and the remaining <ix:nonFraction unitRef="shares" contextRef="ib5403a39d9824c61b323a823a99f5bd8_D20160801-20160831" decimals="INF" format="ixt:numdotdecimal" name="arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzc1NTg_500b46c2-5f29-4db5-a239-8c4356f0f57e">827,177</ix:nonFraction> shares will vest on a monthly basis thereafter. In July 2018, performance conditions prescribed by the Stock Purchase Agreement were met and <ix:nonFraction unitRef="shares" contextRef="id48658e6817e4f45934cd7313bbee944_D20180701-20180731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzc3MDI_803a73cf-e6ce-4d31-9252-449c9461c3f6">84,835</ix:nonFraction> shares of the restricted common stock were fully vested. During the three months ended March 31, 2020 and 2019, <ix:nonFraction unitRef="shares" contextRef="i30fec8c2358b4835911058e60fbd15e1_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzE2NDkyNjc0Nzg1ODU_9dac6dd0-3e4d-4e8e-913b-c26fe2e2d87e">68,931</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i923788d1801d4b67b74f8a5857599515_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzE2NDkyNjc0Nzg1OTI_9e97ce06-c67a-4553-adc2-d90babb1d9b1">68,931</ix:nonFraction> shares of restricted common stock were vested, respectively. As of March&#160;31, 2020, <ix:nonFraction unitRef="shares" contextRef="ie85017a9a46f4ab9a78c0cc301027ce2_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzMyOTg1MzQ5MDcxNTI_9e159f06-70e3-4837-a97e-e038c5907750">68,932</ix:nonFraction> shares of restricted stock are unvested.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2020 Employee Stock Purchase Plan</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted the 2020 Employee Stock Purchase Plan, or the ESPP, which became effective upon the completion of the IPO on January 31, 2020. The ESPP is designed to allow the Company&#8217;s eligible employees to purchase shares of the Company&#8217;s common stock, at semi-annual intervals, with their accumulated payroll deductions. Under the ESPP, participants are offered the option to purchase shares of the Company&#8217;s common stock at a discount during a series of successive offering periods. The option purchase price will be the lower of <ix:nonFraction unitRef="number" contextRef="ia32c63d0cf494637ad7c5a2bccd2b22f_D20200131-20200131" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2NTQ_ec71467b-9f62-4df0-9eca-fef7f2521075">85</ix:nonFraction>% of the closing trading price per share of the Company&#8217;s common stock on the first trading date of an offering period in which a participant is enrolled or <ix:nonFraction unitRef="number" contextRef="ia32c63d0cf494637ad7c5a2bccd2b22f_D20200131-20200131" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2NTk_b14c0207-ad4d-48dc-848a-c20056de7855">85</ix:nonFraction>% of the closing trading price per share on the purchase date, which will occur on the last trading day of each offering period. The Company commenced an offering period on January 31, 2020.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 19</span></div></div></div><hr style="page-break-after:always"/><div style="height:76.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i5ee6ac144772416aac8f64e402dd06bf">The ESPP is intended to qualify under Section 423 of the U.S. Internal Revenue Service Code of 1986, as amended. The maximum number of the Company&#8217;s common stock which will be authorized for sale under the ESPP is equal to the sum of (a) <ix:nonFraction unitRef="shares" contextRef="iae37041cedde4d51858dc7cf3548eb6d_I20200131" decimals="INF" format="ixt:numdotdecimal" name="arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2NjQ_28a5a178-df5c-4a20-b844-d3047e43beb1">351,000</ix:nonFraction> shares of common stock and (b) an annual increase on the first day of each year beginning in 2021 and ending in 2030, equal to the lesser of (i) <ix:nonFraction unitRef="number" contextRef="i7383296af1344aea9cce30492f252802_I20200131" decimals="INF" name="arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2ODQ_8e8097bf-9811-478c-b4ed-816aa34e61c5">1</ix:nonFraction>% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company&#8217;s board of directors; provided, however, no more than <ix:nonFraction unitRef="shares" contextRef="iae37041cedde4d51858dc7cf3548eb6d_I20200131" decimals="INF" format="ixt:numdotdecimal" name="arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2NzM_e80d15a7-ee19-4d60-8977-33ebf5925191">5,265,000</ix:nonFraction> shares of the Company&#8217;s common stock may be issued under the ESPP.</ix:continuation></span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_175"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">9. <ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90ZXh0cmVnaW9uOmJhY2YwYzFiMGQ5MDQ5YjlhOGQzMTJkOTM1ZTU3NDY2XzQ5NDc4MDIzMjUyMTA_f21b5890-4165-4a73-85de-9c3ec3b568c6" continuedAt="i93fe9c133ef94d21b4d1c3e6f1844cdb" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="i93fe9c133ef94d21b4d1c3e6f1844cdb"><ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90ZXh0cmVnaW9uOmJhY2YwYzFiMGQ5MDQ5YjlhOGQzMTJkOTM1ZTU3NDY2XzQ5NDc4MDIzMjUyMDk_4f93ea07-9900-4906-8bd7-edc9dfab8ce3" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.906%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.181%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.183%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible preferred stock on an as-converted basis</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7e60ec54b5354f6d99fb37ca976d041f_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzItMS0xLTEtMA_0b0e7103-4e54-4370-b922-8396bcca4f82">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i99939ac91f9f4fa590b1fa4017ae602b_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzItMy0xLTEtMA_6839b02b-ccea-48e6-b2af-c6fe66ddbcb7">16,262,425</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idc6873c2e10d441d9cc0b8acba203bb7_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzMtMS0xLTEtMA_eeab33fa-34ff-4a26-8ef8-c710874badf6">3,061,521</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6ddaa5b1d44a4fab8efeb9d63d3c55d8_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzMtMy0xLTEtMA_f65a83af-3bb0-48b8-a7ec-004a984fae80">1,461,191</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Early exercised options subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i03053d48c20241778d8e2cfc418e60ae_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzQtMS0xLTEtMA_68c8872a-012f-4965-87b9-110e7f59e6ff">613,627</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaf2d176bc07e46b8a8d5d35b4960c50d_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzQtMy0xLTEtMA_fe8e0ca8-b834-4f93-b3ad-51e8d2ee78eb">578,298</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i213a41c41500492487811d690788ac4f_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzUtMS0xLTEtMA_d30876a2-2b42-4bd5-b3d9-b80b7b371573">198,992</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if6465c3a5b5c4daf823adc5f743d64b4_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzUtMy0xLTEtMA_6803aea7-2665-40d9-add0-8214fb68003d">344,657</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ESPP shares subject to future issuance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5ef81aa3fd074f2f9ad3100002a964f9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzYtMS0xLTEtNzUxMw_bc422414-1f18-4f6b-973e-46b08d30210d">11,392</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i875d6445002045038d95abd268509dc1_D20190101-20190331" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzYtMy0xLTEtNzUxMw_a1ddc274-d3d5-42ad-9212-80adda418c25">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzYtMS0xLTEtMA_acd282f7-0e4b-45ae-9829-81999045f4a5">3,885,532</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzYtMy0xLTEtMA_98d6eaef-3d37-46a7-8dc7-e6f6ee1407d3">18,646,571</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_1649"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">10. <ix:nonNumeric contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3NzM4_4072d641-1fba-4122-93f3-d69e75684ed6" continuedAt="i66afffc12bc34d79a1b042007956d1be" escape="true">Subsequent Event  </ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i66afffc12bc34d79a1b042007956d1be" continuedAt="i3bc159b49b3d44b69a16ee0ad9add4bc">In April 2020, the Company amended its lease agreement for its facility in Westlake Village, California to relocate to a new expanded space comprising <ix:nonFraction unitRef="sqft" contextRef="i5d533bf2a9414af8876f332d4c35941e_D20200401-20200430" decimals="0" format="ixt:numdotdecimal" name="arqt:LesseeOperatingLeaseSquareFootageOfLeasedSpace" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3NzQw_660a3e34-6610-49ed-a28f-fd5f2c4523dd">22,643</ix:nonFraction> square feet.  The lease will begin when the tenant improvements are substantially complete and terminates <ix:nonNumeric contextRef="i8b84137f69724a55827a9c4614fa776b_I20200430" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3ODAy_34b53f70-fad6-4e10-b766-e526bf1a877b">91</ix:nonNumeric> months thereafter, with a renewal option for a term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3NzUy_a7f3f3c6-d01a-43c9-8f08-52810289a778">five</span> years.  The Company will have a one-time option to cancel the lease after month <ix:nonNumeric contextRef="i5d533bf2a9414af8876f332d4c35941e_D20200401-20200430" format="ixt-sec:durmonth" name="arqt:LesseeOperatingLeaseTermForTerminationOption" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3ODA4_5f0828bd-16b5-4ecd-8456-071f786dea2d">67</ix:nonNumeric>.  </ix:continuation></span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i3bc159b49b3d44b69a16ee0ad9add4bc"> The lease is subject to fixed rate escalation increases with an initial base rent of $<ix:nonFraction unitRef="usd" contextRef="i5d533bf2a9414af8876f332d4c35941e_D20200401-20200430" decimals="-3" format="ixt:numdotdecimal" name="arqt:LesseeOperatingLeaseMonthlyRentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3Nzcz_1ccca901-8cfb-4553-a0f7-e7e9e597edfc">76,000</ix:nonFraction> per month and includes rent free periods aggregating approximately <ix:nonNumeric contextRef="i5d533bf2a9414af8876f332d4c35941e_D20200401-20200430" format="ixt-sec:duryear" name="arqt:LesseeOperatingLeaseFreeRentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3ODE2_7f23ac6b-6da5-495a-8354-4ca96a92d354">1</ix:nonNumeric> year. As a result, the Company recognizes rent expense on a straight-line basis for the full amount of the commitment including the minimum rent increases over the life of the lease and the free rent period.  The amended lease agreement provides for a tenant improvement allowance up to $<ix:nonFraction unitRef="usd" contextRef="i5d533bf2a9414af8876f332d4c35941e_D20200401-20200430" decimals="-4" format="ixt:numdotdecimal" name="arqt:LesseeOperatingLeaseTenantImprovementAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3NzU4_5cbc91c3-1cda-428d-bf55-a99adea38018">1.25</ix:nonFraction>&#160;million. It also requires the Company to have an available letter of credit of $<ix:nonFraction unitRef="usd" contextRef="i8b84137f69724a55827a9c4614fa776b_I20200430" decimals="-5" format="ixt:numdotdecimal" name="arqt:LesseeOperatingLeaseLetterOfCreditRequirement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3Nzgy_3d3e252b-a5f9-4856-a064-1e25aedd4ac8">1.5</ix:nonFraction>&#160;million upon commencement, which is allowed to be reduced throughout the lease period as rent obligations are met.</ix:continuation> </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 20</span></div></div></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_46"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2.  MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The following discussion and analysis of our financial condition and results of operations should be read together with our unaudited condensed financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q, and the audited financial statements and notes thereto as of and for the year ended December 31, 2019 and the related Management's Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2019, which has been filed with the Securities and Exchange Commission. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans, objectives, expectations, projections and strategy for our business, includes forward-looking statements that involve risks and uncertainties. These statements are often identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; or &#8220;continue,&#8221; and similar expressions or variations. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. As a result of many factors, including those factors identified below and those set forth in the &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q, our actual results and the timing of selected events could differ materially from the forward-looking statements contained in the following discussion and analysis.</span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_49"></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Our current portfolio is comprised of topical treatments with significant potential to address immune-mediated dermatological diseases and conditions, or immuno-dermatology. Our strategy is to identify and develop treatments against validated biological targets in dermatology that deliver a differentiated clinical profile that addresses major shortcomings of existing therapies in our targeted indications. We believe this strategy uniquely positions us to rapidly progress towards our goal of bridging the treatment innovation gap in dermatology, while maximizing our probability of technical success and financial resources.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our lead product candidate, topical roflumilast cream (ARQ-151), is in Phase 3 clinical trials in plaque psoriasis. Roflumilast cream is a topical cream formulation of roflumilast, a highly potent and selective phosphodiesterase type 4, or PDE4, inhibitor, which we are developing for the treatment of plaque psoriasis, including psoriasis in intertriginous regions such as the groin, axillae, and inframammary areas, as well as atopic dermatitis. In July 2018, we executed a worldwide licensing agreement with AstraZeneca AB, or AstraZeneca, for exclusive worldwide rights to all topical dermatological uses of roflumilast. We have successfully completed a Phase 2b study of roflumilast cream in plaque psoriasis, and, in August 2019, paid AstraZeneca the first milestone payment of $2.0 million that was earned upon the achievement of positive Phase 2 data for any AZ-Licensed Product (as defined in &#8220;&#8212;License Agreements&#8212;AstraZeneca License Agreement&#8221;). We have initiated three Phase 3 studies in plaque psoriasis, including two pivotal studies (DERMIS-1 and DERMIS-2) and an open label extension study (DERMIS-OLE), with topline data expected in the first half of 2021.  We also completed a Phase 2 proof of concept study of roflumilast cream in atopic dermatitis (AD) and plan to initiate a Phase 2b study in AD in the second half of 2020, with topline results expected in the second half of 2021. In addition, we are developing ARQ-154, a topical foam formulation of roflumilast cream, and have initiated a Phase 2 proof of concept study in seborrheic dermatitis and a Phase 2b study in scalp psoriasis. We expect to report topline data in the second half of 2020 with respect to seborrheic dermatitis and in Q4 2020/Q1 2021 with respect to scalp psoriasis. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Beyond this, we also began enrolling patients in the safety cohort of a Phase1/2b study of ARQ-252, a potent and highly selective topical janus kinase type 1, or JAK1, inhibitor for the treatment of chronic hand eczema, and will begin enrolling the efficacy cohort in the second half of 2020, with topline data expected in the second half of 2021.  We also plan to initiate a Phase 2a study of ARQ-252 in vitiligo in the second half of 2020. Additionally, we have formulation and preclinical efforts underway for ARQ-255, an alternative topical formulation of ARQ-252 designed to reach deeper into the skin in order to potentially treat alopecia areata. In January 2018, we executed an exclusive option and license agreement with Jiangsu Hengrui Medicine Co., Ltd. of China, or Hengrui, to the active pharmaceutical ingredient in ARQ-252 and ARQ-255 for all topical formulations for dermatological uses in the United States, Canada, Europe and Japan. In December 2019, we exercised our exclusive option associated with </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 21</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">this agreement, for which we made a $1.5 million cash payment, and also contemporaneously amended the agreement to expand the territory to additionally include Canada.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since our inception in 2016, we have invested a significant portion of our efforts and financial resources in research and development activities. We have not generated any revenue from product sales and, prior to our IPO completed in January 2020, have funded our operations primarily with $162.5 million in net cash proceeds from private placements of our convertible preferred stock.  On January 31, 2020, we </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">completed our IPO of 10,781,250 shares of common stock at an offering price of $17.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 1,406,250 additional shares of common stock.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Our net proceeds, after deducting underwriting discounts, commissions and offering related transaction costs, were $167.2 million.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred net losses in each year since inception, including net losses of $28.0 million and $6.7 million for the three months ended March 31, 2020 and 2019, respectively.  As of March&#160;31, 2020 and December&#160;31, 2019, we had an accumulated deficit of $94.3 million and $66.3 million, respectively, and cash, cash equivalents and marketable securities of</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">$249.3 million and $101.3 million, respectively.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to continue to incur losses for the foreseeable future and expect to incur increased expenses as we advance our product candidates through clinical trials and regulatory submissions. We do not expect to generate revenue from product sales unless, and until, we obtain regulatory approval or clearance from the FDA or other foreign regulatory authorities for our product candidates. If we obtain regulatory approval or clearance for our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. In addition, we expect that our expenses will increase substantially as we continue preclinical studies and clinical trials for, and research and development of, our product candidates and maintain, expand and protect our intellectual property portfolio.</span><span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result, we will need substantial additional funding to support our operating activities. Adequate funding may not be available to us on acceptable terms, or at all. We currently anticipate that we will seek to fund our operations through equity or debt financings or other sources, such as future potential collaboration agreements. Our failure to obtain sufficient funds on acceptable terms as and when needed could have a material adverse effect on our business, results of operations and financial condition. See &#8220;&#8212;Liquidity, Capital Resources and Requirements&#8221; below and Note&#160;1 to the unaudited condensed financial statements for additional information. Based on our current planned operations, we expect our current cash, cash equivalent, and marketable securities will be sufficient to fund our operations through 2021.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on third parties in the conduct of our preclinical studies and clinical trials and for manufacturing and supply of our product candidates. We have no internal manufacturing capabilities, and we will continue to rely on third parties, many of whom are single-source suppliers, for our preclinical and clinical trial materials, as well as the commercial supply of our products. In addition, we do not yet have a sales organization or commercial infrastructure. Accordingly, we expect to incur significant expenses to develop a sales organization or commercial infrastructure in advance of generating any product sales.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">COVID-19 Update</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In March 2020, the World Health Organization declared a pandemic related to the global novel coronavirus disease 2019 (COVID-19) outbreak.  COVID-19 has placed strains on the providers of healthcare services, including the sites where we conduct our clinical trials.  These strains have resulted in some clinical sites slowing or halting enrollment in clinical trials and restricting the on-site monitoring of clinical trials.  We follow FDA guidance on clinical trial conduct during the COVID-19 pandemic, including the remote monitoring of clinical data.  We are monitoring the potential impact COVID-19 may have on the clinical development of our product candidates, including potential delays or modifications to ongoing and planned trials.  Thus far, we have seen limited impact on our clinical trials including some disruptions in screening, enrollment and monitoring, however at this time, we do not expect delays to previously disclosed clinical timelines, including those for roflumilast cream, topical roflumilast foam (ARQ-154) and ARQ-252.  We cannot, at this time, predict the specific extent, duration, or full impact that the COVID-19 outbreak will have on our ongoing and planned clinical trials and other business operations. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">There have been no disruptions in our supply chain of drug manufacturers necessary to conduct our clinical trials and, given our drug inventories, we believe that we will be able to supply the drug needs of our ongoing clinical studies.  </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In alignment with public health guidance designed to slow the spread of COVID-19, we implemented a remote work plan for all employees as of mid-March 2020. We may need to undertake additional actions that could </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 22</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">impact our operations as required by applicable laws or regulations, or which we determine to be in the best interests of our employees. </span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_52"></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">License Agreements</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">AstraZeneca License Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2018, we entered into an exclusive license agreement, or the AstraZeneca License Agreement, with AstraZeneca, granting us a worldwide exclusive license, with the right to sublicense through multiple tiers, under certain AstraZeneca-controlled patent rights, know-how and regulatory documentation, to research, develop, manufacture, commercialize and otherwise exploit products containing roflumilast in topical forms, as well as delivery systems sold with or for the administration of roflumilast, or collectively, the AZ-Licensed Products, for all diagnostic, prophylactic and therapeutic uses for human dermatological indications, or the Dermatology Field. Under this agreement, we have sole responsibility for development, regulatory, and commercialization activities for the AZ-Licensed Products in the Dermatology Field, at our expense, and we shall use commercially reasonable efforts to develop, obtain and maintain regulatory approvals for, and commercialize the AZ-Licensed Products in the Dermatology Field in each of the United States, Italy, Spain, Germany, the United Kingdom, France, China, and Japan.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We paid AstraZeneca an upfront non-refundable cash payment of $1.0 million and issued 484,388 shares of our Series B Preferred stock, valued at $3.0 million on the date of the AstraZeneca License Agreement. We subsequently paid AstraZeneca the first milestone cash payment of $2.0&#160;million upon the completion of a Phase 2b study of roflumilast cream in plaque psoriasis in August 2019 for the achievement of positive Phase 2 data for an AZ-Licensed Product. We have agreed to make additional cash payments to AstraZeneca of up to an aggregate of $12.5 million upon the achievement of specific regulatory approval milestones with respect to the AZ-Licensed Products and payments up to an additional aggregate amount of $15.0 million upon the achievement of certain aggregate worldwide net sales milestones. With respect to any AZ-Licensed Products we commercialize under the AstraZeneca License Agreement, we will pay AstraZeneca a low to high single-digit percentage royalty rate on our, our affiliates&#8217; and our sublicensees&#8217; net sales of such AZ-Licensed Products, until, as determined on an AZ-Licensed Product-by-AZ-Licensed Product and country-by-country basis, the later of the date of the expiration of the last-to-expire AstraZeneca-licensed patent right containing a valid claim in such country and ten years from the first commercial sale of such AZ-Licensed Product in such country.  See Note&#160;5 to the unaudited condensed financial statements for additional information.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Hengrui Exclusive Option and License Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2018, we entered into an exclusive option and license agreement, or Hengrui License Agreement, with Hengrui, whereby Hengrui granted us an exclusive option to obtain certain exclusive rights to research, develop and commercialize products containing the compound designated by Hengrui as SHR0302, a JAK 1 inhibitor, in topical formulations for the treatment of skin diseases, disorders, and conditions in the United States, Canada, Japan, and the European Union (including for clarity the United Kingdom). We made a $0.4 million upfront non-refundable cash payment to Hengrui upon execution of the Hengrui Option and License Agreement. In December 2019, we exercised our exclusive option under the agreement, for which we made a $1.5 million cash payment, and also contemporaneously amended the agreement to expand the territory to additionally include Canada. In addition, we have agreed to make cash payments of up to an aggregate of $20.5 million upon our achievement of specified clinical development and regulatory approval milestones with respect to the licensed products and cash payments of up to an additional aggregate of $200.0 million in sales-based milestones based on achieving certain aggregate annual net sales volumes with respect to a licensed product. With respect to any products we commercialize under the Hengrui License Agreement, we will pay tiered royalties to Hengrui on net sales of each licensed product by us, or our affiliates, or our sublicensees, ranging from mid single-digit to sub-teen percentage rates based on tiered annual net sales bands subject to specified reductions. We are obligated to pay royalties until the later of (1)&#160;expiration of the last valid claim of the licensed patent rights covering such licensed product in such country and (2)&#160;the expiration of regulatory exclusivity for the relevant licensed product in the relevant country, on a licensed product-by-licensed product and country-by-country basis. Additionally, we are obligated to pay Hengrui a specified percentage, ranging from the low-thirties to the sub-teens, of certain non-royalty sublicensing income we receive from sublicensees of our rights to the licensed products, such percentage decreasing as the development stage of the licensed products advance. See Note&#160;5 to the unaudited condensed financial statements for additional information.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 23</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Hawkeye Collaboration Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2019, we entered into a collaboration agreement, or the Hawkeye Agreement, with Hawkeye Therapeutics, Inc., or Hawkeye, a related party with common ownership, to collaborate on the research and development of one or more new applications of roflumilast. The Hawkeye Agreement grants Hawkeye an exclusive license to certain intellectual property developed under the agreement as it relates to the applications. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contemporaneously with the execution of the Hawkeye Agreement, we entered into a stock purchase agreement, purchasing 995,000 shares of Hawkeye&#8217;s common stock at $0.0001 per share, representing 19.9% of the outstanding common stock of Hawkeye. See Note&#160;5 to the unaudited condensed financial statements for additional information.</span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_55"></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Components of Our Results of Operations</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since our inception, we have focused significant resources on our research and development activities, including conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for our product candidates. Research and development costs are expensed as incurred. These costs include direct program expenses, which are payments made to third parties that specifically relate to our research and development, such as payments to clinical research organizations, clinical investigators, manufacturing of clinical material, preclinical testing and consultants. In addition, employee costs, including salaries, payroll taxes, benefits, stock-based compensation and travel, for employees contributing to research and development activities are classified as research and development costs. We allocate direct external costs to our product candidates; internal costs are not allocated to specific product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to continue to incur substantial research and development expenses in the future as we develop our product candidates. In particular, we expect to incur substantial research and development expenses for the Phase 3 trials (DERMIS-1 and DERMIS 2) of roflumilast cream for plaque psoriasis, the preclinical studies and clinical trials for the continued development of roflumilast cream for atopic dermatitis, roflumilast foam for seborrheic dermatitis and scalp psoriasis, ARQ-252 for hand eczema and vitiligo, and ARQ-255 for alopecia areata.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have entered, and may continue to enter, into license agreements to access and utilize certain molecules for the treatment of dermatological diseases and disorders. We evaluate if the license agreement is an acquisition of an asset or a business. To date, none of our license agreements have been considered to be an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval, are immediately recognized as research and development expense when due, provided there is no alternative future use of the rights in other research and development projects.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs required to complete the remaining development of&#160;roflumilast cream, roflumilast foam, ARQ-252 and ARQ-255 or any future product candidates. This is due to the numerous risks and uncertainties associated with the development of product candidates. See &#8220;Risk Factors&#8221; for a discussion of the risks and uncertainties associated with the development of our product candidates.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our general and administrative expenses consist primarily of salaries and related costs, including payroll taxes, benefits, stock-based compensation and travel. Other general and administrative expenses include legal costs of pursuing patent protection of our intellectual property, insurance, and professional services fees for auditing, tax and general legal services. We expect our general and administrative expenses to continue to increase in the future as we expand our operating activities and prepare for potential commercialization of our product candidates, increase our headcount and support our operations as a public company, including increased expenses related to legal, accounting, insurance, regulatory and tax-related services associated with maintaining compliance with exchange listing and Securities and Exchange Commission requirements, directors and officers liability insurance premiums and investor relations activities.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 24</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Income (Expense), Net</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income (expense), net primarily consists of interest income earned on our marketable securities.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 25</span></div></div></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_58"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comparison of the Three Months Ended March 31, 2020 and 2019</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth our results of operations for the periods indicated:</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830%;"><tr><td style="width:1.0%;"></td><td style="width:49.035%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.686%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.686%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.686%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.690%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,182&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,979&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">306&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,469&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">749&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,720&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total operating expenses</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,651&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,952&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,699&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">312&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Loss from operations</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28,651)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,952)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,699)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">312&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">638&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">294&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">344&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28,013)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,658)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,355)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">321&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:48.292%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.426%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.702%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Direct Costs:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Preclinical and clinical</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,736&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Manufacturing</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,254&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">692&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,562&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">370&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indirect Costs:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation and personnel-related</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,267&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,444&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">925&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">362&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">563&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">156&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,182&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,979&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">306&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses increased by $19.0 million, or 306%, for the three months ended March 31, 2020 compared to the three months ended March 31, 2019. The increase was due to an increase in clinical trial costs of $14.4 million, an increase in manufacturing costs of $2.6 million, an increase in compensation and personnel-related expenses of $1.4 million, and an increase of $0.6 million in other costs, including regulatory, research and clinical consulting costs. The increases in clinical trial costs and manufacturing costs, and the increase in the corresponding consulting costs, relate to new and ongoing studies of roflumilast cream, including three Phase 3 studies of roflumilast cream for plaque psoriasis and a Phase 1 pediatric study of roflumilast cream for atopic dermatitis. Additionally, there were new and ongoing costs related to the Phase 2b study of roflumilast foam for scalp psoriasis and a Phase 2 Proof of Concept clinical trial of roflumilast foam for seborrheic dermatitis. The increase in compensation and personnel-related expenses, which includes stock compensation, was primarily due to an increase in headcount. </span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative Expenses</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses increased by $2.7 million, or 363%, for the three months ended March 31, 2020 compared to the three months ended March 31, 2019. The increase was primarily due to an increase in compensation and personnel-related expenses of $1.4 million, an increase in professional services of $0.7 million, and an increase in insurance costs of $0.5 million. The increase in compensation and personnel-related expenses, which includes stock compensation, was due to an increase in headcount. The increases in professional services, which includes accounting and audit fees of $0.3 million, and insurance costs were mainly due to the costs associated with being a public company.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 26</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Income, Net</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income, net increased by $0.3 million, or 117%, for the three months ended March 31, 2020 compared to the three months ended March 31, 2019 . The increase was primarily due to interest earned on our marketable securities from the funds received from our IPO in February 2020 and from the issuance of our Series&#160;C convertible preferred stock in the year ended December 31, 2019.</span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_61"></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity, Capital Resources and Requirements</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sources of Liquidity</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred operating losses since our inception and have an accumulated deficit as a result of ongoing efforts to develop our product candidates, including conducting preclinical and clinical trials and providing general and administrative support for these operations. As of March&#160;31, 2020 and December&#160;31, 2019, we had cash, cash equivalents and marketable securities of $249.3 million and $101.3 million, respectively, and an accumulated deficit of $94.3 million and $66.3 million, respectively.  We anticipate that operating losses and net cash used in operating activities will increase over the next several years as we further develop roflumilast cream, roflumilast foam, ARQ-252 and ARQ-255, move into later and more costly stages of product development, develop new product candidates, hire personnel and prepare for regulatory submissions and the commercialization of our product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have historically financed our operations primarily through private placements of preferred stock as well as our IPO completed in January 2020, and will continue to be dependent upon equity, debt financing or collaborations or other forms of capital at least until we are able to generate positive cash flows from our operations.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flows</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth our cash flows for the periods indicated:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:62.327%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.982%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.107%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash used in operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,010)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,074)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash used in investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,326)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,270)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">168,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">127,557&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,344)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Cash Used in Operating Activities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020, net cash used in operating activities was $21.0 million, which consisted of a net loss of $28.0 million, offset by a change in net operating assets and liabilities of $6.1 million and net non-cash charges of $0.9 million. The change in net operating assets and liabilities was due to an increase of $7.3 million in accounts payable and accrued liabilities due to our overall growth, increased research and development spending and timing of payments, partially offset by an increase of $1.1 million in prepaid expenses and other current assets for premiums paid on insurance policies and other advances made for clinical trial costs. The net non-cash charges were primarily related to stock-based compensation expense of $1.0 million.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2019, net cash used in operating activities was $7.1 million&#160;and consisted primarily of a net loss of $6.7 million and a change in our net operating assets and liabilities of $0.4 million. The change in net operating assets and liabilities was primarily due to an increase of $0.4 million in prepaid expenses and other assets for advances made for clinical trial costs and manufacturing.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Cash Used in Investing Activities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During three months ended March 31, 2020, net cash used in investing activities was $20.3 million, which was comprised primarily of purchases of marketable securities of $35.3 million, partially offset by proceeds from the maturities of marketable securities of $15.0 million.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 27</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2019, net cash used in investing activities was $9.3 million, which was comprised primarily of purchases of marketable securities of $11.7 million, partially offset by proceeds from maturities of marketable securities of $2.6 million.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Cash Provided by Financing Activities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020, net cash provided by financing activities was $168.9 million, which was comprised primarily of the net cash proceeds received from the IPO of $168.6 million. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2019, there were no financing activities.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Funding Requirements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have historically incurred significant losses and negative cash flows from operations since our inception and had an accumulated deficit of $94.3 million and $66.3 million as of March&#160;31, 2020 and December&#160;31, 2019, respectively. We had cash, cash equivalents and marketable securities of $249.3 million and $101.3 million as of March&#160;31, 2020 and December&#160;31, 2019, respectively.  Based on our current planned operations, we expect that our current cash, cash equivalents and marketable securities will be sufficient to fund our operations through 2021. Our ability to continue as a going concern is dependent upon our ability to successfully secure sources of financing and ultimately achieve profitable operations.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will need to raise substantial additional capital to fund our operations through the sale of our equity securities, incurring debt, entering into licensing or collaboration agreements with partners, grants or other sources of financing. There can be no assurance that sufficient funds will be available to us at all or on attractive terms when needed from these sources. If we are unable to obtain additional funding from these or other sources when needed it may be necessary to significantly reduce our current rate of spending through reductions in staff and delaying, scaling back, or stopping certain research and development programs. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the scope, progress, results and costs of researching and developing our lead product candidates or any future product candidates, and conducting preclinical studies and clinical trials, in particular our currently ongoing Phase 3 studies (DERMIS-1 and DERMIS 2) of roflumilast cream in plaque psoriasis, our planned Phase 2b study of roflumilast cream in atopic dermatitis, our currently ongoing Phase 2 proof of concept study of roflumilast foam in seborrheic dermatitis, our currently ongoing Phase 2b study of roflumilast foam in scalp psoriasis, our currently ongoing Phase&#160;1/2b study of ARQ-252 in hand eczema, our planned Phase 2a study of ARQ-252 in vitiligo and our formulation and preclinical efforts for ARQ-255 for alopecia areata.</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:95%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:4.8pt;">suspensions or delays in the enrollment or changes to the number of patients we decide to enroll in our ongoing clinical trials as a result of the COVID-19 pandemic; </span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the timing of, and the costs involved in, obtaining regulatory approvals for our lead product candidate or our other product candidates;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the number and characteristics of any additional product candidates we develop or acquire;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the cost of manufacturing our lead product candidates or any future product candidates and any products we successfully commercialize, including costs associated with building out our supply chain;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the cost of commercialization activities if our lead product candidates or any future product candidates are approved for sale, including marketing, sales and distribution costs;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the cost of building a sales force in anticipation of product commercialization;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of any such agreements that we may enter into;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 28</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the costs related to milestone payments to AstraZeneca or Hengrui, upon the achievement of predetermined milestones;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">any product liability or other lawsuits related to our products;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the expenses needed to attract and retain skilled personnel;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the costs associated with being a public company;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, and the outcome of this and any other future patent litigation we may be involved in; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the timing, receipt and amount of sales of any future approved products, if any.</span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_64"></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual Obligations and Contingent Liabilities</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2020, we amended our lease agreement for its facility in Westlake Village, California to relocate to a new expanded space including 22,643 square feet.  The lease will begin when the tenant improvements, the allowance for which is up to $1.25 million, are substantially complete and terminates 91 months thereafter, with a renewal option for a term of 5 years.  We will have a one-time option to cancel the lease after month 67.  </span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The lease is subject to fixed rate escalation increases with an initial base rent of $76,000 per month and includes rent free periods aggregating approximately 1 year.  The amended lease agreement provides for a tenant improvement allowance up to $1.25 million. It also requires that we deliver a letter of credit to the landlord of $1.5 million upon commencement, which is allowed to be reduced throughout the lease period as rent obligations are met. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no other material changes to our contractual obligations and contingent liabilities as described under the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Indemnification</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the normal course of business, we enter into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. Our exposure under these agreements is unknown because it involves claims that may be made against us in the future, but have not yet been made. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. However, we may record charges in the future as a result of these indemnification obligations.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In accordance with our certificate of incorporation and bylaws, we have indemnification obligations to our officers and directors for specified events or occurrences, subject to some limits, while they are serving at our request in such capacities. There have been no claims to date, and we have director and officer insurance that may enable us to recover a portion of any amounts paid for future potential claims.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Critical Accounting Policies and Use of Estimates</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of our condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the year ended December 31, 2019. There were no material changes to our critical accounting policies during the three months ended March 31, 2020.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 29</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See Note 2 to our unaudited condensed financial statements.  </span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_67"></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Emerging Growth Company Status</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we are (i) no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. We early adopted ASU 2016-01, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments&#8212;Overall (Topic 825)&#8212;Recognition and Measurement of Financial Assets and Financial Liabilities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, ASU 2016-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Compensation&#8212;Stock Compensation (Topic 718)&#8212;Improvements to Employee Share Based Payment Accounting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, ASU No.&#160;2018-07, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and ASU No.&#160;2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> as the JOBS Act does not preclude an emerging growth company from early adopting a new or revised accounting standard earlier than the time such standard applies to private companies. We expect to use the extended transition period for any other new or revised accounting standards during the period in which we remain an emerging growth company.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of the completion of our IPO. However, if certain events occur prior to the end of such five-year period, including if we become a &#8220;large accelerated filer,&#8221; our annual gross revenues exceed $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.</span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_70"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. As of March&#160;31, 2020, we had cash and cash equivalents of $190.9 million and marketable securities of $58.4 million, which consist of bank deposits, money market funds, commercial paper and government securities. The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. Because our investments are primarily short-term in duration, we believe that our exposure to interest rate risk is not significant, and a 1% movement in market interest rates would not have a significant impact on the total value of our portfolio. We had no debt outstanding as of March&#160;31, 2020.</span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_79"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 4. CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-indent:24.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives of ensuring that information we are required to disclose in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosures, and is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. There is no assurance that our disclosure controls and procedures will operate effectively under all circumstances.</span></div><div style="text-indent:24.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Management, with the participation of our CEO and CFO, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2020. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, or the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their desired control objectives, and management necessarily is required to </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 30</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2020, our CEO and CFO have concluded that, as of March 31, 2020, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Changes in Internal Control over Financial Reporting</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_13"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II. OTHER INFORMATION</span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_28"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1.   LEGAL PROCEEDINGS</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We may from time to time be involved in various legal proceedings of a character normally incident to the ordinary course of our business. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are not currently a party to any material litigation or other material legal proceedings.</span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_19"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1A.   RISK FACTORS</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">This Quarterly Report on Form 10-Q contains forward-looking information based on our current expectations. Because our business is subject to many risks and our actual results may differ materially from any forward-looking statements made by or on behalf of us, this section includes a discussion of important factors that could affect our business, operating results, financial condition and the trading price of our common stock. This discussion should be read in conjunction with the other information in this Quarterly Report on Form 10-Q, including our unaudited condensed financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, and our Annual Report on Form 10-K for the year ended December 31, 2019. The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</span></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are a late-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale, and we have incurred significant losses since our inception. We anticipate that we will continue to incur losses for the foreseeable future, which, together with our limited operating history, makes it difficult to assess our future viability.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a late-stage biopharmaceutical company with a limited operating history. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We have no products approved for commercial sale and have not generated any revenue from product sales and have incurred losses in each year since our inception in June 2016. We have a limited operating history upon which you can evaluate our business and prospects, and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, identifying potential product candidates, establishing licensing arrangements, undertaking various research and preclinical studies and conducting clinical trials for our product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have never generated any revenue from product sales and have incurred losses in each year since our inception in June 2016. We have not yet demonstrated our ability to successfully complete later-stage clinical trials, obtain regulatory approvals, manufacture a drug on a commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our net loss for the three months ended March 31, 2020 and 2019 was approximately $28.0 million and $6.7 million, respectively.  As of March&#160;31, 2020, we had an accumulated deficit of $94.3 million. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase as we continue to develop our product candidates, conduct clinical trials and pursue research and development activities. We may never achieve profitability and, even if we do, we may not be able to sustain profitability in subsequent periods. We </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 31</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">will continue to incur significant research and development and other expenses related to our ongoing operations and the development of our product candidates. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. We will need to transition at some point from a company with a development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since our inception, we have invested substantially all of our efforts and financial resources in research and development activities, and we expect to continue to expend substantial resources for the foreseeable future in connection with the development of our current product candidates, roflumilast cream, roflumilast foam, ARQ-252 and ARQ-255, the development or acquisition of additional product candidates and the maintenance and expansion of our business operations and capabilities. These expenditures will include costs associated with conducting preclinical studies and clinical trials, obtaining regulatory approvals, and securing manufacturing and supply of product candidates, and marketing and selling any products approved for sale. These expenditures may also include costs associated with in-licensing dermatology assets consistent with our core strategy. In addition, other unanticipated costs may arise. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our lead product candidates and any future product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, we had capital resources consisting of cash, cash equivalents and marketable securities of $249.3 million. Based on our planned operations, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operations through 2021. However, our operating plans may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. Such financing may result in dilution to stockholders, imposition of burdensome debt covenants and repayment obligations, or other restrictions that may affect our business. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our future capital requirements depend on many factors, including, but not limited to:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the scope, progress, results and costs of researching and developing our lead product candidates or any future product candidates, and conducting preclinical studies and clinical trials, in particular our currently ongoing Phase 3 clinical trials of roflumilast cream in plaque psoriasis, our planned Phase 2b study of roflumilast cream in atopic dermatitis, our currently ongoing Phase 2 proof of concept study of roflumilast foam in seborrheic dermatitis, our currently ongoing Phase 2b study of roflumilast foam in scalp psoriasis, our currently ongoing Phase&#160;1/2b study of ARQ-252 in hand eczema, our planned Phase 2a study of ARQ-252 in vitiligo and our formulation and preclinical efforts for ARQ-255 in alopecia areata;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:4.8pt;">suspensions or delays in the enrollment, issues with data collection, or changes to the number of patients we decide to enroll in our ongoing clinical trials as a result of the COVID-19 pandemic; </span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the number and scope of clinical programs we decide to pursue;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the cost, timing and outcome of regulatory review of our product candidates;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the cost of manufacturing our product candidates and any products we commercialize, including costs associated with building out our supply chain;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the cost of commercialization activities if any of our product candidates are approved for sale, including marketing, sales and distribution costs, and any discounts or rebates to channel to obtain access</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the cost of building a sales force in anticipation of product commercialization;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of any such agreements that we may enter into;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 32</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the timing and amount of milestone payments due to AstraZeneca, Jiangsu Hengrui Medicine Co., Ltd., or Hengrui, or any future collaboration or licensing partners upon the achievement of negotiated milestones;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the expenses needed to attract and retain skilled personnel;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the costs associated with being a public company; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the timing, receipt and amount of sales of any future approved products, if any.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Adequate additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis or on attractive terms, we may be required to reduce our workforce, delay, limit, reduce or terminate our research and development activities, preclinical studies, clinical trials or other development activities and future commercialization efforts, or grant rights to develop and market product candidates, such as roflumilast cream, that we would otherwise develop and market ourselves.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our future operating results to fall below expectations.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our operations to date have been primarily limited to researching and developing our product candidates and undertaking preclinical studies and clinical trials of our product candidates. We have not yet obtained regulatory approvals for any of our product candidates. Furthermore, our operating results may fluctuate due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">delays in the commencement, enrollment and the timing of clinical testing for our product candidates, especially in light of the COVID-19 pandemic;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">any delays in regulatory review and approval of product candidates in clinical development, or failure to obtain such approvals;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the timing and cost of, and level of investment in, research and development activities relating to our product candidates, which may change from time to time;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the cost of manufacturing our product candidates, which may vary depending on U.S. Food and Drug Administration, or FDA, guidelines and requirements, and the quantity of production;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our ability to obtain additional funding to develop our product candidates;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">expenditures that we will or may incur to acquire or develop additional product candidates and technologies, which may include obligations to make significant upfront and milestone payments;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the level of demand for our product candidates, should they receive approval, which may vary significantly;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">potential side effects of our product candidates that could delay or prevent commercialization or cause an approved drug to be taken off the market;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for our product candidates, if approved;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our dependency on CROs and third-party manufacturers to supply or manufacture our product candidates;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our ability to establish an effective sales, marketing and distribution infrastructure in a timely manner;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">market acceptance of our product candidates, if approved, and our ability to forecast demand for those product candidates;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our ability to receive approval and commercialize our product candidates both within and outside of the United States;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 33</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our ability to establish and maintain collaborations, licensing or other arrangements with respect to our product candidates;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our ability to maintain and enforce our intellectual property position;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">costs related to and outcomes of potential litigation or other disputes in respect of our product candidates and our business;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our ability to adequately support future growth;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our ability to attract and retain key personnel to manage our business effectively;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">potential liabilities associated with hazardous materials;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our ability to maintain adequate insurance policies; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">future accounting pronouncements or changes in our accounting policies.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award as determined by our board of directors, and recognize the cost as an expense over the employee&#8217;s requisite service period. As the variables that we use as a basis for valuing these awards change over time, including our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our estimated market opportunities for our product candidates are subject to numerous uncertainties and may prove to be inaccurate. If we have overestimated the size of our market opportunities, our future growth may be limited.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our estimated addressable markets and market opportunities for our product candidates are based on a variety of inputs, including data published by third parties, our own market insights and internal market intelligence, and internally generated data and assumptions. We have not independently verified any third-party information and cannot assure you of its accuracy or completeness. Market opportunity estimates, whether obtained or derived from third-party sources or developed internally, are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. While we believe our market opportunity estimates are reasonable, such information is inherently imprecise. In addition, our assumptions and estimates of market opportunities are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including but not limited to those described in this Quarterly Report on Form 10-Q. If this third-party or internally generated data prove to be inaccurate or we make errors in our assumptions based on that data, our actual market may be more limited than our estimates. In addition, these inaccuracies or errors may cause us to misallocate capital and other critical business resources, which could harm our business. The estimates of our market opportunities included in this Quarterly Report on Form 10-Q should not be taken as indicative of our ability to grow our business. </span></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Development and Commercialization</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business is dependent on the development, regulatory approval and commercialization of our current product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have no products that are approved for commercial sale. Our current portfolio includes our lead product candidate roflumilast cream, a potent PDE4 inhibitor topical cream for the treatment of plaque psoriasis and atopic dermatitis, and our additional product candidates roflumilast foam, a topical foam formulation of roflumilast cream for the treatment of scalp psoriasis and seborrheic dermatitis, ARQ-252, a potent and highly selective topical JAK1 inhibitor for the treatment of chronic hand eczema, and ARQ-255, a potential topical treatment for alopecia areata. We currently do not have a drug discovery or research and development effort to discover new product candidates, and we have no intention to develop one. The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of these current product candidates. We expect to conduct most of our clinical trials in the United States and Canada, with current limited plans for clinical trials in Australia and the European Union. We currently anticipate seeking regulatory approvals in the United States and Canada, but may in the future be subject to additional foreign regulatory authorities and may out-license our product candidates or approved products, if any, in additional foreign markets. In the future, we may also become dependent on other product candidates that we may acquire or in-license. The clinical and commercial success of our product candidates will depend on a number of factors, including the following:</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 34</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the ability to raise any additional required capital on acceptable terms, or at all;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">timely completion of our preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate, particularly as a result of the impact of the COVID-19 pandemic, and will depend substantially upon the performance of third-party contractors;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">whether we are required by the FDA or similar foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">acceptance of our proposed indications and primary and secondary endpoint assessments relating to the proposed indications of our product candidates by the FDA and similar foreign regulatory authorities;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future approved products, if any;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to our lead product candidates or any future product candidates or approved products, if any;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the willingness of physicians and patients to utilize or adopt our product candidates;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the ability of third parties upon which we rely to manufacture clinical trial and commercial supplies of our product candidates or any future product candidates to remain in good standing with relevant regulatory authorities and to develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices, or cGMP;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates or any future product candidates in the United States and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in collaboration with others;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates or any future product candidates, if approved, including relative to alternative and competing treatments;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">patient demand for our product candidates, if approved;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, because each of our product candidates targets one or more indications in the medical dermatology field, if any of our product candidates encounter safety or efficacy problems, developmental delays, regulatory issues, supply issues, or other problems, our development plans for the affected product candidate and some or all of our other product candidates could be significantly harmed, which would harm our business. Further, competitors who are developing products in the dermatology field or that target the same indications as us with products that have a similar mechanism of action may experience problems with their products that could indicate or result in class-wide problems or additional requirements that would potentially harm our business.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The factors outlined above, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our product candidates or any future product candidates to continue our business.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 35</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The risk of failure for our product candidates is high. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. For example, our Phase&#160;2 proof of concept study in atopic dermatitis had a limited number of patients and it did not reach statistical significance for the primary endpoint or the secondary endpoint of IGA Success, which we expect will be the primary endpoint in any registrational trial, but did show significance in certain secondary efficacy endpoints. While we believe this is evidence of the ability of roflumilast cream to treat the signs and symptoms of atopic dermatitis, these results may not be replicated or improved in later studies. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs. For example, we are developing roflumilast foam, including ongoing Phase&#160;2 clinical trials in patients with seborrheic dermatitis and in patients with scalp psoriasis, based on our clinical experience with roflumilast cream in psoriasis. Despite our observations of roflumilast cream in a similar dermatological indication, roflumilast foam may not demonstrate comparable results in seborrheic dermatitis or scalp psoriasis. In addition, given its different formulation there is a risk that we selected an incorrect dose for roflumilast foam, as the clinical effect of roflumilast foam may differ from roflumilast cream at a similar dosing level or we may observe unexpected side effects not previously observed with roflumilast cream.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may experience numerous unforeseen events during or as a result of clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">clinical site closures, delays to patient enrollment, subjects discontinuing treatment or follow up visits, issues with data collection, or changes to trial protocols as a result of the COVID-19 pandemic;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites or prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">clinical trials of our product candidates may produce negative or inconclusive results, including failure to demonstrate statistical significance, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional review boards to suspend or terminate the trials;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical development for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the cost of clinical trials of our product candidates may be greater than we anticipate; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the institutional review boards of the institutions in which such trials are being conducted, by the data safety monitoring board for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 36</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">resulting in the imposition of a clinical hold, unforeseen safety issues or side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of our product candidates and adversely impact our potential to generate revenue, our business and our results of operations.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To gain approval to market our product candidates, we must provide the FDA and foreign regulatory authorities with preclinical and clinical data that adequately demonstrate the safety and efficacy of the product for the intended indication applied for in the applicable regulatory filing. Product development is long, expensive and uncertain processes, and delay or failure can occur at any stage of any of our preclinical and clinical development programs. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after promising results in earlier preclinical or clinical studies. These setbacks have been caused by, among other things, preclinical findings made while clinical studies were underway and safety or efficacy observations made in clinical studies, including previously unreported adverse events. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and the results of clinical trials by other parties may not be indicative of the results in trials we may conduct.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our lead product candidate, roflumilast cream, and roflumilast foam, its foam formulation, are currently in clinical development. Our product candidate ARQ-252 has just entered clinical development for chronic hand eczema and will do so in the second half of 2020 for vitiligo. ARQ-255 is in formulation and preclinical development for the potential treatment of alopecia areata. We currently have no products approved for sale, and we may never obtain regulatory approval to commercialize our lead product candidates. The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of drug products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, and such regulations differ from country to country. We are not permitted to market our product candidates in the United States or in any foreign countries until they receive the requisite approval from the applicable regulatory authorities of such jurisdictions, including pricing approval in the European Union.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA or any foreign regulatory authorities can delay, limit or deny approval of our product candidates for many reasons, including:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory authority that any of our product candidates is safe and effective for the requested indication;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the FDA or other relevant foreign regulatory authorities may disagree with the number, design, size, conduct or implementation of our clinical trials, including the design of our Phase 3 clinical trials of roflumilast cream for the treatment of plaque psoriasis;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the FDA or other relevant foreign regulatory authorities may not find the data from preclinical studies or clinical trials sufficient to demonstrate that the clinical and other benefits of these products candidates outweigh their safety risks or that there is an acceptable risk-benefit profile;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the results of our clinical trials may not meet the level of statistical significance or clinical meaningfulness required by the FDA or other relevant foreign regulatory authorities for marketing approval;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the FDA&#8217;s or the applicable foreign regulatory authority&#8217;s requirement for additional preclinical studies or clinical trials which would increase our costs and prolong our development timelines;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the FDA or other relevant foreign regulatory authorities may disagree with our interpretation of data or significance of results from the preclinical studies and clinical trials of any product candidate, or may require that we conduct additional studies;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 37</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the FDA or other relevant foreign regulatory authorities may not accept data generated from our clinical trial sites;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the contract research organizations, or CROs, that we retain to conduct clinical trials may take actions outside of our control, or otherwise commit errors or breaches of protocols, that adversely impact our clinical trials and ability to obtain market approvals;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">if our NDA or other foreign application is reviewed by an advisory committee, the FDA or other relevant foreign regulatory authority, as the case may be, may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our application or may recommend that the FDA or other relevant foreign regulatory authority, as the case may be, require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the FDA or other relevant foreign regulatory authorities may require development of a risk evaluation and mitigation strategy, or REMS, or its equivalent, as a condition of approval;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the FDA or other relevant foreign regulatory authorities may require additional post-marketing studies and/or a patient registry, which would be costly;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the FDA or other relevant foreign regulatory authorities may find the chemistry, manufacturing and controls data insufficient to support the quality of our product candidates;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the FDA or other relevant foreign regulatory authorities may identify deficiencies in the manufacturing processes or facilities of our third-party manufacturers; or</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the FDA or other relevant foreign regulatory authorities may change their approval policies or adopt new regulations.</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the FDA&#8217;s or the applicable foreign regulatory authority&#8217;s non-approval of the formulation, dosing, labeling or specifications;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the FDA&#8217;s or the applicable foreign regulatory authority&#8217;s failure to approve the manufacturing processes of third-party manufacturers upon which we rely or the failure of the facilities of our third-party manufacturers to maintain a compliance status acceptable to the FDA or the applicable foreign regulatory authority; or</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory authorities to significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Of the large number of biopharmaceutical products in development, only a small percentage successfully complete the FDA or other regulatory approval processes and are commercialized.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if we eventually complete clinical testing and receive approval from the FDA or applicable foreign agencies for any of our product candidates, the FDA or the applicable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials which may be required after approval. The FDA or the applicable foreign regulatory authority also may approve our lead product candidates for a more limited indication or a narrower patient population than we originally requested, and the FDA, or applicable foreign regulatory authority, may not approve our product candidates with the labeling that we believe is necessary or desirable, or may approve them with labeling that includes warnings or precautions or limitations of use that may not be desirable, for the successful commercialization of such product candidates. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of our product candidates and would materially adversely impact our business and prospects.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we may publicly disclose interim, topline, or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a full analyses of all data related to the particular trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline, or preliminary results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 38</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. We may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim, topline, or preliminary data and final data could significantly harm our business prospects.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our business in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, product candidate or our business. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Certain of the endpoints in our planned clinical trials rely on a subjective assessment of the effect of the product candidate in the subject by either the physician or patient, and may prove difficult to meet in patients with more severe disease, which exposes us to a variety of risks for the successful completion of our clinical trials.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain of our primary and secondary endpoints in our clinical trials, including our currently ongoing Phase 3 clinical trials of roflumilast cream in plaque psoriasis, involve subjective assessments by physician and patients, which can increase the uncertainty of clinical trial outcomes. For example, one of the secondary endpoints requires patients to report pruritus (itching) as measured by the Worst Itch &#8211; Numeric Rating Scale and complete or deliver patient or caregiver reported outcomes over the course of our clinical trials. This and other assessments are inherently subjective, which can increase the variability of clinical results across clinical trials and create a significant degree of uncertainty in determining overall clinical benefit. Such assessments can be influenced by factors outside of our control, and can vary widely from day-to-day for a particular patient, and from patient-to-patient and site-to-site within a clinical trial. In addition, frequent reporting requirements may lead to rating fatigue and a loss of accuracy and reliability of the data resulting from our clinical trials. Further, the FDA or comparable foreign regulatory authority may not accept such patient or caregiver reported outcomes as sufficiently validated. Accordingly, these subjective assessments can complicate clinical trial design, adversely impact the ability of a study to show a statistically significant improvement and generally adversely impact a clinical development program by introducing additional uncertainties.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patient reported outcome instruments, their use in our Phase 3 clinical trials of roflumilast cream and the inclusion of such data in the product labeling will depend on, but is not limited to, the FDA&#8217;s review of the following:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the relevance and importance of the concept(s) of interest to the target patient population;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the strengths and limitations of the instrument within the given context of use;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the design and conduct of the trials;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the adequacy of the submitted data, for example, rigorous data collection and methods to handle missing data; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the magnitude of the statistically significant treatment effect should be meaningful to patients.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, different results may be achieved depending upon the characteristics of the population enrolled in our studies and which analysis population is used to analyze results. For example, the primary endpoint in our Phase 3 clinical trials of roflumilast cream in plaque psoriasis is based on the percentage of patients achieving a score of &#8220;clear&#8221; or &#8220;almost clear&#8221; plus at least a 2-grade improvement from baseline on the 5 point Investigator&#8217;s Global Assessment (or IGA) scale, referred to as &#8220;IGA Success&#8221;. Success in our Phase&#160;3 clinical trials, or other clinical trials with these or similar endpoints, requires the enrollment of patients with conditions that are severe enough to facilitate a two-grade improvement in the IGA scale, but not so severe that they cannot achieve a &#8220;clear&#8221; </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 39</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">or &#8220;almost clear&#8221; in IGA score in light of the severity of their disease. It is therefore possible that we enroll patients with conditions so severe that they do not or are unable to realize an IGA of 0 (clear) or 1 (almost clear) during the period covered by the clinical trial. As a result, there is no guarantee that our Phase&#160;3 clinical trials will produce the same statistically significant results in &#8220;IGA Success&#8221;, which will serve as the primary endpoint, as our Phase 2b clinical trial, and there can be no guarantee that the characteristics of the population enrolled in our Phase 3 clinical trials does not adversely impact the results reported for such trial, any of which could have an adverse effect on our ability to secure regulatory approval for our product candidates.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Enrollment and retention of subjects in clinical trials is expensive and time consuming and may result in additional costs and delays in our product development activities, or in the failure of such activities.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may not be able to initiate or continue clinical trials for roflumilast cream or our other product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. In addition, some of our competitors are currently conducting clinical trials for product candidates that treat the same indications as roflumilast cream, roflumilast foam, ARQ-252 and ARQ-255, and patients who are otherwise eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patient enrollment is affected by other factors including:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the severity of the disease under investigation;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the selection of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the eligibility criteria for the study in question;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the frequency and extent of clinical trial site visits and study assessments;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the perceived risks and benefits of the product candidate under study;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the efforts to facilitate timely enrollment in clinical trials;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the patient referral practices of physicians;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the ability to monitor patients adequately during and after treatment; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the proximity and availability of clinical trial sites for prospective patients.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, any negative results that we may report in preclinical studies or clinical trials of our product candidates may make it difficult or impossible to recruit and retain subjects in other clinical trials of that same or any similar product candidate. Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary regulatory approvals. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and impede our ability to obtain additional financing.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As we continue our development of our product candidates and initiate additional preclinical studies or clinical trials of these or future product candidates, if any, serious adverse events, unacceptable levels of toxicity, undesirable side effects or unexpected characteristics may emerge, causing us to abandon these product candidates or limit their development to more narrow uses, lower potency levels or subpopulations in which the serious adverse events, unacceptable levels of toxicity, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk/benefit perspective.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our product candidates are associated with adverse effects in clinical trials or have characteristics that are unexpected, we may need to abandon their development, institute burdensome monitoring programs, or limit development to more narrow uses or lower or less frequent dosing in which the side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. The FDA or an institutional review board, or similar regulatory authorities outside the United States, may also require that we suspend, discontinue, or limit our clinical trials based on safety information. Such findings could further result in regulatory </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 40</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">authorities failing to provide marketing authorization for our product candidates. Many product candidates that initially showed promise in early stage testing have later been found to cause side effects that prevented further development of the product candidate.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, if one or more of our product candidates receives marketing approval, and we or others identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">regulatory authorities may withdraw approvals of such product;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">regulatory authorities may require additional warnings on the labels;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">we may be required to implement a risk evaluation and mitigation strategy, or REMS;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">we may be required to conduct Phase 4 clinical trials as post-marketing requirements, or PMRs;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">we could be sued and held liable for harm caused to patients; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our reputation and physician or patient acceptance of our products may suffer.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">As a company, we have never completed a Phase 3 program or obtained marketing approval for any product candidate and we may be unable to successfully do so in a timely manner, if at all, for any of our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Conducting Phase 3 clinical trials and preparing, and obtaining marketing approval for, a product candidate is a complicated process. Although members of our management team have participated in pivotal trials and obtained marketing approvals for product candidates in the past while employed at other companies, we as a company have not done so. As a result, these activities may require more time and cost more than we anticipate, and we may be unable to successfully complete them for any of our product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, we have completed two Phase 2 studies in plaque psoriasis and a Phase 2 proof of concept study in atopic dermatitis with roflumilast cream, and have initiated a Phase 3 program in plaque psoriasis, which includes three studies comprised of two pivotal studies (DERMIS-1 and DERMIS-2) and an open label extension. We also anticipate commencing more advanced clinical trials of roflumilast cream in the treatment of atopic dermatitis. Failure to successfully complete, or delays in, our pivotal trials or related regulatory submissions would prevent us from or delay us in obtaining regulatory approval for our product candidates.&#160;In addition, it is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our applications that they are insufficient to obtain marketing approval of our product candidates. If the FDA does not accept our applications or issue marketing authorizations for our product candidates, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA for any other applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs. Additionally, similar risks could apply to receipt of marketing authorizations by comparable regulatory authorities in foreign jurisdictions.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if our lead product candidate or our other product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 41</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if our lead product candidate or our other product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If our product candidates do not achieve an adequate level of acceptance, we may not generate adequate product revenue or become profitable. The degree of market acceptance of a product candidate, if approved for commercial sale, will depend on a number of factors, including but not limited to:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the safety, efficacy, risk-benefit profile and potential advantages compared to alternative or existing treatments, such as steroids topical treatments, oral treatments, and biologic injections for the treatment of psoriasis, which physicians may perceive to be adequately effective for some or all patients;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">side effects that may be attributable to our product candidates and the difficulty of or costs associated with resolving such side effects;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">limitations or warnings contained in the labeling approved for our product candidates by FDA or other applicable foreign regulatory authorities;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">any restrictions on the use of our products, and the prevalence and severity of any side effects;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the content of the approved product label;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the effectiveness of sales and marketing efforts;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the cost of treatment in relation to alternative treatments, including any similar generic treatments and over-the-counter,&#160;or OTC treatments;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our ability to offer our products for sale at competitive prices;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the convenience and ease of administration compared to alternative treatments;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies over existing therapies;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the strength of marketing and distribution support;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the availability of third-party coverage and adequate reimbursement at any given price level of each of our product candidates;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">utilization controls imposed by third-party payors, such as prior authorizations and step edits; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">any restrictions on the use of any of our product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We cannot assure you that our current or future product candidates, if approved, will achieve market acceptance among physicians, patients, third-party payors or others in the medical community necessary for commercial success. Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would harm our results of operations.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may choose not to continue developing or commercializing any of our product candidates at any time during development or after approval, which would reduce or eliminate our potential return on investment for those product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At any time, we may decide to discontinue the development or commercialization of any of our products or product candidates for a variety of reasons, including the appearance of new technologies that render our product obsolete, competition from a competing product or changes in or inability to comply with applicable regulatory requirements. If we terminate a program in which we have invested significant resources, we will not receive any return on our investment and we will have missed the opportunity to allocate those resources to potentially more productive uses.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to achieve and maintain coverage and adequate levels of reimbursement for any of our product candidates for which we receive regulatory approval, or any future products we may seek to commercialize, their commercial success may be severely hindered.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As to any of our product candidates that become available by prescription only, our success will depend on the availability of coverage and adequate reimbursement for our product from third-party payors. Patients who are prescribed medicine for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. The availability of coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and private third-party payors is critical to new </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 42</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. If any of our product candidates fail to demonstrate attractive efficacy profiles, they may not qualify for coverage and reimbursement. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use our prescription-only products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the market for certain of our product candidates will depend significantly on access to third-party payors&#8217; drug formularies, or lists of medications for which third-party payors provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In addition, in the United States, although private third-party payors tend to follow Medicare, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, we believe that future coverage and reimbursement will likely be subject to increased restrictions in both the United States and in international markets. Third-party coverage and reimbursement for any of our product candidates for which we may receive regulatory approval may not be available or adequate in either the United States or international markets, which could harm our business, financial condition, operating results and prospects.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We currently have limited sales, marketing or distribution capabilities and have no experience as a company in commercializing products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our current sales and marketing organization consists of two employees, our Chief Commercial Officer and our Vice President of Marketing.  To achieve commercial success for any product for which we obtain marketing approval, we will need to build a significantly more robust sales and marketing organization. We do not currently have any infrastructure for the sales, marketing, or distribution of any product, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any product that may be approved, we must build our sales, distribution, marketing, managerial and other nontechnical capabilities or make arrangements with third parties to perform these services.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently expect to build a dermatologist-focused sales, distribution and marketing infrastructure to market our product candidates in North America, if approved. There are significant expenses and risks involved with establishing our own sales, marketing and distribution capabilities, including our ability to hire, retain and appropriately incentivize qualified individuals, provide adequate training to sales and marketing personnel, and effectively manage geographically dispersed sales and marketing teams to generate sufficient demand. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could delay any product launch, which would adversely impact its commercialization. If the commercial launch of any of our product candidates, if approved, for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to establish adequate sales, marketing, and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing any of our product candidates and may not become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we seek to market any products in our pipeline in countries other than the United States, we will need to comply with the regulations of each country in which we seek to market our products.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 43</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None of our product candidates are currently approved for sale by any government authority in any jurisdiction. If we fail to comply with regulatory requirements in any market we decide to enter, or to obtain and maintain required approvals, or if regulatory approvals in the relevant markets are delayed, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. Marketing approval in one jurisdiction, including the United States, does not ensure marketing approval in another, but a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the regulatory process in others. Failure to obtain a marketing approval in countries in which we seek to market our products or any delay or setback in obtaining such approval would impair our ability to develop foreign markets for any of our products.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our license agreements obligate us to make certain milestone payments, some of which will be triggered prior to our commercialization of any of our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain of the milestone payments payable by us to AstraZeneca and Hengrui, are due upon events that will occur prior to our planned commercialization of the applicable product candidates. Accordingly, we will be required to make such payments prior to the time at which we are able to generate revenue, if any, from sales of any of our product candidates, if approved.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For example, upon regulatory approval from the FDA to commercialize roflumilast cream in the United States, but prior to commencement of commercialization or sales of roflumilast cream, we will be required to make certain milestone payments to AstraZeneca. We paid AstraZeneca the first milestone cash payment of $2.0&#160;million upon the completion of a Phase&#160;2b study of roflumilast cream in plaque psoriasis in August 2019 for the achievement of positive Phase&#160;2 data for an AZ-Licensed Product (as defined below). We have agreed to make additional cash payments to AstraZeneca of up to an aggregate of $12.5&#160;million upon the achievement of specified regulatory approval milestones with respect to products containing roflumilast in topical forms, as well as delivery systems sold with or for the administration of roflumilast, or collectively, AZ-Licensed Products, and payments up to an additional aggregate amount of $15.0 million upon the achievement of certain aggregate worldwide net sales milestones. With respect to any AZ-Licensed Products we commercialize under the agreement, we will pay AstraZeneca a low to high single-digit percentage royalty rate on our, our affiliates&#8217; and our sublicensees&#8217; net sales of such AZ-Licensed Products, until, as determined on an AZ-Licensed Product-by-AZ-Licensed Product and country-by-country basis, the later of the date of the expiration of the last-to-expire AstraZeneca-licensed patent right containing a valid claim in such country and ten years from the first commercial sale of such AZ-Licensed Product in such country.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the exercise of our exclusive option with Hengrui in December 2019, we made a $1.5 million cash payment and also contemporaneously amended the agreement to expand the territory to additionally include Canada. In addition, we have agreed to make cash payments of up to an aggregate of $20.5 million upon our achievement of specified clinical development and regulatory approval milestones with respect to the licensed products and cash payments of up to an additional $200.0&#160;million in sales-based milestones based on achieving certain aggregate annual net sales volumes with respect to a licensed product. With respect to any products we commercialize under the agreement, we will pay tiered royalties to Hengrui on net sales of each licensed product by us, or our affiliates, or our sublicensees, ranging from mid single-digit to sub-teen percentage rates based on tiered annual net sales bands subject to specified reductions. We are obligated to pay royalties until the later of (1) the expiration of the last valid claim of the licensed patent rights covering such licensed product in such country and (2) the expiration of regulatory exclusivity for the relevant licensed product in the relevant country, on a licensed product-by-licensed product and country-by-country basis. Additionally, we are obligated to pay Hengrui a specified percentage, ranging from the low-thirties to the sub-teens, of certain non-royalty sublicensing income we receive from sublicensees of our rights to the licensed products, such percentage decreasing as the development stage of the licensed products advance.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There can be no assurance that we will have the funds necessary to make such payments, or be able to raise such funds when needed, on terms acceptable to us, or at all. Furthermore, if we are forced to raise additional funds, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and market ourselves. If we are unable to raise additional funds or maintain sufficient liquidity to make our payment obligations if and when they become due, including payment obligations under the license agreement with AstraZeneca and under the option and license agreement with Hengrui, we may be in material breach of our agreements and our counterparties may seek legal action or remedies against us (including by seeking to terminate the relevant agreements), which would harm our business, financial condition, results of operations and prospects.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 44</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We face significant competition from other biotechnology and pharmaceutical companies targeting medical dermatological indications, and our operating results will suffer if we fail to compete effectively.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The markets for dermatological therapies are competitive and are characterized by significant technological development and new product introduction. For example, there are several large and small pharmaceutical companies focused on delivering therapeutics for our targeted inflammatory and medical dermatological indications. We anticipate that, if we obtain regulatory approval of our product candidates, we will face significant competition from other approved therapies or drugs that become available in the future for the treatment of our target indications. If approved, our product candidates may also compete with unregulated, unapproved and&#160;off-label&#160;treatments. Even if another branded or generic product or OTC product is less effective than our product candidates, a less effective branded, generic or OTC product may be more quickly adopted by physicians and patients than our competing product candidates based upon cost or convenience.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain of our product candidates, if approved, will have to compete with existing therapies, some of which are widely known and accepted by physicians and patients. To compete successfully in this market, we will have to demonstrate that the relative cost, safety and efficacy of our approved products, if any, provide an attractive alternative to existing and other new therapies to gain a share of some patients&#8217; discretionary budgets and for physicians&#8217; attention within their clinical practices. Some of the companies that offer competing products also have a broad range of other product offerings, large direct sales forces and long-term customer relationships with our target physicians, which could inhibit our market penetration efforts. Such competition could lead to reduced market share for our product candidates and contribute to downward pressure on the pricing of our product candidates, which could harm our business, financial condition, operating results and prospects.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are aware of several companies that are working to develop drugs that would compete against our product candidates for the treatment of psoriasis, atopic dermatitis, hand eczema, vitiligo and alopecia areata.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For psoriasis, our primary competitors include injected biologic therapies such as Humira, marketed by AbbVie Inc. and Eisai Co., Ltd., and Enbrel, marketed by Amgen Inc. and Pfizer Inc.; non-injectable systemic therapies used to treat plaque psoriasis such as Otezla, marketed by Amgen Inc.; topical therapies such as branded and generic versions of clobetasol, such as Clobex, marketed by Galderma Laboratories, LP, generic versions of calcipotriene and the combination of betamethasone dipropionate/calcipotriene; and other treatments including various lasers and ultraviolet light-based therapies. In addition, there are several prescription product candidates under development that could potentially be used to treat psoriasis and compete with roflumilast cream, including topical tapinarof, under development by Dermavant Sciences, Inc., and PF-06700841, an oral Tyk2/JAK1 inhibitor under development by Pfizer, Inc.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For atopic dermatitis, our primary competitors include topical therapies such as Eucrisa, marketed by Pfizer Inc., and generic and branded versions of low to mid-potency steroids such as hydrocortisone and betamethasone; and the injected biologic therapy Dupixent, marketed by Regeneron Pharmaceuticals, Inc. In addition, there are several prescription product candidates under development that could potentially be used to treat atopic dermatitis and compete with roflumilast cream, including but not limited to: topical tapinarof and topical cerdulatinib, both under development by Dermavant Sciences, Inc., topical ruxolitinib, under development by Incyte Corporation, topical delgocitinib, under development by LEO Pharma A/S and Japan Tobacco, Inc., topical PF-06700841, a Tyk2/JAK1 inhibitor under development by Pfizer, Inc., topical difamilast ointment, under development by Medimetriks/Otsuka Pharma, oral PF-04965842, under development by Pfizer Inc., oral upatacitinib, under development by AbbVie, Inc., and injectable lebrikizumab, under development by Dermira, Inc. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For hand eczema, our primary competitors include topical therapies such as branded and generic versions of clobetasol, such as Clobex, and generic versions of betamethasone dipropionate. The only other prescription product candidate we are aware of under development for the treatment of hand eczema that would compete with ARQ-252 is delgocitinib, which recently showed proof-of-concept in a Phase 2a trial and has been approved in a different formulation in Japan (Corectim).</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For vitiligo, our primary competitors include topical therapies such as generic and branded versions of calcineurin inhibitors, including Elidel, marketed by Bausch Health; branded and generic versions of high potency steroids, including Clobex, marketed by Galderma Laboratories, LP; and other treatments including various lasers and ultraviolet light-based therapies. In addition, there are several prescription product candidates under development that could potentially be used to treat vitiligo and compete with ARQ-252, including but not limited to: topical cerdulatinib, under development by Dermavant Sciences, Inc., topical ruxolitinib, under development by Incyte Corporation, and both oral PF-06651600 and oral PF-06700841, under development by Pfizer Inc.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 45</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For alopecia areata, our primary competitors include topical therapies such as branded and generic versions of high potency steroids, including Clobex, marketed by Galderma Laboratories, LP; intralesional corticosteroid injections such as branded and generic versions of triamcinolone, including Kenalog, marketed by Bristol-Myers Squib; and systemic immunosuppressants including generic versions of systemic steroids such as prednisone, branded and generic versions of cyclosporine, including Sandimmune, marketed by Sandoz, and branded systemic JAK inhibitors, including Xeljanz, marketed by Pfizer, Inc. In addition, there are several prescription product candidates under development that could potentially be used to treat alopecia areata and compete with ARQ-255, including but not limited to: topical PF-06700841 and oral PF-06651600, under development by Pfizer, Inc., oral CTP-543, under development by Concert Pharmaceuticals, and oral baricitinib, under development by Eli Lilly and Company.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of our existing or potential competitors have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, as well as in obtaining regulatory approvals of those product candidates in the United States and in foreign countries. Many of our current and potential future competitors also have significantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources being concentrated among a smaller number of our competitors. Competition may reduce the number and types of patients available to us to participate in clinical trials, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Due to less stringent regulatory requirements in certain foreign countries, there are many more dermatological products and procedures available for use in those international markets than are approved for use in the United States. In certain international markets, there are also fewer limitations on the claims that our competitors can make about the effectiveness of their products and the manner in which they can market their products. As a result, we expect to face more competition in these markets than in the United States.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ability to compete successfully will depend largely on our ability to:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">develop and commercialize therapies that are superior to other products in the market;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">demonstrate through our clinical trials that our product candidates are differentiated from existing and future therapies;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">attract qualified scientific, product development and commercial personnel;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">obtain patent or other proprietary protection for our technologies and product;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">obtain required regulatory approvals, including approvals to market our product candidates in ways that are differentiated from existing and future therapies and OTC products and treatments;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">successfully commercialize our product candidates, if approved;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">obtain coverage and adequate reimbursement from, and negotiate competitive pricing with, third-party payors; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new therapies.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The availability of our competitors&#8217; products could limit the demand and the price we are able to charge for any product candidate we develop. The inability to compete with existing or subsequently introduced drugs or OTC treatments would have an adverse impact on our business, financial condition and prospects.</span></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Business and Operations</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will need to increase the size of our organization, and we may experience difficulties in executing our growth strategy and managing any growth.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, we had 43 full-time employees. We will need to continue to expand our managerial, operational, finance and other resources in order to manage our operations and clinical trials, continue our development activities and commercialize our lead product candidates or any future product candidates.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 46</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management and personnel, systems and facilities currently in place are not adequate to support our future growth. In order to effectively execute our growth strategy, we will need to identify, recruit, retain, incentivize and integrate additional employees in order to expand our ability to:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">manage our clinical trials effectively;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">manage our internal development and operational efforts effectively while carrying out our contractual obligations to third parties;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">continue to improve our operational, financial, management and regulatory compliance controls and reporting systems and procedures;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">develop a marketing, sales and distribution capability;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">manage our commercialization activities for our product candidates effectively and in a cost-effective manner;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">establish and maintain relationships with development and commercialization partners;&#160;and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">manage our third-party supply and manufacturing operations effectively and in a cost-effective manner, while increasing production capabilities for our current product candidates to commercial levels.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to successfully identify, recruit, retain, incentivize and integrate additional employees and otherwise expand our managerial, operational, finance and other resources, our business and operational performance will be materially and adversely affected.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are not successful in acquiring, developing, and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although a substantial amount of our effort will focus on the continued preclinical and clinical testing and potential approval of our current product candidates, a key element of our strategy is to acquire, develop and commercialize a diverse portfolio of product candidates to serve the dermatology market. We do not currently intend to conduct drug discovery or research and development efforts to discover new product candidates, but rather we intend to acquire or in-license rights to existing molecules to develop for dermatological indications. In addition, while we believe that our strategy allows us to move more rapidly through clinical development and at a potentially lower cost, we may be unable to progress product candidates more quickly or at a lower cost.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the event we seek to identify and acquire or&#160;in-license&#160;additional product candidates in the dermatology field, our process for doing so may be slow and may ultimately be unsuccessful for a number of reasons, including those discussed in these risk factors and also:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">potential product candidates may, upon further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">potential product candidates may not be effective in treating their targeted diseases; or</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the acquisition or in-licensing transactions can entail numerous operational and functional risks, including exposure to unknown liabilities, disruption of our business, or incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, or higher than expected acquisition or integration costs.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may choose to focus our efforts and resources on an in-licensing or acquiring a potential product candidate that ultimately proves to be unsuccessful. We also cannot be certain that, following an acquisition or&#160;in-licensing&#160;transaction, we will achieve the revenue or specific net income that justifies such transaction. If we are unable to identify and acquire suitable product candidates for clinical development, this would adversely impact our business strategy, our financial position and share price.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize future product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may seek collaboration arrangements for the commercialization, or potentially for the development, of certain of our product candidates depending on the merits of retaining commercialization rights for ourselves as compared to entering into collaboration arrangements. We will face, to the extent that we decide to enter into </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 47</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">collaboration agreements, significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time-consuming to negotiate, document, implement and maintain. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements should we so chose to enter into such arrangements. The terms of any collaborations or other arrangements that we may establish may not be favorable to us. Any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include risks that:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to their acquisition of competitive products or their internal development of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">a collaborator with sales, marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our current or future product candidates or that results in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">collaborations may be terminated, and, if terminated, this may result in a need for additional capital to pursue further development or commercialization of the applicable current or future product candidates;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">collaborators may own or co-own intellectual property covering products that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">disputes may arise with respect to the ownership of any intellectual property developed pursuant to our collaborations; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">a collaborator&#8217;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, we cannot assure you that following any such collaboration, or other strategic transaction, we will achieve the expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 48</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop our current and any future product candidates, commercialize our product candidates or otherwise implement our business plan.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ability to compete in the highly competitive pharmaceuticals industry depends upon our ability to attract and retain highly qualified managerial, scientific, medical, sales and marketing and other personnel. We are highly dependent on our management and scientific personnel, including our Chief Executive Officer, Todd Franklin Watanabe, our Chief Medical Officer, Howard G. Welgus, M.D., and our Chief Technical Officer, David W. Osborne, Ph.D.  The loss of the services of any of these individuals could impede, delay or prevent the successful development of our product pipeline, completion of our planned clinical trials, commercialization of our products or in-licensing or acquisition of new assets and could negatively impact our ability to successfully implement our business plan. If we lose the services of any of these individuals, we might not be able to find suitable replacements on a timely basis or at all, and our business could be harmed as a result. We do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We employ all of our executive officers and key personnel on an at-will basis and their employment can be terminated by us or them at any time, for any reason and without notice. In order to retain valuable employees at our company, in addition to salary and cash incentives, we provide stock options and restricted stock units that vest over time. The value to employees of stock options and restricted stock units that vest over time will be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract offers from other companies.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses, particularly in the Northern Los Angeles Area where we are headquartered. We could have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts. Many of the other pharmaceutical companies with whom we compete for qualified personnel have greater financial and other resources, different risk profiles and longer histories in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that will harm our ability to implement our business strategy and achieve our business objectives.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we have scientific and clinical advisors who assist us in formulating our development and clinical strategies. These advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In addition, our advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranty. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">decreased demand for our current or future product candidates;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">injury to our reputation;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">withdrawal of clinical trial participants;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">costs to defend the related litigation;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">a diversion of management&#8217;s time and our resources;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 49</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">substantial monetary awards to trial participants or patients;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">loss of revenue; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the inability to commercialize our current or any future product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of our current or any future&#160;product candidates we develop. Although we currently carry product liability insurance covering our clinical trials, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess&#160;of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient funds to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing any of our product candidates, we intend to expand our insurance coverage to include the sale of such product candidate; however, we may be unable to obtain this liability insurance on commercially reasonable terms or at all.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">As a new public company, we will incur significant costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section&#160;404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm our business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We completed our IPO in January 2020 and are subject to public company reporting obligations under the Securities Exchange Act of 1934, as amended, or the Exchange Act, We will incur significant legal, accounting and other expenses as a public company, including costs resulting from such public company reporting obligations and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Global Select Market and the rules of the Securities and Exchange Commission, or SEC, require that we satisfy certain corporate governance requirements relating to director independence, filing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to Section&#160;404 of The Sarbanes-Oxley Act of 2002, or Section&#160;404, and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Beginning with our next annual report that we will be required to file with the SEC, Section&#160;404 requires an annual management assessment of the effectiveness of our internal control over financial reporting. However, for so long as we remain an emerging growth company as defined in the JOBS Act, or a "smaller reporting company" (SRC) and non-accelerated filer, we intend to take advantage of certain exemptions from various reporting requirements, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404. Once we are no longer an emerging growth company and otherwise do not meet the definition of a SRC and non-accelerated filer or, if prior to such date, we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public accounting firm on the effectiveness of our internal controls over financial reporting. We will remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of the completion of our IPO. However, if certain events occur prior to the end of such five-year period, including if we become a &#8220;large accelerated filer,&#8221; our annual gross revenues exceed $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.  We could qualify as a SRC if the market value of our common stock held by non-affiliates is below $250 million (or $700 million if our annual revenue is less than $100 million) as of June 30 in any given year. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 50</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we expect that we will need to implement an enterprise resource planning, or ERP, system for our company. An ERP system is intended to combine and streamline the management of our financial, accounting, human resources, sales and marketing and other functions, enabling us to manage operations and track performance more effectively. However, an ERP system would likely require us to complete many processes and procedures for the effective use of the system or to run our business using the system, which may result in substantial costs. Additionally, during the conversion process, we may be limited in our ability to convert any business that we acquire to the ERP. Any disruptions or difficulties in implementing or using an ERP system could adversely affect our controls and harm our business, including our ability to forecast or make sales and collect our receivables. Moreover, such disruption or difficulties could result in unanticipated costs and diversion of management attention.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, we have never conducted a review of our internal control for the purpose of providing the reports required by these rules. During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we will be required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Global Select Market or other adverse consequences that would materially harm to our business.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A global financial crisis or a global or regional political disruption could cause extreme volatility in the capital and credit markets. For example outbreaks of epidemic, pandemic, or contagious diseases, such as the recent COVID-19 outbreak, could disrupt our business. Business disruptions could include disruptions to the enrollment, clinical site availability, patient accessibility and conduct of our clinical trials, as well as temporary closures of the facilities of suppliers or contract manufacturers in the biotechnology supply chain.  In addition, the COVID-19 outbreak may result in a severe economic downturn and has already significantly affected the financial markets of many countries.  A severe or prolonged economic downturn or political disruption could result in a variety of risks to our business, including our ability to raise capital when needed on acceptable terms, if at all.  A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our corporate headquarters and other facilities are located in the Northern Los Angeles Area, which in the past has experienced both severe earthquakes and wildfires. We do not carry earthquake insurance. Earthquakes, wildfires or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If a natural disaster, power outage or other event occurred, including an epidemic, pandemic or contagious disease outbreak such as COVID-19 that disrupted operations, we may experience difficulties in operating our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, our third-party manufacturers or suppliers are similarly vulnerable to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 51</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We depend on our information technology systems, and any failure of these systems, or those of our CROs or other contractors or consultants we may utilize, could harm our business. Security breaches, cyber-attacks, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations, financial condition and prospects.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have established physical, electronic, and organizational measures to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools, and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. Our internal information technology systems and infrastructure, and those of our current and any future collaborators, contractors and consultants and other third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Moreover, if a computer security breach affects our systems or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various federal and state privacy and security laws (and other similar non-U.S. laws), if applicable, including the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Clinical Health Act of 2009, and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. By way of example, on June 28, 2018, California enacted the California Consumer Privacy Act, or CCPA, which takes effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and similar laws have been proposed at the federal level and in other states as well as in non-U.S. jurisdictions. We would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our future commercial partners, as well as our employees and independent contractors, including principal investigators, consultants, suppliers, service providers and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to the risk that our future commercial partners, as well as our employees and independent contractors, including principal investigators, consultants, suppliers, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar foreign regulatory authorities, including those laws that require the reporting of true, complete and accurate information to such foreign regulatory authorities; manufacturing standards; U.S. federal and state healthcare fraud </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 52</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and abuse, data privacy laws and other similar non-U.S. laws; or laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third-parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use and disposal of hazardous materials owned by us, including the components of our product and product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage.</span></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We currently rely on single source third-party manufacturers to manufacture preclinical and clinical supplies of our product candidates and we intend to rely on third parties to produce commercial supplies of any approved product candidate. The loss of these manufacturers, or their failure to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.  </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not currently have nor do we plan to build or acquire the infrastructure or capability internally to manufacture supplies of our product candidates or the materials necessary to produce our product candidates for use in the conduct of our preclinical studies or clinical trials, and we lack the internal resources and the capability to manufacture any of our product candidates on a preclinical, clinical or commercial scale. Instead, we currently rely on single source third-party manufacturers to manufacture preclinical and clinical supplies of our product candidates and we intend to rely on third parties to produce commercial supplies of any approved product candidate.  In the fourth quarter of 2019, we received a batch of our product candidate that we believe is representative of our anticipated early commercial batch requirements. However, as a late-stage company with no prior history of product sales or commercialization of products, representative batches of our product candidate received to date may not represent what will be required to meet our future commercial requirements or be manufactured at scale.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 53</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We and the manufacturers of our products rely on suppliers of raw materials used in the production of our products. Some of these materials are available from only one source. Additionally, we have not yet engaged any manufacturer for the commercial supply of our product candidates. Although we intend to enter into such agreements prior to commercial launch of any of our product candidates, we may be unable to enter into any such agreement or do so on commercially reasonable terms, which could have a material adverse impact upon our business. Moreover, if there is a disruption to one or more of our third-party suppliers&#8217; relevant operations, or if we are unable to enter into arrangements for the commercial manufacture of our product candidates, we will have no other means of producing our lead product candidates until they restore the affected facilities or we or they procure alternative manufacturing facilities or sources of supply. Our ability to progress our preclinical and clinical programs could be materially and adversely impacted if any of the third-party suppliers upon which we rely were to experience a significant business challenge, disruption or failure due to issues such as financial difficulties or bankruptcy, issues relating to other customers such as regulatory or quality compliance issues, or other financial, legal, regulatory or reputational issues. Additionally, any damage to or destruction of our third-party manufacturer&#8217;s facilities or equipment may significantly impair our ability to manufacture our product candidates on a timely basis.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, there are a limited number of suppliers for materials we use in our product candidates, which exposes us to the risk of disruption in the supply of the materials necessary to manufacture our product candidates for our preclinical studies and clinical trials, and if approved, ultimately for commercial sale. In the case of ARQ-252 and ARQ-255, we have an agreement with Hengrui for the supply of SHR0302 API for preclinical studies and clinical trials. We do not have any control over the process or timing of the acquisition or manufacture of materials by our manufacturers. In addition, any significant delay in, or quality control problems with respect to, the supply of a product candidate, or the raw material components thereof, for an ongoing study or trial could considerably delay completion of our preclinical studies or clinical trials, product testing and potential regulatory approval of our product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, to manufacture our product candidates in the quantities that we believe would be required to meet anticipated market demand, our third-party manufacturers may need to increase manufacturing capacity and, in some cases, we plan to secure alternative sources of commercial supply, which could involve significant challenges and may require additional regulatory approvals Neither we nor our third-party manufacturers may successfully complete any required increase to existing manufacturing capacity in a timely manner, or at all. If our manufacturers or we are unable to purchase the raw materials necessary for the manufacture of our product candidates on acceptable terms, at sufficient quality levels, or in adequate quantities, if at all, the commercial launch of our lead product candidates or any future product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of such product candidates, if approved.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If our third-party manufacturers fail to comply with manufacturing or other regulations, our financial results and financial condition will be adversely affected.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable regulatory authorities in foreign jurisdictions, we may not be able to rely on their manufacturing facilities for the manufacture or our product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Before beginning commercial manufacture of roflumilast cream, roflumilast foam, ARQ-252 or ARQ-255, the process and systems used in the manufacture of roflumilast cream, roflumilast foam, ARQ-252 or ARQ-255 must be approved and each facility must have a compliance status that is acceptable to the FDA and other regulatory authorities. In addition, pharmaceutical manufacturing facilities are continuously subject to inspection by the FDA and foreign regulatory authorities, before and after product approval. Due to the complexity of the processes used to manufacture pharmaceutical products and product candidates, any potential third-party manufacturer may be unable to continue to pass or initially pass federal, state or international regulatory inspections.&#160;Furthermore, although we do not have day-to-day control over the operations of our contract manufacturers, we are responsible for ensuring compliance with applicable laws and regulations, including cGMPs.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If a third-party manufacturer with whom we contract is unable to comply with applicable laws and regulations, including cGMPs, roflumilast cream, roflumilast foam, ARQ-252 or ARQ-255 may not be approved, or we may be subject to fines, unanticipated compliance expenses, recall or seizure of our products, total or partial </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 54</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">suspension of production and/or enforcement actions, including injunctions, and criminal or civil prosecution. These possible sanctions would adversely affect our financial results and financial condition.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We rely on third parties to conduct our non-clinical studies and our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize roflumilast cream, roflumilast foam, ARQ-252, ARQ-255 or any future product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not have the ability to independently conduct non-clinical studies and clinical trials. We rely on third parties, such as CROs, to conduct preclinical studies and clinical trials of roflumilast cream, roflumilast foam, ARQ-252 and ARQ-255. The third parties with whom we contract for execution of our preclinical studies and clinical trials play a significant role in the conduct of these studies and trials and the subsequent collection and analysis of data. However, these third parties are not our employees, and except for contractual duties and obligations, we have limited ability to control the amount or timing of resources that they devote to our programs. These third parties may also have relationships with other commercial entities, some of which may compete with us. In some cases, these third parties could terminate their agreements with us without cause.  Furthermore, external events such as the COVID-19 pandemic could interfere with some operations of these CROs.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we rely on third parties to conduct our preclinical studies and clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in&#160;accordance with its investigational plan and protocol. Moreover, the FDA and foreign regulatory authorities require us to comply with regulations and standards, including some regulations commonly referred to as good clinical practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that appropriate human subjects protections are in place, including that the trial subjects are adequately informed of the potential risks and other consequences of participating in clinical trials.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the execution of non-clinical studies and clinical trials, and the subsequent compilation and analysis of the data produced, requires coordination among various parties. In order for these functions to be carried out effectively and efficiently, it is imperative that these parties communicate and coordinate with one another. If the third parties conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties, which could be difficult, costly or impossible, and our clinical trials may be extended, delayed or terminated or may need to be repeated, which would have a material adverse effect on our business.</span></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Intellectual Property</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to obtain, maintain or enforce patent rights or other intellectual property rights that cover our product candidates and technologies that are of sufficient breadth to prevent third parties from competing against us.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our success with respect to our product candidates and technologies will depend in part on our and our licensors&#8217; ability to obtain and maintain patent protection in both the United States and other countries, to preserve our trade secrets and to prevent third parties from infringing upon our proprietary rights. Our ability to protect any of our product candidates from unauthorized or infringing use by third parties depends in substantial part on our ability to obtain and maintain valid and enforceable patents.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our patent portfolio includes patents and patent applications in the United States and foreign jurisdictions where we believe there is a market opportunity for our products. The covered technology and the scope of coverage vary from country to country. For those countries where we do not have granted patents, we may not have any ability to prevent the unauthorized use of our technologies. Any patents that we may obtain may be narrow in scope and thus easily circumvented by competitors. Further, in countries where we do not have granted patents, third parties may be able to make, use or sell products identical to or substantially similar to, our product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The patent application process, also known as patent prosecution, is expensive and time-consuming, and we and our current licensors, or any future licensors or licensees may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our current licensors, or any future licensors or licensees, will fail to identify patentable aspects of inventions made </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 55</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, our patents and applications may not be prosecuted, and as a result may not be able to be enforced in a manner consistent with the best interests of our business. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, such as with respect to proper priority claims, inventorship, claim scope or patent term adjustments. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and unenforceable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how to our processes, methods, and know-how which we consider our trade secrets. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business, financial condition and operating results.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Due to legal standards relating to patentability, validity, enforceability and claim scope of patents covering pharmaceutical inventions, our and our licensor&#8217;s ability to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions. Accordingly, rights under our existing patents or any patents we might obtain or license may not cover our product candidates, or may not provide us with sufficient protection for our product candidates to afford a commercial advantage against competitive products or processes, including those from branded and generic pharmaceutical companies. In addition, we cannot guarantee that any patents will issue from any pending or future patent applications owned by or licensed to us. Even with respect to our patents that have issued or will issue, we cannot guarantee that the claims of these patents are or will be held valid or enforceable by the courts or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we or our licensors were the first to make the inventions claimed in our patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our technology or drugs, in whole or in part, or which effectively prevent others from commercializing competitive technologies and drugs. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Competitors in the field of dermatologic therapeutics have created a substantial amount of prior art, including scientific publications, patents and patent applications. Our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Although we believe that our technology includes certain inventions that are unique and not duplicative of any prior art, we do not have outstanding issued patents covering all of the recent developments in our technology and we are unsure of the patent protection that we will be successful in obtaining, if any, over such aspects of our technology. Even if patents do successfully issue covering such aspects of our technology, third parties may design around or challenge the validity, enforceability or scope of such issued patents or any other issued patents we own or license, which may result in such patents being narrowed, invalidated or held unenforceable. If the breadth or strength of protection provided by the patents we own or license with respect to our product candidates is challenged, it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize, our product candidates. Even if the patent applications that we own or license issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or drugs in a non-infringing manner.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The laws of some foreign jurisdictions do not provide intellectual property rights to the same extent as in the United States and many companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. If we encounter such difficulties in protecting or are otherwise precluded from effectively protecting our intellectual property in foreign jurisdictions, our business prospects could be substantially harmed. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 56</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The degree of future protection of our proprietary rights is uncertain. Patent protection may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">we might not have been the first to invent or the first to file the inventions covered by each of our pending patent applications and issued patents;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the patents of others may have an adverse effect on our business;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">any patents we obtain or our licensors&#8217; issued patents may not encompass commercially viable products, may not provide us with any competitive advantages or may be challenged by third parties;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">for some product candidates, we expect that composition of matter patent protection for the active pharmaceutical ingredient will not be available at the time we expect to commercialize, and we will therefore need to rely on formulation, method of use and other forms of claims for patent protection;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">any patents we obtain or our in-licensed issued patents may not be valid or enforceable; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">we may not develop additional proprietary technologies that are patentable.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20&#160;years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our product candidates, we may be open to competition from generic versions of our product candidates. Further, the extensive period of time between patent filing and regulatory approval for a product candidate limits the time during which we can market a product candidate under patent protection, which may particularly affect the profitability of our early-stage product candidates. Our issued U.S. patents relating to roflumilast cream and roflumilast foam with claims directed to, among other things, formulating roflumilast in combination with hexylene glycol are currently projected to expire on June&#160;7, 2037 and the issued U.S. patents which we have exclusive rights to from Hengrui as a result of the exercise of our exclusive option with Hengrui in December 2019 for the amount of $1.5 million cash, related to the composition of matter of the active ingredient in ARQ-252 and ARQ-255 (or bisulfate or crystal forms thereof) are currently projected to expire between January&#160;21, 2033 and October&#160;15, 2035 unless a patent term extension is granted. Proprietary trade secrets and unpatented know-how are also very important to our business. Although we have taken steps to protect our trade secrets and unpatented know-how by entering into confidentiality agreements with third parties, and intellectual property protection agreements with certain employees, consultants and advisors, third parties may still obtain this information or we may be unable to protect our rights. We also have limited control over the protection of trade secrets used by our suppliers, manufacturers and other third parties. There can be no assurance that binding agreements will not be breached, that we would have adequate remedies for any breach or that our trade secrets and unpatented know-how will not otherwise become known or be independently discovered by our competitors. If trade secrets are independently discovered, we would not be able to prevent their use. Enforcing a claim that a third party illegally obtained and is using our trade secrets or unpatented know-how is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secret information.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may become subject to claims alleging infringement of third parties&#8217; patents or proprietary rights and/or claims seeking to invalidate our patents, which would be costly, time consuming and, if successfully asserted against us, delay or prevent the development and commercialization of roflumilast cream, roflumilast foam, ARQ-252, ARQ-255 or any future product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been many lawsuits and other proceedings asserting patents and other intellectual property rights in the pharmaceutical and biotechnology industries. We cannot assure you that our exploitation of roflumilast cream, roflumilast foam, ARQ-252 or ARQ-255 will not infringe existing or future third-party patents. Because patent applications can take many years to issue and may be confidential for 18&#160;months or more after filing, there may be applications now pending of which we are unaware and which may later result in issued patents that we may infringe by commercializing roflumilast cream, roflumilast foam, ARQ-252 or ARQ-255. Moreover, we may face claims from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may thus have no deterrent effect. We may be unaware of one or more issued patents that would be infringed by the manufacture, sale or use of roflumilast cream, roflumilast foam, ARQ-252 or ARQ-255.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 57</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may be subject to third-party claims in the future against us or our collaborators that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages, including treble damages and attorney&#8217;s fees if we are found to be willfully infringing a third party&#8217;s patents. We may be required to indemnify future collaborators against such claims. If a patent&#160;infringement suit were brought against us or our future collaborators, we or they could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we or our collaborators may choose to seek, or be required to seek, a license from the third-party and would most likely be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we or our future collaborators were able to obtain a license, the rights obtained may be nonexclusive, which would not confer a competitive advantage to us from an exclusivity perspective. Ultimately, we could be prevented from commercializing a product, or forced to redesign it, or to cease some aspect of our business operations if, as a result of actual or threatened patent infringement claims, we or our collaborators are unable to enter into licenses on acceptable terms to necessary third party patent rights. Even if we are successful in defending against such claims, such litigation can be expensive and time consuming to litigate and would divert management&#8217;s attention from our core business. Any of these events could harm our business significantly.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to infringement claims against us, if third parties prepare and file patent applications in the United States that also claim technology similar or identical to ours, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office, or the USPTO, to determine which party is entitled to a patent on the disputed invention. We may also become&#160;involved in similar opposition proceedings in the European Patent Office or similar offices in other jurisdictions regarding our intellectual property rights with respect to our products and technology. Since patent applications are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be subject to claims by third parties asserting that we, our employees or our licensors have misappropriated their intellectual property, including trade secrets, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of our employees and our licensor&#8217;s employees were previously employed at other biotechnology or pharmaceutical companies. Although we and our licensors try to ensure that our employees and our licensor&#8217;s employees do not use the proprietary information or know-how of others in their work for us, including by contract, we or our licensors may be subject to claims that these employees, our licensors or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may in the future be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we or our licensor fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we and our licensor are successful in prosecuting or defending against such claims, litigation could result in substantial costs.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The validity, scope and enforceability of any patents listed in the Orange Book that cover roflumilast cream, roflumilast foam, ARQ-252 or ARQ-255 can be challenged by competitors.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If roflumilast cream, roflumilast foam, ARQ-252 or ARQ-255 is approved by the FDA, one or more third parties may challenge the patents covering roflumilast cream, roflumilast foam, ARQ-252 or ARQ-255, which could result in the invalidation of, or render unenforceable, some or all of the relevant patent claims or a finding of non-infringement. For example, if a third party files an abbreviated new drug application, or ANDA, for a generic drug bioequivalent to roflumilast cream, roflumilast foam, ARQ-252 or ARQ-255, and relies in whole or in part on studies conducted by or for us, the third party will be required to certify to the FDA that either: (1)&#160;there is no patent information listed in the FDA&#8217;s Orange Book with respect to our NDA for the applicable approved drug candidate; (2)&#160;the patents listed in the Orange Book have expired; (3)&#160;the listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration; or (4)&#160;the listed patents are invalid or will not be </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 58</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">infringed by the manufacture, use or sale of the third party&#8217;s generic drug. A certification that the new drug will not infringe the Orange Book-listed patents for the applicable approved drug candidate, or that such patents are invalid, is called a paragraph&#160;IV certification. If the third party submits a paragraph&#160;IV certification to the FDA, a notice of the paragraph&#160;IV certification must also be sent to us once the third party&#8217;s ANDA is accepted for filing by the FDA. We may then initiate a lawsuit to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45&#160;days of receipt of the notice automatically prevents the FDA from approving the third party&#8217;s ANDA until the earliest of 30&#160;months or the date on which the patent expires, the lawsuit is settled, or the court reaches a decision in the infringement lawsuit in favor of the third party. If we do not file&#160;a patent infringement lawsuit within the required 45-day period, the third party&#8217;s ANDA will not be subject to the 30-month stay of FDA approval. Litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could limit our ability to prevent third parties from competing with our product candidates.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent term for our product candidates, our business may be materially harmed.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our commercial success will largely depend on our ability to obtain and maintain patent and other intellectual property in the United States and other countries with respect to our proprietary technology, product candidates and our target indications. Our issued U.S. patents, with claims directed to roflumilast formulations with reduced crystal growth, encompassing roflumilast cream, are currently projected to expire on June&#160;7, 2037. Certain issued U.S. patents that we have licensed from Hengrui relating to, among other things, treatment of several diseases or disorders, including various cancers, allograft rejection, graft versus host disease, rheumatoid arthritis, atopic dermatitis, and psoriasis with SHR0302, or bisulfate and crystal forms thereof, are currently projected to expire beginning in 2033. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our product candidates might expire before or shortly after such candidates begin to be commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of the U.S. patents covering our product candidates may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal expiration of the patent as compensation for patent term lost during development and the FDA regulatory review process, which is limited to the approved indication (or any additional indications approved during the period of extension). This extension is limited to only one patent that covers the approved product. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to obtain approval of competing products following our patent expiration and launch their product earlier than might otherwise be the case.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 59</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may need to license additional intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additional third parties, apart from our current licensors, may hold intellectual property, including patent rights, that are important or necessary to the development of our product candidates. It may be necessary for us to use the patented or proprietary technology of these third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms. Such a license may not be available, or it may not be available on commercially reasonable terms, in which case our business would be harmed. The risks described elsewhere pertaining to our intellectual property rights also apply to the intellectual property rights that we in-license, and any failure by us or our licensors to obtain, maintain, defend and enforce these rights could harm our business. In some cases we may not have control over the prosecution, maintenance or enforcement of the patents that we license, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and our licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Filing, prosecuting and defending patents on product candidates, including all of the licensed rights under our exclusive supply and license agreements with AstraZeneca and Hengrui, in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The United States has enacted and implemented wide-ranging patent reform legislation, and that legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The United States Patent Office recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March&#160;16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and pending patent applications.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 60</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The United States Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the United States Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The United States federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable,&#160;paid-up&#160;license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with&#160;&#8220;march-in&#160;rights.&#8221;&#160;March-in&#160;rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. Having a mandatory non-exclusive license grant may diminish the value of our patents as well as making it more difficult to protect our products.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and other foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits,&#160;non-payment&#160;of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering any of our product candidates, our competitors might be able to enter the market earlier than anticipated, which would harm our business.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic or conflict with third-party rights. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. In addition, third parties may file first for our trademarks in certain countries. If they succeeded in registering such trademarks, and if we were not successful in challenging such third-party rights, we may not be able to use these trademarks to market our products in those countries. In such cases, over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then our marketing abilities may be impacted.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have not yet registered trademarks for a commercial trade name for our lead candidates in the United States or foreign jurisdictions and failure to secure such registrations could adversely affect our business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not yet registered trademarks for a commercial trade name for our lead product candidates in the United States or any foreign jurisdiction. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 61</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Moreover, any name we propose to use with our product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may not be able to protect our proprietary information and technology adequately. Although we use reasonable efforts to protect our proprietary information, technology, and know-how, our employees, consultants, contractors, outside scientific advisors, licensors or licensees may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third party illegally obtained and is using any of our proprietary information, technology or know-how is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect proprietary information, technology, and know-how. We rely, in part, on non-disclosure and confidentiality agreements with our employees, consultants and other parties to protect our proprietary information, technology, and know-how. These agreements may be breached and we may not have adequate remedies for any breach. Moreover, others may independently develop similar or equivalent proprietary information, and third parties may otherwise gain access to our proprietary knowledge.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have licensed or acquired certain intellectual property rights covering our current product candidates from third parties, including AstraZeneca and Hengrui. We are heavily dependent on our agreements with such third parties for our current product candidates. If, for any reason, one or more of our agreements with such third parties is terminated or we otherwise lose those rights, it could harm our business. Our license and other agreements impose, and any future collaboration agreements or license agreements we enter into are likely to impose various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. If we breach any such material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology, or having to negotiate new or reinstated licenses on less favorable terms, or enable a competitor to gain access to the licensed technology.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and time-consuming.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Competitors may infringe our intellectual property, including our patents or the patents of our licensors. As a result, we may be required to file infringement claims or inform and cooperate with our licensors to stop third-party infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant an injunction against an infringer are not satisfied. An adverse determination of any litigation or other proceedings could put one or more of our patents at risk of being invalidated, interpreted narrowly or amended such that they do not cover our product candidates. Moreover, such adverse determinations could put our patent applications at risk of not issuing, or issuing with limited and potentially inadequate scope to cover our product candidates or to prevent others from marketing similar products.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interference, derivation or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with respect to our patent applications or those of our licensors or potential partners. Litigation or USPTO proceedings brought by us may fail or may be invoked against us by third parties. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs. We may not be able, alone or with our licensors or potential partners, to prevent misappropriation </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 62</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate patents or other proprietary rights, may delay or prevent the development and commercialization of any of our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our commercial success depends in part on our and our licensors avoiding infringement and other violations of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation and administrative law proceedings, inter partes review and post-grant review before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent was to be held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting&#160;know-how&#160;and inventions.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 63</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays, or prohibit us from manufacturing, marketing or otherwise commercializing our products, services and technology. Any uncertainties resulting from the initiation and continuation of any litigation could adversely impact our ability to raise additional funds or otherwise harm our business, results of operation, financial condition or cash flows.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could adversely impact the price of our common shares. If securities analysts or investors perceive these results to be negative, it could adversely impact the price of our common shares. The occurrence of any of these events may harm our business, results of operation, financial condition or cash flows.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We cannot provide any assurances that third-party patents do not exist which might be enforced against our drugs or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities, and have a harmful effect on the success of our business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could adversely impact the price of our common shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials and internal research programs, or&#160;in-license&#160;needed technology or other product candidates. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development collaborations that would help us commercialize our product candidates, if approved.</span></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Government Regulation</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if we receive regulatory approval of our product candidates, we will be subject to extensive and ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any regulatory approvals or other marketing authorizations we obtain for our product candidates may be subject to limitations on the indicated uses for which the product may be marketed or the conditions of approval or marketing authorization, or contain requirements for potentially costly post-market testing and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS as a condition of approval of our drug product candidates, such as roflumilast cream, roflumilast foam, ARQ-252 and ARQ-255, which could include requirements for a medication guide, physician communication plans or additional elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority authorizes our product candidates for marketing, the </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 64</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">fines, warning or untitled letters or holds on clinical trials;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">refusal by the FDA to accept new marketing applications or supplements, approve or otherwise authorize for marketing pending applications or supplements to applications filed by us or suspension or revocation of approvals or other marketing authorizations;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">injunctions or the imposition of civil or criminal penalties.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current presidential administration may impact our business and industry. Namely, the current presidential administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would harm our business. For example, over the last several years, including for 35 days beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could harm our business.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our product candidates, if authorized for marketing, may cause or contribute to adverse medical events that we are required to report to the FDA, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our product candidates, or a recall of our products either voluntarily or at the direction of </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 65</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">the FDA or another governmental authority, if such products are marketed, could have a negative impact on us.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to any of our product candidates in clinical testing or approved by FDA, we will be subject to the FDA&#8217;s safety reporting requirements. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our reporting obligations, the FDA could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our approval or delay in approval of future products.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may choose to voluntarily recall a product if any material deficiency is found. A recall could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other errors may occur in the future. Recalls involving our product candidates, if and when they are approved or otherwise authorized for marketing, could be particularly harmful to our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be subject to healthcare laws and regulations relating to our business, and could face substantial penalties if we are determined not to have fully complied with such laws, which would have an adverse impact on our business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, customers and patients, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a U.S. healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the U.S. federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">U.S. federal civil and criminal false claims laws and civil monetary penalties laws, including the civil False Claims Act, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. government;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the U.S. Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing regulations, which also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 66</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">associates that perform certain services for or on their behalf involving the use or disclosure of individually identifiable health information;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the U.S. Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the government information related to payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, (as well as certain other healthcare professionals beginning in 2022) and requires applicable manufacturers and group purchasing organizations to report annually to the government ownership and investment interests held by the physicians described above and their immediate family members;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">state privacy laws and regulations, such as those of California, that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information (for example, in June 2018, California enacted the California Consumer Privacy Act (which will go into effect on January&#160;1, 2020) that gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used, and provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation; resulting in increased compliance costs and potential liability);</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">analogous state and non-U.S. laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical and device companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information; and state and non-U.S. laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities may conclude that our business practices, including our consulting arrangements with and/or ownership interests by physicians and other healthcare providers, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of these or any other health regulatory laws that may apply to us, we may be subject to significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have conducted and may in the future conduct clinical trials for our product candidates outside the United States and the FDA and applicable foreign regulatory authorities may not accept data from such trials.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 67</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have conducted and may in the future choose to conduct one or more of our clinical trials outside the United States, including in Canada and Europe. Although the FDA or applicable foreign regulatory authority may accept data from clinical trials conducted outside the United States or the applicable jurisdiction, acceptance of such study data by the FDA or applicable foreign regulatory authority may be subject to certain conditions. Where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless those data are applicable to the U.S. population and U.S. medical practice; the studies were performed by clinical investigators of recognized competence; and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Many foreign regulatory authorities have similar requirements. In addition, such foreign studies would be subject to the applicable local laws of the foreign jurisdictions where the studies are conducted. There can be no assurance the FDA or applicable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or applicable foreign regulatory authority does not accept such data, it would likely result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the United States and some non-U.S. jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the Affordable Care Act, was enacted in the United States to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The law has continued the downward pressure on the pricing of medical items and services, especially under the Medicare program, and increased the industry&#8217;s regulatory burdens and operating costs. Among the provisions of the Affordable Care Act of importance to our potential product candidates are the following:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">an annual, nondeductible fee payable by any entity that manufactures or imports specified branded prescription drugs and biologic agents;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">extension of manufacturers&#8217; Medicaid rebate liability to individuals enrolled in Medicaid managed care organizations;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">expansion of eligibility criteria for Medicaid programs in certain states;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">an independent payment advisory board that will submit recommendations to Congress to reduce Medicare spending if projected Medicare spending exceeds a specified growth rate.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 68</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. The current presidential administration and U.S. Congress have sought and will likely continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the Affordable Care Act. For example, the Tax Cuts and Jobs Act of 2017, or TCJA, was enacted, which includes a provision that repealed, effective January&#160;1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On December&#160;14, 2018, a U.S. District Court Judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the Affordable Care Act, and therefore, because it was repealed as part of the TCJA, the remaining provisions of the Affordable Care Act are invalid as well. While the Trump administration and CMS have both stated that the ruling will have no immediate effect, it is unclear how this decision, subsequent appeals, if any, and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act and our business. It is uncertain the extent to which any such changes may impact our business or financial condition.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. These changes include the Budget Control Act of 2011, which, among other things, resulted in reductions to Medicare payments to providers of 2%&#160;per fiscal year and will remain in effect through 2029; the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years; and the Medicare Access and CHIP Reauthorization Act of 2015, which, among other things, ended the use of the sustainable growth rate formula and provides for a 0.5% update to physician payment rates for each calendar year through 2019, after which there will be a 0% annual update each year through 2025. More recently, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products to purchase and which suppliers will be included in their prescription drug and other healthcare programs.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that the Affordable Care Act, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to new requirements or policies, or if we are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If any of our product candidates are approved for marketing and we are found to have improperly promoted off-label uses, or if physicians misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, product liability claims and significant fines, penalties and sanctions, and our brand and reputation could be harmed.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA and other foreign regulatory authorities strictly regulate the marketing of and promotional claims that are made about drug products. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or such other foreign regulatory authorities as reflected in the product&#8217;s approved labeling. In addition, although we believe our product candidates may exhibit a lower risk of side effects or more favorable tolerability profile or better symptomatic improvement than other products for the indications we are studying, without head-to-head data, we will be unable to make comparative claims for our product candidates, if approved. If we receive regulatory approval for any of our products and are found to have promoted any of our products for off-label uses, we may become subject to significant liability, which would materially harm our business. Both federal </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 69</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and state governments have levied large civil and criminal fines against companies for alleged improper promotion and have enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management&#8217;s attention could be diverted from our business operations, significant legal expenses could be incurred, and our brand and reputation could be damaged. The FDA has also previously requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use, we could be subject to FDA regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they determine our business activities constitute promotion of an off-label use, which could result in significant penalties, including criminal, civil or administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment or restructuring of our operations.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We cannot, however, prevent a physician from using our product candidates in ways that fall outside the scope of the approved indications, as he or she may deem appropriate in his or her medical judgment. Physicians may also misuse our product candidates or use improper techniques, which may lead to adverse results, side effects or injury and, potentially, subsequent product liability claims. Furthermore, the use of our product candidates for indications other than those approved by the FDA and/or other regulatory authorities may not effectively treat such conditions, which could harm our brand and reputation among both physicians and patients.</span></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Common Stock</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The stock price of our common stock may be volatile or may decline and investors may not be able to resell their shares at or above the IPO price.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The market price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">limited daily trading volume resulting in the lack of a liquid market;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the development status of our product candidates, including whether any of our product candidates receive regulatory approval;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the performance of third parties on whom we rely for clinical trials, manufacturing, marketing, sales and distribution, including their ability to comply with regulatory requirements;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">regulatory, legal or political developments in the United States and foreign countries;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the results of our clinical trials and preclinical studies;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the clinical results of our competitors or potential competitors;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the execution of our partnering and manufacturing arrangements;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our execution of collaboration, co-promotion, licensing or other arrangements, and the timing of payments we may make or receive under these arrangements;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">variations in the level of expenses related to our preclinical and clinical development programs, including relating to the timing of invoices from, and other billing practices of, our CROs and clinical trial sites;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">variations in the level of expenses related to our commercialization activities, if any product candidates are approved;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the success of, and fluctuations in, the commercial sales any product candidates approved for commercialization in the future;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">overall performance of the equity markets;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">changes in operating performance and stock market valuations of other pharmaceutical companies;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt;">market conditions or trends in our industry or the economy as a whole, including as a result of market volatility related to global health concerns and, in particular, the extreme volatility experienced during the ongoing COVID-19 pandemic;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 70</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the public&#8217;s response to press releases or other public announcements by us or third parties, including our filings with the SEC, and announcements relating to acquisitions, strategic transactions, licenses, joint ventures, capital commitments, intellectual property, litigation or other disputes impacting us or our business;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">developments with respect to intellectual property rights;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">our commencement of, or involvement in, litigation;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">FDA or foreign regulatory actions affecting us or our industry;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">changes in the structure of healthcare payment systems;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the financial projections we may provide to the public, any changes in these projections or our failure to meet these projections;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">changes in financial estimates by any securities analysts who follow our common stock, our failure to meet these estimates or failure of those analysts to initiate or maintain coverage of our common stock;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">ratings downgrades by any securities analysts who follow our common stock;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the development and sustainability of an active trading market for our common stock;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the size of our market float;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the expiration of market standoff or contractual lock-up agreements and future sales of our common stock by our officers, directors and significant stockholders;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">recruitment or departure of key personnel;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">changes in accounting principles;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">other events or factors, including those resulting from war, incidents of terrorism, natural disasters or responses to these events; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">any other factors discussed in this Quarterly Report on Form 10-Q.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many pharmaceutical companies. Due to the COVID-19 outbreak, there has been significant stock market exchange volatility, including temporary trading halts. Stock prices of many pharmaceutical companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have instituted securities class action litigation following periods of market volatility. If we were involved in securities litigation, we could incur substantial costs and our resources and the attention of management could be diverted from our business.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">An active, liquid and orderly market for our common stock may not develop.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to our IPO, there had been no public market for shares of our common stock, and an active public market for our shares may not develop or be sustained. The lack of an active market may impair the ability to sell our shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses, applications, or technologies using our shares as consideration.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We only recently completed our IPO and just recently obtained research coverage by securities and industry analysts. If only a limited number of securities or industry analysts commence coverage of us or the few analysts that have initiated coverage, drop coverage, the trading price for our stock would be negatively impacted. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 71</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We qualify as an &#8220;emerging growth company&#8221; as defined in the JOBS Act and we have decided to avail ourselves of reduced disclosure requirements applicable to emerging growth companies, including delaying adopting new or revised accounting standards, which could make our common stock less attractive to investors.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We qualify as an &#8220;emerging growth company&#8221; as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;emerging growth companies&#8221; including certain reduced financial statement reporting obligations, reduced disclosure obligations about our executive compensation arrangements, exemptions from the requirement that we solicit non-binding advisory votes on executive compensation or golden parachute arrangements and exemption from the auditor&#8217;s attestation requirements of Section&#160;404(b) of the Sarbanes-Oxley Act. We may take advantage of these reporting exemptions until we are no longer an &#8220;emerging growth company.&#8221; We will remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of the completion of the IPO. However, if certain events occur prior to the end of such five-year period, including if we become a &#8220;large accelerated filer,&#8221; our annual gross revenues exceed $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards. Until the date that we are no longer an &#8220;emerging growth company&#8221; or affirmatively and irrevocably opt out of the exemption provided by Section&#160;7(a)(2)(B) of the Securities Act, upon issuance of a new or revised accounting standard that applies to our financial statements and that has a different effective date for public and private companies, we will disclose the date on which adoption is required for non-emerging growth companies and the date on which we will adopt the recently issued accounting standard.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Raising additional funds by issuing securities may cause dilution to existing shareholders, raising additional funds through debt financings may involve restrictive covenants, and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that significant additional capital will be needed in the future to continue our planned operations. Until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, strategic alliances and license and development agreements or other collaborations. To the extent that we raise additional capital by issuing equity securities, our existing shareholders&#8217; ownership may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that could harm the rights of a common shareholder. Additionally, any agreements for future debt or preferred equity financings, if available, may involve covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 48% of our voting stock.   Therefore, these stockholders will have the ability to influence us through this ownership position, including the ability to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 72</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Moreover, holders of approximately 24.4 million shares of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We have registered and intend to continue to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of our outstanding warrant or options, or the perception that such sales may occur, could adversely affect the market price of our common stock.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also expect that significant additional capital may be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. To the extent that additional capital is raised through the sale and issuance of shares or other securities convertible into shares, our stockholders will be diluted. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our ability to utilize our net operating loss, or NOL, carryforwards and research and development income tax credit carryforwards may be limited.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, we had NOL carryforwards available to reduce future taxable income, if any, for federal and California income tax purposes of $54.6 million and $55.1 million, respectively. If not utilized, California NOL carryforwards will expire beginning in 2036.  Of the federal net operating losses, $3.5 million originated before the 2019 tax year and will expire beginning in 2036.  Under the Tax Act, the remaining $51.0 million of federal NOL carryforwards generated after December&#160;31, 2017 will carryforward indefinitely with utilization limited to 80% of taxable income. As of December&#160;31, 2019, we had federal and California research and development tax credit carryforwards of $2.0 million and $0.7 million, respectively. If not utilized, the federal research and development tax credit carryforwards will begin to expire in 2037. The California research and development tax credit carryforwards are available indefinitely.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under Section&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership by certain stockholders over a three year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. A formal study has not been completed to determine if a change in ownership, as defined by Section 382, has occurred. We believe that we may undergo an &#8220;ownership change&#8221; limitation as a result of our IPO (some of which shifts are outside of our control). We may also experience additional ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our restated certificate of incorporation and restated bylaws contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions include the following:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">a classified board of directors with three year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 73</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the ability of our board of directors to alter our bylaws without obtaining stockholder approval;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the required approval of a super-majority of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our restated certificate of incorporation regarding the election and removal of directors;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">the requirement that a special meeting of stockholders may be called only by the chief executive officer or the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, these provisions would apply even if we were to receive an offer that some stockholders may consider beneficial.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also subject to the anti-takeover provisions contained in Section&#160;203 of the Delaware General Corporation Law. Under Section&#160;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our restated certificate of incorporation and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, as permitted by Section&#160;145 of the Delaware General Corporation Law, our restated bylaws to be effective immediately prior to the completion of our IPO and our indemnification agreements that we have entered into with our directors and officers provide that:</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">We will not be obligated pursuant to our restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 74</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">The rights conferred in our restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.</span></div><div style="text-indent:-9pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">We may not retroactively amend our restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our restated certificate of incorporation, to the fullest extent permitted by law, provides that the Court of Chancery of the State of Delaware will be the exclusive forum for: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, or the DGCL, our restated certificate of incorporation, or our restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision and asserts claims under the Securities Act, inasmuch as Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rule and regulations thereunder. There is uncertainty as to whether a court would enforce such provision with respect to claims under the Securities Act, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 75</span></div></div></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_37"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:18pt;"><span><br/></span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2.   UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">From January 1, 2020 through March 31, 2020, we sold and issued the following unregistered securities:</span></div><div style="text-indent:18pt;padding-left:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">1.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt;">We sold an aggregate of 43,000 shares of common stock to employees and consultants for cash consideration in the aggregate amount of $145,000 upon the exercise of stock options.  </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:95%;">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions or any public offering, and the Registrant believes each transaction was exempt from the registration requirements of the Securities Act as stated above. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Use of Proceeds</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On January 30, 2020, the U.S. Securities and Exchange Commission declared effective our registration statement on Form S-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">1 (File No. 333-235806), </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">as amended, filed in connection with our IPO. There has been no material change in the planned use of proceeds from our IPO from that described in the related prospectus dated January 30, 2020, filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Issuer Purchases of Equity Securities</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We did not repurchase any of our equity securities during the three months ended March 31, 2020.</span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_1640"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_1630"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 4.   MINE SAFETY DISCLOSURES</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_82"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 5. OTHER INFORMATION</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_109"></div><div style="margin-top:18pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">ITEM&#160;6. EXHIBITS </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:48.805%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.298%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.784%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.784%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.788%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exhibit</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration: underline;">Number</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description of Document</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Incorporated by Reference Form</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Filed Herewith</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit31postipocertif.htm">Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit32postipobylaws.htm">Restated Bylaws.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex41.htm">Form of Common Stock Certificate.</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">  </span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/21/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2&#8224;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520001990/d784371dex42.htm">Amended and Restated Investors&#8217; Rights Agreement, dated October 8, 2019, by and among the Registrant and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/21/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000178730620000005/ex43descriptionofregis.htm">Description of Arcutis Biotherapeutics&#8217; Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/19/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520001990/d784371dex101.htm">Form of Indemnity Agreement.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/6/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520001990/d784371dex102.htm">2017 Stock Incentive Plan and forms of award agreements.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/6/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex103.htm">2020 Stock Incentive Plan and forms of award agreements.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/21/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex104.htm">2020 Employee Stock Purchase Plan and forms of award agreements.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/21/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">76</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:48.805%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.298%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.784%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.784%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.788%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5#</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex105.htm">Offer Letter, dated January 9, 2020, by and between the Registrant and Todd Franklin Watanabe.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/21/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.6#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex106.htm">Offer Letter, dated January 9, 2020, by and between the Registrant and David W. Osborne.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/21/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.6</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.7#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex107.htm">Offer Letter, dated January 9, 2020, by and between the Registrant and Howard G. Welgus, M.D.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/21/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.7</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex108.htm">Offer Letter, dated January 9, 2020, by and between the Registrant and John W. Smither.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/21/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.9#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex109.htm">Offer Letter, dated January 9, 2020, by and between the Registrant and Kenneth A. Lock.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/21/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.9</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.10#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex1010.htm">Offer Letter, dated January 9, 2020, by and between the Registrant and Patricia A. Turney.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/21/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.10</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.11#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520001990/d784371dex1011.htm">Consulting Agreement, dated August 16, 2016, by and between Bhaskar Chaudhuri and the Registrant.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/6/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.11</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.12&#8224;&#94;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520001990/d784371dex1012.htm">License Agreement, dated July 23, 2018, by and between AstraZeneca AB and the Registrant.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/6/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.12</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.13&#8224;&#94;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520001990/d784371dex1013.htm">Exclusive Option and License Agreement, dated January 4, 2018, by and between Jiangsu Hengrui Medicine Co., Ltd. and the Registrant.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/6/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.13</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.14&#8224;&#94;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520001990/d784371dex1014.htm">Collaboration Agreement, dated June 28, 2019, by and between Hawkeye Therapeutics, Inc. and the Registrant.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/6/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.14</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.15#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520001990/d784371dex1015.htm">Transition and Amendment Agreement, dated December&#160;13, 2019 by and between Bhaskar Chaudhuri and the Registrant.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/6/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.15</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520001990/d784371dex1016.htm">Option Notice and Amendment No. 2 to Exclusive Option and License Agreement, dated December 5, 2019, by and between Jiangsu Hengrui Medicine Co., Ltd. and the Registrant.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/6/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.16</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.17#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex1017.htm">Severance &amp; Change in Control Agreement, by and between the Registrant and Todd Franklin Watanabe.  </a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/21/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.17</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.18#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex1018.htm">Severance &amp; Change in Control Agreement, by and between the Registrant and David W. Osborne.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/21/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.18</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.19#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex1019.htm">Severance &amp; Change in Control Agreement, by and between the Registrant and Howard G. Welgus, M.D.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/21/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.19</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.20#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex1020.htm">Severance &amp; Change in Control Agreement, by and between the Registrant and John W. Smither.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/21/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.20</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.21#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex1021.htm">Severance &amp; Change in Control Agreement, by and between the Registrant and Kenneth A. Lock.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/21/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.21</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.22#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1787306/000119312520010664/d784371dex1022.htm">Severance &amp; Change in Control Agreement, by and between the Registrant and Patricia A. Turney.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/21/20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.22</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit311ceo.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit312cfo.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit321ceocfo.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 77</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ieeb33ed1376b4f84a553eb9bccd9731d_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:48.805%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.298%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.784%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.784%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.788%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8224;&#160;Registrant has omitted portions of the exhibit as permitted under Item 601(b)(10) of Regulation&#160;S-K.</span></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#94;&#160;Registrant has omitted schedules and exhibits pursuant to Item&#160;601(b)(2) of Regulation&#160;S-K. The Registrant agrees to furnish supplementally a copy of the omitted schedules and exhibits to the SEC upon request.</span></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;The certifications attached as Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Arcutis Biopharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-top:18pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 78</span></div></div></div><div id="ieeb33ed1376b4f84a553eb9bccd9731d_178"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:4.578%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:45.222%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.093%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:40.107%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ARCUTIS BIOTHERAPEUTICS, INC.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 12, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ John W. Smither</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">John W. Smither</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Chief Financial Officer</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">(Principal Financial and Accounting Officer)</span></div><div><span><br/></span></div></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:48.976%;"><tr><td style="width:1.0%;"></td><td style="width:13.223%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:81.583%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>exhibit31postipocertif.htm
<DESCRIPTION>RESTATED CERTIFICATE OF INCORPORATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i650db89b216142a9bbc467396068546f_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 3.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Arcutis Biotherapeutics, Inc., a Delaware corporation, hereby certifies as follows&#58;</font></div><div style="text-indent:24.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.&#160;&#160;&#160;&#160;The name of the corporation is Arcutis Biotherapeutics, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State was June 1, 2016 under the name Arcutis, Inc.</font></div><div style="text-indent:24.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.&#160;&#160;&#160;&#160;The Restated Certificate of Incorporation of the corporation attached hereto as&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which is incorporated herein by this reference, and which restates, integrates and further amends the provisions of the Certificate of Incorporation of this corporation as previously amended and&#47;or restated, has been duly adopted by this corporation&#8217;s Board of Directors and by the stockholders in accordance with Sections</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">242 and 245 of the General Corporation Law of the State of Delaware, with the approval of the corporation&#8217;s stockholders having been given by written consent without a meeting in accordance with Section&#160;228 of the General Corporation Law of the State of Delaware.</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, this corporation has caused this Restated Certificate of Incorporation to be signed by its duly authorized officer and the foregoing facts stated herein are true and correct.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.916%;"><tr><td style="width:1.0%;"></td><td style="width:43.826%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.618%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:1.764%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.618%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:1.109%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.618%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:42.847%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated&#58; February 4, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ARCUTIS BIOTHERAPEUTICS, INC.</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Todd Franklin Watanabe</font></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="12" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58; Todd Franklin Watanabe</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="12" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58; Chief Executive Officer</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="i650db89b216142a9bbc467396068546f_4"></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE I&#58; NAME</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The name of the corporation is Arcutis Biotherapeutics, Inc. (collectively with its subsidiaries,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Corporation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE II&#58; AGENT FOR SERVICE OF PROCESS</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The address of the Corporation&#8217;s registered office in the State of Delaware is 3500 South Dupont Highway, in the City of Dover, County of Kent 19901.  The name of the registered agent of the Corporation at that address is Incorporating Services, Ltd.</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE III&#58; PURPOSE</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General Corporation Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE IV&#58; AUTHORIZED STOCK</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Total Authorized</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The total number of shares of all classes of stock that the Corporation has authority to issue is Three Hundred Ten Million (310,000,000) shares, consisting of two classes&#58; Three Hundred Million (300,000,000) shares of Common Stock, $0.0001 par value per share (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), and Ten Million (10,000,000) shares of Preferred Stock, $0.0001 par value per share (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Preferred Stock</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Designation of Additional Series</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:48.95pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.1.&#160;&#160;&#160;&#160;The Board of Directors of the Corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) is authorized, subject to any limitations prescribed by the law of the State of Delaware, to provide for the issuance of the shares of Preferred Stock in one or more series, and, by filing a Certificate of Designation pursuant to the applicable law of the State of Delaware (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Certificate of Designation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), to establish from time to time the number of shares to be included in each such series, to fix the designation, vesting, powers (including voting powers), preferences and relative, participating, optional or other special rights, if any, of the shares of each such series and any qualifications, limitations or restrictions thereof, and, except where otherwise provided in the applicable Certificate of Designation, to thereafter increase (but not above the total number of authorized shares of the Preferred Stock) or decrease (but not below the number of shares of such series then outstanding) the number of shares of any such series. The number of authorized shares of Preferred Stock may also be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of&#160;two-thirds&#160;of the voting power of all of the then-outstanding shares of capital stock of the Corporation entitled to vote thereon, without a separate vote of the holders of the Preferred Stock, unless a vote of any such holders is required pursuant to the terms of any certificate or certificates establishing a series of Preferred Stock.</font></div><div style="text-indent:48.95pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.2&#160;&#160;&#160;&#160;Except as otherwise expressly provided in any Certificate of Designation designating any series of Preferred Stock pursuant to the foregoing provisions of this Article IV, any new series of Preferred Stock may be designated, fixed and determined as provided herein by the Board without approval of the holders of Common Stock or the holders of Preferred Stock, or any series thereof, and any such new series may have powers, preferences and rights, including, without limitation, voting rights, dividend rights, liquidation rights, redemption rights and </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">1</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">conversion rights, senior to, junior to or pari passu with the rights of the Common Stock, the Preferred Stock or any future class or series of Preferred Stock or Common Stock.</font></div><div style="text-indent:48.95pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.3&#160;&#160;&#160;&#160;Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders of the Corporation for their vote&#59;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">,&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Restated Certificate of Incorporation (including any Certificate of Designation relating to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon pursuant to this Restated Certificate of Incorporation (including any Certificate of Designation relating to any series of Preferred Stock).</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE V&#58; AMENDMENT OF BYLAWS</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Board shall have the power to adopt, amend or repeal the Bylaws of the Corporation (as the same may be amended and&#47;or restated from time to time, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Bylaws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;). Any adoption, amendment or repeal of the Bylaws by the Board shall require the approval of a majority of the Whole Board. For purposes of this Restated Certificate of Incorporation, the term &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Whole Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean the total number of authorized directors whether or not there exist any vacancies in previously authorized directorships.&#160;The stockholders shall also have power to adopt, amend or repeal the Bylaws&#59;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, that notwithstanding any other provision of this Restated Certificate of Incorporation or any provision of law that might otherwise permit a lesser or no vote, but in addition to any vote of the holders of any class or series of stock of the Corporation required by applicable law or by this Restated Certificate of Incorporation (including any Preferred Stock issued pursuant to a Certificate of Designation), the affirmative vote of the holders of at least&#160;two-thirds&#160;of the voting power of all of the then-outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required for the stockholders to adopt, amend or repeal any provision of the Bylaws&#59;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">further</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, that, in the case of any proposed adoption, amendment or repeal of any provisions of the Bylaws that is approved by the Board and submitted to the stockholders for adoption thereby, if&#160;two-thirds&#160;of the Whole Board has approved such adoption, amendment or repeal of any provisions of the Bylaws, then only the affirmative vote of the holders of a majority of the voting power of all of the then-outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to adopt, amend or repeal any provision of the Bylaws.</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE VI&#58; MATTERS RELATING TO THE BOARD OF DIRECTORS</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Director Powers</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Except as otherwise provided by the General Corporation Law, the conduct of the affairs of the Corporation shall be managed by or under the direction of the Board. In addition to the powers and authority expressly conferred upon them by applicable law or by this Restated Certificate of Incorporation or the Bylaws of the Corporation, the directors are hereby empowered to exercise all such powers and do all such acts and things as may be exercised or done by the Corporation.</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Number of Directors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the total number of directors constituting the Whole Board shall be fixed from time to time exclusively by resolution adopted by a majority of the Whole Board.</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Classified Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Subject to the special rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the directors shall be divided, with respect to the time for which they severally hold office, into three classes designated as Class&#160;I, Class&#160;II and Class&#160;III, respectively (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Classified Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;). The Board may assign members of the Board already in office to the Classified Board, which assignments shall become effective at the same time the Classified Board becomes effective. Directors shall be assigned to each class in accordance with a resolution or resolutions adopted by the Board. The number of directors in each class shall be divided as nearly equal as reasonably possible. The initial term of office of the Class&#160;I directors </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">shall expire at the Corporation&#8217;s first annual meeting of stockholders following the closing of the Corporation&#8217;s initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, relating to the offer and sale of Common Stock to the public (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Initial Public Offering</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), the initial term of office of the Class&#160;II directors shall expire at the Corporation&#8217;s second annual meeting of stockholders following the closing of the Initial Public Offering and the initial term of office of the Class&#160;III directors shall expire at the Corporation&#8217;s third annual meeting of stockholders following the closing of the Initial Public Offering. At each annual meeting of stockholders following the closing of the Initial Public Offering, directors elected to succeed those directors of the class whose terms then expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election.</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Term and Removal</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Each director shall hold office until the annual meeting at which such director&#8217;s term expires and until such director&#8217;s successor is duly elected and qualified, or until such director&#8217;s earlier death, resignation, disqualification or removal. Any director may resign at any time upon notice to the Corporation given in writing or by any electronic transmission permitted in the Bylaws. Subject to the special rights of the holders of any series of Preferred Stock, no director may be removed from the Board except for cause and only by the affirmative vote of the holders of at least&#160;two-thirds&#160;of the voting power of the then-outstanding shares of capital stock of the Corporation entitled to vote at an election of directors, voting together as a single class. No decrease in the authorized number of directors constituting the Whole Board shall shorten the term of any incumbent director.</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Board Vacancies and Newly Created Directorships</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Subject to the special rights of the holders of any series of Preferred Stock, any vacancy occurring in the Board for any cause, and any newly created directorship resulting from any increase in the authorized number of directors, shall, unless (a)&#160;the Board determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders or (b)&#160;as otherwise provided by law, be filled only by the affirmative vote of a majority of the directors then in office, even if less than a quorum, or by a sole remaining director, and shall not be filled by the stockholders.&#160;Any director elected in accordance with the preceding sentence shall hold office for a term expiring at the annual meeting of stockholders at which the term of office of the class to which the director has been assigned expires or until such director&#8217;s successor shall have been duly elected and qualified, or until such director&#8217;s earlier death, resignation, disqualification or removal.</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Vote by Ballot</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Election of directors need not be by written ballot unless the Bylaws shall so provide.</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE VII&#58; DIRECTOR LIABILITY</font></div><div style="text-indent:24.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Limitation of Liability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. To the fullest extent permitted by law, no director of the Corporation shall be personally liable for monetary damages for breach of fiduciary duty as a director. Without limiting the effect of the preceding sentence, if the General Corporation Law is hereafter amended to authorize the further elimination or limitation of the liability of a director, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law, as so amended.</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Change in Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Neither any amendment nor repeal of this Article VII, nor the adoption of any provision of this Restated Certificate of Incorporation inconsistent with this Article VII, shall eliminate, reduce or otherwise adversely affect any limitation on the personal liability of a director of the Corporation existing at the time of such amendment, repeal or adoption of such an inconsistent provision.</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE VIII&#58; MATTERS RELATING TO STOCKHOLDERS</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">No Action by Written Consent of Stockholders</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Subject to the rights of any series of Preferred Stock then outstanding, no action shall be taken by the stockholders of the Corporation except at a duly called annual or special meeting of stockholders and no action shall be taken by the stockholders of the Corporation by written consent.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Special Meeting of Stockholders</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Special meetings of the stockholders of the Corporation may be called only by the Chairperson of the Board, the Chief Executive Officer, the President, or the Board acting pursuant to a resolution adopted by a majority of the Whole Board and may not be called by any other person or persons.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Advance Notice of Stockholder Nominations and Business Transacted at Special Meetings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Advance notice of stockholder nominations for the election of directors of the Corporation and of business to be brought by stockholders before any meeting of stockholders of the Corporation shall be given in the manner provided in the Bylaws. Business transacted at special meetings of stockholders shall be limited to the purpose or purposes stated in the notice of meeting.</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE IX&#58; CHOICE OF FORUM</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware, to the fullest extent permitted by law, shall be the sole and exclusive forum for&#58; (a)&#160;any derivative action or proceeding brought on behalf of the Corporation&#59; (b)&#160;any action asserting a claim of breach of a fiduciary duty owed by, or other wrongdoing by, any director, officer, stockholder, employee or agent of the Corporation to the Corporation or the Corporation&#8217;s stockholders&#59; (c)&#160;any action asserting a claim against the Corporation or any director, officer, stockholder, employee or agent of the Corporation arising pursuant to any provision of the General Corporation Law, this Restated Certificate of Incorporation or the Bylaws&#59; (d)&#160;any action to interpret, apply, enforce or determine the validity of this Restated Certificate of Incorporation or the Bylaws&#59; or (e)&#160;any action asserting a claim against the Corporation or any director, officer, stockholder, employee or agent of the Corporation governed by the internal affairs doctrine. </font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of the Corporation shall be deemed to have notice of and to have consented to the provisions of this Article IX.</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE X&#58; AMENDMENT OF CERTIFICATE OF INCORPORATION</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If any provision of this Restated Certificate of Incorporation becomes or is declared on any ground by a court of competent jurisdiction to be illegal, unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Restated Certificate of Incorporation, and the court will replace such illegal, void or unenforceable provision of this Restated Certificate of Incorporation with a valid and enforceable provision that most accurately reflects the Corporation&#8217;s intent, in order to achieve, to the maximum extent possible, the same economic, business and other purposes of the illegal, void or unenforceable provision. The balance of this Restated Certificate of Incorporation shall be enforceable in accordance with its terms.</font></div><div style="text-indent:24.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Corporation reserves the right to amend or repeal any provision contained in this Restated Certificate of Incorporation in the manner prescribed by the laws of the State of Delaware and all rights conferred upon stockholders are granted subject to this reservation&#59;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">,&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, that, notwithstanding any other provision of this Restated Certificate of Incorporation or any provision of law that might otherwise permit a lesser vote or no vote, but in addition to any vote of the holders of any class or series of the stock of the Corporation required by law or by this Restated Certificate of Incorporation, the affirmative vote of the holders of at least&#160;two-thirds&#160;of the voting power of all of the then-outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend or repeal this Article X or Article V, Article VI, Article VII or Article VIII&#59;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">further</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, that if&#160;two-thirds&#160;of the Whole Board has approved such amendment or repeal of any provisions of this Restated Certificate of Incorporation, then only the affirmative vote of the holders of at least a majority of the voting power of all of the then-outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend or repeal such provisions of this Restated Certificate of Incorporation.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>exhibit32postipobylaws.htm
<DESCRIPTION>RESTATED BYLAWS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i667512b1d57f46438b0719685c9d0c87_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 3.2</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#160;</font></div><div style="margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a Delaware corporation)</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RESTATED BYLAWS</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">February 4, 2020</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#160;</font></div><div style="margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><div id="i667512b1d57f46438b0719685c9d0c87_4"></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a Delaware corporation)</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RESTATED BYLAWS</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.557%;"><tr><td style="width:0.1%;"></td><td style="width:0.938%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.613%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.796%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.613%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:73.934%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.938%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.613%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:1.739%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.616%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;">Article I&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;STOCKHOLDERS</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;1.1&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Annual Meetings</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;1.2&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Special Meetings</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;1.3&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Notice of Meetings</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;1.4&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Adjournments</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;1.5&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Quorum</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;1.6&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Organization</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;1.7&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Voting&#59; Proxies</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;1.8&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Fixing Date for Determination of Stockholders of Record</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;1.9&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">List of Stockholders Entitled to Vote</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;1.10&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Inspectors of Elections</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;1.11&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Notice of Stockholder Business&#59; Nominations.</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="15" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="12" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;">Article II&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;BOARD OF DIRECTORS</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;2.1&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Number&#59; Qualifications</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;2.2&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Election&#59; Resignation&#59; Removal&#59; Vacancies</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;2.3&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Regular Meetings</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;2.4&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Special Meetings</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;2.5&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Remote Meetings Permitted</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;2.6&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Quorum&#59; Vote Required for Action</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;2.7&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Organization</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;2.8&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Unanimous Action by Directors in Lieu of a Meeting</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;2.9&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Powers</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;2.10&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Compensation of Directors</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="15" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="12" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;">Article III&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;COMMITTEES</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;3.1&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Committees</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;3.2&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Committee Rules</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="15" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="12" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;">Article IV&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;OFFICERS&#59; CHAIRPERSON&#59; LEAD INDEPENDENT DIRECTOR</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;4.1&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Generally</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;4.2&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Chief Executive Officer</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;4.3&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Chairperson of the Board</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;4.4&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">President</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;4.5&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Chief Financial Officer</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;4.6&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Treasurer</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;4.7&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Vice President</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;4.8&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Secretary</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;4.9&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Delegation of Authority</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;4.10&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Removal</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.993%;"><tr><td style="width:0.1%;"></td><td style="width:1.302%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.302%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.195%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.841%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:65.278%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.968%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.634%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.841%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.639%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;">Article V&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;STOCK</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;5.1&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Certificates</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;5.2&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Lost, Stolen or Destroyed Stock Certificates&#59; Issuance of New Certificates or Uncertificated Shares</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;5.3&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Other Regulations</font></div><div style="text-indent:-9pt;padding-left:11.25pt;"><font><br></font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="15" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="12" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;">Article VI&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;INDEMNIFICATION</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;6.1&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Indemnification of Officers and Directors</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;6.2&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Advancement of Expenses</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;6.3&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Non-Exclusivity&#160;of Rights</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;6.4&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Indemnification Contracts</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;6.5&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Right of Indemnitee to Bring Suit</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;6.6&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Nature of Rights</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;6.7&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Insurance</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="15" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="12" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;">Article VII&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;NOTICES</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;7.1&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Notice</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;7.2&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Waiver of Notice</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="15" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="12" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;">Article VIII&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;INTERESTED DIRECTORS</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;8.1&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Interested Directors</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;8.2&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Quorum</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="15" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="12" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;">Article IX&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;MISCELLANEOUS</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;9.1&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Fiscal Year</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;9.2&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Seal</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;9.3&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Form of Records</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;9.4&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Reliance upon Books, Records and Experts</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;9.5&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Certificate of Incorporation Governs</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;9.6&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Severability</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Section&#160;9.7&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Time Periods</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="15" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="12" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;">Article X&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;AMENDMENT</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="15" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="12" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div></div></div><div id="i667512b1d57f46438b0719685c9d0c87_7"></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a Delaware corporation)</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RESTATED BYLAWS</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">February 4, 2020</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE I&#58; STOCKHOLDERS</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;1.1&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Annual Meetings</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An annual meeting of stockholders shall be held for the election of directors at such date and time as the Board of Directors (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) of Arcutis Biotherapeutics, Inc. (collectively with its subsidiaries,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Corporation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) shall each year fix. The meeting may be held either at a place, within or without the State of Delaware as permitted by the Delaware General Corporation Law (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">DGCL</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), or by means of remote communication as the Board in its sole discretion may determine. Any proper business may be transacted at the annual meeting.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;1.2&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Special Meetings</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Special meetings of stockholders for any purpose or purposes may be called at any time by the Chairperson of the Board, the Chief Executive Officer, the President or the Board acting pursuant to a resolution adopted by a majority of the Whole Board (as defined below). Special meetings may not be called by any other person or persons. The special meeting may be held either at a place, within or without the State of Delaware, or by means of remote communication as the Board in its sole discretion may determine. Business transacted at any special meeting of stockholders shall be limited to matters relating to the purpose or purposes stated in the notice of the meeting.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;1.3&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Notice of Meetings</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notice of all meetings of stockholders shall be given in writing or by electronic transmission in the manner provided by applicable law (including, without limitation, as set forth in Section&#160;7.1.1 of these Bylaws) stating the date, time and place, if any, of the meeting and the means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting. In the case of a special meeting, such notice shall also set forth the purpose or purposes for which the meeting is called. Unless otherwise required by applicable law or the Restated Certificate of Incorporation of the Corporation (as the same may be amended and&#47;or restated from time to time, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Certificate of Incorporation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), notice of any meeting of stockholders shall be given not less than ten (10), nor more than sixty (60), days before the date of the meeting to each stockholder of record entitled to vote at such meeting.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;1.4&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Adjournments</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The chairperson of the meeting shall have the power to adjourn the meeting to another time, date and place (if any). Any meeting of stockholders may be adjourned from time to time, and notice need not be given of any such adjourned meeting if the time, date and place (if any) thereof and the means of remote communication (if any) by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken&#59;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, that if the adjournment is for more than thirty (30)&#160;days, or if a new record date is fixed for the adjourned meeting, then a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. At the adjourned meeting, the Corporation may transact any business that might have been transacted at the original meeting. To the fullest extent permitted by law, the Board may postpone, reschedule or cancel any previously scheduled special or annual meeting of stockholders before it is to be held, in which case notice shall be provided to the stockholders of the new date, time and place, if any, of the meeting as provided in Section&#160;1.3 above.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;1.5&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Quorum</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At each meeting of stockholders the holders of a majority of the voting power of the shares of stock entitled to vote at the meeting, present in person or represented by proxy, shall constitute a quorum for the transaction of business, unless otherwise required by applicable law. Where a separate vote by a class or classes or series is required, a majority of the voting power of the shares of such class or classes or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. If a quorum shall fail to attend any meeting, the chairperson of the meeting or the holders of a majority of the shares entitled to vote who are present, in person or by proxy, at the meeting may adjourn the meeting. Shares of the Corporation&#8217;s stock belonging to the Corporation (or to another corporation, if a majority of the shares entitled to vote in the election of directors of such other corporation are held, directly or indirectly, by the Corporation), shall neither be entitled to vote nor be counted for quorum purposes&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, that the foregoing shall not limit the right of the Corporation or any other corporation to vote any shares of the Corporation&#8217;s stock held by it in a fiduciary capacity and to count such shares for purposes of determining a quorum</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;1.6&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Organization</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Meetings of stockholders shall be presided over by (a)&#160;such person as the Board may designate, or (b)&#160;in the absence of such a person, the Chairperson of the Board, or (c)&#160;in the absence of such person, the Chief Executive Officer of the Corporation, or (d)&#160;in the absence of such person, the President of the Corporation, or (e)&#160;in the absence of such person, such person as may be chosen by the holders of a majority of the voting power of the shares entitled to vote who are present, in person or by proxy, at the meeting. Such person shall be chairperson of the meeting and, subject to Section&#160;1.10 hereof, shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of discussion as seems to him or her to be in order. The Secretary of the Corporation shall act as secretary of the meeting, but in such person&#8217;s absence the chairperson of the meeting may appoint any person to act as secretary of the meeting.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;1.7&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Voting&#59; Proxies</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for such stockholder by proxy. Such a proxy may be prepared, transmitted and delivered in any manner permitted by applicable law. Except as may be required in the Certificate of Incorporation, directors shall be elected by a plurality of the votes cast. Unless otherwise provided by applicable law, the rules of any stock exchange upon which the Corporation&#8217;s securities are listed, the Certificate of Incorporation or these Bylaws, every matter other than the election of directors shall be decided by a majority of the votes cast for or against the matter</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;1.8&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Fixing Date for Determination of Stockholders of Record</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, unless otherwise required by law, the Board may fix, in advance, a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the Board and which shall not be more than sixty (60), nor less than ten (10), days before the date of such meeting, nor more than sixty (60)&#160;days prior to any other action. If no record date is fixed by the Board, then the record date shall be as provided by applicable law. To the fullest extent permitted by law, a determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, that the Board may fix a new record date for the adjourned meeting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board may fix, in advance, a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the Board and which shall not be more than sixty (60)&#160;days prior to such action. If no such record date is fixed by the Board, then the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;1.9&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">List of Stockholders Entitled to Vote</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A complete list of stockholders entitled to vote at any meeting of stockholders, arranged in alphabetical order and showing the address of each stockholder and the number of shares registered in the name of each stockholder, shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten (10)&#160;days prior to the meeting, either on a reasonably accessible electronic network as permitted by law (provided that the information required to gain access to the list is provided with the notice of the meeting) or during ordinary business hours at the principal place of business of the Corporation. If the meeting is held at a location where stockholders may attend in person, the list shall also be produced and kept at the time and place of the meeting during the whole time thereof and may be inspected by any stockholder who is present at the meeting. If the meeting is held solely by means of remote communication, then the list shall be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access the list shall be provided with the notice of the meeting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section 1.10&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Inspectors of Elections</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.10.1&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Applicability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Unless otherwise required by the Certificate of Incorporation or by the DGCL, the following provisions of this Section&#160;1.10 shall apply only if and when the Corporation has a class of voting stock that is&#58; (a)&#160;listed on a national securities exchange&#59; (b)&#160;authorized for quotation on an interdealer quotation system of a registered national securities association&#59; or (c)&#160;held of record by more than two thousand (2,000) stockholders. In all other cases, observance of the provisions of this Section&#160;1.10 shall be optional, and at the discretion of the Board.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.10.2&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Appointment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Corporation shall, in advance of any meeting of stockholders, appoint one or more inspectors of election to act at the meeting and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting shall appoint one or more inspectors to act at the meeting.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.10.3&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Inspector&#8217;s Oath</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Each inspector of election, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of such inspector&#8217;s ability.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.10.4&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Duties of Inspectors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. At a meeting of stockholders, the inspectors of election shall (a)&#160;ascertain the number of shares outstanding and the voting power of each share, (b)&#160;determine the shares represented at a meeting and the validity of proxies and ballots, (c)&#160;count all votes and ballots, (d)&#160;determine and retain for a reasonable period of time a record of the disposition of any challenges made to any determination by the inspectors, and (e)&#160;certify their determination of the number of shares represented at the meeting, and their count of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.10.5&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Opening and Closing of Polls</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced at the meeting. No ballot, proxies or votes, nor any revocations thereof or changes thereto, shall be accepted by the inspectors after the closing of the polls unless the Court of Chancery upon application by a stockholder shall determine otherwise.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.10.6&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Determinations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. In determining the validity and counting of proxies and ballots, the inspectors shall be limited to an examination of the proxies, any envelopes submitted with those proxies, any information provided in connection with proxies pursuant to Section&#160;211(a)(2)(b)(i) or (iii) of the DGCL, or in accordance with Sections 211(e) or 212(c)(2) of the DGCL, ballots and the regular books and records of the Corporation, except that the inspectors may consider other reliable information for the limited purpose of reconciling proxies and ballots submitted by or on behalf of banks, brokers, their nominees or similar persons which represent more votes than the holder of a proxy is authorized by the record owner to cast or more votes than the stockholder holds of record. If the inspectors consider other reliable information for the limited purpose permitted herein, the inspectors at the time they make their certification of their determinations pursuant to this Section&#160;1.10 shall specify the precise information considered by them, including the person or persons from whom they obtained the information, when </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the information was obtained, the means by which the information was obtained and the basis for the inspectors&#8217; belief that such information is accurate and reliable.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;1.11&#58;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Notice of Stockholder Business&#59; Nominations.</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.11.1&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Annual Meeting of Stockholders</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;Nominations of persons for election to the Board and the proposal of business to be considered by the stockholders shall be made at an annual meeting of stockholders (i) pursuant to the Corporation&#8217;s notice of such meeting, (ii) by or at the direction of the Board or (iii) by any stockholder of the Corporation who was a stockholder of record at the time of giving of the notice provided for in this Section 1.11, who is entitled to vote at such meeting and who complies with the notice procedures set forth in this Section 1.11. For the avoidance of doubt, the foregoing clause (iii) shall be the exclusive means for a stockholder to make nominations or propose business (other than business included in the Corporation&#8217;s proxy materials pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (such act, and the rules and regulations promulgated thereunder, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Exchange Act</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;)), at an annual meeting of stockholders.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;For nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to Section 1.11.1(a)&#58;</font></div><div style="text-indent:49.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)&#160;&#160;&#160;&#160;the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation&#59;</font></div><div style="text-indent:49.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)&#160;&#160;&#160;&#160;such other business must otherwise be a proper matter for stockholder action&#59;</font></div><div style="text-indent:49.5pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)&#160;&#160;&#160;&#160;if the stockholder, or the beneficial owner on whose behalf any such proposal or nomination is made, has provided the Corporation with a Solicitation Notice, as that term is defined in this Section, such stockholder or beneficial owner must, in the case of a proposal, have delivered a proxy statement and form of proxy to holders of at least the percentage of the Corporation&#8217;s voting shares required under applicable law to carry any such proposal, or, in the case of a nomination or nominations, have delivered a proxy statement and form of proxy to holders of a percentage of the Corporation&#8217;s voting shares reasonably believed by such stockholder or beneficial holder to be sufficient to elect the nominee or nominees proposed to be nominated by such stockholder, and must, in either case, have included in such materials the Solicitation Notice&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:49.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (iv)&#160;&#160;&#160;&#160;if no Solicitation Notice relating thereto has been timely provided pursuant to this Section, the stockholder or beneficial owner proposing such business or nomination must not have solicited a number of proxies sufficient to have required the delivery of such a Solicitation Notice under this Section.  </font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To be timely, a stockholder&#8217;s notice must be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the seventy-fifth (75th) day nor earlier than the close of business on the one hundred and fifth (105th) day prior to the first anniversary of the preceding year&#8217;s annual meeting (except in the case of the Corporation&#8217;s first</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">annual meeting following its initial public offering, for which such notice shall be timely if delivered in the same time period as if such meeting were a special meeting governed by Section 1.11.2)&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, that in the event that the date of the annual meeting is more than thirty (30) days before or more than sixty (60) days after such anniversary date, notice by the stockholder to be timely must be so delivered (A) no earlier than the close of business on the one hundred and fifth (105th) day prior to currently proposed annual meeting and (B) no later than the close of business on the later of the seventy&#8209;fifth (75th) day prior to such annual meeting or the close of business on the tenth (10th) day following the day on which Public Announcement of the date of such meeting is first made by the Corporation.  Such stockholder&#8217;s notice shall set forth&#58; </font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (x)&#160;&#160;&#160;&#160;as to each person whom the stockholder proposes to nominate for election or reelection as a director all information relating to such person that would be required to be disclosed in solicitations of proxies for election of directors, or would be otherwise required, in each case pursuant to Regulation 14A under the Exchange Act, including such person&#8217;s written consent to being named in the proxy statement as a nominee and to serving as a director if elected&#59;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(y)&#160;&#160;&#160;&#160;as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material interest in such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made&#59; and</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(z)&#160;&#160;&#160;&#160;as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made, (aa) the name and address of such stockholder, as they appear on the Corporation&#8217;s books, and of such beneficial owner, (bb) the class and number of shares of the Corporation that are owned beneficially and held of record by such stockholder and such beneficial owner, (cc) a description of any agreement, arrangement or understanding with respect to the nomination or proposal between or among such stockholder and such beneficial owner, any of their respective affiliates or associates, and any others acting in concert with any of the foregoing, (dd) a description of any agreement, arrangement or understanding (including any derivative or short positions, profit interests, options, warrants, stock appreciation or similar rights, hedging transactions, and borrowed or loaned shares) that has been entered into as of the date of the stockholder&#8217;s notice by, or on behalf of, such stockholder and such beneficial owners, the effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes for, or increase or decrease the voting power of, such stockholder or such beneficial owner, with respect to shares of stock of the Corporation, (ee) a representation that the stockholder is a holder of record of stock of the Corporation entitled to vote at such meeting and intends to appear in person or by proxy at the meeting to propose such business or nomination and (ff) whether either such stockholder or beneficial owner intends to deliver a proxy statement and form of proxy to holders of, in the case of a proposal, at least the percentage of the Corporation&#8217;s voting shares required under applicable law to carry the proposal or, in the case of a nomination or nominations, a sufficient number of holders of the Corporation&#8217;s voting shares to elect such nominee or nominees (an affirmative statement of such intent being a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Solicitation Notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;).&#160; If requested by the Corporation, the information required under clauses (bb), (cc)&#160;and (dd)&#160;of this subparagraph (z)&#160;shall be supplemented by such stockholder and beneficial owner, if any, not later than 10 days after the record date for the meeting to disclose such information as of the record date.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (c)&#160;&#160;&#160;&#160;Notwithstanding anything in the second sentence of Section 1.11.1(b) to the contrary, in the event that the number of directors to be elected to the Board is increased and there is no Public Announcement by the Corporation naming all of the nominees for director or specifying the size of the increased Board at least seventy five (75) days prior to the first anniversary of the preceding year&#8217;s annual meeting (or, if the annual meeting is held more than thirty (30) days before or sixty (60) days after such anniversary date, at least seventy five (75) days prior to such annual meeting), a stockholder&#8217;s notice required by this Section 1.11 shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be delivered to the Secretary of the Corporation at the principal executive office of the Corporation no later than the close of business on the tenth (10th) day following the day on which such Public Announcement is first made by the Corporation.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.11.2&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Special Meetings of Stockholders</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation&#8217;s notice of such meeting.  Nominations of persons for election to the Board may be made at a special meeting of stockholders at which directors are to be elected pursuant to the Corporation&#8217;s notice of such meeting (a) by or at the direction of the Board or (b) provided that the Board has determined that directors shall be elected at such meeting, by any stockholder of the Corporation who is a stockholder of record at the time of giving of notice of the special meeting, who shall be entitled to vote at the meeting and who complies with the notice procedures set forth in this Section 1.11.  In the event the Corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the Board, any such stockholder may nominate a person or persons (as the case may be), for election to such position(s) as specified in the Corporation&#8217;s notice of meeting, if the stockholder&#8217;s notice required by Section 1.11.1(b) shall be delivered to the Secretary of the Corporation at the principal executive offices of the Corporation (i) no earlier than the one hundred fifth (105th) day prior to such special meeting and (ii) no later than the close of business on the later of the seventy fifth (75th) day prior to such special meeting or the tenth (10th) day following the day on which Public Announcement is first made of the date of the special meeting and of the nominees proposed by the Board to be elected at such meeting.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.11.3&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">General</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;Only such persons who are nominated in accordance with the procedures set forth in this Section 1.11 shall be eligible to serve as directors and only such business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in this Section 1.11.  Except as otherwise provided by law or these Bylaws, the chairperson of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made or proposed, as the case may be, in accordance with the procedures set forth in this Section 1.11 and, if any proposed nomination or business is not in compliance herewith, to declare that such defective proposal or nomination shall be disregarded.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;For purposes of this Section 1.11, the term &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Public Announcement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;Notwithstanding the foregoing provisions of this Section 1.11, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth herein.  Nothing in this Section 1.11 shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation&#8217;s proxy statement pursuant to Rule 14a-8 under the Exchange Act.</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE II&#58; BOARD OF DIRECTORS</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;2.1&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Number&#59; Qualifications</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total number of authorized directors constituting the Board, whether or not there exist any vacancies in previously authorized directorships (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Whole Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) shall be fixed from time to time in the manner set forth in the Certificate of Incorporation. No decrease in the authorized number of directors constituting the Whole Board shall shorten the term of any incumbent director. Directors need not be stockholders of the Corporation.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;2.2&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Election&#59; Resignation&#59; Removal&#59; Vacancies</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The directors shall be divided, with respect to the time for which they severally hold office, into classes as provided in the Certificate of Incorporation, and vacancies occurring in the Board and any newly created directorships resulting from any increase in the authorized number of directors shall be filled, as provided in the Certificate of Incorporation.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;2.3&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Regular Meetings</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Regular meetings of the Board may be held at such places, within or without the State of Delaware, and at such times as the Board may from time to time determine. Notice of regular meetings need not be given if the date, times and places thereof are fixed by resolution of the Board.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;2.4&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Special Meetings</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Special meetings of the Board may be called by the Chairperson of the Board, the Chief Executive Officer, or a majority of the members of the Board then in office and may be held at any time, date or place, within or without the State of Delaware, as the person or persons calling the meeting shall fix. Notice of the time, date and place of such meeting shall be given, orally, in writing or by electronic transmission (including electronic mail), by the person or persons calling the meeting to all directors at least four (4)&#160;days before the meeting if the notice is mailed, or at least twenty-four (24)&#160;hours before the meeting if such notice is given by telephone, hand delivery, telegram, telex, mailgram, facsimile, electronic mail or other means of electronic transmission. Unless otherwise indicated in the notice, any and all business may be transacted at a special meeting.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;2.5&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Remote Meetings Permitted</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Members of the Board, or any committee of the Board, may participate in a meeting of the Board or such committee by means of conference telephone or other communications equipment by means of which all persons </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">participating in the meeting can hear each other, and participation in a meeting pursuant to conference telephone or other communications equipment shall constitute presence in person at such meeting.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;2.6&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Quorum&#59; Vote Required for Action</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the Certificate of Incorporation regarding the ability of members of the Board to fill a vacancy occurring in the Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, a majority of the Whole Board shall constitute a quorum for the transaction of business. If a quorum shall fail to attend any meeting, a majority of those present may adjourn the meeting to another place, date or time with further notice thereof. Except as otherwise provided herein or in the Certificate of Incorporation, or required by law, the vote of a majority of the directors present at a meeting at which a quorum is present shall be the act of the Board.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;2.7&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Organization</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Meetings of the Board shall be presided over by (a)&#160;the Chairperson of the Board, or (b)&#160;in such person&#8217;s absence, by the Chief Executive Officer, or (c)&#160;in such person&#8217;s absence, by a chairperson chosen at the meeting. The Secretary shall act as secretary of the meeting, but in such person&#8217;s absence the chairperson of the meeting may appoint any person to act as secretary of the meeting.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;2.8&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Written Action by Directors</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any action required or permitted to be taken at any meeting of the Board, or of any committee thereof, may be taken without a meeting if all members of the Board or such committee, as the case may be, consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board or committee, respectively, in the minute books of the Corporation. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;2.9&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Powers</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Board may, except as otherwise required by law or the Certificate of Incorporation, exercise all such powers and manage and direct all such acts and things as may be exercised or done by the Corporation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;2.10&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Compensation of Directors</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Members of the Board, as such, may receive, pursuant to a resolution of the Board, fees and other compensation for their services as directors, including without limitation their services as members of committees of the Board.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE III&#58; COMMITTEES</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;3.1&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Committees</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Board may designate one or more committees, each committee to consist of one or more of the directors of the Corporation. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of the committee, the member or members thereof present at any meeting of such committee who are not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in place of any such absent or disqualified member. Any such committee, to the extent provided in a resolution of the Board, shall have and may exercise all the powers and authority of the Board in the management of the business and affairs of the Corporation and may authorize the seal of the Corporation to be affixed to all papers that may require it&#59; but no such committee shall have the power or authority in reference to the following matters&#58; (a)&#160;approving, adopting, or recommending to the stockholders any action or matter (other than the election or removal of members of the Board) expressly required by the DGCL to be submitted to stockholders for approval or (b)&#160;adopting, amending or repealing any bylaw of the Corporation.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;3.2&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Committee Rules</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each committee shall keep records of its proceedings and make such reports as the Board may from time to time request. Unless the Board otherwise provides, each committee designated by the Board may make, alter and repeal rules for the conduct of its business. In the absence of such rules, each committee shall conduct its business in the same manner as the Board conducts its business pursuant to Article II of these Bylaws. Except as otherwise provided in the Certificate of Incorporation, these Bylaws or the resolution of the Board designating the committee, any committee may create one or more subcommittees, each subcommittee to consist of one or more members of the committee, and may delegate to any such subcommittee any or all of the powers and authority of the committee.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE IV&#58; OFFICERS&#59; CHAIRPERSON</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;4.1&#58;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Generally</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The officers of the Corporation shall consist of a Chief Executive Officer (who may be the Chairperson of the Board or the President), a President, a Secretary and a Treasurer and may consist of such other officers, including, without limitation, a Chief Financial Officer, and one or more Vice Presidents, as may from time to time be appointed by the Board. All officers shall be elected by the Board&#59;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, that the Board may empower the Chief Executive Officer of the Corporation to appoint any officer other than the Chief Executive Officer, the President, the Chief Financial Officer or the Treasurer. Except as otherwise provided by law, by the Certificate of Incorporation or these Bylaws, each officer shall hold office until such officer&#8217;s successor is duly elected and qualified or until such officer&#8217;s earlier resignation, death, disqualification or removal. Any number of offices may be held by the same person. Any officer may resign by delivering a resignation in writing or by electronic transmission to the Corporation at its principal office or to the Chairperson of the Board, the Chief Executive Officer, or the Secretary. Such resignation shall be effective upon delivery unless it is specified to be effective at some later time or upon the happening of some later event. Any vacancy occurring in any office of the Corporation by death, resignation, removal or otherwise may be filled by the Board and the Board may, in its discretion, leave unfilled, for such period as it may determine, any offices. </font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;4.2&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Chief Executive Officer</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the control of the Board and such supervisory powers, if any, as may be given by the Board, the powers and duties of the Chief Executive Officer of the Corporation are&#58;</font></div><div style="text-indent:24.75pt;padding-left:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;to act as the general manager and, subject to the control of the Board, to have general supervision, direction and control of the business and affairs of the Corporation&#59;</font></div><div style="text-indent:24.75pt;padding-left:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;subject to Article I, Section&#160;1.6 of these Bylaws, to preside at all meetings of the stockholders&#59;</font></div><div style="text-indent:24.75pt;padding-left:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;subject to Article I, Section&#160;1.2 of these Bylaws, to call special meetings of the stockholders to be held at such times and, subject to the limitations prescribed by law or by these Bylaws, at such places as he or she shall deem proper&#59;</font></div><div style="text-indent:24.75pt;padding-left:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;to affix the signature of the Corporation to all deeds, conveyances, mortgages, guarantees, leases, obligations, bonds, certificates and other papers and instruments in writing which have been authorized by the Board or which, in the judgment of the Chief Executive Officer, should be executed on behalf of the Corporation&#59; to sign certificates for shares of stock of the Corporation (if any)&#59; and, subject to the direction of the Board, to have general charge of the property of the Corporation and to supervise and control all officers, agents and employees of the Corporation&#59; and</font></div><div style="text-indent:24.75pt;padding-left:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;to vote and otherwise act on, or to authorize any officer to vote or otherwise act on, on behalf of the Corporation, in person or by proxy, at any meeting of stockholders of or with respect to any action of stockholders of any other corporation in which this Corporation may hold securities and otherwise to exercise, or authorize any officer otherwise to exercise, any and all rights and powers which this Corporation may possess by reason of its ownership of securities in such other corporation. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The person holding the office of President shall be the Chief Executive Officer of the Corporation unless the Board shall designate another officer to be the Chief Executive Officer. If there is no President, and the Board has not designated any other officer to be the Chief Executive Officer, then the Chairperson of the Board shall be the Chief Executive Officer.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;4.3&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Chairperson of the Board</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the provisions of Section&#160;2.7 of these Bylaws, the Chairperson of the Board shall have the power to preside at all meetings of the Board and shall have such other powers and duties as provided in these Bylaws and as the Board may from time to time prescribe.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;4.4&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">President</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The person holding the office of Chief Executive Officer shall be the President of the Corporation unless the Board shall have designated one individual as the President and a different individual as the Chief Executive Officer of the Corporation. Subject to the provisions of these Bylaws and to the direction of the Board, and subject to the supervisory powers of the Chief Executive&#160;Officer (if the Chief Executive Officer is an officer other than the President), and subject to such supervisory powers and authority as may be given by the Board to the Chairperson of the Board, and&#47;or to any other officer, the President shall have the responsibility for the general management and control of the business and affairs of the Corporation and the general supervision and direction of all of the officers, employees and agents of the Corporation (other than the Chief Executive Officer, if the Chief Executive Officer is an officer other than the President) and shall perform all duties and have all powers that are commonly incident to the office of President or that are delegated to the President by the Board.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;4.5&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Chief Financial Officer</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The person holding the office of Chief Financial Officer shall be the Treasurer of the Corporation unless the Board shall have designated another officer as the Treasurer of the Corporation. Subject to the direction of the Board and the Chief Executive Officer, the Chief Financial Officer shall perform all duties and have all powers that are commonly incident to the office of Chief Financial Officer.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;4.6&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Treasurer</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The person holding the office of Treasurer shall have custody of all monies and securities of the Corporation. The Treasurer shall make such disbursements of the funds of the Corporation as are authorized and shall render from time to time an account of all such transactions. The Treasurer shall also perform such other duties and have such other powers as are commonly incident to the office of Treasurer, or as the Board or the Chief Executive Officer may from time to time prescribe.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;4.7&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Vice Presidents</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any Vice President shall perform such duties and possess such powers as the Board of Directors or the President may from time to time prescribe. In the event of the absence, inability or refusal to act of the President, the Vice President (or if there shall be more than one, the Vice Presidents in the order determined by the Board of Directors) shall perform the duties of the President and when so performing shall have at the powers of and be subject to all the restrictions upon the President. The Board of Directors may assign to any Vice President the title of Executive Vice President, Senior Vice President or any other title selected by the Board of Directors.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;4.8&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Secretary</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Secretary shall issue or cause to be issued all authorized notices for, and shall keep, or cause to be kept, minutes of all meetings of the stockholders and the Board. The Secretary shall have charge of the corporate minute books and similar records and shall perform such other duties and have such other powers as are commonly incident to the office of Secretary, or as the Board or the Chief Executive Officer may from time to time prescribe.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;4.9&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Delegation of Authority</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Board may from time to time delegate the powers or duties of any officer of the Corporation to any other officers or agents of the Corporation, notwithstanding any provision hereof.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;4.10&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Removal</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any officer of the Corporation shall serve at the pleasure of the Board and may be removed at any time, with or without cause, by the Board&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;that if the Board has empowered the Chief Executive Officer to appoint any officer of the Corporation, then such officer may also be removed by the Chief Executive Officer. Such removal shall be without prejudice to the contractual rights of such officer, if any, with the Corporation.</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE V&#58; STOCK</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;5.1&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Certificates</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The shares of capital stock of the Corporation shall be represented by certificates&#59; provided, however, that the Board may provide by resolution or resolutions that some or all of any or all classes or series of its stock may be uncertificated shares. Notwithstanding the adoption of such resolution by the Board, each holder of stock represented by certificates shall be entitled to have a certificate signed by or in the name of the Corporation by the Chairperson or Vice-Chairperson of the Board, or the President or a Vice President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary, of the Corporation, certifying the number of shares owned by such stockholder in the Corporation. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were an officer, transfer agent or registrar at the date of issue</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;5.2&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Lost, Stolen or Destroyed Stock Certificates&#59; Issuance of New Certificates or Uncertificated Shares</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Corporation may issue a new certificate of stock or uncertificated shares in the place of any certificate previously issued by it, alleged to have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such owner&#8217;s legal representative, to agree to indemnify the Corporation and&#47;or to give the Corporation a bond sufficient to indemnify it, against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;5.3&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Other Regulations</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to applicable law, the Certificate of Incorporation and these Bylaws, the issue, transfer, conversion and registration of shares represented by certificates and of uncertificated shares shall be governed by such other regulations as the Board may establish.</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE VI&#58; INDEMNIFICATION</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;6.1&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Indemnification of Officers and Directors</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each person who was or is made a party to, or is threatened to be made a party to, or is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Proceeding</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), by reason of the fact that such person (or a person of whom such person is the legal representative), is or was a member of the Board or officer of the Corporation or a Reincorporated Predecessor (as defined below) or is or was serving at the request of the Corporation or a Reincorporated Predecessor as a member of the board of directors, officer or trustee of another corporation, or of a partnership, joint venture, trust or other enterprise, including service with respect to employee </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:6pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">benefit plans (for purposes of this Article VI, an &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Indemnitee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), shall be indemnified and held harmless by the Corporation to the fullest extent permitted by the DGCL as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), against all expenses, liability and loss (including attorneys&#8217; fees, judgments, fines, ERISA excise taxes and penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such Indemnitee in connection therewith, provided such Indemnitee acted in good faith and in a manner that the Indemnitee reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or Proceeding, had no reasonable cause to believe the Indemnitee&#8217;s conduct was unlawful. Such indemnification shall continue as to an Indemnitee who has ceased to be a director or officer and shall inure to the benefit of such Indemnitees&#8217; heirs, executors and administrators. Notwithstanding the foregoing, the Corporation shall indemnify any such Indemnitee seeking indemnity in connection with a Proceeding (or part thereof) initiated by such Indemnitee only if such Proceeding (or part thereof) was authorized by the Board or such indemnification is authorized by an agreement approved by the Board. As used herein, the term the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reincorporated Predecessor</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; means a corporation that is merged with and into the Corporation in a statutory merger where (a)&#160;the Corporation is the surviving corporation of such merger&#59; (b)&#160;the primary purpose of such merger is to change the corporate domicile of the Reincorporated Predecessor to Delaware. To the extent that a present or former director or officer of the Corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding described in this Section&#160;6.1 or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;6.2&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Advancement of Expenses</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Except as otherwise provided in a written indemnification agreement between the Corporation and an Indemnitee upon written request, the Corporation shall pay all expenses (including attorneys&#8217; fees) incurred by such an Indemnitee in defending any such Proceeding as they are incurred in advance of its final disposition&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, that if the DGCL then so requires, the payment of such expenses incurred by such Indemnitee in advance of the final disposition of such Proceeding shall be made only upon delivery to the Corporation of an undertaking, by or on behalf of such Indemnitee, to repay all amounts so advanced if it should be determined ultimately by final judicial decision from which there is no appeal that such Indemnitee is not entitled to be indemnified under this Article VI or otherwise. Such expenses (including attorneys&#8217; fees) incurred by former directors and officers or other employees and agents of the Corporation or by persons serving at the request of the Corporation as directors, officers, employees or agents of another corporation, partnership, joint venture, trust or other enterprise may be so paid upon such terms and conditions, if any, as the Corporation deems appropriate. The right to advancement of expenses shall not apply to any claim for which indemnity is excluded pursuant to these bylaws, but shall apply to any Proceeding referenced in Section&#160;6.1 prior to a determination that the person is not entitled to be indemnified by the Corporation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;6.3&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Non-Exclusivity&#160;of Rights</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The rights conferred on any person in this Article VI shall not be exclusive of any other right that such person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote or consent of stockholders or disinterested directors, or otherwise. Additionally, nothing in this Article VI shall limit the ability of the Corporation, in its discretion, to indemnify or advance expenses to persons whom the Corporation is not obligated to indemnify or advance expenses pursuant to this Article VI.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;6.4&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Indemnification Contracts</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Board is authorized to cause the Corporation to enter into indemnification contracts with any director, officer, employee or agent of the Corporation, or any person serving at the request of the Corporation as a director, officer, employee, agent or trustee of another corporation, partnership, joint venture, trust or other enterprise, including employee benefit plans, providing indemnification or advancement rights to such person. Such rights may be greater than those provided in this Article VI.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;6.5&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Right of Indemnitee to Bring Suit</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following shall apply to the extent not in conflict with any indemnification contract provided for in Section&#160;6.4 of these Bylaws.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6.5.1&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Right to Bring Suit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. If a claim under Section&#160;6.1 or 6.2 of these Bylaws is not paid in full by the Corporation within sixty (60)</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"> </sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">days after a written claim has been received by the Corporation, the Indemnitee may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim. If successful in whole or in part in any such suit, or in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Indemnitee shall be entitled to be paid, to the fullest extent permitted by law, the expense of prosecuting or defending such suit. In (a)&#160;any suit brought by the Indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by the Indemnitee to enforce a right to an advancement of expenses) it shall be a defense that, and (b)&#160;in any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that, the Indemnitee has not met any applicable standard for indemnification set forth in applicable law.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6.5.2&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Effect of Determination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Neither the failure of the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such suit that indemnification of the Indemnitee is proper in the circumstances because the Indemnitee has met the applicable standard of conduct set forth in applicable law, nor an actual determination by the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) that the Indemnitee has not met such applicable standard of conduct, shall create a presumption that the Indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the Indemnitee, be a defense to such suit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6.5.3&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Burden of Proof</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. In any suit brought by the Indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the Indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this Article VI, or otherwise, shall be on the Corporation.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;6.6&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Nature of Rights</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The rights conferred upon Indemnitees in this Article&#160;VI shall be contract rights and such rights shall continue as to an Indemnitee who has ceased to be a director, officer or trustee and shall inure to the benefit of the Indemnitee&#8217;s heirs, executors and administrators. Any amendment, repeal or modification of any provision of this Article VI that adversely affects any right of an Indemnitee or an Indemnitee&#8217;s successors shall be prospective only, and shall not adversely affect any right or protection conferred on a person pursuant to this Article VI and existing at the time of such amendment, repeal or modification.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;6.7&#58;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Insurance</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Corporation may purchase and maintain insurance, at its expense, on behalf of any person who is or was a director, officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss asserted against such person and incurred by such person in any such capacity, or arising out of such person&#8217;s status as such, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the provisions of the DGCL</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE VII&#58; NOTICES</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;7.1&#58;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Notice</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7.1.1&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Form and Delivery</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Except as otherwise specifically required in these Bylaws (including, without limitation, Section&#160;7.1.2 of these Bylaws) or by applicable law, all notices required to be given pursuant to these Bylaws shall be in writing and may (a)&#160;in every instance in connection with any delivery to a member of the Board, be effectively given by hand delivery (including use of a delivery service), by depositing such notice in the mail, postage prepaid, or by sending such notice by overnight express courier, facsimile, electronic mail or other form of electronic transmission and (b)&#160;be effectively delivered to a stockholder when given by hand delivery, by depositing such notice in the mail, postage prepaid or, if specifically consented to by the stockholder as described in Section&#160;7.1.2 of these Bylaws, by sending such notice by facsimile, electronic mail or other form of electronic transmission. Any such notice shall be addressed to the person to whom notice is to be given at such person&#8217;s address as it appears on the records of the Corporation. The notice shall be deemed given (a)&#160;in the case of hand delivery, when received by the person to whom notice is to be given or by any person accepting such notice on behalf of such person, (b)&#160;in the case of delivery by mail, upon deposit in the mail, (c)&#160;in the case of delivery by overnight express courier, when dispatched, and (d)&#160;in the case of delivery via facsimile, electronic mail or other form of electronic transmission, at the time provided in Section&#160;7.1.2 of these Bylaws.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7.1.2&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Electronic Transmission</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Corporation under any provision of the DGCL, the Certificate of Incorporation, or these Bylaws shall be effective if given by a form of electronic transmission consented to by the stockholder to whom the notice is given in accordance with Section&#160;232 of the DGCL. Any such consent shall be revocable by the stockholder by written notice to the Corporation. Any such consent shall be deemed revoked if (a)&#160;the Corporation is unable to deliver by electronic transmission two consecutive notices given by the Corporation in accordance with such consent and (b)&#160;such inability becomes known to the Secretary or an Assistant Secretary of the Corporation or to the transfer agent, or other person responsible for the giving of notice&#59;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action. Notice given pursuant to this Section&#160;7.1.2 shall be deemed given&#58; (i)&#160;if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice&#59; (ii)&#160;if by electronic mail, when directed to an electronic mail address at which the stockholder has consented to receive notice&#59; (iii)&#160;if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of such posting and the giving of such separate notice&#59; and (iv)&#160;if by any other form of electronic transmission, when directed to the stockholder.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7.1.3&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Affidavit of Giving Notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. An affidavit of the Secretary or an Assistant Secretary or of the transfer agent or other agent of the Corporation that the notice has been given in writing or by a form of electronic transmission shall, in the absence of fraud, be prima facie evidence of the facts stated therein.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;7.2&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Waiver of Notice</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Whenever notice is required to be given under any provision of the DGCL, the Certificate of Incorporation or these Bylaws, a written waiver of notice, signed by the person entitled to notice, or waiver by electronic transmission by such person, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders, directors or members of a committee of directors need be specified in any waiver of notice.</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE VIII&#58; INTERESTED DIRECTORS</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;8.1&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Interested Directors</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No contract or transaction between the Corporation and one or more of its members of the Board or officers, or between the Corporation and any other corporation, partnership, association or other organization in which one or more of its directors or officers are members of the board of directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board or committee thereof that authorizes the contract or transaction, or solely because his, her or their votes are counted for such purpose, if&#58; (a)&#160;the material facts as to his, her or their relationship or interest and as to the contract or transaction are disclosed or are known to the Board or the committee, and the Board or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum&#59; (b)&#160;the material facts as to his, her or their relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders&#59; or (c)&#160;the contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified by the Board, a committee thereof, or the stockholders.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;8.2&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Quorum</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interested directors may be counted in determining the presence of a quorum at a meeting of the Board or of a committee which authorizes the contract or transaction.</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE IX&#58; MISCELLANEOUS</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;9.1&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Fiscal Year</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fiscal year of the Corporation shall be determined by resolution of the Board.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;9.2&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Seal</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Board may provide for a corporate seal, which may have the name of the Corporation inscribed thereon and shall otherwise be in such form as may be approved from time to time by the Board.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;9.3&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Form of Records</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any records administered by or on behalf of the Corporation in the regular course of its business, including its stock ledger, books of account and minute books, may be kept on or by means of, or be in the form of, any other information storage device, method or one or more electronic networks or databases (including one or more distributed electronic networks or databases), electronic or otherwise,&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;that the records so kept can be converted into clearly legible paper form within a reasonable time and otherwise comply with the DGCL. The Corporation shall so convert any records so kept upon the request of any person entitled to inspect such records pursuant to any provision of the DGCL.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:24.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;9.4&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Reliance upon Books, Records and Experts</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A member of the Board, or a member of any committee designated by the Board shall, in the performance of such person&#8217;s duties, be fully protected in relying in good faith upon the books and records of the Corporation and upon such information, opinions, reports or statements presented to the Corporation by any of the Corporation&#8217;s officers or employees, or committees of the Board, or by any other person as to matters the member reasonably believes are within such other person&#8217;s professional or expert competence and who has been selected with reasonable care by or on behalf of the Corporation.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;9.5&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Certificate of Incorporation Governs</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the event of any conflict between the provisions of the Certificate of Incorporation and Bylaws, the provisions of the Certificate of Incorporation shall govern.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;9.6&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Severability</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If any provision of these Bylaws shall be held to be invalid, illegal, unenforceable or in conflict with the provisions of the Certificate of Incorporation, then such provision shall nonetheless be enforced to the maximum extent possible consistent with such holding and the remaining provisions of these Bylaws (including without limitation, all portions of any section of these Bylaws containing any such provision held to be invalid, illegal, unenforceable or in conflict with the Certificate of Incorporation, that are not themselves invalid, illegal, unenforceable or in conflict with the Certificate of Incorporation) shall remain in full force and effect.</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Section&#160;9.7&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Time Periods</font></div><div style="text-indent:24.75pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In applying any provision of these Bylaws which requires that an act be done or not be done a specified number of days prior to an event or that an act be done during a period of a specified number of days prior to an event, calendar days shall be used, the day of the doing of the act shall be excluded, and the day of the event shall be included.</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARTICLE X&#58; AMENDMENT</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notwithstanding any other provision of these Bylaws, any alteration, amendment or repeal of these Bylaws, and any adoption of new Bylaws, shall require the approval of the Board or the stockholders of the Corporation as expressly provided in the Certificate of Incorporation.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="padding-left:193.5pt;padding-right:166.5pt;text-align:center;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF RESTATED BYLAWS</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OF</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ARCUTIS BIOTHERAPEUTICS, INC.</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a Delaware corporation)</font></div><div style="text-indent:24.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Keith Klein, certify that I am Secretary of Arcutis Biotherapeutics, Inc., a Delaware corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Corporation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), that I am duly authorized to make and deliver this certification, that the attached Bylaws are a true and complete copy of the Restated Bylaws of the Corporation in effect as of the date of this certificate.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dated&#58; February 4, 2020</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:right;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:39.903%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Keith Klein</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Keith Klein</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Secretary</font></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit311ceo.htm
<DESCRIPTION>RULE 13A-14(A) CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i2e465d3871704dbf8b98e05d5bf90ecc_1"></div><div style="height:36pt;width:100%;"><div style="margin-bottom:0.08pt;"><font><br></font></div></div><div style="text-align:right;margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Todd Franklin Watanabe, certify that&#58;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt;">I have reviewed this Quarterly Report on Form 10-Q of Arcutis Biotherapeutics, Inc&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:72pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.91pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:72pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.34pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:72pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.91pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:72pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:72pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:85.000%;"><tr><td style="width:1.0%;"></td><td style="width:36.235%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.725%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:46.040%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; May 12, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Todd Franklin Watanabe</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Todd Franklin Watanabe</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">President, Chief Executive Officer and Director</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                    </font></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:0.08pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit312cfo.htm
<DESCRIPTION>RULE 13A-14(A) CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i687ec02b130d4995a05991e3491dff60_1"></div><div style="height:36pt;width:100%;"><div style="margin-bottom:0.08pt;"><font><br></font></div></div><div style="text-align:right;margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, John W. Smither, certify that&#58;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt;">I have reviewed this Quarterly Report on Form 10-Q of Arcutis Biotherapeutics, Inc.&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:72pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.91pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:72pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.34pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:72pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.91pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:10.5pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:72pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:72pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:85.000%;"><tr><td style="width:1.0%;"></td><td style="width:36.235%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.725%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:46.040%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; May 12, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; John W. Smither</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">John W. Smither </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Chief Financial Officer</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Principal Accounting and Financial Officer)</font></div></td></tr></table></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                    </font></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:0.08pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit321ceocfo.htm
<DESCRIPTION>SECTION 1350 CERTIFICATIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="idf8cd37ce6b049b7a4b4830d6d0d7e99_1"></div><div style="height:72pt;width:100%;"><div style="margin-bottom:0.08pt;"><font><br></font></div></div><div style="text-align:right;margin-top:18pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:center;margin-top:18pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report of Arcutis Biotherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Todd Franklin Watanabe, Chief Executive Officer of the Company, and John W. Smither, Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-indent:18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="text-indent:18pt;padding-left:36pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:36pt;margin-top:6pt;"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:36.235%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.725%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:46.040%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; May 12, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Todd Franklin Watanabe</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Todd Franklin Watanabe</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">President, Chief Executive Officer and Director</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Principal Executive Officer)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; May 12, 2020</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; John W. Smither</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">John W. Smither </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Chief Financial Officer</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Principal Accounting and Financial Officer)</font></div></td></tr></table></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                    </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:0.08pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>arqt-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:600b0262-d663-4687-ae47-6802ec869b02,g:c1b67e0b-9b7c-4732-b64c-b3f7b7d96647-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arqt="http://arcutis.com/20200331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://arcutis.com/20200331">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arqt-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arqt-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arqt-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arqt-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://arcutis.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheets" roleURI="http://arcutis.com/role/CondensedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsParenthetical" roleURI="http://arcutis.com/role/CondensedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofOperationsandComprehensiveLoss" roleURI="http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" roleURI="http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit">
        <link:definition>1004005 - Statement - Condensed Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" roleURI="http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical">
        <link:definition>1005006 - Statement - Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofCashFlows" roleURI="http://arcutis.com/role/CondensedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://arcutis.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusinessDetails" roleURI="http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails">
        <link:definition>2402401 - Disclosure - Organization and Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://arcutis.com/role/FairValueMeasurements">
        <link:definition>2106103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://arcutis.com/role/FairValueMeasurementsTables">
        <link:definition>2307301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails" roleURI="http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails">
        <link:definition>2408403 - Disclosure - Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>2409404 - Disclosure - Fair Value Measurements - Estimated Value of Cash and Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://arcutis.com/role/BalanceSheetComponents">
        <link:definition>2110104 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://arcutis.com/role/BalanceSheetComponentsTables">
        <link:definition>2311302 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>2412405 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAccruedLiabilitiesDetails" roleURI="http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails">
        <link:definition>2413406 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://arcutis.com/role/LicenseAgreements">
        <link:definition>2114105 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsAstraZenecaDetails" roleURI="http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails">
        <link:definition>2415407 - Disclosure - License Agreements - AstraZeneca (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsHengruiDetails" roleURI="http://arcutis.com/role/LicenseAgreementsHengruiDetails">
        <link:definition>2416408 - Disclosure - License Agreements - Hengrui (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsHawkeyeDetails" roleURI="http://arcutis.com/role/LicenseAgreementsHawkeyeDetails">
        <link:definition>2417409 - Disclosure - License Agreements - Hawkeye (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://arcutis.com/role/CommitmentsandContingencies">
        <link:definition>2118106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://arcutis.com/role/CommitmentsandContingenciesTables">
        <link:definition>2319303 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://arcutis.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2420410 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesOperatingLeasePaymentsDetails" roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails">
        <link:definition>2421411 - Disclosure - Commitments and Contingencies - Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesOperatingLeasePaymentsDetails_1" roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails_1">
        <link:definition>2421411 - Disclosure - Commitments and Contingencies - Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails" roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails">
        <link:definition>2422412 - Disclosure - Commitments and Contingencies - Operating Lease Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesOperatingLeaseAdditionalInformationDetails" roleURI="http://arcutis.com/role/CommitmentandContingenciesOperatingLeaseAdditionalInformationDetails">
        <link:definition>2423413 - Disclosure - Commitment and Contingencies - Operating Lease Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockandStockholdersEquityDeficit" roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficit">
        <link:definition>2124107 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockandStockholdersEquityDeficitTables" roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitTables">
        <link:definition>2325304 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails" roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails">
        <link:definition>2426414 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Components of Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockandStockholdersEquityDeficitDetails" roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails">
        <link:definition>2427415 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails" roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails">
        <link:definition>2428416 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Shares of Common Stock for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://arcutis.com/role/StockBasedCompensation">
        <link:definition>2129108 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://arcutis.com/role/StockBasedCompensationTables">
        <link:definition>2330305 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationDetails" roleURI="http://arcutis.com/role/StockBasedCompensationDetails">
        <link:definition>2431417 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2432418 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitActivityDetails" roleURI="http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails">
        <link:definition>2433419 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://arcutis.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2434420 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails" roleURI="http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails">
        <link:definition>2435421 - Disclosure - Stock-Based Compensation - Assumptions in Calculating Stock Option Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://arcutis.com/role/NetLossPerShare">
        <link:definition>2136109 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://arcutis.com/role/NetLossPerShareTables">
        <link:definition>2337306 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetails" roleURI="http://arcutis.com/role/NetLossPerShareDetails">
        <link:definition>2438422 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://arcutis.com/role/SubsequentEvent">
        <link:definition>2139110 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventDetails" roleURI="http://arcutis.com/role/SubsequentEventDetails">
        <link:definition>2440423 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="arqt_StockPurchaseAgreementNumberOfTranches" abstract="false" name="StockPurchaseAgreementNumberOfTranches" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arqt_LesseeOperatingLeaseTermForTerminationOption" abstract="false" name="LesseeOperatingLeaseTermForTerminationOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration" abstract="false" name="CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arqt_LeaseDescriptionDomain" abstract="true" name="LeaseDescriptionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="arqt_StockPurchaseAgreementNumberOfSharesIssuable" abstract="false" name="StockPurchaseAgreementNumberOfSharesIssuable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arqt_OperatingLeaseRightOfUseAssetAmortizationExpense" abstract="false" name="OperatingLeaseRightOfUseAssetAmortizationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" abstract="false" name="StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock" abstract="false" name="UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="arqt_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="arqt_LesseeOperatingLeaseFreeRentPeriod" abstract="false" name="LesseeOperatingLeaseFreeRentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arqt_StockPurchaseAgreementTrancheOneMember" abstract="true" name="StockPurchaseAgreementTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="arqt_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_VariableInterestEntitiesNumberOfSharesHeld" abstract="false" name="VariableInterestEntitiesNumberOfSharesHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arqt_StockAwardsFutureGrantMember" abstract="true" name="StockAwardsFutureGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="arqt_EarlyExercisedOptionsMember" abstract="true" name="EarlyExercisedOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration" abstract="false" name="CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_StockPurchaseAgreementTranchesTwoAndThreeMember" abstract="true" name="StockPurchaseAgreementTranchesTwoAndThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="arqt_WestlakeVillageCaliforniaLeaseArrangementMember" abstract="true" name="WestlakeVillageCaliforniaLeaseArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace" abstract="false" name="LesseeOperatingLeaseSquareFootageOfLeasedSpace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" abstract="false" name="CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_LesseeOperatingLeasesNumberFacilitiesLeased" abstract="false" name="LesseeOperatingLeasesNumberFacilitiesLeased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arqt_TemporaryEquitySharesConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquitySharesConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="arqt_A2017EquityIncentivePlanMember" abstract="true" name="A2017EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="arqt_LesseeOperatingLeaseLetterOfCreditRequirement" abstract="false" name="LesseeOperatingLeaseLetterOfCreditRequirement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_TemporaryEquityValueConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquityValueConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arqt_PrepaidClinicalTrialTestCostsCurrent" abstract="false" name="PrepaidClinicalTrialTestCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_HengruiMember" abstract="true" name="HengruiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares" abstract="false" name="StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arqt_LesseeOperatingLeaseMonthlyRentExpense" abstract="false" name="LesseeOperatingLeaseMonthlyRentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arqt_A2020EquityIncentivePlanMember" abstract="true" name="A2020EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="arqt_LeaseDescriptionAxis" abstract="true" name="LeaseDescriptionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="arqt_ClinicalTrialAccrualCurrent" abstract="false" name="ClinicalTrialAccrualCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_EmergingGrowthCompanyStatusPolicyTextBlock" abstract="false" name="EmergingGrowthCompanyStatusPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="arqt_LesseeOperatingLeaseTenantImprovementAllowance" abstract="false" name="LesseeOperatingLeaseTenantImprovementAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="arqt_PerformanceConditionRestrictedStockMember" abstract="true" name="PerformanceConditionRestrictedStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arqt_ServiceConditionRestrictedStockMember" abstract="true" name="ServiceConditionRestrictedStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="arqt_DeferredFinancingCostsIncurredButNotYetPaid" abstract="false" name="DeferredFinancingCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_StockOptionsIssuedAndOutstandingMember" abstract="true" name="StockOptionsIssuedAndOutstandingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="arqt_HawkeyeMember" abstract="true" name="HawkeyeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" abstract="false" name="StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arqt_CommonStockVotingRightsNumberOfVotesPerShare" abstract="false" name="CommonStockVotingRightsNumberOfVotesPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arqt_StockPurchaseAgreementTrancheThreeMember" abstract="true" name="StockPurchaseAgreementTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties" abstract="false" name="ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_StockPurchaseAgreementPricePerShare" abstract="false" name="StockPurchaseAgreementPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue" abstract="false" name="StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arqt_StockPurchaseAgreementTrancheTwoMember" abstract="true" name="StockPurchaseAgreementTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock" abstract="false" name="PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>arqt-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:600b0262-d663-4687-ae47-6802ec869b02,g:c1b67e0b-9b7c-4732-b64c-b3f7b7d96647-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://arcutis.com/role/CoverPage" xlink:type="simple" xlink:href="arqt-20200331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5fa52f0b-6191-4868-97a6-f07c36bb8c5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_90ae5965-c39f-434c-a48a-ef373d916f41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5fa52f0b-6191-4868-97a6-f07c36bb8c5c" xlink:to="loc_us-gaap_AccountsPayableCurrent_90ae5965-c39f-434c-a48a-ef373d916f41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_287f5444-5d83-4519-aefd-5d55ef2db273" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5fa52f0b-6191-4868-97a6-f07c36bb8c5c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_287f5444-5d83-4519-aefd-5d55ef2db273" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f8d53ebc-305d-4495-9faf-60e0c02107a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5fa52f0b-6191-4868-97a6-f07c36bb8c5c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f8d53ebc-305d-4495-9faf-60e0c02107a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_44c3daf9-ed92-4792-9f3c-05b652bedad3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2a33f185-a7fb-4908-a4e9-3c6e38abe1df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_44c3daf9-ed92-4792-9f3c-05b652bedad3" xlink:to="loc_us-gaap_AssetsCurrent_2a33f185-a7fb-4908-a4e9-3c6e38abe1df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ad59c4d0-eddd-4418-b85c-dfe9ac734470" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_44c3daf9-ed92-4792-9f3c-05b652bedad3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ad59c4d0-eddd-4418-b85c-dfe9ac734470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba126c92-1ba3-4131-98ef-1a8167c1a492" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_44c3daf9-ed92-4792-9f3c-05b652bedad3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba126c92-1ba3-4131-98ef-1a8167c1a492" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0684d909-d08e-48e8-847f-ac3870a9949a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_44c3daf9-ed92-4792-9f3c-05b652bedad3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0684d909-d08e-48e8-847f-ac3870a9949a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_858b081a-2a05-420a-be5e-08de29b72b75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0fbd434e-ea3a-4520-9dac-a4d20d507195" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_858b081a-2a05-420a-be5e-08de29b72b75" xlink:to="loc_us-gaap_LiabilitiesCurrent_0fbd434e-ea3a-4520-9dac-a4d20d507195" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cfdb33f3-1ea5-444a-8511-b07ba33555ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_858b081a-2a05-420a-be5e-08de29b72b75" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cfdb33f3-1ea5-444a-8511-b07ba33555ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_59b46eb8-3499-43d3-9e4d-f328de6d28d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_858b081a-2a05-420a-be5e-08de29b72b75" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_59b46eb8-3499-43d3-9e4d-f328de6d28d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8ba2bea8-028f-4fbf-844b-9ee97196d1e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9521c3cf-c0ab-40fc-8a0e-9d0afb00a6d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8ba2bea8-028f-4fbf-844b-9ee97196d1e2" xlink:to="loc_us-gaap_Liabilities_9521c3cf-c0ab-40fc-8a0e-9d0afb00a6d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_53cac785-e681-4dd7-96f2-4318ebe299e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8ba2bea8-028f-4fbf-844b-9ee97196d1e2" xlink:to="loc_us-gaap_StockholdersEquity_53cac785-e681-4dd7-96f2-4318ebe299e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a3145667-291d-4d6e-a7ca-6ab2d962f465" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8ba2bea8-028f-4fbf-844b-9ee97196d1e2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a3145667-291d-4d6e-a7ca-6ab2d962f465" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_a5d2d5d1-cf60-40f1-9014-1f53429db5ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8ba2bea8-028f-4fbf-844b-9ee97196d1e2" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_a5d2d5d1-cf60-40f1-9014-1f53429db5ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c0bd4141-d5da-4f4c-8b03-0cfa4ff8fe34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ade56688-9056-49b8-a533-be1a3b8dd34c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c0bd4141-d5da-4f4c-8b03-0cfa4ff8fe34" xlink:to="loc_us-gaap_CommonStockValue_ade56688-9056-49b8-a533-be1a3b8dd34c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f3dd085d-8b5f-436a-8223-2b1d909272f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c0bd4141-d5da-4f4c-8b03-0cfa4ff8fe34" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f3dd085d-8b5f-436a-8223-2b1d909272f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bfc86da4-1a2e-4da3-afcc-1dc7d2cb7cd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c0bd4141-d5da-4f4c-8b03-0cfa4ff8fe34" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bfc86da4-1a2e-4da3-afcc-1dc7d2cb7cd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e31cfbcd-d679-4601-99a6-cf2ffd2978ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c0bd4141-d5da-4f4c-8b03-0cfa4ff8fe34" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e31cfbcd-d679-4601-99a6-cf2ffd2978ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d60ce39d-3dfa-4378-b00c-23222e34f9cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c0bd4141-d5da-4f4c-8b03-0cfa4ff8fe34" xlink:to="loc_us-gaap_PreferredStockValue_d60ce39d-3dfa-4378-b00c-23222e34f9cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6ffc9fe1-23db-4ee9-a95d-873c466318f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9fe39819-fef2-43b1-92e3-bfa64a869acb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6ffc9fe1-23db-4ee9-a95d-873c466318f3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9fe39819-fef2-43b1-92e3-bfa64a869acb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e9e54a97-7c65-4cc5-b950-97949ec0f548" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6ffc9fe1-23db-4ee9-a95d-873c466318f3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e9e54a97-7c65-4cc5-b950-97949ec0f548" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_046439c5-4f78-4c2c-a2d8-d2ef9c865ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6ffc9fe1-23db-4ee9-a95d-873c466318f3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_046439c5-4f78-4c2c-a2d8-d2ef9c865ea8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_257c5a06-bcb4-4b4b-90e8-edf1301797e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_909e366b-e0b5-4bae-8e7f-2bf56dd0a725" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_257c5a06-bcb4-4b4b-90e8-edf1301797e2" xlink:to="loc_us-gaap_OperatingIncomeLoss_909e366b-e0b5-4bae-8e7f-2bf56dd0a725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ea901efa-dd7a-4b15-811d-e99b343e315d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_257c5a06-bcb4-4b4b-90e8-edf1301797e2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ea901efa-dd7a-4b15-811d-e99b343e315d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6903682d-d54e-43b3-9168-fac892ddab46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_adb913ed-d6d0-4ccd-895a-803b89e36cc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6903682d-d54e-43b3-9168-fac892ddab46" xlink:to="loc_us-gaap_NetIncomeLoss_adb913ed-d6d0-4ccd-895a-803b89e36cc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5223220f-b614-44e3-bf94-60423ac207a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6903682d-d54e-43b3-9168-fac892ddab46" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5223220f-b614-44e3-bf94-60423ac207a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8ac0a376-77b2-477f-aaa5-3fd924920561" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1060442b-de3a-43f6-b598-90efcbef0fba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8ac0a376-77b2-477f-aaa5-3fd924920561" xlink:to="loc_us-gaap_OperatingExpenses_1060442b-de3a-43f6-b598-90efcbef0fba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8b7dbb8d-a04e-4f7c-af73-d2bcac914af2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9e66518a-4427-4a5f-9268-1de275719513" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8b7dbb8d-a04e-4f7c-af73-d2bcac914af2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9e66518a-4427-4a5f-9268-1de275719513" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1aa96bfc-5780-4906-8ef4-f1bac205ac37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8b7dbb8d-a04e-4f7c-af73-d2bcac914af2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1aa96bfc-5780-4906-8ef4-f1bac205ac37" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ab7fafe-186b-4c95-9581-afff2d36d744" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9ca69acf-c4bd-4892-851a-2a8956ed4c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ab7fafe-186b-4c95-9581-afff2d36d744" xlink:to="loc_us-gaap_NetIncomeLoss_9ca69acf-c4bd-4892-851a-2a8956ed4c7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_66ce404a-1f62-4079-aeac-86171465fd54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ab7fafe-186b-4c95-9581-afff2d36d744" xlink:to="loc_us-gaap_Depreciation_66ce404a-1f62-4079-aeac-86171465fd54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_OperatingLeaseRightOfUseAssetAmortizationExpense_cf13e50e-122a-48aa-9d24-d7fdc223cee9" xlink:href="arqt-20200331.xsd#arqt_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ab7fafe-186b-4c95-9581-afff2d36d744" xlink:to="loc_arqt_OperatingLeaseRightOfUseAssetAmortizationExpense_cf13e50e-122a-48aa-9d24-d7fdc223cee9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_58020181-986a-4524-a0fa-3e3b93849dc4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ab7fafe-186b-4c95-9581-afff2d36d744" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_58020181-986a-4524-a0fa-3e3b93849dc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_990c1240-3881-46f6-b39b-47a64d307af4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ab7fafe-186b-4c95-9581-afff2d36d744" xlink:to="loc_us-gaap_ShareBasedCompensation_990c1240-3881-46f6-b39b-47a64d307af4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_02c361be-426d-4f23-8ea6-7bd8e1714972" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ab7fafe-186b-4c95-9581-afff2d36d744" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_02c361be-426d-4f23-8ea6-7bd8e1714972" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_04d36c4a-733c-4af0-8b31-0562faf779fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ab7fafe-186b-4c95-9581-afff2d36d744" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_04d36c4a-733c-4af0-8b31-0562faf779fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fe7abbce-40f9-4c62-8fec-c7e5b19ce177" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ab7fafe-186b-4c95-9581-afff2d36d744" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fe7abbce-40f9-4c62-8fec-c7e5b19ce177" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3b274e24-48e0-4c2a-8507-6b49dacb21d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ab7fafe-186b-4c95-9581-afff2d36d744" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3b274e24-48e0-4c2a-8507-6b49dacb21d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_IncreaseDecreaseInOperatingLeaseLiabilities_7668893d-752f-4d69-b797-cb16b9ce5511" xlink:href="arqt-20200331.xsd#arqt_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ab7fafe-186b-4c95-9581-afff2d36d744" xlink:to="loc_arqt_IncreaseDecreaseInOperatingLeaseLiabilities_7668893d-752f-4d69-b797-cb16b9ce5511" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9267e43e-4caf-45f6-bf93-af77300adfc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81a6b207-a548-40de-9cd3-f70a15ab145c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9267e43e-4caf-45f6-bf93-af77300adfc9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81a6b207-a548-40de-9cd3-f70a15ab145c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35084f6c-467f-4eb5-8ced-1ab9d1550b14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9267e43e-4caf-45f6-bf93-af77300adfc9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35084f6c-467f-4eb5-8ced-1ab9d1550b14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_535aaacc-9471-4fa7-8a52-1203a64d56be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9267e43e-4caf-45f6-bf93-af77300adfc9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_535aaacc-9471-4fa7-8a52-1203a64d56be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9a70a953-6d54-4cd6-a7de-0955fec69363" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5ff54350-35ae-4774-a723-d4174f1534ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9a70a953-6d54-4cd6-a7de-0955fec69363" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5ff54350-35ae-4774-a723-d4174f1534ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_417eddc5-5c5b-49c8-82c0-84935328ae82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9a70a953-6d54-4cd6-a7de-0955fec69363" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_417eddc5-5c5b-49c8-82c0-84935328ae82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f9699b51-ac20-4764-b288-f284c0f319b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_dfb116aa-1a4b-40c6-8cfd-5cac44c5580f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f9699b51-ac20-4764-b288-f284c0f319b5" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_dfb116aa-1a4b-40c6-8cfd-5cac44c5580f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_1ea52ab9-cbad-41ca-ab16-6db2b120f0ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f9699b51-ac20-4764-b288-f284c0f319b5" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_1ea52ab9-cbad-41ca-ab16-6db2b120f0ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ebc6c6f6-8ebf-40c5-a19f-02c4e38428db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f9699b51-ac20-4764-b288-f284c0f319b5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ebc6c6f6-8ebf-40c5-a19f-02c4e38428db" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="arqt-20200331.xsd#OrganizationandDescriptionofBusiness"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#OrganizationandDescriptionofBusinessDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="arqt-20200331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="arqt-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="arqt-20200331.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_73c4e241-041b-467a-bd74-938679593acc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_a6a24851-1c37-4eb3-b82f-d50c463e201c" xlink:href="arqt-20200331.xsd#arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_73c4e241-041b-467a-bd74-938679593acc" xlink:to="loc_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_a6a24851-1c37-4eb3-b82f-d50c463e201c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_794d0304-917f-4d1a-93ee-57e36b493c24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_73c4e241-041b-467a-bd74-938679593acc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_794d0304-917f-4d1a-93ee-57e36b493c24" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6c808ce2-cd42-4e2b-b087-49756c703c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d4dbfcb6-36fb-4ed7-8669-6b048557d020" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6c808ce2-cd42-4e2b-b087-49756c703c7f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d4dbfcb6-36fb-4ed7-8669-6b048557d020" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dba6443a-18cd-43f1-be71-7a793c205139" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6c808ce2-cd42-4e2b-b087-49756c703c7f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dba6443a-18cd-43f1-be71-7a793c205139" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cf65416e-9b4e-4c64-b8a8-fe63a382dc90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6c808ce2-cd42-4e2b-b087-49756c703c7f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cf65416e-9b4e-4c64-b8a8-fe63a382dc90" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="arqt-20200331.xsd#BalanceSheetComponents"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/BalanceSheetComponents" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#BalanceSheetComponentsTables"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/BalanceSheetComponentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c22daf47-c424-4396-aa15-f70cb06093d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_0bf93cba-837d-42cb-a32c-04b4feb090c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c22daf47-c424-4396-aa15-f70cb06093d5" xlink:to="loc_us-gaap_PrepaidInsurance_0bf93cba-837d-42cb-a32c-04b4feb090c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PrepaidClinicalTrialTestCostsCurrent_a388289b-9bf9-4859-943d-d171e4c906c6" xlink:href="arqt-20200331.xsd#arqt_PrepaidClinicalTrialTestCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c22daf47-c424-4396-aa15-f70cb06093d5" xlink:to="loc_arqt_PrepaidClinicalTrialTestCostsCurrent_a388289b-9bf9-4859-943d-d171e4c906c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_e4a5f2cd-12eb-4ee3-81c4-4b67733f794d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c22daf47-c424-4396-aa15-f70cb06093d5" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_e4a5f2cd-12eb-4ee3-81c4-4b67733f794d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_cd3d0f01-ea7d-4aaf-9491-670396910627" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c22daf47-c424-4396-aa15-f70cb06093d5" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_cd3d0f01-ea7d-4aaf-9491-670396910627" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7c48e2ca-112b-4239-ab23-67f69245fa1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ClinicalTrialAccrualCurrent_59878acf-dda1-4a14-85e7-db32858c5e8a" xlink:href="arqt-20200331.xsd#arqt_ClinicalTrialAccrualCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7c48e2ca-112b-4239-ab23-67f69245fa1d" xlink:to="loc_arqt_ClinicalTrialAccrualCurrent_59878acf-dda1-4a14-85e7-db32858c5e8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6b521726-13e7-44c4-9878-b2591efec4bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7c48e2ca-112b-4239-ab23-67f69245fa1d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6b521726-13e7-44c4-9878-b2591efec4bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_22852bdd-652c-4221-99bf-abc767d62482" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7c48e2ca-112b-4239-ab23-67f69245fa1d" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_22852bdd-652c-4221-99bf-abc767d62482" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8e78db1a-03ce-4b7f-b6c6-56a3d2e44a19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7c48e2ca-112b-4239-ab23-67f69245fa1d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8e78db1a-03ce-4b7f-b6c6-56a3d2e44a19" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreements" xlink:type="simple" xlink:href="arqt-20200331.xsd#LicenseAgreements"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/LicenseAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#LicenseAgreementsAstraZenecaDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsHengruiDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#LicenseAgreementsHengruiDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/LicenseAgreementsHengruiDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsHawkeyeDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#LicenseAgreementsHawkeyeDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/LicenseAgreementsHawkeyeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentsandContingenciesDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentsandContingenciesOperatingLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_19416d4a-f7fb-4ee5-83cc-2a6a8ee595df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e7d65dcf-beb9-4dcb-8b16-a73dcb7fa107" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_19416d4a-f7fb-4ee5-83cc-2a6a8ee595df" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e7d65dcf-beb9-4dcb-8b16-a73dcb7fa107" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b42262a-66f6-47bc-bf16-d6e8beebd5f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_19416d4a-f7fb-4ee5-83cc-2a6a8ee595df" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b42262a-66f6-47bc-bf16-d6e8beebd5f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a8c65fb8-e87f-479d-a43d-dd5967982d41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_178a206e-528b-40e5-8eaa-2877fe8044fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a8c65fb8-e87f-479d-a43d-dd5967982d41" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_178a206e-528b-40e5-8eaa-2877fe8044fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f47714b1-8a3d-4b2c-b4af-a64c598f50d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a8c65fb8-e87f-479d-a43d-dd5967982d41" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f47714b1-8a3d-4b2c-b4af-a64c598f50d9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails_1" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentsandContingenciesOperatingLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5b05fa52-261c-40f7-be6e-f81526924a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9491bd0c-51f8-4b7f-a34f-eb1ba355ce06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5b05fa52-261c-40f7-be6e-f81526924a0e" xlink:to="loc_us-gaap_OperatingLeaseLiability_9491bd0c-51f8-4b7f-a34f-eb1ba355ce06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_214023af-8638-4470-ac19-0d0bdcaf1fe0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5b05fa52-261c-40f7-be6e-f81526924a0e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_214023af-8638-4470-ac19-0d0bdcaf1fe0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentandContingenciesOperatingLeaseAdditionalInformationDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentandContingenciesOperatingLeaseAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/CommitmentandContingenciesOperatingLeaseAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="arqt-20200331.xsd#ConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#ConvertiblePreferredStockandStockholdersEquityDeficitTables"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#ConvertiblePreferredStockandStockholdersEquityDeficitDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_e9ef20e1-0ffd-415d-928a-4d2efc934552" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_b6ea6a0f-333b-4f58-a23c-c5336c2eedde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_e9ef20e1-0ffd-415d-928a-4d2efc934552" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_b6ea6a0f-333b-4f58-a23c-c5336c2eedde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_5ef1e57e-ddf7-4268-8887-fcf97c586379" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_e9ef20e1-0ffd-415d-928a-4d2efc934552" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_5ef1e57e-ddf7-4268-8887-fcf97c586379" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/NetLossPerShare" xlink:type="simple" xlink:href="arqt-20200331.xsd#NetLossPerShare"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/NetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#NetLossPerShareTables"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/NetLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#NetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/NetLossPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/SubsequentEvent" xlink:type="simple" xlink:href="arqt-20200331.xsd#SubsequentEvent"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/SubsequentEvent" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#SubsequentEventDetails"/>
  <link:calculationLink xlink:role="http://arcutis.com/role/SubsequentEventDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>arqt-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:600b0262-d663-4687-ae47-6802ec869b02,g:c1b67e0b-9b7c-4732-b64c-b3f7b7d96647-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://arcutis.com/role/CoverPage" xlink:type="simple" xlink:href="arqt-20200331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/CoverPage" xlink:type="extended" id="i9c7e827969de4e5bb2a944a3075e914e_CoverPage"/>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedBalanceSheets"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/CondensedBalanceSheets" xlink:type="extended" id="ic9de316bd93f455c8ea87e78495656dc_CondensedBalanceSheets"/>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended" id="ic537b9179c084113b4926327e770a37a_CondensedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="i797a32ae9b6c44a48c6d5f0b19bf1352_CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended" id="ibc5a1b57839a407fa329de28cc9dadd2_CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_84e96e7b-9779-44b4-95af-c219b178d4d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4d1dc41-1fdd-4b43-890a-30c8c336733a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_84e96e7b-9779-44b4-95af-c219b178d4d4" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4d1dc41-1fdd-4b43-890a-30c8c336733a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_ab6c9b35-74ab-4bdb-91da-bae4631c1a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4d1dc41-1fdd-4b43-890a-30c8c336733a" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_ab6c9b35-74ab-4bdb-91da-bae4631c1a9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_fc87b854-ff4f-4856-b2f7-f2571b3fab52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4d1dc41-1fdd-4b43-890a-30c8c336733a" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_fc87b854-ff4f-4856-b2f7-f2571b3fab52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TemporaryEquitySharesConversionOfConvertibleSecurities_a658f2e7-8bb6-4942-9ad5-6a6d0ef915cd" xlink:href="arqt-20200331.xsd#arqt_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4d1dc41-1fdd-4b43-890a-30c8c336733a" xlink:to="loc_arqt_TemporaryEquitySharesConversionOfConvertibleSecurities_a658f2e7-8bb6-4942-9ad5-6a6d0ef915cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TemporaryEquityValueConversionOfConvertibleSecurities_fffd2cf4-85bf-47d8-898e-fa205504272e" xlink:href="arqt-20200331.xsd#arqt_TemporaryEquityValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4d1dc41-1fdd-4b43-890a-30c8c336733a" xlink:to="loc_arqt_TemporaryEquityValueConversionOfConvertibleSecurities_fffd2cf4-85bf-47d8-898e-fa205504272e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_2f6363b8-ea2f-4d07-9086-65dfb45482f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_d96cae7e-1ca8-435b-9d0b-1ec4885e9364" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_84e96e7b-9779-44b4-95af-c219b178d4d4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_dae9f7b1-6640-4183-9f4a-ae8b812a706d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_SharesOutstanding_dae9f7b1-6640-4183-9f4a-ae8b812a706d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c963c2b3-da75-41de-885d-ad3f9f512162" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_StockholdersEquity_c963c2b3-da75-41de-885d-ad3f9f512162" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares_491fddc7-626d-4bb5-856f-bdd245262e7f" xlink:href="arqt-20200331.xsd#arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares_491fddc7-626d-4bb5-856f-bdd245262e7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue_fc84cc57-ffd2-4a3b-b784-ca990c10a8b6" xlink:href="arqt-20200331.xsd#arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue_fc84cc57-ffd2-4a3b-b784-ca990c10a8b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_47498c99-592a-4daf-8c44-4962d3a2560d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_47498c99-592a-4daf-8c44-4962d3a2560d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_665c8b85-a238-4c32-b768-300d9b25d9aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_665c8b85-a238-4c32-b768-300d9b25d9aa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_adfc06c6-d762-4780-bbec-28f5892aabb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_adfc06c6-d762-4780-bbec-28f5892aabb7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_c384b1c8-0745-44df-8e1a-28e07fdabb4d" xlink:href="arqt-20200331.xsd#arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_c384b1c8-0745-44df-8e1a-28e07fdabb4d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises_a2d1ff06-8021-48c1-b6a7-407f2b063eee" xlink:href="arqt-20200331.xsd#arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises_a2d1ff06-8021-48c1-b6a7-407f2b063eee" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5a983b8b-7063-4d1c-b358-a27bdd148c85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5a983b8b-7063-4d1c-b358-a27bdd148c85" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_571f1576-f452-4299-add6-ef034a24db63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_571f1576-f452-4299-add6-ef034a24db63" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8a2560a0-028b-4ebc-ba5a-f8c5e515b1e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8a2560a0-028b-4ebc-ba5a-f8c5e515b1e2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20adf8f9-c098-409c-a047-513c7f87a6fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20adf8f9-c098-409c-a047-513c7f87a6fe" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_21c58dc1-6514-4551-b59b-cd34bda97c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_21c58dc1-6514-4551-b59b-cd34bda97c7c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_14622c05-464e-4eb9-b1ae-85bbfb56e450" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_14622c05-464e-4eb9-b1ae-85bbfb56e450" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b6117cbd-8ca0-465f-8657-61005ac2dc3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_NetIncomeLoss_b6117cbd-8ca0-465f-8657-61005ac2dc3f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2f6033e1-e33a-4823-a698-4571bfe66cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ca37a3c8-bcd5-49d3-aaef-7fcafbc1034b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e934c51a-ed0f-446d-9fe5-d267c843a595" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_84e96e7b-9779-44b4-95af-c219b178d4d4" xlink:to="loc_us-gaap_StatementTable_e934c51a-ed0f-446d-9fe5-d267c843a595" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c8183cd7-646c-4380-a20f-fb31249059d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e934c51a-ed0f-446d-9fe5-d267c843a595" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c8183cd7-646c-4380-a20f-fb31249059d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c8183cd7-646c-4380-a20f-fb31249059d5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c8183cd7-646c-4380-a20f-fb31249059d5" xlink:to="loc_us-gaap_EquityComponentDomain_c8183cd7-646c-4380-a20f-fb31249059d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_591209dd-2986-4e2d-8df9-3b8c9649659f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c8183cd7-646c-4380-a20f-fb31249059d5" xlink:to="loc_us-gaap_EquityComponentDomain_591209dd-2986-4e2d-8df9-3b8c9649659f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5bfd22e2-148a-4dc6-b8f6-6c752e53c37f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_591209dd-2986-4e2d-8df9-3b8c9649659f" xlink:to="loc_us-gaap_CommonStockMember_5bfd22e2-148a-4dc6-b8f6-6c752e53c37f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6fec8d39-0a7d-499a-a5a1-a6b95e3415b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_591209dd-2986-4e2d-8df9-3b8c9649659f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6fec8d39-0a7d-499a-a5a1-a6b95e3415b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7fbca021-c598-4aef-80ff-643d13098a9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_591209dd-2986-4e2d-8df9-3b8c9649659f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7fbca021-c598-4aef-80ff-643d13098a9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ea92f2d5-8a1b-48f6-8edf-f9b34dcc4797" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_591209dd-2986-4e2d-8df9-3b8c9649659f" xlink:to="loc_us-gaap_RetainedEarningsMember_ea92f2d5-8a1b-48f6-8edf-f9b34dcc4797" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="extended" id="i6ec4f2ee46d243fa94f8a210a54c3f74_CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e5bd7c5a-6520-491e-9e86-a3c105f88d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_ec0955cf-c330-42d8-baed-c487e9d5dbf5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e5bd7c5a-6520-491e-9e86-a3c105f88d8d" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_ec0955cf-c330-42d8-baed-c487e9d5dbf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_84ca50fb-44ba-44aa-a5c1-bb1bc000419b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e5bd7c5a-6520-491e-9e86-a3c105f88d8d" xlink:to="loc_us-gaap_StatementTable_84ca50fb-44ba-44aa-a5c1-bb1bc000419b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_da355292-80ea-492f-8ac5-e4c7d7eadaa7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_84ca50fb-44ba-44aa-a5c1-bb1bc000419b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_da355292-80ea-492f-8ac5-e4c7d7eadaa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_da355292-80ea-492f-8ac5-e4c7d7eadaa7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_da355292-80ea-492f-8ac5-e4c7d7eadaa7" xlink:to="loc_us-gaap_EquityComponentDomain_da355292-80ea-492f-8ac5-e4c7d7eadaa7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_afa549e9-49b1-4d4c-808e-e3af05d8dc74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_da355292-80ea-492f-8ac5-e4c7d7eadaa7" xlink:to="loc_us-gaap_EquityComponentDomain_afa549e9-49b1-4d4c-808e-e3af05d8dc74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_45131337-05ef-4c84-893a-2dddc02b5a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_afa549e9-49b1-4d4c-808e-e3af05d8dc74" xlink:to="loc_us-gaap_CommonStockMember_45131337-05ef-4c84-893a-2dddc02b5a8b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/CondensedStatementsofCashFlows" xlink:type="extended" id="ie4bc6e1d72d241b79ef06453a36ac807_CondensedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://arcutis.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="arqt-20200331.xsd#OrganizationandDescriptionofBusiness"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended" id="ib8259884052546c3abe5a2493a5a6b9f_OrganizationandDescriptionofBusiness"/>
  <link:roleRef roleURI="http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#OrganizationandDescriptionofBusinessDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="extended" id="iaae720a3ab914833b948590c32b2fdc0_OrganizationandDescriptionofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0ade3f7a-e10f-4b56-8e31-69d70d7d0b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0ade3f7a-e10f-4b56-8e31-69d70d7d0b8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dc832f30-fb89-4fc6-be63-49bca2b19280" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dc832f30-fb89-4fc6-be63-49bca2b19280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_45355970-291a-451a-bb63-edd8994c13a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_45355970-291a-451a-bb63-edd8994c13a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_271d2fbe-32f9-4de5-bfa8-1348051ac924" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_271d2fbe-32f9-4de5-bfa8-1348051ac924" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_51e9e269-d6fc-4f5a-b783-d1c0951594d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_51e9e269-d6fc-4f5a-b783-d1c0951594d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1163bed5-40ee-4fa1-9245-564e32bcde50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1163bed5-40ee-4fa1-9245-564e32bcde50" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_5497bde1-fe00-4a63-aee8-03d0dbca09a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_5497bde1-fe00-4a63-aee8-03d0dbca09a1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3a156362-2761-4a43-9fa4-df70bf8926c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3a156362-2761-4a43-9fa4-df70bf8926c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6f97af40-c28b-4e17-9172-d8c27bd6139a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3a156362-2761-4a43-9fa4-df70bf8926c1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6f97af40-c28b-4e17-9172-d8c27bd6139a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6f97af40-c28b-4e17-9172-d8c27bd6139a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6f97af40-c28b-4e17-9172-d8c27bd6139a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6f97af40-c28b-4e17-9172-d8c27bd6139a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5e9ced7-96b3-4d6e-a16d-6b691a3773e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6f97af40-c28b-4e17-9172-d8c27bd6139a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5e9ced7-96b3-4d6e-a16d-6b691a3773e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_e90621ba-53b3-4707-9965-2610673e44c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5e9ced7-96b3-4d6e-a16d-6b691a3773e1" xlink:to="loc_us-gaap_IPOMember_e90621ba-53b3-4707-9965-2610673e44c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_8dd05a2f-acfa-4e1b-995f-479c31f1b2e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5e9ced7-96b3-4d6e-a16d-6b691a3773e1" xlink:to="loc_us-gaap_OverAllotmentOptionMember_8dd05a2f-acfa-4e1b-995f-479c31f1b2e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f9017fbe-b3f7-4125-98df-b6ae4b07b2e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3a156362-2761-4a43-9fa4-df70bf8926c1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f9017fbe-b3f7-4125-98df-b6ae4b07b2e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f9017fbe-b3f7-4125-98df-b6ae4b07b2e1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f9017fbe-b3f7-4125-98df-b6ae4b07b2e1" xlink:to="loc_us-gaap_EquityComponentDomain_f9017fbe-b3f7-4125-98df-b6ae4b07b2e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_45562812-4017-4ede-9dea-7ec5ed04ca30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f9017fbe-b3f7-4125-98df-b6ae4b07b2e1" xlink:to="loc_us-gaap_EquityComponentDomain_45562812-4017-4ede-9dea-7ec5ed04ca30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_94b0e24b-f945-44a9-bda0-a8de45e860bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45562812-4017-4ede-9dea-7ec5ed04ca30" xlink:to="loc_us-gaap_CommonStockMember_94b0e24b-f945-44a9-bda0-a8de45e860bd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="arqt-20200331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i0427b557221d4c1bab7735331bb19ac0_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="arqt-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i649a3f3abc404bda9e4b5cea130a22d4_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="id3b29a467347435dbc12e12175531fe9_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_47a37d3c-b307-4088-a0e9-0926de1c2211" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_47a37d3c-b307-4088-a0e9-0926de1c2211" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_c93e2cba-a32d-4c2f-80b7-5e96a14890b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_c93e2cba-a32d-4c2f-80b7-5e96a14890b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b9f7d687-cfca-46d1-9ea4-e7b9e56696b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b9f7d687-cfca-46d1-9ea4-e7b9e56696b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d93fe186-5408-44e7-b066-c9b548c241e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d93fe186-5408-44e7-b066-c9b548c241e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_b7231a94-9bc9-488d-adc7-9ad0a8f00faa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_b7231a94-9bc9-488d-adc7-9ad0a8f00faa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d549ed5e-e976-4014-9cbb-9b3f3fb5c535" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d549ed5e-e976-4014-9cbb-9b3f3fb5c535" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a67e1170-7d06-4fbd-bde7-7d17fac354f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a67e1170-7d06-4fbd-bde7-7d17fac354f3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e10441cc-c03d-4b72-8ca7-e7ab90a484e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e10441cc-c03d-4b72-8ca7-e7ab90a484e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_302b5453-74cc-4227-b0fb-bd645a82adea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e10441cc-c03d-4b72-8ca7-e7ab90a484e5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_302b5453-74cc-4227-b0fb-bd645a82adea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_302b5453-74cc-4227-b0fb-bd645a82adea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_302b5453-74cc-4227-b0fb-bd645a82adea" xlink:to="loc_us-gaap_EquityComponentDomain_302b5453-74cc-4227-b0fb-bd645a82adea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_82516892-1916-4037-84ea-03548a056d00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_302b5453-74cc-4227-b0fb-bd645a82adea" xlink:to="loc_us-gaap_EquityComponentDomain_82516892-1916-4037-84ea-03548a056d00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f1571f3d-f5fc-4e44-905d-4e36f4aee525" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_82516892-1916-4037-84ea-03548a056d00" xlink:to="loc_us-gaap_CommonStockMember_f1571f3d-f5fc-4e44-905d-4e36f4aee525" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="arqt-20200331.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/FairValueMeasurements" xlink:type="extended" id="i7daa76d69be941e3be3fe19073225fa0_FairValueMeasurements"/>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i00e8a19eb762464ca70aede04bace89f_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="extended" id="i111fc6e17576493fa27c882a5756c9f5_FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7a3da2d-7fad-4b84-b625-202cff44a084" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_03711e31-e32a-4e4b-875d-5fa7e72632e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7a3da2d-7fad-4b84-b625-202cff44a084" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_03711e31-e32a-4e4b-875d-5fa7e72632e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_170704a2-2359-4905-934c-8d59891d5da7" xlink:href="arqt-20200331.xsd#arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7a3da2d-7fad-4b84-b625-202cff44a084" xlink:to="loc_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_170704a2-2359-4905-934c-8d59891d5da7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f726e43e-c904-4aca-bf22-576e7df12586" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7a3da2d-7fad-4b84-b625-202cff44a084" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f726e43e-c904-4aca-bf22-576e7df12586" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64d340c2-b78e-4072-9c7f-e7257fa9bf01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7a3da2d-7fad-4b84-b625-202cff44a084" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64d340c2-b78e-4072-9c7f-e7257fa9bf01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09cd6f4e-8de5-405e-9dea-ddc15cf851a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64d340c2-b78e-4072-9c7f-e7257fa9bf01" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09cd6f4e-8de5-405e-9dea-ddc15cf851a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_09cd6f4e-8de5-405e-9dea-ddc15cf851a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09cd6f4e-8de5-405e-9dea-ddc15cf851a9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_09cd6f4e-8de5-405e-9dea-ddc15cf851a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad8be0b6-6c20-4e1c-b543-4067dde5478a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09cd6f4e-8de5-405e-9dea-ddc15cf851a9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad8be0b6-6c20-4e1c-b543-4067dde5478a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9b0ca00b-6d91-4d13-aba1-223f1fa312df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad8be0b6-6c20-4e1c-b543-4067dde5478a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9b0ca00b-6d91-4d13-aba1-223f1fa312df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b65edb43-f03e-4f7c-9cc0-22fdf9862a58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad8be0b6-6c20-4e1c-b543-4067dde5478a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b65edb43-f03e-4f7c-9cc0-22fdf9862a58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_434a5362-af85-44c3-8821-13e272f4f311" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad8be0b6-6c20-4e1c-b543-4067dde5478a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_434a5362-af85-44c3-8821-13e272f4f311" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_853953fb-6f1d-472e-86b7-30bc988b3eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64d340c2-b78e-4072-9c7f-e7257fa9bf01" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_853953fb-6f1d-472e-86b7-30bc988b3eb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_853953fb-6f1d-472e-86b7-30bc988b3eb6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_853953fb-6f1d-472e-86b7-30bc988b3eb6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_853953fb-6f1d-472e-86b7-30bc988b3eb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ef68ceda-725e-4042-82c3-1d01afa02170" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_853953fb-6f1d-472e-86b7-30bc988b3eb6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ef68ceda-725e-4042-82c3-1d01afa02170" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d3ef77d3-61e4-4ea2-80f6-a5dce9b3a9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ef68ceda-725e-4042-82c3-1d01afa02170" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d3ef77d3-61e4-4ea2-80f6-a5dce9b3a9bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f7eb66f8-9b60-4e0c-bfa1-5b92418f5e23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64d340c2-b78e-4072-9c7f-e7257fa9bf01" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f7eb66f8-9b60-4e0c-bfa1-5b92418f5e23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f7eb66f8-9b60-4e0c-bfa1-5b92418f5e23_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f7eb66f8-9b60-4e0c-bfa1-5b92418f5e23" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f7eb66f8-9b60-4e0c-bfa1-5b92418f5e23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3401c0b4-9de7-419d-a7d0-5a6366a1a690" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f7eb66f8-9b60-4e0c-bfa1-5b92418f5e23" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3401c0b4-9de7-419d-a7d0-5a6366a1a690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_87c972f0-f18d-4ca5-a0eb-14fcabbba1c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3401c0b4-9de7-419d-a7d0-5a6366a1a690" xlink:to="loc_us-gaap_CommercialPaperMember_87c972f0-f18d-4ca5-a0eb-14fcabbba1c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2cfa28cf-b62c-43c2-b4fe-b94699d6bf04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3401c0b4-9de7-419d-a7d0-5a6366a1a690" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2cfa28cf-b62c-43c2-b4fe-b94699d6bf04" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended" id="i557738cb1b9648aa8cd8f5f07900656c_FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_e5c5d08a-5da8-461c-a57e-e7f92f0694dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f144c013-49ba-4dce-bfb8-b32e3c84e4b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_e5c5d08a-5da8-461c-a57e-e7f92f0694dc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f144c013-49ba-4dce-bfb8-b32e3c84e4b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_595cae2b-a3be-4498-ac6b-ccc0e7b327d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_e5c5d08a-5da8-461c-a57e-e7f92f0694dc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_595cae2b-a3be-4498-ac6b-ccc0e7b327d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2fa3ddec-08fe-4b4d-b792-49c9fd753fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_e5c5d08a-5da8-461c-a57e-e7f92f0694dc" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2fa3ddec-08fe-4b4d-b792-49c9fd753fbd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_83a6ef8a-84bd-4d8a-9cc5-8499894ba059" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2fa3ddec-08fe-4b4d-b792-49c9fd753fbd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_83a6ef8a-84bd-4d8a-9cc5-8499894ba059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_83a6ef8a-84bd-4d8a-9cc5-8499894ba059_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_83a6ef8a-84bd-4d8a-9cc5-8499894ba059" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_83a6ef8a-84bd-4d8a-9cc5-8499894ba059_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8db3b21a-851b-4f85-a364-10684332e5fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_83a6ef8a-84bd-4d8a-9cc5-8499894ba059" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8db3b21a-851b-4f85-a364-10684332e5fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6f5a304e-7800-466c-9b62-3a9e51053678" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8db3b21a-851b-4f85-a364-10684332e5fd" xlink:to="loc_us-gaap_CommercialPaperMember_6f5a304e-7800-466c-9b62-3a9e51053678" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3e53229f-180d-4709-8e6a-a8aa2ed90a40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8db3b21a-851b-4f85-a364-10684332e5fd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3e53229f-180d-4709-8e6a-a8aa2ed90a40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_38495b46-9738-4433-8072-a0916a49b7d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8db3b21a-851b-4f85-a364-10684332e5fd" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_38495b46-9738-4433-8072-a0916a49b7d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e0248022-6dd3-4caf-953c-6b4416c5e292" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_03bd0dcb-61ba-48d7-82b2-d8bd0a84cd02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e0248022-6dd3-4caf-953c-6b4416c5e292" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_03bd0dcb-61ba-48d7-82b2-d8bd0a84cd02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_411f343a-9d19-4464-acd8-9fd3cd5eccd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e0248022-6dd3-4caf-953c-6b4416c5e292" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_411f343a-9d19-4464-acd8-9fd3cd5eccd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_994998e3-00ad-4ee4-bb33-675a4faeb280" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e0248022-6dd3-4caf-953c-6b4416c5e292" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_994998e3-00ad-4ee4-bb33-675a4faeb280" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e0e15d7c-38cd-4e62-8209-a152c32b3056" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e0248022-6dd3-4caf-953c-6b4416c5e292" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e0e15d7c-38cd-4e62-8209-a152c32b3056" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_295a2f15-65a1-459b-91f0-aeafede9b605" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e0248022-6dd3-4caf-953c-6b4416c5e292" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_295a2f15-65a1-459b-91f0-aeafede9b605" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0c475b97-b488-4728-9650-05066d6d903e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_295a2f15-65a1-459b-91f0-aeafede9b605" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0c475b97-b488-4728-9650-05066d6d903e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c475b97-b488-4728-9650-05066d6d903e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0c475b97-b488-4728-9650-05066d6d903e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c475b97-b488-4728-9650-05066d6d903e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c88b1d7c-cb38-4367-b1d6-1f794841465b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0c475b97-b488-4728-9650-05066d6d903e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c88b1d7c-cb38-4367-b1d6-1f794841465b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_29431661-c219-45eb-a3b0-7343dafc85c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c88b1d7c-cb38-4367-b1d6-1f794841465b" xlink:to="loc_us-gaap_CommercialPaperMember_29431661-c219-45eb-a3b0-7343dafc85c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_816ee23e-7a5e-4da0-a9c6-800cd9915dec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c88b1d7c-cb38-4367-b1d6-1f794841465b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_816ee23e-7a5e-4da0-a9c6-800cd9915dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2288c25c-fc27-458d-ba17-9050d763be7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c88b1d7c-cb38-4367-b1d6-1f794841465b" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2288c25c-fc27-458d-ba17-9050d763be7c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="arqt-20200331.xsd#BalanceSheetComponents"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/BalanceSheetComponents" xlink:type="extended" id="i4dd7e11e4fd744c58cb540065f6fa73b_BalanceSheetComponents"/>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#BalanceSheetComponentsTables"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/BalanceSheetComponentsTables" xlink:type="extended" id="i57b5349f386848c3a1ee71160ed7a472_BalanceSheetComponentsTables"/>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended" id="i88db2c9ed76542ddaef4212f00f88556_BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended" id="ie530ea952ec74e6c9670b031662d4431_BalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreements" xlink:type="simple" xlink:href="arqt-20200331.xsd#LicenseAgreements"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/LicenseAgreements" xlink:type="extended" id="i3181b8eac1fb446a82564ffeabb291d1_LicenseAgreements"/>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#LicenseAgreementsAstraZenecaDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails" xlink:type="extended" id="i352b30057c604ef2b0bd57e4e1b3cf92_LicenseAgreementsAstraZenecaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_dc8224ea-c6b5-4ad8-9b46-891fb16d8eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_a52900b9-bea8-4c2c-9e4d-22d2f320d6a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_dc8224ea-c6b5-4ad8-9b46-891fb16d8eeb" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_a52900b9-bea8-4c2c-9e4d-22d2f320d6a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c69b24a7-d491-486a-9498-bf9a1658820b" xlink:href="arqt-20200331.xsd#arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_dc8224ea-c6b5-4ad8-9b46-891fb16d8eeb" xlink:to="loc_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c69b24a7-d491-486a-9498-bf9a1658820b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_4cd15573-e605-43ce-9339-2a4dfd286fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_dc8224ea-c6b5-4ad8-9b46-891fb16d8eeb" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_4cd15573-e605-43ce-9339-2a4dfd286fb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments_753b1688-5791-4bf5-8495-c025f1a9f363" xlink:href="arqt-20200331.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_dc8224ea-c6b5-4ad8-9b46-891fb16d8eeb" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments_753b1688-5791-4bf5-8495-c025f1a9f363" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_0644d9bd-9d79-40c2-9b30-b7f8fbee38ef" xlink:href="arqt-20200331.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_dc8224ea-c6b5-4ad8-9b46-891fb16d8eeb" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_0644d9bd-9d79-40c2-9b30-b7f8fbee38ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_69561fd2-5c93-44e5-a350-03c2af7462ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_dc8224ea-c6b5-4ad8-9b46-891fb16d8eeb" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_69561fd2-5c93-44e5-a350-03c2af7462ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cda3de63-57ca-4165-8ebb-94a43e55438e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_69561fd2-5c93-44e5-a350-03c2af7462ca" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cda3de63-57ca-4165-8ebb-94a43e55438e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cda3de63-57ca-4165-8ebb-94a43e55438e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cda3de63-57ca-4165-8ebb-94a43e55438e" xlink:to="loc_us-gaap_ClassOfStockDomain_cda3de63-57ca-4165-8ebb-94a43e55438e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_87f6af91-7372-4cf6-ad1d-ab9b28426871" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cda3de63-57ca-4165-8ebb-94a43e55438e" xlink:to="loc_us-gaap_ClassOfStockDomain_87f6af91-7372-4cf6-ad1d-ab9b28426871" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_d7bf6398-cedf-46be-8029-bf931184b667" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_87f6af91-7372-4cf6-ad1d-ab9b28426871" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_d7bf6398-cedf-46be-8029-bf931184b667" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1ee5190d-623d-44ad-bbc9-d66ced95600a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_69561fd2-5c93-44e5-a350-03c2af7462ca" xlink:to="loc_srt_CounterpartyNameAxis_1ee5190d-623d-44ad-bbc9-d66ced95600a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ee5190d-623d-44ad-bbc9-d66ced95600a_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1ee5190d-623d-44ad-bbc9-d66ced95600a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ee5190d-623d-44ad-bbc9-d66ced95600a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_417e5fc1-4e9f-4775-a56f-206f503c09f8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1ee5190d-623d-44ad-bbc9-d66ced95600a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_417e5fc1-4e9f-4775-a56f-206f503c09f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AstraZenecaMember_cd6313ff-18cb-4534-af04-de21f1995bf2" xlink:href="arqt-20200331.xsd#arqt_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_417e5fc1-4e9f-4775-a56f-206f503c09f8" xlink:to="loc_arqt_AstraZenecaMember_cd6313ff-18cb-4534-af04-de21f1995bf2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsHengruiDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#LicenseAgreementsHengruiDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/LicenseAgreementsHengruiDetails" xlink:type="extended" id="if1f17150f1804292b4e4ecb54cabf552_LicenseAgreementsHengruiDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6dd7a947-af96-4eca-839b-c3beb2d3d856" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_aacfe86d-31f5-447b-b4f2-4f8240a012c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6dd7a947-af96-4eca-839b-c3beb2d3d856" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_aacfe86d-31f5-447b-b4f2-4f8240a012c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments_8fb857f4-3ece-4842-bd66-b489cea696d5" xlink:href="arqt-20200331.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6dd7a947-af96-4eca-839b-c3beb2d3d856" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments_8fb857f4-3ece-4842-bd66-b489cea696d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_22f61a1e-4073-4e31-9d7f-86a57ee3c587" xlink:href="arqt-20200331.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6dd7a947-af96-4eca-839b-c3beb2d3d856" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_22f61a1e-4073-4e31-9d7f-86a57ee3c587" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_90a6b186-3ffb-43ef-8e4c-f5bf7335a22d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6dd7a947-af96-4eca-839b-c3beb2d3d856" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_90a6b186-3ffb-43ef-8e4c-f5bf7335a22d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9f8bd2cb-403c-45b7-8df9-c3a812f527e0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_90a6b186-3ffb-43ef-8e4c-f5bf7335a22d" xlink:to="loc_srt_CounterpartyNameAxis_9f8bd2cb-403c-45b7-8df9-c3a812f527e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f8bd2cb-403c-45b7-8df9-c3a812f527e0_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9f8bd2cb-403c-45b7-8df9-c3a812f527e0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f8bd2cb-403c-45b7-8df9-c3a812f527e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_12bd3fa3-c0a4-4432-a96d-fbf475269517" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9f8bd2cb-403c-45b7-8df9-c3a812f527e0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_12bd3fa3-c0a4-4432-a96d-fbf475269517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_HengruiMember_bd4083c7-cfa4-4fce-85c2-8186b6483479" xlink:href="arqt-20200331.xsd#arqt_HengruiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_12bd3fa3-c0a4-4432-a96d-fbf475269517" xlink:to="loc_arqt_HengruiMember_bd4083c7-cfa4-4fce-85c2-8186b6483479" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsHawkeyeDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#LicenseAgreementsHawkeyeDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/LicenseAgreementsHawkeyeDetails" xlink:type="extended" id="ib8c95d9abf5f4a5aafb5893a19c8dae7_LicenseAgreementsHawkeyeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_98de0aca-6ad7-439e-8e22-82e902189efc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_VariableInterestEntitiesNumberOfSharesHeld_d94c2ef7-3690-4c67-af35-5da154573210" xlink:href="arqt-20200331.xsd#arqt_VariableInterestEntitiesNumberOfSharesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_98de0aca-6ad7-439e-8e22-82e902189efc" xlink:to="loc_arqt_VariableInterestEntitiesNumberOfSharesHeld_d94c2ef7-3690-4c67-af35-5da154573210" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_32066422-29ff-460b-92a9-ad5c0cf8e2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_98de0aca-6ad7-439e-8e22-82e902189efc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_32066422-29ff-460b-92a9-ad5c0cf8e2c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_79de063d-b97e-44b5-bf0b-33a5dc5761a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_98de0aca-6ad7-439e-8e22-82e902189efc" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_79de063d-b97e-44b5-bf0b-33a5dc5761a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration_8cf29dad-fa2c-45a8-8fee-21d3b3491834" xlink:href="arqt-20200331.xsd#arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_98de0aca-6ad7-439e-8e22-82e902189efc" xlink:to="loc_arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration_8cf29dad-fa2c-45a8-8fee-21d3b3491834" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration_90f7ac8e-f0cd-4866-a23c-2873f36ea6fd" xlink:href="arqt-20200331.xsd#arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_98de0aca-6ad7-439e-8e22-82e902189efc" xlink:to="loc_arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration_90f7ac8e-f0cd-4866-a23c-2873f36ea6fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties_829254f7-bda4-4bd9-b446-beb5f25bd78a" xlink:href="arqt-20200331.xsd#arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_98de0aca-6ad7-439e-8e22-82e902189efc" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties_829254f7-bda4-4bd9-b446-beb5f25bd78a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a8e60e65-768a-4a93-9f4c-d0e90112b4ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_98de0aca-6ad7-439e-8e22-82e902189efc" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a8e60e65-768a-4a93-9f4c-d0e90112b4ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d91a5e37-dbe6-4591-8849-97de98348596" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a8e60e65-768a-4a93-9f4c-d0e90112b4ef" xlink:to="loc_dei_LegalEntityAxis_d91a5e37-dbe6-4591-8849-97de98348596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d91a5e37-dbe6-4591-8849-97de98348596_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d91a5e37-dbe6-4591-8849-97de98348596" xlink:to="loc_dei_EntityDomain_d91a5e37-dbe6-4591-8849-97de98348596_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c98bd814-12d9-433b-84bf-f7e266d8959d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d91a5e37-dbe6-4591-8849-97de98348596" xlink:to="loc_dei_EntityDomain_c98bd814-12d9-433b-84bf-f7e266d8959d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_HawkeyeMember_8fe6f416-22e3-4860-9e5e-c8fe12e7fb6f" xlink:href="arqt-20200331.xsd#arqt_HawkeyeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c98bd814-12d9-433b-84bf-f7e266d8959d" xlink:to="loc_arqt_HawkeyeMember_8fe6f416-22e3-4860-9e5e-c8fe12e7fb6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_105591ed-d10c-4b07-b4c0-f85b9c5d1824" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a8e60e65-768a-4a93-9f4c-d0e90112b4ef" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_105591ed-d10c-4b07-b4c0-f85b9c5d1824" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_105591ed-d10c-4b07-b4c0-f85b9c5d1824_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_105591ed-d10c-4b07-b4c0-f85b9c5d1824" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_105591ed-d10c-4b07-b4c0-f85b9c5d1824_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_6fe3f646-b2bb-44fe-ad50-6eec9c44472d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_105591ed-d10c-4b07-b4c0-f85b9c5d1824" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_6fe3f646-b2bb-44fe-ad50-6eec9c44472d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_1af3ee12-1820-4fba-a24a-d9d19f56c3b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_6fe3f646-b2bb-44fe-ad50-6eec9c44472d" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_1af3ee12-1820-4fba-a24a-d9d19f56c3b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_40f73396-a520-42d2-b185-047cb05c6416" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a8e60e65-768a-4a93-9f4c-d0e90112b4ef" xlink:to="loc_srt_CounterpartyNameAxis_40f73396-a520-42d2-b185-047cb05c6416" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_40f73396-a520-42d2-b185-047cb05c6416_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_40f73396-a520-42d2-b185-047cb05c6416" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_40f73396-a520-42d2-b185-047cb05c6416_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e4df0c7-2c35-4364-9bfb-0c71891174d9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_40f73396-a520-42d2-b185-047cb05c6416" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e4df0c7-2c35-4364-9bfb-0c71891174d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_HawkeyeMember_48bf5d65-6a0c-4157-b1d0-eb67178c1fed" xlink:href="arqt-20200331.xsd#arqt_HawkeyeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e4df0c7-2c35-4364-9bfb-0c71891174d9" xlink:to="loc_arqt_HawkeyeMember_48bf5d65-6a0c-4157-b1d0-eb67178c1fed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/CommitmentsandContingencies" xlink:type="extended" id="i8c1e861118a94596bd9a6155becf4b61_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="iaad60b355546438d8b8b2efbeb91a001_CommitmentsandContingenciesTables"/>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="iec90cf071b074127b50d71f5bb7eedcb_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f893400d-5d30-4dab-851e-29fd47036fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeasesNumberFacilitiesLeased_7bcf7cf6-b150-443a-b70a-c8698620be7c" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeasesNumberFacilitiesLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f893400d-5d30-4dab-851e-29fd47036fbf" xlink:to="loc_arqt_LesseeOperatingLeasesNumberFacilitiesLeased_7bcf7cf6-b150-443a-b70a-c8698620be7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5c64bccb-ef16-4764-afcd-ac1d6a426cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f893400d-5d30-4dab-851e-29fd47036fbf" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5c64bccb-ef16-4764-afcd-ac1d6a426cdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_a40c679e-422f-461d-ab69-0667d5003db6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f893400d-5d30-4dab-851e-29fd47036fbf" xlink:to="loc_us-gaap_OperatingLeaseExpense_a40c679e-422f-461d-ab69-0667d5003db6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_67a70e62-3f27-4521-a62e-ead2471c67c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f893400d-5d30-4dab-851e-29fd47036fbf" xlink:to="loc_us-gaap_VariableLeaseCost_67a70e62-3f27-4521-a62e-ead2471c67c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7351f8ac-3f61-4d0b-b07a-9dbbc978013f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f893400d-5d30-4dab-851e-29fd47036fbf" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7351f8ac-3f61-4d0b-b07a-9dbbc978013f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eadc08e3-d5c6-470f-bbc6-acb75f0c5542" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7351f8ac-3f61-4d0b-b07a-9dbbc978013f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eadc08e3-d5c6-470f-bbc6-acb75f0c5542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eadc08e3-d5c6-470f-bbc6-acb75f0c5542_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eadc08e3-d5c6-470f-bbc6-acb75f0c5542" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eadc08e3-d5c6-470f-bbc6-acb75f0c5542_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a5f9235d-c4dd-4f86-bb86-ff178faf52b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eadc08e3-d5c6-470f-bbc6-acb75f0c5542" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a5f9235d-c4dd-4f86-bb86-ff178faf52b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_a31f60b1-8254-4d7b-bd6e-6a0c9ceed07f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a5f9235d-c4dd-4f86-bb86-ff178faf52b8" xlink:to="loc_us-gaap_BuildingMember_a31f60b1-8254-4d7b-bd6e-6a0c9ceed07f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentsandContingenciesOperatingLeasePaymentsDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails" xlink:type="extended" id="i233826e6c7b94186ac896e4c45bffbb3_CommitmentsandContingenciesOperatingLeasePaymentsDetails"/>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails" xlink:type="extended" id="ia1429a10a06d4e9d85c8e0f1afc7d304_CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails"/>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentandContingenciesOperatingLeaseAdditionalInformationDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentandContingenciesOperatingLeaseAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/CommitmentandContingenciesOperatingLeaseAdditionalInformationDetails" xlink:type="extended" id="i9f2aaa58a25c4fa5ae4967ddbfa18e24_CommitmentandContingenciesOperatingLeaseAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="arqt-20200331.xsd#ConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended" id="i402ed2a26d064dafb66570ec231424cf_ConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:roleRef roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#ConvertiblePreferredStockandStockholdersEquityDeficitTables"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitTables" xlink:type="extended" id="i6e1f964e9b2a4ebbb7f391d529480c35_ConvertiblePreferredStockandStockholdersEquityDeficitTables"/>
  <link:roleRef roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails" xlink:type="extended" id="i3217dc2fef3d4116a0ba6a07dbe27bbe_ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_7478f610-be88-4bcc-8e01-b1fbd7c3b531" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_bfa03131-cf80-41f0-bddf-2504421abab7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7478f610-be88-4bcc-8e01-b1fbd7c3b531" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_bfa03131-cf80-41f0-bddf-2504421abab7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_0feb097e-170e-427b-a52c-19f154348b72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7478f610-be88-4bcc-8e01-b1fbd7c3b531" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_0feb097e-170e-427b-a52c-19f154348b72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_38302dee-06d1-4db3-8125-a0671eff6fec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7478f610-be88-4bcc-8e01-b1fbd7c3b531" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_38302dee-06d1-4db3-8125-a0671eff6fec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4b41eb76-33d8-4c1e-9818-9eb45eb78e1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7478f610-be88-4bcc-8e01-b1fbd7c3b531" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4b41eb76-33d8-4c1e-9818-9eb45eb78e1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_26855445-4c6f-49a6-b162-0861f53d064d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7478f610-be88-4bcc-8e01-b1fbd7c3b531" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_26855445-4c6f-49a6-b162-0861f53d064d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_133812ba-df58-42df-889d-4434c38f694c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7478f610-be88-4bcc-8e01-b1fbd7c3b531" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_133812ba-df58-42df-889d-4434c38f694c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4c543478-d796-44b1-9b90-5f6191ffcafd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_133812ba-df58-42df-889d-4434c38f694c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4c543478-d796-44b1-9b90-5f6191ffcafd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4c543478-d796-44b1-9b90-5f6191ffcafd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4c543478-d796-44b1-9b90-5f6191ffcafd" xlink:to="loc_us-gaap_ClassOfStockDomain_4c543478-d796-44b1-9b90-5f6191ffcafd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5da8b1a1-66ec-45fe-a1b9-4f44d743f4c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4c543478-d796-44b1-9b90-5f6191ffcafd" xlink:to="loc_us-gaap_ClassOfStockDomain_5da8b1a1-66ec-45fe-a1b9-4f44d743f4c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_529bbef8-05f8-4f90-b7dd-7fda8bd54a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5da8b1a1-66ec-45fe-a1b9-4f44d743f4c0" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_529bbef8-05f8-4f90-b7dd-7fda8bd54a1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1c29eef5-781f-4e0e-89f1-3619989231c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5da8b1a1-66ec-45fe-a1b9-4f44d743f4c0" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1c29eef5-781f-4e0e-89f1-3619989231c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_7410f1b6-7177-4ef1-92a9-91ee3e243a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5da8b1a1-66ec-45fe-a1b9-4f44d743f4c0" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_7410f1b6-7177-4ef1-92a9-91ee3e243a5d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#ConvertiblePreferredStockandStockholdersEquityDeficitDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails" xlink:type="extended" id="i8cd7e4d20e8f4c70aeb3be1f3246c629_ConvertiblePreferredStockandStockholdersEquityDeficitDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_cf81ebc3-095f-436d-b3ad-d9e54e41a289" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_cf81ebc3-095f-436d-b3ad-d9e54e41a289" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c38ce7b2-e9fb-43d0-8097-36faa5ea7229" xlink:href="arqt-20200331.xsd#arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c38ce7b2-e9fb-43d0-8097-36faa5ea7229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare_b6f35939-571b-427e-a022-cf456ec2a294" xlink:href="arqt-20200331.xsd#arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare_b6f35939-571b-427e-a022-cf456ec2a294" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_f1151763-4eba-48ee-9d83-74247357957e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_f1151763-4eba-48ee-9d83-74247357957e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementNumberOfSharesIssuable_82be54ec-37e8-4e43-82b4-059c90d7e623" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementNumberOfSharesIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_arqt_StockPurchaseAgreementNumberOfSharesIssuable_82be54ec-37e8-4e43-82b4-059c90d7e623" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_84c4281a-6c9f-4587-9444-b0c855fe71d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_84c4281a-6c9f-4587-9444-b0c855fe71d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementPricePerShare_13ddfaa9-71c1-4056-94c9-9a4339229ef8" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_arqt_StockPurchaseAgreementPricePerShare_13ddfaa9-71c1-4056-94c9-9a4339229ef8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementNumberOfTranches_30ae2452-4a85-4f66-92ab-5d30526899e8" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_arqt_StockPurchaseAgreementNumberOfTranches_30ae2452-4a85-4f66-92ab-5d30526899e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cf16849e-9283-4073-9217-171a3f3bdafb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cf16849e-9283-4073-9217-171a3f3bdafb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f68a4e60-0aec-4952-aecb-fd9286e04091" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f68a4e60-0aec-4952-aecb-fd9286e04091" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_bc35fffc-0f20-4344-a098-f742710338a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_DerivativeLiabilities_bc35fffc-0f20-4344-a098-f742710338a1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CommonStockVotingRightsNumberOfVotesPerShare_b2402e61-ac4a-4de0-93b6-ebcbfde3677a" xlink:href="arqt-20200331.xsd#arqt_CommonStockVotingRightsNumberOfVotesPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_arqt_CommonStockVotingRightsNumberOfVotesPerShare_b2402e61-ac4a-4de0-93b6-ebcbfde3677a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e678e759-6faf-41d8-8d6c-3ee01e4a5cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e678e759-6faf-41d8-8d6c-3ee01e4a5cf6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_592823ae-3c33-487c-a4d6-26b0329ce9cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_592823ae-3c33-487c-a4d6-26b0329ce9cd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_b51de963-80f5-41a0-b22e-689523a62c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_b51de963-80f5-41a0-b22e-689523a62c0b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_0ab76573-8c89-4faf-80ee-c75ce96bdc2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_0ab76573-8c89-4faf-80ee-c75ce96bdc2f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3a2f42a6-61b9-4fb4-936d-a5f2d13ab1d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3a2f42a6-61b9-4fb4-936d-a5f2d13ab1d6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_688e4ccd-619e-4783-b199-0e55888383ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_688e4ccd-619e-4783-b199-0e55888383ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_71143d6d-9b7d-48c8-a309-6cdb6987a2d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_688e4ccd-619e-4783-b199-0e55888383ae" xlink:to="loc_us-gaap_StatementClassOfStockAxis_71143d6d-9b7d-48c8-a309-6cdb6987a2d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_71143d6d-9b7d-48c8-a309-6cdb6987a2d3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_71143d6d-9b7d-48c8-a309-6cdb6987a2d3" xlink:to="loc_us-gaap_ClassOfStockDomain_71143d6d-9b7d-48c8-a309-6cdb6987a2d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_26b4c039-2a3b-4678-b2e4-36c073e66a52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_71143d6d-9b7d-48c8-a309-6cdb6987a2d3" xlink:to="loc_us-gaap_ClassOfStockDomain_26b4c039-2a3b-4678-b2e4-36c073e66a52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_c1675459-ef37-4a7e-a088-31507a01a766" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_26b4c039-2a3b-4678-b2e4-36c073e66a52" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_c1675459-ef37-4a7e-a088-31507a01a766" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_b0d867ca-8ecc-4586-93eb-2d081e7342dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_26b4c039-2a3b-4678-b2e4-36c073e66a52" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_b0d867ca-8ecc-4586-93eb-2d081e7342dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5622cddb-6e0e-4972-9629-e316017e2465" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_26b4c039-2a3b-4678-b2e4-36c073e66a52" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5622cddb-6e0e-4972-9629-e316017e2465" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a34d5b69-6554-4a90-a8c3-c0f01b7572a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_688e4ccd-619e-4783-b199-0e55888383ae" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a34d5b69-6554-4a90-a8c3-c0f01b7572a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a34d5b69-6554-4a90-a8c3-c0f01b7572a5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a34d5b69-6554-4a90-a8c3-c0f01b7572a5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a34d5b69-6554-4a90-a8c3-c0f01b7572a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de70091e-728a-4a9c-9a44-2619ff555054" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a34d5b69-6554-4a90-a8c3-c0f01b7572a5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de70091e-728a-4a9c-9a44-2619ff555054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementTrancheOneMember_c50e9f7e-cd76-43fc-9d23-c270f747d179" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de70091e-728a-4a9c-9a44-2619ff555054" xlink:to="loc_arqt_StockPurchaseAgreementTrancheOneMember_c50e9f7e-cd76-43fc-9d23-c270f747d179" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementTrancheTwoMember_ec6c0582-6db0-49d0-ad31-4af8dbb006ba" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de70091e-728a-4a9c-9a44-2619ff555054" xlink:to="loc_arqt_StockPurchaseAgreementTrancheTwoMember_ec6c0582-6db0-49d0-ad31-4af8dbb006ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementTrancheThreeMember_66f03421-e3f5-4f81-bc73-3e0fa7615142" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de70091e-728a-4a9c-9a44-2619ff555054" xlink:to="loc_arqt_StockPurchaseAgreementTrancheThreeMember_66f03421-e3f5-4f81-bc73-3e0fa7615142" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementTranchesTwoAndThreeMember_9294dc3e-9acb-466b-a010-edc872ecb03e" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementTranchesTwoAndThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de70091e-728a-4a9c-9a44-2619ff555054" xlink:to="loc_arqt_StockPurchaseAgreementTranchesTwoAndThreeMember_9294dc3e-9acb-466b-a010-edc872ecb03e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f9245f6a-9bc0-4f3d-b8dd-1d301f22307e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_688e4ccd-619e-4783-b199-0e55888383ae" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f9245f6a-9bc0-4f3d-b8dd-1d301f22307e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f9245f6a-9bc0-4f3d-b8dd-1d301f22307e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f9245f6a-9bc0-4f3d-b8dd-1d301f22307e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f9245f6a-9bc0-4f3d-b8dd-1d301f22307e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a4554e66-385c-4e76-b589-c057b5a61664" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f9245f6a-9bc0-4f3d-b8dd-1d301f22307e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a4554e66-385c-4e76-b589-c057b5a61664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_2c7d26f3-de69-4460-b7d7-419614aae452" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a4554e66-385c-4e76-b589-c057b5a61664" xlink:to="loc_us-gaap_ConvertibleDebtMember_2c7d26f3-de69-4460-b7d7-419614aae452" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5927b54e-c8c8-4499-b0cf-6cbc4a1a1bad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_688e4ccd-619e-4783-b199-0e55888383ae" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5927b54e-c8c8-4499-b0cf-6cbc4a1a1bad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5927b54e-c8c8-4499-b0cf-6cbc4a1a1bad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5927b54e-c8c8-4499-b0cf-6cbc4a1a1bad" xlink:to="loc_us-gaap_EquityComponentDomain_5927b54e-c8c8-4499-b0cf-6cbc4a1a1bad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d478cf9e-4100-401c-a0a7-470799c4c3e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5927b54e-c8c8-4499-b0cf-6cbc4a1a1bad" xlink:to="loc_us-gaap_EquityComponentDomain_d478cf9e-4100-401c-a0a7-470799c4c3e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_acf9c3e9-45dc-47ca-9c1b-09ed0e989009" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d478cf9e-4100-401c-a0a7-470799c4c3e2" xlink:to="loc_us-gaap_CommonStockMember_acf9c3e9-45dc-47ca-9c1b-09ed0e989009" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails" xlink:type="extended" id="ide3d47fd787c46229f504d8bb57f3713_ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ef6e19fa-551f-4afe-a26c-375869d8e444" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_93309d78-a01e-4728-9b5a-585057a65c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ef6e19fa-551f-4afe-a26c-375869d8e444" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_93309d78-a01e-4728-9b5a-585057a65c3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c7c15086-0e62-4c6f-bf37-9378d80b869c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_ef6e19fa-551f-4afe-a26c-375869d8e444" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c7c15086-0e62-4c6f-bf37-9378d80b869c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6c0b56c5-6742-4304-8c2e-b198addf4be2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c7c15086-0e62-4c6f-bf37-9378d80b869c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6c0b56c5-6742-4304-8c2e-b198addf4be2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6c0b56c5-6742-4304-8c2e-b198addf4be2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6c0b56c5-6742-4304-8c2e-b198addf4be2" xlink:to="loc_us-gaap_ClassOfStockDomain_6c0b56c5-6742-4304-8c2e-b198addf4be2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6462c2c4-dd18-4c41-9d3f-9518e658950e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6c0b56c5-6742-4304-8c2e-b198addf4be2" xlink:to="loc_us-gaap_ClassOfStockDomain_6462c2c4-dd18-4c41-9d3f-9518e658950e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_507d67f6-05fc-4c5f-9984-5d0648df64e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6462c2c4-dd18-4c41-9d3f-9518e658950e" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_507d67f6-05fc-4c5f-9984-5d0648df64e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0cebe457-2432-402c-a0ef-a5aa5ae634cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c7c15086-0e62-4c6f-bf37-9378d80b869c" xlink:to="loc_us-gaap_AwardTypeAxis_0cebe457-2432-402c-a0ef-a5aa5ae634cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0cebe457-2432-402c-a0ef-a5aa5ae634cf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0cebe457-2432-402c-a0ef-a5aa5ae634cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0cebe457-2432-402c-a0ef-a5aa5ae634cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75fc5c9a-22b6-40d0-9637-438e84c7d11d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0cebe457-2432-402c-a0ef-a5aa5ae634cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75fc5c9a-22b6-40d0-9637-438e84c7d11d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockOptionsIssuedAndOutstandingMember_15e58359-606a-4e37-a9bd-3f42f817a321" xlink:href="arqt-20200331.xsd#arqt_StockOptionsIssuedAndOutstandingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75fc5c9a-22b6-40d0-9637-438e84c7d11d" xlink:to="loc_arqt_StockOptionsIssuedAndOutstandingMember_15e58359-606a-4e37-a9bd-3f42f817a321" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockAwardsFutureGrantMember_8df7a7c9-45ea-41e5-9bc1-f13c95e91023" xlink:href="arqt-20200331.xsd#arqt_StockAwardsFutureGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75fc5c9a-22b6-40d0-9637-438e84c7d11d" xlink:to="loc_arqt_StockAwardsFutureGrantMember_8df7a7c9-45ea-41e5-9bc1-f13c95e91023" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0d568e1a-e728-4b31-b95c-f16129962c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75fc5c9a-22b6-40d0-9637-438e84c7d11d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0d568e1a-e728-4b31-b95c-f16129962c3e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/StockBasedCompensation" xlink:type="extended" id="iacb512ed5d164e7e8ea2d3a5413bf7f8_StockBasedCompensation"/>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/StockBasedCompensationTables" xlink:type="extended" id="i0e14108c504942cba51cc67993342b79_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/StockBasedCompensationDetails" xlink:type="extended" id="i93879feb30634d818c700aaa5cc3ef00_StockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7e733f54-f6c2-4177-bd47-78e6b0739df7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7e733f54-f6c2-4177-bd47-78e6b0739df7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_4d68658e-a8ce-499c-ab23-c53b34a211ed" xlink:href="arqt-20200331.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_4d68658e-a8ce-499c-ab23-c53b34a211ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable_8b1b6b20-a4f5-4127-90e0-0e7215b7e1d3" xlink:href="arqt-20200331.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable_8b1b6b20-a4f5-4127-90e0-0e7215b7e1d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0c26071f-c1bd-42bb-85b3-e455be51abfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0c26071f-c1bd-42bb-85b3-e455be51abfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2a457efe-093b-48e7-8fd1-ccd76d9694ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2a457efe-093b-48e7-8fd1-ccd76d9694ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_525eccbf-81bb-4101-a757-b744c3140903" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_525eccbf-81bb-4101-a757-b744c3140903" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2bdd594a-3856-4e1c-b962-fcad2378e6be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2bdd594a-3856-4e1c-b962-fcad2378e6be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bceb77da-c1f4-4e0c-a2dc-a1df5dfa157a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bceb77da-c1f4-4e0c-a2dc-a1df5dfa157a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c9d362c3-3137-4355-bc7b-752020402626" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_96889e80-611c-4570-a98b-61eae085acdc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_96889e80-611c-4570-a98b-61eae085acdc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dbaf0d48-34e9-4f64-ba55-9d0ab20d3156" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dbaf0d48-34e9-4f64-ba55-9d0ab20d3156" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_19eb3bba-32fe-4336-84fe-72df3aad439c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_19eb3bba-32fe-4336-84fe-72df3aad439c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_13981028-c7b3-477c-b8ee-e17ebabb39b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_13981028-c7b3-477c-b8ee-e17ebabb39b6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_f12427fc-5113-4012-b4c2-f677336b0a45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_f12427fc-5113-4012-b4c2-f677336b0a45" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_d83613cb-3586-43f6-8d77-9664418fd44a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_d83613cb-3586-43f6-8d77-9664418fd44a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_233a5459-bf61-46b5-8db8-90c500712dce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_233a5459-bf61-46b5-8db8-90c500712dce" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f00c2906-0716-4776-99ab-c09959a47956" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f00c2906-0716-4776-99ab-c09959a47956" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis_402af94e-8a87-44b4-9bd6-f2f3d733d673" xlink:href="arqt-20200331.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis_402af94e-8a87-44b4-9bd6-f2f3d733d673" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e8dcce5-0ab1-488d-8e74-a986d487a925" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e8dcce5-0ab1-488d-8e74-a986d487a925" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f74ae458-254e-4ff1-91ab-d5b01ce4e891" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f74ae458-254e-4ff1-91ab-d5b01ce4e891" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_442369e2-e4c2-4064-8bb0-8cd6bd56a647" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_442369e2-e4c2-4064-8bb0-8cd6bd56a647" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized_8c756003-664a-43e8-9a49-a9daea8c5293" xlink:href="arqt-20200331.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized_8c756003-664a-43e8-9a49-a9daea8c5293" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_cc76f9bf-3677-4b16-aa0c-4d2f2ba16df1" xlink:href="arqt-20200331.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_62b84e53-e5f4-4f3b-b227-a58a92c353a5" xlink:href="arqt-20200331.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_62b84e53-e5f4-4f3b-b227-a58a92c353a5" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516b8e66-9a40-47d9-ae12-108f04181a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516b8e66-9a40-47d9-ae12-108f04181a3a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6cea9f28-2e1d-4283-b573-5992fb05c41c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516b8e66-9a40-47d9-ae12-108f04181a3a" xlink:to="loc_us-gaap_PlanNameAxis_6cea9f28-2e1d-4283-b573-5992fb05c41c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6cea9f28-2e1d-4283-b573-5992fb05c41c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6cea9f28-2e1d-4283-b573-5992fb05c41c" xlink:to="loc_us-gaap_PlanNameDomain_6cea9f28-2e1d-4283-b573-5992fb05c41c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c143f780-dd4d-42d4-879e-fe5f4c192f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6cea9f28-2e1d-4283-b573-5992fb05c41c" xlink:to="loc_us-gaap_PlanNameDomain_c143f780-dd4d-42d4-879e-fe5f4c192f7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_A2020EquityIncentivePlanMember_329c75d3-14c2-43f4-97ef-9185fece96d8" xlink:href="arqt-20200331.xsd#arqt_A2020EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c143f780-dd4d-42d4-879e-fe5f4c192f7c" xlink:to="loc_arqt_A2020EquityIncentivePlanMember_329c75d3-14c2-43f4-97ef-9185fece96d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_A2017EquityIncentivePlanMember_2e99026d-832d-48ca-a0c8-55e2148f89a6" xlink:href="arqt-20200331.xsd#arqt_A2017EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c143f780-dd4d-42d4-879e-fe5f4c192f7c" xlink:to="loc_arqt_A2017EquityIncentivePlanMember_2e99026d-832d-48ca-a0c8-55e2148f89a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9639ff3f-3a87-4a07-9d8f-815961494cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516b8e66-9a40-47d9-ae12-108f04181a3a" xlink:to="loc_us-gaap_AwardTypeAxis_9639ff3f-3a87-4a07-9d8f-815961494cc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9639ff3f-3a87-4a07-9d8f-815961494cc2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9639ff3f-3a87-4a07-9d8f-815961494cc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9639ff3f-3a87-4a07-9d8f-815961494cc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72dddbf-8af4-4fec-b444-d7d83e884d10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9639ff3f-3a87-4a07-9d8f-815961494cc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72dddbf-8af4-4fec-b444-d7d83e884d10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0a0e1ce2-1399-4a71-a2ed-e178d1985eb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72dddbf-8af4-4fec-b444-d7d83e884d10" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0a0e1ce2-1399-4a71-a2ed-e178d1985eb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8f5f6989-ae8d-4450-8d67-ef140fb5f0e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72dddbf-8af4-4fec-b444-d7d83e884d10" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8f5f6989-ae8d-4450-8d67-ef140fb5f0e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c18dc5a6-61eb-45dc-9590-e3d76b020a83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72dddbf-8af4-4fec-b444-d7d83e884d10" xlink:to="loc_us-gaap_RestrictedStockMember_c18dc5a6-61eb-45dc-9590-e3d76b020a83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ServiceConditionRestrictedStockMember_bc95597d-7099-408b-b8c0-9ff563c153c5" xlink:href="arqt-20200331.xsd#arqt_ServiceConditionRestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72dddbf-8af4-4fec-b444-d7d83e884d10" xlink:to="loc_arqt_ServiceConditionRestrictedStockMember_bc95597d-7099-408b-b8c0-9ff563c153c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PerformanceConditionRestrictedStockMember_359da081-25de-4bcc-9e9c-a65a323f9a13" xlink:href="arqt-20200331.xsd#arqt_PerformanceConditionRestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72dddbf-8af4-4fec-b444-d7d83e884d10" xlink:to="loc_arqt_PerformanceConditionRestrictedStockMember_359da081-25de-4bcc-9e9c-a65a323f9a13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_13195123-9834-40f4-aadf-b18cab85e06d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72dddbf-8af4-4fec-b444-d7d83e884d10" xlink:to="loc_us-gaap_EmployeeStockMember_13195123-9834-40f4-aadf-b18cab85e06d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dded327f-3f32-4ccc-8b3e-18e296800292" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516b8e66-9a40-47d9-ae12-108f04181a3a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dded327f-3f32-4ccc-8b3e-18e296800292" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dded327f-3f32-4ccc-8b3e-18e296800292_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dded327f-3f32-4ccc-8b3e-18e296800292" xlink:to="loc_us-gaap_EquityComponentDomain_dded327f-3f32-4ccc-8b3e-18e296800292_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_618522db-c107-4b12-bdb8-4fc75032e34c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dded327f-3f32-4ccc-8b3e-18e296800292" xlink:to="loc_us-gaap_EquityComponentDomain_618522db-c107-4b12-bdb8-4fc75032e34c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_96333657-cc4f-45a1-a1eb-0d9c12e015d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_618522db-c107-4b12-bdb8-4fc75032e34c" xlink:to="loc_us-gaap_CommonStockMember_96333657-cc4f-45a1-a1eb-0d9c12e015d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_5f0ae3d8-8966-40f4-965e-689637a3d3a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516b8e66-9a40-47d9-ae12-108f04181a3a" xlink:to="loc_us-gaap_VestingAxis_5f0ae3d8-8966-40f4-965e-689637a3d3a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_5f0ae3d8-8966-40f4-965e-689637a3d3a7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_5f0ae3d8-8966-40f4-965e-689637a3d3a7" xlink:to="loc_us-gaap_VestingDomain_5f0ae3d8-8966-40f4-965e-689637a3d3a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a82cb175-56d4-4a6d-b694-8417a44d0a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_5f0ae3d8-8966-40f4-965e-689637a3d3a7" xlink:to="loc_us-gaap_VestingDomain_a82cb175-56d4-4a6d-b694-8417a44d0a3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3620b963-5a48-4be1-b76a-caa485cb7111" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a82cb175-56d4-4a6d-b694-8417a44d0a3f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3620b963-5a48-4be1-b76a-caa485cb7111" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1a625c39-c669-4f99-8af3-eaf447b49ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a82cb175-56d4-4a6d-b694-8417a44d0a3f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1a625c39-c669-4f99-8af3-eaf447b49ab8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="i9da6997c3c6045128468966ed93e5a77_StockBasedCompensationStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended" id="i783174c01040447aaa32ab5e3748b50f_StockBasedCompensationRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c78c94e-1b57-41fa-a84b-17e6177bb87e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_25686660-5097-45a4-9154-c4398902e79c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c78c94e-1b57-41fa-a84b-17e6177bb87e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_25686660-5097-45a4-9154-c4398902e79c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d90132c7-6496-47cf-8780-4bb4c81faf45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_25686660-5097-45a4-9154-c4398902e79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d90132c7-6496-47cf-8780-4bb4c81faf45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fa22501b-e766-4f5f-858a-e7900f074a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_25686660-5097-45a4-9154-c4398902e79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fa22501b-e766-4f5f-858a-e7900f074a5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fe87d03e-1fbd-4eb3-b340-f60b528ea348" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_25686660-5097-45a4-9154-c4398902e79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fe87d03e-1fbd-4eb3-b340-f60b528ea348" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_734c1464-e5c0-4621-8ad0-ca42597b6aea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_25686660-5097-45a4-9154-c4398902e79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_734c1464-e5c0-4621-8ad0-ca42597b6aea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7987bf8c-6660-41de-8757-e44f88fa222c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e763772c-4e6c-42cb-b0e4-7a34185d7e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c78c94e-1b57-41fa-a84b-17e6177bb87e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e763772c-4e6c-42cb-b0e4-7a34185d7e7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_218459e7-8aee-45be-9005-794c587c7ced" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e763772c-4e6c-42cb-b0e4-7a34185d7e7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_218459e7-8aee-45be-9005-794c587c7ced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bb5df2a2-fc78-4cbf-8e43-5231d26d26af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e763772c-4e6c-42cb-b0e4-7a34185d7e7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bb5df2a2-fc78-4cbf-8e43-5231d26d26af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_f31342fa-bb8c-4075-92af-e4205d8880dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e763772c-4e6c-42cb-b0e4-7a34185d7e7b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_f31342fa-bb8c-4075-92af-e4205d8880dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f47d4038-65d6-49e6-a282-ee3d91b1c558" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e763772c-4e6c-42cb-b0e4-7a34185d7e7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f47d4038-65d6-49e6-a282-ee3d91b1c558" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a2ec7ae0-066d-4781-8d84-12907df6a8c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1440551c-8bec-49c3-b5e4-4d217fde340b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c78c94e-1b57-41fa-a84b-17e6177bb87e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1440551c-8bec-49c3-b5e4-4d217fde340b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7d838a60-3034-44c4-8959-c7fecda05b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1440551c-8bec-49c3-b5e4-4d217fde340b" xlink:to="loc_us-gaap_AwardTypeAxis_7d838a60-3034-44c4-8959-c7fecda05b2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d838a60-3034-44c4-8959-c7fecda05b2a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7d838a60-3034-44c4-8959-c7fecda05b2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d838a60-3034-44c4-8959-c7fecda05b2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a633a66f-15f7-4dda-81cc-65fb3db0bbb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7d838a60-3034-44c4-8959-c7fecda05b2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a633a66f-15f7-4dda-81cc-65fb3db0bbb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8b3d5368-cefd-4797-9b61-5bf373c00450" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a633a66f-15f7-4dda-81cc-65fb3db0bbb8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8b3d5368-cefd-4797-9b61-5bf373c00450" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="i5c6c98ca86164aa58fb9b4865550fadd_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5a11771f-eb90-4b26-a2ad-8aa5ca5dc69c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f096d712-1d21-44f4-8275-2a52c05529be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5a11771f-eb90-4b26-a2ad-8aa5ca5dc69c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f096d712-1d21-44f4-8275-2a52c05529be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a4e7561b-18df-4342-85a4-d348fdf23ae8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5a11771f-eb90-4b26-a2ad-8aa5ca5dc69c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a4e7561b-18df-4342-85a4-d348fdf23ae8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5f4e176d-7474-476e-bd9d-080fdce56425" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a4e7561b-18df-4342-85a4-d348fdf23ae8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5f4e176d-7474-476e-bd9d-080fdce56425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5f4e176d-7474-476e-bd9d-080fdce56425_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5f4e176d-7474-476e-bd9d-080fdce56425" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5f4e176d-7474-476e-bd9d-080fdce56425_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33797838-a504-49f3-8e61-b440c392a4d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5f4e176d-7474-476e-bd9d-080fdce56425" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33797838-a504-49f3-8e61-b440c392a4d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c9a878ce-198f-446d-be48-bf7806afb641" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33797838-a504-49f3-8e61-b440c392a4d9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c9a878ce-198f-446d-be48-bf7806afb641" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_57196c97-f1a8-40e7-bd62-becfcbac6d21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33797838-a504-49f3-8e61-b440c392a4d9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_57196c97-f1a8-40e7-bd62-becfcbac6d21" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails" xlink:type="extended" id="i08366dbc8b26416683e9367a9c515e1f_StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9df5764-b88b-415c-bee5-3633a322a0d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0e4d1b79-c40b-4d77-917d-c077b862828d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9df5764-b88b-415c-bee5-3633a322a0d4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0e4d1b79-c40b-4d77-917d-c077b862828d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ce528a76-cfc5-4f12-8cb6-c628e3cb67bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9df5764-b88b-415c-bee5-3633a322a0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ce528a76-cfc5-4f12-8cb6-c628e3cb67bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_60d4684f-8b24-4a49-a51e-b308b4cb711c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9df5764-b88b-415c-bee5-3633a322a0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_60d4684f-8b24-4a49-a51e-b308b4cb711c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_5da5fe65-ec24-4dc1-8e09-dd05acdae96e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9df5764-b88b-415c-bee5-3633a322a0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_5da5fe65-ec24-4dc1-8e09-dd05acdae96e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3fc96fd1-faf3-4dbe-af7c-f320b184c14f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9df5764-b88b-415c-bee5-3633a322a0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3fc96fd1-faf3-4dbe-af7c-f320b184c14f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_288d311c-78ad-4d6a-8d95-457853b08417" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9df5764-b88b-415c-bee5-3633a322a0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_288d311c-78ad-4d6a-8d95-457853b08417" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_835a996f-b0fb-429d-aaca-ab4158b00d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9df5764-b88b-415c-bee5-3633a322a0d4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_835a996f-b0fb-429d-aaca-ab4158b00d9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1847b2a6-ce7d-474f-bf9e-7e72169ba742" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_835a996f-b0fb-429d-aaca-ab4158b00d9d" xlink:to="loc_srt_RangeAxis_1847b2a6-ce7d-474f-bf9e-7e72169ba742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1847b2a6-ce7d-474f-bf9e-7e72169ba742_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1847b2a6-ce7d-474f-bf9e-7e72169ba742" xlink:to="loc_srt_RangeMember_1847b2a6-ce7d-474f-bf9e-7e72169ba742_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b3e9b141-b6ae-435f-8f58-99b5aa0facd5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1847b2a6-ce7d-474f-bf9e-7e72169ba742" xlink:to="loc_srt_RangeMember_b3e9b141-b6ae-435f-8f58-99b5aa0facd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d4802862-c5d8-402b-af4a-e95ff69b7d93" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b3e9b141-b6ae-435f-8f58-99b5aa0facd5" xlink:to="loc_srt_MinimumMember_d4802862-c5d8-402b-af4a-e95ff69b7d93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_519272aa-332c-4d4e-b981-3fa511c2d41f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b3e9b141-b6ae-435f-8f58-99b5aa0facd5" xlink:to="loc_srt_MaximumMember_519272aa-332c-4d4e-b981-3fa511c2d41f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_05b6ed50-c35e-491a-9ad7-7872c4249bef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_835a996f-b0fb-429d-aaca-ab4158b00d9d" xlink:to="loc_us-gaap_AwardTypeAxis_05b6ed50-c35e-491a-9ad7-7872c4249bef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05b6ed50-c35e-491a-9ad7-7872c4249bef_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_05b6ed50-c35e-491a-9ad7-7872c4249bef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05b6ed50-c35e-491a-9ad7-7872c4249bef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8ee887d-4aa6-46c9-9c11-8c9574e1974d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_05b6ed50-c35e-491a-9ad7-7872c4249bef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8ee887d-4aa6-46c9-9c11-8c9574e1974d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0315c7de-d5d3-4d12-b84b-0fa3577b9c68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8ee887d-4aa6-46c9-9c11-8c9574e1974d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0315c7de-d5d3-4d12-b84b-0fa3577b9c68" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/NetLossPerShare" xlink:type="simple" xlink:href="arqt-20200331.xsd#NetLossPerShare"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/NetLossPerShare" xlink:type="extended" id="i406ae48b4252448aba743eb5d4e96243_NetLossPerShare"/>
  <link:roleRef roleURI="http://arcutis.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#NetLossPerShareTables"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/NetLossPerShareTables" xlink:type="extended" id="i6e6f868193194e75977cfb2b6e54900b_NetLossPerShareTables"/>
  <link:roleRef roleURI="http://arcutis.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#NetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/NetLossPerShareDetails" xlink:type="extended" id="i61b8bfc3a36f410ba563dafa5bcbbea2_NetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6894385b-17e1-4248-b754-d54ff43f1281" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5af84544-d22f-4bc4-82c5-c1d9a779c2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6894385b-17e1-4248-b754-d54ff43f1281" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5af84544-d22f-4bc4-82c5-c1d9a779c2cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_da42ae12-5586-4994-9f86-93b80130dc97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6894385b-17e1-4248-b754-d54ff43f1281" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_da42ae12-5586-4994-9f86-93b80130dc97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dad8f075-adb9-418c-b13e-215c23a9e859" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_da42ae12-5586-4994-9f86-93b80130dc97" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dad8f075-adb9-418c-b13e-215c23a9e859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dad8f075-adb9-418c-b13e-215c23a9e859_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dad8f075-adb9-418c-b13e-215c23a9e859" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dad8f075-adb9-418c-b13e-215c23a9e859_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77ca42f3-cd18-43be-a4e5-c0da9588b8a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dad8f075-adb9-418c-b13e-215c23a9e859" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77ca42f3-cd18-43be-a4e5-c0da9588b8a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_7e17213e-2c97-4d1f-8ad7-ecada8e0e614" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77ca42f3-cd18-43be-a4e5-c0da9588b8a1" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_7e17213e-2c97-4d1f-8ad7-ecada8e0e614" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c24f6d7c-e0c8-4fa1-8745-95f2e691793c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77ca42f3-cd18-43be-a4e5-c0da9588b8a1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c24f6d7c-e0c8-4fa1-8745-95f2e691793c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_EarlyExercisedOptionsMember_d348faef-dc3a-45f8-9324-0df077d71bdd" xlink:href="arqt-20200331.xsd#arqt_EarlyExercisedOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77ca42f3-cd18-43be-a4e5-c0da9588b8a1" xlink:to="loc_arqt_EarlyExercisedOptionsMember_d348faef-dc3a-45f8-9324-0df077d71bdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_30d25a23-1c85-4a97-9bb9-cb8234fc1950" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77ca42f3-cd18-43be-a4e5-c0da9588b8a1" xlink:to="loc_us-gaap_RestrictedStockMember_30d25a23-1c85-4a97-9bb9-cb8234fc1950" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_6cc98f5d-415b-4008-a1b7-2bf4e8e683dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77ca42f3-cd18-43be-a4e5-c0da9588b8a1" xlink:to="loc_us-gaap_EmployeeStockMember_6cc98f5d-415b-4008-a1b7-2bf4e8e683dc" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcutis.com/role/SubsequentEvent" xlink:type="simple" xlink:href="arqt-20200331.xsd#SubsequentEvent"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/SubsequentEvent" xlink:type="extended" id="ib63199c01c2f4679846701fff0ae0eb7_SubsequentEvent"/>
  <link:roleRef roleURI="http://arcutis.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#SubsequentEventDetails"/>
  <link:definitionLink xlink:role="http://arcutis.com/role/SubsequentEventDetails" xlink:type="extended" id="ide332cff8b2b4221b6502b9733cae99f_SubsequentEventDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace_c0202aa5-dcab-4d45-ac2c-bc5aadee5241" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:to="loc_arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace_c0202aa5-dcab-4d45-ac2c-bc5aadee5241" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ee3db104-b5ba-4ddf-9249-295ac4196cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ee3db104-b5ba-4ddf-9249-295ac4196cc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_49862663-6954-49cd-b75c-4fa1756eddfb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_49862663-6954-49cd-b75c-4fa1756eddfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseTermForTerminationOption_2a6152cc-141e-43f2-9e93-274e818275b3" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseTermForTerminationOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:to="loc_arqt_LesseeOperatingLeaseTermForTerminationOption_2a6152cc-141e-43f2-9e93-274e818275b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseMonthlyRentExpense_e2076460-1d83-4df7-a409-054a5da804d5" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseMonthlyRentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:to="loc_arqt_LesseeOperatingLeaseMonthlyRentExpense_e2076460-1d83-4df7-a409-054a5da804d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseFreeRentPeriod_4f667ec5-b40a-4f52-8e87-8710343601c6" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseFreeRentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:to="loc_arqt_LesseeOperatingLeaseFreeRentPeriod_4f667ec5-b40a-4f52-8e87-8710343601c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseTenantImprovementAllowance_e088a5c1-6707-4c46-b869-f1ec3d5430a6" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseTenantImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:to="loc_arqt_LesseeOperatingLeaseTenantImprovementAllowance_e088a5c1-6707-4c46-b869-f1ec3d5430a6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseLetterOfCreditRequirement_abfda0b1-f5ba-44cc-9991-b4f196bfebe2" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseLetterOfCreditRequirement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:to="loc_arqt_LesseeOperatingLeaseLetterOfCreditRequirement_abfda0b1-f5ba-44cc-9991-b4f196bfebe2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_43e88426-d993-4628-aff6-fe40cb562ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:to="loc_us-gaap_SubsequentEventTable_43e88426-d993-4628-aff6-fe40cb562ac0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b9779487-a436-4b2f-a08b-37ef744e0f88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_43e88426-d993-4628-aff6-fe40cb562ac0" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b9779487-a436-4b2f-a08b-37ef744e0f88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b9779487-a436-4b2f-a08b-37ef744e0f88_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b9779487-a436-4b2f-a08b-37ef744e0f88" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b9779487-a436-4b2f-a08b-37ef744e0f88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_30641997-f509-4d33-9357-2d6ab15beba9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b9779487-a436-4b2f-a08b-37ef744e0f88" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_30641997-f509-4d33-9357-2d6ab15beba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3c7548bb-4570-4a8b-a143-f663d7d5dc21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_30641997-f509-4d33-9357-2d6ab15beba9" xlink:to="loc_us-gaap_SubsequentEventMember_3c7548bb-4570-4a8b-a143-f663d7d5dc21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LeaseDescriptionAxis_df8dadf5-4ccd-49cc-a90a-727a1791ff6d" xlink:href="arqt-20200331.xsd#arqt_LeaseDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_43e88426-d993-4628-aff6-fe40cb562ac0" xlink:to="loc_arqt_LeaseDescriptionAxis_df8dadf5-4ccd-49cc-a90a-727a1791ff6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LeaseDescriptionDomain_df8dadf5-4ccd-49cc-a90a-727a1791ff6d_default" xlink:href="arqt-20200331.xsd#arqt_LeaseDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_arqt_LeaseDescriptionAxis_df8dadf5-4ccd-49cc-a90a-727a1791ff6d" xlink:to="loc_arqt_LeaseDescriptionDomain_df8dadf5-4ccd-49cc-a90a-727a1791ff6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LeaseDescriptionDomain_f364d8da-9e3c-4b88-b281-e5fbd3f6e0d8" xlink:href="arqt-20200331.xsd#arqt_LeaseDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_arqt_LeaseDescriptionAxis_df8dadf5-4ccd-49cc-a90a-727a1791ff6d" xlink:to="loc_arqt_LeaseDescriptionDomain_f364d8da-9e3c-4b88-b281-e5fbd3f6e0d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_WestlakeVillageCaliforniaLeaseArrangementMember_3cdcb129-f5be-4f69-a5b6-93bebf82a05d" xlink:href="arqt-20200331.xsd#arqt_WestlakeVillageCaliforniaLeaseArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arqt_LeaseDescriptionDomain_f364d8da-9e3c-4b88-b281-e5fbd3f6e0d8" xlink:to="loc_arqt_WestlakeVillageCaliforniaLeaseArrangementMember_3cdcb129-f5be-4f69-a5b6-93bebf82a05d" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>arqt-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:600b0262-d663-4687-ae47-6802ec869b02,g:c1b67e0b-9b7c-4732-b64c-b3f7b7d96647-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_c34e8e3b-afcb-43eb-9583-357651e49d19_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_85f21754-5a77-4b8b-afe1-a9bcffb19270_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_48aa1646-d65e-4e9a-8451-a5e89ae40ef5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8696ebf4-7023-4d99-ba79-725744bd3c2a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_1993cd4f-be19-4900-a4c8-5368ad77a218_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e6750099-fc19-4cab-b63f-64730013c21d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_e75a697b-80a9-40ac-bd09-2a7a026fcb91_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid expenses and current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_d2040737-9667-4bf1-9bac-d79ffd834136_terseLabel_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_label_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:to="lab_us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0ec84358-2880-4f11-9c10-1b67ad021874_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_a1d006e6-9c96-42fd-93de-b4b33452067a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_625bc9ae-b8e9-48f3-9605-93b01df427a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_05a03b88-513d-4ba6-b742-cc858ce36c1b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d41dafb1-8d2e-4b60-8777-6eae52412916_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ebcffcd9-9b3a-4376-812b-4272da2e4965_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted common stock vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_531706ed-82f8-4562-85b4-1b6869d877ea_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LesseeOperatingLeaseFreeRentPeriod_159a8bf7-9c39-4859-8261-eb28dd96a855_terseLabel_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseFreeRentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free rent period</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseFreeRentPeriod_label_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseFreeRentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Free Rent Period</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseFreeRentPeriod_documentation_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseFreeRentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Free Rent Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseFreeRentPeriod" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseFreeRentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LesseeOperatingLeaseFreeRentPeriod" xlink:to="lab_arqt_LesseeOperatingLeaseFreeRentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments_0dfbfe06-ba39-4050-81b0-7267dc802915_terseLabel_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payments for licensed products</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments_label_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others. Maximum Product Milestone Payments</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments_documentation_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others. Maximum Product Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments" xlink:href="arqt-20200331.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments" xlink:to="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4d26b586-2184-4f90-ba81-f92b2daac667_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_fbca583d-1de9-4d95-a0c1-39e871ac8c54_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ce11516-054f-44c9-8757-1021b8b1134d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, number of options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc074356-443f-41fe-83f9-31f937864f58_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, number of options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_aa2511c7-0d54-4911-822a-0575a1c8df67_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares of common stock, net of issuance costs of $16.0 million</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_793e364e-80dc-430b-95b1-bdfcdbdf25eb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_8f0c9c4e-a106-45d8-bcda-30c97e3eaf92_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from initial public offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1a4aa72f-3b1a-4a68-af44-136f97816ffe_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_924864a1-94ec-4dd8-87e5-96c87e04b394_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e3cf6c1d-b582-4262-b3f7-326514bab6a3_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cca56c8a-ecba-4b66-a3d2-68acecd9fe8c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_447247bd-54ea-4bac-9c45-4e6dfed342a4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_bcdfb798-9593-4845-ac3d-b06f2a5386ca_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e2658a28-4fa5-4c0d-bff9-661521f05521_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c19c26b9-f9ee-41f0-88e4-fa776ca1ed0f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining contractual term, exercisable (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8b559bd8-3705-4e09-984e-182acb326400_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5cfea822-278c-434c-82a2-b3bbd7d3a23c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4be7ddb0-aba8-4051-9e0c-8153f9a5970e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_ed91bdb7-c7b8-4831-a429-3cd4c7526326_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises_08402011-d3ce-4124-8f82-528930c8697e_terseLabel_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of repurchase rights related to common stock issued pursuant to early exercises</link:label>
    <link:label id="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises_label_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Lapse Of Repurchase Rights Pursuant To Early Stock Exercises</link:label>
    <link:label id="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises_documentation_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Lapse Of Repurchase Rights Pursuant To Early Stock Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" xlink:href="arqt-20200331.xsd#arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" xlink:to="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_e26ce3c3-a832-42ed-b5fb-55df48e4cc2c_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_614136bd-f89e-4d12-bc12-1fefa3788cb2_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_a33291e8-ab07-4fe3-922c-81042d051121_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage of VIE</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_fa9f7e63-b5d1-40bb-81e9-91eadfccd392_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_bc73bbcd-4ce6-4f72-9be0-105cb109b0d9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock subject to future vesting</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_56d530c3-0bef-4f36-bad7-b776b5e97cc5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_93faf17a-c5b9-4031-8978-a737fd5e811a_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset obtained in exchange for lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_StockPurchaseAgreementPricePerShare_c8ddc193-50e3-457b-bf97-80f45a4f4d20_terseLabel_en-US" xlink:label="lab_arqt_StockPurchaseAgreementPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (in USD per share)</link:label>
    <link:label id="lab_arqt_StockPurchaseAgreementPricePerShare_label_en-US" xlink:label="lab_arqt_StockPurchaseAgreementPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Price Per Share</link:label>
    <link:label id="lab_arqt_StockPurchaseAgreementPricePerShare_documentation_en-US" xlink:label="lab_arqt_StockPurchaseAgreementPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementPricePerShare" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_StockPurchaseAgreementPricePerShare" xlink:to="lab_arqt_StockPurchaseAgreementPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_e72c1a98-f21f-4891-8c41-8e038a97a964_terseLabel_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in shares available for grant, percentage of shares outstanding</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_label_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_documentation_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:href="arqt-20200331.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:to="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_f26fe8a9-9455-4c2e-9933-548c17dd3cd1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0279b541-5520-4f85-b7e6-e7a823e6fb20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_A2017EquityIncentivePlanMember_8b161ea3-ad34-48d2-9ba0-a79dd8aa6683_terseLabel_en-US" xlink:label="lab_arqt_A2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:label id="lab_arqt_A2017EquityIncentivePlanMember_label_en-US" xlink:label="lab_arqt_A2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_arqt_A2017EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_arqt_A2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_A2017EquityIncentivePlanMember" xlink:href="arqt-20200331.xsd#arqt_A2017EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_A2017EquityIncentivePlanMember" xlink:to="lab_arqt_A2017EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_98cd6f84-f376-4d13-b207-5793a26d5776_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_e760b85d-eaea-4227-886f-e840cee962a4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_90aa93d1-da6f-4c4d-bcc6-37ec474b3661_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_e6d852f6-22f5-475f-8697-0e1652b47b23_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5fe745f5-1f84-4d87-b1e4-cda2a37c2f25_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_acd1d402-f735-4656-8c92-6596b1206dbb_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c9bffe9a-cec9-431c-8f49-369dd7c37ba7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_e9bf66dc-0319-4f0a-8c70-9dd28e23ec2e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_df0bc24a-7cad-4047-a2f0-f378ae1d6970_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c1b67154-12ff-4c8e-a67c-7ea24bc68b89_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_46bd7a4e-849c-4fe6-a635-5ce0cef38595_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_66d1fe7e-3e9f-4dab-be85-6041c4104d64_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_33e94e9d-c717-4cf8-82d5-186e929b510a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_e61050f5-22fd-4c80-b2c0-7228416dcc58_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_33f746b1-6c1f-4339-82d8-2a2f816700cd_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a7228111-ca94-4142-813a-77710ba4c667_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_464acfdd-8bc9-4d3f-8b06-3ce75b6d1598_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period of stock-based awards granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_52decbeb-a32b-4c70-826b-f0171eaa1b0a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8c32221c-930f-48c5-8388-5a98275e3203_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per share information:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_1bc9ff89-703b-4471-8d84-10a9eb4de82c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_87468e16-e583-4433-b672-db0fa81d41c4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_96195696-1413-41da-81c4-623c4fdedb45_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e02aafe7-763f-41f9-8f86-1523dae758d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions in Calculating Stock Option Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_ad87a0cb-b6a2-4119-8680-f9b603a084a2_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5833979b-3a0e-4265-8dd8-6779a11af7fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_HengruiMember_230f9d1c-f8c6-424e-af1d-77ba0ab93312_terseLabel_en-US" xlink:label="lab_arqt_HengruiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hengrui</link:label>
    <link:label id="lab_arqt_HengruiMember_label_en-US" xlink:label="lab_arqt_HengruiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hengrui [Member]</link:label>
    <link:label id="lab_arqt_HengruiMember_documentation_en-US" xlink:label="lab_arqt_HengruiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hengrui</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_HengruiMember" xlink:href="arqt-20200331.xsd#arqt_HengruiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_HengruiMember" xlink:to="lab_arqt_HengruiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_8671f4c0-cda6-465b-99e6-4c6a2b93128e_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock_56cb6360-8829-4ec6-baa8-ddaf48066157_terseLabel_en-US" xlink:label="lab_arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical and Clinical Accruals and Costs</link:label>
    <link:label id="lab_arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock_label_en-US" xlink:label="lab_arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical And Clinical Accruals And Costs [Policy Text Block]</link:label>
    <link:label id="lab_arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock_documentation_en-US" xlink:label="lab_arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical And Clinical Accruals And Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock" xlink:href="arqt-20200331.xsd#arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock" xlink:to="lab_arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized_e148b6b1-3d40-439c-b79b-6ec9a5821d42_terseLabel_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized for sale under the ESPP (in shares)</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized_label_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Base Amount Of Common Stock Shares Authorized</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized_documentation_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Base Amount Of Common Stock Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" xlink:href="arqt-20200331.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" xlink:to="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7f15111a-c24c-48a3-9013-3902ecf4b68d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_HawkeyeMember_b74d7833-f8e8-4d0a-9ea5-b894be39f4f4_terseLabel_en-US" xlink:label="lab_arqt_HawkeyeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hawkeye</link:label>
    <link:label id="lab_arqt_HawkeyeMember_label_en-US" xlink:label="lab_arqt_HawkeyeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hawkeye [Member]</link:label>
    <link:label id="lab_arqt_HawkeyeMember_documentation_en-US" xlink:label="lab_arqt_HawkeyeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hawkeye</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_HawkeyeMember" xlink:href="arqt-20200331.xsd#arqt_HawkeyeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_HawkeyeMember" xlink:to="lab_arqt_HawkeyeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_160f1adb-3188-4ae3-b093-fbaf4195eb83_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6883a821-35ce-49bf-9888-a1d17bbb4491_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_PrepaidClinicalTrialTestCostsCurrent_6c484d15-4300-4a8c-9bfd-a1a0d3e2c0d4_terseLabel_en-US" xlink:label="lab_arqt_PrepaidClinicalTrialTestCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid clinical trial costs</link:label>
    <link:label id="lab_arqt_PrepaidClinicalTrialTestCostsCurrent_label_en-US" xlink:label="lab_arqt_PrepaidClinicalTrialTestCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical Trial Test Costs, Current</link:label>
    <link:label id="lab_arqt_PrepaidClinicalTrialTestCostsCurrent_documentation_en-US" xlink:label="lab_arqt_PrepaidClinicalTrialTestCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical Trial Test Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PrepaidClinicalTrialTestCostsCurrent" xlink:href="arqt-20200331.xsd#arqt_PrepaidClinicalTrialTestCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_PrepaidClinicalTrialTestCostsCurrent" xlink:to="lab_arqt_PrepaidClinicalTrialTestCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c5bd8ca9-5268-48b7-a6d9-ccc9b3d42864_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised during the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_84fd1d94-49c2-42b9-a807-39d4c23c9592_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, weighted-average exercise price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9abd6aac-4e5b-4d02-9768-20de1c8f5556_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, weighted-average exercise price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_e1808889-c671-4db0-9786-bf784a5c46d9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_297ea7d9-3b0c-4347-ae48-f86b0cde780f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_266b6160-6b75-4b21-924f-fc2771882131_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_00410fdd-6e70-4e0a-91ce-179f1ef96d39_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d59236e-9d0f-4e37-92da-336009d154a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_StockPurchaseAgreementTranchesTwoAndThreeMember_50e5b2b6-8a1f-42e0-9505-fc5668d4e1e7_terseLabel_en-US" xlink:label="lab_arqt_StockPurchaseAgreementTranchesTwoAndThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Tranches Two And Three</link:label>
    <link:label id="lab_arqt_StockPurchaseAgreementTranchesTwoAndThreeMember_label_en-US" xlink:label="lab_arqt_StockPurchaseAgreementTranchesTwoAndThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Tranches Two And Three [Member]</link:label>
    <link:label id="lab_arqt_StockPurchaseAgreementTranchesTwoAndThreeMember_documentation_en-US" xlink:label="lab_arqt_StockPurchaseAgreementTranchesTwoAndThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Tranches Two And Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementTranchesTwoAndThreeMember" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementTranchesTwoAndThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_StockPurchaseAgreementTranchesTwoAndThreeMember" xlink:to="lab_arqt_StockPurchaseAgreementTranchesTwoAndThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_526286b9-cfa5-48a8-a808-f834b27143b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_655f1cc5-e223-4c48-a24b-5020eb3e1037_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7ffae090-963a-4496-a2da-7466651171bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_709d82de-0e3d-4c00-b8ed-94759563a8b1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Assets Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_23024564-ccf2-4364-af55-05cecd0a1dd8_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_69f91703-d8b5-4aef-8448-a837d329553b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f2b977ab-7945-4984-b3e6-789e32b5f3c6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_94c8182c-6bc8-4a3f-a082-25171d0503ba_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, cash payment</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ab8b64b9-4625-41bd-b058-e76e81aaaca5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ffbfbf69-d1f6-4b8e-bdfa-54dfffffdbee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4b4aa874-8bc2-4fe9-a389-878b17309b98_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_ff8de732-5c66-4360-8ff3-33666b0dbab3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_ea8d6cef-33f4-4e2c-8197-df3fa5290ea9_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_da480a34-ad0f-4968-9e4b-9537bfbaa97e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6da5804b-145f-4ed2-9488-b1ac131ecb26_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ea45d72f-c420-453b-90cd-5da588037d52_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ad49de84-7359-4f03-adbf-0dc7582c527f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_222eeee2-c577-4085-8f59-c1a45c197139_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5ef2a63a-9e8d-43bf-983c-7758542d5fba_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ServiceConditionRestrictedStockMember_ff7d82dd-f431-4323-af70-028e488d92f6_terseLabel_en-US" xlink:label="lab_arqt_ServiceConditionRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Condition Restricted Stock</link:label>
    <link:label id="lab_arqt_ServiceConditionRestrictedStockMember_label_en-US" xlink:label="lab_arqt_ServiceConditionRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Condition Restricted Stock [Member]</link:label>
    <link:label id="lab_arqt_ServiceConditionRestrictedStockMember_documentation_en-US" xlink:label="lab_arqt_ServiceConditionRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Condition Restricted Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ServiceConditionRestrictedStockMember" xlink:href="arqt-20200331.xsd#arqt_ServiceConditionRestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ServiceConditionRestrictedStockMember" xlink:to="lab_arqt_ServiceConditionRestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a72b2af9-07c6-43a4-b0ed-6f7ec204cf6b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock_9f55d41d-c15b-40b7-923c-dbdcd2a50403_terseLabel_en-US" xlink:label="lab_arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Condensed Financial Statements</link:label>
    <link:label id="lab_arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Condensed Financial Statements, Policy [Policy Text Block]</link:label>
    <link:label id="lab_arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Condensed Financial Statements, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock" xlink:href="arqt-20200331.xsd#arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock" xlink:to="lab_arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_4ff14b13-2041-482a-8b43-90b35b724c3f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Straight-line rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_598a5b26-5fee-4900-abae-04b4b549dce8_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_18fd068a-283f-458e-a02b-23664636b52c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_c12e1ba8-2c9b-4fdb-82ea-020a6e01e9a7_terseLabel_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares to be issued</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_label_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_documentation_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:href="arqt-20200331.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:to="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_67f1c405-c517-49ac-9c68-ed5d4a32fdc0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_bf4da259-3f02-4765-962e-7e04405f026b_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, par value (In USD per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cd4c3e9c-637c-470f-90a7-cce7fd590d46_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4914562e-d984-4e7e-980f-b27f09c5091b_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bab8671a-57cb-45d0-9a5d-f577a4114538_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e8276312-433b-4dd0-82dd-243b8b06bc08_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon the exercise of stock option (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e62c143a-5edd-4cc3-a64f-75fb35b8bc2a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_5414d0f4-9540-4454-a59d-1e5cb21ff2c8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b6da4387-28c4-47d7-aaf2-e0efb9b39139_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2a556ee6-87d6-478b-990b-dcd1148d3d0d_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a7e9fc74-47a0-41ec-8900-b7ae19015dba_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ac9aa5ea-1552-4b77-97b7-024039d56eee_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6e150d19-ce5e-4d86-bbc6-00a8078f0049_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5d72e4c9-781e-4d9a-b71e-2937b1be7086_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_55e0b1e5-a490-4f5e-ada2-9a7713592f3c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d57e85ca-0fd3-49d6-8932-e2405a7a85ee_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8fcc517c-d1c0-4a4a-b609-42bf9bfab371_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_StockPurchaseAgreementNumberOfTranches_a2cf0bf1-d2ed-492f-a99b-f242e5aaef68_terseLabel_en-US" xlink:label="lab_arqt_StockPurchaseAgreementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches (in tranches)</link:label>
    <link:label id="lab_arqt_StockPurchaseAgreementNumberOfTranches_label_en-US" xlink:label="lab_arqt_StockPurchaseAgreementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Number of Tranches</link:label>
    <link:label id="lab_arqt_StockPurchaseAgreementNumberOfTranches_documentation_en-US" xlink:label="lab_arqt_StockPurchaseAgreementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Number of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementNumberOfTranches" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_StockPurchaseAgreementNumberOfTranches" xlink:to="lab_arqt_StockPurchaseAgreementNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_e88bc240-7fb4-4100-a3bd-95ed1abab4af_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c07cc3c5-55fc-44cb-8dfa-e14dbf6a84f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LeaseDescriptionDomain_2835ea70-ac98-43b4-ae4d-ea9191962980_terseLabel_en-US" xlink:label="lab_arqt_LeaseDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Description [Domain]</link:label>
    <link:label id="lab_arqt_LeaseDescriptionDomain_label_en-US" xlink:label="lab_arqt_LeaseDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Description [Domain]</link:label>
    <link:label id="lab_arqt_LeaseDescriptionDomain_documentation_en-US" xlink:label="lab_arqt_LeaseDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LeaseDescriptionDomain" xlink:href="arqt-20200331.xsd#arqt_LeaseDescriptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LeaseDescriptionDomain" xlink:to="lab_arqt_LeaseDescriptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_StockPurchaseAgreementTrancheOneMember_773db7fd-8150-400c-8d8a-618a58958ad4_terseLabel_en-US" xlink:label="lab_arqt_StockPurchaseAgreementTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Tranche One</link:label>
    <link:label id="lab_arqt_StockPurchaseAgreementTrancheOneMember_label_en-US" xlink:label="lab_arqt_StockPurchaseAgreementTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Tranche One [Member]</link:label>
    <link:label id="lab_arqt_StockPurchaseAgreementTrancheOneMember_documentation_en-US" xlink:label="lab_arqt_StockPurchaseAgreementTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementTrancheOneMember" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_StockPurchaseAgreementTrancheOneMember" xlink:to="lab_arqt_StockPurchaseAgreementTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a76e1f67-aef0-4956-9f84-cb6728c2f563_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d3d3e294-c6a4-42db-8b41-e7e126c8b7da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_060a4336-4dee-4ecb-94d4-0bc2db996e66_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_DeferredFinancingCostsIncurredButNotYetPaid_7dfb7b2d-86e2-468b-8a7e-2c8b5caf1e94_terseLabel_en-US" xlink:label="lab_arqt_DeferredFinancingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_arqt_DeferredFinancingCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_arqt_DeferredFinancingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_arqt_DeferredFinancingCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_arqt_DeferredFinancingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DeferredFinancingCostsIncurredButNotYetPaid" xlink:href="arqt-20200331.xsd#arqt_DeferredFinancingCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_DeferredFinancingCostsIncurredButNotYetPaid" xlink:to="lab_arqt_DeferredFinancingCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_e8bda11b-aa4d-4943-ab8f-1daa910c08af_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6008f49f-9f4e-44ff-9b81-3b848eace135_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_5bff8f67-ea42-459a-8f82-941a884724a7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_42d3762d-b248-4086-a648-0af6a251a626_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock into common stock upon initial public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ad4f173b-1ab4-4f3d-8d26-95f3b0e4b65b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued as a result of conversion of promissory notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c935b7c0-de49-499d-8dc7-514874e10974_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_402ed3f4-aeaf-4784-a51c-2f99ad58c364_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ed09e8d2-a503-4297-91ae-6bdee27f6f6a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_f23bdb8e-e322-482c-b8b9-1fe0c7f2f33d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_d096d9ab-9582-4de6-939e-9360b6ca25e3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration_1b2e0eaf-b9aa-4ac9-8d5c-97569908bde7_terseLabel_en-US" xlink:label="lab_arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, threshold of proceeds from stock issuance for additional consideration</link:label>
    <link:label id="lab_arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration_label_en-US" xlink:label="lab_arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Threshold Of Proceeds From Stock Issuance For Additional Consideration</link:label>
    <link:label id="lab_arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration_documentation_en-US" xlink:label="lab_arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Threshold Of Proceeds From Stock Issuance For Additional Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration" xlink:href="arqt-20200331.xsd#arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration" xlink:to="lab_arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_17fee669-f8bd-41e2-958d-10813b9e9773_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c0cbd455-d357-4889-b06b-ef31a3da3ff2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d41a5ade-55f1-4c58-b779-d548cb3ac5b7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from stock purchase agreement</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_41dbae11-b5fc-425f-88eb-9de610028bc9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_cb875116-36c8-4ac1-9c4b-858676805b15_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_3bbff6d3-bfe9-4d06-85b0-31f2997ddddc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_cd3fffd9-2323-4533-a125-401847bb1586_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_150fa7d5-ea10-4306-8aa5-69e680063ff5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares Issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a16b8ea3-9919-4a85-aa55-2e0fb62605cb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of options vested during the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_95ec2075-813d-4aa0-99d4-69316380570e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_60c40a61-f901-4455-a850-4039567ab1ac_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_dae260aa-4e4a-4ef0-9125-082e36cdfe3d_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_ac969127-e7f5-4fa2-8ba9-fcdd79c4bdb9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gains (losses) on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_TemporaryEquitySharesConversionOfConvertibleSecurities_4ae3ff22-c142-49c3-ae7b-d2f462c80d37_negatedTerseLabel_en-US" xlink:label="lab_arqt_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock into common stock (in shares)</link:label>
    <link:label id="lab_arqt_TemporaryEquitySharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_arqt_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares, Conversion Of Convertible Securities</link:label>
    <link:label id="lab_arqt_TemporaryEquitySharesConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_arqt_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares, Conversion Of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:href="arqt-20200331.xsd#arqt_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:to="lab_arqt_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_69d3ba7f-ac1e-47d8-9bae-5a6ecc96c809_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Antidilutive Shares Excluded from the Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_27ce6c81-dce0-4eec-9464-5eddb966afb5_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_TemporaryEquityValueConversionOfConvertibleSecurities_6a8e12d9-2585-41e6-93cf-d6c9d7829cbf_negatedTerseLabel_en-US" xlink:label="lab_arqt_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock into common stock upon initial public offering</link:label>
    <link:label id="lab_arqt_TemporaryEquityValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_arqt_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Value, Conversion Of Convertible Securities</link:label>
    <link:label id="lab_arqt_TemporaryEquityValueConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_arqt_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Value, Conversion Of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:href="arqt-20200331.xsd#arqt_TemporaryEquityValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:to="lab_arqt_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_65f4fbab-87f7-4940-9b95-a297b611fb3d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_d2ce4e35-bf3b-4baf-ac54-37a27ba40d48_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercise liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_StockOptionsIssuedAndOutstandingMember_8786c018-5b68-4f2b-ab17-87b2de6ed224_terseLabel_en-US" xlink:label="lab_arqt_StockOptionsIssuedAndOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options issued and outstanding</link:label>
    <link:label id="lab_arqt_StockOptionsIssuedAndOutstandingMember_label_en-US" xlink:label="lab_arqt_StockOptionsIssuedAndOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Issued and Outstanding [Member]</link:label>
    <link:label id="lab_arqt_StockOptionsIssuedAndOutstandingMember_documentation_en-US" xlink:label="lab_arqt_StockOptionsIssuedAndOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Issued and Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockOptionsIssuedAndOutstandingMember" xlink:href="arqt-20200331.xsd#arqt_StockOptionsIssuedAndOutstandingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_StockOptionsIssuedAndOutstandingMember" xlink:to="lab_arqt_StockOptionsIssuedAndOutstandingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9de9781e-aeb8-45d1-86dc-f3cb94c1e463_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_333e2807-756e-4c22-bccf-23f9287fcb27_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis_9e8ae325-c8e0-4fb8-afbf-078e15c19aff_terseLabel_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares vesting on a monthly basis (in shares)</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis_label_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Vesting On A Monthly Basis</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis_documentation_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Vesting On A Monthly Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis" xlink:href="arqt-20200331.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis" xlink:to="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace_0ce0408b-3352-4d6e-8bdd-7440332716b1_terseLabel_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square footage of leased space</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace_label_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Square Footage Of Leased Space</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace_documentation_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Square Footage Of Leased Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace" xlink:to="lab_arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_StockAwardsFutureGrantMember_099a474d-446a-4281-a212-99d1da7e0dec_terseLabel_en-US" xlink:label="lab_arqt_StockAwardsFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock awards available for grant under employee benefit plans</link:label>
    <link:label id="lab_arqt_StockAwardsFutureGrantMember_label_en-US" xlink:label="lab_arqt_StockAwardsFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Awards, Future Grant [Member]</link:label>
    <link:label id="lab_arqt_StockAwardsFutureGrantMember_documentation_en-US" xlink:label="lab_arqt_StockAwardsFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Awards, Future Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockAwardsFutureGrantMember" xlink:href="arqt-20200331.xsd#arqt_StockAwardsFutureGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_StockAwardsFutureGrantMember" xlink:to="lab_arqt_StockAwardsFutureGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_d1c27b8f-ef13-4632-b778-adf42e486e14_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_b56c9cac-b1a8-4669-9cb6-4d61649adb4b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_133d797c-2dfe-4b34-83a6-aecace1301b4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_99aa542b-b146-4f4f-9bba-a210c9d3c828_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_b5f2ed99-4632-40b2-94b7-a5511a76b933_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of restricted stock issued to founders (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration_91831cdc-2e4b-401c-83c8-151e94498e15_terseLabel_en-US" xlink:label="lab_arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, numerator for determining additional consideration</link:label>
    <link:label id="lab_arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration_label_en-US" xlink:label="lab_arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Numerator For Determining Additional Consideration</link:label>
    <link:label id="lab_arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration_documentation_en-US" xlink:label="lab_arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Numerator For Determining Additional Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration" xlink:href="arqt-20200331.xsd#arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration" xlink:to="lab_arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a3d60b8e-119f-4c3d-ba76-6dc10eebb33a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c3f8beaf-8179-4c16-9147-a0a732e5ff36_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_29805065-892b-446b-86e0-fc1a24975186_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_995fdef2-eba0-4f5b-adca-38cb4d67bbd0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_7928f329-4bda-4bc6-ba82-0fd4ec0d2b98_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable_5e4704a9-1d7a-4f3f-8e39-a55670c3746a_terseLabel_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Based number of options issuable (in shares)</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable_label_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Base Number Of Options Issuable</link:label>
    <link:label id="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable_documentation_en-US" xlink:label="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Base Number Of Options Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" xlink:href="arqt-20200331.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" xlink:to="lab_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1bbfa77e-865c-4d38-aa72-30923b7f0bb7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_fa4021ff-a14e-4821-a743-0d7b5ed25265_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6e9da17a-fe0b-4f76-a04e-0cec4a4429e0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_A2020EquityIncentivePlanMember_d9653de9-4f01-4182-b9ed-5ecb1f287783_terseLabel_en-US" xlink:label="lab_arqt_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan</link:label>
    <link:label id="lab_arqt_A2020EquityIncentivePlanMember_label_en-US" xlink:label="lab_arqt_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_arqt_A2020EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_arqt_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_A2020EquityIncentivePlanMember" xlink:href="arqt-20200331.xsd#arqt_A2020EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_A2020EquityIncentivePlanMember" xlink:to="lab_arqt_A2020EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LesseeOperatingLeasesNumberFacilitiesLeased_0754d10d-69fe-4f6a-a353-09c53c4fae11_terseLabel_en-US" xlink:label="lab_arqt_LesseeOperatingLeasesNumberFacilitiesLeased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating leases (in leases)</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeasesNumberFacilitiesLeased_label_en-US" xlink:label="lab_arqt_LesseeOperatingLeasesNumberFacilitiesLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Number Facilities Leased</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeasesNumberFacilitiesLeased_documentation_en-US" xlink:label="lab_arqt_LesseeOperatingLeasesNumberFacilitiesLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Number Facilities Leased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeasesNumberFacilitiesLeased" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeasesNumberFacilitiesLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LesseeOperatingLeasesNumberFacilitiesLeased" xlink:to="lab_arqt_LesseeOperatingLeasesNumberFacilitiesLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_54ec2d58-376f-42c0-9d2f-c9d5e6e1f815_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1e5be038-bdb5-4d72-b865-aba857f8d667_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8606e2c1-4905-4bde-a239-535e08e9c2e9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c1a44702-c5a7-4289-9e4e-fed92d3b7231_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_OperatingLeaseRightOfUseAssetAmortizationExpense_de6ec0ce-cbc5-40f6-896f-3b1b30abf9ac_terseLabel_en-US" xlink:label="lab_arqt_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset amortization</link:label>
    <link:label id="lab_arqt_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_arqt_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:label id="lab_arqt_OperatingLeaseRightOfUseAssetAmortizationExpense_documentation_en-US" xlink:label="lab_arqt_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="arqt-20200331.xsd#arqt_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_arqt_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4a6cddec-42fe-46d2-acad-83564bcc96cf_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, $0.0001 par value; no shares and 48,787,898 shares authorized at March 31, 2020 and December&#160;31, 2019, respectively; no shares and 24,385,388 shares issued and outstanding at March 31, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_be71b528-df16-4dc3-a46f-c87896598de9_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_5ca84742-ebf7-4a41-96ca-eb393e07147d_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_f67b8de3-8a00-4076-9037-c3d07b98af30_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_e24de256-0921-442d-9ac6-1e7e6b0bad1d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5fbc17f0-bdeb-40c2-b6c5-6521f7b58dd4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9b273e6f-2d19-4823-b509-bb4f74f74fe6_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_d9b49182-dc89-48af-a8c9-c795c28e6ecd_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock outstanding</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_f772ae4f-b3bc-47ad-8bfe-6e1ad2741743_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock on an as-converted basis</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_dd2aee3e-3300-4226-a3c9-504f36fc85b2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercise liability, current</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3b8cb780-7baf-45cc-a6bf-44b775a246f5_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_f53f9bfd-e8c1-47eb-a9bc-d2050ec7c586_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare_6a6ea630-b54c-4e27-95cb-d01af009d2db_terseLabel_en-US" xlink:label="lab_arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price per share (in USD per share)</link:label>
    <link:label id="lab_arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare_label_en-US" xlink:label="lab_arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Price Per Share</link:label>
    <link:label id="lab_arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare_documentation_en-US" xlink:label="lab_arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:href="arqt-20200331.xsd#arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:to="lab_arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c065fb89-4d7c-419f-9d81-7421badd1956_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4ef7ef4b-11c6-4e21-a8df-4e9989abd839_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on short term investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f21b651b-a0ea-48fc-aed8-ce7be2819d48_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_35ea820a-c196-4009-8660-965a0daa4205_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_cc689387-954e-4c50-b64d-29339ebf4ea4_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_IncreaseDecreaseInOperatingLeaseLiabilities_7c077446-2f8f-4afb-bef0-7534b3891192_terseLabel_en-US" xlink:label="lab_arqt_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_arqt_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_arqt_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</link:label>
    <link:label id="lab_arqt_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_arqt_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="arqt-20200331.xsd#arqt_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_arqt_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_abb69240-2db6-4917-aee3-0ff5eb1cd80e_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_342639cf-bae3-42b6-bd6b-0976c93c2a46_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c62da5d3-def8-46c3-b966-5639c007d809_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5dde2116-4e0d-426a-b30e-ca341aa61571_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_237da2a7-fb7e-431a-800e-b7f59da48a42_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_921b7397-b34e-48a5-8b4f-6a2351d1169f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_67056c06-ffea-430d-b0a8-bbfc7f05e1c6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_64bfc29e-32ad-4dce-b43c-ea2a7e8e4256_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_f70da38a-c6e7-4bcd-8d70-d71ced88ff9d_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d42856f9-84b6-4bc3-b376-77d5a5334c74_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_StockPurchaseAgreementNumberOfSharesIssuable_d706ace9-538f-4f5b-9da7-14245c2491e6_terseLabel_en-US" xlink:label="lab_arqt_StockPurchaseAgreementNumberOfSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issuable (in shares)</link:label>
    <link:label id="lab_arqt_StockPurchaseAgreementNumberOfSharesIssuable_label_en-US" xlink:label="lab_arqt_StockPurchaseAgreementNumberOfSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Number Of Shares Issuable</link:label>
    <link:label id="lab_arqt_StockPurchaseAgreementNumberOfSharesIssuable_documentation_en-US" xlink:label="lab_arqt_StockPurchaseAgreementNumberOfSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Number Of Shares Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementNumberOfSharesIssuable" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementNumberOfSharesIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_StockPurchaseAgreementNumberOfSharesIssuable" xlink:to="lab_arqt_StockPurchaseAgreementNumberOfSharesIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_c7096127-b8b0-4e50-9cf9-306a768f7aed_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_56104eba-d66a-490e-884c-695eccc9be6a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_b74d273b-501a-4c87-8e93-857a95109273_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_82c423a3-e9f3-4a4b-b239-89e47252e4f5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4ca67052-1a4d-47a0-b149-14def8761356_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_e07957f4-490b-464e-aa2c-e82f1e7a2f6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_StockPurchaseAgreementTrancheThreeMember_a8ca7fc6-b0b6-4420-91c5-76b467e75229_terseLabel_en-US" xlink:label="lab_arqt_StockPurchaseAgreementTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Tranche Three</link:label>
    <link:label id="lab_arqt_StockPurchaseAgreementTrancheThreeMember_label_en-US" xlink:label="lab_arqt_StockPurchaseAgreementTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Tranche Three [Member]</link:label>
    <link:label id="lab_arqt_StockPurchaseAgreementTrancheThreeMember_documentation_en-US" xlink:label="lab_arqt_StockPurchaseAgreementTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementTrancheThreeMember" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_StockPurchaseAgreementTrancheThreeMember" xlink:to="lab_arqt_StockPurchaseAgreementTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9f2ca8cd-50a4-4ee2-9509-7910af7374c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ff3df031-84c3-4a17-a3d8-506ba0a1f570_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue_438f2a45-bd73-44b4-b25b-e732f696925a_terseLabel_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of founder shares subject to repurchase</link:label>
    <link:label id="lab_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue_label_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Vesting Of Founder Shares Subject To Repurchase, Value</link:label>
    <link:label id="lab_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue_documentation_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Vesting Of Founder Shares Subject To Repurchase, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue" xlink:href="arqt-20200331.xsd#arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue" xlink:to="lab_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_340b19d4-3eb0-4938-aa17-199c443f62e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Weighted-Average Exercise Price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_a662bd42-1122-4559-abda-e8c9af9215e2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercise liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_00ec958f-72f9-4d86-b7b5-a3156866c280_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_56e3a87f-c507-4696-9000-cd15c2d0771b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_e27e0f57-feb8-4147-a94e-04a2746380e7_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_be74df8c-cbbf-42d3-a044-8c809b975ec4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6dd4763e-bfdb-453c-baa8-ae005baf9979_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2eb256aa-2740-45b6-afe7-d18d9a0a259c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_bf06b151-f7bc-402d-ad0b-c458acdb638c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6f96e92b-8ce7-42ac-b4ae-3bd1953fc9b2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_cfea1b5f-1b7a-46f3-950a-f346ff6e0352_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_62d986d4-7b2b-4a24-8b94-b76736736b23_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_35d9e65a-7d5a-45bf-b221-50e86c7e3d0d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8f44b0d4-dfeb-4df8-9aa1-0a921665e6af_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_46ba35df-f2f6-41a3-9151-d0bf777301a5_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_8e3fec29-6699-4593-b13e-b8f6c1356501_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments (segment)</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3bb1698e-15be-4f86-b708-341691898edc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_0fbc1d94-83ac-4bb7-b122-556304ae59d2_terseLabel_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payments for net worldwide sales</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_label_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Maximum Sales Milestone Payments</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_documentation_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Maximum Sales Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" xlink:href="arqt-20200331.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" xlink:to="lab_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_df9d63e4-f253-4afa-b6d3-b0fe049913f8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split ratio for capital stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_b2f5f548-ea68-4ec0-89fd-a9266d8e1863_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_187e63bf-cdb9-4ddf-9970-a674a337f0cd_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e42bcb5-a535-4ca2-b98e-c1df1d627462_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_74e3a8ca-3de0-47cd-9267-3c38c9abfbf0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_AstraZenecaMember_ceb739f8-d5db-4140-b3a6-63540ee33b10_terseLabel_en-US" xlink:label="lab_arqt_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_arqt_AstraZenecaMember_label_en-US" xlink:label="lab_arqt_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_arqt_AstraZenecaMember_documentation_en-US" xlink:label="lab_arqt_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AstraZenecaMember" xlink:href="arqt-20200331.xsd#arqt_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_AstraZenecaMember" xlink:to="lab_arqt_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_VariableInterestEntitiesNumberOfSharesHeld_6d263a44-e58a-4428-806d-ef54510c6ea4_terseLabel_en-US" xlink:label="lab_arqt_VariableInterestEntitiesNumberOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares held in VIE (in shares)</link:label>
    <link:label id="lab_arqt_VariableInterestEntitiesNumberOfSharesHeld_label_en-US" xlink:label="lab_arqt_VariableInterestEntitiesNumberOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities, Number Of Shares Held</link:label>
    <link:label id="lab_arqt_VariableInterestEntitiesNumberOfSharesHeld_documentation_en-US" xlink:label="lab_arqt_VariableInterestEntitiesNumberOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities, Number Of Shares Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_VariableInterestEntitiesNumberOfSharesHeld" xlink:href="arqt-20200331.xsd#arqt_VariableInterestEntitiesNumberOfSharesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_VariableInterestEntitiesNumberOfSharesHeld" xlink:to="lab_arqt_VariableInterestEntitiesNumberOfSharesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_199b8c06-5694-4d4b-a7e0-761d098f277d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amounts representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_00f5a89d-cdcd-438f-9095-2ae4efaf9999_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_600bffff-bcc2-4c1a-a5c8-36ff23b9e771_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_f680d4f8-3c47-4424-be4c-7066c8691e32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56f0bfdc-ccf1-4bc6-ae32-aa747f7f170c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2fe85a2c-40d0-4f2c-88ce-2c00bb1c0c84_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_be41d201-84d0-4363-a034-a362f320ddbf_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_27d59c89-ee27-417b-a448-61ebc2efed3a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ClinicalTrialAccrualCurrent_53093b54-d4d1-41af-8022-56d622679645_terseLabel_en-US" xlink:label="lab_arqt_ClinicalTrialAccrualCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial accruals</link:label>
    <link:label id="lab_arqt_ClinicalTrialAccrualCurrent_label_en-US" xlink:label="lab_arqt_ClinicalTrialAccrualCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial Accrual, Current</link:label>
    <link:label id="lab_arqt_ClinicalTrialAccrualCurrent_documentation_en-US" xlink:label="lab_arqt_ClinicalTrialAccrualCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ClinicalTrialAccrualCurrent" xlink:href="arqt-20200331.xsd#arqt_ClinicalTrialAccrualCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ClinicalTrialAccrualCurrent" xlink:to="lab_arqt_ClinicalTrialAccrualCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8983fb84-9fc8-4c8c-8f58-3571740c6c6b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_c9fbdd1f-b74d-43d8-b376-c8b668db9ff7_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_880c40dc-e820-4a55-9370-186eb6675725_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4f72e947-814e-49c6-b98c-b4175c2779f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_61b84fa8-54d6-4432-8f18-44c0c05fb33c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_c85813ea-89a1-4bf5-8480-bd71a5812cec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_18d1c0f9-aaf9-4d96-89ff-ae452a592442_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_68fe6cd5-7d63-4cca-90eb-bf2386929961_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_PerformanceConditionRestrictedStockMember_15a6872b-6800-4d02-aa1e-60db4c7cbddc_terseLabel_en-US" xlink:label="lab_arqt_PerformanceConditionRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Condition Restricted Stock</link:label>
    <link:label id="lab_arqt_PerformanceConditionRestrictedStockMember_label_en-US" xlink:label="lab_arqt_PerformanceConditionRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Condition Restricted Stock [Member]</link:label>
    <link:label id="lab_arqt_PerformanceConditionRestrictedStockMember_documentation_en-US" xlink:label="lab_arqt_PerformanceConditionRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Condition Restricted Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PerformanceConditionRestrictedStockMember" xlink:href="arqt-20200331.xsd#arqt_PerformanceConditionRestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_PerformanceConditionRestrictedStockMember" xlink:to="lab_arqt_PerformanceConditionRestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_05982048-15a9-4803-8acb-b926acf71c8b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease payments</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_f492ef40-e9b5-46f3-93b5-5a3c8a91a5d3_terseLabel_en-US" xlink:label="lab_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="arqt-20200331.xsd#arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_EmergingGrowthCompanyStatusPolicyTextBlock_a0fa8641-8b77-444c-8e18-ba01e63b2a9e_terseLabel_en-US" xlink:label="lab_arqt_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Growth Company Status</link:label>
    <link:label id="lab_arqt_EmergingGrowthCompanyStatusPolicyTextBlock_label_en-US" xlink:label="lab_arqt_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Growth Company Status [Policy Text Block]</link:label>
    <link:label id="lab_arqt_EmergingGrowthCompanyStatusPolicyTextBlock_documentation_en-US" xlink:label="lab_arqt_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Growth Company Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:href="arqt-20200331.xsd#arqt_EmergingGrowthCompanyStatusPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="lab_arqt_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3b3caba9-e625-45d7-b218-970538d65912_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f23e393f-06f6-43f0-ac57-5d93be07a4d8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_7c6f607d-d6bf-4b9d-a3a4-c31961b2c7e3_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5bd68074-1c55-40a7-a345-f59c86861ae4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6c7dc094-5d5a-4200-ade8-2e0421fde989_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c4eeb989-b6c9-4a45-a537-b7521dceba9c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2a54791c-c3fe-4519-bb74-9989d7e94917_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0cfb194d-11c6-4f4c-b759-5bc73a788144_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_33469a82-cd49-4981-a785-59f0749fec3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b66945d3-f7e2-4762-bd89-5ce0f0f4e0b1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9a72ff1e-b7c6-4c61-a831-7942bf13a4f7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_0261e449-bea5-4d09-83d5-b1e4340b132b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_d105850b-9061-4a51-84eb-c1caa8a6c3f1_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_4583d6e7-0e46-439f-ae5f-f2446b5ab696_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cb9ac553-aa1f-48a8-b067-171556fd813e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (April through December)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1cae42bd-bdd3-48d7-b829-4e85e50997e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_92a96b8d-f6dc-4b17-805e-abe35ac06b7a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (in months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9dbde226-3264-4fdb-b49f-f893aae8a3f6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_3f0b04ee-8bf7-4dda-aed4-13834bf8058b_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LeaseDescriptionAxis_d7341337-f49c-472f-8eb4-d319d85198af_terseLabel_en-US" xlink:label="lab_arqt_LeaseDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Description [Axis]</link:label>
    <link:label id="lab_arqt_LeaseDescriptionAxis_label_en-US" xlink:label="lab_arqt_LeaseDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Description [Axis]</link:label>
    <link:label id="lab_arqt_LeaseDescriptionAxis_documentation_en-US" xlink:label="lab_arqt_LeaseDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LeaseDescriptionAxis" xlink:href="arqt-20200331.xsd#arqt_LeaseDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LeaseDescriptionAxis" xlink:to="lab_arqt_LeaseDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_cc540b28-ccd6-4fc8-a624-7c3b82eb2ead_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_5a43e7a3-ea5f-4d18-b4d6-9a293462428b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_b2339234-56a1-4ef6-86f8-2a68f12f24c3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9346ed90-5f9a-4ee6-a07d-6006dabcd1a0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_643b94a1-2f80-4d52-b3a2-4619f0a773b8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e10af814-c1e7-4b7f-bac4-6211377ed8f5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_77e1f7b8-79e1-41da-8ebf-9490030afd13_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters' option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8265411d-607f-4b19-8d0f-1d0156a86d8b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9dbf3861-381a-4d11-88a8-9400025eb029_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ed484f16-970a-48ff-ba48-3320c4e37356_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_f59b607b-06ef-45f2-a5ee-19d4420c1945_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_052a1b4c-b30c-4869-a376-3dd0e7c97d35_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_b4c42855-f430-4da6-b184-bee5d45246ec_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_d40723e4-3f02-4b81-93c8-55caccf99240_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_826f1794-0e50-4546-a489-e04cd99ce51d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition period for unrecognized compensation costs related to unvested options expected to vest</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_427a96f4-c6e8-4437-b94b-40d436797e8a_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation Preference</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Liquidation Preference</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1e185add-31a6-4f44-b79c-e6a975faf493_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_84efe809-c806-4361-9952-218b5dcc7e74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_74ba927a-ba71-4c0e-9a27-182b2dd084c7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_230c3c71-762a-4281-b66f-58f95847a791_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_01fbf0a9-d4cd-4e5f-adae-d9defe989b16_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_c4f0014f-58a2-42a7-bace-3e641c9e8cd2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LesseeOperatingLeaseMonthlyRentExpense_1c432ac6-70fd-4f92-afed-19ce0f406992_terseLabel_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseMonthlyRentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Straight-line rent expense</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseMonthlyRentExpense_label_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseMonthlyRentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Expense</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseMonthlyRentExpense_documentation_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseMonthlyRentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseMonthlyRentExpense" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseMonthlyRentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LesseeOperatingLeaseMonthlyRentExpense" xlink:to="lab_arqt_LesseeOperatingLeaseMonthlyRentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_2a5b2acb-3136-435f-9a3c-84303ba2297e_terseLabel_en-US" xlink:label="lab_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and debt securities, available for sale</link:label>
    <link:label id="lab_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_label_en-US" xlink:label="lab_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Debt Securities, Available For Sale, Fair Value Disclosure</link:label>
    <link:label id="lab_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_documentation_en-US" xlink:label="lab_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Debt Securities, Available For Sale, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" xlink:href="arqt-20200331.xsd#arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" xlink:to="lab_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28af1bc7-5c88-4a20-ace7-9576487c844e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_bbac3ae9-2b28-4346-8ee9-b41adaafc0c4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock, as a percentage of closing trading price per share</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties_2e1d6dd6-c367-4ba4-b4c1-3834d9a4073b_terseLabel_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments, milestones or royalties</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties_label_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Payments, Milestones, Or Royalties</link:label>
    <link:label id="lab_arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties_documentation_en-US" xlink:label="lab_arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Payments, Milestones, Or Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties" xlink:href="arqt-20200331.xsd#arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties" xlink:to="lab_arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_b5a005f9-0526-4e2b-b870-839e5f48e8d0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Current, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d30996ef-ba06-48bc-b9b6-fe78da80941a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_846a3f09-ad90-4be5-8c7d-917098bce10a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_e03b671e-b298-465b-837a-c18470831acd_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0861c185-163b-4f7a-b988-8d3bdc5401bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First anniversary date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_bbefe442-a472-467f-8854-e9a91ece8e63_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_35d593c3-8cbc-4f88-ac88-311c914b3a2f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_78c9969e-2104-4a2e-8e25-011825c59217_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_be6e3856-a810-4ff8-816e-c95ca0577be5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly basis</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_d3f53797-1cec-49e1-851f-2cf842da8cc9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_18df7cf3-6df1-4f33-b8e9-e40d3fa43f26_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_b550d36e-a3cb-4a9d-8472-99e12ae75733_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e1493e37-5148-4867-96a2-1b6fd265ad03_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_238ddb04-45a6-4f57-b2d9-45fba88ef5a9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f2c9aacd-fc73-4137-87df-8a4780229d1a_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_26af97a6-6bf8-4bd9-973a-e72e2430927c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_WestlakeVillageCaliforniaLeaseArrangementMember_67c9d7aa-4c31-457b-b457-dbd0f514153c_terseLabel_en-US" xlink:label="lab_arqt_WestlakeVillageCaliforniaLeaseArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Westlake Village, California Lease Arrangement</link:label>
    <link:label id="lab_arqt_WestlakeVillageCaliforniaLeaseArrangementMember_label_en-US" xlink:label="lab_arqt_WestlakeVillageCaliforniaLeaseArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Westlake Village, California Lease Arrangement [Member]</link:label>
    <link:label id="lab_arqt_WestlakeVillageCaliforniaLeaseArrangementMember_documentation_en-US" xlink:label="lab_arqt_WestlakeVillageCaliforniaLeaseArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Westlake Village, California Lease Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_WestlakeVillageCaliforniaLeaseArrangementMember" xlink:href="arqt-20200331.xsd#arqt_WestlakeVillageCaliforniaLeaseArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_WestlakeVillageCaliforniaLeaseArrangementMember" xlink:to="lab_arqt_WestlakeVillageCaliforniaLeaseArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_60fe3ff2-dec2-4f7b-a946-21dc02eda043_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_145a7db5-05d0-488a-8d41-c474244841c4_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_eec14115-d562-4fe7-ae3c-24fea656a383_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1ec9e51c-9389-42d0-8292-2bc8474f9838_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LesseeOperatingLeaseLetterOfCreditRequirement_b8b7f60b-1072-49c5-a91a-2fa773fb4d98_terseLabel_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseLetterOfCreditRequirement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available letter of credit</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseLetterOfCreditRequirement_label_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseLetterOfCreditRequirement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Letter Of Credit Requirement</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseLetterOfCreditRequirement_documentation_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseLetterOfCreditRequirement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Letter Of Credit Requirement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseLetterOfCreditRequirement" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseLetterOfCreditRequirement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LesseeOperatingLeaseLetterOfCreditRequirement" xlink:to="lab_arqt_LesseeOperatingLeaseLetterOfCreditRequirement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7bd7bd98-762a-430e-bb66-0979d12f8094_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_250d9dd2-8cc9-471f-9eda-067523a93401_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a3309583-47e4-4a5d-9508-8357c40597d9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_20aa6801-9a48-497e-942f-737669bef356_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_27e5d942-af3e-4ec9-86cb-5c09cf5824b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Shares of Stock for Issuance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares_04d34b41-061c-465c-9e6d-a45fabe8cc40_terseLabel_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of founder shares subject to repurchase (in shares)</link:label>
    <link:label id="lab_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares_label_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Vesting Of Founder Shares Subject To Repurchase, Shares</link:label>
    <link:label id="lab_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares_documentation_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Vesting Of Founder Shares Subject To Repurchase, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares" xlink:href="arqt-20200331.xsd#arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares" xlink:to="lab_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LesseeOperatingLeaseTermForTerminationOption_dd04387f-42c8-429e-9e91-03c527921a72_terseLabel_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseTermForTerminationOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term prior to termination option</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseTermForTerminationOption_label_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseTermForTerminationOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term For Termination Option</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseTermForTerminationOption_documentation_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseTermForTerminationOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term For Termination Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseTermForTerminationOption" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseTermForTerminationOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LesseeOperatingLeaseTermForTerminationOption" xlink:to="lab_arqt_LesseeOperatingLeaseTermForTerminationOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_08d29a4c-1749-4eba-81b7-1c229b980fc2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8021df59-9aaf-4510-b730-b570f053de98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3482d9f0-58b2-4d85-a69d-c682c907f458_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ea82d597-1ef4-47f4-b993-196c204caafe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_StockPurchaseAgreementTrancheTwoMember_ec1b8a85-382b-4510-9a6c-e361501a77f6_terseLabel_en-US" xlink:label="lab_arqt_StockPurchaseAgreementTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Tranche Two</link:label>
    <link:label id="lab_arqt_StockPurchaseAgreementTrancheTwoMember_label_en-US" xlink:label="lab_arqt_StockPurchaseAgreementTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Tranche Two [Member]</link:label>
    <link:label id="lab_arqt_StockPurchaseAgreementTrancheTwoMember_documentation_en-US" xlink:label="lab_arqt_StockPurchaseAgreementTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementTrancheTwoMember" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_StockPurchaseAgreementTrancheTwoMember" xlink:to="lab_arqt_StockPurchaseAgreementTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_849974cd-d5f0-4942-bd89-d685aab10bba_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f81abe25-0cc0-4773-a6a1-e0240f56fc1c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_99075672-ab8e-4a6b-9b8f-f1d979bf4c7e_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units outstanding</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0aca7a06-05de-4e55-9121-e81f2ba6e0c2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_464700c3-7c76-48f3-8fa4-48f4805dcde6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_8ebf05b7-f0f4-4925-9931-145b52cf0c61_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04d28916-cec6-47a6-bfcd-e75cd34ce8e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_d63c26f7-f1c8-4283-8c7d-e8b9dfc12535_terseLabel_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of repurchase rights related to common stock issued pursuant to early exercises (in shares)</link:label>
    <link:label id="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_label_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Lapse of Repurchase Rights Related to Common Stock Issued Pursuant to Early Exercises, Shares</link:label>
    <link:label id="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_documentation_en-US" xlink:label="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Lapse of Repurchase Rights Related to Common Stock Issued Pursuant to Early Exercises, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:href="arqt-20200331.xsd#arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:to="lab_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_b40a14fb-c76f-4328-aea1-f4f7945f603c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_e78b86d1-4e17-4b8d-abac-3337b685b173_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 300,000,000 and 65,820,000 shares authorized at March 31, 2020 and December&#160;31, 2019, respectively; 38,154,550 and 2,879,763 shares issued at March 31, 2020 and December&#160;31, 2019, respectively; 37,471,997 and 2,120,853 shares outstanding at March 31, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_c9ace830-08a7-4c74-b979-61905ba6652c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_2ce6d04e-5c87-435d-a12a-2a42db76c7da_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_EarlyExercisedOptionsMember_c0a6d62e-0254-431c-b6f6-18823da7b4bd_verboseLabel_en-US" xlink:label="lab_arqt_EarlyExercisedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercised options subject to future vesting</link:label>
    <link:label id="lab_arqt_EarlyExercisedOptionsMember_label_en-US" xlink:label="lab_arqt_EarlyExercisedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Exercised Options [Member]</link:label>
    <link:label id="lab_arqt_EarlyExercisedOptionsMember_documentation_en-US" xlink:label="lab_arqt_EarlyExercisedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Exercised Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_EarlyExercisedOptionsMember" xlink:href="arqt-20200331.xsd#arqt_EarlyExercisedOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_EarlyExercisedOptionsMember" xlink:to="lab_arqt_EarlyExercisedOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_1ac2a753-adb6-42f1-bdbf-2c8ae1fd8648_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_db24a5c1-f3bb-46aa-bfff-8f0eeb567cc4_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_91b0cf42-99d9-4ac8-bec4-1253426d77d5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_05b79cba-7552-4302-85ce-1c16162ca681_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_ec495d56-f914-43ba-83e2-552da68d2bd4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_78880159-b6e5-4913-8ed9-22da0b1373fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b44d801-8900-40ea-bf8b-fa4fe276eaa7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_68fb6894-5ad5-43b6-acca-5f5f4e0c318b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_f32ba0a4-8157-40af-9463-952ae83992ea_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e2255c00-64ce-4fe2-9dbd-ea0ed9d78784_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_362fc786-2b71-4001-adeb-86fc810c6e37_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c6af675c-88d6-4a98-973c-7277f4c8d64f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_443fa8cb-6f5e-42e6-b311-c3af229354c0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_9903c027-7582-4ff8-862c-b690a5cb2251_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_63ef1125-e326-43bb-8f89-08d83d207596_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9bb6a3dc-3ba5-4bc0-9aa1-b78857bfc8ee_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fc8ebdea-8704-483e-9689-557121c8f5cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_e19ae31d-5bba-4ef8-a3eb-e596d1993462_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of options vested during the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_afe04440-a1ab-4de2-92fe-1c9b9899050f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization/accretion on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_51ed0897-4cad-4054-9c5b-6bec132fe1cd_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ef25e2c0-73a7-40d2-8faf-369d6cb12298_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_LesseeOperatingLeaseTenantImprovementAllowance_3a394ca4-a3e8-4361-868a-20ab140e3865_terseLabel_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseTenantImprovementAllowance_label_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Tenant Improvement Allowance</link:label>
    <link:label id="lab_arqt_LesseeOperatingLeaseTenantImprovementAllowance_documentation_en-US" xlink:label="lab_arqt_LesseeOperatingLeaseTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Tenant Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseTenantImprovementAllowance" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseTenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_LesseeOperatingLeaseTenantImprovementAllowance" xlink:to="lab_arqt_LesseeOperatingLeaseTenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_ed868373-0064-4c20-96b5-1b09ff7c34bd_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_59b2f722-1d51-4a73-a74f-9c508e5ce58d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock into common stock upon initial public offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_4c02cffb-8ad2-4076-9e7d-54805caac821_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 and no shares authorized at March 31, 2020 and December 31, 2019, respectively; no shares issued and outstanding at March 31, 2020 and December 31, 2019;</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_8c71afd9-562b-4f91-ac4c-8677cde032c1_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_de5c9699-91bb-4c08-8654-9567d135b8a2_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_222de590-c611-45ec-aca7-cafa54486ec9_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_bc9b0ca6-b2d3-4722-8105-de5a28b438df_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8fa08109-d2c1-430a-a0df-3ead6b0e1bde_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, estimated fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_eca02289-5a7d-4b4e-b310-44dacd0cb02e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_752c114a-ae54-48bd-b1b6-86f9515fc913_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially antidilutive shares excluded from the calculation of net loss per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_4ebb8193-9c58-4cc2-95df-a2458873e097_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_11aaf7fb-6022-49a7-a727-46bf18b97b36_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_92f3cc89-109c-4d2a-9b3e-8741bb9fea3e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d9e18ce-8574-4379-8e0a-e47be21627be_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6fb9e271-888d-4639-b0f4-8c9330b247bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ad526ac8-867f-463a-b760-e03ebbdd99f8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arqt_CommonStockVotingRightsNumberOfVotesPerShare_2eaecfd5-739d-4578-a9a6-a4b8616f7390_terseLabel_en-US" xlink:label="lab_arqt_CommonStockVotingRightsNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Votes per share of common stock</link:label>
    <link:label id="lab_arqt_CommonStockVotingRightsNumberOfVotesPerShare_label_en-US" xlink:label="lab_arqt_CommonStockVotingRightsNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes Per Share</link:label>
    <link:label id="lab_arqt_CommonStockVotingRightsNumberOfVotesPerShare_documentation_en-US" xlink:label="lab_arqt_CommonStockVotingRightsNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CommonStockVotingRightsNumberOfVotesPerShare" xlink:href="arqt-20200331.xsd#arqt_CommonStockVotingRightsNumberOfVotesPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arqt_CommonStockVotingRightsNumberOfVotesPerShare" xlink:to="lab_arqt_CommonStockVotingRightsNumberOfVotesPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_61579140-f6d3-4581-95f2-5e2ea3114579_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_039768e4-8a4c-4905-b877-24e3af9441b3_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0bb3564c-8d65-4b72-ad24-aa8bd1795e5e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c4606168-f124-4ef7-beff-10df0463f958_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_251eac61-3272-4322-92fb-19b3d5fd09d4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_9327960a-ee44-4322-8e9c-eaea2e66d9fd_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP shares subject to future issuance</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_fdccb493-cdca-45c6-ae76-863b0ecf89e7_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>arqt-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:600b0262-d663-4687-ae47-6802ec869b02,g:c1b67e0b-9b7c-4732-b64c-b3f7b7d96647-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://arcutis.com/role/CoverPage" xlink:type="simple" xlink:href="arqt-20200331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_cf2fd039-1a0a-4976-9c1d-7262ca561e04" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_DocumentType_cf2fd039-1a0a-4976-9c1d-7262ca561e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_474bc2a6-6a93-4425-a17b-29f8b146c1eb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_DocumentQuarterlyReport_474bc2a6-6a93-4425-a17b-29f8b146c1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_17c32d57-01f2-4904-a586-a09f5ca3c084" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_DocumentPeriodEndDate_17c32d57-01f2-4904-a586-a09f5ca3c084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_63770c45-3b4a-4c3a-a4ca-ea26110661e9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_DocumentTransitionReport_63770c45-3b4a-4c3a-a4ca-ea26110661e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a8931cae-91cd-4352-b2c8-8735a688372e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntityFileNumber_a8931cae-91cd-4352-b2c8-8735a688372e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6ea520dd-634a-4c1d-8f9c-905cadc12913" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntityRegistrantName_6ea520dd-634a-4c1d-8f9c-905cadc12913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4dbdce95-2bd6-4991-b8c4-a76ab9cfc557" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4dbdce95-2bd6-4991-b8c4-a76ab9cfc557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_44360953-4868-4dac-94b8-50f1bc27b1cb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntityTaxIdentificationNumber_44360953-4868-4dac-94b8-50f1bc27b1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_bbac4422-1088-44a4-a233-11e55ffd0cfd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntityAddressAddressLine1_bbac4422-1088-44a4-a233-11e55ffd0cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_90abfa5a-df49-459c-ad06-138755dc5ae9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntityAddressAddressLine2_90abfa5a-df49-459c-ad06-138755dc5ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_fe7c3995-4a82-4f56-b53a-baf76552f89e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntityAddressCityOrTown_fe7c3995-4a82-4f56-b53a-baf76552f89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_135ba487-24eb-4666-b09b-1c3d7347be1b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntityAddressStateOrProvince_135ba487-24eb-4666-b09b-1c3d7347be1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_700bcc40-fd52-412e-87b8-d65a78b3eedc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntityAddressPostalZipCode_700bcc40-fd52-412e-87b8-d65a78b3eedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f79c64c8-038a-4213-b0b5-4f0c194bc803" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_CityAreaCode_f79c64c8-038a-4213-b0b5-4f0c194bc803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_278c7def-49a8-46b3-891e-536ea6aa486d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_LocalPhoneNumber_278c7def-49a8-46b3-891e-536ea6aa486d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2e3a5f36-7554-41d1-afbc-39fe54481d3c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_Security12bTitle_2e3a5f36-7554-41d1-afbc-39fe54481d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a85d3b7b-6daa-4453-9fc0-c6f76b8ba3c6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_TradingSymbol_a85d3b7b-6daa-4453-9fc0-c6f76b8ba3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_293769ff-fce0-43ee-b3a8-faaa98771e58" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_SecurityExchangeName_293769ff-fce0-43ee-b3a8-faaa98771e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_330a4229-4808-43cf-b796-50a2ba17cb04" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntityCurrentReportingStatus_330a4229-4808-43cf-b796-50a2ba17cb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_8167979e-3bc3-4314-913f-28fe930e5247" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntityInteractiveDataCurrent_8167979e-3bc3-4314-913f-28fe930e5247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2bf678c1-99fa-49cb-b8ad-e804fb345193" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntityFilerCategory_2bf678c1-99fa-49cb-b8ad-e804fb345193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_64aacd51-92f1-44fd-b685-f9a6f2efc649" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntitySmallBusiness_64aacd51-92f1-44fd-b685-f9a6f2efc649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_336156f7-3955-4c4a-8259-b6e89ca69b96" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntityEmergingGrowthCompany_336156f7-3955-4c4a-8259-b6e89ca69b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_eab60774-55c9-4648-b61f-8f25d321af5b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntityExTransitionPeriod_eab60774-55c9-4648-b61f-8f25d321af5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4a72aad0-1fd6-4559-93c7-3f273f701013" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntityShellCompany_4a72aad0-1fd6-4559-93c7-3f273f701013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_933b089a-1795-4b84-aeea-c2653dfaab4e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_933b089a-1795-4b84-aeea-c2653dfaab4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d593c818-30c8-4b72-90e8-5d8af0d0367b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_EntityCentralIndexKey_d593c818-30c8-4b72-90e8-5d8af0d0367b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_11295c8b-54a0-40a3-8d60-334062f535ff" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_CurrentFiscalYearEndDate_11295c8b-54a0-40a3-8d60-334062f535ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2f399162-b643-4083-b220-01ee2c88f759" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_DocumentFiscalYearFocus_2f399162-b643-4083-b220-01ee2c88f759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_95d2244c-6131-4c9e-a6e1-56394dca1d84" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_95d2244c-6131-4c9e-a6e1-56394dca1d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4501d8d9-7feb-4794-8310-bdd11aa1a067" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2b3ae536-2457-4161-918e-6de937549b6a" xlink:to="loc_dei_AmendmentFlag_4501d8d9-7feb-4794-8310-bdd11aa1a067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9d0d693c-f325-4386-94f0-2fdb9c663074" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ff3d668e-f1a2-4c78-a2d7-e002a9c12bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9d0d693c-f325-4386-94f0-2fdb9c663074" xlink:to="loc_us-gaap_AssetsAbstract_ff3d668e-f1a2-4c78-a2d7-e002a9c12bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c841cfbe-1ced-4ef3-b2ea-548027ce568c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ff3d668e-f1a2-4c78-a2d7-e002a9c12bb4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c841cfbe-1ced-4ef3-b2ea-548027ce568c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8828c31-533d-44dd-a3cf-0d66531a86f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c841cfbe-1ced-4ef3-b2ea-548027ce568c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8828c31-533d-44dd-a3cf-0d66531a86f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_84c1a438-13b7-4139-b0a6-1a682323c892" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c841cfbe-1ced-4ef3-b2ea-548027ce568c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_84c1a438-13b7-4139-b0a6-1a682323c892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9e715001-51af-4f04-93fc-a9c9bc92287c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c841cfbe-1ced-4ef3-b2ea-548027ce568c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9e715001-51af-4f04-93fc-a9c9bc92287c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_88ddae65-44d7-4057-8700-f3c26bc0d114" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c841cfbe-1ced-4ef3-b2ea-548027ce568c" xlink:to="loc_us-gaap_AssetsCurrent_88ddae65-44d7-4057-8700-f3c26bc0d114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2e737cf0-3cf1-4804-ac28-d6f9554928bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ff3d668e-f1a2-4c78-a2d7-e002a9c12bb4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2e737cf0-3cf1-4804-ac28-d6f9554928bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_67728a3a-830b-4439-8c5c-b20f5ba8b254" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ff3d668e-f1a2-4c78-a2d7-e002a9c12bb4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_67728a3a-830b-4439-8c5c-b20f5ba8b254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2b2b64f7-7bab-4191-8e25-48e249f748dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ff3d668e-f1a2-4c78-a2d7-e002a9c12bb4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2b2b64f7-7bab-4191-8e25-48e249f748dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7f062db1-2276-4d58-93f1-827668797fe0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ff3d668e-f1a2-4c78-a2d7-e002a9c12bb4" xlink:to="loc_us-gaap_Assets_7f062db1-2276-4d58-93f1-827668797fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_68cd6808-1129-4867-a36e-5292ca8ea6a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9d0d693c-f325-4386-94f0-2fdb9c663074" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_68cd6808-1129-4867-a36e-5292ca8ea6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_50f666ea-59f2-4468-b0a4-58e3245e452e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_68cd6808-1129-4867-a36e-5292ca8ea6a7" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_50f666ea-59f2-4468-b0a4-58e3245e452e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8e324987-a7ff-483c-9c75-62578ac6fb3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_50f666ea-59f2-4468-b0a4-58e3245e452e" xlink:to="loc_us-gaap_AccountsPayableCurrent_8e324987-a7ff-483c-9c75-62578ac6fb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4dadbc52-1884-4f80-b50f-f72554ecb99e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_50f666ea-59f2-4468-b0a4-58e3245e452e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4dadbc52-1884-4f80-b50f-f72554ecb99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9f236c01-d28f-45ad-9927-a94d697aac71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_50f666ea-59f2-4468-b0a4-58e3245e452e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9f236c01-d28f-45ad-9927-a94d697aac71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_634dca24-7cbc-4cf9-9da2-34678146f2b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_50f666ea-59f2-4468-b0a4-58e3245e452e" xlink:to="loc_us-gaap_LiabilitiesCurrent_634dca24-7cbc-4cf9-9da2-34678146f2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b0cf7e60-d199-4c42-aefa-884f06d7c486" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_68cd6808-1129-4867-a36e-5292ca8ea6a7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b0cf7e60-d199-4c42-aefa-884f06d7c486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3a5de8b4-d81b-4c85-b3ad-feea5b39d081" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_68cd6808-1129-4867-a36e-5292ca8ea6a7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3a5de8b4-d81b-4c85-b3ad-feea5b39d081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_868509ca-17e4-415a-a506-b6b1730db00a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_68cd6808-1129-4867-a36e-5292ca8ea6a7" xlink:to="loc_us-gaap_Liabilities_868509ca-17e4-415a-a506-b6b1730db00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_f30748bd-7615-4c42-9bc9-61d6ba877234" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_68cd6808-1129-4867-a36e-5292ca8ea6a7" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_f30748bd-7615-4c42-9bc9-61d6ba877234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_11ca23e6-636c-468c-8ff3-a015d6cbc72e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_68cd6808-1129-4867-a36e-5292ca8ea6a7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_11ca23e6-636c-468c-8ff3-a015d6cbc72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_edafec28-bbed-4811-a274-62aade19cc20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_68cd6808-1129-4867-a36e-5292ca8ea6a7" xlink:to="loc_us-gaap_StockholdersEquityAbstract_edafec28-bbed-4811-a274-62aade19cc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_dee7bc0d-7c42-49ff-8836-abf6abace9bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edafec28-bbed-4811-a274-62aade19cc20" xlink:to="loc_us-gaap_PreferredStockValue_dee7bc0d-7c42-49ff-8836-abf6abace9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2a73c872-8b33-4579-b3c5-1b5a91f5fe75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edafec28-bbed-4811-a274-62aade19cc20" xlink:to="loc_us-gaap_CommonStockValue_2a73c872-8b33-4579-b3c5-1b5a91f5fe75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a29fdac4-7c33-441f-848c-c2c2d903af40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edafec28-bbed-4811-a274-62aade19cc20" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a29fdac4-7c33-441f-848c-c2c2d903af40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b48583c4-53a5-4e73-9eb0-f4fb81dfbffe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edafec28-bbed-4811-a274-62aade19cc20" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b48583c4-53a5-4e73-9eb0-f4fb81dfbffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fc6f8dae-5580-43b3-9d90-5d1f80e7394e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edafec28-bbed-4811-a274-62aade19cc20" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fc6f8dae-5580-43b3-9d90-5d1f80e7394e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b2058be1-6c6d-43d9-86a0-a1f06af33b37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_edafec28-bbed-4811-a274-62aade19cc20" xlink:to="loc_us-gaap_StockholdersEquity_b2058be1-6c6d-43d9-86a0-a1f06af33b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7281c1fe-8489-4093-b485-badee4e1516b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_68cd6808-1129-4867-a36e-5292ca8ea6a7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_7281c1fe-8489-4093-b485-badee4e1516b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a6d32d17-1199-4e2a-b1a9-1b956eb37467" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_2bff066d-f77e-4f68-981e-df587671e03b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6d32d17-1199-4e2a-b1a9-1b956eb37467" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_2bff066d-f77e-4f68-981e-df587671e03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_51686155-320a-4137-828f-065b864be188" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6d32d17-1199-4e2a-b1a9-1b956eb37467" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_51686155-320a-4137-828f-065b864be188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_afb7139c-10ea-4e62-8086-13ab1b51ba94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6d32d17-1199-4e2a-b1a9-1b956eb37467" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_afb7139c-10ea-4e62-8086-13ab1b51ba94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_6f774a59-7f57-4874-9f34-646800c15cc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6d32d17-1199-4e2a-b1a9-1b956eb37467" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_6f774a59-7f57-4874-9f34-646800c15cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_aab54205-bc17-4448-b3bc-a07bcd726f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6d32d17-1199-4e2a-b1a9-1b956eb37467" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_aab54205-bc17-4448-b3bc-a07bcd726f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7e65942f-ab76-41b0-be85-62fcc4b1381e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6d32d17-1199-4e2a-b1a9-1b956eb37467" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7e65942f-ab76-41b0-be85-62fcc4b1381e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4e8cecac-96fa-4949-9f53-36c5650db49e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6d32d17-1199-4e2a-b1a9-1b956eb37467" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4e8cecac-96fa-4949-9f53-36c5650db49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e5b413f0-f39c-4342-997f-952067c058f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6d32d17-1199-4e2a-b1a9-1b956eb37467" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e5b413f0-f39c-4342-997f-952067c058f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f6587e32-d5b2-496f-a673-2aa9c330b1d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6d32d17-1199-4e2a-b1a9-1b956eb37467" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f6587e32-d5b2-496f-a673-2aa9c330b1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_886eb431-173c-400d-8f03-8e4a8e608e58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6d32d17-1199-4e2a-b1a9-1b956eb37467" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_886eb431-173c-400d-8f03-8e4a8e608e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_fae26638-0e63-4402-9aca-fe09e033b9eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6d32d17-1199-4e2a-b1a9-1b956eb37467" xlink:to="loc_us-gaap_CommonStockSharesIssued_fae26638-0e63-4402-9aca-fe09e033b9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_379996fb-f7aa-4586-8263-6e11380c58a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6d32d17-1199-4e2a-b1a9-1b956eb37467" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_379996fb-f7aa-4586-8263-6e11380c58a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7dcd06c5-85c5-422b-9d80-e4144d153087" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_96d58892-928f-4c01-8dc6-2edd5e162c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7dcd06c5-85c5-422b-9d80-e4144d153087" xlink:to="loc_us-gaap_OperatingExpensesAbstract_96d58892-928f-4c01-8dc6-2edd5e162c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_71594006-b476-43e5-9b82-cddc0358adc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_96d58892-928f-4c01-8dc6-2edd5e162c3b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_71594006-b476-43e5-9b82-cddc0358adc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_08f7a251-5e8d-44aa-bd01-2229acc9e496" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_96d58892-928f-4c01-8dc6-2edd5e162c3b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_08f7a251-5e8d-44aa-bd01-2229acc9e496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0fdb291f-381b-4a75-adde-4897531e4934" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_96d58892-928f-4c01-8dc6-2edd5e162c3b" xlink:to="loc_us-gaap_OperatingExpenses_0fdb291f-381b-4a75-adde-4897531e4934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_05f69c30-071c-42cc-b4f6-6929ea650f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7dcd06c5-85c5-422b-9d80-e4144d153087" xlink:to="loc_us-gaap_OperatingIncomeLoss_05f69c30-071c-42cc-b4f6-6929ea650f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d167f486-7714-4113-bddb-68362aa43fa7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7dcd06c5-85c5-422b-9d80-e4144d153087" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d167f486-7714-4113-bddb-68362aa43fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fe56e065-6b6d-41d3-b42d-a11cd291ad25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7dcd06c5-85c5-422b-9d80-e4144d153087" xlink:to="loc_us-gaap_NetIncomeLoss_fe56e065-6b6d-41d3-b42d-a11cd291ad25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b8fe95bb-6dbe-4e78-bf26-d5b31f522916" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7dcd06c5-85c5-422b-9d80-e4144d153087" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b8fe95bb-6dbe-4e78-bf26-d5b31f522916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a561c401-6add-4bed-9f9a-a5ec73c1c046" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b8fe95bb-6dbe-4e78-bf26-d5b31f522916" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a561c401-6add-4bed-9f9a-a5ec73c1c046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ac51e917-b048-49ef-b106-6dfd4b73eba1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b8fe95bb-6dbe-4e78-bf26-d5b31f522916" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ac51e917-b048-49ef-b106-6dfd4b73eba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_e2fa5dcc-0c71-458f-ac87-c2ef3639d6dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7dcd06c5-85c5-422b-9d80-e4144d153087" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_e2fa5dcc-0c71-458f-ac87-c2ef3639d6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_c38b1baf-4453-4407-ab04-d22e95c360f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_e2fa5dcc-0c71-458f-ac87-c2ef3639d6dc" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_c38b1baf-4453-4407-ab04-d22e95c360f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_a83629f3-ebf3-499a-91bf-cd092b96bd0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_e2fa5dcc-0c71-458f-ac87-c2ef3639d6dc" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_a83629f3-ebf3-499a-91bf-cd092b96bd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6c2d4bb0-6a1c-49cb-afb5-f1b560a1628b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e934c51a-ed0f-446d-9fe5-d267c843a595" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6c2d4bb0-6a1c-49cb-afb5-f1b560a1628b" xlink:to="loc_us-gaap_StatementTable_e934c51a-ed0f-446d-9fe5-d267c843a595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c8183cd7-646c-4380-a20f-fb31249059d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e934c51a-ed0f-446d-9fe5-d267c843a595" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c8183cd7-646c-4380-a20f-fb31249059d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_591209dd-2986-4e2d-8df9-3b8c9649659f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c8183cd7-646c-4380-a20f-fb31249059d5" xlink:to="loc_us-gaap_EquityComponentDomain_591209dd-2986-4e2d-8df9-3b8c9649659f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5bfd22e2-148a-4dc6-b8f6-6c752e53c37f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_591209dd-2986-4e2d-8df9-3b8c9649659f" xlink:to="loc_us-gaap_CommonStockMember_5bfd22e2-148a-4dc6-b8f6-6c752e53c37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6fec8d39-0a7d-499a-a5a1-a6b95e3415b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_591209dd-2986-4e2d-8df9-3b8c9649659f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6fec8d39-0a7d-499a-a5a1-a6b95e3415b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7fbca021-c598-4aef-80ff-643d13098a9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_591209dd-2986-4e2d-8df9-3b8c9649659f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7fbca021-c598-4aef-80ff-643d13098a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ea92f2d5-8a1b-48f6-8edf-f9b34dcc4797" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_591209dd-2986-4e2d-8df9-3b8c9649659f" xlink:to="loc_us-gaap_RetainedEarningsMember_ea92f2d5-8a1b-48f6-8edf-f9b34dcc4797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_84e96e7b-9779-44b4-95af-c219b178d4d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e934c51a-ed0f-446d-9fe5-d267c843a595" xlink:to="loc_us-gaap_StatementLineItems_84e96e7b-9779-44b4-95af-c219b178d4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4d1dc41-1fdd-4b43-890a-30c8c336733a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_84e96e7b-9779-44b4-95af-c219b178d4d4" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4d1dc41-1fdd-4b43-890a-30c8c336733a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_ab6c9b35-74ab-4bdb-91da-bae4631c1a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4d1dc41-1fdd-4b43-890a-30c8c336733a" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_ab6c9b35-74ab-4bdb-91da-bae4631c1a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_fc87b854-ff4f-4856-b2f7-f2571b3fab52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4d1dc41-1fdd-4b43-890a-30c8c336733a" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_fc87b854-ff4f-4856-b2f7-f2571b3fab52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TemporaryEquitySharesConversionOfConvertibleSecurities_a658f2e7-8bb6-4942-9ad5-6a6d0ef915cd" xlink:href="arqt-20200331.xsd#arqt_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4d1dc41-1fdd-4b43-890a-30c8c336733a" xlink:to="loc_arqt_TemporaryEquitySharesConversionOfConvertibleSecurities_a658f2e7-8bb6-4942-9ad5-6a6d0ef915cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TemporaryEquityValueConversionOfConvertibleSecurities_fffd2cf4-85bf-47d8-898e-fa205504272e" xlink:href="arqt-20200331.xsd#arqt_TemporaryEquityValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4d1dc41-1fdd-4b43-890a-30c8c336733a" xlink:to="loc_arqt_TemporaryEquityValueConversionOfConvertibleSecurities_fffd2cf4-85bf-47d8-898e-fa205504272e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_2f6363b8-ea2f-4d07-9086-65dfb45482f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4d1dc41-1fdd-4b43-890a-30c8c336733a" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_2f6363b8-ea2f-4d07-9086-65dfb45482f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_d96cae7e-1ca8-435b-9d0b-1ec4885e9364" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4d1dc41-1fdd-4b43-890a-30c8c336733a" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_d96cae7e-1ca8-435b-9d0b-1ec4885e9364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_84e96e7b-9779-44b4-95af-c219b178d4d4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_dae9f7b1-6640-4183-9f4a-ae8b812a706d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_SharesOutstanding_dae9f7b1-6640-4183-9f4a-ae8b812a706d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c963c2b3-da75-41de-885d-ad3f9f512162" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_StockholdersEquity_c963c2b3-da75-41de-885d-ad3f9f512162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares_491fddc7-626d-4bb5-856f-bdd245262e7f" xlink:href="arqt-20200331.xsd#arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares_491fddc7-626d-4bb5-856f-bdd245262e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue_fc84cc57-ffd2-4a3b-b784-ca990c10a8b6" xlink:href="arqt-20200331.xsd#arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue_fc84cc57-ffd2-4a3b-b784-ca990c10a8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_47498c99-592a-4daf-8c44-4962d3a2560d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_47498c99-592a-4daf-8c44-4962d3a2560d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_665c8b85-a238-4c32-b768-300d9b25d9aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_665c8b85-a238-4c32-b768-300d9b25d9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_adfc06c6-d762-4780-bbec-28f5892aabb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_adfc06c6-d762-4780-bbec-28f5892aabb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_c384b1c8-0745-44df-8e1a-28e07fdabb4d" xlink:href="arqt-20200331.xsd#arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_c384b1c8-0745-44df-8e1a-28e07fdabb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises_a2d1ff06-8021-48c1-b6a7-407f2b063eee" xlink:href="arqt-20200331.xsd#arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises_a2d1ff06-8021-48c1-b6a7-407f2b063eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5a983b8b-7063-4d1c-b358-a27bdd148c85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5a983b8b-7063-4d1c-b358-a27bdd148c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_571f1576-f452-4299-add6-ef034a24db63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_571f1576-f452-4299-add6-ef034a24db63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8a2560a0-028b-4ebc-ba5a-f8c5e515b1e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8a2560a0-028b-4ebc-ba5a-f8c5e515b1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20adf8f9-c098-409c-a047-513c7f87a6fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20adf8f9-c098-409c-a047-513c7f87a6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_21c58dc1-6514-4551-b59b-cd34bda97c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_21c58dc1-6514-4551-b59b-cd34bda97c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_14622c05-464e-4eb9-b1ae-85bbfb56e450" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_14622c05-464e-4eb9-b1ae-85bbfb56e450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b6117cbd-8ca0-465f-8657-61005ac2dc3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_NetIncomeLoss_b6117cbd-8ca0-465f-8657-61005ac2dc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2f6033e1-e33a-4823-a698-4571bfe66cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_StockholdersEquity_2f6033e1-e33a-4823-a698-4571bfe66cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ca37a3c8-bcd5-49d3-aaef-7fcafbc1034b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_175d4e62-de76-439e-987c-6bdff5ed1e7e" xlink:to="loc_us-gaap_SharesOutstanding_ca37a3c8-bcd5-49d3-aaef-7fcafbc1034b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_49142d3a-4a9b-4824-b26c-87f8e18d3567" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_84ca50fb-44ba-44aa-a5c1-bb1bc000419b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_49142d3a-4a9b-4824-b26c-87f8e18d3567" xlink:to="loc_us-gaap_StatementTable_84ca50fb-44ba-44aa-a5c1-bb1bc000419b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_da355292-80ea-492f-8ac5-e4c7d7eadaa7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_84ca50fb-44ba-44aa-a5c1-bb1bc000419b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_da355292-80ea-492f-8ac5-e4c7d7eadaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_afa549e9-49b1-4d4c-808e-e3af05d8dc74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_da355292-80ea-492f-8ac5-e4c7d7eadaa7" xlink:to="loc_us-gaap_EquityComponentDomain_afa549e9-49b1-4d4c-808e-e3af05d8dc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_45131337-05ef-4c84-893a-2dddc02b5a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_afa549e9-49b1-4d4c-808e-e3af05d8dc74" xlink:to="loc_us-gaap_CommonStockMember_45131337-05ef-4c84-893a-2dddc02b5a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e5bd7c5a-6520-491e-9e86-a3c105f88d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_84ca50fb-44ba-44aa-a5c1-bb1bc000419b" xlink:to="loc_us-gaap_StatementLineItems_e5bd7c5a-6520-491e-9e86-a3c105f88d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_ec0955cf-c330-42d8-baed-c487e9d5dbf5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e5bd7c5a-6520-491e-9e86-a3c105f88d8d" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_ec0955cf-c330-42d8-baed-c487e9d5dbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="arqt-20200331.xsd#CondensedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6911347a-efd2-419c-8316-360d25c300f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_260ad736-0f78-46a5-bf63-7d01e7efb466" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6911347a-efd2-419c-8316-360d25c300f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_260ad736-0f78-46a5-bf63-7d01e7efb466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e0cd1e8a-7c18-48b5-8b10-f240ee54aa1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_260ad736-0f78-46a5-bf63-7d01e7efb466" xlink:to="loc_us-gaap_NetIncomeLoss_e0cd1e8a-7c18-48b5-8b10-f240ee54aa1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0ccd4845-f773-410e-977f-d18236f02144" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_260ad736-0f78-46a5-bf63-7d01e7efb466" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0ccd4845-f773-410e-977f-d18236f02144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0cc05cf2-1cb9-4b59-8fe2-658f5c06643a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0ccd4845-f773-410e-977f-d18236f02144" xlink:to="loc_us-gaap_Depreciation_0cc05cf2-1cb9-4b59-8fe2-658f5c06643a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_OperatingLeaseRightOfUseAssetAmortizationExpense_c30ee8f0-eef6-40d0-a4a6-79063c7b7224" xlink:href="arqt-20200331.xsd#arqt_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0ccd4845-f773-410e-977f-d18236f02144" xlink:to="loc_arqt_OperatingLeaseRightOfUseAssetAmortizationExpense_c30ee8f0-eef6-40d0-a4a6-79063c7b7224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6a98d9fe-6087-41ce-bc4a-f68570d7639b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0ccd4845-f773-410e-977f-d18236f02144" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6a98d9fe-6087-41ce-bc4a-f68570d7639b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6e9823d9-64b3-414d-83c6-2efb7b68a075" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0ccd4845-f773-410e-977f-d18236f02144" xlink:to="loc_us-gaap_ShareBasedCompensation_6e9823d9-64b3-414d-83c6-2efb7b68a075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_748ba772-485f-4821-bf5b-28ac42cdfd49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0ccd4845-f773-410e-977f-d18236f02144" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_748ba772-485f-4821-bf5b-28ac42cdfd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ba96d514-3e06-4864-8bd1-daa59ab72291" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_748ba772-485f-4821-bf5b-28ac42cdfd49" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ba96d514-3e06-4864-8bd1-daa59ab72291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_95302000-c885-4c46-8446-ac73bbc44d87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_748ba772-485f-4821-bf5b-28ac42cdfd49" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_95302000-c885-4c46-8446-ac73bbc44d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6ca42b27-96d1-4c1f-b010-c6413b7cbcef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_748ba772-485f-4821-bf5b-28ac42cdfd49" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6ca42b27-96d1-4c1f-b010-c6413b7cbcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e74b8b17-9d32-4467-b388-368642510d7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_748ba772-485f-4821-bf5b-28ac42cdfd49" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e74b8b17-9d32-4467-b388-368642510d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_IncreaseDecreaseInOperatingLeaseLiabilities_0316f431-125f-4ca4-bfa3-f1bd59c0d0f0" xlink:href="arqt-20200331.xsd#arqt_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_748ba772-485f-4821-bf5b-28ac42cdfd49" xlink:to="loc_arqt_IncreaseDecreaseInOperatingLeaseLiabilities_0316f431-125f-4ca4-bfa3-f1bd59c0d0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff88f670-35d4-4b5a-baa0-abc36dbd3ffa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_260ad736-0f78-46a5-bf63-7d01e7efb466" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff88f670-35d4-4b5a-baa0-abc36dbd3ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_adeaa25d-c80b-4abd-873b-409d11eccff0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6911347a-efd2-419c-8316-360d25c300f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_adeaa25d-c80b-4abd-873b-409d11eccff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5e5e1d7a-1dcb-4647-9c3b-7fe9331ceb20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_adeaa25d-c80b-4abd-873b-409d11eccff0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5e5e1d7a-1dcb-4647-9c3b-7fe9331ceb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7fda2469-e485-47db-88c1-3a753ac70011" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_adeaa25d-c80b-4abd-873b-409d11eccff0" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7fda2469-e485-47db-88c1-3a753ac70011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0c4f54dd-19f9-4f81-853d-5018871461bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_adeaa25d-c80b-4abd-873b-409d11eccff0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0c4f54dd-19f9-4f81-853d-5018871461bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_74d76acf-47eb-46e0-ba76-53cdfa3f99ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_adeaa25d-c80b-4abd-873b-409d11eccff0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_74d76acf-47eb-46e0-ba76-53cdfa3f99ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e0d76ead-86b5-48f9-8ca9-fb3e723ffadd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6911347a-efd2-419c-8316-360d25c300f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e0d76ead-86b5-48f9-8ca9-fb3e723ffadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a238922b-b62d-4a45-b795-13f8e4fd222e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e0d76ead-86b5-48f9-8ca9-fb3e723ffadd" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a238922b-b62d-4a45-b795-13f8e4fd222e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_ccadd5fd-ce5c-4130-9bb0-75b58c5d98a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e0d76ead-86b5-48f9-8ca9-fb3e723ffadd" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_ccadd5fd-ce5c-4130-9bb0-75b58c5d98a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_96b16495-242f-4f37-a27d-0f0103e562bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e0d76ead-86b5-48f9-8ca9-fb3e723ffadd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_96b16495-242f-4f37-a27d-0f0103e562bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_21e6e8a3-e9f3-4436-b005-a5ec8d113558" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6911347a-efd2-419c-8316-360d25c300f7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_21e6e8a3-e9f3-4436-b005-a5ec8d113558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_efaa9d88-4873-406e-9d8e-b483b0501e53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6911347a-efd2-419c-8316-360d25c300f7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_efaa9d88-4873-406e-9d8e-b483b0501e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0dc83448-a41f-4c3c-9bed-20aa287265a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6911347a-efd2-419c-8316-360d25c300f7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0dc83448-a41f-4c3c-9bed-20aa287265a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_47ecf1ad-a0a4-429e-9308-c87f7e2cdae3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6911347a-efd2-419c-8316-360d25c300f7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_47ecf1ad-a0a4-429e-9308-c87f7e2cdae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_74b41edb-5472-41fb-82dc-c9db9c40c5fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_47ecf1ad-a0a4-429e-9308-c87f7e2cdae3" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_74b41edb-5472-41fb-82dc-c9db9c40c5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_DeferredFinancingCostsIncurredButNotYetPaid_a79ee9fa-0204-48a6-9949-571520f2a07b" xlink:href="arqt-20200331.xsd#arqt_DeferredFinancingCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_47ecf1ad-a0a4-429e-9308-c87f7e2cdae3" xlink:to="loc_arqt_DeferredFinancingCostsIncurredButNotYetPaid_a79ee9fa-0204-48a6-9949-571520f2a07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="arqt-20200331.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad143c40-3f9d-47f3-9744-9f4c54a3a35d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_398d8d42-34eb-47da-95bc-7c7b4deb62e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad143c40-3f9d-47f3-9744-9f4c54a3a35d" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_398d8d42-34eb-47da-95bc-7c7b4deb62e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#OrganizationandDescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8c612190-caca-4851-a9bf-8a856a3f2e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3a156362-2761-4a43-9fa4-df70bf8926c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8c612190-caca-4851-a9bf-8a856a3f2e0b" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3a156362-2761-4a43-9fa4-df70bf8926c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6f97af40-c28b-4e17-9172-d8c27bd6139a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3a156362-2761-4a43-9fa4-df70bf8926c1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6f97af40-c28b-4e17-9172-d8c27bd6139a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5e9ced7-96b3-4d6e-a16d-6b691a3773e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6f97af40-c28b-4e17-9172-d8c27bd6139a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5e9ced7-96b3-4d6e-a16d-6b691a3773e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_e90621ba-53b3-4707-9965-2610673e44c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5e9ced7-96b3-4d6e-a16d-6b691a3773e1" xlink:to="loc_us-gaap_IPOMember_e90621ba-53b3-4707-9965-2610673e44c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_8dd05a2f-acfa-4e1b-995f-479c31f1b2e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5e9ced7-96b3-4d6e-a16d-6b691a3773e1" xlink:to="loc_us-gaap_OverAllotmentOptionMember_8dd05a2f-acfa-4e1b-995f-479c31f1b2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f9017fbe-b3f7-4125-98df-b6ae4b07b2e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3a156362-2761-4a43-9fa4-df70bf8926c1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f9017fbe-b3f7-4125-98df-b6ae4b07b2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_45562812-4017-4ede-9dea-7ec5ed04ca30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f9017fbe-b3f7-4125-98df-b6ae4b07b2e1" xlink:to="loc_us-gaap_EquityComponentDomain_45562812-4017-4ede-9dea-7ec5ed04ca30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_94b0e24b-f945-44a9-bda0-a8de45e860bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45562812-4017-4ede-9dea-7ec5ed04ca30" xlink:to="loc_us-gaap_CommonStockMember_94b0e24b-f945-44a9-bda0-a8de45e860bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3a156362-2761-4a43-9fa4-df70bf8926c1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0ade3f7a-e10f-4b56-8e31-69d70d7d0b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0ade3f7a-e10f-4b56-8e31-69d70d7d0b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dc832f30-fb89-4fc6-be63-49bca2b19280" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dc832f30-fb89-4fc6-be63-49bca2b19280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_45355970-291a-451a-bb63-edd8994c13a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_45355970-291a-451a-bb63-edd8994c13a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_271d2fbe-32f9-4de5-bfa8-1348051ac924" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_271d2fbe-32f9-4de5-bfa8-1348051ac924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_51e9e269-d6fc-4f5a-b783-d1c0951594d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_51e9e269-d6fc-4f5a-b783-d1c0951594d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1163bed5-40ee-4fa1-9245-564e32bcde50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1163bed5-40ee-4fa1-9245-564e32bcde50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_5497bde1-fe00-4a63-aee8-03d0dbca09a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d2bf0852-2383-4e20-8f06-913c294b1c2c" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_5497bde1-fe00-4a63-aee8-03d0dbca09a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="arqt-20200331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8842a07e-daf0-43b0-87c7-f87c5f89f1d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_d5f025db-07c8-47ca-abb5-831dafcdc3e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8842a07e-daf0-43b0-87c7-f87c5f89f1d3" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_d5f025db-07c8-47ca-abb5-831dafcdc3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="arqt-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_118138cd-ee6f-4734-bd82-70faeda09b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_118138cd-ee6f-4734-bd82-70faeda09b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_c36b7a61-1873-4bc7-b911-a6c9b82ffcc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_us-gaap_UseOfEstimates_c36b7a61-1873-4bc7-b911-a6c9b82ffcc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3c035eac-2d62-4405-81fb-6edadfd3a5fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3c035eac-2d62-4405-81fb-6edadfd3a5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock_4fed795a-a1b0-4201-b9cd-2895725c89de" xlink:href="arqt-20200331.xsd#arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock_4fed795a-a1b0-4201-b9cd-2895725c89de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0ef22df8-5737-4e08-9976-98d1564aed5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0ef22df8-5737-4e08-9976-98d1564aed5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_723fb1e2-255f-45fa-bd84-823b71fa57ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_723fb1e2-255f-45fa-bd84-823b71fa57ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_ad7c3ef9-7dce-44b2-a798-7badafa4afb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_ad7c3ef9-7dce-44b2-a798-7badafa4afb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_ab9b1c18-9172-440b-8262-602f631cefd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_ab9b1c18-9172-440b-8262-602f631cefd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_30eac42e-a3e9-4023-99c6-d7bf3a9927dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_30eac42e-a3e9-4023-99c6-d7bf3a9927dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock_1894cef0-b055-4583-bbe2-92fc0b455b2a" xlink:href="arqt-20200331.xsd#arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock_1894cef0-b055-4583-bbe2-92fc0b455b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_63b19c50-2d42-4bd7-ad04-980dd730a202" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_63b19c50-2d42-4bd7-ad04-980dd730a202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f2a8b042-ae1e-4ee1-b85e-f25e5e0b8c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f2a8b042-ae1e-4ee1-b85e-f25e5e0b8c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_99e101dd-c5eb-4bd3-b818-c73ca9472622" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_99e101dd-c5eb-4bd3-b818-c73ca9472622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_4a5d3329-7650-430b-832a-7cf962446ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_4a5d3329-7650-430b-832a-7cf962446ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_88333a1b-9c76-4bb0-899d-ace39ed1b5b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_88333a1b-9c76-4bb0-899d-ace39ed1b5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2d7e61cc-3e8f-49e2-a389-31cb012ebc2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2d7e61cc-3e8f-49e2-a389-31cb012ebc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_EmergingGrowthCompanyStatusPolicyTextBlock_153d8591-15e4-4c24-8f51-8a07de8d83c5" xlink:href="arqt-20200331.xsd#arqt_EmergingGrowthCompanyStatusPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_arqt_EmergingGrowthCompanyStatusPolicyTextBlock_153d8591-15e4-4c24-8f51-8a07de8d83c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f36e382d-0d53-43b7-8fff-7331b47f63a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce739df7-fb9b-4e4f-bc16-57cc0c83e370" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f36e382d-0d53-43b7-8fff-7331b47f63a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ffeda867-cabb-4671-9b65-23d18616d8f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e10441cc-c03d-4b72-8ca7-e7ab90a484e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ffeda867-cabb-4671-9b65-23d18616d8f5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e10441cc-c03d-4b72-8ca7-e7ab90a484e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_302b5453-74cc-4227-b0fb-bd645a82adea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e10441cc-c03d-4b72-8ca7-e7ab90a484e5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_302b5453-74cc-4227-b0fb-bd645a82adea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_82516892-1916-4037-84ea-03548a056d00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_302b5453-74cc-4227-b0fb-bd645a82adea" xlink:to="loc_us-gaap_EquityComponentDomain_82516892-1916-4037-84ea-03548a056d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f1571f3d-f5fc-4e44-905d-4e36f4aee525" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_82516892-1916-4037-84ea-03548a056d00" xlink:to="loc_us-gaap_CommonStockMember_f1571f3d-f5fc-4e44-905d-4e36f4aee525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e10441cc-c03d-4b72-8ca7-e7ab90a484e5" xlink:to="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_47a37d3c-b307-4088-a0e9-0926de1c2211" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_47a37d3c-b307-4088-a0e9-0926de1c2211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_c93e2cba-a32d-4c2f-80b7-5e96a14890b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_c93e2cba-a32d-4c2f-80b7-5e96a14890b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b9f7d687-cfca-46d1-9ea4-e7b9e56696b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b9f7d687-cfca-46d1-9ea4-e7b9e56696b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d93fe186-5408-44e7-b066-c9b548c241e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d93fe186-5408-44e7-b066-c9b548c241e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_b7231a94-9bc9-488d-adc7-9ad0a8f00faa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_b7231a94-9bc9-488d-adc7-9ad0a8f00faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d549ed5e-e976-4014-9cbb-9b3f3fb5c535" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d549ed5e-e976-4014-9cbb-9b3f3fb5c535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a67e1170-7d06-4fbd-bde7-7d17fac354f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_aa494c2a-bbdd-4344-b168-f0ba7d79d21d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a67e1170-7d06-4fbd-bde7-7d17fac354f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="arqt-20200331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0c36ce2f-83f8-40c2-a768-ed86d49882d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_915a847c-9fcd-4321-ac18-734a30d25aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0c36ce2f-83f8-40c2-a768-ed86d49882d1" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_915a847c-9fcd-4321-ac18-734a30d25aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f580e1b9-be7e-4b70-9ced-693467bb73bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9f1fed5f-7cb6-40db-99ed-21a8be3961b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f580e1b9-be7e-4b70-9ced-693467bb73bf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9f1fed5f-7cb6-40db-99ed-21a8be3961b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_e6ad10bb-517c-4946-8f0e-9fd5a614fb46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f580e1b9-be7e-4b70-9ced-693467bb73bf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_e6ad10bb-517c-4946-8f0e-9fd5a614fb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5a6524d5-1009-401a-891a-9e9ba2ada5c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f580e1b9-be7e-4b70-9ced-693467bb73bf" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5a6524d5-1009-401a-891a-9e9ba2ada5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0c73fe71-c02a-4ca5-97df-bb946602b246" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64d340c2-b78e-4072-9c7f-e7257fa9bf01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0c73fe71-c02a-4ca5-97df-bb946602b246" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64d340c2-b78e-4072-9c7f-e7257fa9bf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09cd6f4e-8de5-405e-9dea-ddc15cf851a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64d340c2-b78e-4072-9c7f-e7257fa9bf01" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09cd6f4e-8de5-405e-9dea-ddc15cf851a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad8be0b6-6c20-4e1c-b543-4067dde5478a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09cd6f4e-8de5-405e-9dea-ddc15cf851a9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad8be0b6-6c20-4e1c-b543-4067dde5478a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9b0ca00b-6d91-4d13-aba1-223f1fa312df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad8be0b6-6c20-4e1c-b543-4067dde5478a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9b0ca00b-6d91-4d13-aba1-223f1fa312df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b65edb43-f03e-4f7c-9cc0-22fdf9862a58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad8be0b6-6c20-4e1c-b543-4067dde5478a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b65edb43-f03e-4f7c-9cc0-22fdf9862a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_434a5362-af85-44c3-8821-13e272f4f311" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad8be0b6-6c20-4e1c-b543-4067dde5478a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_434a5362-af85-44c3-8821-13e272f4f311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_853953fb-6f1d-472e-86b7-30bc988b3eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64d340c2-b78e-4072-9c7f-e7257fa9bf01" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_853953fb-6f1d-472e-86b7-30bc988b3eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ef68ceda-725e-4042-82c3-1d01afa02170" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_853953fb-6f1d-472e-86b7-30bc988b3eb6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ef68ceda-725e-4042-82c3-1d01afa02170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d3ef77d3-61e4-4ea2-80f6-a5dce9b3a9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ef68ceda-725e-4042-82c3-1d01afa02170" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d3ef77d3-61e4-4ea2-80f6-a5dce9b3a9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f7eb66f8-9b60-4e0c-bfa1-5b92418f5e23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64d340c2-b78e-4072-9c7f-e7257fa9bf01" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f7eb66f8-9b60-4e0c-bfa1-5b92418f5e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3401c0b4-9de7-419d-a7d0-5a6366a1a690" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f7eb66f8-9b60-4e0c-bfa1-5b92418f5e23" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3401c0b4-9de7-419d-a7d0-5a6366a1a690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_87c972f0-f18d-4ca5-a0eb-14fcabbba1c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3401c0b4-9de7-419d-a7d0-5a6366a1a690" xlink:to="loc_us-gaap_CommercialPaperMember_87c972f0-f18d-4ca5-a0eb-14fcabbba1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2cfa28cf-b62c-43c2-b4fe-b94699d6bf04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3401c0b4-9de7-419d-a7d0-5a6366a1a690" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2cfa28cf-b62c-43c2-b4fe-b94699d6bf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7a3da2d-7fad-4b84-b625-202cff44a084" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64d340c2-b78e-4072-9c7f-e7257fa9bf01" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7a3da2d-7fad-4b84-b625-202cff44a084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_03711e31-e32a-4e4b-875d-5fa7e72632e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7a3da2d-7fad-4b84-b625-202cff44a084" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_03711e31-e32a-4e4b-875d-5fa7e72632e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_170704a2-2359-4905-934c-8d59891d5da7" xlink:href="arqt-20200331.xsd#arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7a3da2d-7fad-4b84-b625-202cff44a084" xlink:to="loc_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure_170704a2-2359-4905-934c-8d59891d5da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f726e43e-c904-4aca-bf22-576e7df12586" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7a3da2d-7fad-4b84-b625-202cff44a084" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f726e43e-c904-4aca-bf22-576e7df12586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_be7e5455-c8d8-4b2f-8db7-80210c1cb0b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2fa3ddec-08fe-4b4d-b792-49c9fd753fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_be7e5455-c8d8-4b2f-8db7-80210c1cb0b1" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2fa3ddec-08fe-4b4d-b792-49c9fd753fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_83a6ef8a-84bd-4d8a-9cc5-8499894ba059" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2fa3ddec-08fe-4b4d-b792-49c9fd753fbd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_83a6ef8a-84bd-4d8a-9cc5-8499894ba059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8db3b21a-851b-4f85-a364-10684332e5fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_83a6ef8a-84bd-4d8a-9cc5-8499894ba059" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8db3b21a-851b-4f85-a364-10684332e5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6f5a304e-7800-466c-9b62-3a9e51053678" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8db3b21a-851b-4f85-a364-10684332e5fd" xlink:to="loc_us-gaap_CommercialPaperMember_6f5a304e-7800-466c-9b62-3a9e51053678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3e53229f-180d-4709-8e6a-a8aa2ed90a40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8db3b21a-851b-4f85-a364-10684332e5fd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3e53229f-180d-4709-8e6a-a8aa2ed90a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_38495b46-9738-4433-8072-a0916a49b7d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8db3b21a-851b-4f85-a364-10684332e5fd" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_38495b46-9738-4433-8072-a0916a49b7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_e5c5d08a-5da8-461c-a57e-e7f92f0694dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_2fa3ddec-08fe-4b4d-b792-49c9fd753fbd" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_e5c5d08a-5da8-461c-a57e-e7f92f0694dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f144c013-49ba-4dce-bfb8-b32e3c84e4b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_e5c5d08a-5da8-461c-a57e-e7f92f0694dc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f144c013-49ba-4dce-bfb8-b32e3c84e4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_595cae2b-a3be-4498-ac6b-ccc0e7b327d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_e5c5d08a-5da8-461c-a57e-e7f92f0694dc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_595cae2b-a3be-4498-ac6b-ccc0e7b327d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_295a2f15-65a1-459b-91f0-aeafede9b605" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_be7e5455-c8d8-4b2f-8db7-80210c1cb0b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_295a2f15-65a1-459b-91f0-aeafede9b605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0c475b97-b488-4728-9650-05066d6d903e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_295a2f15-65a1-459b-91f0-aeafede9b605" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0c475b97-b488-4728-9650-05066d6d903e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c88b1d7c-cb38-4367-b1d6-1f794841465b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0c475b97-b488-4728-9650-05066d6d903e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c88b1d7c-cb38-4367-b1d6-1f794841465b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_29431661-c219-45eb-a3b0-7343dafc85c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c88b1d7c-cb38-4367-b1d6-1f794841465b" xlink:to="loc_us-gaap_CommercialPaperMember_29431661-c219-45eb-a3b0-7343dafc85c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_816ee23e-7a5e-4da0-a9c6-800cd9915dec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c88b1d7c-cb38-4367-b1d6-1f794841465b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_816ee23e-7a5e-4da0-a9c6-800cd9915dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2288c25c-fc27-458d-ba17-9050d763be7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c88b1d7c-cb38-4367-b1d6-1f794841465b" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2288c25c-fc27-458d-ba17-9050d763be7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e0248022-6dd3-4caf-953c-6b4416c5e292" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_295a2f15-65a1-459b-91f0-aeafede9b605" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e0248022-6dd3-4caf-953c-6b4416c5e292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_03bd0dcb-61ba-48d7-82b2-d8bd0a84cd02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e0248022-6dd3-4caf-953c-6b4416c5e292" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_03bd0dcb-61ba-48d7-82b2-d8bd0a84cd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_411f343a-9d19-4464-acd8-9fd3cd5eccd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e0248022-6dd3-4caf-953c-6b4416c5e292" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_411f343a-9d19-4464-acd8-9fd3cd5eccd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_994998e3-00ad-4ee4-bb33-675a4faeb280" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e0248022-6dd3-4caf-953c-6b4416c5e292" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_994998e3-00ad-4ee4-bb33-675a4faeb280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e0e15d7c-38cd-4e62-8209-a152c32b3056" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e0248022-6dd3-4caf-953c-6b4416c5e292" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e0e15d7c-38cd-4e62-8209-a152c32b3056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_8b88facf-78d1-4716-8324-7900d8c800b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_be7e5455-c8d8-4b2f-8db7-80210c1cb0b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_8b88facf-78d1-4716-8324-7900d8c800b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="arqt-20200331.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6ff6ee79-427a-4161-9a19-4848ab183190" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3c14450d-ea58-4cbf-82f6-16bc60a00c32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6ff6ee79-427a-4161-9a19-4848ab183190" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3c14450d-ea58-4cbf-82f6-16bc60a00c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_afc7e0d4-eae0-4cd2-b85b-69b4b830df04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_aa6fd8af-70c1-4f22-b3e5-3a87f1cafb3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_afc7e0d4-eae0-4cd2-b85b-69b4b830df04" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_aa6fd8af-70c1-4f22-b3e5-3a87f1cafb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_dcd51785-572a-4be6-9c20-42f727a69c49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_afc7e0d4-eae0-4cd2-b85b-69b4b830df04" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_dcd51785-572a-4be6-9c20-42f727a69c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e8e95351-bde8-4577-a1ba-76bb20c45992" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_1cc193d8-a629-403d-bd17-492162f2533e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e8e95351-bde8-4577-a1ba-76bb20c45992" xlink:to="loc_us-gaap_PrepaidInsurance_1cc193d8-a629-403d-bd17-492162f2533e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PrepaidClinicalTrialTestCostsCurrent_795bcbca-a10e-4c99-964e-ee5fdd948dc6" xlink:href="arqt-20200331.xsd#arqt_PrepaidClinicalTrialTestCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e8e95351-bde8-4577-a1ba-76bb20c45992" xlink:to="loc_arqt_PrepaidClinicalTrialTestCostsCurrent_795bcbca-a10e-4c99-964e-ee5fdd948dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_1e888e24-53ac-4565-b5b2-4628ed80c63c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e8e95351-bde8-4577-a1ba-76bb20c45992" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_1e888e24-53ac-4565-b5b2-4628ed80c63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_9d96e242-2a62-4cc0-a870-6d896a95608c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e8e95351-bde8-4577-a1ba-76bb20c45992" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_9d96e242-2a62-4cc0-a870-6d896a95608c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f0016cb7-4f9d-4961-ba00-cc3b9c36818f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e8e95351-bde8-4577-a1ba-76bb20c45992" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f0016cb7-4f9d-4961-ba00-cc3b9c36818f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_60d14203-fb39-4e26-b173-573eb747867b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ClinicalTrialAccrualCurrent_97b050a2-7561-493c-bc5d-541b58af9f74" xlink:href="arqt-20200331.xsd#arqt_ClinicalTrialAccrualCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_60d14203-fb39-4e26-b173-573eb747867b" xlink:to="loc_arqt_ClinicalTrialAccrualCurrent_97b050a2-7561-493c-bc5d-541b58af9f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_80f9a149-79d2-4418-ae87-e8743d2a7c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_60d14203-fb39-4e26-b173-573eb747867b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_80f9a149-79d2-4418-ae87-e8743d2a7c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_670a7ffb-e104-4bcf-aa3f-b877b1f3d834" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_60d14203-fb39-4e26-b173-573eb747867b" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_670a7ffb-e104-4bcf-aa3f-b877b1f3d834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_069c97b9-79c2-438e-aae4-4bebf055c612" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_60d14203-fb39-4e26-b173-573eb747867b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_069c97b9-79c2-438e-aae4-4bebf055c612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_21a96568-76d2-49d4-b2ad-a9ea28b8b6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_60d14203-fb39-4e26-b173-573eb747867b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_21a96568-76d2-49d4-b2ad-a9ea28b8b6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreements" xlink:type="simple" xlink:href="arqt-20200331.xsd#LicenseAgreements"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/LicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a88d524-7492-4b57-a42e-e360c93251a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_490eb200-f0ee-4b8a-b5ac-dff0368d210e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a88d524-7492-4b57-a42e-e360c93251a8" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_490eb200-f0ee-4b8a-b5ac-dff0368d210e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#LicenseAgreementsAstraZenecaDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a3688cc1-07f8-4348-9dbe-6f13e211299c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_69561fd2-5c93-44e5-a350-03c2af7462ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a3688cc1-07f8-4348-9dbe-6f13e211299c" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_69561fd2-5c93-44e5-a350-03c2af7462ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cda3de63-57ca-4165-8ebb-94a43e55438e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_69561fd2-5c93-44e5-a350-03c2af7462ca" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cda3de63-57ca-4165-8ebb-94a43e55438e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_87f6af91-7372-4cf6-ad1d-ab9b28426871" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cda3de63-57ca-4165-8ebb-94a43e55438e" xlink:to="loc_us-gaap_ClassOfStockDomain_87f6af91-7372-4cf6-ad1d-ab9b28426871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_d7bf6398-cedf-46be-8029-bf931184b667" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_87f6af91-7372-4cf6-ad1d-ab9b28426871" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_d7bf6398-cedf-46be-8029-bf931184b667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1ee5190d-623d-44ad-bbc9-d66ced95600a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_69561fd2-5c93-44e5-a350-03c2af7462ca" xlink:to="loc_srt_CounterpartyNameAxis_1ee5190d-623d-44ad-bbc9-d66ced95600a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_417e5fc1-4e9f-4775-a56f-206f503c09f8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1ee5190d-623d-44ad-bbc9-d66ced95600a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_417e5fc1-4e9f-4775-a56f-206f503c09f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_AstraZenecaMember_cd6313ff-18cb-4534-af04-de21f1995bf2" xlink:href="arqt-20200331.xsd#arqt_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_417e5fc1-4e9f-4775-a56f-206f503c09f8" xlink:to="loc_arqt_AstraZenecaMember_cd6313ff-18cb-4534-af04-de21f1995bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_dc8224ea-c6b5-4ad8-9b46-891fb16d8eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_69561fd2-5c93-44e5-a350-03c2af7462ca" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_dc8224ea-c6b5-4ad8-9b46-891fb16d8eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_a52900b9-bea8-4c2c-9e4d-22d2f320d6a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_dc8224ea-c6b5-4ad8-9b46-891fb16d8eeb" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_a52900b9-bea8-4c2c-9e4d-22d2f320d6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c69b24a7-d491-486a-9498-bf9a1658820b" xlink:href="arqt-20200331.xsd#arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_dc8224ea-c6b5-4ad8-9b46-891fb16d8eeb" xlink:to="loc_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c69b24a7-d491-486a-9498-bf9a1658820b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_4cd15573-e605-43ce-9339-2a4dfd286fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_dc8224ea-c6b5-4ad8-9b46-891fb16d8eeb" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_4cd15573-e605-43ce-9339-2a4dfd286fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments_753b1688-5791-4bf5-8495-c025f1a9f363" xlink:href="arqt-20200331.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_dc8224ea-c6b5-4ad8-9b46-891fb16d8eeb" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments_753b1688-5791-4bf5-8495-c025f1a9f363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_0644d9bd-9d79-40c2-9b30-b7f8fbee38ef" xlink:href="arqt-20200331.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_dc8224ea-c6b5-4ad8-9b46-891fb16d8eeb" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_0644d9bd-9d79-40c2-9b30-b7f8fbee38ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsHengruiDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#LicenseAgreementsHengruiDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/LicenseAgreementsHengruiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8af8b95a-d7c1-421f-8787-7a05b38d42c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_90a6b186-3ffb-43ef-8e4c-f5bf7335a22d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8af8b95a-d7c1-421f-8787-7a05b38d42c3" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_90a6b186-3ffb-43ef-8e4c-f5bf7335a22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9f8bd2cb-403c-45b7-8df9-c3a812f527e0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_90a6b186-3ffb-43ef-8e4c-f5bf7335a22d" xlink:to="loc_srt_CounterpartyNameAxis_9f8bd2cb-403c-45b7-8df9-c3a812f527e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_12bd3fa3-c0a4-4432-a96d-fbf475269517" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9f8bd2cb-403c-45b7-8df9-c3a812f527e0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_12bd3fa3-c0a4-4432-a96d-fbf475269517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_HengruiMember_bd4083c7-cfa4-4fce-85c2-8186b6483479" xlink:href="arqt-20200331.xsd#arqt_HengruiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_12bd3fa3-c0a4-4432-a96d-fbf475269517" xlink:to="loc_arqt_HengruiMember_bd4083c7-cfa4-4fce-85c2-8186b6483479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6dd7a947-af96-4eca-839b-c3beb2d3d856" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_90a6b186-3ffb-43ef-8e4c-f5bf7335a22d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6dd7a947-af96-4eca-839b-c3beb2d3d856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_aacfe86d-31f5-447b-b4f2-4f8240a012c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6dd7a947-af96-4eca-839b-c3beb2d3d856" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_aacfe86d-31f5-447b-b4f2-4f8240a012c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments_8fb857f4-3ece-4842-bd66-b489cea696d5" xlink:href="arqt-20200331.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6dd7a947-af96-4eca-839b-c3beb2d3d856" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments_8fb857f4-3ece-4842-bd66-b489cea696d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_22f61a1e-4073-4e31-9d7f-86a57ee3c587" xlink:href="arqt-20200331.xsd#arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6dd7a947-af96-4eca-839b-c3beb2d3d856" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments_22f61a1e-4073-4e31-9d7f-86a57ee3c587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/LicenseAgreementsHawkeyeDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#LicenseAgreementsHawkeyeDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/LicenseAgreementsHawkeyeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62bbefa0-23ac-4848-b6aa-701d3d855f4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a8e60e65-768a-4a93-9f4c-d0e90112b4ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62bbefa0-23ac-4848-b6aa-701d3d855f4b" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a8e60e65-768a-4a93-9f4c-d0e90112b4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d91a5e37-dbe6-4591-8849-97de98348596" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a8e60e65-768a-4a93-9f4c-d0e90112b4ef" xlink:to="loc_dei_LegalEntityAxis_d91a5e37-dbe6-4591-8849-97de98348596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c98bd814-12d9-433b-84bf-f7e266d8959d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d91a5e37-dbe6-4591-8849-97de98348596" xlink:to="loc_dei_EntityDomain_c98bd814-12d9-433b-84bf-f7e266d8959d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_HawkeyeMember_8fe6f416-22e3-4860-9e5e-c8fe12e7fb6f" xlink:href="arqt-20200331.xsd#arqt_HawkeyeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c98bd814-12d9-433b-84bf-f7e266d8959d" xlink:to="loc_arqt_HawkeyeMember_8fe6f416-22e3-4860-9e5e-c8fe12e7fb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_105591ed-d10c-4b07-b4c0-f85b9c5d1824" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a8e60e65-768a-4a93-9f4c-d0e90112b4ef" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_105591ed-d10c-4b07-b4c0-f85b9c5d1824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_6fe3f646-b2bb-44fe-ad50-6eec9c44472d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_105591ed-d10c-4b07-b4c0-f85b9c5d1824" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_6fe3f646-b2bb-44fe-ad50-6eec9c44472d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_1af3ee12-1820-4fba-a24a-d9d19f56c3b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_6fe3f646-b2bb-44fe-ad50-6eec9c44472d" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_1af3ee12-1820-4fba-a24a-d9d19f56c3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_40f73396-a520-42d2-b185-047cb05c6416" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a8e60e65-768a-4a93-9f4c-d0e90112b4ef" xlink:to="loc_srt_CounterpartyNameAxis_40f73396-a520-42d2-b185-047cb05c6416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e4df0c7-2c35-4364-9bfb-0c71891174d9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_40f73396-a520-42d2-b185-047cb05c6416" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e4df0c7-2c35-4364-9bfb-0c71891174d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_HawkeyeMember_48bf5d65-6a0c-4157-b1d0-eb67178c1fed" xlink:href="arqt-20200331.xsd#arqt_HawkeyeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e4df0c7-2c35-4364-9bfb-0c71891174d9" xlink:to="loc_arqt_HawkeyeMember_48bf5d65-6a0c-4157-b1d0-eb67178c1fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_98de0aca-6ad7-439e-8e22-82e902189efc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a8e60e65-768a-4a93-9f4c-d0e90112b4ef" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_98de0aca-6ad7-439e-8e22-82e902189efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_VariableInterestEntitiesNumberOfSharesHeld_d94c2ef7-3690-4c67-af35-5da154573210" xlink:href="arqt-20200331.xsd#arqt_VariableInterestEntitiesNumberOfSharesHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_98de0aca-6ad7-439e-8e22-82e902189efc" xlink:to="loc_arqt_VariableInterestEntitiesNumberOfSharesHeld_d94c2ef7-3690-4c67-af35-5da154573210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_32066422-29ff-460b-92a9-ad5c0cf8e2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_98de0aca-6ad7-439e-8e22-82e902189efc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_32066422-29ff-460b-92a9-ad5c0cf8e2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_79de063d-b97e-44b5-bf0b-33a5dc5761a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_98de0aca-6ad7-439e-8e22-82e902189efc" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_79de063d-b97e-44b5-bf0b-33a5dc5761a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration_8cf29dad-fa2c-45a8-8fee-21d3b3491834" xlink:href="arqt-20200331.xsd#arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_98de0aca-6ad7-439e-8e22-82e902189efc" xlink:to="loc_arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration_8cf29dad-fa2c-45a8-8fee-21d3b3491834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration_90f7ac8e-f0cd-4866-a23c-2873f36ea6fd" xlink:href="arqt-20200331.xsd#arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_98de0aca-6ad7-439e-8e22-82e902189efc" xlink:to="loc_arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration_90f7ac8e-f0cd-4866-a23c-2873f36ea6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties_829254f7-bda4-4bd9-b446-beb5f25bd78a" xlink:href="arqt-20200331.xsd#arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_98de0aca-6ad7-439e-8e22-82e902189efc" xlink:to="loc_arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties_829254f7-bda4-4bd9-b446-beb5f25bd78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_74024220-dfdf-424c-889c-cc9eae38d9c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_707db18b-987a-4e6b-b297-a08bea88c938" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_74024220-dfdf-424c-889c-cc9eae38d9c2" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_707db18b-987a-4e6b-b297-a08bea88c938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_85105a52-14e6-48ef-a912-79797c279d68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_91eff3dc-82e8-4b91-bfbd-da6d5a06aa49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_85105a52-14e6-48ef-a912-79797c279d68" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_91eff3dc-82e8-4b91-bfbd-da6d5a06aa49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_5ee65f78-273d-4eb0-aa09-7c246882c310" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_85105a52-14e6-48ef-a912-79797c279d68" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_5ee65f78-273d-4eb0-aa09-7c246882c310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_03f0dd22-2324-4c76-8382-cc0b54afa61e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7351f8ac-3f61-4d0b-b07a-9dbbc978013f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_03f0dd22-2324-4c76-8382-cc0b54afa61e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7351f8ac-3f61-4d0b-b07a-9dbbc978013f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eadc08e3-d5c6-470f-bbc6-acb75f0c5542" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7351f8ac-3f61-4d0b-b07a-9dbbc978013f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eadc08e3-d5c6-470f-bbc6-acb75f0c5542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a5f9235d-c4dd-4f86-bb86-ff178faf52b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eadc08e3-d5c6-470f-bbc6-acb75f0c5542" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a5f9235d-c4dd-4f86-bb86-ff178faf52b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_a31f60b1-8254-4d7b-bd6e-6a0c9ceed07f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a5f9235d-c4dd-4f86-bb86-ff178faf52b8" xlink:to="loc_us-gaap_BuildingMember_a31f60b1-8254-4d7b-bd6e-6a0c9ceed07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f893400d-5d30-4dab-851e-29fd47036fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7351f8ac-3f61-4d0b-b07a-9dbbc978013f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_f893400d-5d30-4dab-851e-29fd47036fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeasesNumberFacilitiesLeased_7bcf7cf6-b150-443a-b70a-c8698620be7c" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeasesNumberFacilitiesLeased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f893400d-5d30-4dab-851e-29fd47036fbf" xlink:to="loc_arqt_LesseeOperatingLeasesNumberFacilitiesLeased_7bcf7cf6-b150-443a-b70a-c8698620be7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5c64bccb-ef16-4764-afcd-ac1d6a426cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f893400d-5d30-4dab-851e-29fd47036fbf" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5c64bccb-ef16-4764-afcd-ac1d6a426cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_a40c679e-422f-461d-ab69-0667d5003db6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f893400d-5d30-4dab-851e-29fd47036fbf" xlink:to="loc_us-gaap_OperatingLeaseExpense_a40c679e-422f-461d-ab69-0667d5003db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_67a70e62-3f27-4521-a62e-ead2471c67c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f893400d-5d30-4dab-851e-29fd47036fbf" xlink:to="loc_us-gaap_VariableLeaseCost_67a70e62-3f27-4521-a62e-ead2471c67c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentsandContingenciesOperatingLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a6294d77-9299-4800-bf1e-70ab482b0b15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ae523ff1-6747-48e1-a697-e19886d2af1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a6294d77-9299-4800-bf1e-70ab482b0b15" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ae523ff1-6747-48e1-a697-e19886d2af1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_49f63198-8758-425b-8c7f-b59c242eb104" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a6294d77-9299-4800-bf1e-70ab482b0b15" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_49f63198-8758-425b-8c7f-b59c242eb104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a1dc8b29-6288-49c2-a1a5-ab1ef03c711e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a6294d77-9299-4800-bf1e-70ab482b0b15" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a1dc8b29-6288-49c2-a1a5-ab1ef03c711e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_24ad4567-9108-48c1-a5c1-1e9775fc6fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a6294d77-9299-4800-bf1e-70ab482b0b15" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_24ad4567-9108-48c1-a5c1-1e9775fc6fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2d4612a6-2160-4a24-8f42-9d847a4ab6e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a6294d77-9299-4800-bf1e-70ab482b0b15" xlink:to="loc_us-gaap_OperatingLeaseLiability_2d4612a6-2160-4a24-8f42-9d847a4ab6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1a63a068-dc6c-4e1b-8043-42f96d2835bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a6294d77-9299-4800-bf1e-70ab482b0b15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1a63a068-dc6c-4e1b-8043-42f96d2835bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4334c233-0a33-4f40-8007-c7017d882d34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a6294d77-9299-4800-bf1e-70ab482b0b15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4334c233-0a33-4f40-8007-c7017d882d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_fec37015-0999-4560-a32e-7d187deab497" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a6294d77-9299-4800-bf1e-70ab482b0b15" xlink:to="loc_us-gaap_OperatingLeaseLiability_fec37015-0999-4560-a32e-7d187deab497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails_1" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentsandContingenciesOperatingLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_504605d1-8ab0-4e53-9416-4fc6db73eb48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_3e0053f8-2028-4cb5-a3a7-203bc53e88cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_504605d1-8ab0-4e53-9416-4fc6db73eb48" xlink:to="loc_us-gaap_OperatingLeasePayments_3e0053f8-2028-4cb5-a3a7-203bc53e88cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/CommitmentandContingenciesOperatingLeaseAdditionalInformationDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#CommitmentandContingenciesOperatingLeaseAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/CommitmentandContingenciesOperatingLeaseAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4cfe0f9-8ec0-4430-8f8d-8ab367f0ee06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5a129563-1b39-4ca4-ba2c-41a263b20b0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4cfe0f9-8ec0-4430-8f8d-8ab367f0ee06" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5a129563-1b39-4ca4-ba2c-41a263b20b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_13d788ef-2ad1-4018-bc3d-1d6eccd35d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4cfe0f9-8ec0-4430-8f8d-8ab367f0ee06" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_13d788ef-2ad1-4018-bc3d-1d6eccd35d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="arqt-20200331.xsd#ConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e1e0db4c-38e7-48e5-921f-a7c5594d7995" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4dc55e27-25e6-46b5-bb66-caa08ad1ff81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e1e0db4c-38e7-48e5-921f-a7c5594d7995" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4dc55e27-25e6-46b5-bb66-caa08ad1ff81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#ConvertiblePreferredStockandStockholdersEquityDeficitTables"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_aa681338-1295-408b-9fc4-55b7823702fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_38a84019-04d2-425a-9676-4d1cf28da2fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_aa681338-1295-408b-9fc4-55b7823702fa" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_38a84019-04d2-425a-9676-4d1cf28da2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_2f26d051-15ed-4908-8c17-876ac780b994" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_aa681338-1295-408b-9fc4-55b7823702fa" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_2f26d051-15ed-4908-8c17-876ac780b994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6591a07d-206d-41d3-b320-c6964c461f30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_133812ba-df58-42df-889d-4434c38f694c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6591a07d-206d-41d3-b320-c6964c461f30" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_133812ba-df58-42df-889d-4434c38f694c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4c543478-d796-44b1-9b90-5f6191ffcafd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_133812ba-df58-42df-889d-4434c38f694c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4c543478-d796-44b1-9b90-5f6191ffcafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5da8b1a1-66ec-45fe-a1b9-4f44d743f4c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4c543478-d796-44b1-9b90-5f6191ffcafd" xlink:to="loc_us-gaap_ClassOfStockDomain_5da8b1a1-66ec-45fe-a1b9-4f44d743f4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_529bbef8-05f8-4f90-b7dd-7fda8bd54a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5da8b1a1-66ec-45fe-a1b9-4f44d743f4c0" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_529bbef8-05f8-4f90-b7dd-7fda8bd54a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1c29eef5-781f-4e0e-89f1-3619989231c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5da8b1a1-66ec-45fe-a1b9-4f44d743f4c0" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1c29eef5-781f-4e0e-89f1-3619989231c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_7410f1b6-7177-4ef1-92a9-91ee3e243a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5da8b1a1-66ec-45fe-a1b9-4f44d743f4c0" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_7410f1b6-7177-4ef1-92a9-91ee3e243a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_7478f610-be88-4bcc-8e01-b1fbd7c3b531" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_133812ba-df58-42df-889d-4434c38f694c" xlink:to="loc_us-gaap_TemporaryEquityLineItems_7478f610-be88-4bcc-8e01-b1fbd7c3b531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_bfa03131-cf80-41f0-bddf-2504421abab7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7478f610-be88-4bcc-8e01-b1fbd7c3b531" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_bfa03131-cf80-41f0-bddf-2504421abab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_0feb097e-170e-427b-a52c-19f154348b72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7478f610-be88-4bcc-8e01-b1fbd7c3b531" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_0feb097e-170e-427b-a52c-19f154348b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_38302dee-06d1-4db3-8125-a0671eff6fec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7478f610-be88-4bcc-8e01-b1fbd7c3b531" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_38302dee-06d1-4db3-8125-a0671eff6fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4b41eb76-33d8-4c1e-9818-9eb45eb78e1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7478f610-be88-4bcc-8e01-b1fbd7c3b531" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4b41eb76-33d8-4c1e-9818-9eb45eb78e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_26855445-4c6f-49a6-b162-0861f53d064d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7478f610-be88-4bcc-8e01-b1fbd7c3b531" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_26855445-4c6f-49a6-b162-0861f53d064d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#ConvertiblePreferredStockandStockholdersEquityDeficitDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_51bf2a0c-55a0-4c12-a71d-2c1d39970ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_688e4ccd-619e-4783-b199-0e55888383ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_51bf2a0c-55a0-4c12-a71d-2c1d39970ddd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_688e4ccd-619e-4783-b199-0e55888383ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_71143d6d-9b7d-48c8-a309-6cdb6987a2d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_688e4ccd-619e-4783-b199-0e55888383ae" xlink:to="loc_us-gaap_StatementClassOfStockAxis_71143d6d-9b7d-48c8-a309-6cdb6987a2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_26b4c039-2a3b-4678-b2e4-36c073e66a52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_71143d6d-9b7d-48c8-a309-6cdb6987a2d3" xlink:to="loc_us-gaap_ClassOfStockDomain_26b4c039-2a3b-4678-b2e4-36c073e66a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_c1675459-ef37-4a7e-a088-31507a01a766" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_26b4c039-2a3b-4678-b2e4-36c073e66a52" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_c1675459-ef37-4a7e-a088-31507a01a766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_b0d867ca-8ecc-4586-93eb-2d081e7342dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_26b4c039-2a3b-4678-b2e4-36c073e66a52" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_b0d867ca-8ecc-4586-93eb-2d081e7342dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5622cddb-6e0e-4972-9629-e316017e2465" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_26b4c039-2a3b-4678-b2e4-36c073e66a52" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5622cddb-6e0e-4972-9629-e316017e2465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a34d5b69-6554-4a90-a8c3-c0f01b7572a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_688e4ccd-619e-4783-b199-0e55888383ae" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a34d5b69-6554-4a90-a8c3-c0f01b7572a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de70091e-728a-4a9c-9a44-2619ff555054" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a34d5b69-6554-4a90-a8c3-c0f01b7572a5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de70091e-728a-4a9c-9a44-2619ff555054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementTrancheOneMember_c50e9f7e-cd76-43fc-9d23-c270f747d179" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de70091e-728a-4a9c-9a44-2619ff555054" xlink:to="loc_arqt_StockPurchaseAgreementTrancheOneMember_c50e9f7e-cd76-43fc-9d23-c270f747d179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementTrancheTwoMember_ec6c0582-6db0-49d0-ad31-4af8dbb006ba" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de70091e-728a-4a9c-9a44-2619ff555054" xlink:to="loc_arqt_StockPurchaseAgreementTrancheTwoMember_ec6c0582-6db0-49d0-ad31-4af8dbb006ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementTrancheThreeMember_66f03421-e3f5-4f81-bc73-3e0fa7615142" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de70091e-728a-4a9c-9a44-2619ff555054" xlink:to="loc_arqt_StockPurchaseAgreementTrancheThreeMember_66f03421-e3f5-4f81-bc73-3e0fa7615142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementTranchesTwoAndThreeMember_9294dc3e-9acb-466b-a010-edc872ecb03e" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementTranchesTwoAndThreeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_de70091e-728a-4a9c-9a44-2619ff555054" xlink:to="loc_arqt_StockPurchaseAgreementTranchesTwoAndThreeMember_9294dc3e-9acb-466b-a010-edc872ecb03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f9245f6a-9bc0-4f3d-b8dd-1d301f22307e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_688e4ccd-619e-4783-b199-0e55888383ae" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f9245f6a-9bc0-4f3d-b8dd-1d301f22307e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a4554e66-385c-4e76-b589-c057b5a61664" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f9245f6a-9bc0-4f3d-b8dd-1d301f22307e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a4554e66-385c-4e76-b589-c057b5a61664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_2c7d26f3-de69-4460-b7d7-419614aae452" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a4554e66-385c-4e76-b589-c057b5a61664" xlink:to="loc_us-gaap_ConvertibleDebtMember_2c7d26f3-de69-4460-b7d7-419614aae452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5927b54e-c8c8-4499-b0cf-6cbc4a1a1bad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_688e4ccd-619e-4783-b199-0e55888383ae" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5927b54e-c8c8-4499-b0cf-6cbc4a1a1bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d478cf9e-4100-401c-a0a7-470799c4c3e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5927b54e-c8c8-4499-b0cf-6cbc4a1a1bad" xlink:to="loc_us-gaap_EquityComponentDomain_d478cf9e-4100-401c-a0a7-470799c4c3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_acf9c3e9-45dc-47ca-9c1b-09ed0e989009" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d478cf9e-4100-401c-a0a7-470799c4c3e2" xlink:to="loc_us-gaap_CommonStockMember_acf9c3e9-45dc-47ca-9c1b-09ed0e989009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_688e4ccd-619e-4783-b199-0e55888383ae" xlink:to="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_cf81ebc3-095f-436d-b3ad-d9e54e41a289" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_cf81ebc3-095f-436d-b3ad-d9e54e41a289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c38ce7b2-e9fb-43d0-8097-36faa5ea7229" xlink:href="arqt-20200331.xsd#arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c38ce7b2-e9fb-43d0-8097-36faa5ea7229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare_b6f35939-571b-427e-a022-cf456ec2a294" xlink:href="arqt-20200331.xsd#arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare_b6f35939-571b-427e-a022-cf456ec2a294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_f1151763-4eba-48ee-9d83-74247357957e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_f1151763-4eba-48ee-9d83-74247357957e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementNumberOfSharesIssuable_82be54ec-37e8-4e43-82b4-059c90d7e623" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementNumberOfSharesIssuable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_arqt_StockPurchaseAgreementNumberOfSharesIssuable_82be54ec-37e8-4e43-82b4-059c90d7e623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_84c4281a-6c9f-4587-9444-b0c855fe71d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_84c4281a-6c9f-4587-9444-b0c855fe71d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementPricePerShare_13ddfaa9-71c1-4056-94c9-9a4339229ef8" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_arqt_StockPurchaseAgreementPricePerShare_13ddfaa9-71c1-4056-94c9-9a4339229ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockPurchaseAgreementNumberOfTranches_30ae2452-4a85-4f66-92ab-5d30526899e8" xlink:href="arqt-20200331.xsd#arqt_StockPurchaseAgreementNumberOfTranches"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_arqt_StockPurchaseAgreementNumberOfTranches_30ae2452-4a85-4f66-92ab-5d30526899e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cf16849e-9283-4073-9217-171a3f3bdafb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cf16849e-9283-4073-9217-171a3f3bdafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f68a4e60-0aec-4952-aecb-fd9286e04091" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f68a4e60-0aec-4952-aecb-fd9286e04091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_bc35fffc-0f20-4344-a098-f742710338a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_DerivativeLiabilities_bc35fffc-0f20-4344-a098-f742710338a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_CommonStockVotingRightsNumberOfVotesPerShare_b2402e61-ac4a-4de0-93b6-ebcbfde3677a" xlink:href="arqt-20200331.xsd#arqt_CommonStockVotingRightsNumberOfVotesPerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_arqt_CommonStockVotingRightsNumberOfVotesPerShare_b2402e61-ac4a-4de0-93b6-ebcbfde3677a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e678e759-6faf-41d8-8d6c-3ee01e4a5cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e678e759-6faf-41d8-8d6c-3ee01e4a5cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_592823ae-3c33-487c-a4d6-26b0329ce9cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_592823ae-3c33-487c-a4d6-26b0329ce9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_b51de963-80f5-41a0-b22e-689523a62c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_b51de963-80f5-41a0-b22e-689523a62c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_0ab76573-8c89-4faf-80ee-c75ce96bdc2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_0ab76573-8c89-4faf-80ee-c75ce96bdc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3a2f42a6-61b9-4fb4-936d-a5f2d13ab1d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4c3455cc-ef60-47c0-a5fb-25801f6dd2f8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3a2f42a6-61b9-4fb4-936d-a5f2d13ab1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9fa4578b-408e-4c31-a20a-451daba66365" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c7c15086-0e62-4c6f-bf37-9378d80b869c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9fa4578b-408e-4c31-a20a-451daba66365" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c7c15086-0e62-4c6f-bf37-9378d80b869c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6c0b56c5-6742-4304-8c2e-b198addf4be2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c7c15086-0e62-4c6f-bf37-9378d80b869c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6c0b56c5-6742-4304-8c2e-b198addf4be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6462c2c4-dd18-4c41-9d3f-9518e658950e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6c0b56c5-6742-4304-8c2e-b198addf4be2" xlink:to="loc_us-gaap_ClassOfStockDomain_6462c2c4-dd18-4c41-9d3f-9518e658950e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_507d67f6-05fc-4c5f-9984-5d0648df64e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6462c2c4-dd18-4c41-9d3f-9518e658950e" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_507d67f6-05fc-4c5f-9984-5d0648df64e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0cebe457-2432-402c-a0ef-a5aa5ae634cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c7c15086-0e62-4c6f-bf37-9378d80b869c" xlink:to="loc_us-gaap_AwardTypeAxis_0cebe457-2432-402c-a0ef-a5aa5ae634cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75fc5c9a-22b6-40d0-9637-438e84c7d11d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0cebe457-2432-402c-a0ef-a5aa5ae634cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75fc5c9a-22b6-40d0-9637-438e84c7d11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockOptionsIssuedAndOutstandingMember_15e58359-606a-4e37-a9bd-3f42f817a321" xlink:href="arqt-20200331.xsd#arqt_StockOptionsIssuedAndOutstandingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75fc5c9a-22b6-40d0-9637-438e84c7d11d" xlink:to="loc_arqt_StockOptionsIssuedAndOutstandingMember_15e58359-606a-4e37-a9bd-3f42f817a321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_StockAwardsFutureGrantMember_8df7a7c9-45ea-41e5-9bc1-f13c95e91023" xlink:href="arqt-20200331.xsd#arqt_StockAwardsFutureGrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75fc5c9a-22b6-40d0-9637-438e84c7d11d" xlink:to="loc_arqt_StockAwardsFutureGrantMember_8df7a7c9-45ea-41e5-9bc1-f13c95e91023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0d568e1a-e728-4b31-b95c-f16129962c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75fc5c9a-22b6-40d0-9637-438e84c7d11d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0d568e1a-e728-4b31-b95c-f16129962c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ef6e19fa-551f-4afe-a26c-375869d8e444" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c7c15086-0e62-4c6f-bf37-9378d80b869c" xlink:to="loc_us-gaap_ClassOfStockLineItems_ef6e19fa-551f-4afe-a26c-375869d8e444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_93309d78-a01e-4728-9b5a-585057a65c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ef6e19fa-551f-4afe-a26c-375869d8e444" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_93309d78-a01e-4728-9b5a-585057a65c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3e99acd-e927-4221-a2a3-40785aa8a316" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_df2c096b-eb39-4236-9520-93336284184a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3e99acd-e927-4221-a2a3-40785aa8a316" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_df2c096b-eb39-4236-9520-93336284184a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5a0dcae-6fe0-4154-b570-3f154bc19858" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_69bad0b3-5d4d-4830-8300-7cac35c2dc97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5a0dcae-6fe0-4154-b570-3f154bc19858" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_69bad0b3-5d4d-4830-8300-7cac35c2dc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_6cd1a0c9-0107-42a3-b09c-169c9a0952e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5a0dcae-6fe0-4154-b570-3f154bc19858" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_6cd1a0c9-0107-42a3-b09c-169c9a0952e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_fdb0d710-26e4-4e68-97cf-3143f95aba60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5a0dcae-6fe0-4154-b570-3f154bc19858" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_fdb0d710-26e4-4e68-97cf-3143f95aba60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_adbc7b4e-3450-4e56-85ca-b9ceeb5a24c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5a0dcae-6fe0-4154-b570-3f154bc19858" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_adbc7b4e-3450-4e56-85ca-b9ceeb5a24c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c256eaea-15de-4231-bc65-c4528f97e39f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516b8e66-9a40-47d9-ae12-108f04181a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c256eaea-15de-4231-bc65-c4528f97e39f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516b8e66-9a40-47d9-ae12-108f04181a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6cea9f28-2e1d-4283-b573-5992fb05c41c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516b8e66-9a40-47d9-ae12-108f04181a3a" xlink:to="loc_us-gaap_PlanNameAxis_6cea9f28-2e1d-4283-b573-5992fb05c41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c143f780-dd4d-42d4-879e-fe5f4c192f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6cea9f28-2e1d-4283-b573-5992fb05c41c" xlink:to="loc_us-gaap_PlanNameDomain_c143f780-dd4d-42d4-879e-fe5f4c192f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_A2020EquityIncentivePlanMember_329c75d3-14c2-43f4-97ef-9185fece96d8" xlink:href="arqt-20200331.xsd#arqt_A2020EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c143f780-dd4d-42d4-879e-fe5f4c192f7c" xlink:to="loc_arqt_A2020EquityIncentivePlanMember_329c75d3-14c2-43f4-97ef-9185fece96d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_A2017EquityIncentivePlanMember_2e99026d-832d-48ca-a0c8-55e2148f89a6" xlink:href="arqt-20200331.xsd#arqt_A2017EquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c143f780-dd4d-42d4-879e-fe5f4c192f7c" xlink:to="loc_arqt_A2017EquityIncentivePlanMember_2e99026d-832d-48ca-a0c8-55e2148f89a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9639ff3f-3a87-4a07-9d8f-815961494cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516b8e66-9a40-47d9-ae12-108f04181a3a" xlink:to="loc_us-gaap_AwardTypeAxis_9639ff3f-3a87-4a07-9d8f-815961494cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72dddbf-8af4-4fec-b444-d7d83e884d10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9639ff3f-3a87-4a07-9d8f-815961494cc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72dddbf-8af4-4fec-b444-d7d83e884d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0a0e1ce2-1399-4a71-a2ed-e178d1985eb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72dddbf-8af4-4fec-b444-d7d83e884d10" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0a0e1ce2-1399-4a71-a2ed-e178d1985eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8f5f6989-ae8d-4450-8d67-ef140fb5f0e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72dddbf-8af4-4fec-b444-d7d83e884d10" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8f5f6989-ae8d-4450-8d67-ef140fb5f0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c18dc5a6-61eb-45dc-9590-e3d76b020a83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72dddbf-8af4-4fec-b444-d7d83e884d10" xlink:to="loc_us-gaap_RestrictedStockMember_c18dc5a6-61eb-45dc-9590-e3d76b020a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ServiceConditionRestrictedStockMember_bc95597d-7099-408b-b8c0-9ff563c153c5" xlink:href="arqt-20200331.xsd#arqt_ServiceConditionRestrictedStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72dddbf-8af4-4fec-b444-d7d83e884d10" xlink:to="loc_arqt_ServiceConditionRestrictedStockMember_bc95597d-7099-408b-b8c0-9ff563c153c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_PerformanceConditionRestrictedStockMember_359da081-25de-4bcc-9e9c-a65a323f9a13" xlink:href="arqt-20200331.xsd#arqt_PerformanceConditionRestrictedStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72dddbf-8af4-4fec-b444-d7d83e884d10" xlink:to="loc_arqt_PerformanceConditionRestrictedStockMember_359da081-25de-4bcc-9e9c-a65a323f9a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_13195123-9834-40f4-aadf-b18cab85e06d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72dddbf-8af4-4fec-b444-d7d83e884d10" xlink:to="loc_us-gaap_EmployeeStockMember_13195123-9834-40f4-aadf-b18cab85e06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dded327f-3f32-4ccc-8b3e-18e296800292" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516b8e66-9a40-47d9-ae12-108f04181a3a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dded327f-3f32-4ccc-8b3e-18e296800292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_618522db-c107-4b12-bdb8-4fc75032e34c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dded327f-3f32-4ccc-8b3e-18e296800292" xlink:to="loc_us-gaap_EquityComponentDomain_618522db-c107-4b12-bdb8-4fc75032e34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_96333657-cc4f-45a1-a1eb-0d9c12e015d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_618522db-c107-4b12-bdb8-4fc75032e34c" xlink:to="loc_us-gaap_CommonStockMember_96333657-cc4f-45a1-a1eb-0d9c12e015d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_5f0ae3d8-8966-40f4-965e-689637a3d3a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516b8e66-9a40-47d9-ae12-108f04181a3a" xlink:to="loc_us-gaap_VestingAxis_5f0ae3d8-8966-40f4-965e-689637a3d3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a82cb175-56d4-4a6d-b694-8417a44d0a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_5f0ae3d8-8966-40f4-965e-689637a3d3a7" xlink:to="loc_us-gaap_VestingDomain_a82cb175-56d4-4a6d-b694-8417a44d0a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3620b963-5a48-4be1-b76a-caa485cb7111" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a82cb175-56d4-4a6d-b694-8417a44d0a3f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3620b963-5a48-4be1-b76a-caa485cb7111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1a625c39-c669-4f99-8af3-eaf447b49ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a82cb175-56d4-4a6d-b694-8417a44d0a3f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1a625c39-c669-4f99-8af3-eaf447b49ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_516b8e66-9a40-47d9-ae12-108f04181a3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7e733f54-f6c2-4177-bd47-78e6b0739df7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7e733f54-f6c2-4177-bd47-78e6b0739df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_4d68658e-a8ce-499c-ab23-c53b34a211ed" xlink:href="arqt-20200331.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_4d68658e-a8ce-499c-ab23-c53b34a211ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable_8b1b6b20-a4f5-4127-90e0-0e7215b7e1d3" xlink:href="arqt-20200331.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable_8b1b6b20-a4f5-4127-90e0-0e7215b7e1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0c26071f-c1bd-42bb-85b3-e455be51abfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0c26071f-c1bd-42bb-85b3-e455be51abfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2a457efe-093b-48e7-8fd1-ccd76d9694ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2a457efe-093b-48e7-8fd1-ccd76d9694ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_525eccbf-81bb-4101-a757-b744c3140903" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_525eccbf-81bb-4101-a757-b744c3140903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2bdd594a-3856-4e1c-b962-fcad2378e6be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2bdd594a-3856-4e1c-b962-fcad2378e6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bceb77da-c1f4-4e0c-a2dc-a1df5dfa157a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bceb77da-c1f4-4e0c-a2dc-a1df5dfa157a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c9d362c3-3137-4355-bc7b-752020402626" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_96889e80-611c-4570-a98b-61eae085acdc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_96889e80-611c-4570-a98b-61eae085acdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dbaf0d48-34e9-4f64-ba55-9d0ab20d3156" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dbaf0d48-34e9-4f64-ba55-9d0ab20d3156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_19eb3bba-32fe-4336-84fe-72df3aad439c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_19eb3bba-32fe-4336-84fe-72df3aad439c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_13981028-c7b3-477c-b8ee-e17ebabb39b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_13981028-c7b3-477c-b8ee-e17ebabb39b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_f12427fc-5113-4012-b4c2-f677336b0a45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_f12427fc-5113-4012-b4c2-f677336b0a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_d83613cb-3586-43f6-8d77-9664418fd44a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_d83613cb-3586-43f6-8d77-9664418fd44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_233a5459-bf61-46b5-8db8-90c500712dce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_233a5459-bf61-46b5-8db8-90c500712dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f00c2906-0716-4776-99ab-c09959a47956" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f00c2906-0716-4776-99ab-c09959a47956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis_402af94e-8a87-44b4-9bd6-f2f3d733d673" xlink:href="arqt-20200331.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis_402af94e-8a87-44b4-9bd6-f2f3d733d673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e8dcce5-0ab1-488d-8e74-a986d487a925" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e8dcce5-0ab1-488d-8e74-a986d487a925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f74ae458-254e-4ff1-91ab-d5b01ce4e891" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f74ae458-254e-4ff1-91ab-d5b01ce4e891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_442369e2-e4c2-4064-8bb0-8cd6bd56a647" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_442369e2-e4c2-4064-8bb0-8cd6bd56a647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized_8c756003-664a-43e8-9a49-a9daea8c5293" xlink:href="arqt-20200331.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized_8c756003-664a-43e8-9a49-a9daea8c5293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding_cc76f9bf-3677-4b16-aa0c-4d2f2ba16df1" xlink:href="arqt-20200331.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_62b84e53-e5f4-4f3b-b227-a58a92c353a5" xlink:href="arqt-20200331.xsd#arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_939cc3fd-1f7e-45df-a5e7-1c96d5df04c6" xlink:to="loc_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable_62b84e53-e5f4-4f3b-b227-a58a92c353a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02a994b1-3841-4b5c-b3f5-3fe7b3f4d40a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d7646f5-dc66-410c-93b4-9cfdb700486a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02a994b1-3841-4b5c-b3f5-3fe7b3f4d40a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d7646f5-dc66-410c-93b4-9cfdb700486a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9a99b90b-4e62-4c0e-9580-71c840f5a604" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d7646f5-dc66-410c-93b4-9cfdb700486a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9a99b90b-4e62-4c0e-9580-71c840f5a604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a3ec4c9d-819f-44b1-ba40-a759ca8d52bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d7646f5-dc66-410c-93b4-9cfdb700486a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a3ec4c9d-819f-44b1-ba40-a759ca8d52bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4196e510-42c3-4ac5-bebf-cc334e12cd95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d7646f5-dc66-410c-93b4-9cfdb700486a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4196e510-42c3-4ac5-bebf-cc334e12cd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_900332f7-b31d-4d70-bc7f-d72c832315aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d7646f5-dc66-410c-93b4-9cfdb700486a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_900332f7-b31d-4d70-bc7f-d72c832315aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e7ac696e-7f11-485a-85ba-81dec10b8fe2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02a994b1-3841-4b5c-b3f5-3fe7b3f4d40a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e7ac696e-7f11-485a-85ba-81dec10b8fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_718004d9-f7f8-4ddb-b471-692515a785ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e7ac696e-7f11-485a-85ba-81dec10b8fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_718004d9-f7f8-4ddb-b471-692515a785ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_578c5b56-9a6b-4525-b985-330a95adc8cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e7ac696e-7f11-485a-85ba-81dec10b8fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_578c5b56-9a6b-4525-b985-330a95adc8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_761f6c3c-7d7e-4d08-b77c-d6c70e74b316" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e7ac696e-7f11-485a-85ba-81dec10b8fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_761f6c3c-7d7e-4d08-b77c-d6c70e74b316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7ed79584-dba5-40a4-bfc3-89f5cc660127" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e7ac696e-7f11-485a-85ba-81dec10b8fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7ed79584-dba5-40a4-bfc3-89f5cc660127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ee4beb47-2282-4e87-9599-8e8cbe4de986" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e7ac696e-7f11-485a-85ba-81dec10b8fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ee4beb47-2282-4e87-9599-8e8cbe4de986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4cd310ef-d7ea-4b43-9dc0-7c659550a093" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ee4beb47-2282-4e87-9599-8e8cbe4de986" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4cd310ef-d7ea-4b43-9dc0-7c659550a093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1bf33e23-e68e-46a8-9064-3072c82e123f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ee4beb47-2282-4e87-9599-8e8cbe4de986" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1bf33e23-e68e-46a8-9064-3072c82e123f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fb82f026-5922-4f31-ae3d-14784925adb5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ee4beb47-2282-4e87-9599-8e8cbe4de986" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fb82f026-5922-4f31-ae3d-14784925adb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7f72710e-5c8e-4315-8c11-bb0402c5c412" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ee4beb47-2282-4e87-9599-8e8cbe4de986" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7f72710e-5c8e-4315-8c11-bb0402c5c412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e80d12ca-328a-47f9-88a1-e7797181d6a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ee4beb47-2282-4e87-9599-8e8cbe4de986" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e80d12ca-328a-47f9-88a1-e7797181d6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d71dc01f-4c66-4367-9f91-a96cac7de896" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ee4beb47-2282-4e87-9599-8e8cbe4de986" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d71dc01f-4c66-4367-9f91-a96cac7de896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30571229-0075-4c47-97e4-153f9acf114d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1440551c-8bec-49c3-b5e4-4d217fde340b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30571229-0075-4c47-97e4-153f9acf114d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1440551c-8bec-49c3-b5e4-4d217fde340b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7d838a60-3034-44c4-8959-c7fecda05b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1440551c-8bec-49c3-b5e4-4d217fde340b" xlink:to="loc_us-gaap_AwardTypeAxis_7d838a60-3034-44c4-8959-c7fecda05b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a633a66f-15f7-4dda-81cc-65fb3db0bbb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7d838a60-3034-44c4-8959-c7fecda05b2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a633a66f-15f7-4dda-81cc-65fb3db0bbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8b3d5368-cefd-4797-9b61-5bf373c00450" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a633a66f-15f7-4dda-81cc-65fb3db0bbb8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8b3d5368-cefd-4797-9b61-5bf373c00450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c78c94e-1b57-41fa-a84b-17e6177bb87e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1440551c-8bec-49c3-b5e4-4d217fde340b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c78c94e-1b57-41fa-a84b-17e6177bb87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_25686660-5097-45a4-9154-c4398902e79c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c78c94e-1b57-41fa-a84b-17e6177bb87e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_25686660-5097-45a4-9154-c4398902e79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d90132c7-6496-47cf-8780-4bb4c81faf45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_25686660-5097-45a4-9154-c4398902e79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d90132c7-6496-47cf-8780-4bb4c81faf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fa22501b-e766-4f5f-858a-e7900f074a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_25686660-5097-45a4-9154-c4398902e79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fa22501b-e766-4f5f-858a-e7900f074a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fe87d03e-1fbd-4eb3-b340-f60b528ea348" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_25686660-5097-45a4-9154-c4398902e79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fe87d03e-1fbd-4eb3-b340-f60b528ea348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_734c1464-e5c0-4621-8ad0-ca42597b6aea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_25686660-5097-45a4-9154-c4398902e79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_734c1464-e5c0-4621-8ad0-ca42597b6aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7987bf8c-6660-41de-8757-e44f88fa222c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_25686660-5097-45a4-9154-c4398902e79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7987bf8c-6660-41de-8757-e44f88fa222c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e763772c-4e6c-42cb-b0e4-7a34185d7e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c78c94e-1b57-41fa-a84b-17e6177bb87e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e763772c-4e6c-42cb-b0e4-7a34185d7e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_218459e7-8aee-45be-9005-794c587c7ced" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e763772c-4e6c-42cb-b0e4-7a34185d7e7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_218459e7-8aee-45be-9005-794c587c7ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bb5df2a2-fc78-4cbf-8e43-5231d26d26af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e763772c-4e6c-42cb-b0e4-7a34185d7e7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bb5df2a2-fc78-4cbf-8e43-5231d26d26af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_f31342fa-bb8c-4075-92af-e4205d8880dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e763772c-4e6c-42cb-b0e4-7a34185d7e7b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_f31342fa-bb8c-4075-92af-e4205d8880dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f47d4038-65d6-49e6-a282-ee3d91b1c558" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e763772c-4e6c-42cb-b0e4-7a34185d7e7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f47d4038-65d6-49e6-a282-ee3d91b1c558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a2ec7ae0-066d-4781-8d84-12907df6a8c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e763772c-4e6c-42cb-b0e4-7a34185d7e7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a2ec7ae0-066d-4781-8d84-12907df6a8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73247856-b58d-4997-82c5-cb0368191b60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a4e7561b-18df-4342-85a4-d348fdf23ae8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73247856-b58d-4997-82c5-cb0368191b60" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a4e7561b-18df-4342-85a4-d348fdf23ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5f4e176d-7474-476e-bd9d-080fdce56425" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a4e7561b-18df-4342-85a4-d348fdf23ae8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5f4e176d-7474-476e-bd9d-080fdce56425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33797838-a504-49f3-8e61-b440c392a4d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5f4e176d-7474-476e-bd9d-080fdce56425" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33797838-a504-49f3-8e61-b440c392a4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c9a878ce-198f-446d-be48-bf7806afb641" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33797838-a504-49f3-8e61-b440c392a4d9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c9a878ce-198f-446d-be48-bf7806afb641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_57196c97-f1a8-40e7-bd62-becfcbac6d21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33797838-a504-49f3-8e61-b440c392a4d9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_57196c97-f1a8-40e7-bd62-becfcbac6d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5a11771f-eb90-4b26-a2ad-8aa5ca5dc69c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a4e7561b-18df-4342-85a4-d348fdf23ae8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5a11771f-eb90-4b26-a2ad-8aa5ca5dc69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f096d712-1d21-44f4-8275-2a52c05529be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5a11771f-eb90-4b26-a2ad-8aa5ca5dc69c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f096d712-1d21-44f4-8275-2a52c05529be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_50a507e3-3c6f-40d8-9451-176df3f76a52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_835a996f-b0fb-429d-aaca-ab4158b00d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_50a507e3-3c6f-40d8-9451-176df3f76a52" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_835a996f-b0fb-429d-aaca-ab4158b00d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1847b2a6-ce7d-474f-bf9e-7e72169ba742" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_835a996f-b0fb-429d-aaca-ab4158b00d9d" xlink:to="loc_srt_RangeAxis_1847b2a6-ce7d-474f-bf9e-7e72169ba742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b3e9b141-b6ae-435f-8f58-99b5aa0facd5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1847b2a6-ce7d-474f-bf9e-7e72169ba742" xlink:to="loc_srt_RangeMember_b3e9b141-b6ae-435f-8f58-99b5aa0facd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d4802862-c5d8-402b-af4a-e95ff69b7d93" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b3e9b141-b6ae-435f-8f58-99b5aa0facd5" xlink:to="loc_srt_MinimumMember_d4802862-c5d8-402b-af4a-e95ff69b7d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_519272aa-332c-4d4e-b981-3fa511c2d41f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b3e9b141-b6ae-435f-8f58-99b5aa0facd5" xlink:to="loc_srt_MaximumMember_519272aa-332c-4d4e-b981-3fa511c2d41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_05b6ed50-c35e-491a-9ad7-7872c4249bef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_835a996f-b0fb-429d-aaca-ab4158b00d9d" xlink:to="loc_us-gaap_AwardTypeAxis_05b6ed50-c35e-491a-9ad7-7872c4249bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8ee887d-4aa6-46c9-9c11-8c9574e1974d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_05b6ed50-c35e-491a-9ad7-7872c4249bef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8ee887d-4aa6-46c9-9c11-8c9574e1974d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0315c7de-d5d3-4d12-b84b-0fa3577b9c68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8ee887d-4aa6-46c9-9c11-8c9574e1974d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0315c7de-d5d3-4d12-b84b-0fa3577b9c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9df5764-b88b-415c-bee5-3633a322a0d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_835a996f-b0fb-429d-aaca-ab4158b00d9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9df5764-b88b-415c-bee5-3633a322a0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0e4d1b79-c40b-4d77-917d-c077b862828d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9df5764-b88b-415c-bee5-3633a322a0d4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0e4d1b79-c40b-4d77-917d-c077b862828d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ce528a76-cfc5-4f12-8cb6-c628e3cb67bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9df5764-b88b-415c-bee5-3633a322a0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ce528a76-cfc5-4f12-8cb6-c628e3cb67bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_60d4684f-8b24-4a49-a51e-b308b4cb711c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9df5764-b88b-415c-bee5-3633a322a0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_60d4684f-8b24-4a49-a51e-b308b4cb711c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_5da5fe65-ec24-4dc1-8e09-dd05acdae96e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9df5764-b88b-415c-bee5-3633a322a0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_5da5fe65-ec24-4dc1-8e09-dd05acdae96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3fc96fd1-faf3-4dbe-af7c-f320b184c14f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9df5764-b88b-415c-bee5-3633a322a0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3fc96fd1-faf3-4dbe-af7c-f320b184c14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_288d311c-78ad-4d6a-8d95-457853b08417" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9df5764-b88b-415c-bee5-3633a322a0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_288d311c-78ad-4d6a-8d95-457853b08417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/NetLossPerShare" xlink:type="simple" xlink:href="arqt-20200331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5f515c11-e5ca-44cc-a377-70507e775463" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_42a60527-4bce-41d7-a54e-bedf0642a0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5f515c11-e5ca-44cc-a377-70507e775463" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_42a60527-4bce-41d7-a54e-bedf0642a0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="arqt-20200331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7f96ffbb-7d76-4af5-8ad4-e4583da9bb30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_aa8f85fd-c83f-4bf9-9598-68c1bcc59d13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7f96ffbb-7d76-4af5-8ad4-e4583da9bb30" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_aa8f85fd-c83f-4bf9-9598-68c1bcc59d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#NetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d7cfaa48-e0a5-422d-bb95-81c62d17c061" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_da42ae12-5586-4994-9f86-93b80130dc97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d7cfaa48-e0a5-422d-bb95-81c62d17c061" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_da42ae12-5586-4994-9f86-93b80130dc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dad8f075-adb9-418c-b13e-215c23a9e859" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_da42ae12-5586-4994-9f86-93b80130dc97" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dad8f075-adb9-418c-b13e-215c23a9e859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77ca42f3-cd18-43be-a4e5-c0da9588b8a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dad8f075-adb9-418c-b13e-215c23a9e859" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77ca42f3-cd18-43be-a4e5-c0da9588b8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_7e17213e-2c97-4d1f-8ad7-ecada8e0e614" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77ca42f3-cd18-43be-a4e5-c0da9588b8a1" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_7e17213e-2c97-4d1f-8ad7-ecada8e0e614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c24f6d7c-e0c8-4fa1-8745-95f2e691793c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77ca42f3-cd18-43be-a4e5-c0da9588b8a1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c24f6d7c-e0c8-4fa1-8745-95f2e691793c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_EarlyExercisedOptionsMember_d348faef-dc3a-45f8-9324-0df077d71bdd" xlink:href="arqt-20200331.xsd#arqt_EarlyExercisedOptionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77ca42f3-cd18-43be-a4e5-c0da9588b8a1" xlink:to="loc_arqt_EarlyExercisedOptionsMember_d348faef-dc3a-45f8-9324-0df077d71bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_30d25a23-1c85-4a97-9bb9-cb8234fc1950" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77ca42f3-cd18-43be-a4e5-c0da9588b8a1" xlink:to="loc_us-gaap_RestrictedStockMember_30d25a23-1c85-4a97-9bb9-cb8234fc1950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_6cc98f5d-415b-4008-a1b7-2bf4e8e683dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77ca42f3-cd18-43be-a4e5-c0da9588b8a1" xlink:to="loc_us-gaap_EmployeeStockMember_6cc98f5d-415b-4008-a1b7-2bf4e8e683dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6894385b-17e1-4248-b754-d54ff43f1281" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_da42ae12-5586-4994-9f86-93b80130dc97" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6894385b-17e1-4248-b754-d54ff43f1281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5af84544-d22f-4bc4-82c5-c1d9a779c2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6894385b-17e1-4248-b754-d54ff43f1281" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5af84544-d22f-4bc4-82c5-c1d9a779c2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/SubsequentEvent" xlink:type="simple" xlink:href="arqt-20200331.xsd#SubsequentEvent"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_38e07975-8e46-431f-a312-a2a129c15ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_840bc305-f0cf-44e3-b45e-d29d4b6dcc9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_38e07975-8e46-431f-a312-a2a129c15ae4" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_840bc305-f0cf-44e3-b45e-d29d4b6dcc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcutis.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="arqt-20200331.xsd#SubsequentEventDetails"/>
  <link:presentationLink xlink:role="http://arcutis.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_2381006d-6b5a-4334-a546-e69253998b7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_43e88426-d993-4628-aff6-fe40cb562ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_2381006d-6b5a-4334-a546-e69253998b7c" xlink:to="loc_us-gaap_SubsequentEventTable_43e88426-d993-4628-aff6-fe40cb562ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b9779487-a436-4b2f-a08b-37ef744e0f88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_43e88426-d993-4628-aff6-fe40cb562ac0" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b9779487-a436-4b2f-a08b-37ef744e0f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_30641997-f509-4d33-9357-2d6ab15beba9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b9779487-a436-4b2f-a08b-37ef744e0f88" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_30641997-f509-4d33-9357-2d6ab15beba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3c7548bb-4570-4a8b-a143-f663d7d5dc21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_30641997-f509-4d33-9357-2d6ab15beba9" xlink:to="loc_us-gaap_SubsequentEventMember_3c7548bb-4570-4a8b-a143-f663d7d5dc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LeaseDescriptionAxis_df8dadf5-4ccd-49cc-a90a-727a1791ff6d" xlink:href="arqt-20200331.xsd#arqt_LeaseDescriptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_43e88426-d993-4628-aff6-fe40cb562ac0" xlink:to="loc_arqt_LeaseDescriptionAxis_df8dadf5-4ccd-49cc-a90a-727a1791ff6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LeaseDescriptionDomain_f364d8da-9e3c-4b88-b281-e5fbd3f6e0d8" xlink:href="arqt-20200331.xsd#arqt_LeaseDescriptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_LeaseDescriptionAxis_df8dadf5-4ccd-49cc-a90a-727a1791ff6d" xlink:to="loc_arqt_LeaseDescriptionDomain_f364d8da-9e3c-4b88-b281-e5fbd3f6e0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_WestlakeVillageCaliforniaLeaseArrangementMember_3cdcb129-f5be-4f69-a5b6-93bebf82a05d" xlink:href="arqt-20200331.xsd#arqt_WestlakeVillageCaliforniaLeaseArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arqt_LeaseDescriptionDomain_f364d8da-9e3c-4b88-b281-e5fbd3f6e0d8" xlink:to="loc_arqt_WestlakeVillageCaliforniaLeaseArrangementMember_3cdcb129-f5be-4f69-a5b6-93bebf82a05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_43e88426-d993-4628-aff6-fe40cb562ac0" xlink:to="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace_c0202aa5-dcab-4d45-ac2c-bc5aadee5241" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:to="loc_arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace_c0202aa5-dcab-4d45-ac2c-bc5aadee5241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ee3db104-b5ba-4ddf-9249-295ac4196cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ee3db104-b5ba-4ddf-9249-295ac4196cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_49862663-6954-49cd-b75c-4fa1756eddfb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_49862663-6954-49cd-b75c-4fa1756eddfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseTermForTerminationOption_2a6152cc-141e-43f2-9e93-274e818275b3" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseTermForTerminationOption"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:to="loc_arqt_LesseeOperatingLeaseTermForTerminationOption_2a6152cc-141e-43f2-9e93-274e818275b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseMonthlyRentExpense_e2076460-1d83-4df7-a409-054a5da804d5" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseMonthlyRentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:to="loc_arqt_LesseeOperatingLeaseMonthlyRentExpense_e2076460-1d83-4df7-a409-054a5da804d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseFreeRentPeriod_4f667ec5-b40a-4f52-8e87-8710343601c6" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseFreeRentPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:to="loc_arqt_LesseeOperatingLeaseFreeRentPeriod_4f667ec5-b40a-4f52-8e87-8710343601c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseTenantImprovementAllowance_e088a5c1-6707-4c46-b869-f1ec3d5430a6" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseTenantImprovementAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:to="loc_arqt_LesseeOperatingLeaseTenantImprovementAllowance_e088a5c1-6707-4c46-b869-f1ec3d5430a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arqt_LesseeOperatingLeaseLetterOfCreditRequirement_abfda0b1-f5ba-44cc-9991-b4f196bfebe2" xlink:href="arqt-20200331.xsd#arqt_LesseeOperatingLeaseLetterOfCreditRequirement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9b04c799-5103-417d-809d-4f4b2dde06ad" xlink:to="loc_arqt_LesseeOperatingLeaseLetterOfCreditRequirement_abfda0b1-f5ba-44cc-9991-b4f196bfebe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6621685632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6617371808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Hengrui (Details) - Hengrui - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">License agreement, cash payment</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments', window );">Maximum milestone payments for licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments', window );">Maximum milestone payments for net worldwide sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others. Maximum Product Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Maximum Sales Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arqt_HengruiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arqt_HengruiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6778385008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value of Assets Measured on a Recurring Basis</a></td>
<td class="text">The following table sets forth the Company&#8217;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):<div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:48.951%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.714%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Assets:</span></div></td><td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds(1)</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial paper</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,396&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,396&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Government securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,030&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,030&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195,923&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,396&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">249,319&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:48.951%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.714%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Level 1</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Level 2</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Level 3</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Assets:</span></div></td><td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds(1)</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,689&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,689&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Government securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,576&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,689&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101,265&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt;">This balance includes cash requirements settled on a nightly basis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Marketable Securities</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the estimated value of the Company&#8217;s cash, cash equivalents and marketable securities and the gross unrealized holding gains and losses (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:48.951%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.714%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents:</span></div></td><td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,396&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,396&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,030&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,426&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt;">This balance includes cash requirements settled on a nightly basis.</span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:49.461%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.702%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents:</span></td><td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,780&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,780&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds(1)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,998&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,998&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,909&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,909&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,021&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,930&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,929&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the estimated value of the Company&#8217;s cash, cash equivalents and marketable securities and the gross unrealized holding gains and losses (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:48.951%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.714%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents:</span></div></td><td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,396&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,396&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,030&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,426&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt;">This balance includes cash requirements settled on a nightly basis.</span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:49.461%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.702%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents:</span></td><td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,780&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,780&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds(1)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,998&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,998&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,909&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,909&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,021&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,930&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,929&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779036592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prepaid Expenses and Other Current Assets</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:73.877%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid clinical trial costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,583&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,998&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred financing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,747&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other prepaid expenses and current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">650&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">402&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,209&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Liabilities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:73.877%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical trial accruals</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,114&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,497&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">806&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,379&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Early exercise liability, current</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">269&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">553&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total accrued liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,654&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779033872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation  In January 2020, the Company&#8217;s board of directors approved the 2020 Equity Incentive Plan, or the 2020 Plan, which became effective upon the completion of the IPO on January 31, 2020. The 2020 Plan serves as the successor incentive award plan to the Company&#8217;s 2017 Equity Incentive Plan, or the 2017 Plan, and has 2,134,000 shares of common stock available for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock-based awards, plus 1,550,150 shares of common stock that were reserved for issuance pursuant to future awards under the 2017 Plan at the time the 2020 Plan became effective, plus shares represented by awards outstanding under the 2017 Plan that are forfeited or lapse unexercised and which following the effective date of the 2020 Plan are not issued under the 2017 Plan. In addition, the 2020 Plan reserve will increase on January 1, 2021 <div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and each subsequent anniversary through 2030, by an amount equal to the lesser of (a) four percent of the shares of stock outstanding (on an as converted basis) on the day immediately prior to the date of increase and (b) such smaller number of shares of stock as determined by our board of directors; provided, however, that no more than 11,000,000 shares of stock may be issued upon the exercise of incentive stock options.  As of March&#160;31, 2020, the Company had 2,900,890 shares available for future grant under the 2020 Plan.</span><span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2020 Plan provides for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the board of directors and consultants of the Company under terms and provisions established by the board of directors. Under the terms of the 2020 Plan, options may be granted at an exercise price not less than fair market value. The Company generally grants stock-based awards with service conditions. Options granted typically vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzY4NA_1160bc3e-4896-43bb-92b1-9fd3b49a3ce7">four</span>-year period but may be granted with different vesting terms.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following the Company&#8217;s IPO and in connection with the effectiveness of the Company&#8217;s 2020 Plan, the 2017 Plan terminated and no further awards will be granted under that plan. However, all outstanding awards under the 2017 Plan will continue to be governed by their existing terms.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Option Activity</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following summarizes option activity (in thousands, except share amounts):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:45.807%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.947%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.701%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Number of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Weighted-</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Term</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Aggregate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Intrinsic</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance&#8212;December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,516,470&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.44</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,673&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">653,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.92&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(108,149)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance&#8212;March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,061,521&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.52&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.35</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable&#8212;March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,686,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.85&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.24</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,408&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt;">Options exercisable includes early exercisable options.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock as of March&#160;31, 2020. As of December&#160;31, 2019, prior to the Company's IPO, the estimated fair value of the Company's common stock was determined by the board of directors.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The intrinsic value of options exercised for the three months ended March 31, 2020 was $1.5 million. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total grant-date fair value of the options vested during the three months ended March 31, 2020 was $367,000. The weighted-average grant-date fair value of employee options granted during the three months ended March 31, 2020 was $16.94.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Unit Activity</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes information regarding our restricted stock units (RSUs):</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:60.719%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.992%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance&#8212;December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested Balance&#8212;March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The grant date fair value of an RSU equals the closing price of our common stock on the grant date.  RSUs generally vest equally over 4 years.  There were no RSU grants prior to January 1, 2020.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation Expense</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation expense recognized in our Condensed Statements of Operations and Comprehensive Loss was as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:56.333%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.906%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.031%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">574&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stock-based compensation expense</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">990&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, there was $15.8 million of total unrecognized compensation cost related to unvested options that are expected to vest, which is expected to be recognized over a weighted-average period of 3.4 years.  As of March&#160;31, 2020, there was $3.6 million of total unrecognized compensation cost related to RSUs that is expected to vest, which is expected to be recognized over a weighted-average period of 3.9 years.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining the fair value of the stock options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment.</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair value of common stock&#8212;  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For options granted prior to IPO in the year ended December 31, 2019, given the absence of a public trading market, the Company&#8217;s board of directors with input from management considered numerous objective and subjective factors to determine the fair value of common stock. The factors included, but were not limited to: (i)&#160;third-party valuations of the Company&#8217;s common stock; (ii)&#160;the Company&#8217;s stage of development; (iii)&#160;the status of research and development efforts; (iv)&#160;the rights, preferences and privileges of the Company&#8217;s convertible preferred stock relative to those of the Company&#8217;s common stock; (v)&#160;the Company&#8217;s operating results and financial condition, including the Company&#8217;s levels of available capital resources; and (vi)&#160;equity market conditions affecting comparable public companies; (vii)&#160;general U.S. market conditions; and (viii)&#160;the lack of marketability of the Company&#8217;s common stock. For options granted after IPO, the Company uses its closing stock price as reported on Nasdaq on the grant date for the fair value of its stock.</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Term</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The Company&#8217;s expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding. The Company used the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term.</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Volatility</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;Since the Company does not have sufficient trading history for its common stock, the expected volatility was estimated based on the average historical volatilities for comparable publicly traded pharmaceutical companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle and area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-Free Interest Rate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Dividend Yield</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of stock option awards granted was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.736%;"><tr><td style="width:1.0%;"/><td style="width:61.425%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.901%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.571%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.903%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expected term (in years)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.5 &#8211; 6.1</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.1 &#8211; 6.6</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expected volatility</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">71.2&#160;&#8211;&#160;73.3%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">68.6&#160;&#8211;&#160;72.5%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Risk-free interest rate</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.5 &#8211; 1.4%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.6 &#8211; 2.6%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dividend yield</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td></tr></table></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Early Exercise of Employee Options</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The terms of the 2017 and 2020 Plans permit certain option holders to exercise options before their options are vested, subject to certain limitations. Upon early exercise, the awards become subject to a restricted stock agreement. The shares of restricted stock granted upon early exercise of the options are subject to the same vesting provisions in the original stock option awards. Shares issued as a result of early exercise that have not vested are subject to repurchase by the Company upon termination of the purchaser&#8217;s employment, at the price paid by the purchaser. Such shares are not deemed to be issued for accounting purposes until they vest and are therefore excluded from shares outstanding and from basic and diluted net loss per share until the repurchase right lapses and the shares are no longer subject to the repurchase feature. The liability is reclassified into common stock and additional paid-in capital as the shares vest and the repurchase right lapses. Accordingly, the Company has recorded the unvested portion of the exercise proceeds of $475,000 and $409,000 as a liability from the early exercise in the accompanying balance sheet as of March&#160;31, 2020 and December&#160;31, 2019, respectively. As of March&#160;31, 2020 and December&#160;31, 2019,  there were $269,000 and  $225,000 recorded in accrued liabilities, respectively, and $206,000 and  $184,000 recorded in other long-term liabilities, respectively related to shares that were subject to repurchase.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Founder Awards</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2016, the Company issued 1,187,738 shares of restricted common stock to founders of which 1,102,903 shares vest under a service condition and 84,835 shares vest under a performance condition. The shares were issued under the terms of the respective restricted stock purchase agreements, or the Stock Purchase Agreement, and unvested shares are subject to repurchase by the Company at the original purchase price per share upon the holder&#8217;s termination of his relationship with the Company. The restricted shares are not deemed to be issued for accounting purposes until they vest and are therefore excluded from shares outstanding and from basic and diluted net loss per share until the repurchase right lapses and the shares are no longer subject to the repurchase feature. One-fourth of the 1,102,903 shares of restricted common stock were vested on the first-anniversary date and the remaining 827,177 shares will vest on a monthly basis thereafter. In July 2018, performance conditions prescribed by the Stock Purchase Agreement were met and 84,835 shares of the restricted common stock were fully vested. During the three months ended March 31, 2020 and 2019, 68,931 shares and 68,931 shares of restricted common stock were vested, respectively. As of March&#160;31, 2020, 68,932 shares of restricted stock are unvested.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2020 Employee Stock Purchase Plan</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted the 2020 Employee Stock Purchase Plan, or the ESPP, which became effective upon the completion of the IPO on January 31, 2020. The ESPP is designed to allow the Company&#8217;s eligible employees to purchase shares of the Company&#8217;s common stock, at semi-annual intervals, with their accumulated payroll deductions. Under the ESPP, participants are offered the option to purchase shares of the Company&#8217;s common stock at a discount during a series of successive offering periods. The option purchase price will be the lower of 85% of the closing trading price per share of the Company&#8217;s common stock on the first trading date of an offering period in which a participant is enrolled or 85% of the closing trading price per share on the purchase date, which will occur on the last trading day of each offering period. The Company commenced an offering period on January 31, 2020.</span></div>The ESPP is intended to qualify under Section 423 of the U.S. Internal Revenue Service Code of 1986, as amended. The maximum number of the Company&#8217;s common stock which will be authorized for sale under the ESPP is equal to the sum of (a) 351,000 shares of common stock and (b) an annual increase on the first day of each year beginning in 2021 and ending in 2030, equal to the lesser of (i) 1% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company&#8217;s board of directors; provided, however, no more than 5,265,000 shares of the Company&#8217;s common stock may be issued under the ESPP.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001787306-20-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001787306-20-000010-xbrl.zip
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MH>FZL#0^W_3_,[P\W?3=R; U>.5ZG=?IU1"E>'*B#U>WS6\Y".[50>_;:S@
M)V.=(9Q=G9Y.\;>N&#="O!X=O#RUW>H>W6CR*<W/Q5KKU_G1R:DGP_Z#[Z9?
MP]')B:U!CQ$LO]<1HS,F%]QIP\VSTV%K!I-N>[BU2127K1UD!\8<7YX<S<#F
MIXX/W-=M@]9]]X8VX-?_KG[<<<W0,=EM(;;.'FHZ3A*'QH>DYY/3!_WAW3;!
ME_>TIW4VO/_65W=]/>R;[B#V^ATSA-&5;L(S1#(BKMTD VVY<:.)]OSH/FK2
MF#=MTSWX:RETL]V=)5#Y8/S*GYTP-)5TURS\YZ3U[:^E=[WN$ 9R5C\_AMYQ
MHT]_+0W#V?!U+IK7*__G__R?/X>M83NL)-W/)GK^Y^O1EW^^'MW:]OSYRI^^
M]:TR&)ZWPU]+OC4X;IOS-]U>-T #6F=OTHFA/_JSY7WHYG_"\1J@2;_E1L\_
M&VZ'^-=2*SALN _$8F*9,58I'P+QVEAJO8YZ?RUO"H;^OQI[7=-)CPZM-^M=
M:-_Y.WB=OFEO=GTX^]]POE1I>;BUIU_.[5KOVT>R_:U!JR?^</W;WGM]N-7Y
MTFX<5B_VOGX^JUXXTCC<[FRM;3=K]5WX;I,W.K7#O;4C6KW8./I(:^W&Q7$;
MOK^HDB]'U7J5UCJ;:._P #7JNQB^:VU]_7#8()]Y[:)ZMK>AT$>R=][XZD3C
M8OUTJ]Z@</_FWMKZ>6WM2VOO\(C6ZD<7U<YV9^]]^MQLU\CG;_[]1LN^WQ55
MLM>LK350@U3QWN&73NU]E54O#EB5;)[6OFY"6QVJ?JVRK??5\35?X%F\NU?O
M7>QUUE'M</NP<0'7?85[7!Q<;*T=7#0.5W'C<*]5N_A\!M^Q!E87'^OKP^H.
M.H/?M+JVN4\IMR@0G&GG.*!S#)F)4@-$>TD9D8"^>FD%@2"DDA2)/U_?D.GT
M13S2>+CZ;/C&@_7IP!V;WIQ?%_Z[DWX?)+_1&CC3;@337^_Z-3BWE/^/Y(]O
MRU^K0!#G.A/$RHQ9;S)C2,A0D/"]MB(0M[2"298@X9E%?R7@"0.YDO &?#,H
MY?LC^9[5SG/9YC*N03OWA2+:1JHRCHG)F/$QL_!59CQ2D5MJF+9+*TD(,Y/O
M)[A_SY<2?IR$M][=EG!T'@FKLZ Y#&% [,P:%V'$2L:U,X@QO[3R^?G'[W7H
MMKU>.YAN-.W$$J\DOPIB][GHV^:@E/:/I;US2]I&"ZP]Y\E_$AF+6&36<I01
MHKWD5'!FR=+*1NKW!P2^T3<N4<K*2;<U$G?WI&-#?^FF"OA(G)5!>J4#TPZ4
M"U1)"((QM4%C,E$!++/)'TL5'URK \_^:XE-I#YF]V]VACUWU.RU@2,.UH&>
M#L]KO6'(O]TY;K>&P%7''NEV8KR@3PD;X 9HMFIR5JL[.E&5V@5<=[$+(C_"
M6_7-L]K[QL76U\USN*99.W2X]O7#4;6ST=RK'X#8OS#_KP_M/=+^9@][M IM
MK-6_=+;JN[QZN [/K/+&86K?.JG!/1N=S_",C?86J.96_3/=6EL]KUYLXEJ]
MBO9QE(X8\(R]%0#C6/+,V #&FGJJG0P1M %XVBNFM9K(?2+H[XYT%03C''X8
M1\ Z,(NLHMPQZ33(7J#O(/FE9)NF'_X&=]"_ZW6.0W>0>RRK?7!@#D(:ZW^?
M7YWRR9RGKU9/3=_G/[Z$P;#5/1@9 3QK61\>?=OK?FCN71P?5=]O-*LPK/<.
M&[C6J:*]]WN=1J=!&F0C_;[8.ZQU:O556MW1:._?3>0Z7[KFJS[9ZGP^;7Q=
M/VU<-*$UNZ1QL7VTU]D#"($[?4V_X6ZD@:MK[NS?%PU66]W'6"#K:,B8TC"H
MJ;69!NS-=/34,FVH"W)IY1-K_-J0=B$&%CD !8.[JF !R24(E >*C0DNR1I:
MHG)9IS^2K*^&]&9MXU[1VQ^+WGY/]-LI>#0 !7!PU!R$ HW\ W8Y\K_NXAI(
MJWJQW=Y:@Y&\MM$"36@UOF[B!MEN BI0N.=%@^S>'OEXK[Y+:X<'%[7WNW!]
M%0P#/ <0HW'XY7#O_3J@@H/V0UN_W!SYU;75TWWO$2?)O$>C-'AHEL*@URY#
MP@%[PXQ2%]/()_QIX]XJAJF,0DN2HFB*2*,=$YA%(Z6P^YOY<&<4W9;YQS 8
MA+!U'/HF2>]C -ENAVXX->UZZ'=F+;/#SWPBLZWW8(B_5GGM_3J#<\YJ:]73
MVAH8UJ^[IWOO8>2!T:\>^G:U<T=F# QQLW%Q!,]I0GO64?5B%6VM-0'9_SZ"
MYV- ^_,:V3V_*3-HW\7N^;Z1D4;J1.81!K2F3F<J(N#@1&%$E(8>5C">^=WQ
M_/IF]*0/(Q9<71<&*W^FH-N;01[R A%6\DC@F^'Y,8AFT.H<MU/\*_^NV4\2
MOA'.>74V  [XY^N;]Q@][OHS\H^#WDD__Y1'3]^,U68DUI\AAI,;A3QF,_G4
M\NES;(5^)6]0N#<@]F[S?V^&'VY?O#+YZN;=CW-S,ODT&)K^,$4(<D<GQ?00
MGEQW=>RRF?[:J33W?&\>F7R>/.3UC8Z:W"=A<=YI@X2 @\MNZ," .>F'E?'C
M\X.36TR.33ZG>]PK!\9#X,X:P\"#<]AJ)CQ"FK'H@?1+-AZ^'!6A^T<!VN&X
M1_FUSI\<>6*/GN3:?+/+QA'L-[L[:T_N31AO'#L'*,@%T]AKC45 5F@PR\9I
M/N[-8BCSS=Z\KI]/Z\T;/>"TC3RYC=$:!I9?.X%A2 NNB3#$^M0#&%A_P7H
MZVP<F_I5?0+ZD3.5R]?SK6_0K.NGYB!MAKW^3ZK>G>O3EVNAV^NTNO?=]K$
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MT0#S(X%Q$238%RJ$EI* B0$0DL #)5\8T<S"!YZ>F!S@!#.,.R,Q8Y%J QP
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M-0$O2SD+_<DM\4LK"MV),/[S.?WQCSVP<I^:O6Z9IUH]7+_8M\@CXL$-%LB
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MBN=OYP7 T2,!_%I%!<!,4VG#^X6*<0X O&\2"B=,ZR<N>^^W%1A%V;T'!AU
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M$A/GA^LN7$#U7:_3:0W39KV#?!?Y!#?0RM!U  "5/VJ]8:B(GRL%.9UJR(_
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M7L@_PC(>NOZ1/U8_$H3/!^%HUE15N99":P>T#58JB=U5A,T)H-I9**A%FND
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M@)B\R&>:Q<N-02YMP:VVAMW+CJL^U_FIAE!EXS?F;J#21(F/H\0?LTZ"$EY
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M&B4_[\>U@>CR*<#]P[=SG ,\=IVS7JG*\Z'S-V39F0. #3KQ9T8G_LZ^AGO
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MMYXK)VD#Q2(!2+(9DLWPHE1^%8E*R>%LJ,,YF\"DC-.0YSD@QE) .)) $Z8
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M9P/=+DSX8?A1>+)E'<6<KRO'6EA0M^/_C?FPSD!%K4,:(DV4TD)8YY"5*O"
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M,16XY?-^I Z(5F6U)P*8CP NG6^5VD(AI 8*^GB^54,@#"1 2FEQKH5G*A
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MPDPCR4.M/6GW=%3]7B#$P"33Z1OE7-:TF?VT>_3?_3< RI]CT*N>UE?9SHB
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MJSS.*H$SEB7%+4N4EWQ,*9(8((55XB8-*FYD6LY3Y.\O8[U)M=[OTR+_DK(
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M(#.U0(QQC217\%O.>>G@,V_TJS>\6.'E$^K0>ZT#]T1<DB^V%V(KA5HI=)5
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M8YM9/U*L$A:7<.>@,\RTZJJ><5FG9[ICZX8)+WX0 .,'+M1X#+.A&XVZSF;
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M-RFV%5FMR&I%UHL06=<)3=U<9K6AJ<>73HV2#0<VDU.,HSP/P#/:**2(R)'
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M[T;$[C9-"R:%,<&6*#D&$0MZ#U*VD,CF6BN>^Q('2.IRA0B\=#ZDNSQQR\+
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M=[X/WY=]-V80N/WY5Q/#NX\_I'OX&VL>?S[;VSUDV_CO8GOW3YA/\[C9#GU
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MHKLL2Z4S!EF UM! 1R,AB4="$.SAZ(0GH+4\"A6_';JL%KU9?=5D=<UP9:C
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MR$GN+,;(QV+G)@_-@H5!TF$FG?1<VN! $HV<\ ;.ZX(-S[GH>4WUGCW5J]U
MMZ)XTVX@:4TN0906P1=$G85/RBBD,P\Z$TX]9>[9@$/M!KH7F. BE88 )#"2
M*D0)5TAIFR%"X<P$G**3=.V=;!!.&X(M,L&:*]9<\75QQ25&IUO1P-I[L5HT
ML9AJ@Y11XCU&PJ0249]+I*V12#&>.HP5$$6@B2QOP)G6]*^F?S7]>VSZ5QO=
M[X/D31G=A64:*)Y%#LX25 /!D) I1SFH! 0;YC4!U8")1XJD?:$D[\E3.IY)
MP>'*@OY^U1S:3Q-I_,SYQ5*S@;*8ZY3+++,62(R5-,^D \DJ$]P[7=O.5XY=
M;$_;SKDS#A@^1]+G&:)YCI&T("8;ZPTWA.><AO@>#A"2-3@6*^>G74VZMYIA
M/#75>_94KS:6WI[L31E+C=+>XE0A;YE'5'&&)+<$R8R1S"J=YO3&>11/!A.U
M/^6NX& =PVF>,I0S;( +6@G@P"E2N1"":1S\*FOO1"/#N"$Y6?T4BIHKUESQ
MD6U'MR-_M>U\M6CBM&9 ,IP"BTP#GZ3:*20$Q2C+M&(IYDHJM?9.T@8FLJ9_
M-?VKZ=]CT[_:=GX?)&_*=DY):JSE'&4L=X@Z14 "E P1F6I"?9;KK"1Y; 4#
MUI\-R5NQF'2QLL;SW>Y M6I/Z^6=2ZLKU;L(7+3=8:@I?)V^IJO.99;:&8S4
MGL'8WFM%>2JDX9DFFC,)0AG6MK:XKQJ3^3QM<:=$"6.!M9A<:D0EUTAGF41:
M$*8=MYGA9NT=%8U<Y TA'\/B_KBXN%I$MHYGJ:GL2E'9VL)_>S([9=+5(,Q[
M20P2CBD@LZE 4FB!B,>$>)KB7-%G Q.UA?^NX&!SXBRQ'&&&)8"#SA"<6XY2
M;@%(3)H22=;>8=H@@L'?1:Y;L^%7R(8?326]-\Z["F=YKR4QG@(I5EU@630^
MWHXSU<Z7U6)7$R71:9I3P?-0"3='U$L#GR1'P+)TJKR6:<I#6!9O4)G5K*EF
M335KJEE3S9IJO]C]<:,IOQC1)/-9)I# RB(J"$4J8Q;E)B0%">-2[TMN1%8P
MJ>3%<Z/H4/L]RE[3?=*GVSS?9_O>T?8_6/&EC,768YU 1SJN)#"GQ>!HNJ']
M_^LG6Y]V0D_YOU5G"*B?A';0C42U6J,^O=6=52OL?M*=&-;*'KVQZZ^YI"_P
MJ0N-?(< '"K"5>ML=#O<4G0&W>1F]J-,20_((Q56C@K,1(Z59#K#0A'M=3[?
MW#J[BR$I=M(L#4>;PQXL^A,<1->6!J6R^68?IKSCIQIQ?G4&;AT48>;/W-9T
M^X[9'W!S\\<9W)_N (G<V=PZP#(#4I=QQ 1AB%KB0J!PCAS3&BN2T]RR2XU'
M,_#6;G<[)8"M)Y>W/;H(2_$UL/21"Z:-<7;'#+K:]6+O[,8T'B9%V4OPABB3
M<LPSH3#-);4\4T99T'V82;TPJ>8!94!Z2"/*A ^W01G5^\]@P?!Z&?HTW6F\
M]*K1Y'1G]T>VO?L![VQ^ ^EAZT#Z5&I+!<+8I(CF:8I$KC*4V0QGCJHTS]/+
MHJBGL&24-W@I>5:#1"4GPYXY4OUPM3 N/)O\]V72*1QC/,-Y. /Q%.BNY3(U
M5#@@U-QD5FJN=9ISKBHI=1EXW1B&/H693N910U %07L'5G* (">0ATU'%'.'
M!*46":^I3%-&&0-"FV7KRZ#G!*A.A*" \,D@!,\D0!+[?0"-+DBJ-D+6I<!Q
MO\0'L1NPZT_5'#_VNNT ,@ITEAG>/.Z1':%J##;\U8/-CP-+4T484X@IER/*
MJ412Y0IQ:161W&HF8]S>^F+SBU*<!@[8@M\:H!RT(PTY/2K,42G_@937<RT5
M1+X3U0NRT0MBVU67WPX0W).!:U>,6RQEW#?DW(SX3*0IR+EY1E/'05)B0J1:
MI<1EU-B(/"*5)?+ !Y+6G/L)$*BY:PYRE2J/N45<\0Q13QD*;=>0XUAQ#/*N
M9^EEM<,6.?>?M^'<MV'<. VI6X0J+5)J,P,<1#'/@5YG*L^]CHQ[.735C/M^
M &C3'&">@\SD '8PQ:&'GT< ."PDT(&*1*B65*R]X^O98JK(4KY]6XY]1Z)3
M<^Q'(3@?#I@U.=:>(R<S"AIUJ%W)%49YI@05Q*9Y@!>6KU^46G1#COUB&/98
MS]X JMD*S#J?9=:Q1_+(/*62"'K)IQ&IW3CL.=>&>TJ#6@&P"A2YUU^ZCW.;
MV @;&V6!&TH"DF*G* 5=$#B+X5A8#:>O%!P]!O5*1Z3,4UHB)7RXM2005SM:
M['BMS6$0;';\))8JF$I?,?W^1G<V#JAUF07-!N5Y#BBHC4$"R"=*&1&9X"K5
MP:C/&D2"QIXM.ID7>?[&53S_5OP]UYP[F LQ.;6@I3N;IXY8+ZRD#)=I50LP
M@Z\!%C4W+Z%A+]W^#)IW[C#W#G0FHA -B9Z*A= #;*G5@@ 3-VOO\/H2_\X4
M R\Z%Y.&00\8Y-'\\:J<Y@8+X,564\RR$*TI,J>E4#0GJ;HA;0"*:@)]..WV
M;-]U;D <=LOIO6:]8"]KGAYP[[G%  -*$2 +V*<(Z+1!S#A*#*;.>-"E!T>P
M?8N04)TQ:,B[P))\T>L/1M\UPKGWB_X@N%^ 9MPP\I9BJ84CG#%'4VIT:G.6
MT4R&:)C4LWMA(6//"9P_<(L +HNLP]FM3H"5?CGO5PPNYG3[](!)XSS6!B0W
MXH"+"(4$!2Y"<^H]=B;5.= -TF R;0BZ:'\9<9$@^G?<X-:"_QT!Y$:"_Q1\
MO \P;5TO!AM\<<85/YW=60H@KT_L-^< (!)S(BRW0$5"@3'F*=(N3Y&6N<ED
MFFHAW=J[?'V)@#&6\4]5/_C-3EHNB*/#$P %]\N9802*RMNK1@1]/=FPM@B7
M@L/V'EQ0CR*^UE[;.P+;X2]@7EH2J5*<(T]SH$%.AXI.DJ 4*^$SGDN9QVZ5
MLB$IO[M$VP<%"QX8M@8C*#3C$UJ,+>BV ?RZO;.DTQW V%$! \5R.BP!=+J.
M*4Y4*U$QK/:F5% ICCE([RG+-7#J5)H\%ZFS"OBV REKN;!\HUBK3:<'6YW^
MH#<,R/91&5=& +]BT/N!=SX?$(:]\=ZCG&? "'/GD?:*(0&RE'<@.,E, .@Q
MNK3P+@""C0#4=X-!J]30*Y "[E+\!/[RTR6M0NFB50S.;@H7MU.B;@@7HVG^
MNYKEZZ9''TZWC[<.M+;"I9BAV*V%9IXAI8$J8: D/%.9%200))8NA8J78[8J
M_4Q!*1A3UK'MJ0JS:O6[R2'(38'%>^#E8Z(8X^_ZP?@4#5&!/@ZBJJG&?'ZL
M>$3;GRKZ,!Z(#YVB/6S?%%>LRJV4WN<4 ZY0#8(*S;@ST@CCN,2U)/D$R 3O
MW#CPP@,1C<@4/ W>A"I]J46<>L4-42E)<] UUI?$!HQ%R5)X;%51A?HLDEC=
M53T;X,06/;@28!+X<&L8P4\-DI93H,AV.VY$D\= /'Z@$<:J/%KAJ9N)F'>$
MN5J]?0B8.VL>'QZDS$F:>HE$R@-;MQE2+B4HDSY71!-M+ $"WN L;Y",/I65
M5-E<@K*;JA"LPD!?245F;)83*Q4%W%C.X.>]H+6=]%* .-\^_G!@34:\P@01
MX2P A#1($R909G,&LIYD62JN92@=G';';*L1U(.?0/X!#(;F:$*@N@94NP =
MH!E$Y^C$[R-+(]OT,",3F[,WM[!EPHB<".8YPQ1S'WJ),9YB82PU@M86MJ>
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M@[::D0RT;QK"]@%5O/(8@THDO2.S1/U9F*> *9X$N?NG:YV5PO7(;P3+#^8
M%VRTH*$%$\#8?%7E%TZ;J4;15J7&5P:L7:CVE>)9VPTJ:Z\O.L7(L:5F+6%^
M#(K%V +?"&X(>/*L-*.UW&',4[1NH& 2X5U!\NN[$P6T#A86/&<]4_3C)=_K
MMJ<,&E?,- AGC22H(0M/3'FCDG'88Q5\-K('PYYN]&_[;/0!PO>@DI:+*K=K
MHBCYY*C; B+>']EHX&\'+>9\-I)B  /!LOHNVAK5E%D=#D_#V,8$CT:P0\)B
MX4U>%;WDIVH-R\WL 1%0_6&8)5QTL,]AP&XOAC:<1'_=2[/<OC]2G4,7S&+3
MFU%%"9KN82=4!2T=8H<*;H)]:X7,F_ 1#J(7[&DAP/"-^W42R.IOC>CM#VIP
M<'J,"&LXN^Y)903MKR<[Y74#8U5A(X/YN)(PQD6QD&%JO1)KPWV 5H Z4_.?
ML>;=#!QOZIB[E7VF=L#<057:.MO9W3C(<)81S$%Y)C2D[N8A$"&5R/*,6FQ!
M=\JSM7<XD\O=<KZB=GV ),#\D9=N<%3T[!@")VZ)*7>%#N!GAR9\%6&XJI<T
M ;UKT]R71DRV.LFV A:Y)-5H$N4QM>NC?1Z1@7 *MXKD$"%+P4H  B>I<B#"
M*.(R#+JT,!FM;%PB):/L '*G_/O:HG$M-$UAS(/4>9\[QI%SN4+4JQPI"\<
M..HM4T[FH=X5:62,-W)Q=S,[,/H9(>X^,Y)XAF6FG5 Z6,F85MQ[H/V".X6U
M]K+*2%H&7+4M_KI0D^UL'AYX#6IY;@42EFA$A?)(8RH1H\Z(S"DI,+O:%G_7
MT,,[4I7:8?P0\(&#KR;7DH%"FB..G4&4V%"W0]H0A^%#I!23.F:E7>PP+M7
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M -@W6*$C@W3P"1$,;0SM+>&!31!#=*K%($Y9-E:X 8-\F'"!2\TK>DE\WHB
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M4E+(XYQF13G5V7@,$JDH63%O3Q@M^(B)<>]WX\/(Q2HD.TS"P')BSP2U:;,
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MPZ<P8;&7@$U@<R?1'0[N3 @"28\M+^46MY( I;$7]$+;7,N]=Q>%H67[09"
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MV0 ># V<HY. L,;QMRGL$UBJB^RT%^GF-,=$+II'39-KDF.L#9X !I3B,*6
M",TKXGR\T*I 47HVC&?#JK5B0U]"*A/6,OM)%;*<$,T2<.2%LX')75B%7JU
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ME<X6V$%3P7&H+<"<!SZ%5[FD^P&G-5(K U@0B!WPF\%W3N@'8\X3.,AG<#I
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MW5'\-!FK+1C\]S_ V?46-+7?X'_S9XZ4>>?QDQP=!0$N0TMA+HG/MAU2A K
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MD1D0R76YXU];_!RN:[&VJ3=TR9;FFSU!&K<2RD(/_2@ U(%B>D@.1J FU_"
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MX)@\@E?GC-06I^0JAM2[ 8T"TR<HEDII%<X=1O_(]MD/TV])&CE_T&TCD<K
MA.%RZD:O[)II,><TW\W5N^B]_TQO]>C4-F*..4K7$KCXA?$_VC/3S\_ND&>K
M^X(XI^]JJ2'5E'K-:9!YEU]-G/OR4P6MF)GA"2T.N>$G <^:U+Q8,=,9#<WH
M)97)[8_]H6AR;67A(^/U>OU?A5M]76UN,:E?%FU>^ O>;;;Z<[>]Y5O(EY6_
MU9>#/SSXX"+^W;<[_W(-_OTY,M@\($1N##9(AH0@%U(0CHB AH 0'?';SOU<
M#D<<OOCSJ"PZ>E<-MFAL&@51QYDV'FS*>NVZO*W+R'3WAG[V4_IM?\A+6./J
MS]RZ4S,1S9^_S:8?FY<^I*X)HUDYT[%[6"LWAO\0?3&1DU"3&+ET:CFDHZES
MOTG^_G-S[AFIHYA/([[7NF^IB.-$S-A[KB:_+XBM=562/4F9+\S0H"PZOJLD
M5(,3>YCSCO9J)#P9Y <LT>G:#9<YK"^[>Q/\3&"?#-A75]F_@#_ ZUTV,0B_
M5E_00B&'^/T&P:9?*+(3-N)OO[IY\3M_W?^W3UYFW!GM'_G#Z=VKW_SI];^_
MU(,/C7D3SV;[YN<]W=&(9_D__]^Z^<W_>?:?79Y#FO#/CSFF^2WZ9>_-K!WL
M;N-'LF3STG_KIK8[3@ WAV)[ ^/ST6<0'M9OVI^V3;TA_B[L.#S*[L'/PTZ=
M<Z/>N/IC\1,JT':XWSF,S^^4;Y,KO5C>^]MKHY5ZYIZ;T/<>[T.>-OGIQC5;
MM'95Q3IC#I=G[E)]4M/_5%,S)1XT^0S_^9-_C3=U<Y2L9OQK?S^ZJS=G__S/
M7[Z5]5J]_LWW>(L_Y;3A?JC]7MO4PP&EKN.7.0TSP +;DJ:]+JJ.80V3?T\4
M4MY(F^)=^YNW7=N_RV78HI]-X_KDL]]]^F^?O)IY0K*=\#>]OQOEYZ>'8P+K
M.\UA7KJU'T_Q<W_(Y_Z>5AB!!K; E07.Y :3F/27.\!?$Z/,_<U\;,$D=R!)
MU$OF.><38.9Z0Q@O]60T;^9FZH+ I<SO_N/FU:>OI)G>[%:^N!&Z =U9[;Y^
MX.Q!O;OQ_^>O:Y3L0!\/HX!7KW)JFQ#JD#U-*J%O0N(!GV2",QGQ087(_*]X
MTW_DW0@ES@X?7]LECVQ5KTR_QE ?.X,1M5:.-"6B2TQX-[XL*6^5GIV_S_MV
M0[5I(M?[_-'= $CM\(BWW_&L\/W:8NOD9CRUV9YZN*?'^#_T!(=YU<"BZZ'[
MNT]?_N[%"UZK9G@2/W;B+47^YQ7Y/UV*_$N1_^_=)W[9I^,@A_C?&<W]O<\O
M*D!3&4 :ENAV2P49/%<"=GSU4\='8=3!'^-^TJL$K?;OSG]!?3<XO/W5O:O+
MFV].=#I^_[>^6/.1&I)]!2F,U<3H0@G\/#U=IP80_G)T?_=/V%:XNV>/!\TG
M'S:W_E ITK?XGDY9&I)+7X1^7O^<);%-&(F_Y,T$-/^_*_^:5S]/)2_>^]4_
MM>FYB.#3IT8$YLP=',1\.I\]B#-[]WSSP[<WGW[RVYD_>$/1?=.-,RGA2]<Y
MU7[.A14^SES]N0"]C_^C-TS?>6UA_3>FE3>42&LKQ68]%^J,I%#0Y6HR=V08
MQ+^MA;!L%<D6<9'RM_O*2EA1Y?\!+)?YB,U=GV;(4Y5;CC3/T&\(RJR4:6X2
MR1!;%1."@DEN"Q1=IY7E)IMS)9,1N L"F0(14,095?93E/_"C$98<YC86,6=
MX XUDS$D[C+%,_QU>F/=U5IX!0OJ-ZZYT_M'OO%NMBT"3S*JH2F2"%XL :0)
MJWWDY^/R)HB)[U4,(Z[TVJ'MIP;S88..!V8=SQFZ1"7X'@U?.EUQ1FZQX;0@
MS-3)P([30.6OD#$\';E3(2!+(LH'X'9NLF@"/*DPPA^X[5.CM=OD1/6=U/LA
MY<1B%)A:AK2 5X7HWY78BI^!$5*UDFK6_I/IYS2O$":$3(S=O"&8L6]_95[F
MBQZK 6@1&5!UASZ@>4X;[5\9[2][_(%>#C8W0*<ES6T@2=E",R&:!NT,6G%8
M?HW_F"#/9E^%S)7=4N$/!TX!Y[2.?(:-.XX>6W[G2"H&)Z42F4E//#50*?8C
M-0YTD7"3^9H(\- 0-63>[43JRTP$BVY4E6LBXPL:"_AY %>D?S9@Z7]PAA(6
MX#Q,OD5N\+2T+IW!R<FZ,A-_FY+;3$*DK(H),#BL7Y+RXOSO1:?Z\G2J;5M0
MVEAJ &0*<O'W%!=H7RP&*THG8W<L2O07N=(6IMA J 4.. T:HF>>X84+A0+6
M7P1<.<$@2A08[&>QA@NT!L&3&L;N*!V33;8MIAXB,AXORWN!RRO]"=*7K@KW
M*^9M=UW.''N=,%N$;@DK<RTA)MG!LL27N\2A)WGJ^F^S5S$G\!25 BI7Q(/_
MV3X?/S3=%!*HAQKB8E$7:%%)2)\&@T]HVUB6] *7="AAFL_KL]&FSJ2#[Z[&
M3D]: [6E@++C4XJ%J&PL-G!Y-C#8UJJO('6.V2[+87HZ.Q,-&K;/I/?HVG(A
M/TRHR0^26-H=92@(T?-#F3"AC#E@%TKBBK:5&]*54ONM"@X;C9@$=R:KH;*L
M$RF:M&-N*,&LO;G^/.=DN_0_&J"/T64!91;4:%2+1O([9SN&GM4>E* _+J0E
M_GP#_'?08OK.E4IZ1+FRW\N$< @4N#6>1/+\'@W_%S3_)QH6JE3)G$V(&7AO
M6'&U3,101&0M5'\HOBPV/5-S4='E)[?I.]6B\J__X"V9<Q="'P 9*%5XX0]<
M36\33_#K5K3^-GMNF_[MRVSUZL6K%T+3MUU]\EN0RM^ ^3C("D;=FB@OX@/W
MJG>&(Y [%U52+HL<,/0/WLC.@/]BZ:M(Y.X@Q67H%Y1#9E2("D.@#R?G""7W
MH\;D..I$L^3$'45<HUP\GD/OO0#;)H%MOUN ;0NP[9\'V/8V>, 0SQK50:5^
M1FXCWP3QOJ")P@S=&P[;"!04M0WKJ-#5!ZHW.:(2N5 K:\@GGILZ[\9Z45""
M+7:G3$7Z5)XQ2]08&<KA'X%HWQ"YA;,B<>?F:%B*=I<RP,D;G3EXA]4;8U-+
M0N:RERZ(^PWOU2884RZ)Q%<\[(N2*#>;YL0ALB(I*M1TB#'7DB:"W]1(*"YV
M<8%V86-T?\&FC&H:6,? ' '[X.@RR7^(3A0Y@^KHCE^*<+"C,PFTQ.9PBR"B
MQ2PNT"P"/,-*JT8!VFF!U<7S7^)2VD-[E#@UU^ S!$#V$!"<;CX0J!<@W&(!
M%V@!1C<Y52L<<5 ]GFFGL]RO<_LYYX:6TLO['N!C>]X6S.A^6(8\9K^CH T<
MEB:-]O2]GDE *!E80Z(V$I]7WZ+P_2G^<"OJM2K)$*^NC#/%=IY2_OW=+M@A
MAPH2]E^9?<V2BLOHKB#BW_AK5413^G*Q(JGAT+]@1>=T["ZD!//<PD1<7$K+
MI/+P: YI$$2)BPU:]2/E^+B:4\"'@>2G6=AD>43[AE52.)]#3*.0+_$[6$ML
M:R=2HK]45_!BO?;KDL3L[_;4&A/;JXR8&?JS<,D5;EPB]PW- G(K L%A2'6D
M%08744BQ$VG(QCOO\(BKYIT[K5P9%(K,8IV(?H,T>& X+IC-1+&"*#2X0$KW
MK%U=%O5T!Q>\C6M$#R-V>*C8,0HXVQKF:Q..G:NTG,/@S*:_,]UC4!9H'=6+
M1IUDFD4@=D+Y@X2GV4X'=3GZ=R?'\^#,U\H40$BY4KT8(T\1"LV'NG2;OG2)
M:,4$"W7*/IS(4.$\>Z"NKQ+;)V"28PVP+.N'5J5DZ;;,/5KYL=CZV5* \ZS$
M% ';D@Y1_SCPD+:=%8"(YX.?JCOJT9VD1;8<P2(Y8AYX=<<G;TX(PUII93TU
M8Q\>S(4CU&@S$K&>\Z\!?&(VQZYP962FACPTC*I&2J/6%6N)ZXPCJQ.1D11T
M DH'<&5. V K3)L>A4Y@E+?ZV=1 11NF;UOFR>$>H*9HWU%9@#L<*U9J6S+E
M%QB QQ-AFLU<I&YWK VT@B1K!C/:$W=T)[VKA)$BHVF)C9GC[S:BJB-9?@OR
M>7@K\6Z1$OHD 6=9O"-[](]>NX@2BO+**ELU(6YN(PI!\(KDD0_YEBO_!VA_
M..37ILT13H806$)R7A@- ^^)"&'3?NY-;UGLRUML%N$-[>=)I(3E;/P7YL(X
M0KVICA) )1U"KB$:+7N98U1]M9%_TI&3'$[^QE&#\9N:P2NFNB^+<-7/R%J:
M_JBPS!2JAY%Q;+D1A=<8FV_=&BTCVZ+LV23;MB</PQ*1_OTHA>%#O*90G3[H
M3,:WHQ"57*4J&7(8Q-]+#"^0Y*+W1].MVXYGC>_4A<@C7%T"XD<.,#?[FB(,
M:CKF6T^X"VG)1F%7K$2<6!/%+WJ=M;'L!%H4AXN)A5!>:N4(LE$12YY X".O
MQ#5IWS?+G_A[C0^P^,(U6+9!G.<_HW(?P3 BE$&/,=9*\)%DCYN%Z$1N(/DI
M4HX8_5_[EGK3E$K(/'-:O&XR%FV]Z>(#,ZSK4[>%C,4?^)X>TR<*@K47_@C8
M / CP&$5-L:T(&#Y!^KWZE(OKRL+,,<;-Q!M.*@T2A? GU3\IHU>#S1KS*$8
M[3)5*Q@FL8;)F/D[^B] "WZ061?Q+[B8G5D0Y28=E1>RA"FGC)*SR<8P<JRS
M.A/""@"')2WB_IU8>)!3JLP<,JQO2%Y!$M8L4TF,-^A/:)2OI&/I)YC1_'M&
M1"QQ.V0J^.H7-C!& 4^_*;8N/)<?NH!(GP<B_=<%1+J 2'^E!.+%>M6!APD2
MK-FLEAM)Y(J6*R[Q_MCGMCI]$ BAOJD;1RG9[)RO5J6^TOW$O4-^Y8GKN>T/
MHCL3VO9\[._#2?;1!?U%R'IJS1D><?*D5?8GDS%.R];Q@<E@33K$ZE,EK]#N
M<7Q3QI!:G"3T-=Z6J0P3STW-32SN#";]T_RWSD8:8?CFA7?YO7]$X-*Z7;V.
MO02#;]!GF7%.SAR/5?X=&\-F%]1RYNQ=?E\P9XZ0'H4[@$&&C)XI=&+)<)FG
M!04F&(7>+>4"R7$4DWHQ62=^@;=<,I@7F%1(5GO$I&=$VVCG;AWK14OR:.8R
M&3.2?!4#&&$802UXP,NW!O5#1Q\A]^YI_;DS83H(%5$%W3#)J>T;0VF1ZH4#
M&?L)6!)5R?*#"ES60TY"U8W+*&GN7:%6>@I;'N=DR);!L/S+)-.P&_2E2PJ=
MKRC%#+!ZYJ^R43\OJ=Q+?H5/%KHGX'%2\8DZ$WF\^UOU*NPO%(/]J$P.IX&"
M3.?:1.ZPJ#F/MNRW#V*_;?U][S1N<%2ISJ(BR>D"7$K!E+C6.-@)LE6\-74
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M]/O4Q7P4[K%HW5)3@.*FFD4^E=$S,\>LF[.M5>X &437/O%"F7QBW"T8QZ_
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MHZ(C!'3=I'T15<KPRBY=[CDZY ;'":L3^=-0<(Y>-L&;^EZ//I4L82!%-'_
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M,PXP_K/,-\<G[[8(L[;4*)2'*(0;.5X*?][H>R!@R9EFK117.JQC]@$&WY3
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M9',)EHYI K-)Y7A%HQGV[ P)\5[%0U34/YA$1F*\Z$PX\V=:N](652D%1Y6
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MH200'X!)A1KD4WDP6KS<1L'H8E[?[''_>]LE$K7QEQ/3G+K<$U)/B4-F7$U
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M !67;H)D5I*"W8E#X_O4DU'@"\KE-M4NE@#-?U*DN*,=&-1&J7J'ID[5CU&
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M"M\+8U05AAD%-4DI_?;4C]&$;<CYKYTDGY/ED&CUZ565B;?Q/U-]<6'YBU-
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M?*9+%FQ B4)$806HDE&YVH6K4$Y[I'CI;A+;;.)S:B61$\8,$L1%\X^RZ-=
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MTQ&QKBB^[[F01[=_]\,K#@?2J_G<0;X*#F&OZ#!@.DN25D&CO2%M.;-%=R3
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M@% 874&0//KJ[UX0C&P;863ZD..WU!IP.(TIA3(]T=\(JLS]DEI^".!:(6Y
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MQN("^?O5NRLSJ.FE=7&X+(5+3Z3]*2;:B]Y8O##MK&9%??)EX5R.<(WD:<'
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ME.Q5:9#JH$1,"N%@EZCAS*DAI"OZ(LJ4U&P69$\U*%%E=-56D2J2%)^[4+:
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M:'1D;=1?+V?2<KJJ?_UL'MM'?O L<7B$MWM'X6O(#IX&GI >(#TX:GI@(#U
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MH:TA!D<,GC/9(09_.F++)_Q #+[WC%80@R,&1PR>-PN!&/R8,'@E3J<9C^E
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M!X'5?S'79>&(M#1RY5D_$%8CK$9876CY 0C+)[A 6+WWC!H(JQ%6(ZS.A5E
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M#5VK-G8=,A+/HQS9$Y;QRVP(;=NI4#\'GCWC_QN%D_&'_P=02P,$%     @
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MPR,I5?J&3>M@[C@Z;6?=GE3++_4L>%CFT+M80KYAC[)SEN.V4UA)6C7L'!S
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MR#V7E0T30IE=L!<07J8/\XF/G]HF_8%ND=WY)8W)9VJJC4O^-&_UUL(@PUE
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M\E:))""4%HQY"-CA6=).K>.&.KG+&=$S9U["9/*-8+TX'U^,9B]FL\DP7LR
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M\5K[DT6MYS&>C"H7<Q:T8&]:6!>M%_8TZ7V2M%@3;=\[V^U>3_5W_&/^H^G
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M&LR1UEBXJHTK7:)#/G&"5G()WDHP35K-WH/IN;%D%U4<:"]1ER-YE 936V4
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MI+/55)I^!'X8*GA7+!0R1YURDNE4N^UGD1E$<OR]EM:[-DUT#T2!!Y+V#L:
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MGGJQ;4)TK"24OC6_VI"M%PVT:J6PQ'-9ZM@!4?,F';<@'2>_I">=K6N"L+_
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M?&_XI%YEUR4EVXKH8TD*E"U:\ C&J@SDE<44(X)<%5X_*=8O1K-A'IY=U(J
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M6U9!#\.Y.V_>U<D"UT+H;ZGZ-*WF=/S_ED\W4R%'2"0YRW .DQ@CB!2)M%F
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M"6.MUV[@B_V-K]H_4E:WD\9.^FH.>VXGFL6T.<7K=67$,R8PIP1F28XAPJR
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M_RG%*"Z4E'E.H-++O&E!GYB=A8!QA..4$4F*PFD_<7JXH2WDG[8CMZ[:B!U
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MG&-S&!E#PA&#.,-YD>,H8[%5]8X38PR-0)9B@D9.8 0%M:3V>3''X#Q-%YY
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MA)$,TH04+(]CQ=SB$@Z.,C1KL\DO7F4<=P]).(RIG?UY,5*!R;\+2.[9D:=
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M\)$49>V*4#;!RU-7L^A9L)7@ORWGZC:ZZIN.POE<+'1/TEF&I,@83T'.LP1
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MA#L^V*AVU5F==XV=\Q<,/-!B/P1_F8L[6;O4W[W>S$E5]2@B%RG'NH.#3 2
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MJ&/C/A6$%O-ZP,^"Z+ X?K=XT$+H$UGU@2_+1=G]^(Y41?5IW<@FA#Q&.,H
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M$#[[Y9>&W>;2'O(WI/I1'XA7/S[\STOQD\SU$7F3C:<S(3&C!.1I&@.8A#%
M*1,@8E$693$C&;+*AC0:=7+\UNN#KN5M75#JFY[DPS(BS6;!D-9<8^N;S)S
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M$T,> R2)!$F&><9H%,?8JAW$R=&F1@*]P+S/@FA9!R33G\;7C!.<H>:9&WJ
M;64L>4F1-P+%)5N<'G!4UC#2?9<]S"X:T(CKDZ@J(;837Q_%@BQ6MT_/Y?)G
M_=JLJ_?-$I)@94M ?<"' $RR"* ,$04[H1$,18(RH^+P \:>&L,TD@;%1M2
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MM:^"1C.'>4(N@7::-N1$L'&SB%QBN9=4Y/3FP]C^O7@N!2N:>$@H*$413G2
M!@*0L1C@5&TO20Q3A/)$A-BJEG__YE/CWKYL=J2Y!9D9]PT%PC.%&6%@S3^'
ME'5)(UOW'Y4-#FFV^U(?_,S 0,WEXKMZ%9YT;M&CND7=#B**")&YI"!3^RH
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MKCMEJ&-<V+XA/IO_+B_J3\P?^R1Q>?$'4$L#!!0    (  V$K%!8%@GKF'8
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MUYG$-RW334[CTBHJ)0WSFGQH9QRH'&@!J.A L\+)P[:1IR'"DR>)V DPKG?
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MO0'!Q* G064/1L4J/Y4IIDP&!'E(-AH7F&TS4W8K.>/VLNH.H /HK /3^K"
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M9FAID446SFLK='(^?]?-&H:4D:<X#PNY$;33@>&[[#9TOQ'</:88%B%R<21
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MWEH+8Y>#W\HH7)K;E(WDLM2122F"TE)!*$Q!IBBG<.]U+/=.M1XI$WGPZ/&
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M9MP2RI9P.E[X'2#HJ@;E.L4[,398AD:06R L*"TX!",0*'X1RG)B+ND6Z'E
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MN#%P"#7B8=DG+I!QG9N\+']WDAZ&EAXEW>U=S >PN@.L_$9>XG3V>:4XNK!
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M7VQ^5/\=G^08"LO*@5182S^,@AC(FOG,0A0L2ZZ;&++3DKF;GKW6)'/'D.I
MX0X6SJTO=&]R[T]__8&U#?#M].LTXRQ?D,\TX1ZCC)'B$U%(=E(:<(I^9T4N
M,H2LI.\KG[ K9;NIU6M+3/<)G"Y\[+>;+WZP\N,VIK]?'/9N&N+TLG:(7"^J
MK-_,,EF@M/[#A$OO.!,.R*>6H*REB-XAUHDI]%$Q2A_;+!T;YOR[Z<5K2TR/
M"8+#[Y%ZS[7%_@\OD3TI7"AA2P+->=U75KNBZA3(8JPEI8\L*'U2N+]XY-T0
M_EISRB<2=0?.T2&Z7->73LL4[^MR=M)PF2)([4R=;DHW6;86O#%*<5>R:K0/
M<9CS[P;WUYHL'@,$'6#_8*ZO*T9J6=5=NF(BI Q::0^Q& [*1$W$1P>>)<V8
MY2*G=JFLH:C830_^D_H=&A!=./<'Y^_NOSU?U+S"\J[H=E(82\(S T2RJ5Z>
M >]#A,2\USXHZ]L\0#6A9C?]^$^"MQ5 SK8$^V&QX885[V=O_CF?7?U^^8W^
M_70Y44R$XA6"6\W655&!C]E $45F\AZSL8UKL7<YYFXZ\-K2L)V)_YS=IYMA
M^,NKQ?7*JWQ_]3LN/OT>9D\6@DP<NIP2:F ATD7J7 :'5M4LC\G*V>!%D^CY
M5 3NIE#^E2E4US#JQQ]KPIG;7-#:+DV*50&5=B TF1]5"@?/Z0K..C*>4*'S
MIQP4,3R%NS78O=8\?)] ZN4*.\2A_7"]2+_3#S\LIFF]%N^FRW?CV$Z4$M)X
M%("K=3_,*' Q,G IFYBU"4:UV6W?C*3==.BUYM@[@<K9!D#U!V^^S*]G5P]X
ML&F^NK[Z?;ZH%0<3EZPV=&HP1@50$ET=(.'IELX!@TM:^!/TH^YPTMW4X;7E
MQOL#P=EJQ$ =["E94WPL((U=35PT$ )+H+(H(@9N<N%M%:;%#(13">&?X:_I
ME^LO=P^XJT9I(Z)3J"74Y6[DQL@(40A+ZN$H2DA2R[#CV/]!S[6;R7EM2=FQ
M!7PV&]?O5<6^25?3K^2Z#[Z$_9GO:+.7?5>B^EC5SD3PGFPP2*<X&6.=(,JB
M01:T]!N5%6N3!A]W5?N1K2GW;H&+^>4E71?U+R<F6Z,,<2^G.N.3TZ7F97T4
M325'RYARILNNIJ?).>LE[OO@>NC&I0'0T<M3PS!<V+RU>!))]"R"0E-'LS,$
MKQT#RY-3K.A@F.I</?9XG.OO76% >+;3F .P<K"R_+%Z9_]X%1977:C,PX['
M?RSFR^4D2$PJ^0R.^U)S;!QBG4\9K/8IN*Q%[*M4?SLM9SHTKE^U.18O/=PR
MU5M>UR&]O5[<MH*NHY_[77,W4RKR1'%O4',&JK:[JI T1(P%*$Z3"KE(V;?)
MKNY]U#.=!M<0\&VEO3^>_1K/,_Q<G<I//3M/-= 5Q9(;RS.H;%GM[RZ0K4A.
M"LEUZ#VVV,-YZN])J-];X#BL'.D\_33+O2G,HTD1-Z9DE<ZJ,BL;F:$-R9!Q
M 5MX+:_0H8[+HU]XQL19= 7;K',[.:GC.EZO(Y)O@:H>_*_3<&ABN2,KF#T4
M6QR9I!PA*LO!>*')'-G*HS-6ME?S(M $YN-HY5Z8.Y\WA*U;+'89F_200=JZ
MI*.N&R],78 NR+?VCDRK9,'KD)-+XPQ-'8[&5_/FT(5BCH2]<[@G7V+-=U,V
MGS==AA>39 *;:]HY,P>QMIMGDRQ#J\BQ'V>:UZ!DOIKWD;-0SG8(/ ?]',JG
MP&R]=@IR#!HH]% 02Y+@?-&)8G_&1;LJV4[\V'-XG.E"(T? W"MYSGF3\VIV
M5[B\>SVX>Q) 5!')E0<AG "%SH+7=44@NA119?2NKUF7NU!UIM/_SU/UAL/7
M*[C[-A*J=8:;!V25LN0,ZXLQ!E!12? Y,;#):*\U"^QQ37L?"O8=)>?]+C,@
M2MOL##@0,J]+9YZ]NWDL4J*0@,:1&VU"':=A%$A6<S$"N6BS!?U$])WW\\I9
MZ-=@\.I%ZP[I27O1R[C NI^:?O[C?+82WW6X_(2++V)2HA.%"0/:"U$KYSD$
ME!FXLDYYH4..[9KQ3TOK>;^G--;&CF'W"C1SN\':QB(^L<4*2SX#Z%2-E^0:
M7*)0(,:ZKR#II'B[!/QI:3WO=Y5^-;,U['K1S&$B\T<[O="QS$6JPYP=N>RV
MD,Q<X(#6>LLI##>AKR$:+U%TWD\H_7JCPT"H%UT:QMP\9 2?9,LIW.4%U*H"
M4!J23_%TZ7N30K(9G>]K:N"+))WI4L5SNK.. ='9=/E>(#%]6E<)K/[^7[/I
M5;-NWQV^JTW7[[Y$]M']*YFV7 BR*\QJ ATIA+>H@&M9?$B%<]6D &CD[M_T
M.^;KRYN9#@?EU#^MNO*Y4DQKGL!%3*!\DA U\4]EP6W)*!6+38S^4!2<=8_O
M/NC]SHB/@H$.7*#UR>D?O_EKNIS8[*0+AH%DDHY,/ 1'%R$D6S#EP'043<IR
M'YQBY"3-.$B8#R66#C!U../NR)[E#Y=A]FOX@F_G-7*?!"-E,*:0.A=;JW=K
M9C@E,+I$F2.+,;I1HM,#B!D7X4=@:[ :M($$W0'8G_#TEA<?__5/7*5!'1U9
M2^,@8<D4$'NZDZ+AH&.15B;&E&8M4/OLJ3K/@C<'S;R5!#N X\%Q\KO;&5<Z
M69?J&&\>-?&2EP#!J0C<HN'6$B=M7XM ;H\^<OJY"\_AQ  X9\CO/AWX?F^O
MT,890Q>F9F0+E X*/-<*DI+>>2;0=K8L\R R.[\C!@;QZ>=-'XJHOX>^;8K(
MLF=<BF3!*%\WJZ0"SCH&*D:5'(FTM%D[>#(*SU3+3@#ST2; [X.Y\^D2/9@]
M#UOX)B4(H1F/@+9F)(HF[F@7Z(^>L<*L"OK,+K^'!)YI >-K4L@C$/>J+\='
MVV *.IN9)/^F1(I+,5*,0'$!%,.B%@Z#5..\AYURJ5!_Q8NO21./0-RKUD22
M6L'I?=98J1)71@'J1*Z"$1Q<R Q24$)[&TW OL:9[$_CF98LOB9]/ YWKUHE
M'WOQUCL;BTNPDJ+B&<F+UQ90J>)<]2G$F?FIAT2._=4VOB9U/ 9SY]Z7O3MS
M'M5AK[S[M^$*?P[3Q:K,[;Z@R<>7UHI4QSRG.N(S0F2HP))OP9W.%FV; IJ^
M^'"F4>C9/+XVP^3?XXY]D7T3P9W2'BUY(UC7Y$0$BM8U6*^2=C;9A.-,$CL!
M\:_^3;>=]G1H"?:"\M_N/?AE]L6H<Q%!0*$K 52*!1PJ"5I(GH6A_T)?#>]#
M<^!,[_*_E3EH">I>7((C.E1^V]%4%LFE$N3KD7]'PJU5V%Z$0@&08#H[YUAN
M=^NWI^_5OTB?5I,[ V0O>MKRY;#VO.W -66S8M*!T=F \F@@U+8X1)D]CSQI
M?6:9I7W(?_7OW*_@OFX&YU=M!/8(>H+ 9 ,R8,;4HF?'P66G@ O/;"XFN-37
MP+=3Q^_G_++^"@Q (R@/^BI_DFW)W_WTI[_J;['-WN27OJWA!N6]".VCF]I*
M07#3!J)VA#SO+3B1-*3(I'&<[A[3I/>GEV[JGPAM\V^('W'Q=9IPBS6X7'TD
M_>Y]N< T_SR;_A\=:J5/JY.N.R*"0JL-C\!=+J#(JP=7TX!9*E<H%I<!V_BD
M+:@YZR[K?5"]O<MZ+&QTX.#],B-[AQ])X*L[\-V&Q%4SIBX*N:5[RBJKZ+(R
M"#'[#,RQDA-JHT23@O=GSM1+-_9HB)FW$5^_2-RT5$IIO744-P7-B!A?)#@T
M'*)2+$DO@LK^A%CLH7-Z,-GOAJD#!-$!JBY()G2 W]_,\EO\BI?S/RI-&W=M
MTU2;?'#6)03N7=U*3&R+J!S$8ATSH42CFHR:V^%L72+L$"1\W^4\J%@Z0-H_
M<$91WR51]"9_F<ZFU4.YFG[%AT1IR[U)Y*84'APHAI84TPBB+)440S)9-,':
M3J<;-SO8#FW#BZ8#O WC@MRKD@J<6\L+8/2UP4S4E\F0P86@4] YF3:=Q /3
MT4O7?2\>XI@PZ4!+-I1A?IKPC068%.9-MEP )R6GNZ8HBB.M!A&T2$QKX6.3
M*1.['6]<+V!4!#V>1#6\.,]F5.6;Y?+ZR_K%>3K[,5RFZTOZ^>SSZE^OGZ)7
M[]7+P9];]_[F-D^OQS&@CV=8S<A_L2A!)D.FG&4'7FD.-5@KLEA#"'W-S[#'
M#J-Q4@?OB761E0A*4$P;0@H0HN+:1<8HRFW[]'HD!6?]W+H/>ML-M=P' R.Z
M(,O%U>2BDK1ZD>%.V2B"@82V9OX4';]X!(M6<.-CL&H7Q:</O0=:^M-CP#[X
MUEZ>2T\J\?FQ[.\!,YN8-$KTD2L*<TVHZR#JO(&B2>M\U"&P$E+>Y0E^=]2,
M^>QTA,0>R_P ]HTL]7].9],OUU\V!\_*,>&,@*1S?8L0$4)1 =#K4HAXFW?:
M<;B3W!]\\\B2/T1N\R&8.+;TPU_W#JZY%U:$ %+66I>LL*Z?)Z&5H#E/(BN^
M2YO";M*__\WC/)X,)OV#F=C#0\6#.;A,1X-9,TA2$PL\#^!#MF"=%4D)1?%K
MDT:5_4=?G\$ RT.\A^/%T@&F#F?<,\-MLT-TKE[)@2YG99('7S=4N>2U5<B]
M;;.6H04Q/8V^W@M;IQA]O8^@.P#[[3/EW6O0YB9@DNNZGP:RSI)N BX@UOYO
MNDFDMC;Z9)J4:VT]4>=-N<W!LBU%<93D.H#@ +,*Z"HJVAI%=#JZJXA\B(@:
M9!TI+H4(+*M1K.LPXZ[;-:1UX2V<& "]0/Z0YKG;FOA[K_HU?5,GWZ]783(D
MA8_60U*,.)&M!<_)PB1&FD]AG1.NKP;.%TGJW.X/#,ZAVBR'14HO.G.(()[C
MQ&_SF@R[G%Y]NPA7N'D(F234P@5K()6D016Z0%V*]$=B"DKZG8U]C3#:F\0S
MG6@PH$[UAZ2_B8ZMGYLFA@1DG"K@HE#D_RH/07.$*)F+*D7+>5_3_?8F\4QG
M#9R/CAV I->F8Q?3Y;]_7F#=.HL$L*O[MD?GH L:#9@J7W*BN!*9AYR9#BD'
M]*:O'4![$GBF7?X=ZM=0*/I;:-?&ZLB2*-S-'$HH]9$E(H1B$Q0I6.2NSO3M
M:RC6G@2>:0O]N6C7 2AZ;=IU<ZN_G7Z=9ISERI>)<"Y+NK#!NI")(2: RYY<
M9VV=EI$YQ6WW:O4493OID_F//IT -QW6+O^*5^_FR^4'7*SX<$@1\N./.+::
M^-DC#506_%-8S*:SS[=?<E<R630!C/,Z%#_4C;8)@K06+*N5E-9J99H,K]EV
MH*/3;(\^]Q,Q\ ?Z!_^>*!$,T\*"B@GKQ'%+T4NMNL!<F*&_9:E- ]&V$XW<
M-C$$(KY+E0W"_?[-QBH5<U 'P],?-+ )>>IXK0V)+>1?E1C!9FM A:+K=@T%
MJ+23.?@899,!+JT,R5W&[LWL:IJGE]>U)?,CINO%]&J*=#FFRVOBY\^D6?6N
MO;[:M!=MUX$07'&Z9$A.%E*$XL%K[\"XQ&-*VF?>9E#8X*1T:KKVP>#V^O]1
MY-V_S3NB;6O+)PUL]5JV56V%7+:IA* <( OD! N1(49RAQU/1F1N$S--&N;[
M-WNK:H4<Z&I'+D!K5^=)>@6^T.^\C(YQR7+R;:+,0<GHU-SM@[UVYFYO.7?P
MO'(DS3]\>_H#5H62.617ZO3DD*,G3]=1^,XE@B"O6LC@T>DFHX :TM1+G];I
MH?JXW+H3W'2K0O=*+JVMB_6*A)2Y R7KBZM"#8F1)Z:=BRXTN1E?.MC(1=6]
M(&@G9!\HS@[@^6,=>KNXFI+&?[@YPJJ =U.Z:Y%;L6).':FC,B\U5+" *>3@
MD*'A30I97SA7C^ \% 3S=A+I &#;J\*34,60;T9N62(FE<#!6:4I]BL"C>?6
MR[:3B@ZJYV]6@]845,-(X6 X$:#C_$A U7"Y^OB7WW[Z"Q=INL2;S1TW?:)U
MC%+  CG) $H71[Z*4, R&7N;+8^/-\5\'X&_]"7CEE U@<B@?!T5(3=LND *
M_*8U(W??;I+'*G00$GAR% 4&,IZ>PD!(T0FI2N)>-WEX??(TXY8*-34UQW._
MMUMK0X))R;NB<TTU1U",.0@\6A"Q*'1HG,SM[ZL]X-.L%N9T-]4!G._" AT9
MO;R[K7$PSBOI]&K)+0<EZMQ4JQ5DK4I1LG#A3A@<[D] +[WGY_XB<A@B.C"D
M1]+]YLO\>G8UT:$XI151*43-$"6UV0_ LP_6^B3:U"0,<OH>8]76P!L6_0>@
MH,,\X<?KN,3_O:9/^>DK_7)(@O#Q1QP]H/&Y(PV4$GST'7=3Z*1#9KW5=<TI
MF5/)"P1)UC6(P(5/7 =LTR.]Y4!'IP0??>Y=@MLI%I-D&@I+=00Z2HA*(^'8
M9Q5-)O>F3?O>MA.-G*@8 A'?)>H&X7[_9N.8J;!/?]+ 1J1E><%6Y CI.&,F
M@XDZ$'*DJF5S!M!XH:7W+MHVS7NGL25K_U-)=$X) ]E["<H("H-*,5!0L12U
M$2$U><%XZC"=6I!]</""!=F?YQVXVX]IN)E*%#WY1\I9BL.EJ<.ZR;(R%T%:
M+)9,(BNNS:JSI\_3%7H.$/0+R#F$ZWV"YV9K!S.*UZUL13,/*DM)0:^V(+()
MD>N(,32IU=AZHKX =)"\7\;0 <SO#T4W[[^)8D478^U_8: "<25P):$8([/-
M.J<V"W.>/$UWZ#E$TL_CYP"VCXB=50[J'8:Z>G69%M/U$H!5K49Q.>2B0:54
M-T/6+@O/ EAA [>>DXG>+:GWU*>/_#HYU#4T#/=Z$_]&)XHT*A,5X%$FLJG.
M012N=MV4F&4QR+([" !C7B0#2>PY^1_ OK$1\-^XO+H,_\;?II>7X3/^&"ZG
M9;Z83<.*MGO-F;?&+:?(A2=S&1%4,77.1ER]QV,L3@2F=[,->WYQ1Y@Y1,KS
M$[&\/U_D[C';1Z:2]1XT9V1FZY0QQSPI7"&O+6=D)K092K?E0"./YFD<$!W&
M]['-T3M<+A'?_X&+U7JBE49\_-]KXNC/\_D5:<O[LOI9_OA'2#A)9%9$"!IR
M"G5ZG=(0DD@0DPXA(VKQ>/WHUHMJG^_MRI<]4-#STW"] X/T%'5U^&%=XS-;
M/V$ARAPY4Q!U#$11+N"%\B"\#DG5W9:IR6JIEX_6E;M\'-0:R:-3A%W@#/\,
MEY6PB?+."(K^P'A=%["2EQFM3JO*3ZL-$GU-<E$OG*NK"[ =M@Z51(]W827B
MY_FB_M]TML[<KWS2B0B&:T&1"U>\+OXH@OQ2\B&$5>AXW> 8Y<$WX;9O'7GX
MVDGNP4$XWB.4_DG&]O?+;Q=XNSQ\@H)9HPP#GET=1%7JJRHCRZ)5T#DXIAZO
MS-H#1-]_W\C3Q4X"GR.YW"-PZABS2L]Z0^V$ E)C,6F(BM%=7;0 A\Z"L\0^
M)0WCR1P,FH??-?+XK), Y@CN]@B63S@+LZM?OORQF']=/6K4-<1_AAF%$<B<
M"SIQ,)994$D9B,YX*!R3S%I)%@X'SO;OW0E$]KQ!-!#7>P34.[RB3Z=8@<XR
MO;H@7DX7*Q(G(98<6.3UG6PS',I[STES"D4,L6!$<3">MG[M3G!RYPVG87C>
MOLYK\Q?UE[H*X;_^W_\'4$L#!!0    (  V$K% >2"<B0P@  .8M   1
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MFQ\9_H?/%F>?]@2T.8M]^E]02P,$%     @ #82L4#)6PP W"   RBT  !$
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M^W$>8)^(Q250.(ACIGDR0RCI*M#5$<?W,"\0)M>&QDH*S*;,T19YC :(;8X
M-,-)XX]/943"F,]E"7P!4R85[N@4H?JF]1N]=);P*TMG-KQ]A1!N[2V$QROS
M_4X6\"Q$F*8P'H8,+PT&AH0*,&A#]+!)#!H5!!#BDYC)2)MKLP3I6U.XO@Z8
M]&,N<VRGB5WPV,(N$]R' &]+<H H"P!A:Z$T^.9'-)T"Z2%GCO(8+<S6HWT
MAZ:IV7KHJT,S_#IDT4*+C>W:<4<8'C?V$8:X&]LS'![53CR3UPN0N/M# )BU
M]7'0.'K9]VDN=V^BU]\)(-**D>R*SG.!'2"GS9@T3(E6D)I^] [DGF.7>5I
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MJ?KMV3[]=XH#[ [X6/IW)__LR;&(V:68L>MPS(-_.C$@;C<6D1RH&V/Y?P*
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MHM:_3B[>^01I$)Y=E$09%13P/.)35"9$1T,Y%<0-LT@F"7QT =OHB.#P89J
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MVDJ,=UB=OK;7#[T[^&>4C/VW_P]02P,$%     @ #82L4(.-<F'$!0  &B(
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M\9!)#8$>K3"N;-3X4PQ1%)-LQ#4F,^$3GI DY"1>*RQ9EFK0KUF,=U0 (PB
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M7C/XP>\C%-?\K0GS_L;1?U!+ P04    "  -A*Q0W+GMMV);  !_;P0 &@
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MY8FX?G%@;6+PA=UM %\\^?7X2S=FOA@]]. DQ?&,N1@-#C#CX[0 2VH\+A-
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MJK10F:U):LJ8H>X+600KZ_\EK8QJ'N)N0$$RI9!JM*5TGDK'KO:ZJEB:F-Z
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M:*F"CA"5H#")RXS%KK#C +W,BP;@93N&EF1V5L9D :'E11[+>\%2DQO9/,U
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M0"^G@,"6VA':QF(3Y">6FVY4%J*^02R/0KO/TT3NVS1P-DUN .Q*7MU%4YX
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M[T S2,L<]FAKOR<(9-O1K[!P&6RI3!)@.0>G75^0"'K%E#A^P.&@4D)K(/U
M:D)6>4L;4KL9TG,6_]K?7/X%6$_P^G9_)<"]KIN0L;8/>$XAM)Z&MZ8)UD#
MBQ8Y4EFCIQ3LM5+5!HT)2(;$&HU@3V9<3*A0YD9]E@Z6W7FSPN(!FXL%]\ O
M6--!ASY9/+ J_0F:*I!*J6!\RFULOH$N?3TD0(!C;BVI-0I,3%W"!0FX+XOY
MV+N@N?BLS6S<0!]JZ@)'>[VA'$TKV!IQ><&*4?<7!<P-<;_6!3:LJ*?P+ABO
M@/N'D2LEDT="I"+G Z$NDPS"$O0.Y86C[&WP  HF! I-*G8%&$@Q O3)5 ;V
M!I#^C:/BTS"DQ7+ S(>8H;C2T7C"A)I(L%K4$ 8#=#?I/.<^ES[-TEZ4E9"
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M1R8[>*H_WT#_A82$M6-<[F^38.W&?J^JKE_'%@;EY]9QWIO6W5@6U;Y%V:^
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MUWV0^X&&!XD#>DJMEAR1\%KXJJP50!UCK=DL7G:AWN,*O,ED)JH6/:KOGN[
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MG2?TE<QQ!<A_^VDX%?\9%>/XE_\/4$L! A0#%     @ #82L4-7+%^L Q (
MQK4; !$              ( !     &%R<70M,C R,# S,S$N:'1M4$L! A0#
M%     @ #82L4-0J&X5/#P  OYL  !$              ( !+\0" &%R<70M
M,C R,# S,S$N>'-D4$L! A0#%     @ #82L4+ 7IU.8%P  C^X  !4
M         ( !K=," &%R<70M,C R,# S,S%?8V%L+GAM;%!+ 0(4 Q0    (
M  V$K%"1X II@$T  ,EM P 5              "  7CK @!A<G%T+3(P,C P
M,S,Q7V1E9BYX;6Q02P$"% ,4    "  -A*Q0K&N@V<R_  #G, @ %0
M        @ $K.0, 87)Q="TR,#(P,#,S,5]L86(N>&UL4$L! A0#%     @
M#82L4%@6">N8=@  /)$% !4              ( !*OD# &%R<70M,C R,# S
M,S%?<')E+GAM;%!+ 0(4 Q0    (  V$K% >2"<B0P@  .8M   1
M      "  ?5O! !E>&AI8FET,S$Q8V5O+FAT;5!+ 0(4 Q0    (  V$K% R
M5L, -P@  ,HM   1              "  6=X! !E>&AI8FET,S$R8V9O+FAT
M;5!+ 0(4 Q0    (  V$K%!JIBR5C1H  +O?   :              "  <V
M! !E>&AI8FET,S%P;W-T:7!O8V5R=&EF+FAT;5!+ 0(4 Q0    (  V$K%"#
MC7)AQ 4  !HB   4              "  9*;! !E>&AI8FET,S(Q8V5O8V9O
M+FAT;5!+ 0(4 Q0    (  V$K%#<N>VW8EL  ']O!  :              "
M 8BA! !E>&AI8FET,S)P;W-T:7!O8GEL87=S+FAT;5!+!08     "P + -H"
(   B_00    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6617131904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive shares excluded from the calculation of net loss per share</a></td>
<td class="nump">3,885,532<span></span>
</td>
<td class="nump">18,646,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock on an as-converted basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive shares excluded from the calculation of net loss per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,262,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive shares excluded from the calculation of net loss per share</a></td>
<td class="nump">3,061,521<span></span>
</td>
<td class="nump">1,461,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=arqt_EarlyExercisedOptionsMember', window );">Early exercised options subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive shares excluded from the calculation of net loss per share</a></td>
<td class="nump">613,627<span></span>
</td>
<td class="nump">578,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive shares excluded from the calculation of net loss per share</a></td>
<td class="nump">198,992<span></span>
</td>
<td class="nump">344,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP shares subject to future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive shares excluded from the calculation of net loss per share</a></td>
<td class="nump">11,392<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=arqt_EarlyExercisedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=arqt_EarlyExercisedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6639990000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance, number of options (in shares)</a></td>
<td class="nump">2,516,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">653,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(108,149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance, number of options (in shares)</a></td>
<td class="nump">3,061,521<span></span>
</td>
<td class="nump">2,516,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance, weighted-average exercise price (in USD per share)</a></td>
<td class="nump">$ 3.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">26.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance, weighted-average exercise price (in USD per share)</a></td>
<td class="nump">$ 8.52<span></span>
</td>
<td class="nump">$ 3.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">1,686,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted-Average Exercise Price (in USD per share)</a></td>
<td class="nump">$ 5.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Term (Years)</a></td>
<td class="text">9 years 4 months 6 days<span></span>
</td>
<td class="text">9 years 5 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Remaining contractual term, exercisable (years)</a></td>
<td class="text">9 years 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 65,155<span></span>
</td>
<td class="nump">$ 7,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value, exercisable</a></td>
<td class="nump">$ 40,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6622115264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Option Activity</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following summarizes option activity (in thousands, except share amounts):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:45.807%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.947%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.701%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Number of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Weighted-</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Term</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Aggregate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Intrinsic</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance&#8212;December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,516,470&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.44</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,673&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">653,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.92&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(108,149)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance&#8212;March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,061,521&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.52&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.35</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable&#8212;March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,686,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.85&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.24</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,408&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt;">Options exercisable includes early exercisable options.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Stock Unit Activity</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes information regarding our restricted stock units (RSUs):</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:60.719%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.992%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance&#8212;December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested Balance&#8212;March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation Expense</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation expense recognized in our Condensed Statements of Operations and Comprehensive Loss was as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:56.333%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.906%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.031%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">574&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stock-based compensation expense</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">990&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions in Calculating Stock Option Awards</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of stock option awards granted was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.736%;"><tr><td style="width:1.0%;"/><td style="width:61.425%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.901%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.571%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.903%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expected term (in years)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.5 &#8211; 6.1</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.1 &#8211; 6.6</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expected volatility</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">71.2&#160;&#8211;&#160;73.3%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">68.6&#160;&#8211;&#160;72.5%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Risk-free interest rate</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.5 &#8211; 1.4%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.6 &#8211; 2.6%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dividend yield</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796833168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 190,893<span></span>
</td>
<td class="nump">$ 63,336<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">249,319<span></span>
</td>
<td class="nump">101,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">53,396<span></span>
</td>
<td class="nump">44,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">5,030<span></span>
</td>
<td class="nump">13,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">190,893<span></span>
</td>
<td class="nump">43,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">195,923<span></span>
</td>
<td class="nump">56,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">5,030<span></span>
</td>
<td class="nump">13,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">190,893<span></span>
</td>
<td class="nump">43,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">53,396<span></span>
</td>
<td class="nump">44,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">53,396<span></span>
</td>
<td class="nump">44,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure', window );">Cash and cash equivalents and debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents And Debt Securities, Available For Sale, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793064192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARCUTIS BIOTHERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-2974255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2945 Townsgate Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Westlake Village<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">418-5006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARQT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,154,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001787306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6789625472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, convertible preferred stock (in shares) at Dec. 31, 2018</a></td>
<td class="nump">16,262,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 72,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, convertible preferred stock (in shares) at Mar. 31, 2019</a></td>
<td class="nump">16,262,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 72,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,557,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="num">(23,987)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 289<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (24,276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares', window );">Vesting of founder shares subject to repurchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue', window );">Vesting of founder shares subject to repurchase</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares', window );">Lapse of repurchase rights related to common stock issued pursuant to early exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises', window );">Lapse of repurchase rights related to common stock issued pursuant to early exercises</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on short term investments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(6,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,658)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2019</a></td>
<td class="num">$ (30,539)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(30,934)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,692,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, convertible preferred stock (in shares) at Dec. 31, 2019</a></td>
<td class="nump">24,385,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 166,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_TemporaryEquitySharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock (in shares)</a></td>
<td class="num">(24,385,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_TemporaryEquityValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock upon initial public offering</a></td>
<td class="num">$ (166,491)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, convertible preferred stock (in shares) at Mar. 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,120,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="num">(65,029)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,244<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(66,272)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares', window );">Vesting of founder shares subject to repurchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue', window );">Vesting of founder shares subject to repurchase</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,385,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock upon initial public offering</a></td>
<td class="nump">166,491<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">166,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares', window );">Lapse of repurchase rights related to common stock issued pursuant to early exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises', window );">Lapse of repurchase rights related to common stock issued pursuant to early exercises</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,781,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares of common stock, net of issuance costs of $16.0 million</a></td>
<td class="nump">$ 167,241<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">167,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon the exercise of stock option (in shares)</a></td>
<td class="nump">108,149<span></span>
</td>
<td class="nump">51,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon the exercise of stock options</a></td>
<td class="nump">$ 152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on short term investments</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(28,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,013)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 241,882<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 336,145<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="num">$ (94,285)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,471,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Lapse Of Repurchase Rights Pursuant To Early Stock Exercises</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Lapse of Repurchase Rights Related to Common Stock Issued Pursuant to Early Exercises, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Vesting Of Founder Shares Subject To Repurchase, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Vesting Of Founder Shares Subject To Repurchase, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_TemporaryEquitySharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares, Conversion Of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_TemporaryEquitySharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_TemporaryEquityValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Value, Conversion Of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_TemporaryEquityValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>arqt-20200331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arqt="http://arcutis.com/20200331"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arqt-20200331.xsd" xlink:type="simple"/>
    <context id="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i45ee5cbaa43a4c1b946d00944fd45974_I20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <instant>2020-05-01</instant>
        </period>
    </context>
    <context id="idde51cc55856491d9916e0b6960bac95_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic9bf5bacffba46089c61b3b65926a2bd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i68dfa5b4689849b9a3cd771af6075ca9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1ccb7f8264e14d269a33e7f94a0411d7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i004b33aa7ef84638a508f80804c3e4d6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i58223e1e92e7484da16c8646830a5178_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib3bef4868bf94e0b8bcd68b0c08ee9c3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic3d98141ace44b3d91fa1e2bd76e3378_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ibbbb627a865342c3a3c8ca55197e411c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="id40bc8ee44ed48b9b00785b5733d49e4_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i0cd5d9c6ed8543fbae65bfb9bf35030d_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic5c62122ea184197a8cbcd8fac509f93_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i2d4d2679b1f24ea4bbc79894014b1394_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i91f2e456e7ee436697728b99c6737875_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="icf934a45ca7144f39a0071e59f9cc564_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i6be9162e0bdc434cae7c672714f4e731_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i35625a47aaa94266be03155114268268_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if55289982bed4868bd75d4d6010753e2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifb50c31a77604c0d8346a9ea0f57045a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i74375cd2c8a64bbcb8ce7fdbc8b5f486_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i80caeb9df5f44f8e9df282ee72186142_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1d9f4b34db394927811febbebe7ee4a3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8f6595d3666d4c0da7ef44540cc8c105_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i21443e8563474055949c856249beb800_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0fa655ae1882424ea70d7f3ba47275d5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic552471d830f40178487f9d46cbfe905_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ieb89b6585f024b53831de5e9407a4e25_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2b1b978c4e7e4c51afcf56c572945237_D20200131-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-31</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i61f2dde936ae43d5bc9eae7e34c66670_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="ifb9e70228f484fc4a8a0c0a8c7d593b1_D20200131-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-31</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="iafc8add9248145199d7b4082ecba51b7_D20200131-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-31</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="ib256fcf2733e48fca730f3e92edbe1f6_I20200201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <instant>2020-02-01</instant>
        </period>
    </context>
    <context id="idf2cb7e7d89e49ce95ca0662113be912_D20200117-20200117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <startDate>2020-01-17</startDate>
            <endDate>2020-01-17</endDate>
        </period>
    </context>
    <context id="i1a9f8349a2ae4825872a95b128a3bfb7_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i9f576810c09241ed87b2a09e63227467_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i414921aba8984cb389a45a1e86d315ae_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ibec66f62c1084ad691104a439aff6c7e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i270ae80ae8b042ce9201e7cc23f7ee58_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2c8b8d5bfcec459fa278a039725bb9d9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9c16b74ba53841fda7d28ab193530c1c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i543cf22b19c54a4a8b70297fbbf4dcce_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ifff112eac82649f6b53d94ba1b504889_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ife0a9b0f7f7b4864aebd29e91d92b75e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6b5c3e06ddd5402c951cce1ad44ad6a3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic43770461fb141d1a3a708ae92c38e75_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i03cc7f0a6da847ba8562f6f1fa69ad0f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic253eb34e85e4ebebda2388a08544c3e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id45d766b5bb440b8923015575e77b394_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i373b85f92fe343ac855524ea8acaff14_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iae9ee5c735cf46908b0fabb85992ffc9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a1e096ff7d341be8c45b814509791ef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c56f67dfa884523897775d41e68872d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0e5b4edc8170451689fbada6c48b86ed_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic86821562d79485eacbc135601a1eb43_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5950ca979d8342e2995ee8e69c309187_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib206c2db943b4ae485f8d863d2ee1318_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0e5368a4e5b94d8cbc7278e0fef5cad3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iafb6adcdf1a44ac9987418eaf92a8522_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0181ffefb7fd484bacde0b9b979a5d5b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib465f2fbb252499b9bc7fb53a1bf2efe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i97d79ac716284e1a9866aca1e609b683_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i45c31d7adba348da80a2ab2d537cf9e2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i04008b35dd9c4edaa1167973c3f9f16a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if9d55de80fa540a5b40168170c29f746_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifb249010b3884d319f1f8408c75f9f32_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5360332e67b7489285d42523d9c524f4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2b7f744e5e864a09ae29d5de55ad4859_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="id5df7418441b428c98e1af09b1d8f5f6_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i64e39f6e0ee9449382ec819a3c86939a_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="iadbd597452bd467786da57f5e4d20c05_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i27af3865d5bb4f39839b5fb35d6b8164_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia9fd3340448d4bc7b2df04030b621bf3_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HengruiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i6cb916c47d6d4499899eba1d8e7cc49f_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HengruiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i624daddb81734c7dbdc63c375018d9a7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HengruiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3d73b12f38b44b0fb374429942edff05_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HawkeyeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i7ba628de89d3418daf6fc6a0e95c1598_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arqt:HawkeyeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i764c4c795726470f9f77ab82e0e24792_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HawkeyeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic8fd13a77a64486f820343c9c46cc851_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HawkeyeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i0a342eb6a9914eefbcddc6ecd7e9a425_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arqt:HawkeyeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9ded77bb950b4e049558439a9f0bf11d_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i5d311753e065465a809d1745e3b2d439_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i5b476add02454015a5731c133e6fc7d7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5e66cc37420547df82c325e4bd66ee97_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iad26b06911dd45ed94719ead6186feb7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1062618a24794d61acad0065c0f8c0b6_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i1ffb101d690c48ea9f6c1d9b6bb0766a_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i53f18004827140e6b2a5880ba03e14cd_D20180901-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i20520734ab804d1c969a5f694d1a77fb_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i942ea4487a4f4c628dbc72aa9142bb0b_D20170401-20170430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="i27b66ebff3c74dffbed70e3df8d94527_I20170430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-30</instant>
        </period>
    </context>
    <context id="ia747c28018db42518e5a81eb98a4730a_D20170401-20170430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="ic429b8e3655e404cb0d751419b0af0f5_D20170401-20170430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:StockPurchaseAgreementTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="iaa626818057b4ec09c7780eda24ee280_I20170430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-30</instant>
        </period>
    </context>
    <context id="ida7d99ff74274d4bb97416ec9c8ce692_D20170401-20170430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:StockPurchaseAgreementTranchesTwoAndThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="iad794190a8a2452ea081cd173d9a46c3_I20170430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:StockPurchaseAgreementTranchesTwoAndThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-30</instant>
        </period>
    </context>
    <context id="i18c87385f652426f9c3d56028cd4c845_D20170401-20170430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:StockPurchaseAgreementTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="i3d9f11fde515494ebe9f46b322624540_D20170401-20170430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:StockPurchaseAgreementTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="i867ead9d7de94ae2b7a3e1230d8c1445_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:StockPurchaseAgreementTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i61291be8ab45405ba6ff41986ea2bbf9_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:StockPurchaseAgreementTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i0dd4a2ea8e4e424cad9bf90013a09f85_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i152ee54c83c44c9c86787fc4619f617a_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arqt:StockPurchaseAgreementTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i7b0f602239da479bbb94f0b7c7888beb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id0cb10ec032b42cca2753ec0e703a0a9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i207e672bf24642c4940bf0d793c0d8ad_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0a758e1969d84f21965d253803feda4d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9c825f7e0bd049b3873b9f06a243c9cc_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:StockAwardsFutureGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i10726fed81d54f6ab986a0927852ce81_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:StockAwardsFutureGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia583a93b899d4da9a404725241db7368_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if9c67f350dc54f669cff5762e4c650f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i41086ad648ca4627b4da6abb4a3801d2_I20200204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <instant>2020-02-04</instant>
        </period>
    </context>
    <context id="i1b0b464dfc864b54803e7d3f742e0da3_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i547d9f383e9b4debbdbb809301a8f689_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i5b305cb4d63342bea9f25125973619f8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8e6455e64ac24ad4b0b835c47c9e7d60_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="idadd6a2a73da44689130341aaab4e04a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i99319e5db9304bce8368150c3126f923_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i729f8784fd4e49eba8ee589ee7ffb428_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic428fc4a3f5544cdb4cd99f3463113b0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0baf33cc0dc243f780ad057920f62292_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i6ec1cf8ff84648708b4c86b19e7f6130_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i36f41495899d443b9ef4ab7d9ca80854_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic4ad05013c344f86873c31d6f40cb48b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i60fc0bcc4f7e43c9b071698d2cab142b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i79205ea8bd33408992b1551901172816_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i330111f8ba794d7fae3926a5518de13b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i032684c2259b4403a7e8ab7dc81e250c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if4b3c7b09a81456aa8c7c67220c1937a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="icf1aac6536334060af468f8eeb2e8eb9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arqt:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i36e62b08be8541cfb10cebab50e8f747_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i7c280cdb092b45edb7e2214f3ed3cebe_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:ServiceConditionRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i6bbb52f6091c4868b5b32ba40fc51240_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:PerformanceConditionRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i7f0bea76e3b04ffcb5683a3e920f6fb6_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:ServiceConditionRestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="ib5403a39d9824c61b323a823a99f5bd8_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:ServiceConditionRestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="id48658e6817e4f45934cd7313bbee944_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:PerformanceConditionRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i30fec8c2358b4835911058e60fbd15e1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:ServiceConditionRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i923788d1801d4b67b74f8a5857599515_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:ServiceConditionRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ie85017a9a46f4ab9a78c0cc301027ce2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arqt:ServiceConditionRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia32c63d0cf494637ad7c5a2bccd2b22f_D20200131-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-31</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="iae37041cedde4d51858dc7cf3548eb6d_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i7383296af1344aea9cce30492f252802_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="icefe4f59d74b498eb9f973315e31aaec_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i7e60ec54b5354f6d99fb37ca976d041f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i99939ac91f9f4fa590b1fa4017ae602b_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="idc6873c2e10d441d9cc0b8acba203bb7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6ddaa5b1d44a4fab8efeb9d63d3c55d8_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i03053d48c20241778d8e2cfc418e60ae_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">arqt:EarlyExercisedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iaf2d176bc07e46b8a8d5d35b4960c50d_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">arqt:EarlyExercisedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i213a41c41500492487811d690788ac4f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if6465c3a5b5c4daf823adc5f743d64b4_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i5ef81aa3fd074f2f9ad3100002a964f9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i875d6445002045038d95abd268509dc1_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i5d533bf2a9414af8876f332d4c35941e_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="arqt:LeaseDescriptionAxis">arqt:WestlakeVillageCaliforniaLeaseArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i8b84137f69724a55827a9c4614fa776b_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="arqt:LeaseDescriptionAxis">arqt:WestlakeVillageCaliforniaLeaseArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>arqt:segment</measure>
    </unit>
    <unit id="facility">
        <measure>arqt:facility</measure>
    </unit>
    <unit id="tranche">
        <measure>arqt:tranche</measure>
    </unit>
    <unit id="vote">
        <measure>arqt:vote</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF80L2ZyYWc6YzEwOTY3YjRhZDEyNDViZjk3NTkzMmRmZGViZjhlN2QvdGFibGU6M2ZhNDY0Y2M1ZjVmNGM4Mzg4M2IwNWI2Yjc0MWM4OGMvdGFibGVyYW5nZTozZmE0NjRjYzVmNWY0YzgzODgzYjA1YjZiNzQxYzg4Y18zLTEtMS0xLTE3MDI_335b0e21-9cc5-46fe-af79-aed734273f79">0001787306</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF80L2ZyYWc6YzEwOTY3YjRhZDEyNDViZjk3NTkzMmRmZGViZjhlN2QvdGFibGU6M2ZhNDY0Y2M1ZjVmNGM4Mzg4M2IwNWI2Yjc0MWM4OGMvdGFibGVyYW5nZTozZmE0NjRjYzVmNWY0YzgzODgzYjA1YjZiNzQxYzg4Y181LTEtMS0xLTE3MDI_98e20559-62b7-4bda-aa2e-0e72059b6e2c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF80L2ZyYWc6YzEwOTY3YjRhZDEyNDViZjk3NTkzMmRmZGViZjhlN2QvdGFibGU6M2ZhNDY0Y2M1ZjVmNGM4Mzg4M2IwNWI2Yjc0MWM4OGMvdGFibGVyYW5nZTozZmE0NjRjYzVmNWY0YzgzODgzYjA1YjZiNzQxYzg4Y18xNy0xLTEtMS0xNzEw_6829bf38-512a-4adf-b829-ad08f5b3a49b">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF80L2ZyYWc6YzEwOTY3YjRhZDEyNDViZjk3NTkzMmRmZGViZjhlN2QvdGFibGU6M2ZhNDY0Y2M1ZjVmNGM4Mzg4M2IwNWI2Yjc0MWM4OGMvdGFibGVyYW5nZTozZmE0NjRjYzVmNWY0YzgzODgzYjA1YjZiNzQxYzg4Y18xOC0xLTEtMS0xNzEw_6fcd06b9-e957-43f7-bacf-317459ca044d">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF80L2ZyYWc6YzEwOTY3YjRhZDEyNDViZjk3NTkzMmRmZGViZjhlN2QvdGFibGU6M2ZhNDY0Y2M1ZjVmNGM4Mzg4M2IwNWI2Yjc0MWM4OGMvdGFibGVyYW5nZTozZmE0NjRjYzVmNWY0YzgzODgzYjA1YjZiNzQxYzg4Y18xOS0xLTEtMS0xNzEw_a9619d55-6806-4f16-bb50-229d753654b2">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="idf2cb7e7d89e49ce95ca0662113be912_D20200117-20200117"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTc3L2ZyYWc6NzIzMzU1Zjk1OTIxNGYzOWIyOWJhNjc1NWJkMmFhZTgvdGV4dHJlZ2lvbjo3MjMzNTVmOTU5MjE0ZjM5YjI5YmE2NzU1YmQyYWFlOF80OTQ3ODAyMzI1NTM0_1f7c2a7c-db6a-4175-abea-a3d39c7ef806"
      unitRef="number">0.4998</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8e6455e64ac24ad4b0b835c47c9e7d60_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzY4NA_1160bc3e-4896-43bb-92b1-9fd3b49a3ce7">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="icefe4f59d74b498eb9f973315e31aaec_D20160801-20160831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTg4L2ZyYWc6NWU1NzY4MzRlODMzNDFiY2FiYWI1Y2RhMzU3MTMzY2UvdGV4dHJlZ2lvbjo1ZTU3NjgzNGU4MzM0MWJjYWJhYjVjZGEzNTcxMzNjZV80OTQ3ODAyMzI1MDAw_dd0526b9-fa89-46b3-a39c-06cb3a1433cf"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i8b84137f69724a55827a9c4614fa776b_I20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3NzUy_a7f3f3c6-d01a-43c9-8f08-52810289a778">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dei:DocumentType
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6ZjM4NTA2MGViY2MxNGFmNmIwNDdhYzE5MDg5ODExNDIvdGFibGVyYW5nZTpmMzg1MDYwZWJjYzE0YWY2YjA0N2FjMTkwODk4MTE0Ml8wLTEtMS0xLTE1OTU_9b0a989d-5cbe-41c5-bbb4-1ad6e15f627e">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjAw_237dadb8-f045-470a-8106-7dbb155a8519">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF82NTk3MDY5NzcwOTAx_76b26999-01a6-44ec-af9a-890adaf574d4">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjA2_82a84d4d-025c-41ee-8d42-cbfeee2e56e2">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjA3_994207ca-af55-498f-8c88-97151b87087e">001-39186</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MTdiYTQwZTM0MjE0NGMzNWJiZTRhNWJlMWZjY2VkM2YvdGFibGVyYW5nZToxN2JhNDBlMzQyMTQ0YzM1YmJlNGE1YmUxZmNjZWQzZl8xLTAtMS0xLTE4NzMvdGV4dHJlZ2lvbjo4ODk2OTMwM2E0NGQ0YzVhYTg3ODA0MDAxZDEwNzNjNl80OTQ3ODAyMzI1MTA5_aac12579-1603-4fed-ba54-f198bf823176">ARCUTIS BIOTHERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MzhkNTI2ODc3MDYxNDkzMjkyZmEyZjkzYmE1ZWU1NTcvdGFibGVyYW5nZTozOGQ1MjY4NzcwNjE0OTMyOTJmYTJmOTNiYTVlZTU1N18wLTAtMS0xLTE4NzYvdGV4dHJlZ2lvbjo1OTQ4ZTdjMmFiY2E0NTAzYTdjNDRjODY2ZGYzNGYwMl80OTQ3ODAyMzI1MDc1_f879f26c-1e21-4b50-aa79-61fd1f1c05a1">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MzhkNTI2ODc3MDYxNDkzMjkyZmEyZjkzYmE1ZWU1NTcvdGFibGVyYW5nZTozOGQ1MjY4NzcwNjE0OTMyOTJmYTJmOTNiYTVlZTU1N18wLTEtMS0xLTE4NzkvdGV4dHJlZ2lvbjo4YWY1N2E0NDBhNjQ0NDFmYjAxNDYxZGM3NWQ2MmY3Nl80OTQ3ODAyMzI1MTE2_856f7e49-a6f3-40f2-82a6-39b77d1ce57f">81-2974255</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MzhkNTI2ODc3MDYxNDkzMjkyZmEyZjkzYmE1ZWU1NTcvdGFibGVyYW5nZTozOGQ1MjY4NzcwNjE0OTMyOTJmYTJmOTNiYTVlZTU1N18xLTAtMS0xLTE4ODIvdGV4dHJlZ2lvbjozZWNiMmRmMjU2MGU0ODNhYmY4ZTdjNTYwZTNhNzFhZl80OTQ3ODAyMzI1MTI3_eb57d2b8-b786-47fa-a26d-09628324f82a">2945 Townsgate Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MzhkNTI2ODc3MDYxNDkzMjkyZmEyZjkzYmE1ZWU1NTcvdGFibGVyYW5nZTozOGQ1MjY4NzcwNjE0OTMyOTJmYTJmOTNiYTVlZTU1N18xLTAtMS0xLTE4ODIvdGV4dHJlZ2lvbjozZWNiMmRmMjU2MGU0ODNhYmY4ZTdjNTYwZTNhNzFhZl82NTk3MDY5NzY2ODQy_1ae8212d-51fb-4185-9ae4-569fa4683093">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MzhkNTI2ODc3MDYxNDkzMjkyZmEyZjkzYmE1ZWU1NTcvdGFibGVyYW5nZTozOGQ1MjY4NzcwNjE0OTMyOTJmYTJmOTNiYTVlZTU1N18xLTAtMS0xLTE4ODIvdGV4dHJlZ2lvbjozZWNiMmRmMjU2MGU0ODNhYmY4ZTdjNTYwZTNhNzFhZl80OTQ3ODAyMzI1MTQ1_58dc927f-64ae-4ff7-af98-e22fe98708f8">Westlake Village</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MzhkNTI2ODc3MDYxNDkzMjkyZmEyZjkzYmE1ZWU1NTcvdGFibGVyYW5nZTozOGQ1MjY4NzcwNjE0OTMyOTJmYTJmOTNiYTVlZTU1N18xLTAtMS0xLTE4ODIvdGV4dHJlZ2lvbjozZWNiMmRmMjU2MGU0ODNhYmY4ZTdjNTYwZTNhNzFhZl80OTQ3ODAyMzI1MTU3_2c7e5f17-a467-4834-bb43-2a538763f02c">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MzhkNTI2ODc3MDYxNDkzMjkyZmEyZjkzYmE1ZWU1NTcvdGFibGVyYW5nZTozOGQ1MjY4NzcwNjE0OTMyOTJmYTJmOTNiYTVlZTU1N18xLTEtMS0xLTE4OTEvdGV4dHJlZ2lvbjoyZjRkZWY4ZDZjYTU0M2Q1YmY0NzQ0ZDhhNzRiNzg1MF80OTQ3ODAyMzI1MDE3_cf4dee58-816d-4288-aab8-1a3ae044105b">91361</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjA5_1f82b212-ab83-401a-8b92-9a8cbab35b2d">805</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjEz_b0d02d2d-60ab-48b1-8026-5f62f86b7876">418-5006</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MGQyN2Y4YWRjN2MwNDBiZmFmYWFhNjc1MTRkZjZkY2QvdGFibGVyYW5nZTowZDI3ZjhhZGM3YzA0MGJmYWZhYWE2NzUxNGRmNmRjZF8xLTAtMS0xLTE4NjY_a8a9af85-6efd-4ae0-b9c4-6314b2238558">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MGQyN2Y4YWRjN2MwNDBiZmFmYWFhNjc1MTRkZjZkY2QvdGFibGVyYW5nZTowZDI3ZjhhZGM3YzA0MGJmYWZhYWE2NzUxNGRmNmRjZF8xLTEtMS0xLTE4Njg_d07508ec-4477-4055-8de4-1a0226e2fbc1">ARQT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6MGQyN2Y4YWRjN2MwNDBiZmFmYWFhNjc1MTRkZjZkY2QvdGFibGVyYW5nZTowZDI3ZjhhZGM3YzA0MGJmYWZhYWE2NzUxNGRmNmRjZF8xLTItMS0xLTE4NzA_799f309d-2364-4c7c-9e8b-631176d10c9c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjE5_fa8688a5-10c6-401f-91be-9251aecdbe86">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjIw_ba9e73c1-78da-4b3b-8298-42aa4c88554e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6ZDNhMmRmOGRiMzljNDA4ZmEzOGRhZjc4MjQ4MjExM2IvdGFibGVyYW5nZTpkM2EyZGY4ZGIzOWM0MDhmYTM4ZGFmNzgyNDgyMTEzYl8xLTAtMS0xLTE5MDM_b407595b-e30f-4107-9b8a-4e21decdca1a">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6ZDNhMmRmOGRiMzljNDA4ZmEzOGRhZjc4MjQ4MjExM2IvdGFibGVyYW5nZTpkM2EyZGY4ZGIzOWM0MDhmYTM4ZGFmNzgyNDgyMTEzYl8xLTQtMS0xLTE5MTA_52fe1ea8-f84c-4fd0-96cc-5955e2e1aa33">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGFibGU6ZDNhMmRmOGRiMzljNDA4ZmEzOGRhZjc4MjQ4MjExM2IvdGFibGVyYW5nZTpkM2EyZGY4ZGIzOWM0MDhmYTM4ZGFmNzgyNDgyMTEzYl8yLTEtMS0xLTE5MTI_d1eda50b-7965-4929-8295-2f16c40c6624">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjE1_f8c1d40a-2314-4763-b18c-7b41bcb3b48b">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF80OTQ3ODAyMzI5MjE4_da7857c1-e469-402b-aaee-cf918ffa7b36">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i45ee5cbaa43a4c1b946d00944fd45974_I20200501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xL2ZyYWc6ZmQ5ZWMzZDA1MWZlNGRkNThmOGYyYWE5Yzg0MjBjZjQvdGV4dHJlZ2lvbjpmZDllYzNkMDUxZmU0ZGQ1OGY4ZjJhYTljODQyMGNmNF8xNjQ5MjY3NDQ1Nzk5_66659eae-7942-4eda-b019-3e5d166425d1"
      unitRef="shares">38154550</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzQtMS0xLTEtMA_92bd9f88-55bd-4571-9787-8ac3fd683145"
      unitRef="usd">190893000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzQtMy0xLTEtMA_eeaff5c4-795e-4530-9bd0-af7bb2398de9"
      unitRef="usd">63336000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzUtMS0xLTEtMA_0050a9d0-1869-4eb4-b9af-27f649e83b7a"
      unitRef="usd">58426000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzUtMy0xLTEtMA_39478ae2-3218-45f4-82a6-3c7232824a9f"
      unitRef="usd">37929000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzYtMS0xLTEtMA_479b0e5b-d9b4-4532-a394-8a4ddc592f56"
      unitRef="usd">4559000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzYtMy0xLTEtMA_1c545d10-ac7c-4525-b6b3-fcc1a476b735"
      unitRef="usd">5209000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzctMS0xLTEtMA_9c7496dd-59a3-4a9f-b629-1023394fd55d"
      unitRef="usd">253878000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzctMy0xLTEtMA_b94633ea-3947-4a14-a3d3-a047640b1451"
      unitRef="usd">106474000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzgtMS0xLTEtMA_67b7648a-9b79-4876-bac2-6cfa755221c8"
      unitRef="usd">241000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzgtMy0xLTEtMA_b147d080-f5e2-420c-8275-0855ae7d5e74"
      unitRef="usd">227000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzktMS0xLTEtMA_5cce13e3-b97d-4111-9538-7054b6f16da0"
      unitRef="usd">226000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzktMy0xLTEtMA_af8a5f70-0438-40ce-8245-19d25203c2d9"
      unitRef="usd">264000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzEwLTEtMS0xLTA_cebe5291-7a27-4f5e-ae68-7260e977a6e1"
      unitRef="usd">47000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzEwLTMtMS0xLTA_93efda85-6ae7-4937-8cbe-142289ef2ba5"
      unitRef="usd">47000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzExLTEtMS0xLTA_a831ae94-a1b6-4495-89eb-f29c613a7ff8"
      unitRef="usd">254392000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzExLTMtMS0xLTA_d8bf5f75-518d-4d5f-8ae2-56be0f332506"
      unitRef="usd">107012000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE0LTEtMS0xLTA_e1a43353-6cd3-47d5-af2a-fff5b45b06bb"
      unitRef="usd">4759000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE0LTMtMS0xLTA_b42fd4f0-c10c-4295-9058-f255d933782a"
      unitRef="usd">1405000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE1LTEtMS0xLTA_3ad50584-ee41-4d69-8d80-d9082844e4b8"
      unitRef="usd">7281000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE1LTMtMS0xLTA_ada81692-4e3a-463c-92a7-9d393027aa1b"
      unitRef="usd">3654000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE2LTEtMS0xLTA_99d2f304-2582-42f6-8038-e78c8d54c7bc"
      unitRef="usd">182000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE2LTMtMS0xLTA_29fa21b5-abf9-41da-a13b-285cdad6079a"
      unitRef="usd">178000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE3LTEtMS0xLTA_90dcedc8-1e16-4c16-9245-1a4077b9527b"
      unitRef="usd">12222000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE3LTMtMS0xLTA_53178593-9058-4cba-a7ac-a84bdce90050"
      unitRef="usd">5237000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE4LTEtMS0xLTA_0ee20a38-b2f1-4133-b378-2599a35c3175"
      unitRef="usd">82000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE4LTMtMS0xLTA_38b86718-63d3-4453-b54f-c61da570c2c2"
      unitRef="usd">129000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE5LTEtMS0xLTA_d70f2cdb-3a17-497b-b715-d16de39e7eaf"
      unitRef="usd">206000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzE5LTMtMS0xLTA_83a35b22-bc3d-4d0b-9dd9-e2a1e7038699"
      unitRef="usd">184000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIwLTEtMS0xLTA_8035842e-06e9-43b7-bc70-0d49986b6bb2"
      unitRef="usd">12510000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIwLTMtMS0xLTA_e907603b-7d10-4c59-81f5-af1f5f456e43"
      unitRef="usd">5550000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTEtMS0xLTE2MjA_98da0210-30f4-4ec0-a65a-1652e286ac85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTMtMS0xLTE2MjA_fa3151b5-68f1-4474-965b-7439383df62d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NmI1MGE3NTMzZjY0NzJmOWI1ZmIyMmU0NTY5NzVhYV8xNjQ5MjY3NDQxODk5_21b7c539-4a2b-47c4-985f-e43725c0b68e"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NmI1MGE3NTMzZjY0NzJmOWI1ZmIyMmU0NTY5NzVhYV8xNjQ5MjY3NDQxODk5_fb57a25b-aac2-4f2f-9a12-9cdf7f93daf4"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NmI1MGE3NTMzZjY0NzJmOWI1ZmIyMmU0NTY5NzVhYV8xNjQ5MjY3NDQyOTQx_1625fb10-c75f-46c5-9e94-755d6d9ae70c"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NmI1MGE3NTMzZjY0NzJmOWI1ZmIyMmU0NTY5NzVhYV8xNjQ5MjY3NDQxOTE3_83bfa265-8ef6-41a8-b9ba-ae4d8b7236a9"
      unitRef="shares">48787898</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NmI1MGE3NTMzZjY0NzJmOWI1ZmIyMmU0NTY5NzVhYV8yMTk5MDIzMjU2NTYx_22c66e81-6bc2-4f1c-9dcd-dbff38bd5720"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NmI1MGE3NTMzZjY0NzJmOWI1ZmIyMmU0NTY5NzVhYV8yMTk5MDIzMjU2NTYx_2dade523-0799-4658-9c90-c1a5f9d16831"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NmI1MGE3NTMzZjY0NzJmOWI1ZmIyMmU0NTY5NzVhYV80OTQ3ODAyMzI1MjYz_6c30f385-aeed-44fe-8aa6-d66c4f5c54b2"
      unitRef="shares">24385388</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTAtMS0xLTAvdGV4dHJlZ2lvbjo2NmI1MGE3NTMzZjY0NzJmOWI1ZmIyMmU0NTY5NzVhYV80OTQ3ODAyMzI1MjYz_e120cc6a-7751-4c0d-8f8b-eb420d97c522"
      unitRef="shares">24385388</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTEtMS0xLTA_4af4aad3-d95b-4db9-b8fc-2e9b2e14fcec"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzIyLTMtMS0xLTA_f2bea1be-c202-426f-9d6d-ebb51fa57655"
      unitRef="usd">166491000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTAtMS0xLTc4MzUvdGV4dHJlZ2lvbjoyYjhiNzI1YjM0OGY0MjI5OGE3ZGJmMTA4NzI4YmQ4ZF8xNjQ5MjY3NDQxODc1_9232a070-72ee-4963-bf71-a03ce214b52f"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTAtMS0xLTc4MzUvdGV4dHJlZ2lvbjoyYjhiNzI1YjM0OGY0MjI5OGE3ZGJmMTA4NzI4YmQ4ZF8xNjQ5MjY3NDQxODc1_a589da5a-4202-4a5d-9312-84dee826cb5e"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTAtMS0xLTc4MzUvdGV4dHJlZ2lvbjoyYjhiNzI1YjM0OGY0MjI5OGE3ZGJmMTA4NzI4YmQ4ZF8xNjQ5MjY3NDQxODk1_bc17a2da-ded1-48b0-9312-cb51a8669def"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTAtMS0xLTc4MzUvdGV4dHJlZ2lvbjoyYjhiNzI1YjM0OGY0MjI5OGE3ZGJmMTA4NzI4YmQ4ZF8xNjQ5MjY3NDQxOTIx_3d19dbf2-fe43-4947-9ecd-fd4ad0475446"
      unitRef="shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTAtMS0xLTc4MzUvdGV4dHJlZ2lvbjoyYjhiNzI1YjM0OGY0MjI5OGE3ZGJmMTA4NzI4YmQ4ZF8xNjQ5MjY3NDQxOTMy_02be0d22-7c3a-4be0-b811-3bbf4308685b"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTAtMS0xLTc4MzUvdGV4dHJlZ2lvbjoyYjhiNzI1YjM0OGY0MjI5OGE3ZGJmMTA4NzI4YmQ4ZF8xNjQ5MjY3NDQxOTMy_36992631-1951-4905-9093-f2dc296ffa0d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTAtMS0xLTc4MzUvdGV4dHJlZ2lvbjoyYjhiNzI1YjM0OGY0MjI5OGE3ZGJmMTA4NzI4YmQ4ZF8xNjQ5MjY3NDQxOTMy_669da65b-caf0-4bda-ace3-dc42810fdf62"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTAtMS0xLTc4MzUvdGV4dHJlZ2lvbjoyYjhiNzI1YjM0OGY0MjI5OGE3ZGJmMTA4NzI4YmQ4ZF8xNjQ5MjY3NDQxOTMy_a182821e-b8cf-46e2-b574-ac7aa1911410"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTEtMS0xLTc4Njc_d65ddec2-7825-4da1-b953-92a4446e3b77"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTMtMS0xLTc4Njk_257a58f9-46a6-4113-a44e-f220a2df1fe1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMTc4MmJhNTMyMDM0YmVkYjJiNmNjN2E0ZTJkY2NmMl80OTQ3ODAyMzI1MzA4_1fba9eef-4f69-4c8f-ab27-7f83461fb2a4"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMTc4MmJhNTMyMDM0YmVkYjJiNmNjN2E0ZTJkY2NmMl80OTQ3ODAyMzI1MzA4_9fded890-3db8-419d-ab92-ab5f95c548c0"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMTc4MmJhNTMyMDM0YmVkYjJiNmNjN2E0ZTJkY2NmMl8xNjQ5MjY3NDQyMDUz_0e7d22fb-d8eb-4f48-bbb9-81d7499c2a87"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMTc4MmJhNTMyMDM0YmVkYjJiNmNjN2E0ZTJkY2NmMl80OTQ3ODAyMzI1MzIw_e786f420-0fb7-4cbe-9064-51617409c2c3"
      unitRef="shares">65820000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMTc4MmJhNTMyMDM0YmVkYjJiNmNjN2E0ZTJkY2NmMl80OTQ3ODAyMzI1MzQy_2a50310b-742f-4dc5-b83d-c7de4e3bb35f"
      unitRef="shares">38154550</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMTc4MmJhNTMyMDM0YmVkYjJiNmNjN2E0ZTJkY2NmMl80OTQ3ODAyMzI1MzM3_a628ea7d-7f68-4c07-bb65-6cec55cbb896"
      unitRef="shares">2879763</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMTc4MmJhNTMyMDM0YmVkYjJiNmNjN2E0ZTJkY2NmMl80OTQ3ODAyMzI1MzU5_d979f421-5663-4ae4-9da2-97e7ef920223"
      unitRef="shares">37471997</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjpmMTc4MmJhNTMyMDM0YmVkYjJiNmNjN2E0ZTJkY2NmMl80OTQ3ODAyMzI1MzUz_56381985-9b7b-412c-8490-c4d788d5e6d1"
      unitRef="shares">2120853</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTEtMS0xLTA_61aba347-cd1d-4f74-8367-590536236e02"
      unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI0LTMtMS0xLTA_a921a43c-d0ed-4dab-8f0a-89bb02821cc6"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTEtMS0xLTA_d95c870e-562a-413b-92a4-1247faa41325"
      unitRef="usd">336145000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI1LTMtMS0xLTA_000b4a1c-774c-4927-93b0-9f6fa8bc9672"
      unitRef="usd">1244000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI2LTEtMS0xLTA_a0b98bbe-bd3b-49ba-8d04-5bed185d2b6b"
      unitRef="usd">19000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI2LTMtMS0xLTA_2611384b-b863-47db-81bf-81c188a44a44"
      unitRef="usd">-1000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI3LTEtMS0xLTA_134c15f3-eee4-4dc7-820a-a85e1e60ce4e"
      unitRef="usd">-94285000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI3LTMtMS0xLTA_863d0569-cc3e-4543-a046-682f13b7f4c9"
      unitRef="usd">-66272000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI4LTEtMS0xLTA_d33cfab6-c9b6-4ee3-9046-71ed05c74e7d"
      unitRef="usd">241882000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI4LTMtMS0xLTA_00bd8468-5cf6-41ed-a891-68a246a37fd4"
      unitRef="usd">-65029000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI5LTEtMS0xLTA_ef9aaa33-d811-4d1c-ad1a-2a2c770bcc4a"
      unitRef="usd">254392000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMTgvZnJhZzo4ZGE3MjhlM2U2NjU0MmRlYTU3MzdiNGI2N2Y5MWFiMy90YWJsZTowNWJkNmI3YTlmYjM0YjU3YjdlNzM1ZjI0NGY0MThlYS90YWJsZXJhbmdlOjA1YmQ2YjdhOWZiMzRiNTdiN2U3MzVmMjQ0ZjQxOGVhXzI5LTMtMS0xLTA_aef5e7ed-704d-4553-95b4-975841578ee6"
      unitRef="usd">107012000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzMtMS0xLTEtMA_a801d95d-f56c-428d-b076-3bf5fea3d516"
      unitRef="usd">25182000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzMtMy0xLTEtMA_42b39d56-4379-4887-8d3c-ebaff4adec49"
      unitRef="usd">6203000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzQtMS0xLTEtMA_167038a9-eeae-4163-a702-3cbc8a3965d0"
      unitRef="usd">3469000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzQtMy0xLTEtMA_400006ed-8cd5-45fe-aa5d-9ec9d5bc12cc"
      unitRef="usd">749000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzUtMS0xLTEtMA_d71e1f8f-1029-4953-9850-f39845f4c6d6"
      unitRef="usd">28651000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzUtMy0xLTEtMA_57f17d61-8342-48b6-9ab9-e9316d67b656"
      unitRef="usd">6952000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzYtMS0xLTEtMA_e51c63fc-3829-437f-9985-e2d1e34f6469"
      unitRef="usd">-28651000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzYtMy0xLTEtMA_1e8f70e3-7c9a-4b33-aca7-8a6bf9b0276e"
      unitRef="usd">-6952000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzctMS0xLTEtMA_8b18be2c-2d5a-4545-9468-b6e532d34244"
      unitRef="usd">638000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzctMy0xLTEtMA_c8aea642-12cc-4bc9-9106-d6c95d644444"
      unitRef="usd">294000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzgtMS0xLTEtMA_c7a52ace-4c15-4338-bc41-e7ddbf338f1b"
      unitRef="usd">-28013000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzgtMy0xLTEtMA_05c31c2c-889f-43b8-b04a-b988c590f30b"
      unitRef="usd">-6658000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzEwLTEtMS0xLTA_f4044ba9-cab8-4f13-93c3-b116e170c0d3"
      unitRef="usd">20000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzEwLTMtMS0xLTA_9ed55771-21f8-4cd4-9091-cefd651fa776"
      unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzExLTEtMS0xLTA_a8f81aa9-f2af-45b4-b99a-6e69f6734fe9"
      unitRef="usd">-27993000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzExLTMtMS0xLTA_03ed7da0-b062-4811-8ff0-e7abe43f36ca"
      unitRef="usd">-6657000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzEzLTEtMS0xLTA_0c0a429d-eb7d-4de7-83f2-332f64dfe2bc"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzEzLTMtMS0xLTA_871382db-06f5-4a90-bf8d-7ccd61a6a4a4"
      unitRef="usdPerShare">-4.08</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzE0LTEtMS0xLTA_2e24ed0a-a51e-46d9-bb74-b602ba385c95"
      unitRef="shares">24256402</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjQvZnJhZzo0NDljYzIyNWIyZTE0MzRiYjc5MzI1MDAxMmRkMzljMC90YWJsZTplMGNmN2IzMjQwNDg0ODJhODc5YjEyZWIzYzJhOWJkZC90YWJsZXJhbmdlOmUwY2Y3YjMyNDA0ODQ4MmE4NzliMTJlYjNjMmE5YmRkXzE0LTMtMS0xLTA_26b4ff3b-fe7a-439f-8493-270c03e69d5b"
      unitRef="shares">1632694</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i68dfa5b4689849b9a3cd771af6075ca9_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzItMS0xLTEtMA_acea6dab-a590-452f-9713-71ad6444f6f5"
      unitRef="shares">16262425</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i68dfa5b4689849b9a3cd771af6075ca9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzItMy0xLTEtMA_cd125f29-31d2-4f99-a331-6610f0e6a938"
      unitRef="usd">72252000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i1ccb7f8264e14d269a33e7f94a0411d7_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzItNS0xLTEtMA_89a5d598-cd25-4741-a2df-91c2a9e8e467"
      unitRef="shares">1557900</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1ccb7f8264e14d269a33e7f94a0411d7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzItNy0xLTEtMA_8b15fcbc-b69b-44ac-aaaf-ea9de396bd3f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i004b33aa7ef84638a508f80804c3e4d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzItOS0xLTEtMA_88fd821a-f2f1-47fa-8a45-f06b626ddf70"
      unitRef="usd">289000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i58223e1e92e7484da16c8646830a5178_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzItMTEtMS0xLTA_28fb37fd-a01d-4810-ac7f-08410cbe5c76"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3bef4868bf94e0b8bcd68b0c08ee9c3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzItMTMtMS0xLTA_a377d751-da6f-4b75-af5a-230f40ffe99c"
      unitRef="usd">-24276000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i68dfa5b4689849b9a3cd771af6075ca9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzItMTUtMS0xLTA_753da9d8-beef-4c06-b57e-9c2c6eb664e3"
      unitRef="usd">-23987000</us-gaap:StockholdersEquity>
    <arqt:StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares
      contextRef="ic3d98141ace44b3d91fa1e2bd76e3378_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzMtNS0xLTEtMA_6456accc-a5fa-4eb6-8bea-9045658ad437"
      unitRef="shares">68931</arqt:StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares>
    <arqt:StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzMtMTUtMS0xLTA_105aee4c-ee11-4ebc-a197-cb31be848ce5"
      unitRef="usd">0</arqt:StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue>
    <arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares
      contextRef="ic3d98141ace44b3d91fa1e2bd76e3378_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzQtNS0xLTEtMA_a3df24fc-44cc-4ed4-b522-3baabfcc5a9f"
      unitRef="shares">65868</arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares>
    <arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises
      contextRef="ibbbb627a865342c3a3c8ca55197e411c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzQtOS0xLTEtMA_75347866-aa47-40c3-87cd-d40ed9cd48d7"
      unitRef="usd">29000</arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises>
    <arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzQtMTUtMS0xLTA_0e620331-1f3e-4b20-a2a2-18634fad5dee"
      unitRef="usd">29000</arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibbbb627a865342c3a3c8ca55197e411c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzUtOS0xLTEtMA_a8c1829c-f14e-4da4-a162-0da5ffbbb3cf"
      unitRef="usd">76000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzUtMTUtMS0xLTA_aceb1700-4cd5-4729-b46a-5807d2d8d4ea"
      unitRef="usd">76000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id40bc8ee44ed48b9b00785b5733d49e4_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzYtMTEtMS0xLTA_50317093-a97e-4916-8be2-f22a125d0c8c"
      unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzYtMTUtMS0xLTA_bb0b3d5f-5a7b-40c3-bff4-a1366b5ede82"
      unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i0cd5d9c6ed8543fbae65bfb9bf35030d_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzctMTMtMS0xLTA_8e4c47c5-24d8-44c0-ba99-d2d408542e2e"
      unitRef="usd">-6658000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzctMTUtMS0xLTA_8ab8f859-18ae-4e0e-ad30-92438217ec1d"
      unitRef="usd">-6658000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ic5c62122ea184197a8cbcd8fac509f93_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzgtMS0xLTEtMA_c1d155f6-a747-4ba3-bfb8-d102c001ffe4"
      unitRef="shares">16262425</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ic5c62122ea184197a8cbcd8fac509f93_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzgtMy0xLTEtMA_2aa4ed45-8750-48b3-97fd-7841e1b7bc05"
      unitRef="usd">72252000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i2d4d2679b1f24ea4bbc79894014b1394_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzgtNS0xLTEtMA_34387937-8ead-4f81-95b2-b2a72fbb16d3"
      unitRef="shares">1692699</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2d4d2679b1f24ea4bbc79894014b1394_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzgtNy0xLTEtMA_6d1f997f-d4ba-400d-b1df-f6b8b0775cad"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i91f2e456e7ee436697728b99c6737875_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzgtOS0xLTEtMA_a8ccb2cb-e967-471b-9f26-5e31966ce333"
      unitRef="usd">394000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icf934a45ca7144f39a0071e59f9cc564_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzgtMTEtMS0xLTA_cee096e6-b484-45ce-b5e2-5fc14b8f3c96"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6be9162e0bdc434cae7c672714f4e731_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzgtMTMtMS0xLTA_d7c3b66f-28c8-450a-8968-44d14c313bbe"
      unitRef="usd">-30934000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5c62122ea184197a8cbcd8fac509f93_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzgtMTUtMS0xLTA_f19fece9-934a-41ce-b621-59c8f4328293"
      unitRef="usd">-30539000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE3LTEtMS0xLTA_0a0f4b99-cf7c-4b09-9421-0679287d898e"
      unitRef="shares">24385388</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE3LTMtMS0xLTA_b67ddfe5-6dbe-4315-9c98-cab395d9f4ec"
      unitRef="usd">166491000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i35625a47aaa94266be03155114268268_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE3LTUtMS0xLTA_c49d1469-5c12-42c5-b7a4-7e06372f7960"
      unitRef="shares">2120853</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i35625a47aaa94266be03155114268268_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE3LTctMS0xLTA_e6a8f8f9-07ef-4a62-9bf2-d71db4238163"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if55289982bed4868bd75d4d6010753e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE3LTktMS0xLTA_609ce1ab-e649-430d-b241-293fede93abd"
      unitRef="usd">1244000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifb50c31a77604c0d8346a9ea0f57045a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE3LTExLTEtMS0w_c32d2a27-ecc7-4c5d-bbe6-eb21e4233585"
      unitRef="usd">-1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i74375cd2c8a64bbcb8ce7fdbc8b5f486_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE3LTEzLTEtMS0w_03b0eead-48ea-42e3-b1d8-34d493bad66b"
      unitRef="usd">-66272000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE3LTE1LTEtMS0w_e79d19d8-b93a-49b5-9572-587091f69ed3"
      unitRef="usd">-65029000</us-gaap:StockholdersEquity>
    <arqt:TemporaryEquitySharesConversionOfConvertibleSecurities
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzExLTEtMS0xLTMxMDc_759370d6-4e7f-4538-aadc-cc82d55b1c1b"
      unitRef="shares">24385388</arqt:TemporaryEquitySharesConversionOfConvertibleSecurities>
    <arqt:TemporaryEquityValueConversionOfConvertibleSecurities
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzExLTMtMS0xLTMxMDc_60f798a5-93ad-4e10-8e54-8a80e38d8059"
      unitRef="usd">166491000</arqt:TemporaryEquityValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzExLTUtMS0xLTMxMDc_4d21a535-3826-4ee9-a55f-76837af18a9a"
      unitRef="shares">24385388</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzExLTctMS0xLTMxMDc_f08ea993-d7c9-499e-8120-89c9a412d931"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i80caeb9df5f44f8e9df282ee72186142_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzExLTktMS0xLTMxMDc_8be51be9-5c50-4840-9a99-b762c53170f2"
      unitRef="usd">166489000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzExLTE1LTEtMS0zMTA3_631a1cfa-fdad-4847-a2ed-907a3041adb6"
      unitRef="usd">166491000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzExLTAtMS0xLTMwODgvdGV4dHJlZ2lvbjplYjczOWRiNDMyNGM0NjUzOTg2NDY4YzQ0OTZhYjdjNF8yNzQ4Nzc5MDY5NTQ5_4fe5d7c2-0642-4c63-9035-419b0848bd1b"
      unitRef="usd">16000000.0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzEyLTUtMS0xLTMxMTg_6725b639-eaf7-48e8-96f3-9a57ef6defea"
      unitRef="shares">10781250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzEyLTctMS0xLTMxMTg_d1879b0c-6c9b-44a8-9fc0-f71ffc758b01"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i80caeb9df5f44f8e9df282ee72186142_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzEyLTktMS0xLTMxMTg_a07ebe6c-fdd0-40fe-8fa0-cba79d26505e"
      unitRef="usd">167240000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzEyLTE1LTEtMS0zMTE4_7ad1cb87-e674-485e-93a7-c52c91ac56b1"
      unitRef="usd">167241000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE4LTUtMS0xLTA_71a3992d-c8fd-478d-b056-b7009adb408e"
      unitRef="shares">51147</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i80caeb9df5f44f8e9df282ee72186142_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE4LTktMS0xLTA_c3ffb37d-95ac-4912-ac3c-08df8dd08394"
      unitRef="usd">152000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzE4LTE1LTEtMS0w_5e9d1e0f-f839-4758-a4fb-b2bcd8b7759a"
      unitRef="usd">152000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <arqt:StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares
      contextRef="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIwLTUtMS0xLTA_fe0ea664-e17c-4d9d-b1b4-f6f369868259"
      unitRef="shares">68931</arqt:StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares>
    <arqt:StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIwLTE1LTEtMS0w_2680fd65-45a7-4c2c-8bed-3ce2ce94b118"
      unitRef="usd">0</arqt:StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue>
    <arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares
      contextRef="idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIxLTUtMS0xLTA_87761dbf-c4c0-4c09-9a38-126db256ec09"
      unitRef="shares">64428</arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares>
    <arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises
      contextRef="i80caeb9df5f44f8e9df282ee72186142_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIxLTktMS0xLTA_a65f43d1-ba68-455c-ad82-9de8ec92ba84"
      unitRef="usd">30000</arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises>
    <arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIxLTE1LTEtMS0w_0f842ddc-4eed-4008-aae0-273acc3505ad"
      unitRef="usd">30000</arqt:StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i80caeb9df5f44f8e9df282ee72186142_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIyLTktMS0xLTA_11a66138-29c0-457e-89ae-e9ef7c7c1360"
      unitRef="usd">990000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIyLTE1LTEtMS0w_4f596471-bb52-4d70-90d5-aa82b8f5745a"
      unitRef="usd">990000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1d9f4b34db394927811febbebe7ee4a3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIzLTExLTEtMS0w_0c7cf475-9bdb-4323-bcb9-0c8e67f3fe9a"
      unitRef="usd">20000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzIzLTE1LTEtMS0w_19bc5267-2044-43b4-b0ee-a1f2c821aaf5"
      unitRef="usd">20000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i8f6595d3666d4c0da7ef44540cc8c105_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI0LTEzLTEtMS0w_b9cc9439-fb0a-47aa-8219-f2ec3a4314af"
      unitRef="usd">-28013000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI0LTE1LTEtMS0w_6a73e162-6613-4c9b-9710-c070988a672f"
      unitRef="usd">-28013000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI2LTEtMS0xLTA_6736381c-f767-432f-b40f-c565ba185c64"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI2LTMtMS0xLTA_bbd9f1ba-6244-4bfe-8202-c163e0b07c3d"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i21443e8563474055949c856249beb800_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI2LTUtMS0xLTA_99c59e0a-10c9-447a-910e-1054076caf76"
      unitRef="shares">37471997</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i21443e8563474055949c856249beb800_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI2LTctMS0xLTA_0537dea3-22c3-4bc9-bf8e-23ed01543f6a"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0fa655ae1882424ea70d7f3ba47275d5_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI2LTktMS0xLTA_eb8a0379-7799-4d43-ae6a-4e11036f173c"
      unitRef="usd">336145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic552471d830f40178487f9d46cbfe905_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI2LTExLTEtMS0w_7866b74f-d735-482d-8178-427e55a4e627"
      unitRef="usd">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieb89b6585f024b53831de5e9407a4e25_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI2LTEzLTEtMS0w_96356c93-1aa7-49d0-a7bd-90328606efc4"
      unitRef="usd">-94285000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMjcvZnJhZzpkZWQ1ZmY2NzRiMDY0MGEzOGEyNTMxNjU3OTc1ZDJlYS90YWJsZToyMTY4MGNiMWU4MDQ0MTRiOTllOTc5MDc5MDE0MjhmYi90YWJsZXJhbmdlOjIxNjgwY2IxZTgwNDQxNGI5OWU5NzkwNzkwMTQyOGZiXzI2LTE1LTEtMS0w_d17fc8f3-a7dd-4302-aec8-bfa58223c39c"
      unitRef="usd">241882000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzMtMS0xLTEtMA_015c4eb1-e1e7-48dc-bb9e-8369bacc79ce"
      unitRef="usd">-28013000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzMtMy0xLTEtMA_4f911447-439b-4a68-ad8d-13e909e304af"
      unitRef="usd">-6658000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzUtMS0xLTEtMA_dcdab196-723e-4d7a-bb38-b5f3867508c9"
      unitRef="usd">27000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzUtMy0xLTEtMA_5bf6ba19-6e20-4581-9209-70aaf9cf8451"
      unitRef="usd">5000</us-gaap:Depreciation>
    <arqt:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzYtMS0xLTEtMA_3b2c41c3-d7e0-4e15-b8d8-8021cd9c92af"
      unitRef="usd">38000</arqt:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <arqt:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzYtMy0xLTEtMA_bad7b8b0-cff2-4932-8234-16356ce91eb6"
      unitRef="usd">19000</arqt:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzctMS0xLTEtMA_49e49a89-7e2f-4147-a1fb-888cf382d74f"
      unitRef="usd">192000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzctMy0xLTEtMA_783f3696-2944-411f-9a86-9e2e1f657bb0"
      unitRef="usd">120000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzgtMS0xLTEtMA_eefaebfb-c6bb-48df-95ee-90af3353c889"
      unitRef="usd">990000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzgtMy0xLTEtMA_6e1b36c4-4daf-4bbb-a17b-4b86765b0565"
      unitRef="usd">76000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzEzLTEtMS0xLTA_6ac60674-d367-4b38-9ab6-cf8d0498e416"
      unitRef="usd">1097000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzEzLTMtMS0xLTA_b6a405b9-988b-4fee-b103-e5b844fa6ee5"
      unitRef="usd">315000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE0LTEtMS0xLTA_a3d980ee-974a-4177-85e6-b2814de2f506"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE0LTMtMS0xLTA_69d0f957-4977-4519-b9b9-c85740bd599b"
      unitRef="usd">47000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE1LTEtMS0xLTA_544b48a5-9d35-4cfb-a59b-a3e02ab65511"
      unitRef="usd">3412000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE1LTMtMS0xLTA_93cb14da-a795-48f3-b44d-aa8b1a49d02f"
      unitRef="usd">-393000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE2LTEtMS0xLTA_a156cf2e-2690-4555-a1ed-94cffe5cd10e"
      unitRef="usd">3868000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE2LTMtMS0xLTA_9e76941c-e166-446c-82e6-2701a02e76fc"
      unitRef="usd">370000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <arqt:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE3LTEtMS0xLTA_351c9f4a-5b87-4992-8c54-bf96711b1f0a"
      unitRef="usd">-43000</arqt:IncreaseDecreaseInOperatingLeaseLiabilities>
    <arqt:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE3LTMtMS0xLTA_aa02b867-0f70-4f01-9cf2-549c0f75002a"
      unitRef="usd">-11000</arqt:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE4LTEtMS0xLTA_17c59587-efb1-4bcf-9b41-a76085623cec"
      unitRef="usd">-21010000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzE4LTMtMS0xLTA_1b62150b-df23-4d4a-96de-b8ac48ab0cda"
      unitRef="usd">-7074000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzIwLTEtMS0xLTA_362f7ec0-dd8e-4db7-bf5c-27787fb908c9"
      unitRef="usd">35285000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzIwLTMtMS0xLTA_e5d3ba03-b248-47bc-ab27-8c66f7f28bd2"
      unitRef="usd">11687000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzIxLTEtMS0xLTA_5b1eb4fb-880d-4835-b0ec-ae160ccd53fd"
      unitRef="usd">15000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzIxLTMtMS0xLTA_6e362f34-8f62-488d-9a3f-536c4cf8935b"
      unitRef="usd">2600000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzIyLTEtMS0xLTA_27741c26-c4da-4e18-b3d5-a6aed2226d08"
      unitRef="usd">41000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzIyLTMtMS0xLTA_5a7b27e2-d147-4ba0-9bda-5a669faa2fe9"
      unitRef="usd">183000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzIzLTEtMS0xLTA_19e7dc3f-aeaa-42f7-b6e5-8484751b83a3"
      unitRef="usd">-20326000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzIzLTMtMS0xLTA_f62e8032-f377-4261-aab9-58d950e6c3c9"
      unitRef="usd">-9270000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzI1LTEtMS0xLTA_6f9ed742-b573-486f-9ab3-9401a4eb6607"
      unitRef="usd">247000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzI1LTMtMS0xLTA_ac295bbb-c48b-4c82-ba3b-52b56a60e24f"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzI2LTEtMS0xLTA_69e4347c-92d9-46d7-8789-ec9ebce3dba3"
      unitRef="usd">168646000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzI2LTMtMS0xLTA_ff1ad5b3-bb99-47d8-a841-7a36d2e891f3"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzMxLTEtMS0xLTA_7b5661bd-cd17-4eac-ab74-e890022e6e20"
      unitRef="usd">168893000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzMxLTMtMS0xLTA_13679dac-e916-4bfb-ade5-8c5519ff56c5"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzMyLTEtMS0xLTA_0128de46-d463-4be4-a58f-858221c53f1c"
      unitRef="usd">127557000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzMyLTMtMS0xLTA_8ae5c045-ffc1-4ea5-84ed-6d8de57c2516"
      unitRef="usd">-16344000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzMzLTEtMS0xLTA_9bd1889b-a1fa-42b1-8c14-999d30b8f6a6"
      unitRef="usd">63336000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i68dfa5b4689849b9a3cd771af6075ca9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzMzLTMtMS0xLTA_71aabd04-5556-4f69-8d70-54c5c3eca14c"
      unitRef="usd">39394000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzM0LTEtMS0xLTA_5b6206a4-6760-4e4e-b0e3-b013284b8cf7"
      unitRef="usd">190893000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic5c62122ea184197a8cbcd8fac509f93_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzM0LTMtMS0xLTA_77ab0f00-3df1-4832-9183-db0ab140f030"
      unitRef="usd">23050000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzM5LTEtMS0xLTA_41a3581b-0f25-410e-ad97-f7619fb2c71d"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzM5LTMtMS0xLTA_c509e83d-91f8-4a42-a1c9-3e5b9d7798f7"
      unitRef="usd">391000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <arqt:DeferredFinancingCostsIncurredButNotYetPaid
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzQwLTEtMS0xLTA_554b67d4-d471-4e43-a25f-3a538ac79601"
      unitRef="usd">4000</arqt:DeferredFinancingCostsIncurredButNotYetPaid>
    <arqt:DeferredFinancingCostsIncurredButNotYetPaid
      contextRef="ic5c62122ea184197a8cbcd8fac509f93_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzAvZnJhZzpiZmM1Y2I2YTdiODA0ZGQzODNiODRlYjNmZjkxOGUzMS90YWJsZTpmMDEyNWY2NzFhYTI0MzliOWI2ZDlkMGEzYjliOTg5MS90YWJsZXJhbmdlOmYwMTI1ZjY3MWFhMjQzOWI5YjZkOWQwYTNiOWI5ODkxXzQwLTMtMS0xLTA_81babdec-1211-411d-88a2-3e892de9bf02"
      unitRef="usd">0</arqt:DeferredFinancingCostsIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzQ5NDc4MDIzMzUyNzA_922cf613-5cf5-4094-b0e8-4c3cae3a4fb3">Organization and Description of Business&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Arcutis Biotherapeutics, Inc., or the Company, is a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. The Company&#x2019;s current portfolio is comprised of topical treatments with significant promise in addressing immune-mediated dermatological diseases and conditions, or immuno-dermatology. The Company&#x2019;s strategy is to advance treatments that leverage validated biological targets in dermatology in order to deliver clinical profiles that address major shortcomings of existing therapies in its targeted indications. The Company believes this strategy uniquely positions it to rapidly advance its goal of bridging the treatment innovation gap in dermatology while maximizing its probability of technical success.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 17, 2020, the Company's Board of Directors approved a 1-for-2.0007 reverse stock split of the Company&#x2019;s capital stock and the Company filed a certificate of amendment to its restated certificate of incorporation to effect the split. The par value and authorized shares of common stock and convertible preferred stock were not adjusted as a result of the reverse split. All share and per share information included in the accompanying financial statements has been adjusted to reflect this reverse stock split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Initial Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 31, 2020, the Company completed an initial public offering (&#x201c;IPO&#x201d;) issuing and selling &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;10,781,250&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; shares of common stock at a public offering price of $17.00 per share, including &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;1,406,250&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; shares sold pursuant to the underwriters&#x2019; full exercise of their option to purchase additional shares. The aggregate net proceeds received by the Company from the offering were approximately $167.2&#160;million,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; after deducting underwriting discounts, commissions and offering related transaction costs&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. Upon the closing of the IPO, all of the outstanding shares of convertible preferred stock automatically converted into shares of common stock. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding.  The financial statements as of March&#160;31, 2020, including share and per share amounts, incorporate the effects of the IPO. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has incurred significant losses and negative cash flows from operations since its inception and had an accumulated deficit of $94.3 million and $66.3 million as of March&#160;31, 2020 and December&#160;31, 2019, respectively. The Company had cash, cash equivalents and marketable securities of $249.3 million and $101.3 million as of March&#160;31, 2020 and December&#160;31, 2019, respectively. Prior to selling common stock in its IPO, the Company had historically financed its operations primarily through the sale of its convertible preferred stock. Management expects operating losses to continue for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company believes that its existing capital resources will be sufficient to meet the projected operating requirements for at least 12 months from the date of issuance of its financial statements. The Company will be required to raise additional capital to fund future operations. However, no assurance can be given as to whether additional needed financing will be available on terms acceptable to the Company, if at all. If sufficient funds on acceptable terms are not available when needed, the Company may be required to curtail planned activities to significantly reduce its operating expenses. Failure to manage discretionary spending or raise additional financing, as needed, may adversely impact the Company&#x2019;s ability to achieve its intended business objectives and have an adverse effect on its results of operations and future prospects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Coronavirus Outbreak&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In March 2020, the World Health Organization declared a pandemic related to the global novel coronavirus disease 2019 (COVID-19) outbreak. As of May 12, 2020, the Company&#x2019;s operations have not been significantly impacted by the COVID-19 pandemic.  The Company is monitoring the potential impact COVID-19 may have on the clinical development of its product candidates, including potential delays or modifications to its ongoing and planned trials. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak will have on its financial condition and operations, including ongoing and planned clinical trials.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i2b1b978c4e7e4c51afcf56c572945237_D20200131-20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzQ5NDc4MDIzMzAyMzA_fd03f308-9afd-4892-b5bf-cbe3d6fad2f6"
      unitRef="shares">10781250</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i61f2dde936ae43d5bc9eae7e34c66670_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzE2NjY_9ffb586f-5eef-40e0-820a-6a93d921b2d9"
      unitRef="usdPerShare">17.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ifb9e70228f484fc4a8a0c0a8c7d593b1_D20200131-20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzE2OTA_8aa9db4e-a70e-4294-89bb-1558535a62df"
      unitRef="shares">1406250</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="iafc8add9248145199d7b4082ecba51b7_D20200131-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzE4OTA_6345be38-cb29-4919-b5db-32fd9e5cd2c5"
      unitRef="usd">167200000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ib256fcf2733e48fca730f3e92edbe1f6_I20200201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzQ5NDc4MDIzMzAyNTM_512c5237-94a0-49f2-b35a-8e97c06fbb97"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzIxOTkwMjMyNjA4MzQ_992b71b3-0ee4-487b-86e8-f6e390e33824"
      unitRef="usd">-94300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzIxOTkwMjMyNjA4NTg_8e60d194-b76e-4c85-bff1-a461d3b8f1b8"
      unitRef="usd">-66300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzIxOTkwMjMyNjA4ODQ_5ca13861-79df-4336-92b4-220dfd8b2c54"
      unitRef="usd">249300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzYvZnJhZzozNmZkZjlhOTQ0YzQ0NmVlYWJjMTEwYzNjMjYyYTk2NC90ZXh0cmVnaW9uOjM2ZmRmOWE5NDRjNDQ2ZWVhYmMxMTBjM2MyNjJhOTY0XzIxOTkwMjMyNjA4ODc_d46906d9-cddf-46d5-960e-1a364781ee59"
      unitRef="usd">101300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzODk3MjY_06bc9e4f-0dc7-465d-8ceb-1687af616a48">Summary of Significant Accounting Policies&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s condensed financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements and accompanying notes. On an ongoing basis, management evaluates such estimates and assumptions for continued reasonableness. In particular, management makes estimates with respect to accruals for research and development activities, fair value of common stock and convertible preferred stock (prior to the IPO completed in January 2020), stock-based compensation expense and income taxes. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;To date, the Company has viewed its financial information on an aggregate basis for the purposes of evaluating financial performance and allocating the Company&#x2019;s resources. Accordingly, the Company has determined that it operates in one segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Unaudited Interim Condensed Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The interim condensed balance sheet as of March&#160;31, 2020, the interim condensed statements of operations and comprehensive loss, the condensed changes in convertible preferred stock and stockholders&#x2019; equity (deficit) and cash flows for the three months ended March&#160;31, 2020 and 2019 are unaudited. These unaudited interim condensed financial statements have been prepared on the same basis as the Company&#x2019;s audited annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair statement of the Company&#x2019;s financial information. The financial data and the other financial information disclosed in these notes to the condensed financial statements related to the three-month periods are also unaudited. The condensed results of operations for the three months ended March&#160;31, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other future annual or interim period. The condensed balance sheet as of December 31, 2019 included herein was derived from the audited financial statements as of that date. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Therefore, these unaudited interim condensed financial statements should be read in conjunction with the Company&#x2019;s audited financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of money market funds, commercial paper, and government securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities consist of investment grade short to intermediate-term fixed income investments that have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase are classified as current based on their availability for use in current operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses as well as credit losses, if any, on marketable securities are included in other income (expense), net. The Company evaluated the underlying credit quality and credit ratings of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;the issuers during the period. To date, no such credit losses have occurred or have been recorded. The cost of investments sold is based on the specific-identification method. As of March&#160;31, 2020, there were unrealized gains on marketable securities of $19,000 and as of December&#160;31, 2019, there were unrealized losses on marketable securities of  $1,000. Unrealized gains and losses on marketable securities are reported as a component of Accumulated Other Comprehensive Income (Loss) on the balance sheet. There were no realized gains or losses on investments for the three months ended March 31, 2020 and 2019. Interest on marketable securities is included in Other income (expense), net.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash to the extent recorded on the balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s financial instruments, in addition to those presented in Note 3 &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, include cash equivalents, accounts payable and accrued liabilities. The carrying amount of cash equivalents, accounts payable and accrued liabilities approximate their fair values due to their short maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1&#x2014;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company leases a facility with a non-cancelable lease term of 30 months. The term of the lease includes a renewal option at the election of the Company to extend the lease for an additional term. The renewal option has not been considered in the determination of the right-of-use, or ROU, asset or lease liability as the Company did not consider it reasonably certain it would exercise this option.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determines if an arrangement is or contains a lease at inception. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. The classification of the Company&#x2019;s leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. The Company uses its incremental borrowing rate, based on the information available at commencement date, to determine the present value of lease payments when its leases do not provide an implicit rate. The Company uses the implicit rate when readily determinable. The ROU asset is based on the measurement of the lease liability, includes any lease payments made prior to or on lease &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;commencement and excludes lease incentives and initial direct costs incurred, as applicable. Lease expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term. The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s lease agreement includes lease and non-lease components and the Company has elected to not separate such components. Further, the Company elected the short-term lease exception policy, permitting it to not apply the recognition requirements of this standard to leases with terms of 12 months or less (short-term leases) for all classes of assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Preclinical and Clinical Accruals and Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical studies, clinical trials and contract manufacturing activities. These costs are a significant component of the Company&#x2019;s research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. For the three months ended March 31, 2020 and 2019, the Company has not experienced any material differences between accrued costs and actual costs incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prior to its IPO, the Company classified its outstanding convertible preferred stock outside of stockholders&#x2019; equity (deficit) on its balance sheets as the requirements of triggering a deemed liquidation event, as defined within its amended and restated certificate of incorporation, were not entirely within the Company&#x2019;s control. In the event of such a deemed liquidation event, the proceeds from the event were to be distributed in accordance with the liquidation preferences, provided that the holders of convertible preferred stock had not converted their shares into common stock. The Company recorded the issuance of convertible preferred stock at the issuance price less related issuance costs. The Company did not adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because of the uncertainty as to whether or when a deemed liquidation event may have occurred.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the IPO in January 2020, the Company&#x2019;s outstanding shares of convertible preferred stock were automatically converted into 24,385,388 shares of common stock.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research and Development &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, license fees, stock-based compensation expense, materials, supplies, and the cost of services provided by outside contractors. All costs associated with research and development are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are rendered. Such payments are evaluated for current or long-term classification based on when they will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has entered into and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date none of the Company&#x2019;s license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense when paid or become payable, provided there is no alternative future use of the rights in other research and development projects.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for share-based payments at fair value. The fair value of stock options is measured using the Black-Scholes option-pricing model. For share-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date for such awards is the date of grant and the expense is recognized on a straight-line basis, over the expected vesting period. For share-based awards that vest subject to a performance condition, the Company will recognize compensation cost for awards if and when the Company concludes that it is probable that the awards with a performance condition will be achieved on an accelerated attribution method. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company records a valuation allowance to reduce deferred tax assets to an amount for which realization is more likely than not. Due to the Company&#x2019;s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties incurred in relation to the unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) was enacted by the United States Congress on March 27, 2020. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the U.S. economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act includes modifications to the limitations on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. The Company does not expect the CARES Act to have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company reviews agreements it enters into with third-party entities, pursuant to which the Company may have a variable interest in the entity, in order to determine if the entity is a variable interest entity, or VIE. If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that entity. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. If the Company determines it is the primary beneficiary of a VIE, it consolidates that VIE into the Company&#x2019;s financial statements. The Company&#x2019;s determination about whether it should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation or deconsolidation event. The Company currently does not consolidate any VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share since the effects of potentially dilutive securities are antidilutive. Shares of common stock subject to repurchase are excluded from the weighted-average shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In August 2018, the FASB issued ASU No. 2018-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; or ASU No. 2018-13, which removes, modifies, and adds various disclosure requirements on fair value measurements in Topic 820.&#160;ASU No. 2018-13&#160;is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company adopted this standard as of January 1, 2020, and it did not have a material impact on its condensed financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In June&#160;2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Financial Instruments&#x2014;Credit Losses&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;(Topic&#160;326): Measurement of Credit Losses on Financial Instruments,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; or ASU No. 2016-13&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; This update requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations now include forward-looking information in the determination of their credit loss estimates. Many of the previous loss estimation techniques are still permitted, although the inputs to those techniques have changed to reflect the full amount of expected credit losses. In addition, this update amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration.  The Company adopted this standard as of January 1, 2020, and it did not have a material impact on its condensed financial statements.  There was no impact on the Company's condensed financial statements from credit losses for the three months ended March 31, 2020.  &lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In December 2019, the FASB issued ASU No. 2019-12&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;, Income Taxes (Topic 740)&lt;/span&gt; which amends the existing guidance relating to the accounting for income taxes. This standard is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. The standard is effective for public business entities for fiscal years beginning after December 15, 2020, and interim periods therein. Early adoption is permitted. An entity that elects early adoption in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, an entity that elects early adoption should adopt all the amendments in the same period. The Company early adopted this guidance as of January 1, 2020, and it did not have a material impact on its condensed financial statements.</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzODk3MjU_0f9a7ebf-30b7-44c9-8e2f-bb8829638c72">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s condensed financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NDk_6a88b518-6830-4ec4-a0d9-f028e4cfd48d">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements and accompanying notes. On an ongoing basis, management evaluates such estimates and assumptions for continued reasonableness. In particular, management makes estimates with respect to accruals for research and development activities, fair value of common stock and convertible preferred stock (prior to the IPO completed in January 2020), stock-based compensation expense and income taxes. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzU0OTc1NTgxNzkzNjA_219bd832-0039-46a8-9a52-463b323602ea">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;To date, the Company has viewed its financial information on an aggregate basis for the purposes of evaluating financial performance and allocating the Company&#x2019;s resources. Accordingly, the Company has determined that it operates in one segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzE2NDkyNjc0NzYzMjI_2256f6d2-96ce-46f7-bcb4-7cbef7a03a1a"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <arqt:UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NTE_f07e284f-2da3-4a81-8c44-931dbe6564f6">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Unaudited Interim Condensed Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The interim condensed balance sheet as of March&#160;31, 2020, the interim condensed statements of operations and comprehensive loss, the condensed changes in convertible preferred stock and stockholders&#x2019; equity (deficit) and cash flows for the three months ended March&#160;31, 2020 and 2019 are unaudited. These unaudited interim condensed financial statements have been prepared on the same basis as the Company&#x2019;s audited annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair statement of the Company&#x2019;s financial information. The financial data and the other financial information disclosed in these notes to the condensed financial statements related to the three-month periods are also unaudited. The condensed results of operations for the three months ended March&#160;31, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other future annual or interim period. The condensed balance sheet as of December 31, 2019 included herein was derived from the audited financial statements as of that date. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Therefore, these unaudited interim condensed financial statements should be read in conjunction with the Company&#x2019;s audited financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;</arqt:UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NTI_ecd8f69c-ba5a-4128-a16f-b1afeb11afa7">Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of money market funds, commercial paper, and government securities.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NTQ_59ebf8af-efd6-466c-a603-cd30ddcb9ce5">&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities consist of investment grade short to intermediate-term fixed income investments that have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase are classified as current based on their availability for use in current operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses as well as credit losses, if any, on marketable securities are included in other income (expense), net. The Company evaluated the underlying credit quality and credit ratings of &lt;/span&gt;&lt;/div&gt;the issuers during the period. To date, no such credit losses have occurred or have been recorded. The cost of investments sold is based on the specific-identification method.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzOTA4OTE_b85a3a4f-202a-401e-95cb-eb8ad6035cdd"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzMyOTg1MzQ5MjU0MTY_b406ca4e-1273-4936-80a8-1a4af37fec36"
      unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjcwMDY_fe4bb018-8f69-4b9a-b720-a6b0464ffeab"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzM0OTQ_40edad0a-c368-4f7a-8ccc-0e56fa63a6cc"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzM0OTQ_bcc1f679-56c7-4b28-a793-573e09552d42"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzODk3MjI_61563708-07a7-4197-9499-5e56b405ea32">&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash to the extent recorded on the balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NTY_3484a2da-6492-42fd-b605-be53bbaae396">&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s financial instruments, in addition to those presented in Note 3 &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, include cash equivalents, accounts payable and accrued liabilities. The carrying amount of cash equivalents, accounts payable and accrued liabilities approximate their fair values due to their short maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1&#x2014;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NTc_141a4c64-d261-4678-b545-0bddf5444e52">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company leases a facility with a non-cancelable lease term of 30 months. The term of the lease includes a renewal option at the election of the Company to extend the lease for an additional term. The renewal option has not been considered in the determination of the right-of-use, or ROU, asset or lease liability as the Company did not consider it reasonably certain it would exercise this option.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determines if an arrangement is or contains a lease at inception. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. The classification of the Company&#x2019;s leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. The Company uses its incremental borrowing rate, based on the information available at commencement date, to determine the present value of lease payments when its leases do not provide an implicit rate. The Company uses the implicit rate when readily determinable. The ROU asset is based on the measurement of the lease liability, includes any lease payments made prior to or on lease &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;commencement and excludes lease incentives and initial direct costs incurred, as applicable. Lease expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term. The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s lease agreement includes lease and non-lease components and the Company has elected to not separate such components. Further, the Company elected the short-term lease exception policy, permitting it to not apply the recognition requirements of this standard to leases with terms of 12 months or less (short-term leases) for all classes of assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjY5MjE_235a1df2-85ea-4a9d-adf5-7668f7bed6ae">P30M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arqt:PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjY5MDY_fc8a0bde-24de-40e4-b7a9-5500c70a25f6">Preclinical and Clinical Accruals and CostsThe Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical studies, clinical trials and contract manufacturing activities. These costs are a significant component of the Company&#x2019;s research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities.</arqt:PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NTk_9730c5b3-334f-4383-a9e5-97dcf32336c2">Convertible Preferred StockPrior to its IPO, the Company classified its outstanding convertible preferred stock outside of stockholders&#x2019; equity (deficit) on its balance sheets as the requirements of triggering a deemed liquidation event, as defined within its amended and restated certificate of incorporation, were not entirely within the Company&#x2019;s control. In the event of such a deemed liquidation event, the proceeds from the event were to be distributed in accordance with the liquidation preferences, provided that the holders of convertible preferred stock had not converted their shares into common stock. The Company recorded the issuance of convertible preferred stock at the issuance price less related issuance costs. The Company did not adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because of the uncertainty as to whether or when a deemed liquidation event may have occurred.</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i1a9f8349a2ae4825872a95b128a3bfb7_D20200101-20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzE2NDkyNjc0ODM2ODk_7f17467e-91a6-4300-aa63-eefb4dd012e8"
      unitRef="shares">24385388</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NjA_91eacd73-34eb-4a3d-93a1-7c80dba40b81">&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research and Development &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, license fees, stock-based compensation expense, materials, supplies, and the cost of services provided by outside contractors. All costs associated with research and development are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are rendered. Such payments are evaluated for current or long-term classification based on when they will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has entered into and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date none of the Company&#x2019;s license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense when paid or become payable, provided there is no alternative future use of the rights in other research and development projects.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NjE_cd33255b-e58a-4c8f-a995-a21a36f02cf5">Stock-Based Compensation The Company accounts for share-based payments at fair value. The fair value of stock options is measured using the Black-Scholes option-pricing model. For share-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date for such awards is the date of grant and the expense is recognized on a straight-line basis, over the expected vesting period. For share-based awards that vest subject to a performance condition, the Company will recognize compensation cost for awards if and when the Company concludes that it is probable that the awards with a performance condition will be achieved on an accelerated attribution method. The Company accounts for forfeitures as they occur.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzU0OTc1NTgyMTQ4MjM_ed25ae2b-acca-4510-b010-1f127fa7e212">&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company records a valuation allowance to reduce deferred tax assets to an amount for which realization is more likely than not. Due to the Company&#x2019;s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties incurred in relation to the unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) was enacted by the United States Congress on March 27, 2020. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the U.S. economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act includes modifications to the limitations on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. The Company does not expect the CARES Act to have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NjQ_f7458e52-5273-457f-8452-a91e9c0e2e82">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company reviews agreements it enters into with third-party entities, pursuant to which the Company may have a variable interest in the entity, in order to determine if the entity is a variable interest entity, or VIE. If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that entity. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. If the Company determines it is the primary beneficiary of a VIE, it consolidates that VIE into the Company&#x2019;s financial statements. The Company&#x2019;s determination about whether it should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation or deconsolidation event. The Company currently does not consolidate any VIEs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzNjU0NjU_eafdba0f-e285-49e8-861e-cb8b6c2ceef1">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share since the effects of potentially dilutive securities are antidilutive. Shares of common stock subject to repurchase are excluded from the weighted-average shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <arqt:EmergingGrowthCompanyStatusPolicyTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzODk3MjM_d7af14ac-1c5c-4ecd-83bd-06256c77626d">&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;/div&gt;</arqt:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xMzkvZnJhZzoyMzljN2M2YzBiZmI0OTU4YTFmYTM0ODUxZTM3Zjc0NC90ZXh0cmVnaW9uOjIzOWM3YzZjMGJmYjQ5NThhMWZhMzQ4NTFlMzdmNzQ0XzQ5NDc4MDIzODk3MjQ_afde1f12-a88f-400d-aa50-af7490ec35a4">&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In August 2018, the FASB issued ASU No. 2018-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; or ASU No. 2018-13, which removes, modifies, and adds various disclosure requirements on fair value measurements in Topic 820.&#160;ASU No. 2018-13&#160;is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company adopted this standard as of January 1, 2020, and it did not have a material impact on its condensed financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In June&#160;2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Financial Instruments&#x2014;Credit Losses&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;(Topic&#160;326): Measurement of Credit Losses on Financial Instruments,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; or ASU No. 2016-13&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; This update requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations now include forward-looking information in the determination of their credit loss estimates. Many of the previous loss estimation techniques are still permitted, although the inputs to those techniques have changed to reflect the full amount of expected credit losses. In addition, this update amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration.  The Company adopted this standard as of January 1, 2020, and it did not have a material impact on its condensed financial statements.  There was no impact on the Company's condensed financial statements from credit losses for the three months ended March 31, 2020.  &lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In December 2019, the FASB issued ASU No. 2019-12&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;, Income Taxes (Topic 740)&lt;/span&gt; which amends the existing guidance relating to the accounting for income taxes. This standard is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. The standard is effective for public business entities for fiscal years beginning after December 15, 2020, and interim periods therein. Early adoption is permitted. An entity that elects early adoption in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, an entity that elects early adoption should adopt all the amendments in the same period. The Company early adopted this guidance as of January 1, 2020, and it did not have a material impact on its condensed financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90ZXh0cmVnaW9uOjJlYjk3YzZhNTBlNjQ5OWM4NTU1ZGNmYTY2YjRlYTY3XzQ5NDc4MDIzMzE0NzY_14629b79-90ff-4b9b-aa97-ce4201e19f3b">Fair Value Measurements  The following table sets forth the Company&#x2019;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.951%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.714%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Money market funds(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;195,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;249,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.951%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.714%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Money market funds(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;101,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;______________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt;"&gt;This balance includes cash requirements settled on a nightly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Commercial paper, money market funds and government securities are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs. There were no transfers between Levels&#160;1, 2 or 3 for any of the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the estimated value of the Company&#x2019;s cash, cash equivalents and marketable securities and the gross unrealized holding gains and losses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.951%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.714%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;______________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt;"&gt;This balance includes cash requirements settled on a nightly basis.&lt;/span&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.461%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;There were no realized gains or losses on investments for the three months ended March 31, 2020 and 2019.  As of March&#160;31, 2020 and December&#160;31, 2019, unrealized losses on marketable securities were not material, and accordingly, no allowance for credit losses was recorded as of March 31, 2020.  As of March&#160;31, 2020 and December&#160;31, 2019, all securities have a maturity of one year or less and all securities with gross unrealized losses have been in continuous loss position for less than twelve months.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90ZXh0cmVnaW9uOjJlYjk3YzZhNTBlNjQ5OWM4NTU1ZGNmYTY2YjRlYTY3XzQ5NDc4MDIzMzE0Nzc_aa0b158f-35cc-4273-9ad8-f88305720b7c">The following table sets forth the Company&#x2019;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.951%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.714%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Money market funds(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;195,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;249,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.951%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.714%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Money market funds(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;101,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;______________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt;"&gt;This balance includes cash requirements settled on a nightly basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9f576810c09241ed87b2a09e63227467_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzMtMS0xLTEtMA_0f2efead-619a-436e-9404-5bc7c45d76b2"
      unitRef="usd">190893000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i414921aba8984cb389a45a1e86d315ae_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzMtMy0xLTEtMA_fdfb3e57-0088-4c0a-b9d1-3b3c42c5ef25"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibec66f62c1084ad691104a439aff6c7e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzMtNS0xLTEtMA_419ddc65-1cc8-4831-be3e-7854274f9747"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i270ae80ae8b042ce9201e7cc23f7ee58_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzMtNy0xLTEtMA_0b490f87-b4a2-4fc8-b77a-53fc413a632f"
      unitRef="usd">190893000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
      contextRef="i2c8b8d5bfcec459fa278a039725bb9d9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzQtMS0xLTEtMA_57de9e28-b027-488a-a893-2d2c5cb7e6cb"
      unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
      contextRef="i9c16b74ba53841fda7d28ab193530c1c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzQtMy0xLTEtMA_7751fc94-c6df-49df-9a8d-25f508500d99"
      unitRef="usd">53396000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
      contextRef="i543cf22b19c54a4a8b70297fbbf4dcce_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzQtNS0xLTEtMA_5d2ed59a-ce34-46a2-949e-4bbffb98f9d2"
      unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
      contextRef="ifff112eac82649f6b53d94ba1b504889_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzQtNy0xLTEtMA_ccdbee81-d68b-4a41-b659-dd46d3a90ff5"
      unitRef="usd">53396000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
      contextRef="ife0a9b0f7f7b4864aebd29e91d92b75e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzUtMS0xLTEtMA_212d82ee-35b7-4d5f-83a4-d41497521094"
      unitRef="usd">5030000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
      contextRef="i6b5c3e06ddd5402c951cce1ad44ad6a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzUtMy0xLTEtMA_fd5a3d60-1f58-4b1c-8c3d-4f32e6fce020"
      unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
      contextRef="ic43770461fb141d1a3a708ae92c38e75_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzUtNS0xLTEtMA_2a05a750-ffc9-4470-8099-96bf09bad9cb"
      unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
      contextRef="i03cc7f0a6da847ba8562f6f1fa69ad0f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzUtNy0xLTEtMA_a7ba78d5-63fa-4fb9-8539-a719b0b03a84"
      unitRef="usd">5030000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic253eb34e85e4ebebda2388a08544c3e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzYtMS0xLTEtMA_4a34b08a-f481-48dd-afda-97cd18a807dc"
      unitRef="usd">195923000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id45d766b5bb440b8923015575e77b394_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzYtMy0xLTEtMA_fc626ba8-e72b-4f0b-ae11-b21993f9760f"
      unitRef="usd">53396000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i373b85f92fe343ac855524ea8acaff14_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzYtNS0xLTEtMA_0887dcdf-cf45-4130-a015-bfa6e681eb29"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZToxMWVjNWQ5YWVmMzg0NGNhYjQ5MjJlYzk5YjIwMTkxNi90YWJsZXJhbmdlOjExZWM1ZDlhZWYzODQ0Y2FiNDkyMmVjOTliMjAxOTE2XzYtNy0xLTEtMA_afc0c914-5f64-42ed-88e7-d854c0c88bf2"
      unitRef="usd">249319000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iae9ee5c735cf46908b0fabb85992ffc9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzMtMS0xLTEtMjY4_60a04c03-970c-4a42-b22b-f28d8f2d5928"
      unitRef="usd">43558000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0a1e096ff7d341be8c45b814509791ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzMtMy0xLTEtMjY4_5d08cc90-e294-4999-957b-8fcb0410a8a7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8c56f67dfa884523897775d41e68872d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzMtNS0xLTEtMjY4_e3d951c8-d6ed-428f-bf24-09bf3f2b303f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0e5b4edc8170451689fbada6c48b86ed_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzMtNy0xLTEtMjY4_77af00d9-47d6-434f-82be-6ba1c3c5a405"
      unitRef="usd">43558000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
      contextRef="ic86821562d79485eacbc135601a1eb43_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzQtMS0xLTEtMjY4_5b555d74-65ee-4ebc-9753-0ac848a01da3"
      unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
      contextRef="i5950ca979d8342e2995ee8e69c309187_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzQtMy0xLTEtMjY4_28c61355-1a26-45a7-9007-f15e42a6e81d"
      unitRef="usd">44689000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
      contextRef="ib206c2db943b4ae485f8d863d2ee1318_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzQtNS0xLTEtMjY4_01c4a3c9-1873-4707-951a-2969b722b3cf"
      unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
      contextRef="i0e5368a4e5b94d8cbc7278e0fef5cad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzQtNy0xLTEtMjY4_ef84b19e-c111-45dd-ae73-d7f8edfd8149"
      unitRef="usd">44689000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
      contextRef="iafb6adcdf1a44ac9987418eaf92a8522_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzUtMS0xLTEtMjY4_4091db1f-80a5-4d3c-ad6e-c12f1aa2aa07"
      unitRef="usd">13018000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
      contextRef="i0181ffefb7fd484bacde0b9b979a5d5b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzUtMy0xLTEtMjY4_cc033639-07bf-4702-aa23-f5e3b3b534dc"
      unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
      contextRef="ib465f2fbb252499b9bc7fb53a1bf2efe_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzUtNS0xLTEtMjY4_7ad57aaf-6dc4-4c33-97a2-438ca4139338"
      unitRef="usd">0</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure
      contextRef="i97d79ac716284e1a9866aca1e609b683_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzUtNy0xLTEtMjY4_33394c6e-3e99-4f9c-9744-6313679d8387"
      unitRef="usd">13018000</arqt:CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i45c31d7adba348da80a2ab2d537cf9e2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzYtMS0xLTEtMjIwNQ_a0fa957d-63b8-445b-95a8-40557e3b8fcb"
      unitRef="usd">56576000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i04008b35dd9c4edaa1167973c3f9f16a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzYtMy0xLTEtMjIwNQ_3eccd811-3c69-4996-b3a2-1a841fad4a8e"
      unitRef="usd">44689000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if9d55de80fa540a5b40168170c29f746_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzYtNS0xLTEtMjIwNQ_2176cf47-87ec-4fc6-ba9a-d325817f5c37"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo5Y2RjYTk5MDZlYjM0N2NlYTNmYzE3ZTA0ZGNjZDliOC90YWJsZXJhbmdlOjljZGNhOTkwNmViMzQ3Y2VhM2ZjMTdlMDRkY2NkOWI4XzYtNy0xLTEtMjIwNQ_e9ac3541-7d72-45cf-9034-50d3b3c7831d"
      unitRef="usd">101265000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90ZXh0cmVnaW9uOjJlYjk3YzZhNTBlNjQ5OWM4NTU1ZGNmYTY2YjRlYTY3XzU0OTc1NTgxNDY1MDA_367957dd-33e0-45c2-91ac-5507a16a1dd0">&lt;div style="text-indent:36pt;margin-top:12pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the estimated value of the Company&#x2019;s cash, cash equivalents and marketable securities and the gross unrealized holding gains and losses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.951%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.714%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;______________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt;"&gt;This balance includes cash requirements settled on a nightly basis.&lt;/span&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.461%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90ZXh0cmVnaW9uOjJlYjk3YzZhNTBlNjQ5OWM4NTU1ZGNmYTY2YjRlYTY3XzU0OTc1NTgxNDY1MDA_fcd64f18-f699-463d-8c22-36c6df06da58">&lt;div style="text-indent:36pt;margin-top:12pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the estimated value of the Company&#x2019;s cash, cash equivalents and marketable securities and the gross unrealized holding gains and losses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.951%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.714%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;______________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt;"&gt;This balance includes cash requirements settled on a nightly basis.&lt;/span&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.461%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i270ae80ae8b042ce9201e7cc23f7ee58_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzQtMS0xLTEtMA_753b9dec-b94b-4da9-88dd-fd26afcd3075"
      unitRef="usd">190893000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i270ae80ae8b042ce9201e7cc23f7ee58_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzQtNy0xLTEtMA_7a21f1fe-bd87-4309-9ef7-86d61f82a01e"
      unitRef="usd">190893000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzYtMS0xLTEtMA_95dc99b2-cf3d-4ce1-b013-3777850325a2"
      unitRef="usd">190893000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzYtNy0xLTEtMA_275e64f5-e73a-45d1-ae81-74d23d4d7266"
      unitRef="usd">190893000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifff112eac82649f6b53d94ba1b504889_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzgtMS0xLTEtMA_4d17ea91-bc77-4f27-86de-85a6b68ceb1b"
      unitRef="usd">53396000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifff112eac82649f6b53d94ba1b504889_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzgtMy0xLTEtMA_b20a035f-a7bf-44ab-9342-16d46e32d42d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifff112eac82649f6b53d94ba1b504889_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzgtNS0xLTEtMA_2831aa4e-7809-413f-9d73-9f0ad147f5d1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifff112eac82649f6b53d94ba1b504889_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzgtNy0xLTEtMA_99413052-7a3b-4a8a-8296-1ea03e79d60a"
      unitRef="usd">53396000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i03cc7f0a6da847ba8562f6f1fa69ad0f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzktMS0xLTEtMA_b55b6b06-4dd8-4c47-94af-646fd5ee04ca"
      unitRef="usd">5011000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i03cc7f0a6da847ba8562f6f1fa69ad0f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzktMy0xLTEtMA_5d3c8f9b-05c2-4e47-a58b-f769d260e4fc"
      unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i03cc7f0a6da847ba8562f6f1fa69ad0f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzktNS0xLTEtMA_8b693387-47be-48af-ba01-98be1f10ba98"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i03cc7f0a6da847ba8562f6f1fa69ad0f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzktNy0xLTEtMA_893b4dd1-94b1-4f54-bc48-16cc13310e11"
      unitRef="usd">5030000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzEwLTEtMS0xLTA_154aef5d-bf1b-4212-94d1-14dd89e9f125"
      unitRef="usd">58407000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzEwLTMtMS0xLTA_6c131409-50a0-4522-a682-33661670bf66"
      unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzEwLTUtMS0xLTA_afe54542-bad9-4c72-b2a8-d9e7aac3b854"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0ODY5ODQ0NzIxOWE0YWUxYjkyZmVlYWQ5NzRkYzE2ZS90YWJsZXJhbmdlOjQ4Njk4NDQ3MjE5YTRhZTFiOTJmZWVhZDk3NGRjMTZlXzEwLTctMS0xLTA_8dad1662-9f11-46dd-9519-1bab08eb9a59"
      unitRef="usd">58426000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifb249010b3884d319f1f8408c75f9f32_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzMtMS0xLTEtMA_baf445ce-62c2-4971-a3c0-5a3f11f975ff"
      unitRef="usd">11780000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifb249010b3884d319f1f8408c75f9f32_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzMtNy0xLTEtMA_ea337664-e337-4a14-830a-0042e0440692"
      unitRef="usd">11780000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0e5b4edc8170451689fbada6c48b86ed_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzQtMS0xLTEtMA_d015f3c3-4bae-4eb6-a214-95db72cec572"
      unitRef="usd">43558000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0e5b4edc8170451689fbada6c48b86ed_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzQtNy0xLTEtMA_5f0bb22f-7af6-43ab-94f4-6d5a20885509"
      unitRef="usd">43558000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5360332e67b7489285d42523d9c524f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzUtMS0xLTEtMA_e019a980-df2e-4b30-8b34-73197c9eae08"
      unitRef="usd">7998000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5360332e67b7489285d42523d9c524f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzUtNy0xLTEtMA_ba69eac4-90a8-42bd-88ef-01c6cf1f12e7"
      unitRef="usd">7998000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzYtMS0xLTEtMA_ceec2b09-8920-48fd-a0e4-c518eb6000a5"
      unitRef="usd">63336000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzYtNy0xLTEtMA_be355ae5-e32b-4ddc-9bbd-7ba77d9a3fca"
      unitRef="usd">63336000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0e5368a4e5b94d8cbc7278e0fef5cad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzgtMS0xLTEtMA_8dc61d3a-e40d-4bb2-ae63-2fe6e56f59fd"
      unitRef="usd">32909000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0e5368a4e5b94d8cbc7278e0fef5cad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzgtMy0xLTEtMA_bf797245-3a1a-4990-b2dc-75b5afbbda7d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0e5368a4e5b94d8cbc7278e0fef5cad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzgtNS0xLTEtMA_3872fa3b-bf34-44bd-9e14-471252acdba5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0e5368a4e5b94d8cbc7278e0fef5cad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzgtNy0xLTEtMA_76a6c863-3265-4ab2-a5d6-b6a5b4a3d814"
      unitRef="usd">32909000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i97d79ac716284e1a9866aca1e609b683_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzktMS0xLTEtMjc4_63213de2-830f-4c92-96b6-d1db7befdfed"
      unitRef="usd">5021000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i97d79ac716284e1a9866aca1e609b683_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzktMy0xLTEtMjc4_1c19a3cd-9d3d-4b04-8bbe-f905b3e7c863"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i97d79ac716284e1a9866aca1e609b683_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzktNS0xLTEtMjc4_ef79e98b-dc89-412f-9d0a-9a917e450ef8"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i97d79ac716284e1a9866aca1e609b683_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzktNy0xLTEtMjc4_12e7d4bb-6662-441f-926d-5e4992b8862b"
      unitRef="usd">5020000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzktMS0xLTEtMA_caaf9f7f-0c9d-4c52-9da8-c7387175c6f0"
      unitRef="usd">37930000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzktMy0xLTEtMA_5478cd4b-ef4b-415e-ad02-2a293f967adf"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzktNS0xLTEtMA_e175ea45-002b-4bca-a280-81417e5c2700"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90YWJsZTo0MzllOGIyNGUyNjI0Nzc3YWEyNzFhZmU4ZTEzNzk2Yi90YWJsZXJhbmdlOjQzOWU4YjI0ZTI2MjQ3NzdhYTI3MWFmZThlMTM3OTZiXzktNy0xLTEtMA_da8c2859-52c1-481f-938f-b6a690a217ba"
      unitRef="usd">37929000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90ZXh0cmVnaW9uOjJlYjk3YzZhNTBlNjQ5OWM4NTU1ZGNmYTY2YjRlYTY3XzI3NDg3NzkwNzYzMTk_40edad0a-c368-4f7a-8ccc-0e56fa63a6cc"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNDUvZnJhZzoyZWI5N2M2YTUwZTY0OTljODU1NWRjZmE2NmI0ZWE2Ny90ZXh0cmVnaW9uOjJlYjk3YzZhNTBlNjQ5OWM4NTU1ZGNmYTY2YjRlYTY3XzI3NDg3NzkwNzYzMTk_bcc1f679-56c7-4b28-a793-573e09552d42"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90ZXh0cmVnaW9uOjdkNTkzMjM1NzQxZjQyMTc4ZGY4NmUwMDE4MGUwYTAxXzQ5NDc4MDIzMjUyMzQ_5345e280-28b2-4971-8f00-985a57b3f5d3">Balance Sheet Components&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.877%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.698%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other prepaid expenses and current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.877%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.698%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Clinical trial accruals&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Early exercise liability, current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90ZXh0cmVnaW9uOjdkNTkzMjM1NzQxZjQyMTc4ZGY4NmUwMDE4MGUwYTAxXzQ5NDc4MDIzMjUyMzU_548b90fe-6a18-4a27-b726-b9bf44fc011c">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.877%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.698%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other prepaid expenses and current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzItMS0xLTEtNzIyMg_75f9d375-bcd2-4b65-aed4-35b003efc7de"
      unitRef="usd">2326000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzItMy0xLTEtNzIyMg_a61a909b-0720-4aa7-9349-70f7d0902eb3"
      unitRef="usd">62000</us-gaap:PrepaidInsurance>
    <arqt:PrepaidClinicalTrialTestCostsCurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzItMS0xLTEtMA_702ec3a0-ea7c-4499-8d7c-fbdb75e7844e"
      unitRef="usd">1583000</arqt:PrepaidClinicalTrialTestCostsCurrent>
    <arqt:PrepaidClinicalTrialTestCostsCurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzItMy0xLTEtMA_17b887fe-fda7-4961-b7e3-38787eff330b"
      unitRef="usd">2998000</arqt:PrepaidClinicalTrialTestCostsCurrent>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzMtMS0xLTEtMA_a002d181-a52e-4c6d-bec9-7d51ebd419ea"
      unitRef="usd">0</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzMtMy0xLTEtMA_e86af3da-bdad-4bf2-9b39-78b298fa13bf"
      unitRef="usd">1747000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzQtMS0xLTEtMA_81fa4015-35cd-41d5-b66d-cba0b9df516f"
      unitRef="usd">650000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzQtMy0xLTEtMA_1048c16a-12f4-4c7f-a2ba-a38b6909ffd4"
      unitRef="usd">402000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzUtMS0xLTEtMA_9ae41441-754a-4e46-997b-726e7aeebb59"
      unitRef="usd">4559000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNzE4ZjMwNWZmNmE0NWY1OWY1MDU3NTlmYWM4MDBjNi90YWJsZXJhbmdlOjE3MThmMzA1ZmY2YTQ1ZjU5ZjUwNTc1OWZhYzgwMGM2XzUtMy0xLTEtMA_4844bcc8-b482-40a0-a3f8-0688fd5ab642"
      unitRef="usd">5209000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90ZXh0cmVnaW9uOjdkNTkzMjM1NzQxZjQyMTc4ZGY4NmUwMDE4MGUwYTAxXzQ5NDc4MDIzMjUyMzY_bb90b086-b7c0-410f-8839-307dc2cf9d67">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.877%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.698%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Clinical trial accruals&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Early exercise liability, current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <arqt:ClinicalTrialAccrualCurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzItMS0xLTEtMA_866aa505-9793-41a4-a851-b5b44b290f1f"
      unitRef="usd">6114000</arqt:ClinicalTrialAccrualCurrent>
    <arqt:ClinicalTrialAccrualCurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzItMy0xLTEtMA_36ac50f5-bc0f-44f2-84f4-c8937a715a9e"
      unitRef="usd">1497000</arqt:ClinicalTrialAccrualCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzMtMS0xLTEtMA_b6274621-c12b-463c-b49d-42d09d4f3827"
      unitRef="usd">806000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzMtMy0xLTEtMA_26d71977-60bd-4048-a0b5-2b79365880d0"
      unitRef="usd">1379000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzQtMS0xLTEtMA_cbd570af-2827-4ecb-8040-a55d90ab03d9"
      unitRef="usd">269000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzQtMy0xLTEtMA_9703c64c-ec4a-44f9-9132-382e062caa15"
      unitRef="usd">225000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzUtMS0xLTEtMA_95d587a9-fd59-4e54-b8d0-df8ad5402eb2"
      unitRef="usd">92000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzUtMy0xLTEtMA_3190544f-c4fe-4042-b792-08de90beff8e"
      unitRef="usd">553000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzYtMS0xLTEtMA_498cc8d0-751e-4a2b-ad69-d0bba50f71bf"
      unitRef="usd">7281000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTEvZnJhZzo3ZDU5MzIzNTc0MWY0MjE3OGRmODZlMDAxODBlMGEwMS90YWJsZToxNDc4NWI5YWZlOWQ0Y2JiODM0MWMwMTQ3MmRlNzM2My90YWJsZXJhbmdlOjE0Nzg1YjlhZmU5ZDRjYmI4MzQxYzAxNDcyZGU3MzYzXzYtMy0xLTEtMA_3b463d8c-487b-43c9-a07e-e65a0e3f4a90"
      unitRef="usd">3654000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzcxNDY4MjU1ODg3MzA_eded83a9-fe3e-437f-bbe7-0ddbcd6c7307">License Agreements&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;AstraZeneca License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In July 2018, the Company entered into an exclusive license agreement, or the AstraZeneca License Agreement, with AstraZeneca AB, or AstraZeneca, granting the Company a worldwide exclusive license, with the right to sublicense through multiple tiers, under certain AstraZeneca-controlled patent rights, know-how and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;regulatory documentation, to research, develop, manufacture, commercialize and otherwise exploit products containing roflumilast in topical forms, as well as delivery systems sold with or for the administration of roflumilast, or collectively, the AZ-Licensed Products, for all diagnostic, prophylactic and therapeutic uses for human dermatological indications, or the Dermatology Field. Under this agreement, the Company has sole responsibility for development, regulatory, and commercialization activities for the AZ-Licensed Products in the Dermatology Field, at its expense, and it shall use commercially reasonable efforts to develop, obtain and maintain regulatory approvals for, and commercialize the AZ-Licensed Products in the Dermatology Field in each of the United States, Italy, Spain, Germany, the United Kingdom, France, China, and Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company paid AstraZeneca an upfront non-refundable cash payment of $1.0 million and issued 484,388 shares of Series&#160;B preferred stock, valued at $3.0 million on the date of the AstraZeneca License Agreement. The company subsequently paid AstraZeneca the first milestone cash payment of $2.0&#160;million upon the completion of a Phase 2b study of topical roflumilast cream (ARQ-151) in plaque psoriasis in August 2019 for the achievement of positive Phase 2 data for an AZ-licensed Product, which was recorded in research and development expense.  The Company has agreed to make additional cash payments to AstraZeneca of up to an aggregate of $12.5 million upon the achievement of specified regulatory approval milestones with respect to the AZ-Licensed Products and payments up to an additional aggregate amount of $15.0 million upon the achievement of certain aggregate worldwide net sales milestones. With respect to any AZ-Licensed Products the Company commercializes under the AstraZeneca License Agreement, it will pay AstraZeneca a low to high single-digit percentage royalty rate on the Company&#x2019;s, its affiliates&#x2019; and its sublicensees&#x2019; net sales of such AZ-Licensed Products, subject to specified reductions, until, as determined on an AZ-Licensed Product-by-AZ-Licensed Product and country-by-country basis, the later of the date of the expiration of the last-to-expire AstraZeneca-licensed patent right containing a valid claim in such country and ten years from the first commercial sale of such AZ-Licensed Product in such country. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;There were no payments made or due in connection with AZ-licensed Products for the three months ended March 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Hengrui Exclusive Option and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2018, the Company entered into an exclusive option and license agreement, or the Hengrui License Agreement, with Jiangsu Hengrui Medicine Co., Ltd., or Hengrui, whereby Hengrui granted the Company an exclusive option to obtain certain exclusive rights to research, develop and commercialize products containing the compound designated by Hengrui as SHR0302, a JAK 1 inhibitor, in topical formulations for the treatment of skin diseases, disorders, and conditions in the United States, Japan, Canada and the European Union (including for clarity the United Kingdom). The Company made a $0.4 million upfront non-refundable cash payment to Hengrui upon execution of the Hengrui Option and License Agreement which was recorded as research and development expense. In December 2019, the Company exercised its exclusive option under the agreement, for which it made a $1.5&#160;million cash payment, which was recorded in research and development expense, and also contemporaneously amended the agreement to expand the territory to additionally include Canada. In addition, the Company has agreed to make cash payments of up to an aggregate of $20.5 million upon achievement of specified clinical development and regulatory approval milestones with respect to the licensed products and cash payments of up to an additional aggregate of $200 million in sales-based milestones based on certain aggregate annual net sales volumes with respect to a licensed product. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;With respect to any products the Company commercializes under the Hengrui License Agreement, it will pay tiered royalties to Hengrui on net sales of each licensed product by the Company, or its affiliates, or its sublicensees, ranging from mid single-digit to sub-teen percentage rates based on tiered annual net sales bands subject to specified reductions. The Company is obligated to pay royalties until the later of (1)&#160;expiration of the last valid claim of the licensed patent rights covering such licensed product in such country and (2)&#160;expiration of regulatory exclusivity for the relevant licensed product in the relevant country, on a licensed product-by-licensed product and country-by-country basis. Additionally, the Company is obligated to pay Hengrui a specified percentage, ranging from the low-thirties to the sub-teens, of certain non-royalty sublicensing income it receives from sublicensees of its rights to the licensed products, such percentage decreasing as the development stage of the licensed products advance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;There were no payments made or due in connection with Hengrui for the three months ended March 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Hawkeye Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2019, the Company entered into a collaboration agreement, or Hawkeye Agreement, with Hawkeye Therapeutics, Inc., or Hawkeye, a related party with common ownership, for the development of one or more new applications of roflumilast. The Hawkeye Agreement grants Hawkeye an exclusive license to certain intellectual property developed under the agreement as it relates to the applications. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Contemporaneously with the execution of the Hawkeye Agreement, the Company entered into a stock purchase agreement, purchasing 995,000 shares of Hawkeye&#x2019;s common stock at $0.0001 per share, representing 19.9% of the outstanding common stock of Hawkeye.  In the event that Hawkeye issues shares of Series A preferred stock with proceeds over $5.0&#160;million, Hawkeye is required to issue to the Company a number of fully-paid fully-vested shares of common stock determined by dividing (i)&#160;$2,000,000 by (ii)&#160;an amount equal to the cash price per share for Series A preferred stock.  Other than the potential issuance of this common stock, there are no upfront payments, milestones or royalties pursuant to the Hawkeye Agreement. The Company determined that Hawkeye is a variable interest entity for which consolidation is not required as it is not the primary beneficiary.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="i2b7f744e5e864a09ae29d5de55ad4859_D20180701-20180731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzEyOTc_2693b5b3-a556-4a9e-bc23-a232361c5906"
      unitRef="usd">1000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <arqt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="id5df7418441b428c98e1af09b1d8f5f6_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzEzMTE_9c35564a-2da5-4a4c-a7ea-2568af0d47ab"
      unitRef="shares">484388</arqt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="id5df7418441b428c98e1af09b1d8f5f6_D20180701-20180731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzEzNjA_91b395c6-e8d8-4725-ae6a-cd9fbcfb3ddd"
      unitRef="usd">3000000.0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="i64e39f6e0ee9449382ec819a3c86939a_D20190801-20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ5NDc4MDIzMzMxODA_c8f464d7-6a32-40c2-9100-a5d62568635b"
      unitRef="usd">2000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments
      contextRef="iadbd597452bd467786da57f5e4d20c05_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzE4MTY_ceb95fd1-5870-41d2-b339-6e87abac9291"
      unitRef="usd">12500000</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments
      contextRef="iadbd597452bd467786da57f5e4d20c05_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzE5Nzg_0cf453c7-f923-48ae-a5de-34eca82b4c82"
      unitRef="usd">15000000.0</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="i27af3865d5bb4f39839b5fb35d6b8164_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzY1OTcwNjk3NzQ5MTE_62b69ea1-9869-4a28-8c72-8e24933523ef"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="iadbd597452bd467786da57f5e4d20c05_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzY1OTcwNjk3NzQ5MTE_cefc53ee-dac9-43a1-a63f-1f8a8f3cf42c"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="ia9fd3340448d4bc7b2df04030b621bf3_D20180101-20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzM5MDA_b1f27e3f-c033-4be6-9630-5c74013ccdf1"
      unitRef="usd">400000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="i6cb916c47d6d4499899eba1d8e7cc49f_D20191201-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQxNTY_585dafe7-52c4-463f-b219-f5e96381b8bc"
      unitRef="usd">1500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments
      contextRef="i624daddb81734c7dbdc63c375018d9a7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ0MTc_dfa504f3-6ba2-4157-9848-3ce59675292d"
      unitRef="usd">20500000</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments>
    <arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments
      contextRef="i624daddb81734c7dbdc63c375018d9a7_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ1OTg_1d4e14c5-ffed-40e7-aefc-4410d92a8bdd"
      unitRef="usd">200000000</arqt:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="i27af3865d5bb4f39839b5fb35d6b8164_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzIxOTkwMjMyNjQxODg_62b69ea1-9869-4a28-8c72-8e24933523ef"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="iadbd597452bd467786da57f5e4d20c05_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzIxOTkwMjMyNjQxODg_cefc53ee-dac9-43a1-a63f-1f8a8f3cf42c"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <arqt:VariableInterestEntitiesNumberOfSharesHeld
      contextRef="i3d73b12f38b44b0fb374429942edff05_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ5NDc4MDIzMzMyMTA_e839ccf8-ef86-412a-b704-c8709a34f3f8"
      unitRef="shares">995000</arqt:VariableInterestEntitiesNumberOfSharesHeld>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7ba628de89d3418daf6fc6a0e95c1598_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ5NDc4MDIzMzMxOTQ_8f62de8b-4e8b-4ae5-917f-4e36cb973ed9"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="i764c4c795726470f9f77ab82e0e24792_D20190601-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ5NDc4MDIzMzMyMDM_61018faa-c661-4ba7-a5e5-a0aa394689ec"
      unitRef="number">0.199</us-gaap:VariableInterestEntityOwnershipPercentage>
    <arqt:CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration
      contextRef="ic8fd13a77a64486f820343c9c46cc851_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ5NDc4MDIzMzMyMTk_04eb2559-0959-4caf-99b7-d038d2b5a976"
      unitRef="usd">5000000.0</arqt:CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration>
    <arqt:CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration
      contextRef="ic8fd13a77a64486f820343c9c46cc851_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ5NDc4MDIzMzMyMzM_8687c7ba-860d-4133-9291-cb69c93c5523"
      unitRef="usd">2000000</arqt:CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration>
    <arqt:ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties
      contextRef="i0a342eb6a9914eefbcddc6ecd7e9a425_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTQvZnJhZzoyMDk4YWQxM2EyYjU0ZGRiOWNhMzRhNjkzZDk3NDE3OS90ZXh0cmVnaW9uOjIwOThhZDEzYTJiNTRkZGI5Y2EzNGE2OTNkOTc0MTc5XzQ5NDc4MDIzMzMyNDU_6bd45e8b-f177-4db0-840b-59d683ec5b2c"
      unitRef="usd">0</arqt:ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzQ5NDc4MDIzMjc0Mzg_66f6b49f-6ec1-49ab-8eae-354aecb593e1">Commitments and Contingencies&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Operating Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company leases one facility in Westlake Village, California under an operating lease that commenced in February 2019 and has a non-cancelable lease term of 30 months, subject to fixed escalation increases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The minimum annual rental payments of the Company&#x2019;s operating lease liability as of March&#160;31, 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:85.280%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.720%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (April through December)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current portion operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liability, noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Straight-line rent expense recognized for operating leases was $43,000 and $24,000 for the three months ended March 31, 2020 and 2019, respectively . There were no variable lease payments, including non-lease components such as common area maintenance fees, recognized as rent expense for operating leases for the three months ended March 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following information represents supplemental disclosure for the statement of cash flows related to the Company&#x2019;s operating lease (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:66.796%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.304%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.394%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.306%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash flows from operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following summarizes additional information related to the operating lease:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.116%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.884%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.42&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2020, the Company amended its lease agreement.  See Note 10. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by California corporate law. The Company currently has directors&#x2019; and officers&#x2019; insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <arqt:LesseeOperatingLeasesNumberFacilitiesLeased
      contextRef="i9ded77bb950b4e049558439a9f0bf11d_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzQ5NDc4MDIzMjc0NTg_c03a150a-d2c0-4f18-a259-1eb22cfa0f6a"
      unitRef="facility">1</arqt:LesseeOperatingLeasesNumberFacilitiesLeased>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i5d311753e065465a809d1745e3b2d439_I20190228"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzQ5NDc4MDIzMjc0NDY_f46fdf36-8c7b-4e70-bed3-c1d815e35f29">P30M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzQ5NDc4MDIzMjc0NTE_44044eca-c623-43c7-984b-ba2abbaeebb6">&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The minimum annual rental payments of the Company&#x2019;s operating lease liability as of March&#160;31, 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:85.280%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.720%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (April through December)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current portion operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liability, noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTozYzQ4ZjA5YTdkNmM0M2I2YWI2ZWVmY2IxMDVmZDYxMy90YWJsZXJhbmdlOjNjNDhmMDlhN2Q2YzQzYjZhYjZlZWZjYjEwNWZkNjEzXzEtMS0xLTEtMA_be8891df-02a8-4305-80f0-678e64ec2a81"
      unitRef="usd">145000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTozYzQ4ZjA5YTdkNmM0M2I2YWI2ZWVmY2IxMDVmZDYxMy90YWJsZXJhbmdlOjNjNDhmMDlhN2Q2YzQzYjZhYjZlZWZjYjEwNWZkNjEzXzItMS0xLTEtMA_d35b5dda-e0fe-4915-963b-6607384298db"
      unitRef="usd">132000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTozYzQ4ZjA5YTdkNmM0M2I2YWI2ZWVmY2IxMDVmZDYxMy90YWJsZXJhbmdlOjNjNDhmMDlhN2Q2YzQzYjZhYjZlZWZjYjEwNWZkNjEzXzMtMS0xLTEtMA_2f19d174-cdf6-4a03-bb00-724023adc33a"
      unitRef="usd">277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTozYzQ4ZjA5YTdkNmM0M2I2YWI2ZWVmY2IxMDVmZDYxMy90YWJsZXJhbmdlOjNjNDhmMDlhN2Q2YzQzYjZhYjZlZWZjYjEwNWZkNjEzXzQtMS0xLTEtMA_9402598d-d439-4193-966c-b8cb52bd7c36"
      unitRef="usd">13000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTozYzQ4ZjA5YTdkNmM0M2I2YWI2ZWVmY2IxMDVmZDYxMy90YWJsZXJhbmdlOjNjNDhmMDlhN2Q2YzQzYjZhYjZlZWZjYjEwNWZkNjEzXzUtMS0xLTEtMA_a6a6b29e-2e99-4c27-9345-ef6a81366988"
      unitRef="usd">264000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTozYzQ4ZjA5YTdkNmM0M2I2YWI2ZWVmY2IxMDVmZDYxMy90YWJsZXJhbmdlOjNjNDhmMDlhN2Q2YzQzYjZhYjZlZWZjYjEwNWZkNjEzXzYtMS0xLTEtMA_93a7eaf2-a364-4f0a-879b-00d2c1bd65c0"
      unitRef="usd">182000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTozYzQ4ZjA5YTdkNmM0M2I2YWI2ZWVmY2IxMDVmZDYxMy90YWJsZXJhbmdlOjNjNDhmMDlhN2Q2YzQzYjZhYjZlZWZjYjEwNWZkNjEzXzctMS0xLTEtMA_bd509ecc-dcce-463b-893f-8832f5588f38"
      unitRef="usd">82000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTozYzQ4ZjA5YTdkNmM0M2I2YWI2ZWVmY2IxMDVmZDYxMy90YWJsZXJhbmdlOjNjNDhmMDlhN2Q2YzQzYjZhYjZlZWZjYjEwNWZkNjEzXzgtMS0xLTEtMA_5acf0f89-4540-45c2-ad48-70d48a578e79"
      unitRef="usd">264000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzU5Nw_33b5febe-4f6e-4030-a204-74ed9e804007"
      unitRef="usd">43000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzMyOTg1MzQ4ODU3MjM_2458bbad-408d-433c-b59f-af0c62f295d5"
      unitRef="usd">24000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeaseCost
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzE2NDkyNjc0NDQxMDg_01fd8a54-f639-40ea-938f-e4d6c5160249"
      unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzE2NDkyNjc0NDQxMDg_a1c61e6f-fd83-47a8-89f9-16c0d3be6d54"
      unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90ZXh0cmVnaW9uOmQxN2NlYjE0Y2U5NjQyYTg5M2JiMTBlZWNjNmU5MzYzXzQ5NDc4MDIzMzI4OTk_d4eb61fb-3c51-4af6-b9fa-b58db2ebee1f">&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following information represents supplemental disclosure for the statement of cash flows related to the Company&#x2019;s operating lease (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:66.796%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.304%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.394%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.306%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash flows from operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following summarizes additional information related to the operating lease:&lt;/span&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.116%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.884%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.42&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTo3ZmJmZWY1NzdjZGY0MmE3ODEwYzhjZDEyNTc0NTZhYi90YWJsZXJhbmdlOjdmYmZlZjU3N2NkZjQyYTc4MTBjOGNkMTI1NzQ1NmFiXzItMS0xLTEtMA_6b8c67f5-8bfe-49ba-ae7f-4ba90d18a8b6"
      unitRef="usd">47000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTo3ZmJmZWY1NzdjZGY0MmE3ODEwYzhjZDEyNTc0NTZhYi90YWJsZXJhbmdlOjdmYmZlZjU3N2NkZjQyYTc4MTBjOGNkMTI1NzQ1NmFiXzItMi0xLTEtNTk4Mg_66e1afa3-3e06-4787-867a-6e6cd13ddaf1"
      unitRef="usd">16000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTowNWQyYjBhYzQ1ZmM0YTM1OGVmM2ViZjMyZDZjNzRiYi90YWJsZXJhbmdlOjA1ZDJiMGFjNDVmYzRhMzU4ZWYzZWJmMzJkNmM3NGJiXzEtMS0xLTEtMA_bbc10808-e6b5-4312-9515-7a4daed6ec77">P1Y5M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNTcvZnJhZzpkMTdjZWIxNGNlOTY0MmE4OTNiYjEwZWVjYzZlOTM2My90YWJsZTowNWQyYjBhYzQ1ZmM0YTM1OGVmM2ViZjMyZDZjNzRiYi90YWJsZXJhbmdlOjA1ZDJiMGFjNDVmYzRhMzU4ZWYzZWJmMzJkNmM3NGJiXzItMS0xLTEtMA_8fdbdbd0-b212-4dfa-9bdf-efc0f801ae39"
      unitRef="number">0.070</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzQ5NDc4MDIzODMxNDY_8d71f942-01fd-41b5-a1a5-f7552dd281b5">Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit)&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Convertible preferred stock as of December&#160;31, 2019 consisted of the following (in thousands, except share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.219%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.714%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Issued and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Liquidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Preference&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Series A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,897,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Series B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,736,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,364,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Series C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,251,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,122,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,787,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,385,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;166,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;166,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In connection with the Company's IPO in January 2020, all of the Company&#x2019;s outstanding shares of convertible preferred stock were automatically converted into 24,385,388 shares of common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In October 2019, the Company issued 8,122,963 shares of Series C convertible preferred stock at a purchase price of  $11.63 per share for total gross proceeds of $94.5&#160;million, some of which were to related parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In September 2018, the Company issued  9,364,850 shares of Series B convertible preferred stock at a purchase price of $6.19 per share for total proceeds of $57.9&#160;million, some of which were to related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In April 2017, the Company entered into a Stock Purchase Agreement with investors, some of which were related parties, to issue 5,398,111 shares of Series A convertible preferred stock at $2.00 per share in three tranches. The first tranche, consisting of 3,590,845 shares for net proceeds of $7.1 million, was completed upon execution of the agreement. Additionally, the Company issued 149,946 shares of Series A convertible preferred stock as a result of the conversion of convertible promissory notes with an outstanding principal amount of $154,000 and the settlement of the derivative liability of $150,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Series A investors were also granted freestanding rights to participate in additional tranches to raise a minimum of $3.3 million, upon election by the board of directors including at least one of the Series A directors, by purchasing 1,657,314 shares of Series A convertible preferred stock at $2.00 per share in two tranches, provided such election occurred prior to April 2019. The two tranches consisted of 828,654 shares and 828,660 shares, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;respectively. The Company concluded that the investors&#x2019; rights to purchase Series&#160;A convertible preferred shares met the definition of a freestanding financial instrument, as they were legally detachable and separately exercisable from the Series&#160;A convertible preferred stock, or the Series&#160;A Convertible Preferred Stock Liability. As the Series&#160;A Convertible Preferred Stock Liability was redeemable at the election of holders of the then-outstanding shares, it represented a liability to be accounted for at fair value and remeasured at each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Changes in fair value were recognized as a gain or loss in other income (expense), net in the statement of operations. On the closing of the first tranche in April 2017, the Company recorded the initial fair value of the Series&#160;A Convertible Preferred Stock Liability of $219,000 for the second and the third tranche participating rights by reducing the carrying value of Series&#160;A convertible preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2018, the Company completed the second tranche closing and issued 3,156,784 shares of Series A convertible preferred stock to the investors at a purchase price of $2.00 per share for net proceeds of $6.3 million. The Series&#160;A Convertible Preferred Stock Liability was remeasured to fair value just prior to settlement and the carrying value of the liability of $891,000 was reclassified to Series A convertible preferred stock. Concurrently with the closing of the second tranche, the Company amended the Series A convertible preferred stock purchase agreement to merge the second and third tranches and increased the maximum number of shares to be issued in the second tranche to 3,156,784 shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The holders of the Company&#x2019;s common stock have one vote for each share of common stock. Common stockholders are entitled to dividends when, as, and if declared by the Board of Directors. The holders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. As of March&#160;31, 2020, no dividends had been declared by the Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company reserved the following shares of common stock for issuance as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.877%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.698%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Convertible preferred stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,385,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,061,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,516,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock awards available for grant under employee benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,251,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,550,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;130,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total common stock reserved&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,443,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,452,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;"&gt;Authorized Share Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;On February 4, 2020, the Company&#x2019;s certificate of incorporation was amended and restated to provide for 300,000,000 authorized shares of common stock with a par value of $0.0001 per share and 10,000,000 authorized shares of preferred stock with a par value of $0.0001 per share.  There were no shares of preferred stock outstanding as of March&#160;31, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzQ5NDc4MDIzNzc1MDU_89d71b47-0318-4c66-bfe7-e35197cbc0a4">&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Convertible preferred stock as of December&#160;31, 2019 consisted of the following (in thousands, except share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.219%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.714%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Issued and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Liquidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Preference&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Series A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,897,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Series B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,736,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,364,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Series C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,251,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,122,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,787,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,385,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;166,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;166,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i5b476add02454015a5731c133e6fc7d7_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzEtMi0xLTEtMA_f2c1c4b3-95cc-42d5-a4a4-a8eeac8be120"
      unitRef="shares">13800000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i5b476add02454015a5731c133e6fc7d7_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzEtNC0xLTEtMA_4b3b027c-a233-41bb-bd57-f147777853cb"
      unitRef="shares">6897575</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i5b476add02454015a5731c133e6fc7d7_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzEtNC0xLTEtMA_e5d43803-501a-4b07-8cdc-5f08bb3fe9c9"
      unitRef="shares">6897575</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i5b476add02454015a5731c133e6fc7d7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzEtNi0xLTEtMA_31a45924-c5e6-4c19-af97-15abc6d6cecf"
      unitRef="usd">14340000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="i5b476add02454015a5731c133e6fc7d7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzEtOC0xLTEtMA_64a1497b-d523-45d5-a4fb-17c2a9cf7a99"
      unitRef="usd">13800000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i5e66cc37420547df82c325e4bd66ee97_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzItMi0xLTEtMA_8737ed22-fbfe-4c70-a28c-9e259e9f69d0"
      unitRef="shares">18736270</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i5e66cc37420547df82c325e4bd66ee97_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzItNC0xLTEtMA_49dc79fb-827c-4edb-8aca-b1f6ad20f45e"
      unitRef="shares">9364850</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i5e66cc37420547df82c325e4bd66ee97_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzItNC0xLTEtMA_6809c3db-530a-436a-abd1-341238bd6e94"
      unitRef="shares">9364850</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i5e66cc37420547df82c325e4bd66ee97_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzItNi0xLTEtMA_6b143ff2-8c09-4f79-bdc9-a560e22ad6e4"
      unitRef="usd">57912000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="i5e66cc37420547df82c325e4bd66ee97_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzItOC0xLTEtMA_8d5bff2d-ee66-4e85-8906-745e32c5fb3e"
      unitRef="usd">58000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="iad26b06911dd45ed94719ead6186feb7_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzMtMi0xLTEtMA_6ecec376-9f71-4772-9d79-cdfc6c36764f"
      unitRef="shares">16251628</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="iad26b06911dd45ed94719ead6186feb7_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzMtNC0xLTEtMA_cabfd20a-fd5f-4a65-96d3-91531dab074b"
      unitRef="shares">8122963</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="iad26b06911dd45ed94719ead6186feb7_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzMtNC0xLTEtMA_de520705-752c-47d9-9664-a78885b2b1f6"
      unitRef="shares">8122963</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="iad26b06911dd45ed94719ead6186feb7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzMtNi0xLTEtMA_6e31200a-020a-4bea-8842-11ba5026a9aa"
      unitRef="usd">94239000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="iad26b06911dd45ed94719ead6186feb7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzMtOC0xLTEtMA_430cdd66-157e-4ea3-a795-390b34f17b1a"
      unitRef="usd">94500000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzQtMi0xLTEtMA_43a8cda3-c79b-496b-b119-b835be6d1c6c"
      unitRef="shares">48787898</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzQtNC0xLTEtMA_b430f93c-8e5a-4908-98b8-3f233f4027a4"
      unitRef="shares">24385388</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzQtNC0xLTEtMA_d73ed3d6-2529-49b1-b657-06d93cc00393"
      unitRef="shares">24385388</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzQtNi0xLTEtMA_eb474867-a4a7-4f9c-a496-657b0afb9006"
      unitRef="usd">166491000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTowNzlmMDFlMThkY2E0MWM4YTIzZGFmOTM3MTcyNWY3ZC90YWJsZXJhbmdlOjA3OWYwMWUxOGRjYTQxYzhhMjNkYWY5MzcxNzI1ZjdkXzQtOC0xLTEtMA_3b31f118-82ad-4834-a15d-7cee978ce0ff"
      unitRef="usd">166300000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i1a9f8349a2ae4825872a95b128a3bfb7_D20200101-20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzE2NDkyNjc0OTQxODI_2917ce16-5835-4d3e-9157-e5bb2a3747d5"
      unitRef="shares">24385388</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <arqt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i1062618a24794d61acad0065c0f8c0b6_D20191001-20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEwOTk1MTE2ODU5MzI_9f09bd48-22c0-4700-87a1-1d121e4a0770"
      unitRef="shares">8122963</arqt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <arqt:TemporaryEquityStockIssuedDuringPeriodPricePerShare
      contextRef="i1ffb101d690c48ea9f6c1d9b6bb0766a_I20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEwOTk1MTE2ODU5MzY_d969bde8-f076-426e-844d-8fb490054555"
      unitRef="usdPerShare">11.63</arqt:TemporaryEquityStockIssuedDuringPeriodPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i1062618a24794d61acad0065c0f8c0b6_D20191001-20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEwOTk1MTE2ODU5Mzk_d40a355a-5ae7-4649-9a7a-69da396db59a"
      unitRef="usd">94500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <arqt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i53f18004827140e6b2a5880ba03e14cd_D20180901-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEwOTk1MTE2ODU5NTc_7a0af26d-6a61-4f45-be12-e62a62d3ef50"
      unitRef="shares">9364850</arqt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <arqt:TemporaryEquityStockIssuedDuringPeriodPricePerShare
      contextRef="i20520734ab804d1c969a5f694d1a77fb_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEwOTk1MTE2ODU5NDc_267ea9e1-4242-42df-a625-a78bb234b948"
      unitRef="usdPerShare">6.19</arqt:TemporaryEquityStockIssuedDuringPeriodPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i53f18004827140e6b2a5880ba03e14cd_D20180901-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEwOTk1MTE2ODU5NTE_5dc72bf6-e914-4dca-b6a2-71a8483d0748"
      unitRef="usd">57900000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <arqt:StockPurchaseAgreementNumberOfSharesIssuable
      contextRef="i942ea4487a4f4c628dbc72aa9142bb0b_D20170401-20170430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzU4OA_4de1d247-7774-4bcc-853f-0538186a0bff"
      unitRef="shares">5398111</arqt:StockPurchaseAgreementNumberOfSharesIssuable>
    <arqt:StockPurchaseAgreementPricePerShare
      contextRef="i27b66ebff3c74dffbed70e3df8d94527_I20170430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzY0MQ_d97e26fe-693a-4842-a5a7-42d4db83b23c"
      unitRef="usdPerShare">2.00</arqt:StockPurchaseAgreementPricePerShare>
    <arqt:StockPurchaseAgreementNumberOfTranches
      contextRef="ia747c28018db42518e5a81eb98a4730a_D20170401-20170430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzY1Nw_6ff6d23a-aa34-42f0-914c-5ce43c24ecfa"
      unitRef="tranche">3</arqt:StockPurchaseAgreementNumberOfTranches>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ic429b8e3655e404cb0d751419b0af0f5_D20170401-20170430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzcwMw_59cef2bc-713e-4b8a-843f-474ff2ec0b7c"
      unitRef="shares">3590845</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ic429b8e3655e404cb0d751419b0af0f5_D20170401-20170430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzczMw_92638d6d-9171-45f4-be70-b97c1900b89e"
      unitRef="usd">7100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i942ea4487a4f4c628dbc72aa9142bb0b_D20170401-20170430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzgxNw_b939a027-f47f-4eb3-9193-02a8f167997f"
      unitRef="shares">149946</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iaa626818057b4ec09c7780eda24ee280_I20170430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3Xzk2OQ_352fcfff-761e-47ef-bfa5-823afec24918"
      unitRef="usd">154000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i27b66ebff3c74dffbed70e3df8d94527_I20170430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEwMjI_bbd8e025-79fb-41f5-abb3-2efe61a1d83f"
      unitRef="usd">150000</us-gaap:DerivativeLiabilities>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ida7d99ff74274d4bb97416ec9c8ce692_D20170401-20170430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzExNjA_f8f91825-79e1-4fc9-960d-64fa6c3a0307"
      unitRef="usd">3300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ida7d99ff74274d4bb97416ec9c8ce692_D20170401-20170430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEyNjg_05e940f9-806e-47d1-ae03-19f7a3b3bcd3"
      unitRef="shares">1657314</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <arqt:StockPurchaseAgreementPricePerShare
      contextRef="iad794190a8a2452ea081cd173d9a46c3_I20170430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzEzMjE_dc13fa23-38ed-479c-b358-1d7582395108"
      unitRef="usdPerShare">2.00</arqt:StockPurchaseAgreementPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i18c87385f652426f9c3d56028cd4c845_D20170401-20170430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzE0MzI_39462635-ae3e-4bfa-b7b2-3c1ddfac624b"
      unitRef="shares">828654</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3d9f11fde515494ebe9f46b322624540_D20170401-20170430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzE0NDY_dbe30d03-daed-46f0-b663-4035b5b68a8c"
      unitRef="shares">828660</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:DerivativeLiabilities
      contextRef="iad794190a8a2452ea081cd173d9a46c3_I20170430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzIyOTA_12113265-a345-4d7d-9109-d614d2d46f71"
      unitRef="usd">219000</us-gaap:DerivativeLiabilities>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i867ead9d7de94ae2b7a3e1230d8c1445_D20180301-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzI0OTg_0eff7e56-ee7a-4fa7-ad01-4d2fd5ae9706"
      unitRef="shares">3156784</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <arqt:StockPurchaseAgreementPricePerShare
      contextRef="i61291be8ab45405ba6ff41986ea2bbf9_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzI1ODg_fbf847d8-8d3b-48af-b249-54ec81ea9825"
      unitRef="usdPerShare">2.00</arqt:StockPurchaseAgreementPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i867ead9d7de94ae2b7a3e1230d8c1445_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzI2MjE_7b952237-62ec-43de-919d-41ffa62659b8"
      unitRef="usd">6300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DerivativeLiabilities
      contextRef="i0dd4a2ea8e4e424cad9bf90013a09f85_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzI3NzM_2c09ff49-550f-4142-86b4-29ff2f28cfd6"
      unitRef="usd">891000</us-gaap:DerivativeLiabilities>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i152ee54c83c44c9c86787fc4619f617a_D20180301-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzMwNzY_bc9fc96a-d325-4a06-85ab-5bb8778f7b87"
      unitRef="shares">3156784</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <arqt:CommonStockVotingRightsNumberOfVotesPerShare
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3Xzg2OTY_5f3d90ce-7b59-4a57-88bb-4838a4ef2ee6"
      unitRef="vote">1</arqt:CommonStockVotingRightsNumberOfVotesPerShare>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzQ5NDc4MDIzNzc1MDY_6d5e8fab-1d95-4a5f-94b8-3fbbd65456a0">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company reserved the following shares of common stock for issuance as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.877%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.698%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Convertible preferred stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,385,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,061,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,516,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock awards available for grant under employee benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,251,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,550,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;130,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total common stock reserved&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,443,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,452,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7b0f602239da479bbb94f0b7c7888beb_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzItMS0xLTEtMA_12c8196c-9e27-497c-8c87-3c01cb4b3796"
      unitRef="shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id0cb10ec032b42cca2753ec0e703a0a9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzItMy0xLTEtMA_61722cc3-8f66-47f3-a928-83c53ad48d6a"
      unitRef="shares">24385388</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i207e672bf24642c4940bf0d793c0d8ad_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzMtMS0xLTEtMA_63d9906e-87f1-46d3-960d-4354b9ccacca"
      unitRef="shares">3061521</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i0a758e1969d84f21965d253803feda4d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzMtMy0xLTEtMA_ab1529b9-f44c-41a8-ba8f-ee543a023bea"
      unitRef="shares">2516470</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9c825f7e0bd049b3873b9f06a243c9cc_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzQtMS0xLTEtMA_680797c8-5f18-4b35-860a-1765e810e6f8"
      unitRef="shares">3251890</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i10726fed81d54f6ab986a0927852ce81_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzQtMy0xLTEtMA_cb22bdde-6eb8-400c-984f-e84e0baf16d8"
      unitRef="shares">1550150</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia583a93b899d4da9a404725241db7368_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzUtMS0xLTEtMTMzNw_10cf7720-fe3c-4afa-b18f-71dffe355f56"
      unitRef="shares">130060</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="if9c67f350dc54f669cff5762e4c650f0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzUtMy0xLTEtMTMzNw_c5c07561-6f3b-4cdd-9da1-9c225bf97a59"
      unitRef="shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzUtMS0xLTEtMA_5a937a74-c08c-48f3-9ed9-20231e7fc3ec"
      unitRef="shares">6443471</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90YWJsZTphZjYzNDQzZjc1NzY0NzliOTRiZjQ3NDlmYTZmODgyMS90YWJsZXJhbmdlOmFmNjM0NDNmNzU3NjQ3OWI5NGJmNDc0OWZhNmY4ODIxXzUtMy0xLTEtMA_bd77dbae-1054-4029-8887-e1a4b6563332"
      unitRef="shares">28452008</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i41086ad648ca4627b4da6abb4a3801d2_I20200204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzQ5NDc4MDIzNzc0NjQ_a2496e42-d262-4f24-ab89-8bce8b04bbc5"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i41086ad648ca4627b4da6abb4a3801d2_I20200204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzQ5NDc4MDIzNzc0NzY_8904a0d0-3f89-477c-9bde-a2e5b6f601c4"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i41086ad648ca4627b4da6abb4a3801d2_I20200204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzQ5NDc4MDIzNzc0ODU_54a43335-1ecc-4526-b4eb-c787b0c0c62a"
      unitRef="shares">10000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="i41086ad648ca4627b4da6abb4a3801d2_I20200204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzQ5NDc4MDIzNzc0OTc_e5bc15d5-dab4-4ae5-8913-6b80545f7ca7"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzIxOTkwMjMzMTM2NTI_19191384-3824-45d0-8951-fa2467dba51c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjMvZnJhZzpiNzY3MDc0NmI4Y2U0NDFmOTgwNjkwYjc5ZWJiNjIwNy90ZXh0cmVnaW9uOmI3NjcwNzQ2YjhjZTQ0MWY5ODA2OTBiNzllYmI2MjA3XzIxOTkwMjMzMTM2NTI_93c57fbe-0524-4f13-919a-7c02854daa59"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2NTI_212809bc-8539-4a92-a091-fab3e6f37eb1">Stock-Based Compensation  In January 2020, the Company&#x2019;s board of directors approved the 2020 Equity Incentive Plan, or the 2020 Plan, which became effective upon the completion of the IPO on January 31, 2020. The 2020 Plan serves as the successor incentive award plan to the Company&#x2019;s 2017 Equity Incentive Plan, or the 2017 Plan, and has 2,134,000 shares of common stock available for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock-based awards, plus 1,550,150 shares of common stock that were reserved for issuance pursuant to future awards under the 2017 Plan at the time the 2020 Plan became effective, plus shares represented by awards outstanding under the 2017 Plan that are forfeited or lapse unexercised and which following the effective date of the 2020 Plan are not issued under the 2017 Plan. In addition, the 2020 Plan reserve will increase on January 1, 2021 &lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;and each subsequent anniversary through 2030, by an amount equal to the lesser of (a) four percent of the shares of stock outstanding (on an as converted basis) on the day immediately prior to the date of increase and (b) such smaller number of shares of stock as determined by our board of directors; provided, however, that no more than 11,000,000 shares of stock may be issued upon the exercise of incentive stock options.  As of March&#160;31, 2020, the Company had 2,900,890 shares available for future grant under the 2020 Plan.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The 2020 Plan provides for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the board of directors and consultants of the Company under terms and provisions established by the board of directors. Under the terms of the 2020 Plan, options may be granted at an exercise price not less than fair market value. The Company generally grants stock-based awards with service conditions. Options granted typically vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzY4NA_1160bc3e-4896-43bb-92b1-9fd3b49a3ce7"&gt;four&lt;/span&gt;-year period but may be granted with different vesting terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Following the Company&#x2019;s IPO and in connection with the effectiveness of the Company&#x2019;s 2020 Plan, the 2017 Plan terminated and no further awards will be granted under that plan. However, all outstanding awards under the 2017 Plan will continue to be governed by their existing terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following summarizes option activity (in thousands, except share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.807%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.947%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.701%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance&#x2014;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,516,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;653,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(108,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance&#x2014;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,061,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable&#x2014;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,686,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;______________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt;"&gt;Options exercisable includes early exercisable options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair value of the Company&#x2019;s common stock as of March&#160;31, 2020. As of December&#160;31, 2019, prior to the Company's IPO, the estimated fair value of the Company's common stock was determined by the board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The intrinsic value of options exercised for the three months ended March 31, 2020 was $1.5 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The total grant-date fair value of the options vested during the three months ended March 31, 2020 was $367,000. The weighted-average grant-date fair value of employee options granted during the three months ended March 31, 2020 was $16.94.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Restricted Stock Unit Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes information regarding our restricted stock units (RSUs):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:60.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.543%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.992%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.546%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance&#x2014;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;130,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested Balance&#x2014;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;130,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The grant date fair value of an RSU equals the closing price of our common stock on the grant date.  RSUs generally vest equally over 4 years.  There were no RSU grants prior to January 1, 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock-based compensation expense recognized in our Condensed Statements of Operations and Comprehensive Loss was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.333%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.906%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.031%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020, there was $15.8 million of total unrecognized compensation cost related to unvested options that are expected to vest, which is expected to be recognized over a weighted-average period of 3.4 years.  As of March&#160;31, 2020, there was $3.6 million of total unrecognized compensation cost related to RSUs that is expected to vest, which is expected to be recognized over a weighted-average period of 3.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In determining the fair value of the stock options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair value of common stock&#x2014;  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For options granted prior to IPO in the year ended December 31, 2019, given the absence of a public trading market, the Company&#x2019;s board of directors with input from management considered numerous objective and subjective factors to determine the fair value of common stock. The factors included, but were not limited to: (i)&#160;third-party valuations of the Company&#x2019;s common stock; (ii)&#160;the Company&#x2019;s stage of development; (iii)&#160;the status of research and development efforts; (iv)&#160;the rights, preferences and privileges of the Company&#x2019;s convertible preferred stock relative to those of the Company&#x2019;s common stock; (v)&#160;the Company&#x2019;s operating results and financial condition, including the Company&#x2019;s levels of available capital resources; and (vi)&#160;equity market conditions affecting comparable public companies; (vii)&#160;general U.S. market conditions; and (viii)&#160;the lack of marketability of the Company&#x2019;s common stock. For options granted after IPO, the Company uses its closing stock price as reported on Nasdaq on the grant date for the fair value of its stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected Term&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014;The Company&#x2019;s expected term represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding. The Company used the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected Volatility&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014;Since the Company does not have sufficient trading history for its common stock, the expected volatility was estimated based on the average historical volatilities for comparable publicly traded pharmaceutical companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle and area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Dividend Yield&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of stock option awards granted was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.736%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.901%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.571%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.903%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended&lt;br/&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.5 &#x2013; 6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.1 &#x2013; 6.6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;71.2&#160;&#x2013;&#160;73.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;68.6&#160;&#x2013;&#160;72.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0.5 &#x2013; 1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1.6 &#x2013; 2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Early Exercise of Employee Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The terms of the 2017 and 2020 Plans permit certain option holders to exercise options before their options are vested, subject to certain limitations. Upon early exercise, the awards become subject to a restricted stock agreement. The shares of restricted stock granted upon early exercise of the options are subject to the same vesting provisions in the original stock option awards. Shares issued as a result of early exercise that have not vested are subject to repurchase by the Company upon termination of the purchaser&#x2019;s employment, at the price paid by the purchaser. Such shares are not deemed to be issued for accounting purposes until they vest and are therefore excluded from shares outstanding and from basic and diluted net loss per share until the repurchase right lapses and the shares are no longer subject to the repurchase feature. The liability is reclassified into common stock and additional paid-in capital as the shares vest and the repurchase right lapses. Accordingly, the Company has recorded the unvested portion of the exercise proceeds of $475,000 and $409,000 as a liability from the early exercise in the accompanying balance sheet as of March&#160;31, 2020 and December&#160;31, 2019, respectively. As of March&#160;31, 2020 and December&#160;31, 2019,  there were $269,000 and  $225,000 recorded in accrued liabilities, respectively, and $206,000 and  $184,000 recorded in other long-term liabilities, respectively related to shares that were subject to repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Founder Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2016, the Company issued 1,187,738 shares of restricted common stock to founders of which 1,102,903 shares vest under a service condition and 84,835 shares vest under a performance condition. The shares were issued under the terms of the respective restricted stock purchase agreements, or the Stock Purchase Agreement, and unvested shares are subject to repurchase by the Company at the original purchase price per share upon the holder&#x2019;s termination of his relationship with the Company. The restricted shares are not deemed to be issued for accounting purposes until they vest and are therefore excluded from shares outstanding and from basic and diluted net loss per share until the repurchase right lapses and the shares are no longer subject to the repurchase feature. One-fourth of the 1,102,903 shares of restricted common stock were vested on the first-anniversary date and the remaining 827,177 shares will vest on a monthly basis thereafter. In July 2018, performance conditions prescribed by the Stock Purchase Agreement were met and 84,835 shares of the restricted common stock were fully vested. During the three months ended March 31, 2020 and 2019, 68,931 shares and 68,931 shares of restricted common stock were vested, respectively. As of March&#160;31, 2020, 68,932 shares of restricted stock are unvested.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company adopted the 2020 Employee Stock Purchase Plan, or the ESPP, which became effective upon the completion of the IPO on January 31, 2020. The ESPP is designed to allow the Company&#x2019;s eligible employees to purchase shares of the Company&#x2019;s common stock, at semi-annual intervals, with their accumulated payroll deductions. Under the ESPP, participants are offered the option to purchase shares of the Company&#x2019;s common stock at a discount during a series of successive offering periods. The option purchase price will be the lower of 85% of the closing trading price per share of the Company&#x2019;s common stock on the first trading date of an offering period in which a participant is enrolled or 85% of the closing trading price per share on the purchase date, which will occur on the last trading day of each offering period. The Company commenced an offering period on January 31, 2020.&lt;/span&gt;&lt;/div&gt;The ESPP is intended to qualify under Section 423 of the U.S. Internal Revenue Service Code of 1986, as amended. The maximum number of the Company&#x2019;s common stock which will be authorized for sale under the ESPP is equal to the sum of (a) 351,000 shares of common stock and (b) an annual increase on the first day of each year beginning in 2021 and ending in 2030, equal to the lesser of (i) 1% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company&#x2019;s board of directors; provided, however, no more than 5,265,000 shares of the Company&#x2019;s common stock may be issued under the ESPP.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1b0b464dfc864b54803e7d3f742e0da3_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2MDQ_de0d544c-56a1-4fb5-a4e6-3642a3dc395f"
      unitRef="shares">2134000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i547d9f383e9b4debbdbb809301a8f689_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzE2NDkyNjc0NTQ1OTE_138bfbc6-bd74-4b02-ba9a-bae5ab6b9e91"
      unitRef="shares">1550150</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding
      contextRef="i1b0b464dfc864b54803e7d3f742e0da3_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzE2NDkyNjc0NTY2NjI_0dc8575c-2b29-4db5-8011-6192e9829cb7"
      unitRef="number">0.04</arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding>
    <arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable
      contextRef="i1b0b464dfc864b54803e7d3f742e0da3_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzE2NDkyNjc0NTY2NjQ_c2ed2f66-50b4-41c2-8008-9e4fe56440a4"
      unitRef="shares">11000000</arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i5b305cb4d63342bea9f25125973619f8_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzE2NDkyNjc0NjUzOTU_2db755a3-7950-43ab-a125-1b110b7a6323"
      unitRef="shares">2900890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2MTU_13e524d5-b94b-47dc-af1e-5edb50c3925e">&lt;div style="text-indent:36pt;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following summarizes option activity (in thousands, except share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.807%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.947%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.701%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance&#x2014;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,516,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;653,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(108,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance&#x2014;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,061,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable&#x2014;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,686,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;______________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt;"&gt;Options exercisable includes early exercisable options.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzEyLTEtMS0xLTA_65124c9d-addf-4c03-a2e9-ef06098795c7"
      unitRef="shares">2516470</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzEyLTMtMS0xLTA_8f4bfb73-0efd-4978-bd4d-b6b45739b268"
      unitRef="usdPerShare">3.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="idadd6a2a73da44689130341aaab4e04a_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzEyLTUtMS0xLTA_f165a186-d4c8-4a38-9cc9-902f0653448a">P9Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ic9bf5bacffba46089c61b3b65926a2bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzEyLTctMS0xLTA_63af5f7b-616f-4e15-9d7c-7d8b19a8da53"
      unitRef="usd">7673000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzItMS0xLTEtNDcw_90687a65-9d51-4640-a754-a5513278dd56"
      unitRef="shares">653200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzItMy0xLTEtNDcw_c5690a6c-5b6c-4772-881c-909990a25712"
      unitRef="usdPerShare">26.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzMtMS0xLTEtNDcw_60f30dcb-e6e5-49b9-8b8a-a1f4fd44b499"
      unitRef="shares">108149</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzMtMy0xLTEtNDcw_19f0177e-96b9-4562-a65f-2ab844b39f65"
      unitRef="usdPerShare">2.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzYtMS0xLTEtNDcw_424ac7ac-3037-431b-99ab-39e883d7492f"
      unitRef="shares">3061521</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzYtMy0xLTEtNDc2_e1d052fa-0d9c-4485-bc8a-704a7f830139"
      unitRef="usdPerShare">8.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzYtNS0xLTEtNDcw_6773dc05-9831-4824-a23c-aefaaf4896e7">P9Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzYtNy0xLTEtNDcw_cf372b6a-2f8e-4334-ab06-3344e55988dd"
      unitRef="usd">65155000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzEzLTEtMS0xLTA_6a710ea1-9df4-4b58-a1d7-b4b92aa1ec0d"
      unitRef="shares">1686893</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzEzLTMtMS0xLTA_3c96d6d1-c906-4dd8-857a-879be550bf03"
      unitRef="usdPerShare">5.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzEzLTUtMS0xLTA_016f348b-275a-4f0c-b1d8-97686effba6a">P9Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTphYzVhZmFhMjRkNjU0YWYyYjk1ZjJkZmM5NzAyMjYyNC90YWJsZXJhbmdlOmFjNWFmYWEyNGQ2NTRhZjJiOTVmMmRmYzk3MDIyNjI0XzEzLTctMS0xLTA_8823be8b-5a1c-40d6-8baf-c614a97e88fd"
      unitRef="usd">40408000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDU3NDA_6a50ddad-f753-4e37-a82e-b8b87e247204"
      unitRef="usd">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDU3ODg_2c3d371a-3427-411c-85d5-d52ec749aa47"
      unitRef="usd">367000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDU4NzI_c724ac2a-5c16-4409-8623-71e75dd94f87"
      unitRef="usdPerShare">16.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzU0OTc1NTgxNzU3OTg_703c24c5-564b-43be-98f4-d4180258c43e">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes information regarding our restricted stock units (RSUs):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:60.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.543%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.992%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.546%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance&#x2014;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;130,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested Balance&#x2014;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;130,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if9c67f350dc54f669cff5762e4c650f0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzEtMS0xLTEtMTQzMg_b8a7f81a-6dd7-4892-9488-aa71a8f8ab04"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if9c67f350dc54f669cff5762e4c650f0_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzEtMy0xLTEtMTQzMg_53e62f64-784b-41cd-b8e2-f91277104772"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzItMS0xLTEtMTQzMg_b4c8a14e-0ead-4438-b5a2-f001ee58981c"
      unitRef="shares">130060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzItMy0xLTEtMTQzMg_41d8bea5-f5a3-4f83-9d23-8cee12f0696c"
      unitRef="usdPerShare">27.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzMtMS0xLTEtMTQzMg_62e14ecc-3751-4889-b536-836b99219b9e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzMtMy0xLTEtMTQzMg_2e7c30f9-ed79-440c-9327-615d2e02bd09"
      unitRef="usdPerShare">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzQtMS0xLTEtMTQzMg_f143e081-eab7-4aea-ac7f-3f53de9edfeb"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzQtMy0xLTEtMTQzMg_a0e94e2a-b988-491b-8afd-ba819c2f59fb"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia583a93b899d4da9a404725241db7368_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzUtMS0xLTEtMTQzNg_faa4ace1-5cce-4061-91c9-4209b278f29a"
      unitRef="shares">130060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia583a93b899d4da9a404725241db7368_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpmZTVjNjllNjQ1NzY0YTg4YWFjMmFmNjVhNzBlZDNmZi90YWJsZXJhbmdlOmZlNWM2OWU2NDU3NjRhODhhYWMyYWY2NWE3MGVkM2ZmXzUtMy0xLTEtMTQzNg_91ee6784-5a8f-4b0c-b689-09cb2e1370c2"
      unitRef="usdPerShare">27.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzEyNjQ0MzgzNzU2MDU5_dc9c9b7c-d2ca-4516-96fe-2181c3e85e2c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2MTc_cfca0240-f077-488f-a8c6-d5da918a58b9">&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock-based compensation expense recognized in our Condensed Statements of Operations and Comprehensive Loss was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.333%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.906%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.031%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i99319e5db9304bce8368150c3126f923_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTo0MGZkZWNhMjQ2YjE0N2M0YThjMzc5YjZiMzFkZjE2OS90YWJsZXJhbmdlOjQwZmRlY2EyNDZiMTQ3YzRhOGMzNzliNmIzMWRmMTY5XzItMS0xLTEtMA_fd3b8f9c-040e-493d-8138-9001e9a4ffe9"
      unitRef="usd">416000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i729f8784fd4e49eba8ee589ee7ffb428_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTo0MGZkZWNhMjQ2YjE0N2M0YThjMzc5YjZiMzFkZjE2OS90YWJsZXJhbmdlOjQwZmRlY2EyNDZiMTQ3YzRhOGMzNzliNmIzMWRmMTY5XzItMy0xLTEtMA_d86d94d3-e860-4f60-a5c4-20b0b2da2a5e"
      unitRef="usd">31000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic428fc4a3f5544cdb4cd99f3463113b0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTo0MGZkZWNhMjQ2YjE0N2M0YThjMzc5YjZiMzFkZjE2OS90YWJsZXJhbmdlOjQwZmRlY2EyNDZiMTQ3YzRhOGMzNzliNmIzMWRmMTY5XzMtMS0xLTEtMA_900c69d1-cb3e-4575-b28a-ec39ce83a416"
      unitRef="usd">574000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0baf33cc0dc243f780ad057920f62292_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTo0MGZkZWNhMjQ2YjE0N2M0YThjMzc5YjZiMzFkZjE2OS90YWJsZXJhbmdlOjQwZmRlY2EyNDZiMTQ3YzRhOGMzNzliNmIzMWRmMTY5XzMtMy0xLTEtMA_4eed1f78-374f-4b2f-8961-ba903690c560"
      unitRef="usd">45000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTo0MGZkZWNhMjQ2YjE0N2M0YThjMzc5YjZiMzFkZjE2OS90YWJsZXJhbmdlOjQwZmRlY2EyNDZiMTQ3YzRhOGMzNzliNmIzMWRmMTY5XzQtMS0xLTEtMA_657e2a29-62f4-4680-8851-59e77001fb29"
      unitRef="usd">990000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTo0MGZkZWNhMjQ2YjE0N2M0YThjMzc5YjZiMzFkZjE2OS90YWJsZXJhbmdlOjQwZmRlY2EyNDZiMTQ3YzRhOGMzNzliNmIzMWRmMTY5XzQtMy0xLTEtMA_b8cd45cd-fe57-4ef6-bdde-f58dac39dc44"
      unitRef="usd">76000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="idde51cc55856491d9916e0b6960bac95_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzI1NjI_4ad4b2cf-885e-462a-93dc-03d79c30078d"
      unitRef="usd">15800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6ec1cf8ff84648708b4c86b19e7f6130_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzI3MzI_eb015534-16a4-4909-bf2e-d8a3abff3e9e">P3Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ia583a93b899d4da9a404725241db7368_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzIxOTkwMjMyODk1ODg_940aad47-8b8a-4f9a-98fc-54b0daf23207"
      unitRef="usd">3600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzIxOTkwMjMyODk1ODU_90136fdd-2276-42c9-bcd3-3f93741f7909">P3Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i36f41495899d443b9ef4ab7d9ca80854_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzUwOTg_58840bc0-f5a8-4c4e-bb65-f1e42e1b3410"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2MTk_037d96a8-018a-4dbb-87e8-e9e8fd471470">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of stock option awards granted was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.736%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.901%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.571%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.903%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended&lt;br/&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.5 &#x2013; 6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.1 &#x2013; 6.6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;71.2&#160;&#x2013;&#160;73.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;68.6&#160;&#x2013;&#160;72.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0.5 &#x2013; 1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1.6 &#x2013; 2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic4ad05013c344f86873c31d6f40cb48b_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzItMS0xLTEtMC90ZXh0cmVnaW9uOmE5ZjNiMzU3NTZiMDRkNjliYjc4YzhjOTc3NjUxYmE3XzQ5NDc4MDIzMjUwMDg_e6c74bf5-3327-4179-8466-05a61d7c240e">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i60fc0bcc4f7e43c9b071698d2cab142b_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzItMS0xLTEtMC90ZXh0cmVnaW9uOmE5ZjNiMzU3NTZiMDRkNjliYjc4YzhjOTc3NjUxYmE3XzQ5NDc4MDIzMjUwMTM_756971e6-0935-4386-8e31-72d3691d1320">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i79205ea8bd33408992b1551901172816_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzItMy0xLTEtMC90ZXh0cmVnaW9uOjRkZjU0NjRkYzc1YjQyZjBiNjk4YzYyMTcwNDU5OTg2XzQ5NDc4MDIzMjUwMjQ_d6aab670-461b-432e-a537-9944700f417a">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i330111f8ba794d7fae3926a5518de13b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzItMy0xLTEtMC90ZXh0cmVnaW9uOjRkZjU0NjRkYzc1YjQyZjBiNjk4YzYyMTcwNDU5OTg2XzQ5NDc4MDIzMjUwMTM_b0220792-a3cf-4c3d-a9dd-0fdc9ded030a">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i6ec1cf8ff84648708b4c86b19e7f6130_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjFhMTE0MTNiMTBmYjQ1NmQ4YjYwNzk4NDlhNmJlZjNhXzQ5NDc4MDIzMjUwMTI_efdc3ddc-0743-4f9c-ada2-75a8fc60b280"
      unitRef="number">0.712</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i6ec1cf8ff84648708b4c86b19e7f6130_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjFhMTE0MTNiMTBmYjQ1NmQ4YjYwNzk4NDlhNmJlZjNhXzQ5NDc4MDIzMjUwMTk_4ceaed2b-701e-49e5-8524-64c6b41fb6f8"
      unitRef="number">0.733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i032684c2259b4403a7e8ab7dc81e250c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzMtMy0xLTEtMC90ZXh0cmVnaW9uOjRjMTJhNjM2Y2EzMjQxNTNiMTFhYjQxZWQzZTNlYzkwXzQ5NDc4MDIzMjUwMTI_d2101a74-662d-42bd-96cc-0b6b28ac5501"
      unitRef="number">0.686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i032684c2259b4403a7e8ab7dc81e250c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzMtMy0xLTEtMC90ZXh0cmVnaW9uOjRjMTJhNjM2Y2EzMjQxNTNiMTFhYjQxZWQzZTNlYzkwXzQ5NDc4MDIzMjUwMTk_527afd45-8635-4cd6-8baa-34674a83e685"
      unitRef="number">0.725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i6ec1cf8ff84648708b4c86b19e7f6130_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmE0Y2ZkNzRjNmY0NTQ4MTVhMDY2ZjBkODYyYmQ0ZDliXzQ5NDc4MDIzMjUwMDk_688b824b-09be-4b2a-a776-3f1491a26864"
      unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i6ec1cf8ff84648708b4c86b19e7f6130_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmE0Y2ZkNzRjNmY0NTQ4MTVhMDY2ZjBkODYyYmQ0ZDliXzQ5NDc4MDIzMjUwMTU_7a54600c-ee34-4dc9-a6c6-77afbde49985"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i032684c2259b4403a7e8ab7dc81e250c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzQtMy0xLTEtMC90ZXh0cmVnaW9uOmY3ODQzNDJlMjlkYTQwZmQ5M2E2ZDc4NjA3MzMzZTk2XzQ5NDc4MDIzMjUwMDk_98fb9947-4216-4058-b6a9-d1280e49ee45"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i032684c2259b4403a7e8ab7dc81e250c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzQtMy0xLTEtMC90ZXh0cmVnaW9uOmY3ODQzNDJlMjlkYTQwZmQ5M2E2ZDc4NjA3MzMzZTk2XzQ5NDc4MDIzMjUwMTU_1a243354-ae34-4a81-8d57-252da0240849"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6ec1cf8ff84648708b4c86b19e7f6130_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzUtMS0xLTEtMA_dc03b472-7f30-4e6c-9e82-a05b3477d067"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i032684c2259b4403a7e8ab7dc81e250c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90YWJsZTpkY2I4NGQ5MGFiYmY0NjQ0OWM4ZmFjYjEwMDc1MjhkYS90YWJsZXJhbmdlOmRjYjg0ZDkwYWJiZjQ2NDQ5YzhmYWNiMTAwNzUyOGRhXzUtMy0xLTEtMA_9f1e6437-ad7e-4e21-af29-e70207e52f22"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="if4b3c7b09a81456aa8c7c67220c1937a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDU5NTU_badc87b3-5fdc-4ead-83cf-405527a3360b"
      unitRef="usd">475000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="icf1aac6536334060af468f8eeb2e8eb9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDU5Nzc_d3a5e832-e22c-41a5-a2c2-0ac50e5b1de2"
      unitRef="usd">409000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="if4b3c7b09a81456aa8c7c67220c1937a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDYwMDU_b383d1ca-21c3-4202-99ee-aa92e46c0713"
      unitRef="usd">269000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="icf1aac6536334060af468f8eeb2e8eb9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDYwMjc_9493ec11-a50c-4732-b37d-23beba4504a1"
      unitRef="usd">225000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="if4b3c7b09a81456aa8c7c67220c1937a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDYwMzA_3e0d0abb-3d95-4fba-993f-c54717cf53fe"
      unitRef="usd">206000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="icf1aac6536334060af468f8eeb2e8eb9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzM4NDgyOTA3MDYwMzM_596f6165-3c77-4261-84b8-561a88bbe8ea"
      unitRef="usd">184000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i36e62b08be8541cfb10cebab50e8f747_D20160801-20160831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzY3MTE_641cdf98-8124-4b71-b2af-f723397a9274"
      unitRef="shares">1187738</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i7c280cdb092b45edb7e2214f3ed3cebe_D20160801-20160831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzY3Njk_5070470f-9085-408b-b7bf-996318260bc6"
      unitRef="shares">1102903</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i6bbb52f6091c4868b5b32ba40fc51240_D20160801-20160831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzY4MTQ_c0670544-4ae5-4622-858e-d2e9d2023f85"
      unitRef="shares">84835</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i7f0bea76e3b04ffcb5683a3e920f6fb6_D20160801-20160831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzc0NjE_ee0426a6-965f-4228-b0d0-47ebee67ccf1"
      unitRef="shares">1102903</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis
      contextRef="ib5403a39d9824c61b323a823a99f5bd8_D20160801-20160831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzc1NTg_500b46c2-5f29-4db5-a239-8c4356f0f57e"
      unitRef="shares">827177</arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="id48658e6817e4f45934cd7313bbee944_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzc3MDI_803a73cf-e6ce-4d31-9252-449c9461c3f6"
      unitRef="shares">84835</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i30fec8c2358b4835911058e60fbd15e1_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzE2NDkyNjc0Nzg1ODU_9dac6dd0-3e4d-4e8e-913b-c26fe2e2d87e"
      unitRef="shares">68931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i923788d1801d4b67b74f8a5857599515_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzE2NDkyNjc0Nzg1OTI_9e97ce06-c67a-4553-adc2-d90babb1d9b1"
      unitRef="shares">68931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie85017a9a46f4ab9a78c0cc301027ce2_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzMyOTg1MzQ5MDcxNTI_9e159f06-70e3-4837-a97e-e038c5907750"
      unitRef="shares">68932</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ia32c63d0cf494637ad7c5a2bccd2b22f_D20200131-20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2NTQ_ec71467b-9f62-4df0-9eca-fef7f2521075"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ia32c63d0cf494637ad7c5a2bccd2b22f_D20200131-20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2NTk_b14c0207-ad4d-48dc-848a-c20056de7855"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized
      contextRef="iae37041cedde4d51858dc7cf3548eb6d_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2NjQ_28a5a178-df5c-4a20-b844-d3047e43beb1"
      unitRef="shares">351000</arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized>
    <arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding
      contextRef="i7383296af1344aea9cce30492f252802_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2ODQ_8e8097bf-9811-478c-b4ed-816aa34e61c5"
      unitRef="number">0.01</arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding>
    <arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable
      contextRef="iae37041cedde4d51858dc7cf3548eb6d_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjkvZnJhZzpkMGFhMGM4ZjY1NmM0ZGZmYmY2Y2FmYmYzZjNmNTA3MS90ZXh0cmVnaW9uOmQwYWEwYzhmNjU2YzRkZmZiZjZjYWZiZjNmM2Y1MDcxXzQ5NDc4MDIzNDg2NzM_e80d15a7-ee19-4d60-8977-33ebf5925191"
      unitRef="shares">5265000</arqt:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90ZXh0cmVnaW9uOmJhY2YwYzFiMGQ5MDQ5YjlhOGQzMTJkOTM1ZTU3NDY2XzQ5NDc4MDIzMjUyMTA_f21b5890-4165-4a73-85de-9c3ec3b568c6">Net Loss Per Share&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.906%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.181%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.183%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Convertible preferred stock on an as-converted basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,262,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,061,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,461,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Early exercised options subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;613,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;578,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;198,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;344,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ESPP shares subject to future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,885,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,646,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90ZXh0cmVnaW9uOmJhY2YwYzFiMGQ5MDQ5YjlhOGQzMTJkOTM1ZTU3NDY2XzQ5NDc4MDIzMjUyMDk_4f93ea07-9900-4906-8bd7-edc9dfab8ce3">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.906%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.181%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.183%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Convertible preferred stock on an as-converted basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,262,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,061,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,461,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Early exercised options subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;613,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;578,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;198,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;344,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ESPP shares subject to future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,885,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,646,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7e60ec54b5354f6d99fb37ca976d041f_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzItMS0xLTEtMA_0b0e7103-4e54-4370-b922-8396bcca4f82"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i99939ac91f9f4fa590b1fa4017ae602b_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzItMy0xLTEtMA_6839b02b-ccea-48e6-b2af-c6fe66ddbcb7"
      unitRef="shares">16262425</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idc6873c2e10d441d9cc0b8acba203bb7_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzMtMS0xLTEtMA_eeab33fa-34ff-4a26-8ef8-c710874badf6"
      unitRef="shares">3061521</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6ddaa5b1d44a4fab8efeb9d63d3c55d8_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzMtMy0xLTEtMA_f65a83af-3bb0-48b8-a7ec-004a984fae80"
      unitRef="shares">1461191</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i03053d48c20241778d8e2cfc418e60ae_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzQtMS0xLTEtMA_68c8872a-012f-4965-87b9-110e7f59e6ff"
      unitRef="shares">613627</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaf2d176bc07e46b8a8d5d35b4960c50d_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzQtMy0xLTEtMA_fe8e0ca8-b834-4f93-b3ad-51e8d2ee78eb"
      unitRef="shares">578298</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i213a41c41500492487811d690788ac4f_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzUtMS0xLTEtMA_d30876a2-2b42-4bd5-b3d9-b80b7b371573"
      unitRef="shares">198992</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if6465c3a5b5c4daf823adc5f743d64b4_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzUtMy0xLTEtMA_6803aea7-2665-40d9-add0-8214fb68003d"
      unitRef="shares">344657</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5ef81aa3fd074f2f9ad3100002a964f9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzYtMS0xLTEtNzUxMw_bc422414-1f18-4f6b-973e-46b08d30210d"
      unitRef="shares">11392</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i875d6445002045038d95abd268509dc1_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzYtMy0xLTEtNzUxMw_a1ddc274-d3d5-42ad-9212-80adda418c25"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzYtMS0xLTEtMA_acd282f7-0e4b-45ae-9829-81999045f4a5"
      unitRef="shares">3885532</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2ea702bd0e714811a6cc3002ad96fabc_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNzUvZnJhZzpiYWNmMGMxYjBkOTA0OWI5YThkMzEyZDkzNWU1NzQ2Ni90YWJsZTo4NDA4ZmFjYTg3YzQ0ZGEyYWU4ZDU0MGI1NjkyMmI0Yi90YWJsZXJhbmdlOjg0MDhmYWNhODdjNDRkYTJhZThkNTQwYjU2OTIyYjRiXzYtMy0xLTEtMA_98d6eaef-3d37-46a7-8dc7-e6f6ee1407d3"
      unitRef="shares">18646571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3NzM4_4072d641-1fba-4122-93f3-d69e75684ed6">Subsequent Event  In April 2020, the Company amended its lease agreement for its facility in Westlake Village, California to relocate to a new expanded space comprising 22,643 square feet.  The lease will begin when the tenant improvements are substantially complete and terminates 91 months thereafter, with a renewal option for a term of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3NzUy_a7f3f3c6-d01a-43c9-8f08-52810289a778"&gt;five&lt;/span&gt; years.  The Company will have a one-time option to cancel the lease after month 67.   The lease is subject to fixed rate escalation increases with an initial base rent of $76,000 per month and includes rent free periods aggregating approximately 1 year. As a result, the Company recognizes rent expense on a straight-line basis for the full amount of the commitment including the minimum rent increases over the life of the lease and the free rent period.  The amended lease agreement provides for a tenant improvement allowance up to $1.25&#160;million. It also requires the Company to have an available letter of credit of $1.5&#160;million upon commencement, which is allowed to be reduced throughout the lease period as rent obligations are met.</us-gaap:SubsequentEventsTextBlock>
    <arqt:LesseeOperatingLeaseSquareFootageOfLeasedSpace
      contextRef="i5d533bf2a9414af8876f332d4c35941e_D20200401-20200430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3NzQw_660a3e34-6610-49ed-a28f-fd5f2c4523dd"
      unitRef="sqft">22643</arqt:LesseeOperatingLeaseSquareFootageOfLeasedSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i8b84137f69724a55827a9c4614fa776b_I20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3ODAy_34b53f70-fad6-4e10-b766-e526bf1a877b">P91M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arqt:LesseeOperatingLeaseTermForTerminationOption
      contextRef="i5d533bf2a9414af8876f332d4c35941e_D20200401-20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3ODA4_5f0828bd-16b5-4ecd-8456-071f786dea2d">P67M</arqt:LesseeOperatingLeaseTermForTerminationOption>
    <arqt:LesseeOperatingLeaseMonthlyRentExpense
      contextRef="i5d533bf2a9414af8876f332d4c35941e_D20200401-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3Nzcz_1ccca901-8cfb-4553-a0f7-e7e9e597edfc"
      unitRef="usd">76000</arqt:LesseeOperatingLeaseMonthlyRentExpense>
    <arqt:LesseeOperatingLeaseFreeRentPeriod
      contextRef="i5d533bf2a9414af8876f332d4c35941e_D20200401-20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3ODE2_7f23ac6b-6da5-495a-8354-4ca96a92d354">P1Y</arqt:LesseeOperatingLeaseFreeRentPeriod>
    <arqt:LesseeOperatingLeaseTenantImprovementAllowance
      contextRef="i5d533bf2a9414af8876f332d4c35941e_D20200401-20200430"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3NzU4_5cbc91c3-1cda-428d-bf55-a99adea38018"
      unitRef="usd">1250000</arqt:LesseeOperatingLeaseTenantImprovementAllowance>
    <arqt:LesseeOperatingLeaseLetterOfCreditRequirement
      contextRef="i8b84137f69724a55827a9c4614fa776b_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3Nzgy_3d3e252b-a5f9-4856-a064-1e25aedd4ac8"
      unitRef="usd">1500000</arqt:LesseeOperatingLeaseLetterOfCreditRequirement>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6645306048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s condensed financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements and accompanying notes. On an ongoing basis, management evaluates such estimates and assumptions for continued reasonableness. In particular, management makes estimates with respect to accruals for research and development activities, fair value of common stock and convertible preferred stock (prior to the IPO completed in January 2020), stock-based compensation expense and income taxes. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Actual results could differ from those estimates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segments</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, the Company has viewed its financial information on an aggregate basis for the purposes of evaluating financial performance and allocating the Company&#8217;s resources. Accordingly, the Company has determined that it operates in one segment.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unaudited Interim Condensed Financial Statements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The interim condensed balance sheet as of March&#160;31, 2020, the interim condensed statements of operations and comprehensive loss, the condensed changes in convertible preferred stock and stockholders&#8217; equity (deficit) and cash flows for the three months ended March&#160;31, 2020 and 2019 are unaudited. These unaudited interim condensed financial statements have been prepared on the same basis as the Company&#8217;s audited annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair statement of the Company&#8217;s financial information. The financial data and the other financial information disclosed in these notes to the condensed financial statements related to the three-month periods are also unaudited. The condensed results of operations for the three months ended March&#160;31, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other future annual or interim period. The condensed balance sheet as of December 31, 2019 included herein was derived from the audited financial statements as of that date. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Therefore, these unaudited interim condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash and Cash Equivalents </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of money market funds, commercial paper, and government securities. </span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Marketable Securities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities consist of investment grade short to intermediate-term fixed income investments that have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase are classified as current based on their availability for use in current operations. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses as well as credit losses, if any, on marketable securities are included in other income (expense), net. The Company evaluated the underlying credit quality and credit ratings of </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">the issuers during the period. To date, no such credit losses have occurred or have been recorded. The cost of investments sold is based on the specific-identification method. As of March&#160;31, 2020, there were unrealized gains on marketable securities of $19,000 and as of December&#160;31, 2019, there were unrealized losses on marketable securities of  $1,000. Unrealized gains and losses on marketable securities are reported as a component of Accumulated Other Comprehensive Income (Loss) on the balance sheet. There were no realized gains or losses on investments for the three months ended March 31, 2020 and 2019. Interest on marketable securities is included in Other income (expense), net.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash to the extent recorded on the balance sheets.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s financial instruments, in addition to those presented in Note 3 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, include cash equivalents, accounts payable and accrued liabilities. The carrying amount of cash equivalents, accounts payable and accrued liabilities approximate their fair values due to their short maturities.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active;</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company leases a facility with a non-cancelable lease term of 30 months. The term of the lease includes a renewal option at the election of the Company to extend the lease for an additional term. The renewal option has not been considered in the determination of the right-of-use, or ROU, asset or lease liability as the Company did not consider it reasonably certain it would exercise this option.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement is or contains a lease at inception. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The classification of the Company&#8217;s leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. The Company uses its incremental borrowing rate, based on the information available at commencement date, to determine the present value of lease payments when its leases do not provide an implicit rate. The Company uses the implicit rate when readily determinable. The ROU asset is based on the measurement of the lease liability, includes any lease payments made prior to or on lease </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">commencement and excludes lease incentives and initial direct costs incurred, as applicable. Lease expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s lease agreement includes lease and non-lease components and the Company has elected to not separate such components. Further, the Company elected the short-term lease exception policy, permitting it to not apply the recognition requirements of this standard to leases with terms of 12 months or less (short-term leases) for all classes of assets.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Preclinical and Clinical Accruals and Costs</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical studies, clinical trials and contract manufacturing activities. These costs are a significant component of the Company&#8217;s research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. For the three months ended March 31, 2020 and 2019, the Company has not experienced any material differences between accrued costs and actual costs incurred. </span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Convertible Preferred Stock</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to its IPO, the Company classified its outstanding convertible preferred stock outside of stockholders&#8217; equity (deficit) on its balance sheets as the requirements of triggering a deemed liquidation event, as defined within its amended and restated certificate of incorporation, were not entirely within the Company&#8217;s control. In the event of such a deemed liquidation event, the proceeds from the event were to be distributed in accordance with the liquidation preferences, provided that the holders of convertible preferred stock had not converted their shares into common stock. The Company recorded the issuance of convertible preferred stock at the issuance price less related issuance costs. The Company did not adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because of the uncertainty as to whether or when a deemed liquidation event may have occurred.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the IPO in January 2020, the Company&#8217;s outstanding shares of convertible preferred stock were automatically converted into 24,385,388 shares of common stock.  </span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, license fees, stock-based compensation expense, materials, supplies, and the cost of services provided by outside contractors. All costs associated with research and development are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are rendered. Such payments are evaluated for current or long-term classification based on when they will be realized.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has entered into and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date none of the Company&#8217;s license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense when paid or become payable, provided there is no alternative future use of the rights in other research and development projects.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for share-based payments at fair value. The fair value of stock options is measured using the Black-Scholes option-pricing model. For share-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date for such awards is the date of grant and the expense is recognized on a straight-line basis, over the expected vesting period. For share-based awards that vest subject to a performance condition, the Company will recognize compensation cost for awards if and when the Company concludes that it is probable that the awards with a performance condition will be achieved on an accelerated attribution method. The Company accounts for forfeitures as they occur.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company records a valuation allowance to reduce deferred tax assets to an amount for which realization is more likely than not. Due to the Company&#8217;s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties incurred in relation to the unrecognized tax benefits.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was enacted by the United States Congress on March 27, 2020. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the U.S. economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act includes modifications to the limitations on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. The Company does not expect the CARES Act to have a material impact on the Company&#8217;s financial statements.</span></div><div><span><br/></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Variable Interest Entities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company reviews agreements it enters into with third-party entities, pursuant to which the Company may have a variable interest in the entity, in order to determine if the entity is a variable interest entity, or VIE. If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that entity. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. If the Company determines it is the primary beneficiary of a VIE, it consolidates that VIE into the Company&#8217;s financial statements. The Company&#8217;s determination about whether it should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation or deconsolidation event. The Company currently does not consolidate any VIEs.</span></div><div><span><br/></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share since the effects of potentially dilutive securities are antidilutive. Shares of common stock subject to repurchase are excluded from the weighted-average shares.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Emerging Growth Company Status</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> or ASU No. 2018-13, which removes, modifies, and adds various disclosure requirements on fair value measurements in Topic 820.&#160;ASU No. 2018-13&#160;is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company adopted this standard as of January 1, 2020, and it did not have a material impact on its condensed financial statements. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In June&#160;2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Financial Instruments&#8212;Credit Losses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">(Topic&#160;326): Measurement of Credit Losses on Financial Instruments,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> or ASU No. 2016-13</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> This update requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations now include forward-looking information in the determination of their credit loss estimates. Many of the previous loss estimation techniques are still permitted, although the inputs to those techniques have changed to reflect the full amount of expected credit losses. In addition, this update amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration.  The Company adopted this standard as of January 1, 2020, and it did not have a material impact on its condensed financial statements.  There was no impact on the Company's condensed financial statements from credit losses for the three months ended March 31, 2020.  </span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In December 2019, the FASB issued ASU No. 2019-12</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">, Income Taxes (Topic 740)</span> which amends the existing guidance relating to the accounting for income taxes. This standard is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. The standard is effective for public business entities for fiscal years beginning after December 15, 2020, and interim periods therein. Early adoption is permitted. An entity that elects early adoption in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, an entity that elects early adoption should adopt all the amendments in the same period. The Company early adopted this guidance as of January 1, 2020, and it did not have a material impact on its condensed financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6617376128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Westlake Village, California Lease Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace', window );">Square footage of leased space | ft&#178;</a></td>
<td class="nump">22,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in months)</a></td>
<td class="text">91 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_LesseeOperatingLeaseTermForTerminationOption', window );">Lease term prior to termination option</a></td>
<td class="text">67 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_LesseeOperatingLeaseMonthlyRentExpense', window );">Straight-line rent expense</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_LesseeOperatingLeaseFreeRentPeriod', window );">Free rent period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_LesseeOperatingLeaseTenantImprovementAllowance', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_LesseeOperatingLeaseLetterOfCreditRequirement', window );">Available letter of credit</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LesseeOperatingLeaseFreeRentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Free Rent Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LesseeOperatingLeaseFreeRentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LesseeOperatingLeaseLetterOfCreditRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Letter Of Credit Requirement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LesseeOperatingLeaseLetterOfCreditRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LesseeOperatingLeaseMonthlyRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Rent Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LesseeOperatingLeaseMonthlyRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Square Footage Of Leased Space</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LesseeOperatingLeaseTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LesseeOperatingLeaseTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LesseeOperatingLeaseTermForTerminationOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Term For Termination Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LesseeOperatingLeaseTermForTerminationOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LeaseDescriptionAxis=arqt_WestlakeVillageCaliforniaLeaseArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LeaseDescriptionAxis=arqt_WestlakeVillageCaliforniaLeaseArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>158</ContextCount>
  <ElementCount>325</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Statements of Convertible Preferred Stock and Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit</Role>
      <ShortName>Condensed Statements of Convertible Preferred Stock and Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CondensedStatementsofCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficit</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2136109 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://arcutis.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcutis.com/role/FairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcutis.com/role/BalanceSheetComponents</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcutis.com/role/CommitmentsandContingencies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2325304 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitTables</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficit</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2330305 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcutis.com/role/StockBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2337306 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcutis.com/role/NetLossPerShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails</Role>
      <ShortName>Organization and Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcutis.com/role/OrganizationandDescriptionofBusiness</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Fair Value Measurements - Estimated Value of Cash and Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Estimated Value of Cash and Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - License Agreements - AstraZeneca (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails</Role>
      <ShortName>License Agreements - AstraZeneca (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - License Agreements - Hengrui (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/LicenseAgreementsHengruiDetails</Role>
      <ShortName>License Agreements - Hengrui (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - License Agreements - Hawkeye (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/LicenseAgreementsHawkeyeDetails</Role>
      <ShortName>License Agreements - Hawkeye (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcutis.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Commitments and Contingencies - Operating Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Commitments and Contingencies - Operating Lease Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Commitment and Contingencies - Operating Lease Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/CommitmentandContingenciesOperatingLeaseAdditionalInformationDetails</Role>
      <ShortName>Commitment and Contingencies - Operating Lease Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Components of Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity (Deficit) - Components of Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity (Deficit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2428416 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Shares of Common Stock for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity (Deficit) - Shares of Common Stock for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcutis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2432418 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2433419 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2435421 - Disclosure - Stock-Based Compensation - Assumptions in Calculating Stock Option Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions in Calculating Stock Option Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcutis.com/role/NetLossPerShareTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="arqt-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcutis.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcutis.com/role/SubsequentEvent</ParentRole>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="arqt-20200331.htm">arqt-20200331.htm</File>
    <File>arqt-20200331.xsd</File>
    <File>arqt-20200331_cal.xml</File>
    <File>arqt-20200331_def.xml</File>
    <File>arqt-20200331_lab.xml</File>
    <File>arqt-20200331_pre.xml</File>
    <File>exhibit311ceo.htm</File>
    <File>exhibit312cfo.htm</File>
    <File>exhibit31postipocertif.htm</File>
    <File>exhibit321ceocfo.htm</File>
    <File>exhibit32postipobylaws.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6782484320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">130,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">130,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share) | $ / shares</a></td>
<td class="nump">27.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested (in USD per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in USD per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 27.61<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6644740928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Summary of Convertible Preferred Stock</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Convertible preferred stock as of December&#160;31, 2019 consisted of the following (in thousands, except share amounts):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:48.219%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.714%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible Preferred Stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Shares</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Authorized</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Shares</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Issued and</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Outstanding</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Net</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Carrying</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Value</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Liquidation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Preference</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Series A</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,800,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,897,575&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Series B</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,736,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,364,850&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,912&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series C</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,251,628&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,122,963&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48,787,898&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,385,388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">166,491&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">166,300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Components of Shares of Stock for Issuance</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company reserved the following shares of common stock for issuance as follows: </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:73.877%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible preferred stock outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,385,388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options issued and outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,061,521&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,516,470&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock awards available for grant under employee benefit plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,251,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,550,150&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total common stock reserved</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,443,471&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,452,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6618048432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments (segment) | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Debt Securities, Available-for-sale, Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gains (losses) on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued as a result of conversion of promissory notes (in shares) | shares</a></td>
<td class="nump">24,385,388<span></span>
</td>
<td class="nump">24,385,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6621685632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text">Organization and Description of Business<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Arcutis Biotherapeutics, Inc., or the Company, is a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. The Company&#8217;s current portfolio is comprised of topical treatments with significant promise in addressing immune-mediated dermatological diseases and conditions, or immuno-dermatology. The Company&#8217;s strategy is to advance treatments that leverage validated biological targets in dermatology in order to deliver clinical profiles that address major shortcomings of existing therapies in its targeted indications. The Company believes this strategy uniquely positions it to rapidly advance its goal of bridging the treatment innovation gap in dermatology while maximizing its probability of technical success.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 17, 2020, the Company's Board of Directors approved a 1-for-2.0007 reverse stock split of the Company&#8217;s capital stock and the Company filed a certificate of amendment to its restated certificate of incorporation to effect the split. The par value and authorized shares of common stock and convertible preferred stock were not adjusted as a result of the reverse split. All share and per share information included in the accompanying financial statements has been adjusted to reflect this reverse stock split.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Initial Public Offering</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 31, 2020, the Company completed an initial public offering (&#8220;IPO&#8221;) issuing and selling </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10,781,250</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> shares of common stock at a public offering price of $17.00 per share, including </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1,406,250</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> shares sold pursuant to the underwriters&#8217; full exercise of their option to purchase additional shares. The aggregate net proceeds received by the Company from the offering were approximately $167.2&#160;million,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> after deducting underwriting discounts, commissions and offering related transaction costs</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Upon the closing of the IPO, all of the outstanding shares of convertible preferred stock automatically converted into shares of common stock. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding.  The financial statements as of March&#160;31, 2020, including share and per share amounts, incorporate the effects of the IPO. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liquidity</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has incurred significant losses and negative cash flows from operations since its inception and had an accumulated deficit of $94.3 million and $66.3 million as of March&#160;31, 2020 and December&#160;31, 2019, respectively. The Company had cash, cash equivalents and marketable securities of $249.3 million and $101.3 million as of March&#160;31, 2020 and December&#160;31, 2019, respectively. Prior to selling common stock in its IPO, the Company had historically financed its operations primarily through the sale of its convertible preferred stock. Management expects operating losses to continue for the foreseeable future.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes that its existing capital resources will be sufficient to meet the projected operating requirements for at least 12 months from the date of issuance of its financial statements. The Company will be required to raise additional capital to fund future operations. However, no assurance can be given as to whether additional needed financing will be available on terms acceptable to the Company, if at all. If sufficient funds on acceptable terms are not available when needed, the Company may be required to curtail planned activities to significantly reduce its operating expenses. Failure to manage discretionary spending or raise additional financing, as needed, may adversely impact the Company&#8217;s ability to achieve its intended business objectives and have an adverse effect on its results of operations and future prospects.</span></div><div style="margin-top:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Coronavirus Outbreak</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In March 2020, the World Health Organization declared a pandemic related to the global novel coronavirus disease 2019 (COVID-19) outbreak. As of May 12, 2020, the Company&#8217;s operations have not been significantly impacted by the COVID-19 pandemic.  The Company is monitoring the potential impact COVID-19 may have on the clinical development of its product candidates, including potential delays or modifications to its ongoing and planned trials. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak will have on its financial condition and operations, including ongoing and planned clinical trials.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6784068144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 25,182<span></span>
</td>
<td class="nump">$ 6,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,469<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">28,651<span></span>
</td>
<td class="nump">6,952<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(28,651)<span></span>
</td>
<td class="num">(6,952)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">638<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(28,013)<span></span>
</td>
<td class="num">(6,658)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (27,993)<span></span>
</td>
<td class="num">$ (6,657)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in USD per share)</a></td>
<td class="num">$ (1.15)<span></span>
</td>
<td class="num">$ (4.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used in computing net loss per share, basic and diluted (in shares)</a></td>
<td class="nump">24,256,402<span></span>
</td>
<td class="nump">1,632,694<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6782275456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Operating Lease Additional Information (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">1 year 5 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6777738336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Hawkeye (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Feb. 04, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arqt_HawkeyeMember', window );">Hawkeye</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration', window );">Collaboration agreement, threshold of proceeds from stock issuance for additional consideration</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration', window );">Collaborative arrangement, numerator for determining additional consideration</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties', window );">Payments, milestones or royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary | Hawkeye</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_VariableInterestEntitiesNumberOfSharesHeld', window );">Number of shares held in VIE (in shares)</a></td>
<td class="nump">995,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Ownership percentage of VIE</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arqt_HawkeyeMember', window );">Hawkeye</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Threshold Of Proceeds From Stock Issuance For Additional Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Numerator For Determining Additional Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Payments, Milestones, Or Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_VariableInterestEntitiesNumberOfSharesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entities, Number Of Shares Held</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_VariableInterestEntitiesNumberOfSharesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118582676&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arqt_HawkeyeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arqt_HawkeyeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arqt_HawkeyeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arqt_HawkeyeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6624143216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements  The following table sets forth the Company&#8217;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):<div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:48.951%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.714%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Assets:</span></div></td><td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds(1)</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial paper</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,396&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,396&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Government securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,030&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,030&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195,923&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,396&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">249,319&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:48.951%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.714%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Level 1</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Level 2</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Level 3</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Assets:</span></div></td><td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds(1)</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,689&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,689&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Government securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,576&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,689&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101,265&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt;">This balance includes cash requirements settled on a nightly basis.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Commercial paper, money market funds and government securities are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs. There were no transfers between Levels&#160;1, 2 or 3 for any of the periods presented. </span></div><div style="text-indent:36pt;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the estimated value of the Company&#8217;s cash, cash equivalents and marketable securities and the gross unrealized holding gains and losses (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:48.951%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.714%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents:</span></div></td><td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,396&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,396&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,030&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,426&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt;">This balance includes cash requirements settled on a nightly basis.</span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:49.461%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.702%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents:</span></td><td colspan="21" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,780&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,780&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds(1)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,998&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,998&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,909&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,909&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,021&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,930&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,929&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table>There were no realized gains or losses on investments for the three months ended March 31, 2020 and 2019.  As of March&#160;31, 2020 and December&#160;31, 2019, unrealized losses on marketable securities were not material, and accordingly, no allowance for credit losses was recorded as of March 31, 2020.  As of March&#160;31, 2020 and December&#160;31, 2019, all securities have a maturity of one year or less and all securities with gross unrealized losses have been in continuous loss position for less than twelve months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6638637072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Convertible Preferred Stock and Stockholders' Equity (Deficit)</a></td>
<td class="text">Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)<div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Convertible preferred stock as of December&#160;31, 2019 consisted of the following (in thousands, except share amounts):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:48.219%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.714%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible Preferred Stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Shares</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Authorized</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Shares</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Issued and</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Outstanding</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Net</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Carrying</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Value</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Liquidation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Preference</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Series A</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,800,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,897,575&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Series B</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,736,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,364,850&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,912&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series C</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,251,628&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,122,963&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48,787,898&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,385,388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">166,491&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">166,300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In connection with the Company's IPO in January 2020, all of the Company&#8217;s outstanding shares of convertible preferred stock were automatically converted into 24,385,388 shares of common stock. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In October 2019, the Company issued 8,122,963 shares of Series C convertible preferred stock at a purchase price of  $11.63 per share for total gross proceeds of $94.5&#160;million, some of which were to related parties. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2018, the Company issued  9,364,850 shares of Series B convertible preferred stock at a purchase price of $6.19 per share for total proceeds of $57.9&#160;million, some of which were to related parties.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In April 2017, the Company entered into a Stock Purchase Agreement with investors, some of which were related parties, to issue 5,398,111 shares of Series A convertible preferred stock at $2.00 per share in three tranches. The first tranche, consisting of 3,590,845 shares for net proceeds of $7.1 million, was completed upon execution of the agreement. Additionally, the Company issued 149,946 shares of Series A convertible preferred stock as a result of the conversion of convertible promissory notes with an outstanding principal amount of $154,000 and the settlement of the derivative liability of $150,000.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Series A investors were also granted freestanding rights to participate in additional tranches to raise a minimum of $3.3 million, upon election by the board of directors including at least one of the Series A directors, by purchasing 1,657,314 shares of Series A convertible preferred stock at $2.00 per share in two tranches, provided such election occurred prior to April 2019. The two tranches consisted of 828,654 shares and 828,660 shares, </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">respectively. The Company concluded that the investors&#8217; rights to purchase Series&#160;A convertible preferred shares met the definition of a freestanding financial instrument, as they were legally detachable and separately exercisable from the Series&#160;A convertible preferred stock, or the Series&#160;A Convertible Preferred Stock Liability. As the Series&#160;A Convertible Preferred Stock Liability was redeemable at the election of holders of the then-outstanding shares, it represented a liability to be accounted for at fair value and remeasured at each reporting period.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Changes in fair value were recognized as a gain or loss in other income (expense), net in the statement of operations. On the closing of the first tranche in April 2017, the Company recorded the initial fair value of the Series&#160;A Convertible Preferred Stock Liability of $219,000 for the second and the third tranche participating rights by reducing the carrying value of Series&#160;A convertible preferred stock.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2018, the Company completed the second tranche closing and issued 3,156,784 shares of Series A convertible preferred stock to the investors at a purchase price of $2.00 per share for net proceeds of $6.3 million. The Series&#160;A Convertible Preferred Stock Liability was remeasured to fair value just prior to settlement and the carrying value of the liability of $891,000 was reclassified to Series A convertible preferred stock. Concurrently with the closing of the second tranche, the Company amended the Series A convertible preferred stock purchase agreement to merge the second and third tranches and increased the maximum number of shares to be issued in the second tranche to 3,156,784 shares. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The holders of the Company&#8217;s common stock have one vote for each share of common stock. Common stockholders are entitled to dividends when, as, and if declared by the Board of Directors. The holders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. As of March&#160;31, 2020, no dividends had been declared by the Board of Directors.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company reserved the following shares of common stock for issuance as follows: </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:73.877%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible preferred stock outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,385,388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options issued and outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,061,521&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,516,470&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock awards available for grant under employee benefit plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,251,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,550,150&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total common stock reserved</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,443,471&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,452,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Authorized Share Capital</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On February 4, 2020, the Company&#8217;s certificate of incorporation was amended and restated to provide for 300,000,000 authorized shares of common stock with a par value of $0.0001 per share and 10,000,000 authorized shares of preferred stock with a par value of $0.0001 per share.  There were no shares of preferred stock outstanding as of March&#160;31, 2020 and December&#160;31, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6645602512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s condensed financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements and accompanying notes. On an ongoing basis, management evaluates such estimates and assumptions for continued reasonableness. In particular, management makes estimates with respect to accruals for research and development activities, fair value of common stock and convertible preferred stock (prior to the IPO completed in January 2020), stock-based compensation expense and income taxes. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segments</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, the Company has viewed its financial information on an aggregate basis for the purposes of evaluating financial performance and allocating the Company&#8217;s resources. Accordingly, the Company has determined that it operates in one segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock', window );">Unaudited Interim Condensed Financial Statements</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unaudited Interim Condensed Financial Statements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The interim condensed balance sheet as of March&#160;31, 2020, the interim condensed statements of operations and comprehensive loss, the condensed changes in convertible preferred stock and stockholders&#8217; equity (deficit) and cash flows for the three months ended March&#160;31, 2020 and 2019 are unaudited. These unaudited interim condensed financial statements have been prepared on the same basis as the Company&#8217;s audited annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair statement of the Company&#8217;s financial information. The financial data and the other financial information disclosed in these notes to the condensed financial statements related to the three-month periods are also unaudited. The condensed results of operations for the three months ended March&#160;31, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other future annual or interim period. The condensed balance sheet as of December 31, 2019 included herein was derived from the audited financial statements as of that date. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Therefore, these unaudited interim condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of money market funds, commercial paper, and government securities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Marketable Securities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities consist of investment grade short to intermediate-term fixed income investments that have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in fixed income securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase are classified as current based on their availability for use in current operations. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses as well as credit losses, if any, on marketable securities are included in other income (expense), net. The Company evaluated the underlying credit quality and credit ratings of </span></div>the issuers during the period. To date, no such credit losses have occurred or have been recorded. The cost of investments sold is based on the specific-identification method.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash to the extent recorded on the balance sheets.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s financial instruments, in addition to those presented in Note 3 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, include cash equivalents, accounts payable and accrued liabilities. The carrying amount of cash equivalents, accounts payable and accrued liabilities approximate their fair values due to their short maturities.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active;</span></div><div style="text-indent:36pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company leases a facility with a non-cancelable lease term of 30 months. The term of the lease includes a renewal option at the election of the Company to extend the lease for an additional term. The renewal option has not been considered in the determination of the right-of-use, or ROU, asset or lease liability as the Company did not consider it reasonably certain it would exercise this option.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement is or contains a lease at inception. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The classification of the Company&#8217;s leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. The Company uses its incremental borrowing rate, based on the information available at commencement date, to determine the present value of lease payments when its leases do not provide an implicit rate. The Company uses the implicit rate when readily determinable. The ROU asset is based on the measurement of the lease liability, includes any lease payments made prior to or on lease </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">commencement and excludes lease incentives and initial direct costs incurred, as applicable. Lease expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s lease agreement includes lease and non-lease components and the Company has elected to not separate such components. Further, the Company elected the short-term lease exception policy, permitting it to not apply the recognition requirements of this standard to leases with terms of 12 months or less (short-term leases) for all classes of assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock', window );">Preclinical and Clinical Accruals and Costs</a></td>
<td class="text">Preclinical and Clinical Accruals and CostsThe Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical studies, clinical trials and contract manufacturing activities. These costs are a significant component of the Company&#8217;s research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Convertible Preferred Stock</a></td>
<td class="text">Convertible Preferred StockPrior to its IPO, the Company classified its outstanding convertible preferred stock outside of stockholders&#8217; equity (deficit) on its balance sheets as the requirements of triggering a deemed liquidation event, as defined within its amended and restated certificate of incorporation, were not entirely within the Company&#8217;s control. In the event of such a deemed liquidation event, the proceeds from the event were to be distributed in accordance with the liquidation preferences, provided that the holders of convertible preferred stock had not converted their shares into common stock. The Company recorded the issuance of convertible preferred stock at the issuance price less related issuance costs. The Company did not adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because of the uncertainty as to whether or when a deemed liquidation event may have occurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, license fees, stock-based compensation expense, materials, supplies, and the cost of services provided by outside contractors. All costs associated with research and development are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are rendered. Such payments are evaluated for current or long-term classification based on when they will be realized.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has entered into and may continue to enter into, license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date none of the Company&#8217;s license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense when paid or become payable, provided there is no alternative future use of the rights in other research and development projects.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation The Company accounts for share-based payments at fair value. The fair value of stock options is measured using the Black-Scholes option-pricing model. For share-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date for such awards is the date of grant and the expense is recognized on a straight-line basis, over the expected vesting period. For share-based awards that vest subject to a performance condition, the Company will recognize compensation cost for awards if and when the Company concludes that it is probable that the awards with a performance condition will be achieved on an accelerated attribution method. The Company accounts for forfeitures as they occur.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company records a valuation allowance to reduce deferred tax assets to an amount for which realization is more likely than not. Due to the Company&#8217;s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties incurred in relation to the unrecognized tax benefits.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was enacted by the United States Congress on March 27, 2020. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the U.S. economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act includes modifications to the limitations on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. The Company does not expect the CARES Act to have a material impact on the Company&#8217;s financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Variable Interest Entities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company reviews agreements it enters into with third-party entities, pursuant to which the Company may have a variable interest in the entity, in order to determine if the entity is a variable interest entity, or VIE. If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that entity. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. If the Company determines it is the primary beneficiary of a VIE, it consolidates that VIE into the Company&#8217;s financial statements. The Company&#8217;s determination about whether it should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation or deconsolidation event. The Company currently does not consolidate any VIEs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share since the effects of potentially dilutive securities are antidilutive. Shares of common stock subject to repurchase are excluded from the weighted-average shares.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Emerging Growth Company Status</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> or ASU No. 2018-13, which removes, modifies, and adds various disclosure requirements on fair value measurements in Topic 820.&#160;ASU No. 2018-13&#160;is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company adopted this standard as of January 1, 2020, and it did not have a material impact on its condensed financial statements. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In June&#160;2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Financial Instruments&#8212;Credit Losses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">(Topic&#160;326): Measurement of Credit Losses on Financial Instruments,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> or ASU No. 2016-13</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> This update requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations now include forward-looking information in the determination of their credit loss estimates. Many of the previous loss estimation techniques are still permitted, although the inputs to those techniques have changed to reflect the full amount of expected credit losses. In addition, this update amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration.  The Company adopted this standard as of January 1, 2020, and it did not have a material impact on its condensed financial statements.  There was no impact on the Company's condensed financial statements from credit losses for the three months ended March 31, 2020.  </span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In December 2019, the FASB issued ASU No. 2019-12</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">, Income Taxes (Topic 740)</span> which amends the existing guidance relating to the accounting for income taxes. This standard is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. The standard is effective for public business entities for fiscal years beginning after December 15, 2020, and interim periods therein. Early adoption is permitted. An entity that elects early adoption in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, an entity that elects early adoption should adopt all the amendments in the same period. The Company early adopted this guidance as of January 1, 2020, and it did not have a material impact on its condensed financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Emerging Growth Company Status</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preclinical And Clinical Accruals And Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unaudited Interim Condensed Financial Statements, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118582676&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118582676&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=118582676&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116854557&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6624183936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions in Calculating Stock Option Awards (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">71.20%<span></span>
</td>
<td class="nump">68.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">73.30%<span></span>
</td>
<td class="nump">72.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>40
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "arqt-20200331.htm": {
   "axisCustom": 1,
   "axisStandard": 18,
   "contextCount": 158,
   "dts": {
    "calculationLink": {
     "local": [
      "arqt-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arqt-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "arqt-20200331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "arqt-20200331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arqt-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "arqt-20200331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 407,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 4,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 9
   },
   "keyCustom": 39,
   "keyStandard": 286,
   "memberCustom": 15,
   "memberStandard": 30,
   "nsprefix": "arqt",
   "nsuri": "http://arcutis.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://arcutis.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Fair Value Measurements",
     "role": "http://arcutis.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Balance Sheet Components",
     "role": "http://arcutis.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - License Agreements",
     "role": "http://arcutis.com/role/LicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Commitments and Contingencies",
     "role": "http://arcutis.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficit",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Stock-Based Compensation",
     "role": "http://arcutis.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136109 - Disclosure - Net Loss Per Share",
     "role": "http://arcutis.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - Subsequent Event",
     "role": "http://arcutis.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://arcutis.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Balance Sheets",
     "role": "http://arcutis.com/role/CondensedBalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://arcutis.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://arcutis.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325304 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)",
     "role": "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitTables",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330305 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://arcutis.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337306 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://arcutis.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Description of Business (Details)",
     "role": "http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails",
     "shortName": "Organization and Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Details)",
     "role": "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Fair Value Measurements - Estimated Value of Cash and Cash Equivalents and Marketable Securities (Details)",
     "role": "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurements - Estimated Value of Cash and Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "role": "http://arcutis.com/role/CondensedBalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "arqt:ClinicalTrialAccrualCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)",
     "role": "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "arqt:ClinicalTrialAccrualCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "i64e39f6e0ee9449382ec819a3c86939a_D20190801-20190831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - License Agreements - AstraZeneca (Details)",
     "role": "http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails",
     "shortName": "License Agreements - AstraZeneca (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "i64e39f6e0ee9449382ec819a3c86939a_D20190801-20190831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "i6cb916c47d6d4499899eba1d8e7cc49f_D20191201-20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - License Agreements - Hengrui (Details)",
     "role": "http://arcutis.com/role/LicenseAgreementsHengruiDetails",
     "shortName": "License Agreements - Hengrui (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "i6cb916c47d6d4499899eba1d8e7cc49f_D20191201-20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - License Agreements - Hawkeye (Details)",
     "role": "http://arcutis.com/role/LicenseAgreementsHawkeyeDetails",
     "shortName": "License Agreements - Hawkeye (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "ic8fd13a77a64486f820343c9c46cc851_I20190630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arqt:CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://arcutis.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Commitments and Contingencies - Operating Lease Payments (Details)",
     "role": "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails",
     "shortName": "Commitments and Contingencies - Operating Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Commitments and Contingencies - Operating Lease Supplemental Cash Flow Information (Details)",
     "role": "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails",
     "shortName": "Commitments and Contingencies - Operating Lease Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Commitment and Contingencies - Operating Lease Additional Information (Details)",
     "role": "http://arcutis.com/role/CommitmentandContingenciesOperatingLeaseAdditionalInformationDetails",
     "shortName": "Commitment and Contingencies - Operating Lease Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Components of Convertible Preferred Stock (Details)",
     "role": "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit) - Components of Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "ic9bf5bacffba46089c61b3b65926a2bd_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityLiquidationPreference",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "ia747c28018db42518e5a81eb98a4730a_D20170401-20170430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "arqt:StockPurchaseAgreementNumberOfTranches",
      "reportCount": 1,
      "unique": true,
      "unitRef": "tranche",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) (Details)",
     "role": "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "ia747c28018db42518e5a81eb98a4730a_D20170401-20170430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "arqt:StockPurchaseAgreementNumberOfTranches",
      "reportCount": 1,
      "unique": true,
      "unitRef": "tranche",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss",
     "role": "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428416 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Shares of Common Stock for Issuance (Details)",
     "role": "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit) - Shares of Common Stock for Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "i207e672bf24642c4940bf0d793c0d8ad_I20200331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - Stock-Based Compensation (Details)",
     "role": "http://arcutis.com/role/StockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "ic9bf5bacffba46089c61b3b65926a2bd_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432418 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "if9c67f350dc54f669cff5762e4c650f0_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433419 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)",
     "role": "http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "ib78e1ba1c70545f8b38bb80a7e7932b5_D20200101-20200331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://arcutis.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "i6ec1cf8ff84648708b4c86b19e7f6130_D20200101-20200331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435421 - Disclosure - Stock-Based Compensation - Assumptions in Calculating Stock Option Awards (Details)",
     "role": "http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails",
     "shortName": "Stock-Based Compensation - Assumptions in Calculating Stock Option Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "i6ec1cf8ff84648708b4c86b19e7f6130_D20200101-20200331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - Net Loss Per Share (Details)",
     "role": "http://arcutis.com/role/NetLossPerShareDetails",
     "shortName": "Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idde51cc55856491d9916e0b6960bac95_I20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Subsequent Event (Details)",
     "role": "http://arcutis.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "i5d533bf2a9414af8876f332d4c35941e_D20200401-20200430",
      "decimals": "0",
      "lang": "en-US",
      "name": "arqt:LesseeOperatingLeaseSquareFootageOfLeasedSpace",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "i68dfa5b4689849b9a3cd771af6075ca9_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "role": "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
     "shortName": "Condensed Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "i1ccb7f8264e14d269a33e7f94a0411d7_I20181231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
     "shortName": "Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "idd55dd9b16fa435a9f870f1cf68c7239_D20200101-20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Statements of Cash Flows",
     "role": "http://arcutis.com/role/CondensedStatementsofCashFlows",
     "shortName": "Condensed Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Description of Business",
     "role": "http://arcutis.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://arcutis.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arqt-20200331.htm",
      "contextRef": "iec1a5de2b12b4aab88dee2d9ab3bd9f9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 52,
   "tag": {
    "arqt_A2017EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2017 Equity Incentive Plan",
        "label": "2017 Equity Incentive Plan [Member]",
        "terseLabel": "2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "A2017EquityIncentivePlanMember",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arqt_A2020EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2020 Equity Incentive Plan",
        "label": "2020 Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "A2020EquityIncentivePlanMember",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arqt_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AstraZeneca",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arqt_CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash And Cash Equivalents And Debt Securities, Available For Sale, Fair Value Disclosure",
        "label": "Cash And Cash Equivalents And Debt Securities, Available For Sale, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents and debt securities, available for sale"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arqt_ClinicalTrialAccrualCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical Trial Accrual, Current",
        "label": "Clinical Trial Accrual, Current",
        "terseLabel": "Clinical trial accruals"
       }
      }
     },
     "localname": "ClinicalTrialAccrualCurrent",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arqt_CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Threshold Of Proceeds From Stock Issuance For Additional Consideration",
        "label": "Collaboration Agreement, Threshold Of Proceeds From Stock Issuance For Additional Consideration",
        "terseLabel": "Collaboration agreement, threshold of proceeds from stock issuance for additional consideration"
       }
      }
     },
     "localname": "CollaborationAgreementThresholdOfProceedsFromStockIssuanceForAdditionalConsideration",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsHawkeyeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arqt_CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Numerator For Determining Additional Consideration",
        "label": "Collaborative Arrangement, Numerator For Determining Additional Consideration",
        "terseLabel": "Collaborative arrangement, numerator for determining additional consideration"
       }
      }
     },
     "localname": "CollaborativeArrangementNumeratorForDeterminingAdditionalConsideration",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsHawkeyeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arqt_CommonStockVotingRightsNumberOfVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock, Voting Rights, Number Of Votes Per Share",
        "label": "Common Stock, Voting Rights, Number Of Votes Per Share",
        "terseLabel": "Votes per share of common stock"
       }
      }
     },
     "localname": "CommonStockVotingRightsNumberOfVotesPerShare",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arqt_DeferredFinancingCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Financing Costs Incurred But Not Yet Paid",
        "label": "Deferred Financing Costs Incurred But Not Yet Paid",
        "terseLabel": "Deferred financing costs included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "DeferredFinancingCostsIncurredButNotYetPaid",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arqt_EarlyExercisedOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Early Exercised Options",
        "label": "Early Exercised Options [Member]",
        "verboseLabel": "Early exercised options subject to future vesting"
       }
      }
     },
     "localname": "EarlyExercisedOptionsMember",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arqt_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Emerging Growth Company Status",
        "label": "Emerging Growth Company Status [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arqt_HawkeyeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hawkeye",
        "label": "Hawkeye [Member]",
        "terseLabel": "Hawkeye"
       }
      }
     },
     "localname": "HawkeyeMember",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsHawkeyeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arqt_HengruiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hengrui",
        "label": "Hengrui [Member]",
        "terseLabel": "Hengrui"
       }
      }
     },
     "localname": "HengruiMember",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsHengruiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arqt_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Operating Lease Liabilities",
        "label": "Increase (Decrease) in Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arqt_LeaseDescriptionAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease Description",
        "label": "Lease Description [Axis]",
        "terseLabel": "Lease Description [Axis]"
       }
      }
     },
     "localname": "LeaseDescriptionAxis",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arqt_LeaseDescriptionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease Description",
        "label": "Lease Description [Domain]",
        "terseLabel": "Lease Description [Domain]"
       }
      }
     },
     "localname": "LeaseDescriptionDomain",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arqt_LesseeOperatingLeaseFreeRentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Free Rent Period",
        "label": "Lessee, Operating Lease, Free Rent Period",
        "terseLabel": "Free rent period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseFreeRentPeriod",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "arqt_LesseeOperatingLeaseLetterOfCreditRequirement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Letter Of Credit Requirement",
        "label": "Lessee, Operating Lease, Letter Of Credit Requirement",
        "terseLabel": "Available letter of credit"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLetterOfCreditRequirement",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arqt_LesseeOperatingLeaseMonthlyRentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Monthly Rent Expense",
        "label": "Lessee, Operating Lease, Monthly Rent Expense",
        "terseLabel": "Straight-line rent expense"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyRentExpense",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arqt_LesseeOperatingLeaseSquareFootageOfLeasedSpace": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Square Footage Of Leased Space",
        "label": "Lessee, Operating Lease, Square Footage Of Leased Space",
        "terseLabel": "Square footage of leased space"
       }
      }
     },
     "localname": "LesseeOperatingLeaseSquareFootageOfLeasedSpace",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "arqt_LesseeOperatingLeaseTenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Tenant Improvement Allowance",
        "label": "Lessee, Operating Lease, Tenant Improvement Allowance",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTenantImprovementAllowance",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arqt_LesseeOperatingLeaseTermForTerminationOption": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Term For Termination Option",
        "label": "Lessee, Operating Lease, Term For Termination Option",
        "terseLabel": "Lease term prior to termination option"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermForTerminationOption",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "arqt_LesseeOperatingLeasesNumberFacilitiesLeased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Leases, Number Facilities Leased",
        "label": "Lessee, Operating Leases, Number Facilities Leased",
        "terseLabel": "Number of operating leases (in leases)"
       }
      }
     },
     "localname": "LesseeOperatingLeasesNumberFacilitiesLeased",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arqt_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Right-of-use asset amortization"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arqt_PerformanceConditionRestrictedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Condition Restricted Stock",
        "label": "Performance Condition Restricted Stock [Member]",
        "terseLabel": "Performance Condition Restricted Stock"
       }
      }
     },
     "localname": "PerformanceConditionRestrictedStockMember",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arqt_PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preclinical And Clinical Accruals And Costs",
        "label": "Preclinical And Clinical Accruals And Costs [Policy Text Block]",
        "terseLabel": "Preclinical and Clinical Accruals and Costs"
       }
      }
     },
     "localname": "PreclinicalAndClinicalAccrualsAndCostsPolicyTextBlock",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arqt_PrepaidClinicalTrialTestCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid Clinical Trial Test Costs, Current",
        "label": "Prepaid Clinical Trial Test Costs, Current",
        "terseLabel": "Prepaid clinical trial costs"
       }
      }
     },
     "localname": "PrepaidClinicalTrialTestCostsCurrent",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Arrangement, Contract to Perform for Others. Maximum Product Milestone Payments",
        "label": "Research and Development Arrangement, Contract to Perform for Others. Maximum Product Milestone Payments",
        "terseLabel": "Maximum milestone payments for licensed products"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails",
      "http://arcutis.com/role/LicenseAgreementsHengruiDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Arrangement, Contract to Perform for Others, Maximum Sales Milestone Payments",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Maximum Sales Milestone Payments",
        "terseLabel": "Maximum milestone payments for net worldwide sales"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails",
      "http://arcutis.com/role/LicenseAgreementsHengruiDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arqt_ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Payments, Milestones, Or Royalties",
        "label": "Research And Development Arrangement, Payments, Milestones, Or Royalties",
        "terseLabel": "Payments, milestones or royalties"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementPaymentsMilestonesOrRoyalties",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsHawkeyeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arqt_ServiceConditionRestrictedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Service Condition Restricted Stock",
        "label": "Service Condition Restricted Stock [Member]",
        "terseLabel": "Service Condition Restricted Stock"
       }
      }
     },
     "localname": "ServiceConditionRestrictedStockMember",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Base Amount Of Common Stock Shares Authorized",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Base Amount Of Common Stock Shares Authorized",
        "terseLabel": "Number of shares authorized for sale under the ESPP (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Base Number Of Options Issuable",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Base Number Of Options Issuable",
        "terseLabel": "Based number of options issuable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding",
        "terseLabel": "Increase in shares available for grant, percentage of shares outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable",
        "terseLabel": "Maximum shares to be issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Vesting On A Monthly Basis",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Vesting On A Monthly Basis",
        "terseLabel": "Number of shares vesting on a monthly basis (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arqt_StockAwardsFutureGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Awards, Future Grant",
        "label": "Stock Awards, Future Grant [Member]",
        "terseLabel": "Common stock awards available for grant under employee benefit plans"
       }
      }
     },
     "localname": "StockAwardsFutureGrantMember",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Lapse Of Repurchase Rights Pursuant To Early Stock Exercises",
        "label": "Stock Issued During Period, Lapse Of Repurchase Rights Pursuant To Early Stock Exercises",
        "terseLabel": "Lapse of repurchase rights related to common stock issued pursuant to early exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arqt_StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Lapse of Repurchase Rights Related to Common Stock Issued Pursuant to Early Exercises, Shares",
        "label": "Stock Issued During Period, Lapse of Repurchase Rights Related to Common Stock Issued Pursuant to Early Exercises, Shares",
        "terseLabel": "Lapse of repurchase rights related to common stock issued pursuant to early exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodLapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Vesting Of Founder Shares Subject To Repurchase, Shares",
        "label": "Stock Issued During Period, Vesting Of Founder Shares Subject To Repurchase, Shares",
        "terseLabel": "Vesting of founder shares subject to repurchase (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseShares",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "arqt_StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Vesting Of Founder Shares Subject To Repurchase, Value",
        "label": "Stock Issued During Period, Vesting Of Founder Shares Subject To Repurchase, Value",
        "terseLabel": "Vesting of founder shares subject to repurchase"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodVestingOfFounderSharesSubjectToRepurchaseValue",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arqt_StockOptionsIssuedAndOutstandingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Options Issued and Outstanding",
        "label": "Stock Options Issued and Outstanding [Member]",
        "terseLabel": "Options issued and outstanding"
       }
      }
     },
     "localname": "StockOptionsIssuedAndOutstandingMember",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arqt_StockPurchaseAgreementNumberOfSharesIssuable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Purchase Agreement, Number Of Shares Issuable",
        "label": "Stock Purchase Agreement, Number Of Shares Issuable",
        "terseLabel": "Number of shares issuable (in shares)"
       }
      }
     },
     "localname": "StockPurchaseAgreementNumberOfSharesIssuable",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arqt_StockPurchaseAgreementNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Purchase Agreement, Number of Tranches",
        "label": "Stock Purchase Agreement, Number of Tranches",
        "terseLabel": "Number of tranches (in tranches)"
       }
      }
     },
     "localname": "StockPurchaseAgreementNumberOfTranches",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arqt_StockPurchaseAgreementPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Purchase Agreement, Price Per Share",
        "label": "Stock Purchase Agreement, Price Per Share",
        "terseLabel": "Price per share (in USD per share)"
       }
      }
     },
     "localname": "StockPurchaseAgreementPricePerShare",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "arqt_StockPurchaseAgreementTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Purchase Agreement, Tranche One",
        "label": "Stock Purchase Agreement, Tranche One [Member]",
        "terseLabel": "Stock Purchase Agreement, Tranche One"
       }
      }
     },
     "localname": "StockPurchaseAgreementTrancheOneMember",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arqt_StockPurchaseAgreementTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Purchase Agreement, Tranche Three",
        "label": "Stock Purchase Agreement, Tranche Three [Member]",
        "terseLabel": "Stock Purchase Agreement, Tranche Three"
       }
      }
     },
     "localname": "StockPurchaseAgreementTrancheThreeMember",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arqt_StockPurchaseAgreementTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Purchase Agreement, Tranche Two",
        "label": "Stock Purchase Agreement, Tranche Two [Member]",
        "terseLabel": "Stock Purchase Agreement, Tranche Two"
       }
      }
     },
     "localname": "StockPurchaseAgreementTrancheTwoMember",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arqt_StockPurchaseAgreementTranchesTwoAndThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Purchase Agreement, Tranches Two And Three",
        "label": "Stock Purchase Agreement, Tranches Two And Three [Member]",
        "terseLabel": "Stock Purchase Agreement, Tranches Two And Three"
       }
      }
     },
     "localname": "StockPurchaseAgreementTranchesTwoAndThreeMember",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arqt_TemporaryEquitySharesConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Shares, Conversion Of Convertible Securities",
        "label": "Temporary Equity, Shares, Conversion Of Convertible Securities",
        "negatedTerseLabel": "Conversion of preferred stock into common stock (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesConversionOfConvertibleSecurities",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Price Per Share",
        "label": "Temporary Equity, Stock Issued During Period, Price Per Share",
        "terseLabel": "Purchase price per share (in USD per share)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodPricePerShare",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Preferred stock issued (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arqt_TemporaryEquityValueConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Value, Conversion Of Convertible Securities",
        "label": "Temporary Equity, Value, Conversion Of Convertible Securities",
        "negatedTerseLabel": "Conversion of preferred stock into common stock upon initial public offering"
       }
      }
     },
     "localname": "TemporaryEquityValueConversionOfConvertibleSecurities",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arqt_UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unaudited Interim Condensed Financial Statements, Policy",
        "label": "Unaudited Interim Condensed Financial Statements, Policy [Policy Text Block]",
        "terseLabel": "Unaudited Interim Condensed Financial Statements"
       }
      }
     },
     "localname": "UnauditedInterimCondensedFinancialStatementsPolicyPolicyTextBlock",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arqt_VariableInterestEntitiesNumberOfSharesHeld": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable Interest Entities, Number Of Shares Held",
        "label": "Variable Interest Entities, Number Of Shares Held",
        "terseLabel": "Number of shares held in VIE (in shares)"
       }
      }
     },
     "localname": "VariableInterestEntitiesNumberOfSharesHeld",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsHawkeyeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arqt_WestlakeVillageCaliforniaLeaseArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Westlake Village, California Lease Arrangement",
        "label": "Westlake Village, California Lease Arrangement [Member]",
        "terseLabel": "Westlake Village, California Lease Arrangement"
       }
      }
     },
     "localname": "WestlakeVillageCaliforniaLeaseArrangementMember",
     "nsuri": "http://arcutis.com/20200331",
     "presentation": [
      "http://arcutis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsHawkeyeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsHawkeyeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r45",
      "r79"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails",
      "http://arcutis.com/role/LicenseAgreementsHawkeyeDetails",
      "http://arcutis.com/role/LicenseAgreementsHengruiDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails",
      "http://arcutis.com/role/LicenseAgreementsHawkeyeDetails",
      "http://arcutis.com/role/LicenseAgreementsHengruiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Net amortization/accretion on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails",
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r49",
      "r50",
      "r51"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r48",
      "r51",
      "r52",
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r149",
      "r151",
      "r184",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r151",
      "r178",
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially antidilutive shares excluded from the calculation of net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r95",
      "r243",
      "r250"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r42"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized losses",
        "terseLabel": "Marketable securities, unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r100",
      "r112"
     ],
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r97",
      "r101",
      "r112"
     ],
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r99",
      "r112"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r152",
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails",
      "http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails",
      "http://arcutis.com/role/StockBasedCompensationDetails",
      "http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r26",
      "r74"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets",
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, estimated fair value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r75",
      "r77"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r69",
      "r74",
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r69",
      "r217"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails",
      "http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassificationOfVariableInterestEntityDomain": {
     "auth_ref": [
      "r202",
      "r204",
      "r207",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categorization of Variable Interest Entities (VIE) for consolidation and (or) disclosure purposes, whether individually or in aggregate, by: (1) VIEs consolidated because the entity is the primary beneficiary, (2) VIEs not consolidated because the entity is not the primary beneficiary, and (3) VIEs or potential VIEs that are not consolidated because necessary information is not available. In general, a VIE is a corporation, partnership, trust, or any other legal structure used for business purposes that either (a) does not have equity investors with voting rights or (b) has equity investors that do not provide sufficient financial resources for the entity to support its activities. A VIE often holds financial assets, including loans or receivables, real estate or other property. A VIE may be essentially passive or it may engage in research and development or other activities on behalf of another company.",
        "label": "Variable Interest Entity, Classification [Domain]",
        "terseLabel": "Variable Interest Entity, Classification [Domain]"
       }
      }
     },
     "localname": "ClassificationOfVariableInterestEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsHawkeyeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r197",
      "r198",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r35",
      "r126",
      "r245",
      "r254"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r125",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails",
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://arcutis.com/role/StockBasedCompensationDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheetsParenthetical",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://arcutis.com/role/LicenseAgreementsHawkeyeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheetsParenthetical",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 300,000,000 and 65,820,000 shares authorized at March 31, 2020 and December\u00a031, 2019, respectively; 38,154,550 and 2,879,763 shares issued at March 31, 2020 and December\u00a031, 2019, respectively; 37,471,997 and 2,120,853 shares outstanding at March 31, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r54",
      "r56",
      "r57"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r89",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r77",
      "r201",
      "r203",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock on an as-converted basis",
        "verboseLabel": "Convertible preferred stock outstanding"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails",
      "http://arcutis.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r218",
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Outstanding principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r102",
      "r112",
      "r115",
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)",
        "terseLabel": "Realized gains (losses) on investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://arcutis.com/role/StockBasedCompensationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current",
        "terseLabel": "Early exercise liability, current"
       }
      }
     },
     "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails",
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://arcutis.com/role/StockBasedCompensationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent",
        "terseLabel": "Early exercise liability, noncurrent"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://arcutis.com/role/StockBasedCompensationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent",
        "totalLabel": "Early exercise liability"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "auth_ref": [
      "r41",
      "r219"
     ],
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Current, Net",
        "terseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsCurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r72",
      "r121"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r43",
      "r44",
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Per share information:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r83",
      "r84",
      "r85"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Recognition period for unrecognized compensation costs related to unvested options expected to vest"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "verboseLabel": "ESPP shares subject to future issuance"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareDetails",
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Stock options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareDetails",
      "http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails",
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://arcutis.com/role/StockBasedCompensationDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value of Assets Measured on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r212",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r212",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r212",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r212",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r113",
      "r114",
      "r117",
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r77",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Operating Lease Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2020 (April through December)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: Amounts representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term (in months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesDetails",
      "http://arcutis.com/role/SubsequentEventDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r244",
      "r252"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r33",
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r69",
      "r70",
      "r73"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r53",
      "r55",
      "r59",
      "r73",
      "r84",
      "r247",
      "r255"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows",
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments (segment)"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Straight-line rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of future minimum lease payments",
        "totalLabel": "Total operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Current portion operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails",
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeasePaymentsDetails",
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r224",
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesOperatingLeaseSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r232",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentandContingenciesOperatingLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r231",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentandContingenciesOperatingLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r31"
     ],
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r47",
      "r49"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized gain on marketable securities",
        "verboseLabel": "Unrealized gain on short term investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r2",
      "r5"
     ],
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "verboseLabel": "Other prepaid expenses and current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters' option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r63",
      "r65",
      "r98"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r152",
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheetsParenthetical",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 and no shares authorized at March 31, 2020 and December 31, 2019, respectively; no shares issued and outstanding at March 31, 2020 and December 31, 2019;"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r24",
      "r25"
     ],
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails",
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r3",
      "r5",
      "r119",
      "r120"
     ],
     "calculation": {
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows",
      "http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "verboseLabel": "Proceeds from issuance of convertible preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r63",
      "r64",
      "r98"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r67",
      "r181"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r27",
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r123",
      "r253"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant, and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "auth_ref": [
      "r188",
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "terseLabel": "License agreement, cash payment"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails",
      "http://arcutis.com/role/LicenseAgreementsHengruiDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails",
      "http://arcutis.com/role/LicenseAgreementsHengruiDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r187",
      "r257"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r77",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock subject to future vesting",
        "verboseLabel": "Restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareDetails",
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "verboseLabel": "Restricted stock units outstanding"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails",
      "http://arcutis.com/role/StockBasedCompensationDetails",
      "http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r143",
      "r251"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets",
      "http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r230",
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from stock purchase agreement"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares Issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Stock price (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Antidilutive Shares Excluded from the Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Summary of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r151",
      "r177",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r151",
      "r177",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r189",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails",
      "http://arcutis.com/role/LicenseAgreementsHengruiDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r152",
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails",
      "http://arcutis.com/role/StockBasedCompensationDetails",
      "http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r157",
      "r168",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions in Calculating Stock Option Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r37",
      "r80",
      "r131",
      "r134",
      "r135",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r78",
      "r132",
      "r134",
      "r135",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Components of Shares of Stock for Issuance"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r202",
      "r204",
      "r207",
      "r208",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsHawkeyeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period of stock-based awards granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Unvested restricted stock (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails",
      "http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Vested (in shares)",
        "verboseLabel": "Restricted common stock vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://arcutis.com/role/StockBasedCompensationDetails",
      "http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "verboseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails",
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails",
      "http://arcutis.com/role/StockBasedCompensationDetails",
      "http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Weighted-Average Exercise Price (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised during the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Grant date fair value of options vested during the period (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r159",
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance, number of options (in shares)",
        "periodStartLabel": "Beginning balance, number of options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance, weighted-average exercise price (in USD per share)",
        "periodStartLabel": "Beginning balance, weighted-average exercise price (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "verboseLabel": "Shares of restricted stock issued to founders (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r150",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails",
      "http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails",
      "http://arcutis.com/role/StockBasedCompensationDetails",
      "http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "First anniversary date"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Monthly basis"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r77",
      "r152",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r174",
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationAssumptionsinCalculatingStockOptionAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Remaining contractual term, exercisable (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "verboseLabel": "Grant date fair value of options vested during the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock, as a percentage of closing trading price per share"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, shares",
        "periodStartLabel": "Beginning Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitSharesofCommonStockforIssuanceDetails",
      "http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r40",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://arcutis.com/role/StockBasedCompensationDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r39",
      "r136",
      "r137",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock into common stock upon initial public offering (in shares)",
        "verboseLabel": "Shares issued as a result of conversion of promissory notes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r136",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issuance of shares of common stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r136",
      "r143",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock upon the exercise of stock option (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://arcutis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r40",
      "r136",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock into common stock upon initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r136",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of shares of common stock, net of issuance costs of $16.0 million"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r40",
      "r136",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon the exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r21",
      "r22",
      "r96"
     ],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets",
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "auth_ref": [
      "r14",
      "r15",
      "r77",
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.",
        "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio for capital stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r10",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "calculation": {
      "http://arcutis.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Convertible preferred stock, $0.0001 par value; no shares and 48,787,898 shares authorized at March 31, 2020 and December\u00a031, 2019, respectively; no shares and 24,385,388 shares issued and outstanding at March 31, 2020 and December\u00a031, 2019, respectively",
        "verboseLabel": "Net Carrying Value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheets",
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Liquidation Preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r10",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value (In USD per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheetsParenthetical",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheetsParenthetical",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Convertible preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheetsParenthetical",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance, convertible preferred stock (in shares)",
        "periodStartLabel": "Beginning balance, convertible preferred stock (in shares)",
        "terseLabel": "Convertible preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedBalanceSheetsParenthetical",
      "http://arcutis.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitComponentsofConvertiblePreferredStockDetails",
      "http://arcutis.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Preferred stock issued"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsAstraZenecaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r10",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Summary of Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/ConvertiblePreferredStockandStockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "Government securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/FairValueMeasurementsEstimatedValueofCashandCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcutis.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r87",
      "r88",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis": {
     "auth_ref": [
      "r202",
      "r204",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of Variable Interest Entity (VIE).",
        "label": "Variable Interest Entities [Axis]",
        "terseLabel": "Variable Interest Entities [Axis]"
       }
      }
     },
     "localname": "VariableInterestEntitiesByClassificationOfEntityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsHawkeyeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsHawkeyeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsHawkeyeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "terseLabel": "Ownership percentage of VIE"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/LicenseAgreementsHawkeyeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r228",
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease payments"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average shares used in computing net loss per share, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://arcutis.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=116854557&loc=d3e20905-112640"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759068-111685"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5710-111685"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5747-111685"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6228884-111685"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.6(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r258": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r259": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r261": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r262": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r263": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r264": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796935216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,443,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,452,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Grant date fair value of options vested during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value of options vested during the period (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Early exercise liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognition period for unrecognized compensation costs related to unvested options expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock-based awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognition period for unrecognized compensation costs related to unvested options expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted common stock vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares of restricted stock issued to founders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,187,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock | First anniversary date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=arqt_ServiceConditionRestrictedStockMember', window );">Service Condition Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares of restricted stock issued to founders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,102,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted common stock vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,931<span></span>
</td>
<td class="nump">68,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=arqt_ServiceConditionRestrictedStockMember', window );">Service Condition Restricted Stock | First anniversary date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares of restricted stock issued to founders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,102,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=arqt_ServiceConditionRestrictedStockMember', window );">Service Condition Restricted Stock | Monthly basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis', window );">Number of shares vesting on a monthly basis (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">827,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=arqt_PerformanceConditionRestrictedStockMember', window );">Performance Condition Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares of restricted stock issued to founders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted common stock vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding', window );">Increase in shares available for grant, percentage of shares outstanding</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, as a percentage of closing trading price per share</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized', window );">Number of shares authorized for sale under the ESPP (in shares)</a></td>
<td class="nump">351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable', window );">Maximum shares to be issued</a></td>
<td class="nump">5,265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arqt_A2020EquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved (in shares)</a></td>
<td class="nump">2,134,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding', window );">Increase in shares available for grant, percentage of shares outstanding</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable', window );">Based number of options issuable (in shares)</a></td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arqt_A2020EquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock-based awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arqt_A2017EquityIncentivePlanMember', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved (in shares)</a></td>
<td class="nump">1,550,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Early exercise liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Early exercise liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent', window );">Early exercise liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Base Amount Of Common Stock Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseAmountOfCommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Base Number Of Options Issuable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardBaseNumberOfOptionsIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number Of Shares Available For Grant, Percentage Of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrantPercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Maximum Shares Issuable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Vesting On A Monthly Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesVestingOnAMonthlyBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=arqt_ServiceConditionRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=arqt_ServiceConditionRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=arqt_PerformanceConditionRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=arqt_PerformanceConditionRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arqt_A2020EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arqt_A2020EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arqt_A2017EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arqt_A2017EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792790608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 190,893<span></span>
</td>
<td class="nump">$ 63,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">58,426<span></span>
</td>
<td class="nump">37,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,559<span></span>
</td>
<td class="nump">5,209<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">253,878<span></span>
</td>
<td class="nump">106,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">254,392<span></span>
</td>
<td class="nump">107,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,759<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">7,281<span></span>
</td>
<td class="nump">3,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,222<span></span>
</td>
<td class="nump">5,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">12,510<span></span>
</td>
<td class="nump">5,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, $0.0001 par value; no shares and 48,787,898 shares authorized at March 31, 2020 and December&#160;31, 2019, respectively; no shares and 24,385,388 shares issued and outstanding at March 31, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">166,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 and no shares authorized at March 31, 2020 and December 31, 2019, respectively; no shares issued and outstanding at March 31, 2020 and December 31, 2019;</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000,000 and 65,820,000 shares authorized at March 31, 2020 and December&#160;31, 2019, respectively; 38,154,550 and 2,879,763 shares issued at March 31, 2020 and December&#160;31, 2019, respectively; 37,471,997 and 2,120,853 shares outstanding at March 31, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">336,145<span></span>
</td>
<td class="nump">1,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">19<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(94,285)<span></span>
</td>
<td class="num">(66,272)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">241,882<span></span>
</td>
<td class="num">(65,029)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 254,392<span></span>
</td>
<td class="nump">$ 107,012<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6644770128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 16.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795812336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Estimated Value of Cash and Cash Equivalents and Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 190,893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,336,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, estimated fair value</a></td>
<td class="nump">190,893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,336,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">58,407,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,930,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">58,426,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,929,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gains (losses) on investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">53,396,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,909,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">53,396,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,909,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">5,011,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,021,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">5,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,020,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,780,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,780,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">190,893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,558,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, estimated fair value</a></td>
<td class="nump">$ 190,893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,558,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,998,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,998,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6617537344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:73.877%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid clinical trial costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,583&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,998&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred financing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,747&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other prepaid expenses and current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">650&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">402&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,209&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Liabilities</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:73.877%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical trial accruals</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,114&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,497&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">806&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,379&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Early exercise liability, current</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">269&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">553&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total accrued liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,654&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6611311952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Antidilutive Shares Excluded from the Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.906%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.181%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.183%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible preferred stock on an as-converted basis</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,262,425&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,061,521&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,461,191&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Early exercised options subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">613,627&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">578,298&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">198,992&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">344,657&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ESPP shares subject to future issuance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,392&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,885,532&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,646,571&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>48
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    "  -A*Q0T&_EB.X    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+!:L,P#(9?9?B>R'98&2;-I:.G#@8K;.QF;+4UBQ-C:R1]^SE9
MFS*V!]C1TN]/GT"U"<KT$9]C'S"2PW0W^K9+RH0U.Q$%!9#,";U.94YTN7GH
MH]>4G_$(09L/?420G*_ (VFK2<,$+,)"9$UMC3(1-?7Q@K=FP8?/V,XP:P!;
M]-A1 E$*8,TT,9S'MH8;8((11I^^"V@7XES]$SMW@%V28W)+:AB&<JCF7-Y!
MP-O3[F5>MW!=(MT9S+^24W0.N&;7R:_5YG&_98WDDA?\OA!R+U:J$DH^O$^N
M/_QNPKZW[N#^L?%5L*GAUUTT7U!+ P04    "  -A*Q0F5R<(Q &  "<)P
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M=!A,V?_MWWS1RP<G?1_[NFC'_\'^M>WJ<FJEMU)F/Z[7O!JOEZG]]S Y *<
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MARV(9N"X]R*C$C@K+64E< X"]G_4C83+>&DIR+P$#DQ+@0D<A7QD!%PNO4-
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MYL394Y6/P64*"RE!(24@)'&$E%!;8A=6 3!"L@)6@V+83F+_2T0+!:$%1T)
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MD  ##<<Q2;Z-/%X(XXT WHQH.,W$YAQ&P>PBP"[#FQ224"+?\?M9&HF%L40
M2V+]$F" C4*.KS5]C"7@RK\7<"ZA@!Q,,"E+\=B.P&"B^,<;*,*\(< ;T4*1
MY,U$#T48-H2:-;%]9;<VLOPTYHP&G9IAS\2UEIW:-",T)I)&1.*,T))(#!%]
M4DKVY6S]C;A*1AXQ&I--H^:/MYE:-G;6&!H;GY'W3M3;<:YIR37^DK69U@Q3
MP?#3J+?C\-.R<4M3D<NT:)@,9J1&C.0\TI*1*HP31=%8, Q)#2 9\8Y"2_@I
M&Q.'Z1KI^/@ 2+:NQK+&:-.@YXHXVC7HN<($#*741>KZJ33,")-2 U)&Q#-*
MY/APT49+G*JQ@PF-8:H13,61CH0I/U6[F]8,#WTP<0UZ-Q;'/I*X-Y2$BO'_
M_F/=,"7,98.XS#>[ ;PU*DGXPP_H6-8;)-%6M'!W0*=2/@)2<Y-Z\(Z<CQG,
M> ,8'VE>F62\CDVLTI3OC.#J(+<][/\CJU[VAWKV6#9-670GM\]EV3CO-?SD
M_>U<MKU<Y.ZY:;_&_GMU/F0_7S3EL?\!(;C\BK'Z'U!+ P04    "  -A*Q0
MZLD;F;<!  #3 P  &    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;&U3VVZ<
M,!#]%<L?$.\ZL*U6@)1-%+52*ZU2M7WVP@!6?*&V6=*_KR\L10DO>&8X<^;,
M>%Q,VKS:'L"A-RF4+7'OW' DQ-8]2&;O] #*_VFUD<QYUW3$#@98$Y.D('2W
M.Q#)N,)5$6-G4Q5Z=((K.!MD1RF9^7L"H:<2[_$M\,*[WH4 J8J!=? #W,_A
M;+Q'%I:&2U"6:X4,M"5^V!]/6<!'P"\.DUW9*'1RT?HU.%^;$N^"(!!0N\#
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MV4T:6&H>BLA%?W0!7!<[(,WA?0<%54B1\ETH-@LU!E#OLLCX #$;(!X#Q,L
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M@ 2A(,6&&%T.OD4*/$D!:!5J\(3@$0@4@9(P$"C=(,:/!D;DRX;G'S"O=@2
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MT+AP?.?/9AZSV7 X+#^(K=^X_ 502P,$%     @ #82L4#)4C".T 0  T@,
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M^+.9QFPR'/;S#V++-RY^ U!+ P04    "  -A*Q0O _=*K4!  #2 P  &0
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M5<=D_/@]D(:C9F<X_?Y@_VR#-\$<F.+/HOI5'O5E'69A<.0G=JWTB[A_X4-
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M^><3+[G1VH$O97/C:^G\%"^.@,8%\\[;9GK+D^-T/X\I6?X5Y5]02P,$%
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MO^J_@O4'1A_M%[[@_)EQ\P=02P,$%     @ #82L4-LX'FK% P  71(  !D
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M54_.C#=$JB6_(-%Q("=3U% 4!4&*&E*W?I&;O3TO<G:5M&YASSUQ;1K"_^R
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MTTE.C+WJP9=+[F\T$% X2^U 5'.' U"JC13&K\G3GY?4A<O^P_V3R:ZRG(B
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MEW)D[$4//I^WKJ\= 863U"F(:NZP!TIU)N7CUY34G9E:N.P_LG\TQ:MBCD3
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M/AZFXT"R?KHHO/FVJOX 4$L#!!0    (  V$K%!?=9\FVP$  &$$   9
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;'U466[;,!"]"L$#A-KBQ(8D('90
MM$ +&"F:?M/2:$&XJ"1EI;<O2<F*:JO],3FC]]XLG'$Z2/6F&P"#WCD3.L.-
M,=V.$%TTP*F^DQT(^Z62BE-C3543W2F@I2=Q1J(@V!!.6X'SU/N.*D]E;U@K
MX*B0[CFGZO<>F!PR'.*+XZ6M&^,<)$\[6L-W,#^ZH[(6F57*EH/0K11(097A
MIW!W2!S> UY;&/3BCEPE)RG?G/&ES'#@$@(&A7$*U!YG. !C3LBF\6O2Q'-(
M1US>+^J??.VVEA/5<)#L9UN:)L./&)50T9Z9%SE\AJF>>XRFXK_"&9B%NTQL
MC$(R[7]1T6LC^:1B4^'T?3Q;X<]ATK_0U@G11(AF@HW]/T(\$>(/@N\F&3/S
MI3Y30_-4R0&I\;$ZZF8BW,6VF85S^M[Y;[9:;;WG/'[<IN3LA";,?L1$"TPX
M(XA5GT-$:R'VT0T]^CO X181!IOU$/%J%;$7B)<"VW\()*L"B1=(EFW8!E=M
M&#$;CQ$>DSQ<%7(+":_3((N7X:!J/\0:%;(7QO5@X9WWY"ER+WOEW]O]&<?]
M0V9<OF]4U:W0Z"2-G1O_NI64!FR&P9V=Z,;N^VPPJ(R[/MB[&J=^-(SLIH4F
M\[]*_@=02P,$%     @ #82L4/W&>ZZD 0  O0,  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL;5-M;YLP$/XKR#^@#H:^18"T=*HVJ96B3NL^.W $
MJS:FMA.Z?[^S(8A%_H)]Y^?E[K"+49L/VP&XY$O)WI:D<V[84FKK#A2W-WJ
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MZ'Z9F[4<IJIAHT4W3HSQ-+9N_@-02P,$%     @ #82L4.*8O I* @  L0<
M !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULE97;CILP$(9?!?$ ,>:<
MB" E6U6MU$K15MU>.\0): VFMA.V;U_;$,J2B3:]"?8P\W\S)N/).BY>94FI
M<MYJULBU6RK5KA"214EK(A>\I8U^<^2B)DIOQ0G)5E!RL$$U0[[GQ:@F5>/F
MF;7M1)[QLV)50W?"D>>Z)N+/EC+>K5WL7@W/U:E4QH#RK"4G^H.JG^U.Z!T:
M50Y531M9\<81]+AV-WBUQ:$)L!XO%>WD9.V84O:<OYK-U\/:]4Q&E-%"&0FB
M'Q?Z1!DS2CJ/WX.H.S)-X'1]5?]LB]?%[(FD3YS]J@ZJ7+NIZQSHD9R9>N;=
M%SH4%+G.4/TW>J%,NYM,-*/@3-I?ISA+Q>M!1:=2D[?^637VV0WZUS XP!\"
M_#$@L &H!]G,/Q%%\DSPSA']X;?$?&.\\O79%,9HC\*^T\E+;;WDD>=GZ&*$
M!I]M[^-/?/#H@;3ZB/ AQ-:_"8^\ !8(P!P#*Q"\$PAA@1 4"*U ^$X@FA79
M^T36I[$^'HR(0$0$(.(9(KI!X$"WSQU.#')B@)/,./&CI20@(@$0Z0R1/(I(
M040*()8S1/I?I[4$.<O;?PZ^(X ]N#^\VU0QGC=([Q1_?!SX3A=B@'+3AD.O
MX@G&3Q;QG6;$8#=NL ^@@CG*?_3[8KAE<0!0PCDE>)@"]S4&&AO/&WMP2C\X
M-32Y,6LJ3G962*?@Y\8.JHEUG$<;W]ZX_]S[8?:=B%/52&?/E;ZW[>UZY%Q1
MG8VWT-66>GZ.&T:/RBP3O1;]$.DWBK?#@$3CE,[_ E!+ P04    "  -A*Q0
MYHVOM"H"  ![!@  &0   'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6R-56UO
MFS 0_BN('U#S3A(1I"93M4F;%'7:]MDA%T"U,;6=T/W[V890"NZ4+]@^GGON
MGK-]SCK&7T0%()TW2AJQ=2LIVPU"HJB 8O' 6FC4GS/C%$NUY"42+0=\,DZ4
MH,#S$D1QW;AY9FP'GF?L(DG=P($[XD(IYG]W0%BW=7WW9GBNRTIJ \JS%I?P
M$^2O]L#5"HTLIYI"(VK6.!S.6_?1W^Q]3SL8Q.\:.C&9.UK*D;$7O?AVVKJ>
MS@@(%%)38#5<80^$:":5Q^M ZHXQM>-T?F-_,N*5F",6L&?D3WV2U=9=N<X)
MSOA"Y#/KOL(@*':=0?UWN )1<)V)BE$P(LS7*2Y",CJPJ%0H?NO'NC%C-_#?
MW.P.P> 0C XJ]O\<PL$A?'>(C/@^,R/U"Y8XSSCK'-[O5HOUH? WH2IFH8VF
M=N:?4BN4]9K'?I*AJR8:,+L>$TPP_HA BGT,$=A"[(*%>_ QP'Z)\+W$'B*T
MJ@@-0?A!16HGB*P$D2&(IAF$\S+TF,1@&H-9K[V9DB4F_41(;,TC7N;AK>P$
MB94@N;\2J94@O:,2/2:>J(SFAV:_Q(2?G)J5-8^5I1)K.\':2K"^OQ*J#UGO
MAG='+0;0=,OC-)H5PP**XEDN:')E*?#2=#?A%.S22'TY)M:Q@SX&^LK/[#O=
M64TK>*?IV_(/S,NZ$<Z12=50S+4_,R9!I>@]J*VJU$LP+@B<I9ZF:L[[=M@O
M)&N'5H_&]R;_!U!+ P04    "  -A*Q0'CU%BV<"  "W"   &0   'AL+W=O
M<FMS:&5E=',O<VAE970T-2YX;6R55MN.FS 0_17$!ZPQMY 504I25:W42M%6
MW3X[Q EH#::V$[9_7]L0DCB35?N"[>',\9D!SSCON7B3%:7*>V]8*Q=^I53W
MC) L*]H0^<0[VNHW>RX:HO12')#L!"4[Z]0P% 9!BAI2MWZ16]M&%#D_*E:W
M=",\>6P:(OZL*./]PL?^V?!2'RIE#*C(.W*@/ZCZV6V$7J&)95<WM)4U;SU!
M]PM_B9_7.#8.%O%:TUY>S3T3RI;S-[/XNEOX@5%$&2V5H2!Z.-$U9<PP:1V_
M1U)_VM,X7L_/[)]M\#J8+9%TS=FO>J>JA9_YWH[NR9&I%]Y_H6- B>^-T7^C
M)\HTW"C1>Y2<2?OTRJ-4O!E9M)2&O ]CW=JQ'_G/;K!#.#J$DT,8?>@0C0[1
MQ<%F$PW*;*B?B")%+GCOB>%K=<3\%/@YTLDLC='FSK[3T4IM/14)SG)T,D0C
M9C5@PBL,OD6L[Q%Q=L$@K6"2$4(R5N$=0>AL<8](0WB'" PTLO[1M<0H@PEB
MD""V!/%-IN9.I@!,&#B!0)@'N4I (0E X&1K!6$B1PB$B6$A*2@D!0@21PB$
M21TA$&8&"YF!0F8 @?L30QCG\ZT!3!3 0C)02 80.&=E=8^)XYDCY&/,C9 Y
M*&0."'EP7'  %X;@WP\,?E!;,* B<HL+!(K=^@*!D@=BP JSQ"% D3Z@@$L(
M_H\:@N$B@H'3?Y\2".3^(B#(%8.NVD!#Q<%V3.F5_-C:=GUEG;KR,K1MY (?
M6OIW(@YU*[TM5[H9V9:QYUQ1K25XTJ6DTK>(:<'H7IGI3,_%T$J'A>+=>$U
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MV@X3,Y9MJ]%.M&BZ-BKH>[G5/U!+ P04    "  -A*Q0D<"=M5X"  #F!P
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M@_!212"X<-&\*DD23H7BN1 )IT+!Z-5LF+C8!B.]@E];V]U&UJ&);;%]=?_
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MK*O'_0-@RW:7E<&\^O9O+HEDHMLU^T,.L_</YZ/$#?&QY-UA#^A>XN%W?08
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M]XC]!\(C3J#)#7!ZF K- P7@:<.J;(R8_A0AQ3Y.NAAV(FY^[7T]CO9'O^A
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MYPIK% R?4N+F^4/U**:S>W2'8YVS=;4BU5CR^<A0Q.'RJ5JE4R>O-W>+OJ(
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MP-N*AE%/8VE_[>"M*>'.,>"5))Y6=_ RXKG!:X&0!SYGZ*>^03(*-/9#K<S
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MP/+:VY%+9QR*&' 60RPD8@UW1QU$F+5$I(1[E/0Y>N:VR27A+--6/EA[F8!
M.LW)QD<)3@(82)IY5F9B M5BV+":\K#-:VS>4'D@<B"&U?*JNO%;38;G[?N,
MB MF;E )-3X[[)6Z[CG,G/#P.^F_:$MON_6YCPMEW]MNB^W73)ZQ0\;H=7E?
M(Y#O>DI2<-4W_.HS?Z2FPIV)NE0]&$2 37Z?]ZRZVR?#K0D_YS;D_K2M?X[O
MW&9Q<*04+]%&C#A]Y*V9-#;0ABMB(T8:V\E*_",P-#"L%9;K)AO39P!KSG9A
MT<"=HBT9*[6<S:K]K[QV553W&P:!4>2.<K/<8"PSG9XC$@]<HE;1-9[G8P <
M1*\P9R88*=TC5M1'0^00<137$KINRJ7#Z&^S9IW]/91';*MX[_H4:HD8D.1
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M8 BIJAA-D(F^Y%)*UUW9U^G=DACJ3E@;O1944\)?@H77I,'QO<-[.0DYKH[
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MQDF:>/Y,H2<7TV%0IK$K__GL(YYJ6-;1>1\@+PG%/ZM_C_S>'TS*,)5W;(]
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M R,+R>RJEGZ^NM0(:TQ;QLHPQ"NP'L0.M26#M[0*[A+<F@FS&8F@UIF*F*X
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MX^MM0&_CZVU ;[O 60DZ+.'K;4!OX^MM0&_CZVU ;^/K;4!OX^MM0&_CZVU
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M[.>S[E_.R3=02P$"% ,4    "  -A*Q0'R// \     3 @  "P
M    @ $     7W)E;',O+G)E;'-02P$"% ,4    "  -A*Q0)^B'#H(   "Q
M    $               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   (  V$K%#0;^6([@   "L"   1              "  9D!  !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    (  V$K%"97)PC$ 8  )PG   3
M      "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ #82L
M4/IH,)5* P  !1   !@              ( !]P@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    (  V$K%!(=?HTL ,  /<0   8
M      "  7<,  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M"  -A*Q0$@TXGIH"  #R"0  &               @ %=$   >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ #82L4)80\;+$ @  ZPD  !@
M             ( !+1,  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    (  V$K%"IG'X(U 0  -$8   8              "  2<6  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  -A*Q0ZLD;F;<!  #3
M P  &               @ $Q&P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ #82L4$0W/F?P P  W1$  !@              ( !'AT
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (  V$K%!&-HP6
ML $  -(#   8              "  40A  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    "  -A*Q0L# =K[4!  #2 P  &
M@ $J(P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ #82L
M4&H&]Q"U 0  T@,  !D              ( !%24  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    "  -A*Q0K3=O:;0!  #2 P  &0
M        @ $!)P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   (  V$K%"SWHNCL0$  -(#   9              "  >PH  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ #82L4.9H78>V 0  T ,
M !D              ( !U"H  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    "  -A*Q0Z6 1];8!  #2 P  &0              @ '!+
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (  V$K% @IB2Z
MLP$  -(#   9              "  :XN  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ #82L4#)4C".T 0  T@,  !D
M ( !F#   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  -
MA*Q0O _=*K4!  #2 P  &0              @ &#,@  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (  V$K%!]FC%:F@(  *P*   9
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M970R,BYX;6Q02P$"% ,4    "  -A*Q0<;AEF.$!   !!0  &0
M    @ %!/P  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M  V$K%!B0N.3LP$  -(#   9              "  5E!  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ #82L4.V6"A;= @  .@L  !D
M             ( !0T,  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    "  -A*Q0EE>GG7L"  ")"   &0              @ %71@  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (  V$K%#<41"[SP,
M '(4   9              "  0E)  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ #82L4-LX'FK% P  71(  !D              ( !
M#TT  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  -A*Q0
MG\C83@T"  #W!0  &0              @ $+40  >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    (  V$K%!O&YY]$ (  /@%   9
M      "  4]3  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ #82L4.TCEUF@ @  2PD  !D              ( !EE4  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  -A*Q0B$(E,Q,"  "I!0
M&0              @ %M6   >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    (  V$K%# Z%!^BP(  $<)   9              "  ;=:  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ #82L4+4Z>QQ%
M @  &@<  !D              ( !>5T  'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    "  -A*Q0QFB/F"8"  "Y!@  &0
M@ 'U7P  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (  V$
MK%!?=9\FVP$  &$$   9              "  5)B  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ #82L4/W&>ZZD 0  O0,  !D
M         ( !9&0  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
M    "  -A*Q0B:&XL7H#  #H#P  &0              @ $_9@  >&PO=V]R
M:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (  V$K%#:,Y05^P0  -T9
M   9              "  ?!I  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
M4$L! A0#%     @ #82L4$L#V@A4 @  *@@  !D              ( !(F\
M 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  -A*Q0TM=&
MB^L$  #I&P  &0              @ &M<0  >&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;%!+ 0(4 Q0    (  V$K%"/44\GWP(  ,(*   9
M  "  <]V  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
M#82L4.*8O I* @  L0<  !D              ( !Y7D  'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    "  -A*Q0YHVOM"H"  ![!@  &0
M            @ %F?   >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    (  V$K% >/46+9P(  +<(   9              "  <=^  !X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ #82L4(QR6\*G @
MUPD  !D              ( !98$  'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    "  -A*Q0D<"=M5X"  #F!P  &0              @ %#
MA   >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (  V$K%"5
MIW%9#7   .*S 0 4              "  =B&  !X;"]S:&%R9613=')I;F=S
M+GAM;%!+ 0(4 Q0    (  V$K%"&5OV,6 (  &0,   -              "
M 1?W  !X;"]S='EL97,N>&UL4$L! A0#%     @ #82L4-'M6MD"!   Q1\
M  \              ( !FOD  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M  V$K% ?(?K>R@$  .(<   :              "  <G]  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  V$K%#]T  :O@$  .T<   3
M              "  <O_  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     X
- #@ .@\  +H! 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6662859600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text">License Agreements<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">AstraZeneca License Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2018, the Company entered into an exclusive license agreement, or the AstraZeneca License Agreement, with AstraZeneca AB, or AstraZeneca, granting the Company a worldwide exclusive license, with the right to sublicense through multiple tiers, under certain AstraZeneca-controlled patent rights, know-how and </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">regulatory documentation, to research, develop, manufacture, commercialize and otherwise exploit products containing roflumilast in topical forms, as well as delivery systems sold with or for the administration of roflumilast, or collectively, the AZ-Licensed Products, for all diagnostic, prophylactic and therapeutic uses for human dermatological indications, or the Dermatology Field. Under this agreement, the Company has sole responsibility for development, regulatory, and commercialization activities for the AZ-Licensed Products in the Dermatology Field, at its expense, and it shall use commercially reasonable efforts to develop, obtain and maintain regulatory approvals for, and commercialize the AZ-Licensed Products in the Dermatology Field in each of the United States, Italy, Spain, Germany, the United Kingdom, France, China, and Japan.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company paid AstraZeneca an upfront non-refundable cash payment of $1.0 million and issued 484,388 shares of Series&#160;B preferred stock, valued at $3.0 million on the date of the AstraZeneca License Agreement. The company subsequently paid AstraZeneca the first milestone cash payment of $2.0&#160;million upon the completion of a Phase 2b study of topical roflumilast cream (ARQ-151) in plaque psoriasis in August 2019 for the achievement of positive Phase 2 data for an AZ-licensed Product, which was recorded in research and development expense.  The Company has agreed to make additional cash payments to AstraZeneca of up to an aggregate of $12.5 million upon the achievement of specified regulatory approval milestones with respect to the AZ-Licensed Products and payments up to an additional aggregate amount of $15.0 million upon the achievement of certain aggregate worldwide net sales milestones. With respect to any AZ-Licensed Products the Company commercializes under the AstraZeneca License Agreement, it will pay AstraZeneca a low to high single-digit percentage royalty rate on the Company&#8217;s, its affiliates&#8217; and its sublicensees&#8217; net sales of such AZ-Licensed Products, subject to specified reductions, until, as determined on an AZ-Licensed Product-by-AZ-Licensed Product and country-by-country basis, the later of the date of the expiration of the last-to-expire AstraZeneca-licensed patent right containing a valid claim in such country and ten years from the first commercial sale of such AZ-Licensed Product in such country. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no payments made or due in connection with AZ-licensed Products for the three months ended March 31, 2020 and 2019.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Hengrui Exclusive Option and License Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2018, the Company entered into an exclusive option and license agreement, or the Hengrui License Agreement, with Jiangsu Hengrui Medicine Co., Ltd., or Hengrui, whereby Hengrui granted the Company an exclusive option to obtain certain exclusive rights to research, develop and commercialize products containing the compound designated by Hengrui as SHR0302, a JAK 1 inhibitor, in topical formulations for the treatment of skin diseases, disorders, and conditions in the United States, Japan, Canada and the European Union (including for clarity the United Kingdom). The Company made a $0.4 million upfront non-refundable cash payment to Hengrui upon execution of the Hengrui Option and License Agreement which was recorded as research and development expense. In December 2019, the Company exercised its exclusive option under the agreement, for which it made a $1.5&#160;million cash payment, which was recorded in research and development expense, and also contemporaneously amended the agreement to expand the territory to additionally include Canada. In addition, the Company has agreed to make cash payments of up to an aggregate of $20.5 million upon achievement of specified clinical development and regulatory approval milestones with respect to the licensed products and cash payments of up to an additional aggregate of $200 million in sales-based milestones based on certain aggregate annual net sales volumes with respect to a licensed product. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to any products the Company commercializes under the Hengrui License Agreement, it will pay tiered royalties to Hengrui on net sales of each licensed product by the Company, or its affiliates, or its sublicensees, ranging from mid single-digit to sub-teen percentage rates based on tiered annual net sales bands subject to specified reductions. The Company is obligated to pay royalties until the later of (1)&#160;expiration of the last valid claim of the licensed patent rights covering such licensed product in such country and (2)&#160;expiration of regulatory exclusivity for the relevant licensed product in the relevant country, on a licensed product-by-licensed product and country-by-country basis. Additionally, the Company is obligated to pay Hengrui a specified percentage, ranging from the low-thirties to the sub-teens, of certain non-royalty sublicensing income it receives from sublicensees of its rights to the licensed products, such percentage decreasing as the development stage of the licensed products advance.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no payments made or due in connection with Hengrui for the three months ended March 31, 2020 and 2019.</span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Hawkeye Collaboration Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2019, the Company entered into a collaboration agreement, or Hawkeye Agreement, with Hawkeye Therapeutics, Inc., or Hawkeye, a related party with common ownership, for the development of one or more new applications of roflumilast. The Hawkeye Agreement grants Hawkeye an exclusive license to certain intellectual property developed under the agreement as it relates to the applications. </span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contemporaneously with the execution of the Hawkeye Agreement, the Company entered into a stock purchase agreement, purchasing 995,000 shares of Hawkeye&#8217;s common stock at $0.0001 per share, representing 19.9% of the outstanding common stock of Hawkeye.  In the event that Hawkeye issues shares of Series A preferred stock with proceeds over $5.0&#160;million, Hawkeye is required to issue to the Company a number of fully-paid fully-vested shares of common stock determined by dividing (i)&#160;$2,000,000 by (ii)&#160;an amount equal to the cash price per share for Series A preferred stock.  Other than the potential issuance of this common stock, there are no upfront payments, milestones or royalties pursuant to the Hawkeye Agreement. The Company determined that Hawkeye is a variable interest entity for which consolidation is not required as it is not the primary beneficiary.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6639021568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.906%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.181%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.183%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible preferred stock on an as-converted basis</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,262,425&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,061,521&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,461,191&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Early exercised options subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">613,627&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">578,298&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock subject to future vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">198,992&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">344,657&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ESPP shares subject to future issuance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,392&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,885,532&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,646,571&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6782297936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (April through December)</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amounts representing interest</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion operating lease liability</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6662697872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - AstraZeneca (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arqt_AstraZenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">License agreement, cash payment</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments', window );">Maximum milestone payments for licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments', window );">Maximum milestone payments for net worldwide sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Preferred stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,364,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B | AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Preferred stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others. Maximum Product Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumProductMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Maximum Sales Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arqt_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arqt_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6798436416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity (Deficit) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2017 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 04, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_StockPurchaseAgreementNumberOfTranches', window );">Number of tranches (in tranches) | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_CommonStockVotingRightsNumberOfVotesPerShare', window );">Votes per share of common stock | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">65,820,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">48,787,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (In USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock upon initial public offering (in shares)</a></td>
<td class="nump">24,385,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,385,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Preferred stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,122,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare', window );">Purchase price per share (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,251,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Preferred stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,364,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare', window );">Purchase price per share (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,736,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_StockPurchaseAgreementNumberOfSharesIssuable', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,398,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_StockPurchaseAgreementPricePerShare', window );">Price per share (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 891<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Outstanding principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A | Stock Purchase Agreement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares Issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,590,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from stock purchase agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A | Stock Purchase Agreement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares Issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,156,784<span></span>
</td>
<td class="nump">828,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_StockPurchaseAgreementPricePerShare', window );">Price per share (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from stock purchase agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A | Stock Purchase Agreement, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares Issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,156,784<span></span>
</td>
<td class="nump">828,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A | Stock Purchase Agreement, Tranches Two And Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares Issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,657,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_StockPurchaseAgreementPricePerShare', window );">Price per share (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from stock purchase agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_CommonStockVotingRightsNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Voting Rights, Number Of Votes Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_CommonStockVotingRightsNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_StockPurchaseAgreementNumberOfSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Number Of Shares Issuable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_StockPurchaseAgreementNumberOfSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_StockPurchaseAgreementNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_StockPurchaseAgreementNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_StockPurchaseAgreementPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_StockPurchaseAgreementPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_TemporaryEquityStockIssuedDuringPeriodPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arqt_StockPurchaseAgreementTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arqt_StockPurchaseAgreementTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arqt_StockPurchaseAgreementTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arqt_StockPurchaseAgreementTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arqt_StockPurchaseAgreementTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arqt_StockPurchaseAgreementTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arqt_StockPurchaseAgreementTranchesTwoAndThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arqt_StockPurchaseAgreementTranchesTwoAndThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6782275456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Lease</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company leases one facility in Westlake Village, California under an operating lease that commenced in February 2019 and has a non-cancelable lease term of 30 months, subject to fixed escalation increases. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The minimum annual rental payments of the Company&#8217;s operating lease liability as of March&#160;31, 2020 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:85.280%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.720%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (April through December)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total minimum lease payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">277&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Amounts representing interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of future minimum lease payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">264&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">182&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability, noncurrent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">264&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Straight-line rent expense recognized for operating leases was $43,000 and $24,000 for the three months ended March 31, 2020 and 2019, respectively . There were no variable lease payments, including non-lease components such as common area maintenance fees, recognized as rent expense for operating leases for the three months ended March 31, 2020 and 2019.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following information represents supplemental disclosure for the statement of cash flows related to the Company&#8217;s operating lease (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"><tr><td style="width:1.0%;"/><td style="width:66.796%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.304%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.394%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.306%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following summarizes additional information related to the operating lease:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:78.116%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.884%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.42</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average discount rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2020, the Company amended its lease agreement.  See Note 10. </span></div><div style="text-indent:36pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Indemnification</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by California corporate law. The Company currently has directors&#8217; and officers&#8217; insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6660644800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">Subsequent Event  In April 2020, the Company amended its lease agreement for its facility in Westlake Village, California to relocate to a new expanded space comprising 22,643 square feet.  The lease will begin when the tenant improvements are substantially complete and terminates 91 months thereafter, with a renewal option for a term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjMzZWQxMzc2YjRmODRhNTUzZWI5YmNjZDk3MzFkL3NlYzplZWIzM2VkMTM3NmI0Zjg0YTU1M2ViOWJjY2Q5NzMxZF8xNjQ5L2ZyYWc6OGI2YWM5NGE4Y2QxNDMwNDg4YWUwZGY4NTY3MjdlMmUvdGV4dHJlZ2lvbjo4YjZhYzk0YThjZDE0MzA0ODhhZTBkZjg1NjcyN2UyZV80OTQ3ODAyMzM3NzUy_a7f3f3c6-d01a-43c9-8f08-52810289a778">five</span> years.  The Company will have a one-time option to cancel the lease after month 67.   The lease is subject to fixed rate escalation increases with an initial base rent of $76,000 per month and includes rent free periods aggregating approximately 1 year. As a result, the Company recognizes rent expense on a straight-line basis for the full amount of the commitment including the minimum rent increases over the life of the lease and the free rent period.  The amended lease agreement provides for a tenant improvement allowance up to $1.25&#160;million. It also requires the Company to have an available letter of credit of $1.5&#160;million upon commencement, which is allowed to be reduced throughout the lease period as rent obligations are met.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796288416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity (Deficit) - Components of Convertible Preferred Stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Feb. 04, 2020</div></th>
<th class="th"><div>Feb. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,787,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,385,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,385,388<span></span>
</td>
<td class="nump">16,262,425<span></span>
</td>
<td class="nump">16,262,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net Carrying Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,491<span></span>
</td>
<td class="nump">$ 72,252<span></span>
</td>
<td class="nump">$ 72,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,897,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,897,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,736,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,364,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,364,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,251,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,122,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,122,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6621794096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>facility</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Straight-line rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_LesseeOperatingLeasesNumberFacilitiesLeased', window );">Number of operating leases (in leases) | facility</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in months)</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_LesseeOperatingLeasesNumberFacilitiesLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Leases, Number Facilities Leased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_LesseeOperatingLeasesNumberFacilitiesLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6645507328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_ClinicalTrialAccrualCurrent', window );">Clinical trial accruals</a></td>
<td class="nump">$ 6,114<span></span>
</td>
<td class="nump">$ 1,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">806<span></span>
</td>
<td class="nump">1,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Early exercise liability, current</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">553<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 7,281<span></span>
</td>
<td class="nump">$ 3,654<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_ClinicalTrialAccrualCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Accrual, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_ClinicalTrialAccrualCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6624166272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 990<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 574<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6654761168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity (Deficit) - Shares of Common Stock for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved (in shares)</a></td>
<td class="nump">6,443,471<span></span>
</td>
<td class="nump">28,452,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=arqt_StockOptionsIssuedAndOutstandingMember', window );">Options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved (in shares)</a></td>
<td class="nump">3,061,521<span></span>
</td>
<td class="nump">2,516,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=arqt_StockAwardsFutureGrantMember', window );">Common stock awards available for grant under employee benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved (in shares)</a></td>
<td class="nump">3,251,890<span></span>
</td>
<td class="nump">1,550,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved (in shares)</a></td>
<td class="nump">130,060<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,385,388<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=arqt_StockOptionsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=arqt_StockOptionsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=arqt_StockAwardsFutureGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=arqt_StockAwardsFutureGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795527232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (In USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48,787,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,385,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,385,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">65,820,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">38,154,550<span></span>
</td>
<td class="nump">2,879,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">37,471,997<span></span>
</td>
<td class="nump">2,120,853<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795858080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,013)<span></span>
</td>
<td class="num">$ (6,658)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Right-of-use asset amortization</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization/accretion on marketable securities</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">990<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,097)<span></span>
</td>
<td class="num">(315)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,412<span></span>
</td>
<td class="num">(393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">3,868<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(21,010)<span></span>
</td>
<td class="num">(7,074)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(35,285)<span></span>
</td>
<td class="num">(11,687)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(183)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(20,326)<span></span>
</td>
<td class="num">(9,270)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of issuance costs</a></td>
<td class="nump">168,646<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">168,893<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">127,557<span></span>
</td>
<td class="num">(16,344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">63,336<span></span>
</td>
<td class="nump">39,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">190,893<span></span>
</td>
<td class="nump">23,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_DeferredFinancingCostsIncurredButNotYetPaid', window );">Deferred financing costs included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_DeferredFinancingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Financing Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_DeferredFinancingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-of-Use Asset, Amortization Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6640222384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease Payments</a></td>
<td class="text"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The minimum annual rental payments of the Company&#8217;s operating lease liability as of March&#160;31, 2020 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:85.280%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.720%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (April through December)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total minimum lease payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">277&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Amounts representing interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of future minimum lease payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">264&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">182&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability, noncurrent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">264&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Operating Lease Supplemental Cash Flow Information</a></td>
<td class="text"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following information represents supplemental disclosure for the statement of cash flows related to the Company&#8217;s operating lease (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"><tr><td style="width:1.0%;"/><td style="width:66.796%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.304%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.394%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.306%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following summarizes additional information related to the operating lease:</span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:78.116%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.884%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.42</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average discount rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792986752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 17, 2020</div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 01, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio for capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,646<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,262,425<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,385,388<span></span>
</td>
<td class="nump">16,262,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of issuance costs</a></td>
<td class="nump">$ 167,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares Issued in transaction (in shares) | shares</a></td>
<td class="nump">10,781,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters' option | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares Issued in transaction (in shares) | shares</a></td>
<td class="nump">1,406,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6618325824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 2,326<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arqt_PrepaidClinicalTrialTestCostsCurrent', window );">Prepaid clinical trial costs</a></td>
<td class="nump">1,583<span></span>
</td>
<td class="nump">2,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Deferred financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses and current assets</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 4,559<span></span>
</td>
<td class="nump">$ 5,209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arqt_PrepaidClinicalTrialTestCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical Trial Test Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arqt_PrepaidClinicalTrialTestCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arqt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
